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A B S T R A C T
Background
Anaemia associated with cancer and cancer therapy is an important clinical factor in the treatment of malignant diseases. Therapeutic
alternatives are recombinant human erythropoiesis stimulating agents (ESAs) and red blood cell transfusions.
Objectives
To assess the effects of ESAs to either prevent or treat anaemia in cancer patients.
Search methods
This is an update of a Cochrane review first published in 2004. We searched the Central Register of Controlled Trials (CENTRAL),
MEDLINE and EMBASE and other databases. Searches were done for the periods 01/1985 to 12/2001 for the first review, 1/2002 to
04/2005 for the first update and to November 2011 for the current update. We also contacted experts in the field and pharmaceutical
companies.
Selection criteria
Randomised controlled trials on managing anaemia in cancer patients receiving or not receiving anti-cancer therapy that compared the
use of ESAs (plus transfusion if needed).
Data collection and analysis
Several review authors assessed trial quality and extracted data. One review author assessed quality assessment and extracted data, a
second review author checked for correctness.
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Main results
This update of the systematic review includes a total of 91 trials with 20,102 participants. Use of ESAs significantly reduced the relative
risk of red blood cell transfusions (risk ratio (RR) 0.65; 95% confidence interval (CI) 0.62 to 0.68, 70 trials, N = 16,093). On average,
participants in the ESAs group received one unit of blood less than the control group (mean difference (MD) -0.98; 95% CI -1.17 to
-0.78, 19 trials, N = 4,715). Haematological response was observed more often in participants receiving ESAs (RR 3.93; 95% CI 3.10
to 3.71, 31 trials, N = 6,413). There was suggestive evidence that ESAs may improve Quality of Life (QoL). There was strong evidence
that ESAs increase mortality during active study period (hazard ratio (HR) 1.17; 95% CI 1.06 to 1.29, 70 trials, N = 15,935) and some
evidence that ESAs decrease overall survival (HR 1.05; 95% CI 1.00 to 1.11, 78 trials, N = 19,003). The risk ratio for thromboembolic
complications was increased in patients receiving ESAs compared to controls (RR 1.52, 95% CI 1.34 to 1.74; 57 trials, N = 15,498).
ESAs may also increase the risk for hypertension (fixed-effect model: RR 1.30; 95% CI 1.08 to 1.56; random-effects model: RR 1.12;
95% CI 0.94 to 1.33, 31 trials, N = 7,228) and thrombocytopenia/haemorrhage (RR 1.21; 95% CI 1.04 to 1.42; 21 trials, N = 4,507).
There was insufficient evidence to support an effect of ESA on tumour response (fixed-effect RR 1.02; 95% CI 0.98 to 1.06, 15 trials,
N = 5,012).
Authors’ conclusions
ESAs reduce the need for red blood cell transfusions but increase the risk for thromboembolic events and deaths. There is suggestive
evidence that ESAs may improve QoL. Whether and how ESAs affects tumour control remains uncertain. The increased risk of death
and thromboembolic events should be balanced against the potential benefits of ESA treatment taking into account each patient’s
clinical circumstances and preferences. More data are needed for the effect of these drugs on quality of life and tumour progression.
Further research is needed to clarify cellular and molecular mechanisms and pathways of the effects of ESAs on thrombogenesis and
their potential effects on tumour growth.
P L A I N L A N G U A G E S U M M A R Y
Erythropoietin or darbepoetin for patients with cancer
Introduction
Researchers in The Cochrane Collaboration conducted a review of the effect of epoetin and darbepoetin for people with cancer. After
searching for all relevant studies, they found 91 studies with up to 20,102 people. Their findings are summarized below:
What the research says:
In people with cancer-related anaemia:
- Epoetin and darbepoetin decrease the need for red blood cell transfusions; however, they also increase the risk for hypertension,
thromboembolic events and deaths
- It is not clear whether epoetin and darbepoetin improve quality of life, by making you feel less tired
When you have cancer, you often also have anaemia. Anemia means having lower than normal red blood cells in your blood. This
might become even worse with cancer treatment such as chemotherapy and it is measured by the amount of haemoglobin in your red
blood cells. As haemoglobin is responsible for carrying oxygen throughout your body, when you have anaemia you might experience
symptoms such as extreme tiredness, shortness of breath, dizziness and chest pain. In order to treat anaemia, doctors often use red blood
cell transfusions. Transfusions improve the symptoms of anaemia very quickly; however, they can have some infrequent complications
like allergic reactions or transmission of infectious diseases.
Epoetin and darbepoetin belong to a group of medications called ’Erythropoiesis Stimulating Agents’. Erythropoietin is the name of
a hormone produced mainly in the kidney, which takes part in the production of red blood cells. Epoetin and darbepoetin work in
a similar way to this hormone to increase the number of red blood cells and treat anaemia. Epoetin and darbepoetin are not used as
anti-cancer therapy but as supportive treatment to treat anaemia caused by cancer or anticancer therapy. These drugs are marketed as
Epogen®, Procrit®, (Eprex®), Recormon®, and Aranesp® and are given subcutaneously.
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What happens to people with cancer related anaemia who take epoetin or darbepoetin:
- Twenty-five out of 100 persons receiving epoetin or darbepoetin had to undergo red blood cell transfusions, compared to 39 out of
100 persons not receiving epoetin or darbepoetin.
- More people who received epoetin or darbepoetin died during and up to 30 days after the end of study compared with people who
took placebo or underwent standard treatment. The increased risk for people taking epoetin or darbepoetin was 17%. One hundred
and fourteen out of 1,000 persons receiving epoetin or darbepoetin died, compared with 98 out of 1,000 persons not receiving epoetin
or darbepoetin. We could not identify particular characteristics of people or treatment strategies that increased or decreased the risk for
dying.
- Concerning long-term survival people taking epoetin or darbepoetin were 5% more at risk for dying than people taking placebo or
receiving standard treatment.
- People receiving epoetin or darbepoetin rated their fatigue symptoms to be an average of 2.08 points improved on a scale of 0-52
points after 3-4 months, compared with people taking placebo or having standard treatment. This improvement, however, is less than
the 3.0 point increase which is considered to be the minimum required for the patient to feel a difference in his experience of fatigue-
related symptoms using this scale.
- People taking epoetin or darbepoetin rated their fatigue and anaemia symptoms had to be an average of 6.14 points improved after
three to fourmonths, on a scale of 0-80 points. This improvement is considered to reflect a positive change in the way patients experience
their fatigue and anaemia related symptoms, as it is more than four to five points of increase which is the minimum required for this
scale.
- Seven people out of 100 who took epoetin or darbepoetin suffered a thromboembolic event such as stroke and myocardial infarction
compared with five people out of 100 who did not receive epoetin or darbepoetin.
- Six out of 100 people receiving epoetin or darbepoetin developed high blood pressure compared with four out of 100 people who
took placebo or had standard care.
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B A C K G R O U N D
Description of the condition
Anaemia, defined as a deficiency in the concentration of hae-
moglobin-containing red blood cells, is a widely prevalent com-
plication among cancer patients (Knight 2004). The prevalence
of anaemia varies according to the type of neoplasia (Monnerat
1999). Patients with haematological malignancies frequently ex-
perience anaemia. At the time of diagnosis, 30% to 40% of pa-
tients with non-Hodgkin’s lymphoma (NHL) or Hodgkin’s lym-
phoma (HD) and up to 70% of patients with multiple myeloma
are anaemic; the figures are even higher in myelodysplastic syn-
dromes (Garton 1995; Greenberg 1994). The extent of anaemia
is also influenced by the type of cytostatic treatment. It is known
that the proportion of anaemic patients with solid cancers rises
up to 50% after chemotherapy or combined radiochemotherapy
(Dalton 1998; Harrison 2001; Ludwig 1998; Reed 1994).
The National Cancer Institute and others have agreed to use the
following classification for anaemia based on haemoglobin (Hb)
values (Groopman 1999):
• Grade 0, within normal limits, Hb values are 12.0 to 16.0
g/dL for women and 14.0 to 18.0 g/dL for men
• Grade 1, mild (Hb 10 g/dL to normal limits)
• Grade 2, moderate (Hb 8.0 to 10.0 g/dL)
• Grade 3, serious/severe (Hb 6.5 to 7.9 g/dL)
• Grade 4, life threatening (Hb less than 6.5 g/dL).
The pathophysiology of tumour anaemia is multi-factorial (
Mercadante 2000). In advanced stages of haematological ma-
lignancies, bone marrow involvement with malignant cells of-
ten leads to progressive anaemia. After exclusion of other causes,
e.g. iron or vitamin deficiencies, occult bleeding, autoimmune
haemolysis or pure red blood cell aplasia, anaemia can be re-
lated to “anaemia of chronic disorders”. It is characterised by a
close interaction between the tumour cell population and the im-
mune system, leading to the activation of macrophages and in-
creased expression of various cytokines, especially Interferon-g, In-
terleukin-1, Interleukin-6 and tumour necrosis factor. This is fol-
lowed by insufficient endogenous erythropoietin synthesis, sup-
pressed differentiation of erythroid precursor cells in the bonemar-
row and alterations of iron metabolism (Johnson 1990; Ludwig
1998; Nowrousian 2002a; Spivak 1994a). For example, the ele-
vation of interleukin 6 (Il-6) leads to an up-regulation of Hep-
cidin and a diminished erythropoietin-synthesis. Hepcidin is one
of the mediators that are released in inflammatory processes. It
causes the destruction of another protein called ferroportin, which
is important for the transport of Fe2+ from the enterocyte and the
macrophage into the blood (Ganz 2011). The anaemia of chronic
disorders, or chronic tumour anaemia is the most common type
in patients with malignant disease, although it is often aggravated
by chemo- or radiotherapy. In particular, platinum-based chemo-
therapy regimens may diminish endogenous erythropoietin pro-
duction by damaging renal tubular cells (Wood 1995).
Manifestation and severity of anaemia vary considerably among
individual patients. Mild-to-moderate anaemia can cause typi-
cal symptoms including headache, palpitations, tachycardia and
shortness of breath. Chronic anaemia may result in severe or-
gan damage affecting the cardiovascular system, immune system,
lungs, kidneys, muscles and the central nervous system (Ludwig
2001; Nissenson 1992). In addition to physical symptoms, the
subjective impact of cancer-related anaemia on quality of life
(QoL),mental health and social activitiesmay be substantial. Clin-
ical studies have reported correlations betweenHb levels and qual-
ity of life domains, for example mood, appetite (Leitgeb 1994),
and the ability to work (Cella 1998; Thomas 1998).
Another aspect of anaemia in patients with malignant disease is
the effect on the tumour itself. For malignant diseases such as
Hodgkin’s Disease (HD), chronic lymphocytic leukaemia (CLL),
cervical carcinoma and cancer of the head and neck, anaemia has
been reported to be an independent prognostic factor (Caro 2001;
Hasenclever 1998; Nowrousian 2002b; Van Belle 2003). There is
evidence that anaemia, with the consequence of increased tumour
hypoxia, might result in a poorer response to radio- or chemo-
therapy (Hockel 1993; Nordsmark 1996; Van Belle 2003; Vaupel
1989; Vaupel 2000). Severe symptoms of anaemia may also neces-
sitate dose reduction or delay of chemotherapy. All these factors
may lead to a higher tumour burden and a decreased overall sur-
vival (Glaser 2001; Grau 2000; Knocke 1999). These observations
have generated the hypothesis that strategies to diminish cancer-
related anaemia might alleviate not only anaemia-related symp-
toms and improve quality of life, but also might improve tumour
response and extend overall survival time. However, randomised
controlled trials testing this hypothesis have generated conflicting
evidence (Antonadou 2001; Henke 2003; Leyland-Jones 2005).
Historically, blood transfusion was the conventional treatment of
choice for severe cancer-related anaemia. The literature reports a
critical degree of anaemia as a Hb level below 8 g/dL, while mild-
to-moderate anaemia (Hb level 8-10 g/dL) usually has been left
untreated (Carson 2012; Cella 1999; Glaspy 1997a; Henry 1992;
Koeller 1998). Although homologous blood transfusion is the
fastest method to alleviate symptoms, short- and long-term risks
exist (Engert 2000). Potential complications associated with blood
transfusion are transmission of infectious diseases, transfusion re-
actions, allo-immunisation, over-transfusion and immune mod-
ulation with possible adverse effects on tumour growth (Landers
1996). The risk of severe infectious complications of blood trans-
fusions are 1: 30.000 to 1:250.000 units of blood transfused for
Hepatitis B, 1:30.000 to 1:150.000 forHepatitis C and 1:250.000
to 1:1.000.000 forHIV (Goodnough 1999). Other complications
such as allergic reactions and death due to major incompatibilities
are infrequent but may be of concern (Williamson 1999). The
development of intensified anti-neoplastic therapies has increased
the risk for blood transfusion, prompting oncologists to weigh the
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advantages and disadvantages of this treatment.
Description of the intervention
Recombinant human erythropoietin is a treatment option for can-
cer-related anaemia. Human erythropoietin is an acidic glycopro-
tein hormone. Approximately 90% of the hormone is synthesised
in the kidney and 10% in the liver (Koury 1988; Koury 1991).
Basal productionmaintains a relatively constant plasma concentra-
tion of erythropoietin in individuals, within a range from 9 to 26
mU/mL.Tissue hypoxia is themost important trigger for increased
synthesis. The effects of erythropoietin in the bone marrow are
mediated by a specific surface receptor locatedmainly on erythroid
progenitor and precursor cells (D´ Andrea 1989; Spivak 1994b).
Two major functions of erythropoietin are described: stimulat-
ing progenitor cell proliferation and maintaining their viability
(Koury 1990).
Several short- and long-lasting forms of recombinant human
erythropoiesis-stimulating agents (ESAs) are available, including
Epoetin-a and Epoetin-ß and darbepoetin-a (Darbepo) (Glaspy
2003; Halstenson 1991; Hedenus 2002; Joy 2002; Storring 1998;
Vansteenkiste 2002). Recently, novel ESA molecules, such as
continuous erythropoietin receptor activator (CERA) (Gascon
2010b), and biosimilars (epoetin theta, epoetin delta) have been
developed (Jelkmann2010). Clinical trials directly comparing Epo
and Darbepo have been published and suggest that Epo and Dar-
bepo are similarly effective with regard to Hb response and pro-
portion of patients transfused (Alexopoulos 2004; Glaspy 2003;
Schwartzberg 2004; Waltzman 2004). Based on these data, it
seemed justified to combine both short- and long-lasting erythro-
poietin formulations in one meta-analysis.
How the intervention might work
Erythropoietin was first approved for the treatment of anaemia in
chronic kidney failure. In 1990, erythropoietin was introduced in
cancer therapy regimens for patients with multiple myeloma. A
pilot study showed haematological response rates of 85% and an
improved performance status (Ludwig 1990). Adverse effects such
as hypertension, headaches and thrombotic events conclusively
attributable to erythropoietin treatment were reported in very few
patients (Beguin 1998). However, several randomised controlled
trials reported increased incidences of thrombotic events, tumour
progression and deaths (Hedenus 2003; Henke 2003; Leyland-
Jones 2005; Overgaard 2009; Smith 2008; Thomas 2008; Untch
2011_1; Wright 2007).
Why it is important to do this review
Since ESAs were licensed for the treatment of anaemia in cancer
patients, more than 20 systematic reviews and meta-analyses have
been published. While there is clear evidence that ESAs reduce
the need for red blood cell transfusions, increase Hb levels and
also increase the risk for thromboembolic complications, there is
ongoingdebate on the effects of ESAs onQoL, tumour progression
and mortality (Aapro 2006; Aapro 2008; Aapro 2009; Bennett
2008; Bottomley 2002; Cella 2004; Clark 2002; Devon 2009;
Glaspy 2010; Hedenus 2005; Hellström-L 1995; Jones 2004;
Kimel 2008; Lambin 2009; Ludwig 2009; Minton 2008; Minton
2010; Quirt 2003; Quirt 2005; Ross 2003; Ross 2006; Ross 2007;
Seidenfeld 2001b; Seidenfeld 2001a; Seidenfeld 2006; Tonelli
2009; Wilson 2007).
The first Cochrane review (published in 2004 in The Cochrane
Library and 2005 as print publication) on this subject included
27 randomised controlled studies on erythropoietin with 3,287
adults, published between 1985 and April 2002 (Bohlius 2005)
in collaboration with authors from a previous review conducted
for AHRQ (Seidenfeld 2001a; Seidenfeld 2001b). For the first up-
date, we included trials published between 2002 and 2005 in col-
laborationwith an independent review team from theDepartment
of Public Health and Epidemiology at the University of Birming-
ham and the support of the UK Department of Health (Bohlius
2006a). In 2009, we conducted a separate meta-analysis based on
individual patient data (IPD), which focused on on-study mor-
tality and overall survival in all cancer patients and in patients re-
ceiving chemotherapy (Bohlius 2009a; Bohlius 2009b).Given that
this analysis was restricted to survival outcomes, we present here
the second update of the Cochane Review, including all relevant
outcomes and integrating results generated for the IPD analysis as
well as recently published trials.
O B J E C T I V E S
To systematically review evidence on the outcomes of using re-
combinant human erythropoietin or darbepoetin to prevent or al-
leviate anaemia in patients with malignant disease, with respect to
haematological response, red blood cell transfusion need, changes
in quality of life, tumour response, on-study mortality, overall sur-
vival and adverse events.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials using recombinant hu-
man erythropoietin or darbepoetin to treat or prevent anaemia in
patients with malignant disease. Placebo control, as opposed to
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“no treatment”, was not required for inclusion, but was considered
in evaluating study quality. We excluded trials in which patients
were allocated by a quasi-random method, for example date of
birth or day of month, as we considered this study design to be of
poor quality leading to unreliable results. We included only trials
with more than 10 documented participants in each study arm or
relevant stratum.We excluded interim analyses of ongoing studies.
We included studies that were stopped or suspended prematurely.
The searches did not include language restrictions.
Types of participants
We included only participants diagnosed with malignant disease,
using clinical and histological/cytological criteria, regardless of
type or stage of the disease or previous therapy. All study par-
ticipants had to be anaemic or at risk for anaemia from chemo-
therapy, radiotherapy or combination therapy, or the underlying
malignant disease. Other causes of anaemia, such as haemolysis,
iron deficiency and occult bleeding, had to have been excluded.
We included studies with patients of every age. We excluded trials
if more than 80% of participants were diagnosed with an acute
leukaemia.
Types of interventions
We included studies evaluating the use of recombinant human
erythropoiesis-stimulating agents (ESAs) to prevent or reduce
anaemia in cancer patients, given singly or concomitantly with
chemotherapy, radiotherapy or combination therapy. ESAs could
be administered subcutaneously or intravenously. In previous ver-
sions of this review, we required dosages of at least 300 U/kg body
weight per week (epoetin-a and beta) given for at least four weeks.
For the current update we removed this criterion and we included
studies or study arms with low dosages as well. We allowed dose
adaptation of ESAs depending on haematological response. Con-
comitant supportive treatments, e.g. granulocyte colony-stimulat-
ing factors (G-CSF), had to be given equally in all study arms. In
previous versions of this review, this criterion applied to iron sup-
plementation as well. However, for the current update, we have
changed this criterion and included trials using iron supplementa-
tion in the experimental but not in the control arm as well.We ex-
cluded trials on high-dose myeloablative chemotherapy regimens
followed by bone marrow or peripheral blood stem cell transplan-
tation, as well as trials using erythropoietin for short-term preop-
erative treatment to correct anaemia or to support collection of
autologous blood prior to cancer surgery.
Included trials addressed one ormore of the following comparisons
of interest:
1. ESAs versus placebo or no treatment.
2. ESAs and red blood cell (RBC) transfusion as necessary
versus observation and RBC transfusion as necessary, alone or
with placebo.
3. ESAs plus conventional-dose cancer therapy (non-
myeloablative chemotherapy and/or radiotherapy) versus
identical therapy alone or with placebo.
4. ESAs and RBC transfusion as necessary plus conventional-
dose cancer therapy versus observation and RBC transfusion as
necessary plus identical therapy, alone or with placebo.
Types of outcome measures
Primary outcomes
• Haematological response
Measured as a binary outcome (proportion of patients with an
increase inHb level of 2 g/dLormore, or an increase in haematocrit
of 6% points or more; measured as continuous data (change inHb
level from baseline until end of study). Of note, in the previous
review we had restricted this outcome to studies with baseline
Hb levels < 12 g/dL; in the current update we have removed this
restriction.
• Patients receiving RBC transfusions
• Number of RBC units transfused per patient
• Overall survival
• On-study mortality. Of note, we added on-study mortality
as a new outcome to the current update of the review.
Secondary outcomes
• Tumour response (complete response)
• Changes in quality of life including cancer-related fatigue
and anaemia symptoms, measured with the Functional
Assessment of Cancer Therapy Anaemia (FACT-An) Total scale
(47 items), Anaemia sub-scale (20 items), or Fatigue sub-scale
(13 items). We have chosen this instrument and its sub-scales
because they have been widely used in ESA trials and have good
responsiveness to change and good convergent and discriminant
validity (Cella 1997; Cella 2002; Cella 2007; Yellen 1997).
• Adverse events (thromboembolic events, hypertension,
haemorrhage/thrombocytopenia, rash/irritation/pruritus,
seizures)
Search methods for identification of studies
We used the following sources to identify the studies for this up-
dated review:
1. Previous Cochrane reviews on the effects of ESAs on cancer
patients, mainly Bohlius 2006a and Bohlius 2009a; Bohlius
2009b.
2. Electronic search in bibliographic databases.
3. Conference Proceedings.
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4. ODAC Documents 2004, 2007 and 2008 (see next
section).
5. Reference lists of other systematic reviews and meta-
analyses.
Electronic searches Search strategies have been adapted from those
suggested in the Cochrane Handbook for Systemtatic Reviews
of Interventions (Lefebvre 2011). For detailed search strategies
for each database, please refer to Appendix 1; Appendix 2; Ap-
pendix 3.For previous searches for this review see previous version
of the review (Bohlius 2006a). For the current version, we identi-
fied relevant trials in any language through electronic searches of
the Cochrane Central Register of Controlled Trials (CENTRAL),
MEDLINE, and EMBASE. We conducted the initial search for
the period 2004 to September 2009. We updated the search using
the same search strategy in January 2011 and in November 2011.
We did not use language restrictions. The full search strategy is on
file.
Electronic searches
Search strategies have been adapted from those suggested in
the Cochrane Handbook for Systemtatic Reviews of Interventions
(Lefebvre 2011). For detailed search strategies for each database,
please refer to Appendix 1; Appendix 2; Appendix 3.
For previous searches for this review, see previous version of the
review (Bohlius 2006a). For the current version, we identified
relevant trials in any language through electronic searches of the
Cochrane Central Register of Controlled Trials (CENTRAL),
MEDLINE, and EMBASE. We conducted the initial search for
the period 2004 to September 2009. We updated the search using
the same search strategy in January 2011 and in November 2011.




We searched conference proceedings of the American Society of
Clinical Oncology, American Society of Hematology and Euro-
pean Society of Medical Oncology from January 1989 to Decem-
ber 2001 for the original Cochrane review; from January 2000 to
December 2004 for the first update; and from January 2005 to
November 2011 for the present update. We conducted searches
of conference proceedings online, with CD-ROMs or by hand-
searching.
Ongoing trials
For the previous versions of this review,we searched various sources
for ongoing studies. For the current update we did not search
specifically for ongoing trials in online registries.
Contact with authors
For previous versions of this review, we contacted groups or indi-
viduals as well as pharmaceutical companies who conducted ran-
domised trials on recombinant human erythropoietin in cancer
patients. For the current review, we contacted authors only to clar-
ify eligibility of studies, if necessary.
Reference lists
We checked reference lists of identified guidelines, systematic re-
views and clinical trials for additional information.
Oncology Drug Advisory Committee Documents
For the current update, we evaluated documents presented at the
Oncology Drug Advisory Committee (ODAC) hearing at the
USA Food and Drug Administration (FDA), held in May 2004,
May 2007 and March 2008. These documents include briefing
documents plus additional power point presentations prepared by
medical review authors of the FDA (FDA ODAC 2007; FDA
ODAC 2008; Luksenburg 2004), as well as documents and ad-
ditional power point presentations prepared by the companies
Roche, Johnson & Johnson and Amgen (Amgen ODAC 2004;
Amgen ODAC 2007; Amgen ODAC 2008; Johnson & Johnson
ODAC 2004; Roche ODAC 2004). All of these documents are
publicly available at FDA web pages.
Data collection and analysis
Selection of studies
Several review authors screened titles and abstracts of studies iden-
tified from the above sources according to the eligibility crite-
ria stated previously. We did this step in duplicate. For the first
Cochrane review this was undertaken by Simon Langensiepen and
Julia Bohlius, for the first update this was undertaken by Jayne
Wilson, Sunsan Brunskill, Julia Bohlius, Olaf Weingart and Sven
Trelle. For the current update this was done by AnnetteMettler, Ju-
lia Bohlius, Nadège Robert and Thomy Tonia. If eligibility could
not be adequately assessed by screening the title and abstract, we
obtained a full text version of the study for assessment. Studies
that appeared to meet the inclusion criteria in the initial screening
were further assessed for eligibility using a form containing the
following questions.
1. Is the study described as randomised?
2. Did the participants in the study have a previously treated
or untreated malignant disease?
3. Were the participants anaemic or at risk for anaemia from
chemotherapy and/or radiotherapy or their malignant disease?
4. Was one group given Epoetin-a or Epoetin-ß or
Darbepoetin-alfa or any other ESA subcutaneously or
intravenously?
5. Did the control group receive the same care (e.g.
chemotherapy and supportive therapies) with or without
placebo?
6. Did the study document relevant outcome measures?
To be eligible, studies had to meet all of the criteria stated above.
If there was insufficient information to judge eligibility, we con-
tacted the first author of the report for clarification. We resolved
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any disagreements between the review authors by discussion. We
identified duplicate reports.
Data extraction and management
Data extraction was performed by one review author and facts
were checked by a second review author. For the original Cochrane
review this was done by Simon Langensiepen and Julia Bohlius.
For the first update all publications until September 2004 were
extracted by Julia Bohlius, Jayne Wilson and Susan Brunskill. For
the current update, data were extracted by Julia Bohlius, Olaf
Weingart, AnnetteMettler, Nadège Robert and ThomyTonia. For
the previous version QoL data were extracted by Jayne Wilson,
SusanBrunskill andChrisHyde. For the current version,QoLdata
were extracted by Thomy Tonia, Annette Mettler, Nadège Robert
and Julia Bohlius. For data extractions we used a standardised data
extraction form. This form included the following items.
• General information: title, authors, source, contact address
of corresponding author, year of publication, any duplicate
publications, trial setting, recruitment dates, funding.
• Trial characteristics: design, method of randomisation,
concealment of allocation, blinding of patients and clinicians.
• Patients: sampling, inclusion and exclusion criteria, sample
size, baseline characteristics, similarity of groups at baseline,
diagnostic criteria, withdrawals, losses to follow-up.
• Interventions: placebo use, dose, dosing regimen, duration,
route of administration, RBC transfusion trigger, co-medications
with dose, route and timing
• Outcomes: outcomes as specified above.
We resolved disagreements arising at any stage by discussion and
consensus.
Referencing of studies
If we identified several publications for one study, we extracted
the data from the most recent publication and amended this with
information from other publications. We used the following suf-
fixes to indicate the source of data.
• We indicated data that were taken from either full text or
abstract publication or based on personal communication with
author name and year of publication
• We cited data that were taken from the individual patient
data meta-analysis by Bohlius 2009a;Bohlius 2009b using the
reference for the original study and adding the suffix “IPD”. For
example, we cited survival data for the Hedenus 2003 which we
had taken from the individual patient data meta-analysis by
Bohlius 2009a; Bohlius 2009b as “Hedenus 2003 IPD”
• We assigned the following suffixes to data taken from an
ODAC presentation:
◦ J&J 2004 if we took the data from a J&J presentation
for the ODAC 2004 hearing
◦ J&J 2007 if we took the data from a J&J presentation
for the ODAC 2007 hearing
◦ Roche 2004 if we took the data from a Roche
presentation for the ODAC 2004 hearing
◦ FDA 2004 if we took the data from a FDA
presentation for the ODAC 2004 hearing
◦ FDA 2007 if we took the data from a FDA
presentation for the ODAC 2007 hearing
◦ Amgen 2007 if we took the data from an Amgen
presentation for the ODAC 2007 hearing
• For each unique study we assigned a five digit random
number, entered for each reference in the “other” field. These
numbers are identical to the numbers assigned to the studies in
the IPD review by Bohlius 2009a; Bohlius 2009b. We assigned
new five digit numbers for studies which we had not included in
the IPD review.
• For studies comparing more than one experimental arm to
one control arm, we assigned a separate reference for each study
arm. We labelled these study arms with the author and
publication year of the main publication and added the suffixes
a; b; c etc. For example, the study by Cazzola 1995 compared
four different experimental study arms with one control group.
The four different study arms are listed in the included studies
and the data analyses as Cazzola 1995a; Cazzola 1995b; Cazzola
1995c and Cazzola 1995d.
Due to this referencing system a given study may appear more
than once in the list of included studies. The total number of
unique studies included is 91. For these 91 studies, a total of 198
study identifiers are listed in the sections Included studies and
Characteristics of included studies.
Methods for QoL
In the previous review, we included any validatedQoL instrument.
For the current update, we restricted the analysis to studiesmeeting
the inclusion criteria and also reporting QoL data using one of the
following instruments.
a) FACT-F 13: Functional Assessment of Cancer Therapy Fatigue
sub-scale, consisting of 13 fatigue-specific questions
b) FACT-An 20: Functional Assessment of Cancer Therapy
Anaemia sub-scale, consisting of 20 questions (13 from FACT-F,
plus 7 anaemia specific questions)
c) FACT-An 47: Functional Assessment of Cancer Therapy
Anaemia total score, consisting of 47 questions (20 from the
FACT-An sub-scale plus 27 from the FACT-General scale)
In the previous update, we excluded studies that did not clearly
state the number of participants contributing to QoL data. For
the current update, we decided to also include studies that did not
report the exact number of participants contributing QoL data,
in order to get as much information as possible. We included all
studies reporting change between baseline and end of treatment
per group. We limited the included QoL data to scores of the full
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instruments or sub-scales that have been validated as stand-alone
instruments.
Rather than focusing on statistical significance, meaningful in-
terpretation of QoL results emphasizes the degree to which dif-
ferences between treatment and control arms exceed a Clinically
Important Difference (CID) previously established for the QoL
instruments utilized. For FACT-Fatigue, this has been estimated
to be three (Cella 2002) and for FACT-An 20 four to five (Cella,
personal communication, March 2010). For FACT-An 47 a CID
has not yet been established.
Assessment of risk of bias in included studies
Quality Assessment
Two review authors independently assessed the full text articles of
the eligible studies for quality. For the original Cochrane review
this was undertaken by Simon Langensiepen and Julia Bohlius.
For the first update this was done by Julia Bohlius and either Jayne
Wilson or Susan Brunskill for the trials published until Septem-
ber 2004, and Julia Bohlius and Sven Trelle for trials published
between September 2004 and April 2005. For the current update,
this assessment was conducted by AnnetteMettler, Nadège Robert
and Thomy Tonia. For the original Cochrane review, we con-
tacted all first authors or sponsoring pharmaceutical companies of
the included trials in order to obtain detailed information on the
study design. For the previous and current update (years 2002 to
November 2011) this was not undertaken due to time limitations.
However, for the IPD review (Bohlius 2009a; Bohlius 2009b) we
had access to the clinical study reports of the included studies and
used these to assess the quality of studies. We integrated these as-
sessments in the current review update. For all other studies, we
took this information from publications.
To assess the methodological quality and the risk of bias, we de-
signed a quality assessment form specifically for the topic of this
review, according to the recommendations in Chapter Eight of the
Cochrane Handbook for Systematic Reviews ( Higgins 2011a). The
sources we used for designing this form are: Alderson 2005; Jüni
2001; Moher 2001; Verhagen 1998) and the form contains the
following questions.
1. Was allocation truly random?
2. Was the treatment allocation concealed?
3. Were study participants blinded (masked) to the treatment
they received?
4. Were study clinicians blinded (masked) to the treatment
received by individual study participants?
5. Did the analysis include an intention-to-treat (ITT)
analysis?
We excluded studies from the analysis if they were not truly ran-
domised or had inadequately concealed treatment allocation, e.g.
if participants were assigned to treatments in alternate order, or
according to their birth dates, or the day of the week they arrived
at the treatment centre. We tested the effect of individual qual-
ity variables (allocation, blinding, ITT) in subgroup analyses. Be-
cause of the problematic use of quality summary scores, we did
not use summary scores (Jüni 1999; Schulz 1995). We assessed
baseline participant characteristics to see if the groups were bal-
anced at baseline. We also assessed whether the number of patient
withdrawals, dropouts and lost to follow-up was reported for each
study group; however, we did not use this information for the
analyses.
For the present update we applied additional quality criteria to
assess the quality of studies reporting data on tumour control.
These criteria were as follows.
1. The study population had to be homogenous, i.e. all
participants had to have the same tumour type and - if relevant -
the same tumour stage. Alternatively, the study had to be
stratified by tumour type or tumour stage.
2. The participants of the study had to receive a predefined,
identical anticancer therapy. As above, we considered a study to
meet this criterion if the study was stratified by treatment.
3. The study had to be designed to assess tumour response or
tumour control prospectively or tumour control/response had to
be the primary or secondary study outcome.
Dealing with missing data
Incomplete reporting of data
As suggested in Chapter 16 of the Cochrane Handbook for System-
atic Reviews of Interventions (Higgins 2011b), we took the follow-
ing steps in addressing missing data.
For studies that did not report the number of patients evaluated for
a given outcome, we used the number of patients randomised per
study arm as denominator. In studies where only the total num-
ber of population was reported (and not the number of patients
per arm) and where the randomisation was 1:1, we assumed that
randomisation was 1:1 for a given outcome as well, thus assuming
that the outcome was calculated using ITT analysis.
Binary data: if only percentages but not absolute number of events
were reported, we used percentages to calculate numerators.
Continous data: If estimates for mean and standard deviations
(SD) were not reported, we used the methods published by Hozo
et al to convertmedian and range estimates of outcomes such asHb
change into mean and SD (Hozo 2005). If mean change was not
reported, we calculated this as the difference between end of treat-
ment and baseline value. If SDs were not reported, we estimated
them from standard errors, confidence intervals or ranges, when-
ever reported. If numerical data were not reported, we estimated
means and/ or SDs from graphs or figures. If SDs and means were
reported for subgroups only, we calculated a pooled SDby pooling
the SDs of the two different subgroups. For some studies it was not
clear whether the reported numbers were referring to SDs or SEs.
To maximise the likelihood that our assumptions were valid, we
assumed that the numbers were SDs and converted them to SEs
and vice versa. We then assumed that the numbers were referring
to SDs or SEs depending on which one seemedmore likely for this
outcome, as suggested in Deeks 1997. If mean change between
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baseline and end of treatment and corresponding SD was not re-
ported, they were calculated by using a correlation coefficient. In
addition, we used secondary sources to identify data that were not
reported in the original publication. These secondary sources in-
cluded ODAC briefing documents and other meta-analyses. For
example for QoL we retrieved data from secondary publications,
that had attempted to retrieve missing information from authors
(Minton 2008;Minton 2010) or imputed data (Tonelli 2009). To
account for all these calculations, we conducted a subgroup anal-
ysis taking into account the source of data, as well as a sensitivity
analysis differentiating between the studies for which we had to
impute data in some way and those for which we did not impute
any data.
Handling of discrepant data: If a study was published in several
different publications, reports and presentations, we extracted the
most recent or most comprehensive data.We compared the data of
one study taken from different sources. If the data from different
sources were discrepant, we applied the following rules to decide
which data to use for analysis.
• Most complete data set, e.g. where the sample size is largest
OR data with consistent outcome definitions across trials were
chosen for analysis.
• If for one study outcome two different analyses were
available (e.g. adjusted versus unadjusted analysis), we chose the
unadjusted data for analysis.
Age: if age was not reported but the cancer was typical for adults,
e.g. breast cancer or non-small cell lung cancer (NSCLC), we
classified the study as conducted in an “adult“ population.
Assessment of heterogeneity
As suggested in Chapter 9 of the Cochrane Handbook of System-
atic Reviews on Interventions (Deeks 2011), we explored potential
causes of heterogeneity by performing sensitivity and subgroup
analyses for primary and selected secondary outcome measures
(see below). We used the P value of the homogeneity test and the
I² statistic only to describe the extent of heterogeneity inherent in
a meta-analysis.
Assessment of reporting biases
In meta-analyses with at least 10 trials, we generated a funnel plot
and performed a linear regression test (Egger 1997) to examine
the potential presence of bias. We considered a P value of less than
0.1 as significant for the linear regression test (Sterne 2011).
Data synthesis
We performed analyses according to the recommendations of
Chapter 9 of the Cochrane Handbook for Systematic Reviews of In-
terventions (Deeks 2011).
We assumed a fixed-effect model for all meta-analyses. For binary
data, we used the risk ratio as a measure of treatment effect and we
used the Mantel-Haenszel method for pooling. We used the esti-
mated overall RR and a range of plausible values for the baseline-
risk to estimate numbers needed to benefit (NNTB) and numbers
needed to harm (NNTH). For continuous data, we calculated the
mean differences (MD) if the outcome was measured on the same
scale in all trials. For QoL we combined only identical scales and
sub-scales in a givenmeta-analysis. For time to event data, i.e. over-
all survival, we calculated hazard ratios (HR) based on individual
patient data (IPD). If IPD were not available, we calculated the
HR from published reports including secondary analyses (Bohlius
2009a; Bohlius 2009b), using methods described in Parmar et al
(Parmar 1998) or binary mortality data. We performed all analy-
ses using Review Manager (RevMan) 5.1; we used the statistical
software package R (Ihaka 1996) for additional analyses that could
not be done with RevMan 5.1.
In addition to subgroup analyses, we conducted random-effects
meta-regression (see Section 9.6.4, Cochrane Handbook) for the
following outcomes: Hb response, Hb change, participants receiv-
ing red blood cell transfusions, FACT-Fatigue, FACT-An 47 us-
ing R function rma.uni in R package metafor (Viechtbauer 2010).
We used the DerSimonian-Laird method to estimate the between-
study variance in meta-regression. In model selection, we con-
sidered all covariates showing a significant effect (P < 0.05) in a
univariate analysis. We restricted the analysis to studies providing
information on all variables that were statistically significant in
univariate analyses. For model selection, we used a back-wise se-
lection method; we removed consecutively the covariate with the
largest P value as long as the P value was larger than 0.05.
In several studies different ESAs, dosages, and routes or schedules
of administration were compared with one control group (Cazzola
1995; Henke 1999; Kotasek 2003; Kunikane 2001; Osterborg
1996; Smith 2003; Suzuki 2008; Ten Bokkel 1998; Thatcher
1999). For each multi-arm study, we divided and randomly as-
signed control patients to the corresponding number of separate
treatment groups for entry into RevMan (base model). As this
might influence the weighting of the studies and thus the pooled
results, we alternatively merged the two (or more) active arms of
one study into one single experimental arm and compared it to
the entire control group. We compared and described results for
each outcome.
Subgroup analysis and investigation of heterogeneity
We conducted subgroup analyses using the following factors, if
appropriate.·
• Hb at study entry (Hb level < 10 g/dL versus 10 to 12 g/dL
versus >12 g/dL versus unclear/not reported)
• Solid tumours versus haematological malignancies
(excluding myelodysplastic syndrome (MDS)) versus MDS
versus mixed versus unclear versus not reported)
• Age (children versus adults)
• Age (only children versus adults > 18 years versus > 70%
non-elderly adults aged 18-65 versus only non-elderly adults
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versus > 70% elderly adults aged > 65 years versus only elderly
adults aged > 65 years)
• Type of treatment given (chemotherapy versus
radiotherapy/radiochemotherapy versus no therapy versus other)
• Type of treatment given (> 70% of patients receiving
platinum-based chemotherapy versus < 70% of patients receiving
platinum-based chemotherapy versus chemotherapy without
platinum versus chemotherapy some (not quantified) patients
receiving platinum versus chemotherapy no details given versus
radiochemotherapy versus radiotherapy versus no therapy versus
other). We categorised studies with less than 70% of patients
receiving chemotherapy as “other” (P-174 IPD; Rose 1994 IPD)
• Short-lasting ESA versus long-lasting ESA
• Duration of ESA medication (six to nine weeks versus 12 to
16 weeks versus more than 20 weeks)
• Iron supplementation (fixed iron supplementation versus
iron as necessary versus no explicit statement/no iron versus
explicit NO iron versus iron handled differently in study arm)
• Study quality parameters (concealment of allocation,
masking, intention-to-treat analysis)
• Source of data (full text publications versus abstract
publications versus unreported data versus data reported at FDA/
ODAC hearing versus other)
Compared to the previous version of this review, we added new
subgroups to differentiate with more detail different age groups
and different anti-cancer therapy groups. For the subgroup “iron
supplementation”, we added the categories “iron given differently
in both study arms”, because of the change in the inclusion cri-
teria described above and “explicitly stated NO iron”. However,
no study was included in the latter subgroup. For the subgroup
“publication”, we added the category “other”, containing clinical
trial results from sources that did not fit any other category. We
dropped the following subgroup analyses as they did not seem to
be relevant any longer or insufficient information was available:
Number of drop outs documented; use of G-CSF.
Sensitivity analysis
To test the robustness of the results, we conducted random-effects
meta-analyses. We reported the estimates of the random-effects
only a) if they showed a difference to the fixed-effect model or b)
if they were necessary to allow for comparison with other meta-
analyses in the discussion section. We explored the influence of
single large studies and the influence of different data sets, e.g.
adjusted versus unadjusted data.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
Results of the search
Our initial literature search in March 2001 retrieved 1,592 ref-
erences. For the first update of this review the Birmingham team
identified and screened another 1,859 references. For the current
update, we identified and screened a total of 2,207 references (999
at the first search on September 2009 and 1208 at the two searches
conducted in 2011 (January and November)). For details, see the
PRISMA flow diagram in Figure 1.
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Figure 1. Study flow diagram.
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Included studies
The previous update of the Cochrane review (Bohlius 2006a) eval-
uated 57 studies with 9,353 participants. In the current update
we include a total of 91 studies with 20,102 participants. All in-
cluded trials were reported in English. Details are displayed in the
Characteristics of included studies table. For those 91 studies, 198
references were included, see details as described in “Referencing
of studies” in the Methods section.
Studies that were previously excluded and are now included
Four of the previously excluded studies are included in the current
update, due to the change in the iron supplementation rule: for
this update, studies are also included if they had different iron sup-
plementation policies between the different study arms (Blohmer
2011; Moebus 2007; Rosen 2003; Sweeney 1998). We had previ-
ously excluded another study by mistake, we have now included
this study (Gebbia 2003).
Studies that were previously included and are now excluded
We excluded two of the previously included studies (Henze 2002;
Vadhan-Raj 2004 ) because a substantial number of participants
underwent major surgical procedures during ESA treatment.
Studies that were previously ongoing and are now included
We included four studies that were previously ongoing (Aapro
2008; Antonadou 2001; Charu 2007; Pronzato 2010).
Updated data for already included studies
If new publications supplemented or updated information from
earlier sources, we added the new data and cited the new source
as the study name. This led to the following changes: we re-
placed Coiffier 2001 with Boogaerts 2003, Janinis 2003 with
Christodoulou 2009, EPO-CAN-15 with Goss 2005, N93 004
with Grote 2005, EPO-GBR-7 with Hoskin 2009,Machtay 2004
with Machtay 2007, Milroy 2003 with Milroy 2011, Savonije
2004 with Savonije 2005, GOG0109 with Thomas 2008, EPO-
CAN-20 with Wright 2007, we amended Razzouk 2004 with
Razzouk 2006, and Pronzato 2002 with Pronzato 2010.
Newly identified studies
Screening the references of other reviews on this subject, led to
the identification and inclusion of three new studies (Gebbia
2003;ML17616 2006;ML17620 2006 ).We included three stud-
ies (EPO-GER-20 IPD; Kotasek 2002 IPD; OBE/EPO-INT-03
IPD) that were previously unpublished and retrieved for the IPD
review (Bohlius 2009a; Bohlius 2009b). We identified 23 addi-
tional new studies that were published after the search for the
previous review was conducted. We included these studies in
the present update. From those, we had also included 11 in the
IPD review (Aapro 2008; Debus 2006 J&J 2007; Gordon 2008;
Hernandez 2009; Milroy 2011; Pirker 2008; Ray-Coquard 2009;
Smith 2008; Strauss 2008; Untch 2011˙1; Wilkinson 2006) and
we identified twelve from the literature search update (Engert
2010; Fujisaka 2011; Gupta 2009; Katakami 2008; Krzakowski
2008; Mystakidou 2005; Overgaard 2009; Suzuki 2008b; Tsuboi
2009; Tjulandin 2010; Tjulandin 2011; Winquist 2009).
Other changes
In the previous review (Bohlius 2006a), we had excluded studies
and study arms with very low ESA dosages, in the current update
we included all studies and study arms regardless of ESA dosage,
for example see Cazzola 1995.
Study population
Hb level:We grouped studies bymean or median baseline Hb level
at study entry. Thirty studies examined a study population with
meanormedianHbbelow10g/dL at study entry, 38had a baseline
Hb between 10 and 12 g/dL and 18 studies sought to prevent
anaemia, thus Hb at baseline was > 12 g/dL. Because of missing
information, five studies could not be categorizedDebus 2006 J&J
2004; EPO-GER-20 IPD; ML17620 2006; OBE/EPO-INT-03
IPD; P-174 J&J 2004). Trials that directly compared the outcomes
of initiating erythropoietin treatment at alternative Hb thresholds
were not included in the present review.
Disease:Fifty-nine studies analysed participantswith solid tumours
only, 12 studies included patients with haematological malignan-
cies only, two trials included exclusively patientswithMDS (Italian
1998; Thompson 2000) while 18 trials included patients with
both solid tumours and haematological malignancies.
Treatment:Themajority of participants received concomitant che-
motherapy, which was given in 63 studies. In seven studies par-
ticipants were treated with radiotherapy and in eight with ra-
diochemotherapy. In nine trials no concomitant anticancer ther-
apy was given. Finally, we categorized the type of anti-cancer ther-
apy administered as “unclear” in one study (Winquist 2009) and
three studies with less than 70% of patients given chemotherapy
as “other” (P-174 J&J 2004; Rose 1994; Rosenzweig 2004).
Age: All studies but one (Razzouk 2006) evaluated adult partici-
pants.
Intervention: All trials compared erythropoiesis-stimulating treat-
ment initiated at study entry (plus RBC transfusion if necessary)
with observation and transfusion of RBCs when the patient’s Hb
level fell below a defined threshold or at the discretion of the treat-
ing physician.
Study drug: Short-lasting erythropoietins (including epoetin alpha,
epoetin beta, epoetin theta) were administered in 76 studies and
darbepoetin in 15 studies.
Duration: Duration of study medication was up to nine weeks in
17 studies, between 12 and 16 weeks in 50 studies and more than
17 weeks in 21 studies. In three studies the duration of study drug
administration was unclear or not reported (EPO-GER-20 IPD;
EPO-INT-1 J&J 2004; OBE/EPO-INT-03 IPD).
Route of administration: In all but three studies erythropoietin was
administered subcutaneously. In two studies erythropoietin was
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given intravenously (Razzouk 2006;Wurnig 1996). Another study
compared intravenous with subcutaneous administration (Henke
1999).
More details are provided in the table Characteristics of included
studies.
Excluded studies
Overall, we excluded 227 trials, for reasons documented in the
Characteristics of excluded studies. Thirty studies were excluded
as ongoing trials (see next section) while one study was not re-
trievable.The largest groupwas excluded for not being randomised
controlled trials (98 studies). We excluded 48 studies because par-
ticipants of both study arms received ESAs, while we excluded 13
studies since they randomised less than 10 participants per study
arm, our current threshold for inclusion. We excluded two previ-
ously included studies (Henze 2002; Vadhan-Raj 2004) from this
update, since most of their participants underwent surgery during
the study; the same reason for exclusion was applied to another
eight studies. Three studies were excluded due to the participants
not having cancer, while three more due to the participants hav-
ing acute leukaemia. Finally, 21 studies were excluded for other
reasons, documented in the Characteristics of excluded studies.
Ongoing trials
Overall, we identified 30 studies that are currently ongoing.
For the previous Cochrane update, 29 trials were identified
as ongoing. Since then, five were completed and are included
in the present meta-analysis (Aapro 2008; Antonadou 2001;
Charu 2007; Pronzato 2010; Thomas 2008). We identified a
mistake in the ongoing trials of the previous version: namely
CDR0000068669 and EORTC 22996-24002 were in fact the
same study, now identified as Lambin 2006.Three of the pre-
viously ongoing trials are now excluded (Elsaid 2001; Miller
2004; Steensma 2011). Additionally, note that we were uncertain
whetherHThomas 1997 andRThomas 2002 are the same studies
as the included Thomas 2002.We did not contact the authors and
we, therefore, refer to these three documents as separate studies,
with the first two still considered as ongoing trials. The remaining
20 trials are still ongoing.
We newly identified another 10 trials ongoing. We had excluded
one (Gamucci 1993) in the previous Cochrane update and we
identified another six (Boehrer 2010;Delarue 2009;Gascon 2010;
Ghavamzadeh 2010; Liang 2009; Yousseff 2011) by the 2011
literature search. We identified the remaining three (Nitz 2008;
Park 1996 and Rexer 2006) by other sources.
Risk of bias in included studies
For risk of bias table see Figure 2.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study. If for a given study more than one reference was included we reported our judgement only for the main
reference and left the other references of the same study empty.
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Allocation
Randomisation and concealment of allocation.
All included studies were described by the authors as randomised.
For 27 studies we had some information on the methods used
for randomisation, for 64 studies details were unavailable or the
reporting was unclear. For 50 studies we judged the method for
concealing allocation of treatment to be adequate. In 41 studies
the method for allocation concealment could not be determined.
Blinding
Masking
Forty-six trials used a placebo control, 45 trials did not.
Incomplete outcome data
Most studies included intention-to-treat analyses in their reports,
or excluded less than 10% of the patients randomised in the study
from the analysis. However, the number of participants evaluated
in a study varied between the outcomes assessed. Therefore, for
each of the outcomes, we made an assessment as to whether or
not the analysis was based on intention-to-treat or excluded less
than 10% of the participants initially included. This information
is displayed in the specific outcomes section in RevMan.
Selective reporting
For the first version of the Cochrane review, we contacted first
authors to obtain unreported data on study design, participant
characteristics and selected outcome data. For 19 of the 27 trials
included in the first Cochrane review additional unpublished data
were provided by the authors or pharmaceutical companies (Abels
1993; Cascinu 1994; Case 1993; Cazzola 1995; Boogaerts Coiffier
2001; Dammacco 2001; Del Mastro 1997; Henry 1995; Italian
1998; Kurz 1997; Littlewood 2001; Oberhoff 1998; Osterborg
1996; Osterborg 2002; Rose 1994; Ten Bokkel 1998; Thatcher
1999; Thompson 2000; Throuvalas 2000). For the update of the
present review, authors of published reports were not contacted to
obtain missing information.
Publication bias
Funnel plot analyseswere performed to investigate publicationbias
or other biases and are reported in the specific outcome sections.
Reporting bias
No single outcome was reported consistently by all studies (N
= 91) included in this systematic review. Some outcomes were
estimated based on large proportions of the 91 studies and 20,102
participants included:
95% for overall survival (19,003/20,102), 79% for on-study mor-
tality (15,935/20,102), 80% for risk of transfusions (16,093/
20,102), 77% for risk of thromboembolic events (15,498/20,102)
and 58% for change in Hb (11,609/20,102). For other out-
comes, fewer participants were included in themeta-analyses: 36%
(7,228/20,102) for hypertension, 32% (6,413/20,102) for hae-
matologic response, 25% (5,012/20,102) for complete tumour re-
sponse, 25% (5,012/20,102) for number of units transfused and
22% (4,507/20,102) for thrombocytopenia/haemorrhage.
For some outcomes only small proportions of participants could
be evaluated, which questions the validity of the results achieved:
14% (2,890/20.102) for seizure, 12% (2,485/20,102) for rash.
Statistically significant differences between data taken from full
text publications, abstract publications and unpublished data were
found in the subgroups analyses for Hb response, Hb change, risk
for transfusions and number of units transfused.
Other potential sources of bias
For some studies more than one source of data was available (e.g.
unpublished data from the authors, FDA reports, IPD review). As
for intention-to-treat mentioned above, we recorded the source of
data separately for each outcome.
Effects of interventions
See: Summary of findings for the main comparison
Erythropoietin or Darbepoetin for patients with cancer
Primary outcomes
(1) Haematological response
We defined this binary outcome as the proportion of participants
with an increase in haemoglobin (Hb) level of 2 g/dL or more, or
increase in haematocrit of six percentage points or more, unrelated
to transfusion.
Overall, 31 trials including 6,413 participants were analysed.
Of those studies, 22 trials including 4,307 participants were in-
cluded in the previous Cochrane reviews (1985 to 2006). Nine
trials (N= 2,106) were newly identified and added to the anal-
ysis (Aapro 2008; Charu 2007; Milroy 2011; ML17616 2006;
ML17620 2006; Razzouk 2006; Suzuki 2008; Tjulandin 2010;
Tjulandin 2011). As some of the trials (Cazzola 1995; Hedenus
2002; Kotasek 2003; Osterborg 1996; Smith 2003; Suzuki 2008;
Tjulandin 2010) were split into subsets for analysis purposes, the
number of trials displayed is 46.
We observed haematological response in 2,050 out of 3,710 par-
ticipants in the erythropoietin and darbepoetin groups compared
with 434 of 2,703 in the control groups, corresponding to a risk
ratio (RR) for haematological response under the treatment with
20Erythropoietin or darbepoetin for patients with cancer (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
erythropoietin or darbepoetin of (RR 3.39; 95% confidence inter-
val (CI) 3.10 to 3.71). There was significant statistical heterogene-
ity between the trials (I²= 53%), indicating that variation between
trials in the magnitude of ESA effects on haematological response
was larger than what would be expected from chance alone. How-
ever, all studies indicated a beneficial effect of ESAs with regard to
haematological response. The funnel plot analysis was asymmetric
(P = 0.0015), suggesting that beneficial effects were over reported.
In seven studies (Cazzola 1995; Hedenus 2002; Kotasek 2003;
Osterborg 1996; Smith 2003; Suzuki 2008; Tjulandin 2010), two
or more epoetin dosages or preparations were compared with one
control group. Merging the active arms into one experimental
arm for each of those four studies did not influence the overall
result markedly (RR 3.42; 95% CI 3.12 to 3.74). Compared with
the previous review (RR= 3.43 (95% CI 3.07 to 3.84, 22 trials,
N = 4,307, Bohlius 2006a) neither the point estimate, nor the
confidence interval have changed substantially.
To identify the source(s) of heterogeneity, subgroup analyses were
performed. Univariate analyses identified significant differences
(P < 0.05) between subgroups for baseline Hb level, age, type of
anti-cancer therapy, iron supplementation, duration of treatment,
placebo control and type of publication. The backward selection
resulted in a multivariate model containing the covariates Hb at
baseline, age and iron supplementation. The final model is pre-
sented in Additional Table 1. For each combination of Hb at base-
line, age and type of iron supplementation the risk ratio can be
calculated from Table 1. For example, the logarithm of the risk
ratio for a trial including adults with Hb between 10 and 12 g/dL
at baseline and receiving iron as necessary is Intercept + adults +
Hb 10-12 g/dL + iron given as necessary = 0.81 + 0.62 + 0.35 =
1.78. Accordingly, the risk ratio is 5.93.
We calculated numbers needed to benefit (NNTB) for several
hypothetical baseline risks. In a populationwith an underlying risk
[likelihood] of 6% to achieve haematological response, theNNTB
would be 6.97 (95% CI 6.15 to 7.94); thus, about seven patients
would need to be treated to achieve one additional Hb responder.
In a population with an underlying risk of 16% the NNTBwould
be 2.62 (95% CI 2.31 to 2.98); thus, about three patients would
need to be treated to achieve one additional Hb responder. In a
population with a hypothetical baseline risk of 30% the NNTB
would be 1.39 (95% CI 1.23 to 1.59); thus, one to two patients
would need to be treated to achieve one additional Hb responder.
Overall, the analysis confirms prior evidence that ESAs yield
haematological response in most but not all patients with malig-
nant disease.
(2) Change in haemoglobin level from baseline until end of
study
Fifty-six studies including 11,609 participants reported the hb
change from the start until the end of the study. Fifteen of those
were included in the 2006 update (Bohlius 2006a). As some of
the trials hadmultiple experimental arms (Cazzola 1995;Hedenus
2002; Henke 1999; Kotasek 2003; Krzakowski 2008; Kunikane
2001; Osterborg 1996; Smith 2003; Ten Bokkel 1998; Tjulandin
2010), the number of trials displayed in MetaView is 75. For this
update, we included not only studies that reported the mean Hb
change from baseline, but also studies that reported baseline and
end of treatment (EOT) Hb values only, see Methods section.
Themeta-analysis showed that themean difference was 1.57 (95%
CI 1.51 to 1.62), showing a statistically significant difference in
favour of treatment. There was, however, substantial heterogene-
ity between the trials (test for heterogeneity I² = 87%), although
all but one study indicated a beneficial effect of ESAs with regard
to Hb change. Funnel plot analysis did show some evidence for
significant asymmetry (P = 0.037), suggesting that beneficial find-
ings were over reported.Merging each multi-arm trial into a single
data set (i.e. a two-arm trial) did not change the results (mean
difference (MD) 1.56, 95% CI 1.51 to 1.62).
Examining the single studies, most of them reported a statistically
significant change in Hb level for participants treated with ery-
thropoietin or darbepoetin. A few studies, however, did not report
a significant effect on Hb change (Cazzola 1995; Leyland-Jones
2005; Razzouk 2006). Overall, the MD ranged from (MD -0.06;
95% CI -1.77 to 1.65, Cazzola 1995a) to (MD 3.30; 95% CI
1.13 to 5.47, Henke 1999c).
To identify the source(s) of heterogeneity, we performed subgroup
analyses. Univariate analyses identified significant differences be-
tween subgroups for baselineHb level, differentmalignancies, age,
type of anti-cancer therapy, short-lasting versus long-lasting ESA,
duration of ESA treatment, iron supplementation, masking, in-
tention-to-treat and type of publication. The backward selection
resulted in a multivariate model containing the covariates type of
ESA and age. The final model is presented in Additional Table 2
For each combination of type of ESA and age (adults or children)
the mean difference can be calculated from Table 2. For example,
the mean differences for a trial in adult patients receiving short-
lasting ESA is = Intercept + short lasting ESA = 1.15 + 0.56 = 1.71.
Overall, there is a statistically significant effect of ESAs on Hb
change; compared with controls patients receiving ESAs achieve
on average an increase of Hb levels of 1.57 g/dL from baseline to
end of treatment (between 1.51 and 1.62 g/dL in 95%of patients).
(3) Patients receiving RBC transfusions
Overall, the updated analysis included70 trialswith 16,093 partic-
ipants. Of those, 42 trials with 6,510 participants were included in
the previous Cochrane review (Bohlius 2006a). Thirty trials were
newly identified and added to the analysis. (Aapro 2008; Blohmer
2011; Charu 2007; Engert 2010; EPO-INT-3 J&J 2004; Fujisaka
2011; Gebbia 2003; Gordon 2008; Goss 2005; Grote 2005;
Gupta 2009;Hernandez 2009; Katakami 2008; Krzakowski 2008;
Leyland-Jones 2005; Milroy 2011;Moebus 2007; O’Shaughnessy
2005; Pronzato 2010; Pirker 2008; Ray-Coquard 2009; Rosen
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2003; Smith 2008; Strauss 2008; Tjulandin 2010; Tjulandin
2011; Tsuboi 2009; Untch 2011˙1; Wilkinson 2006; Wright
2007). Two studies that were included in the previous review
(Henze 2002; Vadhan-Raj 2004 ) were excluded from the current
version because study participants received major surgery during
ESA treatment. As some trials with multiple experimental arms
were split into subsets (Cazzola 1995; Hedenus 2002; Kotasek
2003; Krzakowski 2008; Kunikane 2001; Osterborg 1996; Smith
2003;Ten Bokkel 1998; Thatcher 1999; Tjulandin 2010) the
number of trials displayed is 88.
The risk ratio to receive red blood cell transfusions was statistically
significantly reduced in the study groups receiving ESAs by 35%
(RR 0.65, 95%CI 0.62 to 0.68). There was statistically significant
heterogeneity between the trials (I² = 60%) indicating that vari-
ation in the effect of ESAs between trials was larger than would
have resulted from chance alone. However, the majority of studies
indicated a beneficial effect of ESAs with regard to the need of
red blood cell transfusions. A funnel plot analysis showed signif-
icant asymmetry between the studies (P < 0.00001), suggesting
that beneficial findings were over reported. Ten studies compared
two or more ESA dosages/formulations with one control group.
Merging the active arms of each study into a single experimental
arm and comparing it to the study’s entire control group did not
substantially change the overall result (RR 0.65; 95% CI 0.62 to
0.68). Compared with the previous version of this review, the re-
sults did not change markedly (Bohlius 2006a: RR 0.64, 95% CI
0.60 to 0.68, 42 trials, N = 6,510).
To identify the source(s) of heterogeneity, we performed subgroup
analyses. Univariate analyses identified significant differences (P <
0.05) between subgroups for baselineHb level, differentmalignan-
cies, age, type of anti-cancer therapy, iron supplementation, con-
cealment of allocation, placebo control, intention-to-treat analy-
sis and type of publication. The backward selection resulted in a
multivariate model containing the covariates Hb at baseline and
underlyingmalignancy. The final model is presented in Additional
Table 3. For each combination ofHb level and type of malignancy,
the risk ratio can be calculated from Table 3. For example, the
logarithm of the risk ratio for a trial in patients with solid tumours
and baseline Hb level 10-12 g/dL is = Intercept + solid + Hb 10
to 12 g/dL = -0.22 + -0.39 + -0.15 = -0.76. Accordingly, the risk
ratio is 0.47.
To estimate the absolute effectiveness of erythropoietin, we ap-
plied the overall risk ratio of (RR 0.65; 95% CI 0.62 to 0.68) to
a range of plausible values for the baseline-risk. In a hypothesised
population with an estimated risk of 30% to require RBC trans-
fusions the NNTB is 9.52 (95% CI 8.77 to 10.42): about nine to
10 patients would need to receive ESAs to spare one patient from
RBC transfusion. In a hypothesised population with an estimated
risk of 50% to require RBC transfusions, the NNTB is 5.71 (95%
CI 5.26 to 6.25): about five to six patients would need to receive
erythropoietin to spare one patient from RBC transfusion. In a
hypothesised population with an estimated risk of 70% to require
RBC transfusions the NNTB is 4.08 (95% CI 3.76 to 4.46). In
this setting about four patients would need to receive erythropoi-
etin to spare one patient from RBC transfusion.
Overall, the data confirm results from prior analyses that ESAs
reduce the risk ratio to receive RBC transfusions in patients with
malignant disease. The effect size might be influenced by the un-
derlying disease.
(4) Number of red blood cell units transfused
Overall, 19 studies evaluating a total of 4,715 patients are included
in this update. Of those, 14 studies with 2,353 patients were in-
cluded in the previous review (Bohlius 2006a). Five trials with
2,362 participants were newly identified and added to the analy-
sis (Engert 2009; Grote 2005; Hernandez 2009; Savonije 2005;
Thatcher 1999). As four multi-arm studies were split into sub-
sets (Ten Bokkel 1998; Thatcher 1999; Osterborg 1996; Cazzola
1995), the number of studies displayed in Meta-View is 25.
The overall mean difference showed a statistically significant ben-
efit for participants receiving ESAs (MD -0.98; 95% CI -1.17 to -
0.78): the ESA group received on average 0.98 units of blood less
per participant than the control group, who received an average
of 3.65 units. Overall, there was moderate statistical heterogeneity
between the trials (I² = 30%). All but one study indicated a reduced
need of red blood cell units in patients receiving ESAs compared
to controls. A funnel plot analysis did not show statistically signif-
icant asymmetry (P = 0.558). In four studies, two or more differ-
ent ESA dosages were compared with one control group (Cazzola
1995; Osterborg 1996; Ten Bokkel 1998; Thatcher 1999). Merg-
ing the active arms of each study into a single experimental arm
and comparing each to that study’s entire control group did not
substantially change the overall result (MD -0.98; 95%CI -1.17 to
-0.78). Compared with the previous review (Bohlius 2006a: MD
-1.05; 95% CI -1.32 to -0.78, 14 trials, N = 2,353), the overall
result did not change markedly.
Subgroup analyses were conducted for all the comparisons and
were found to be statistically significant for different age groups
(test between subgroups P = 0.02), duration of ESA therapy (test
between subgroups P = 0.03) and type of publication (test between
subgroups P = 0.04). However, the absolute differences between
subgroups were small.
Overall, the analysis suggests that ESAs modestly but statistically
significantly reduces the number of RBC units transfused per pa-
tient.
(5) Overall survival
We defined overall survival as longest follow-up available. Over-
all survival data were available from a total of 78 trials includ-
ing 19,003 participants. Of those, 42 trials including 8,167 par-
ticipants were included in the 2006 Cochrane review (Bohlius
2006a). Of these, we excluded one study which we had in-
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cluded in the previous review Vadhan-Raj 2004 from the cur-
rent version because study participants received major surgery
during ESA treatment. For 30 previously included studies data
were updated with newly available information from the indi-
vidual patient meta-analysis (Bohlius 2009a; Bohlius 2009b).
Thirty-seven trials were newly identified and added to the anal-
ysis Aapro 2008; Antonadou 2001; Blohmer 2011; Charu 2007
IPD; Christodoulou 2009; Debus 2006 IPD; Engert 2010;
EPO-GER-20 IPD; Fujisaka 2011; Gordon 2008 IPD; Gupta
2009; Hernandez 2009; Huddart 2002 IPD; Kotasek 2002 IPD;
Krzakowski 2008; Milroy 2003 IPD; ML17616 2006; ML17620
2006; Moebus 2007 IPD; Mystakidou 2005; OBE/EPO-INT-03
IPD; Overgaard 2009; Pirker 2008 IPD; Pronzato 2010 IPD;
Quirt 1996 IPD; Ray-Coquard 2009 IPD; Rosen 2003; Strauss
2008 IPD; Strauss 2008 IPD; Sweeney 1998; Thomas 2002 IPD;
Tjulandin 2010; Tjulandin 2011; Tsuboi 2009; Untch 2011˙2;
Wilkinson 2006 IPD; Winquist 2009. Two studies (Krzakowski
2008; Tjulandin 2010) were split into subsets and four studies
(Cascinu 1994; Hedenus 2002; Kurz 1997; Sweeney 1998) re-
ported zero events; as a result the overall number of studies dis-
played in Meta-View is 80.
The overall estimate is a hazard ratio (HR) of 1.05 (95% CI 1.00
to 1.11) in favour of placebo/no treatment. The heterogeneity
between the trials was low, with an I² of 21%. Funnel plot analysis
did not suggest asymmetry (P = 0.92).
In two studies (Krzakowski 2008; Tjulandin 2010), two different
ESA dosages or formulations were compared with one control
group. Merging the active arms into one single experimental arm
compared with the entire control group did not influence the
overall result (HR 1.05; 95% CI 1.00 to 1.11).
Although no statistically significant heterogeneity was apparent,
we conducted subgroup analysis to explore the underlying clinical
heterogeneity to assess the influence of clinical differences between
the studies. Tests for heterogeneity between subgroups showed
statistically significant differences for the analyses of baseline Hb
levels (P = 0.02), iron supplementation (P = 0.005) and intention-
to-treat analysis (P = 0.02). However, when excluding studies with
unclear values for the subgroup analyses conducted, none of the
analyses remained statistically significant. Statistically significant
differenceswere not detected for any of the other subgroup analyses
conducted.
We further investigated how single large studies influenced the
overall results. There was no single study that contributed more
than 10% weight to the overall analysis. There were four studies
which each contributed more than 5% weight to the analysis (
Aapro 2008 IPD; Debus 2006 IPD; Pirker 2008 IPD; Smith
2008 IPD). Taken together these four studies contributed 27%
weight to the overall analysis. Of those, two suggested a negative
impact on survival (Aapro 2008 IPD; Smith 2008 IPD) and two
suggested a beneficial impact on overall survival (Debus 2006
IPD; Pirker 2008 IPD). Exclusion of the two unfavourable studies
resulted in an HR of 1.04 (95% CI 0.98 to 1.10). Exclusion of
the two favourable studies resulted in an HR of 1.08 (95% CI
1.02 to 1.14). We also investigated the effects of adjusted and
unadjusted data where different results were reported (Henke
2003; Littlewood 2001). Using adjusted instead of unadjusted
data for the Henke 2003 and Littlewood 2001 studies did not
change the overall result (HR 1.05, 95%CI 1.00 to 1.11; adjusted
data).
In summary, there is no evidence that erythropoietin or darbepo-
etin improves overall survival. Based on the data available it was
not possible to clearly identify a subgroup of participants that was
at higher or lower risk to experience detrimental effects fromESAs.
(6) On-study mortality
We defined on-study mortality as deaths occurring up to 30 days
after the active study period. Such data were available for 78 stud-
ies including 15,935 patients. Two studies (Krzakowski 2008;
Tjulandin 2010) were split into subsets and eight studies (Cascinu
1994;DelMastro 1997;Hedenus 2002; Kurz 1997;Moebus 2007
IPD; Strauss 2008 IPD; Sweeney1998;Untch2008 IPD) reported
zero events; as a result, the overall number of studies displayed in
Meta-View is 72.
The overall estimate showed an HR of 1.17 (HR 1.17; 95% CI
1.06 to 1.29) in favour of control. There was no heterogeneity
between the studies (I² = 0%). A funnel plot analysis did not show
evidence for significant asymmetry (P = 0.693).
Although there was no evidence for any statistical heterogeneity
between the studies (I² = 0%), we conducted predefined subgroup
analyses. Univariate analysis identified statistically significant dif-
ferences only for intention-to-treat analyses (P = 0.04). No robust
statistically significant differences were identified for any of the
other subgroups of interest (i.e. baseline Hb level, type of malig-
nancy, duration of treatment, type of anti-cancer therapy, age, iron
supplementation, type of publication, epoetin versus darbepoetin,
type of data, concealment of allocation and masking).
We conducted a sensitivity analysis including eight additional
studies. For seven of those (Antonadou 2001; Blohmer 2011;
Christodoulou 2009; Engert 2009; Gupta 2009; Overgaard 2009;
Winquist 2009), we calculated on-study mortality from Kaplan
Meier curves for overall survival and for the remaining study
(Tsuboi 2009), we used long-term mortality data. This sensitivity
analysis yielded similar results; with an HR of 1.16 (95% CI 1.05
to 1.27, 78 trials, N=19,018).
We further investigated how single large studies influenced the
overall results. There were two studies (Leyland-Jones 2005 IPD;
Smith 2008 IPD) which each contributed more than 10% weight
to the analysis. Taken together these four studies contributed 28%
weight to the overall analysis. Both studies suggested a negative
impact on mortality. Exclusion of these two unfavourable studies
resulted in an HR of 1.09 (95% CI 0.97 to 1.23).
Overall, there is evidence that ESA treatment increasesmortality in
cancer patients during active study period comparedwith controls.
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Secondary outcomes
(7) Tumour response (complete response)
Tumour response (complete response) data were available from a
total of 15 trials including 5,012 participants. Of these, 11 trials
were included in the previous Cochrane review (Bohlius 2006a).
Two previously included studies (Bamias 2003; Vadhan-Raj 2004)
were excluded from the current update since they did not explicitly
state that they evaluated complete tumour response. We replaced
previous data with updated study results where available (Grote
2005; Hoskin 2009;Machtay 2007).We included four additional
studies published since 2006 (Engert 2009; Strauss 2008; Untch
2011˙1; Wilkinson 2006). Since two multi-arm trials were split
into subsets (Cazzola 1995; Ten Bokkel 1998) the number of trials
displayed in MetaView is 19.
The overall estimate shows a risk ratio of 1.02 (RR 1.02; 95% CI
0.98 to 1.06) that was not statistically significant. There was no
significant heterogeneity between the trials (I² = 0%). Funnel plot
analysis did not show strong evidence for asymmetry (P = 0.149).
Merging the multi-arm trial into one data set did not change the
overall result (RR1.02; 95%CI 0.98 to 1.06, 15 trials). Compared
to the previous report (RR fixed-effect: 1.12; 95%CI 1.01 to 1.23,
random-effect: 1.09, 95% CI 0.94 to 1.26, 13 trials , N = 2833),
the updated review shows more conservative results. Only five of
the included studies (Engert 2009; Hoskin 2009 GBR-7 FDA
04; Machtay 2007; Strauss 2008; Untch 2011˙1) met our specific
quality criteria for assessment of tumour response (see Methods
section). For the five studies meeting these criteria, the risk ratio
was 0.99 (95% CI 0.95 to 1.02, five studies, N=2,476). For the
remaining 10 studies with low quality the point estimate for RR
suggested there might be a benefit for patients receiving ESAs,
but the confidence interval did not reach statistical significance
(RR 1.15, 95% CI 0.98 to 1.36, 10 trials, N = 2,536), with some
evidence for a difference between subgroups tested (P = 0.07).
In conclusion, the data available suggest that ESAs do not have a
beneficial effect on tumour control. The data are insufficient to
exclude detrimental effects.
(8) Changes of health-related quality of life
Twenty-three studies including 5,584 patients reported results on
QoL, asmeasuredwith FACT-F, FACT-An20 or FACT-An47. In
order to perform a meta-analysis for the FACT measures, we had
to extract means and SDs. In cases where no numerical data were
given, we calculated means and/ or SDs from graphs or figures
(Boogaerts 2003; Charu 2007; Gordon 2008; Hedenus 2003). In
one trial (Christodoulou 2009) where SDs were reported sepa-
rately for platinumandnonplatinumchemotherapy,we calculated
a pooled SDbypooling the SDs of the twodifferent subgroups. For
the same study we also imputed the mean and the SD for changes
between baseline and end of treatment, by using a correlation co-
efficient. For one study with missing SDs (Littlewood 2001) and
no other way of imputing them, we used the SDs that have been
already published by another meta-analysis (Tonelli 2009). Ac-
cording to the authors of this meta-analysis, the SDs were calcu-
lated as follows: for FACT-fatigue they imputed the SD using the
baseline SD reported in another publication for the same study
(Fairclough 2003) and for the FACT-An the SD was imputed us-
ing the average of the SDs from other studies who reported a SD
for FACT-An (personal communication with Dr. Lloyd, Febru-
ary 2010). For two further studies (Kotasek 2003; Vansteenkiste
2002), we used the mean and SDs reported in a meta-analysis
by Minton and colleagues (Minton 2008). These data were not
available in the publications and were obtained by the authors
of the meta-analysis from the authors of the original studies or
the pharmaceutical companies (personal communication with Dr.
Minton, February 2010). To account for all these calculations, we
conducted a sensitivity analysis, differentiating between the studies
for which we had to impute data in some way and those for which
we did not impute any data. One study (Christodoulou 2009)
reported results separately for participants treated with platinum-
based chemotherapy and those treated with non-platinum-based
chemotherapy. It is therefore included in both the platinum and
non-platinum chemotherapy subgroups for all the QoL outcomes
below.
a) FACT-F 13 sub-scale
A total of 18 studies (4,965 patients) reported data for this out-
come. The MD was 2.08 (95% CI 1.43 to 2.72). Heterogeneity
between the included studies was moderate (I² = 53%). A funnel
plot analysis showed significant asymmetry (P = 0.02772) with
over reporting of studies that showed beneficial effects of ESAs.
The beneficial effect of ESAs on QoL measured with FACT-F 13
was significantly larger in patients receiving chemotherapy than in
those receiving radiotherapy or no anticancer therapy (P<0.0001).
Patients with Hb levels below 12 g/dL also had significantly (P =
0.0025) larger effects compared to patients with baseline Hb level
> 12 g/dL, however, only one trial using radiotherapy hadHb levels
> 12 g/dL at baseline (Hoskin 2009). The effect of epoetin was
significantly (P < 0.0004) different fromdarbepoetin, however, the
association is potentially confounded by three darbepoetin trials
without anticancer therapy (Charu 2007; Gordon 2008; Smith
2008). The observed effect was larger in unblinded trials (MD
3.76, 955CI2.60 to 4.92) comparedwith double-blind trials (MD
1.33, 95% CI 0.56 to 2.10, P = 0.0006). Significant differences
were also observed for age group (adults versus >70% non-elderly
adults, P = 0.008). The backward selection resulted in a model
containing the covariate type of ESA formulation, see Table 4.
The MD for a trial in patients receiving short-lasting ESAs is =
Intercept + short lasting ESA = 1.09 + 2.20 = 3.29. However, in
these analyses single studies were compared to groups of studies
and thus results are not readily interpretable.
One trial (Tsuboi 2009) reported two different sets of scores for
the control group: in one set they substituted the missing data of
two patients by the maximum decrease in score for all patients.
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The other set of results did not include data for these two patients.
We used the scores without the substitution for the main analysis
and we conducted a sensitivity analysis using the scores with the
substituted data. The results did not change much, with the MD
being 2.10 (95% CI 1.46 to 2.75, 18 studies, N = 4,967) and
remained statistically significant (P < 0.00001).
Overall, it appears that there is an effect on fatigue-related symp-
toms for patients treated with erythropoietin or darbepoetin com-
pared with controls; this effect, however, did not reach the thresh-
old for a clinically important difference defined as 3.0 (Cella2002).
b) FACT-An 20
Six studies were included for this outcome (Chang 2005;
Christodoulou 2009; Littlewood 2001; O’Shaughnessy 2005;
Savonije 2005; Wright 2007). The estimated MD is 6.14 (95%
CI 4.55 to 7.73, N = 1,085). There was no evidence for statistical
heterogeneity between the studies (I² = 0%). A funnel plot analysis
was not done, because less than 10 studies were included in this
analysis.
Subgroup analyses did not identify any significant differences in
the magnitude of effect between the different subgroups. Of note,
FACT-An 20 improvements were seen across all Hb baseline sub-
groups (Hb < 10, 10 to 12 and > 12 g/dL).
Overall, the effects of ESAs on fatigue- and anaemia-related symp-
toms appear to be beneficial and the difference between groups
reaches both statistical and clinical significance (clinically impor-
tant difference defined as four to five), however only six studies
were included in this analysis.
c) FACT-An Total 47
Nine studies, including 1,815 participants, reported data for this
outcome. The estimated MD is 6.92 (95% CI 4.59 to 9.25). As
onemulti-arm study (Krzakowski 2008) reported results separately
for each arm, the number of studies appearing in Metaview is
10.Heterogeneity between the studies was quite high (I² = 85%).
A funnel plot analysis was not done, because less than 10 trials
were included in this analysis. Merging the two arms of the multi-
arm study mentioned above in one data set did not change the
results (MD 6.92; 95% CI 4.59 to 9.25, nine studies, N = 1,815)
or heterogeneity markedly (I² = 87%).
One study (Mystakidou 2005) reported an unusually high change
for the treatment group (a mean change of 43.3 when the average
mean change from all the other studies is 5.14). We, therefore,
conducted a sensitivity analysis in which we excluded this study.
The results are indeed different than the original analysis with a
MD of 3.46 (95% CI 0.96 to 5.96, eight studies, N = 1,715). The
statistical heterogeneity between the studies almost disappeared
(I² = 0%). The results, however, remained statistically significant
(P = 0.007).
We conducted sub-group analysis that revealed the following sub-
groups as having significantly different magnitudes of ESA effect
between each other: imputed versus non-imputeddata (P =0.005),
baseline Hb level (P < 0.0001), type of anti-cancer therapy (P <
0.0001), duration of ESA treatment (P < 0.0001) and ITT analysis
(P = 0.01). The backward selection resulted in a model containing
the covariate type of anticancer therapy, see Additional Table 5.
However, differences can also be explained by the study conducted
by Mystakidou 2005 (see paragraph above), when removing this
study no significant differences between subgroups were evident
(data not shown).
Overall, there is a statistically significant difference between pa-
tients treated with ESAs and controls when combining QoL pa-
rameters and fatigue- and anaemia-related symptoms, which is
however, most likely not clinically important.
(9) Adverse events
(9.1) Thromboembolic events
Data from thromboembolic complications were available from a
total of 57 trials, including15,498participants. As threemulti-arm
trials (Osterborg 1996; Ten Bokkel 1998; Thatcher 1999) were
split into subsets and four studies reported zero events (Cascinu
1994; Gupta 2009; P-174 J&J 2004; Thatcher 1999a), the num-
ber of studies displayed is 60. Thirty-five studies including 6,769
participants were included in the 2006 update of the Cochrane
review (Bohlius 2006a), results for 23 studies were newly iden-
tified (Aapro 2008; Blohmer 2011; Charu 2007 Amgen 2007;
Debus 2006 J&J 2007; Engert 2009; Fujisaka 2011; Gordon
2008; Gupta 2009; Hedenus 2003 FDA 2007; Hernandez 2009;
Milroy 2011; Moebus 2007 J&J 2007; Overgaard 2009; Pirker
2008; Pronzato 2010; Ray-Coquard 2009; Smith 2008; Strauss
2008; Tjulandin 2011; Tsuboi 2009; Untch 2011˙1; Wilkinson
2006; Winquist 2009). We removed one study from the analy-
sis because a substantial number of participants underwent major
surgical procedures during ESA treatment (Vadhan-Raj 2004).
The overall risk ratio to suffer thromboembolic complications was
increased by 52% for patients receiving ESAs (RR 1.52; 95% CI
1.34 to 1.74). There was no significant statistical heterogeneity
between the trials (I² = 0%). A funnel plot analysis revealed a sig-
nificant asymmetry (P = 0.02137), suggesting that harmful events
(in this case thrombotic event) have been over reported. Merging
the multi-arm trials into one data set, did not change the results
(RR 1.53; 95% CI 1.34 to 1.74). Compared with the results from
the previous Cochrane review (RR 1.67; 95% CI 1.35 to 2.06,
35 trials, N = 6,769, Bohlius 2006a), results are similar. Subgroup
analyses for predefined variables did not show robust evidence for
statistically significant differences in magnitude or direction of the
ESA effect between any of the subgroups tested (e.g. baseline Hb
level, type of malignancy, duration of treatment, type of anti-can-
cer therapy, age, iron supplementation, type of publication, epo-
etin versus darbepoetin, type of data, concealment of allocation
and masking).
We calculated numbers needed to harm (NNTH) for several hy-
pothetical baseline risks. In a population with an underlying risk
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of 2% the NNTH would be 96 (95% CI 68 to 147), thus one
thromboembolic complication would occur for about every 96
patients treated. In a population with an underlying risk of 5% the
NNTHwould be 38 (95%CI 27 to 59), thus for every 38 patients
treated with ESAs one additional thromboembolic complication
might happen. In a population with a hypothetical baseline risk of
10% the NNTH would be 19 (95% CI 14 to 29), thus for every
19 patients treated one additional thromboembolic complication
may happen.
In conclusion, the data available for the present analysis confirm
and strengthen conclusions from the prior versions of this review
that treatmentwithESAs increases the risk of thrombosis or related
complications.
(9.2) Hypertension
Hypertension data were available from a total of 31 trials including
7,228 participants. Of these trials, 16 including 2,263 randomised
participants were included in the updated Cochrane review of
2006 (Bohlius 2006a), for 15 studies Fujisaka 2011;Gordon2008;
Hernandez 2009; Hoskin 2009; Krzakowski 2008; Milroy 2011;
Osterborg 2002; Pirker 2008; Razzouk 2006; Savonije 2005;
Smith 2008; Tjulandin 2010; Tjulandin 2011; Tsuboi 2009;
Wilkinson 2006 datawere newly identified. As six of the trials were
split into subsets (Krzakowski 2008; Kunikane 2001; Osterborg
1996; Ten Bokkel 1998; Thatcher 1999; Tjulandin 2010) and
two trials reported zero events (Cascinu 1994; Iconomou 2003)
the number of trials displayed in MetaView is 37.
The risk ratio to develop hypertension for erythropoietin-treated
participants was increased by 30% (fixed-effect model RR 1.30;
95%CI 1.08 to 1.56), reaching statistical significance (P = 0.006).
Using the random-effects model, however, the result was not sta-
tistically significant (RR1.12, 95%CI 0.94 to 1.33). There was no
statistical heterogeneity between the trials (I² = 0%). A funnel plot
analysis revealed significant asymmetry (P value < 0.001), suggest-
ing that harmful events (in this case hypertension) have been over
reported. Merging the different arms of the multi-arm trials did
not change the overall result (RR 1.31, 95%CI 1.09 to 1.58). The
updated results are similar to the previous Cochrane review (RR
1.24; 95% CI 1.00 to 1.54, 16 trials, N = 2,263 Bohlius 2006a).
One single study (Rose 1994) contributed 40% weight to this
analysis. Excluding this study, the effect of ESAs on hypertension
increased: fixed-effect: RR 1.52; 95%CI 1.18 to 1.97, random-ef-
fects: RR 1.40; 95% CI 1.07 to 1.83. For another trial, both pub-
lished and unpublished data were available (Dammacco 2001).
In the published sources 3/69 participants in the erythropoietin
group and 1/76 participants in the control group were reported
to suffer from hypertension. In the unpublished study report 43/
69 participants in the erythropoietin group and 36/76 in the con-
trol group had hypertension. Including these data instead of the
published numbers did not change the overall results significantly,
(fixed-effect model: RR 1.29; 95% CI 1.10 to 1.52), random-ef-
fects model: RR 1.16; 95% CI 1.00 to 1.35).
We calculated numbers needed to harm for several hypothetical
baseline risks. In a population with an underlying risk of 2% the
NNTH would be 167 (95% CI 89 to 625), thus one patient
would be affected with hypertension for about every 167 patients
treated. In a population with an underlying risk of 5% theNNTH
would be 67 (95% CI 36 to 250), thus for every about 67 patients
treated with ESAs one additional episode of hypertension might
happen. In a population with a hypothetical baseline risk of 10%
the NNTH would be 33 (95% CI 18 to 125), thus for every
about 33 patients treated, one additional hypertension episode
may happen.
Overall, the data available in this analysis provide suggestive but
not robust evidence, that ESAs in the treatment of cancer patients
may increase the risk ratio to suffer from hypertension.
(9.3) Haemorrhage/Thrombocytopenia
Haemorrhage/thrombocytopenia data were available from a total
of 21 trials including 4,507 participants. Of these trials, 10 includ-
ing 1,488 randomised participants were included in the update
of the Cochrane review in 2006 (Bohlius 2006a). Eleven addi-
tional trials Fujisaka 2011; Gebbia 2003; Goss 2005; Gupta 2009;
Milroy 2011; Pirker 2008; Savonije 2005; Strauss 2008; Tsuboi
2009; Untch 2011˙1; Witzig 2005) including 3,019 participants
were added for this update. As three of the trials were split into sub-
sets (Kunikane 2001; Osterborg 1996; Thatcher 1999) and three
trials report zero events (Cascinu 1994; Gupta 2009; Osterborg
1996b), the number of trials displayed in MetaView is 24.
The risk ratio to develop thrombocytopenia was increased for ery-
thropoietin-treated participants (RR 1.21; 95% CI 1.04 to 1.42),
reaching statistical significance (P = 0.01). When using the ran-
dom-effects model, the results were also statistically significant
(RR 1.18, 95% CI 1.02 to 1.36). There was no statistical hetero-
geneity between the trials (I² = 0%). The funnel plot analysis did
not show a significant asymmetry (P = 0.698). Results are similar
to the previous review (RR = 1.13, 95 % CI 0.08 to 1.60, 10
trials, N = 1,488 Bohlius 2006a), however, the larger number of
included studies and patients increased statistical power and the
updated result reached statistical significance. Merging the arms
of the multi-arm trials mentioned above in one data set did not
substantially change the results (RR 1.21, 95% CI: 1.04 to 1.41).
Subgroup analyses were not performed.
We calculated numbers needed to harm for several hypothetical
baseline risks. In a population with an underlying risk of 2% the
NNTH would be 238 (95% CI 122 to 1,250), thus one patient
would develop thrombocytopenia or haemorrhage for about every
238 patients treated. In a population with an underlying risk of
5% the NNTH would be 95 (95% CI 49 to 500), thus for about
every 95 patients treated with ESAs one additional case of throm-
bocytopenia or haemorrhage might happen. In a population with
a hypothetical baseline risk of 10% the NNTHwould be 48 (95%
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CI 24 to 250), thus for every 48 patients treated one additional
case of thrombocytopenia or haemorrhage might occur.
Overall, there is some evidence, that ESAs may increase the risk
for thrombocytopenia/haemorrhage.
(9.4) Rash, Irritation, Pruritus
Data were available from a total of 16 trials including 2,485 partic-
ipants. Of those, eight trials with 675 participants were included
in the 2006 update (Bohlius 2006a). Data from eight more trials
including 1,810 participants were added for this update. As two of
the trials were split into subsets (Osterborg 1996; Thatcher 1999)
and two trials reported zero events (Gupta 2009; Kurz 1997) the
number of trials in MetaView is 18.
Overall, 53 events of skin rash, irritation or pruritus were reported
in the erythropoietin group (N=1,359) and 27 cases in the control
group (N=1,126) , resulting in a risk ratio of 1.49 (95%CI 0.99 to
2.24). There was no significant heterogeneity between the studies
(I² = 0%).Merging the different subsets of themulti-arm trials into
one did not change the results (RR1.50, 95% CI 1.00 to 2.27).
The funnel plot analysis did not show a significant asymmetry (P
= 0.745). Further sensitivity analyses were not done. Compared
with the previous Cochrane review (Bohlius 2006a), results are
similar (RR 1.17; 95% CI 0.63 to 2.18, eight trials, N = 675
Bohlius 2006a). Based on the data available there is insufficient
evidence to conclude that erythropoietin increases the risk of skin
reactions.
(9.5) Seizures
Data on seizures were available from eight trials including 2,890
participants (Cascinu 1994; Case 1993; Gordon 2008; Henry
1995;Hernandez 2009; Pirker 2008; Savonije 2005; Smith 2008).
Three of those trials (Cascinu 1994; Case 1993; Henry 1995)
including 389 participants were included in the 2006 version of
the Cochrane review (Bohlius 2006a), data from five further tri-
als including 2,501 participants have been added to this update
(Gordon 2008; Hernandez 2009; Pirker 2008; Savonije 2005;
Smith 2008. Overall, 19 events of seizure were reported in the ery-
thropoietin group (N=1,583) and 21 events in the control group
(N = 1,307), resulting in a risk ratio of 0.77 (95% CI 0.42 to
1.41). There was no significant statistical heterogeneity between
the trials (I² = 3%). Overall, there was no evidence for significant
differences between the treatment groups compared.
D I S C U S S I O N
Summary of main results
This systematic review analysed the effectiveness and safety of ery-
thropoiesis-stimulating agents (ESAs) for managing anaemia in
cancer patients. The primary findings of this updated review are
as follows: ESAs significantly reduce the need for red blood cell
transfusions and increase haematological response in cancer pa-
tients. However, there is also strong evidence that ESAs increase
mortality during study period and some evidence that ESAs reduce
overall survival. In addition, there is strong evidence that ESAs
increase the risk for thromboembolic complications and some ev-
idence that ESAs increase the risk of hypertension and throm-
bocytopenia/haemorrhage. The available data are insufficient to
evaluate the effect of ESAs on tumour response. Their effect on
patients’ quality of life (QoL) and specific anaemia- and fatigue-
related symptoms (FACT-An) reaches statistical and clinical sig-
nificance; however, while it reaches statistical significance, it fails
to reach clinical significance for fatigue-related symptoms only
(FACT-F).
Overall completeness and applicability of
evidence
The main strength of the newly updated review is the large num-
ber of studies and patients included. All studies were systemati-
cally evaluated and outcomes from previous versions of this review
updated.
Quality of the evidence
The main weakness of this review are reporting and publication
biases. For the outcomes mortality during study period and over-
all survival this was less of a problem, since we used results that
were generated in an individual patient datameta-analysis (Bohlius
2009a; Bohlius 2009b), which had included the majority of stud-
ies in the field. However, besides survival and mortality, no other
outcomes were assessed in that review and thus for the remaining
outcomes we had to rely on the published evidence. For several of
these outcomes only a few studies could be evaluated. For exam-
ple, hypertension was reported in only 31 of 91 studies, throm-
bocytopenia in 21 and thromboembolic complications in 57 of
91 studies, haemoglobin (Hb) response in 31 and the number of
red blood cell units transfused in 20 of 91 studies. Similarly, nu-
merical QoL data for FACT-An or FACT-F were only reported
in 23 out of 91 trials. For some but not all of these outcomes,
the suspected publication bias was further supported by asymmet-
ric funnel plots. The numbers indicated here underline the lack
of complete outcome reporting for a major part of studies and
outcomes. In the light of these apparent reporting biases, we esti-
mate that both the beneficial (number of patients transfused, QoL
(FACT-F), Hb response, change in Hb) as well as the harmful
effects of ESAs other than mortality (thromboembolic events, hy-
pertension) have been overestimated in our present analysis.
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Agreements and disagreements with other
studies or reviews
This and previous analyses provide consistent evidence that ESAs
reduce the risk for RBC transfusions by approximately 30% to
40%.The point estimated generated in the current update is in line
with previous (Bohlius 2006a) and other systematic reviews and
meta-analyses (Tonelli 2009). fOur analysis also provides consis-
tent evidence that ESAs reduce the average number of RBC units
transfused. Participants on ESAs received on average one unit of
RBCs less (mean difference (MD) -0.98, 95% confidence interval
(CI) -1.17 to -0.78) compared with controls which is in line with
a previous, independent meta-analysis, reporting a weightedmean
difference (WMD) of −0.80 units (95% CI −0.99 to −0.61)
(Tonelli 2009 HTA).
Apart from improving physiologic parameters such as Hb and
haematocrit, erythropoietin was also hypothesised to improve
QoL and to alleviate fatigue. Improved QoL after ESA treatment
was previously reported in community based, single-arm studies
(Demetri 1998; Gabrilove 2001; Glaspy 1997). However, these
data were inconclusive because they lacked controls. Later, sev-
eral randomised controlled studies were conducted to investigate
this question. QoL trials require specific methodological stan-
dards, such as the use of validated instruments, double blinding, a
prospective plan to minimise missing data, investigating the pat-
tern of missing data, and addressing missing data in the analysis
(Aaronson 1991; Brandberg 2000). Our updated analysis does not
provide evidence for a clinically important improvement of fa-
tigue in patients receiving ESAs compared to controls. This result
is more conservative compared to previous meta-analyses on the
same topic (Minton 2010; Tonelli 2009). While previous analy-
ses identified differences for FACT-F just at (MD 3.00; 95% CI
1.36-4.64; 10 RCTs, N = 3,169) (Tonelli 2009) or above (MD
3.72; 95% CI 2.38-5.06; 12 RCTs, N = 2,671) (Minton 2010,
personal communication) the threshold for a clinically important
difference, our analysis showed aMD of 2.08 (95% CI 1.43-2.72,
18 RCTs, N = 4,965) which is below the estimated threshold of
3.0 (Cella 2002) . For FACT-An 20 there seems to be a clinically
important improvement in patients receiving ESAs with a MD of
6.14 (95%CI 4.55 to 7.73, six studies, N = 1,085), which is above
the CID for FACT-An, defined as four to five (Cella, personal
communication March 2010). However, only a small number of
published RCTs on ESAs reported QoL outcomes and therefore
more evidence is needed for definitive conclusions. For FACT-An
47 there is no established CID; however, we expect it to be at least
above five, as this is the threshold for FACT-An 20, which includes
less than half the questions of FACT-An 47. In our analysis there
was no robust evidence for a clinically important improvement of
QoL measured with FACT-An 47.
Besides the beneficial effects of ESAs indicated above, our re-
view also identified harmful effects, including an increased risk for
thromboembolic events, hypertension, thrombocytopenia, death
during study period and potentially decreased overall survival.
The increased risk for thromboembolic events in patients receiv-
ing ESAs has been observed and reported by single RCTs (Aapro
2008; Goss 2005 J&J 2004; Pirker 2008) and previous meta-anal-
yses on the same topic (Aapro 2008; Aapro 2009b; Bennett 2008;
Bohlius 2006a;Glaspy 2010; Ludwig 2009; Ross 2006; Seidenfeld
2006; Tonelli 2009). The effect estimates generated are compa-
rable across the different meta-analyses reported. The impact of
baseline Haemoglobin levels has not been clarified to date. While
one individual patient data meta-analysis restricted to studies us-
ing Darbepoetin for patients receiving chemotherapy suggested
an increased risk for thromboembolic events with higher baseline
haemoglobin levels (Ludwig 2009), this was not confirmed in a
second IPD analysis restricted to RCTs comparing epoetin beta
verus control (Aapro 2009b). In this analysis, the risk for throm-
boembolic events decreased with increasing baseline haemoglo-
bin levels (Aapro 2009b). Besides, there are reports that ESAs are
inherently thrombogenic irrespective of baseline or current Hb
levels (Barbera 2010; Fuste 2002; Malyszko 1995; Stasko 2002;
Stohlawetz 2000). Strategies to reduce the risk for thromboem-
bolic events by using e.g. anti-coagulating drugs have not yet been
evaluated in randomised controlled trials (Aapro 2009a).
Patients receiving ESAs may also have an increased risk for hy-
pertension. In patients with chronic renal failure, hypertension is
a common adverse effect of ESAs (Palmer 2010). This increase
in blood pressure can be partly explained by the elevated blood
viscosity and the loss of hypoxia-induced vasodilatation in asso-
ciation with the increased Hb level (Cirillo 1993). The present
analysis shows some evidence that ESAs also increase the risk for
hypertension in cancer patients by approximately 30%. However,
the result was statistically significant only in the fixed-effect model
and not in the random-effects model. In addition, only 31 of 91
studies reported for this outcome. A funnel plot analysis revealed a
significant asymmetry (P value < 0.001), suggesting that negative
results (in this case no hypertension) have been underreported.
Thus, the effect of ESAs on hypertension might be overestimated
in the present analysis. A previous meta-analysis in cancer patients
has also identified an increased risk (RR 1.41, 95% CI 0.94 to
2.12, 17 studies, 3,792 patients) which failed to reach conven-
tional level of statistical significance (Tonelli 2009).We also found
some evidence that ESAs increase the risk for thrombocytopenia
and haemorrhage (RR 1.21, 95%CI, 1.04 to 1.42, 21 trials, 4,507
patients, no evidence for publication bias), which has not been re-
ported before.While the increased risk for thromboembolic events
has been established, hypertension and thrombocytopenia/haem-
orrhage require closer monitoring in future studies.
In the current update of the systematic review, we found no ev-
idence for a beneficial effect of ESAs on tumour control. At the
same time, uncertainties remain as important information on tu-
mour grade, tumour stage, intensity of anti-neoplastic treatment
received, timing and method of tumour response assessment were
not reported. Relevant studies such as the Henke 2003 or the
Antonadou 2001 study could not be included in the meta-anal-
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ysis, as they did not report data for complete tumour response.
Overall, the data were not sufficient either to exclude or to prove
a tumour promoting effect of erythropoiesis-stimulating factors.
Single randomised controlled trials and previous meta-analyses
based on individual patient data (Bohlius 2009a; Bohlius 2009b)
have reported an increased risk for death during the active study
period. In the current review we have differentiated the active
study period, defined as mortality during ESA treatment plus a
short follow-up time of 30 days, versus overall survival defined as
the longest follow-up available. We integrated the data that were
generated previously for the individual patient data meta-analy-
sis (Bohlius 2009a; Bohlius 2009b) as well as studies which were
not included in the IPD review. The updated review confirms
the previous IPD review (Bohlius 2009a; Bohlius 2009b) show-
ing an increased risk for on-study mortality including all cancer
patients (HR present meta-analysis: 1.17, 95% CI 1.06 to 1.29,
70 studies, 15,935 patients; HR IPD review: 1.17, 95% CI 1.06-
1.30, 53 studies, N = 13,933). These results are in line with other
meta-analyses of on-study mortality regardless of underlying can-
cer therapy. Aapro 2009b reported an HR of 1.13 (95% CI 0.87
to 1.46, 12 studies, N = 2,297) in studies on epoetin beta and Ross
2006 reported an HR of 1.14 (95% CI 0.90 to 1.45, 17 studies).
Both meta-analyses failed to reach conventional levels of statis-
tical significance which may be explained by the fact that fewer
studies and patients were included in each of these analyses. There
was some evidence that ESAs decreased overall survival defined as
longest follow-up available (HR 1.05, 95% CI 1.00 to 1.11). As
in the previous review (Bohlius 2009a; Bohlius 2009b), the ef-
fect was small and of borderline statistical significance. It remains
uncertain whether or not the risk is also increased in the subset
of patients receiving chemotherapy while also receiving an ESA.
In the current updated review the HR for on -study mortality in
patients receiving chemotherapy is 1.10 (95% CI 0.98 to 1.24, 50
studies, 12,058 patients) which is identical to the HR reported in
the previous IPD review (Bohlius 2009a; Bohlius 2009b). How-
ever, there were no statistically significant differences between this
subgroup and the total patient sample in either the prior IPD
meta-analysis or the current update and an increased risk in cancer
patients undergoing chemotherapy and receiving ESAs cannot be
excluded. FDA (FDA 2010) has recommended restricting the use
of ESAs to cancer patients receiving chemotherapy with palliative
intent. ESAs should not be used in patients receiving radiotherapy
or no antic-cancer therapy. However, an increased risk for death
in patients receiving chemotherapy cannot be excluded.
Several hypotheses have been proposed to explain the increased
risk for death in patients receiving ESAs. One is that erythropoi-
etin might directly influence tumour cell growth. In vitro stud-
ies have reported high levels of erythropoietin receptors in breast
cancer cells and other malignancies (Acs 2001; Arcasoy 2002;
Bennett 2010; Henke 2006; Jelkmann 2004; Jelkmann 2008;
McKinney 2011;Yasuda 2003). Either endogenously produced or
exogenously administered, erythropoietin may promote the pro-
liferation and survival of cancer cells expressing erythropoietin re-
ceptor (Acs 2001; Acs 2002; Arcasoy 2002; Bennett 2010; Henke
2006; Jelkmann 2004; Jelkmann 2008; McKinney 2011; Yasuda
2003). However, conflicting evidence has been reported from pre-
clinical studies on the effects of rHu erythropoietin on cultured cell
lines (Bennett 2010). Tumour stimulation through erythropoietin
has been suggested in some studies, whereas other studies have not
observed a relationship between rHuEPO and tumour cell growth
(Bennett 2010; McKinney 2011). An alternative hypothesis sug-
gests that the efficacy of malignancy treatments, both radiother-
apy and oxygen-dependent chemotherapy, can be enhanced by
decreasing tumour hypoxia. Tumour tissue is often hypoxic and
this hypoxia may increase if the patient is anaemic (Becker 2000;
Henke 2000; Tatum 2006; Vaupel 2001; Vaupel 2008). This hy-
pothesis suggests that tumour hypoxia diminishes the effective-
ness of radiotherapy andoxygen-dependent chemotherapy (Tatum
2006; Vaupel 2001; Vaupel 2008). Evidence for this hypothesis
comes from reports that tumour control and overall survival are
better in solid tumour patients with better tumour oxygenation
(Hockel 1993; Knocke 1999). In addition, some authors have re-
ported that the effectiveness of oxygen-dependent radiotherapy is
impaired in anaemic patients (Frommhold 1998;Grau 2000). En-
hanced cytocidal efficacy in adequately oxygenated cells has been
documented for a number of cytotoxic drugs, such as cyclophos-
phamide, carboplatin and doxorubicin (Teicher 1981; Teicher
1994). In animal models, cyclophosphamide (Thews 2001) and
cisplatin (Silver 1999) have yielded better tumour control with
improved tissue oxygenation. Given these observations, it seems
plausible that increasing theHb level with erythropoietin may im-
prove tumour oxygenation and thus tumour control and eventu-
ally overall survival. This has been partly demonstrated in animal
models (Kelleher 1998). However, other pre-clinical studies have
demonstrated that experimental tumour cells acclimatize rapidly
to acute anaemia and return to normal radio sensitivity despite
continuing anaemia (Hirst 1984). Chronic anaemia does not nec-
essarily produce radio-resistance of experimental tumours (Koong
1991) and the correction of anaemia by erythropoietin does not
necessarily increase radio-sensitivity (Joiner 1993).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
ESAs reduce the need for red blood cell transfusions but increase
the risk for thromboembolic events and deaths. There is suggestive
evidence that ESAs may improve QoL. Whether and how ESAs
affects tumour control remains uncertain. The increased risk of
death and thromboembolic events should be balanced against the
potential benefits of ESA treatment taking into account each pa-
tient’s clinical circumstances and preferences.
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Implications for research
More data are needed for the effect of these drugs on quality of life,
tumour progression and other adverse effects. Further research is
needed to clarify cellular andmolecular mechanisms and pathways
of the effects of ESAs on thrombogenesis and their potential effects
on tumour growth.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Aapro 2008
Methods randomised controlled trial, not placebo-controlled
Participants N = 463 randomised: ESA = 231; control = 232
disease: breast cancer (M1)
treatment: chemotherapy
mean/median baseline Hb: 11.4 g/dL
Interventions drug: Epoetin beta
dose: 30000 IU sc weekly
Hb-target: 13-15 g/dL
planned ESA duration: 24 weeks
Outcomes primary: overall survival
secondary: progression free survival, tumour response rate, QoL
Notes full text publication, additional unpublished data were obtained for an individual patient
data meta-analysis study (Bohlius et al 2009, study number = 97413)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk unclear - no description
Allocation concealment (selection bias) Low risk yes - central randomisation
Aapro 2008 IPD
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Abels 1993
Methods randomised controlled trial, placebo-controlled
Participants N = 124 randomised: ESA = 65; control = 59
disease: hematological malignancies, genitourinary, gastrointestinal, and other cancer;
except primary myeloid malignancy or acute leukaemia (category: mixed)
treatment: none
mean/median baseline Hb: 9.3 g/dL;
Interventions drug: Epoetin alpha
dose: 100 IU/kg tiw s.c.
Hb-target: not reported
duration: 8 weeks
Outcomes primary: transfusion, Hct
secondary: QoL, safety
Notes full text publication, additional unpublished data were obtained for the first Cochrane
review (1985-2001) and an individual patient data meta-analysis study (Bohlius et al
2009, study number = 98906)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk yes - computer-generated
Allocation concealment (selection bias) Unclear risk unclear - each patient was assigned a ran-
dom identification number and was as-
signed to a treatment group by a comput-
erised randomisation schedule
Abels 1993 IPD
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Abels 1993 J&J 2004




Notes Data presented by J&J at FDA/ODAC hearing in May 2004
Antonadou 2001
Methods randomised controlled trial, not placebo-controlled
Participants N = 385, randomised: ESA = 190, control = 195
disease: pelvic malignancies
treatment: radiotherapy
baseline Hb: 9.95 g/dL , ESA 9.8, control 10.1, , categorized as < 10g/dL
Interventions drug: Epoetin
dose: 10.000 U 5x/week s.c.
Hb-target: >= 13 g/dL
duration: 5-6 weeks
Outcomes 4 years disease free survival, safety, Hb, tumour control, overall survival
Notes abstract, poster, study number = 10176
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk NR
Allocation concealment (selection bias) Unclear risk NR
Aravantinos 2003
Methods randomised controlled trial, not placebo-controlled
Participants N = 47 randomised: ESA = 24; control = 23
disease: ovarian, lung, stomach, other cancer (categorised as solid)
treatment: platinum-based chemotherapy
Hb baseline: 9.6 g/dL
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Aravantinos 2003 (Continued)
Interventions drug: Epoetin alpha
dose: 150 IU/kg tiw sc
Hb target: 14 g/dL
duration: NR, approx. >9-12 weeks, categorized: 12-16 weeks
Outcomes primary: transfusion requirements (secondary: ?) Hct, Hb, RBC number
Notes full text publication, study number = 11595
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Unclear
Allocation concealment (selection bias) Unclear risk Unclear
Bamias 2003
Methods randomised controlled trial, not placebo-controlled
Participants N = 144 randomised: ESA = 72; control = 72
disease: ovarian, NSCLC, SCLC, other cancer (categorized: solid)
treatment: platinum-based chemotherapy
Hb baseline: 11.5 g/dL
Interventions drug: Epoetin alpha
dose: 10,000 IU tiw sc
Hb target: 13 - 15 g/dL
duration: 21 to 24 weeks (duration of chemotherapy)
Outcomes primary: transfusions
secondary: Hb < 10 g/dL, predictors of response, optional: QoL
Notes full text publication, study number = 16091
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Unclear
Allocation concealment (selection bias) Unclear risk Unclear
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Blohmer 2011
Methods randomised controlled trial, not placebo-controlled
Participants N = 257, randomised: ESA = 128, control = 129
disease: cervical cancer
treatment: platinum-containing chemotherapy in all patients and radiotherapy (catego-
rized as radiochemotherapy)
baseline Hb: 11.9 g/dL , ESA 12.0 g/dL, control 11.8 g/dL, categorised as 10-12 g/dL
Interventions drug: Epoetin alfa
dose: 10’000 IU sc. TIW
Hb-target: >14 g/dL
duration: >20 weeks
Outcomes primary: relapse free survival
Notes full text publication, additional unpublished data were obtained for the first Cochrane
review (1985-2001), study number = 16218
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Yes - computer random-numbers generator
Allocation concealment (selection bias) Low risk Yes - central registration of the patients for
treatment allocation
Boogaerts 2003
Methods randomised controlled trial, not placebo-controlled
Participants N = 262 randomised: ESA = 133; control = 129
disease: multiple myeloma, Non-Hodgkin lymphoma, chronic lymphocytic leukaemia,
Hodgkin disease, ovarian, bone, gastrointestinal, respiratory, other cancer
treatment: chemotherapy
baseline Hb: 9.0 g/dL
Interventions drug: Epoetin beta
dose: 150 IU/kg sc TIW
Hb-target: 12-14 g/dL
planned ESA duration: 12 weeks
Outcomes primary: QoL
secondary: hematologic response, hematopoietic response, Hb change, transfusions, PS,
Hct
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Boogaerts 2003 (Continued)
Notes full text publication of the study previously published as abstract Coiffier 2001, addi-
tional unpublished data were obtained for the first Cochrane review (1985-2001) and an
individual patient data meta-analysis study (Bohlius et al 2009, study number = 36158)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk unclear - no description
Allocation concealment (selection bias) Low risk yes - central randomisation
Boogaerts 2003 IPD












Methods randomised controlled trial, not placebo-controlled
Participants N = 35, randomised: ESA = 20, control = 15
disease: SCLC and ovarian carcinoma
treatment: platinum-containing chemotherapy
baseline Hb: (at randomisation): 10.5 g/dL
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Carabantes 1999 (Continued)
Interventions drug: Epoetin alpha




Outcomes haematologic response, transfusion requirements, QoL
Notes abstract publication, study number = 17026
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk unclear
Allocation concealment (selection bias) Unclear risk unclear
Cascinu 1994
Methods randomised controlled trial, placebo-controlled
Participants N = 100, randomised: ESA = 50; control = 50
disease: various solid tumours
treatment: concomitant platinum-based chemotherapy; some patients received G-CSF
(n = 27)
mean/median baseline Hb: 8.7 g/dL
Interventions drug: Epoetin alpha
dose: 100 U/kg 3x/week s.c.
Hb target: 10 - 12 g/dL
duration: 9 weeks
Outcomes haematologic response, change in Hb values, transfusion requirement, adverse events
Notes full text publication, additional unpublished data were obtained for the first Cochrane
review (1985-2001), study number = 19548
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Yes - computer random-number generator
Allocation concealment (selection bias) Unclear risk unclear - sealed envelopes
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Case 1993
Methods randomised controlled trial, placebo-controlled
Participants N = 157, randomised: ESA = 81; control = 76
disease: non myeloid hematological malignancies, breast, lung, gynaecological, gastroin-
testinal, other cancer
treatment: non-cisplatin chemotherapy
mean/median baseline Hematocrit: 28.9%
Interventions drug: Epoetin alpha
dose: 150U/kg 3x/week s.c.
Hb target: Hct 38%-40%
duration: 12 weeks
Outcomes haematologic response, change in Hct, transfusion requirement, QoL, adverse events
Notes full text publication, additional unpublished data were obtained for the first Cochrane
review (1985-2001) and an individual patient data meta-analysis study (Bohlius et al
2009, study number = 34917)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk yes - computer-generated
Allocation concealment (selection bias) Unclear risk unclear - description is unclear
Case 1993 IPD




Notes study number = 34917
Case 1993 J&J 2004
Methods see Case 1993
Participants
Interventions
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Methods randomised controlled trial, not placebo-controlled
Participants N = 146, randomised: control = 29 (IPD: control:30, EPO: 116), evaluated EPO:114,
control: 29
ESAa = 31; ESAb = 29; ESAc = 31; ESAd = 26; ESAtotal = 117
disease: multiple myeloma, Non-Hodgkin´ s Lymphoma
treatment: chemotherapy, assumed without platinum because of hematological disease
mean/median baseline Hb: 9.4 g/dL
Interventions drug: Epoetin beta
dosages: a: 1000 IU sc 7x/week; b: 2000 IU sc 7x/week; c: 5000 IU sc 7x/ week; d:
10000 IU sc 7x/week
Hb-target: 11-13 g/dL (MM), 11-15 g/dL (NHL)
a: 1000 IU sc 7x/week, b: 2000 IU sc 7x/week; c: 5000 IU sc 7x/ week; d: 10000 IU sc
7x/week
duration: 8 weeks
Outcomes primary: haematologic response
secondary: Hb, Hct, transfusions, reticulocytes, iron, ferritin, safety
Notes full text publication, additional unpublished data obtained for first Cochrane Review
and an individual patient data meta-analysis study (Bohlius et al 2009, study number =
37653)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk unclear - randomisation list
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Methods see Cazzola 1995
Participants
Interventions
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Methods randomised controlled trial, not placebo-controlled
Participants N = 354, randomised: ESA = 176; control = 178
disease: breast cancer, stage I-IV
treatment: chemotherapy
baseline Hb: 11.3 g/dL
Interventions drug: Epoetin alpha
dose: 40,000 IU qw sc
Hb target: 14 g/dL
duration: 16 weeks, max 28 weeks
Outcomes primary: QoL
secondary: maintain Hb above 12 g/dL, tumour response, overall survival
Notes full text publication, additional unpublished data were obtained for an individual patient
data meta-analysis study (Bohlius et al 2009, study number = 99137)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk unclear - no description
Allocation concealment (selection bias) Low risk yes - central randomisation
Chang 2005 IPD




Notes study number = 99137
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Charu 2007
Methods randomised controlled trial, not placebo-controlled
Participants N = 287, randomised: ESA = 228, control = 59
disease: lymphoma, breast, lung, gastrointestinal, genitourinary, gynaecologic, other can-
cer
treatment: none
baseline Hb: 10.2 g/dL
Interventions drug: Darbepoetin alpha
dose: 3.0 µg/kg sc Q2W
Hb-target: 13-14 g/dL (women), 13-15 g/dL (men)
duration: 12 weeks
Outcomes primary: hospitalisation days
secondary: costs, QoL, transfusion, Hb, safety
Notes full text publication, additional unpublished data were obtained for an individual patient
data meta-analysis study (Bohlius et al 2009, study number = 53081)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk unclear - no description
Allocation concealment (selection bias) Low risk yes - central randomisation
Charu 2007 Amgen 2007






Methods see Charu 2007
Participants
Interventions
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Methods randomised controlled trial, not placebo-controlled
Participants N = 399, randomised: NR, evaluated: ESA 167, control = 170
disease: solid tumours
treatment: chemotherapy, platinum and non-platinum containing
baseline Hb: 10.2 g/dL
Interventions drug: Epoetin alfa
dose: 10’000 IU TIW
Hb-target: 12 - 14 g/dL
duration: minimum anticipated duration 12 weeks. categorized 12-16 weeks
Outcomes primary: QoL
secondary: transfusions, anaemia
Notes full text publication, abstract in 2003 (Janinis), study number = 22108
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk yes - block randomisation
Allocation concealment (selection bias) Low risk yes - centrally randomised
Dammacco 2001
Methods randomised controlled trial, placebo-controlled
Participants N = 145, randomised: ESA = 69; control = 76
disease: multiple myeloma
treatment: chemotherapy
mean/median baseline Hb: 9.5 g/dL
Interventions drug: Epoetin alpha
dose: 150U/kg 3x/week s.c.
Hb target: 14 g/dL
duration: 12 weeks
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Dammacco 2001 (Continued)
Outcomes primary: transfusion
secondary: haematologic response, Hb, Hct, reticulocytes, serum erythropoietin levels,
QoL, adverse events
Notes full text publication, additional unpublished data were obtained for the first Cochrane
review (1985-2001) and an individual patient data meta-analysis study (Bohlius et al
2009, study number = 11220)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk unclear - randomisation schedule prepared
by RWJPRI
Allocation concealment (selection bias) Unclear risk unclear - two randomisation lists (pat. prev.
transfused or not), when patient enters the
study the next number was to be assigned
Dammacco 2001 IPD





Dammacco 2001 J&J 2004




Notes Data presented by J&J at FDA/ODAC hearing in May 2004
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Debus 2006 IPD
Methods randomised controlled trial, not placebo-controlled
Participants N = 385, randomised: ESA = 195, control = 190
disease: NSCLC (stage III, primarily inoperable)
treatment: radiochemotherapy
baseline Hb: not reported, unclear
Interventions drug: Epoetin alpha
dose: 40’000 IU sc weekly
Hb-target: 12-14 g/dL, in 11/2003 reduced to 12-13 g/dL
duration: assumed to be 12-16 weeks
Outcomes primary: 2-year-survival rate
secondary: tumour response, QoL, tolerance to epoetin alpha, Hb change, transfusion,
safety
Notes only unpublished data available, were obtained for an individual patient data meta-
analysis study (Bohlius et al 2009, study number = 83322)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk unclear - randomisation code provided by
OrthoBiotech
Allocation concealment (selection bias) Unclear risk unclear - assigned envelopes, sequentially
numbered, but it is unclear whether they
were sealed and opaque
Debus 2006 J&J 2004
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Debus 2006 J&J 2007






Methods randomised controlled trial, not placebo-controlled
Participants N = 62, randomised: ESA = 31, control = 31
disease: breast cancer
treatment: non-platinum based chemotherapy and G-CSF 5µg/kg d4-d11 s.c for all
patients;
radiotherapy and Tamoxifen fore the majority
mean/median baseline Hb: 13.1 g/dL
Interventions drug: Epoetin (?)
dose: 150U/kg 3x/week s.c.
Hb target: 13-15 g/dL
duration: 14 weeks
Outcomes change in Hb values, transfusion requirement, QoL, adverse events
Notes full text publication, additional unpublished data were obtained for the first Cochrane
review (1985-2001), study number = 24367
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Yes - computer random-number generator
Allocation concealment (selection bias) Low risk Yes - central allocation
Dunphy 1999
Methods randomised controlled trial, not placebo-controlled
Participants N = 30, randomised: ESA = 15, control = 15
disease: head and neck cancer, NSCLC
treatment: platinum-based chemotherapy
mean/median baseline Hb: 14.1 g/dL
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Dunphy 1999 (Continued)
Interventions drug: Epoetin (?)
dose: 150U/kg 3x/week s.c.
Hb target: 16-18 g/dL
duration: 6 weeks
Outcomes change in Hb values, transfusion requirement
Notes full text publication, study number = 25455
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Unclear
Allocation concealment (selection bias) Unclear risk Unclear
Engert 2009






Methods randomised controlled trial, placebo-controlled
Participants N = 1,379, randomised ESA: 685, placebo: 694
disease: advanced stage Hodgkin Lymphoma
treatment: chemotherapy without platinum
baseline Hb: 12.5 g/dL
Interventions drug: Epoetin alpha
dose: 40,000 IU /week
Hb target: 12-13 g/dL
duration: > 20 weeks
Outcomes primary: anaemia-related fatigue
secondary: other QoL, number of transfusions needed, Hb during and after treatment,
safety, freedom from treatment failure, OS
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Engert 2010 (Continued)
Notes full-text publication, additional unpublished data, study number = 27258
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk unclear, not reported
Allocation concealment (selection bias) Unclear risk unclear, not reported
EPO-GER-20 IPD
Methods randomised controlled trial, not placebo-controlled
Participants n = 93, randomised: ESA = 45, control = 48
disease: SCLC (extensive stage)
treatment: chemotherapy
baseline Hb: not reported, unclear
Interventions drug: Epoetin alpha
dose: 10000 IU sc TIW
Hb-target: 12-14 g/dL
duration: during chemotherapy
Outcomes primary: rate of patients with anaemia
secondary: QoL, tolerability of ESA, transfusion, effectiveness of chemotherapy
Notes only IPD data, study number = 31678
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk unclear - patients were assigned with a ran-
domisation code provided by Janssen-Cilag
Allocation concealment (selection bias) Unclear risk unclear - assigned envelopes, sequentially
numbered, but it is unclear whether they
were sealed and opaque
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EPO-INT-1 IPD






Methods randomised controlled trial, placebo-controlled
Participants N = 246, randomised: ESA = 165, control = 81
disease: ovarian cancer (stage I-IV)
treatment: chemotherapy
baseline Hb: not reported, eligibility criterion Hb < 11 g/dL or Hb drop 1.5 g/dL,
categorized as Hb 10-12 g/dL
Interventions drug: Epoetin alpha




secondary: Hb change, Hct, QoL, survival
Notes data presented by J&J at FDA/ODAC hearing in may 2004, additional unpublished
data were obtained for an individual patient data meta-analysis study (Bohlius et al 2009,
study number = 53915)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk unclear - no description
Allocation concealment (selection bias) Unclear risk unclear - no description
85Erythropoietin or darbepoetin for patients with cancer (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
EPO-INT-3 IPD






Methods randomised controlled trial, placebo-controlled
Participants N = 201, randomised: ESA = 136, control = 65
disease: breast, NHL, MM, ovarian, SCLC, other cancer
treatment: chemotherapy, < 70% platinum containing
baseline Hb: not reported, eligibility criterion Hb < 12 g/dL or Hb drop 1.5 g/dL,
categorized as Hb 10-12 g/dL
Interventions drug: Epoetin alpha
dose: 150-300 IU/kg tiw sc
Hb-target: 14 g/dL for women and 16 g/dL for men
duration: 12 weeks
Outcomes primary: transfusions
secondary: mortality, disease progression, tumour response, adverse events, Hb, QoL
Notes Data presented by J&J at FDA/ODAC hearing in May 2004, additional unpublished
data were obtained for an individual patient data meta-analysis study (Bohlius et al 2009,
study number = 36274), clinicaltrials.gov
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk unclear - according to randomisation
schedule prepared by RWJPRI
Allocation concealment (selection bias) Low risk yes - central randomisation
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Fujisaka 2011
Methods randomised controlled trial, placebo-controlled
Participants randomised N = 186, evaluated N = 181, ESA = 89, control = 92
disease: lung cancer, gynaecological cancer
treatment: platinum-based chemotherapy
baseline Hb: 9.4 g/dL
duration: 12 weeks




Outcomes primary: proportion of patients receiving RBCTs and/or Hb<8.0 g/dL
secondary: need for transfusions, changes in Hb, QoL
Notes full-text publication, study id: 15478
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk not reported
Allocation concealment (selection bias) Low risk central randomisation system
Gebbia 2003
Methods randomised controlled trial, not placebo-controlled
Participants N = 45, randomised ESA = 22, control = 23
disease: squamous cell carcinoma of the head an neck
treatment: platinum-containing chemotherapy






secondary: transfusion, QoL, clinical outcome
Notes full text publication, study number = 29327
Risk of bias
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Gebbia 2003 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk unclear
Allocation concealment (selection bias) Unclear risk unclear
Gordon 2008
Methods randomised controlled trial, placebo-controlled
Participants N = 220, randomised: ESA = 164, control = 56
disease: non-myeloid hematological malignancies, breast, gastrointestinal, genitourinary,
lung, gynaecological, other cancer (stage I-IV)
therapy: none
baseline Hb: 10.2 g/dL
Interventions drug: Darbepoetin alpha
dose: 6.75 µg/kg sc Q4W
Hb-target: 12-13 g/dL
duration: 16 weeks
Outcomes primary: Hb response
secondary: transfusion, Hb change, QoL, safety
Notes full text publication, additional unpublished data were obtained for an individual patient
data meta-analysis study (Bohlius et al 2009, study number = 65772)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk unclear - randomisation list will be cen-
trally generated by Amgen
Allocation concealment (selection bias) Low risk yes - central randomisation
Gordon 2008 IPD
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Gordon 2008 IPD (Continued)
Notes
Goss 2005
Methods randomised controlled trial, placebo-controlled
Participants N = 104, randomised: ESA = 52, control = 52
disease:SCLC (limited disease)
treatment: radiochemotherapy
baseline Hb: 13.5 g/dL
Interventions drug: Epoetin alpha
dose: 40000 IU sc weekly
Hb-target: 14-16 g/dL, in 10/2002 reduced to 12-14 g/dL
duration: during chemotherapy and radiotherapy
Outcomes disease progression free survival, tumour response, overall survival, local disease progres-
sion, Hb, transfusion, QoL
Notes abstract publication, additional unpublished data obtained for an individual patient data
meta-analysis study (Bohlius et al 2009, study number = 55703)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk yes - computer-generated
Allocation concealment (selection bias) Low risk yes - central randomisation
Goss 2005 FDA 2004
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Goss 2005 IPD





Goss 2005 J&J 2004






Methods randomised controlled trial, placebo-controlled
Participants N = 224, randomised: ESA = 109, control = 115
disease: SCLC (limited and extensive disease)
treatment: chemotherapy
baseline Hb: 12.9 g/dL
Interventions drug: Epoetin alpha
dose: 150 IU/kg sc TIW
Hb-target: 14-16 g/dL
duration: NR, assumed to be 12 weeks (drug given during 3 x 3 weeks chemo plus 3
weeks)
Outcomes primary: assess possible stimulatory effects of ESA on solid tumour growth, tumour
response
secondary: overall survival, Hb, transfusion, safety
Notes full text publication, additional unpublished data were obtained for an individual patient
data meta-analysis study (Bohlius et al 2009, study number = 73807)
Risk of bias
Bias Authors’ judgement Support for judgement
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Grote 2005 (Continued)
Random sequence generation (selection
bias)
Low risk yes - computer-generated
Allocation concealment (selection bias) Unclear risk unclear - description is unclear
Grote 2005 IPD





Grote 2005 J&J 2004






Methods randomised controlled trial, not placebo-controlled
Participants N = 120, randomised: ESA = 60, control = 60
disease: cervical cancer
treatment: platinum-containing in all patients plus radiotherapy
baseline Hb: 10.6 g/dL
Interventions drug: Epoetin beta
dose: 30’000 IU TIW
Hb-target: unclear
duration: unclear
Outcomes primary: Hb, energy level, QoL
secondary: response rate, survival, toxicities, adverse events
Notes full text publication, study number = 30057
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Gupta 2009 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk unclear
Allocation concealment (selection bias) Unclear risk unclear
Hedenus 2002
Methods randomised controlled trial, placebo-controlled
Participants N = 66, randomised: ESA = 55, control = 11
disease: lymphoma: HD, NHL, MM
treatment: NR, assumed to be chemotherapy without platinum
baseline Hb: 9.6 g/dL
Interventions drug: Darbepoetin alpha
dosages: a: 1.0 µg/kg qw sc; b: 2.25 µg/kg qw sc; c:Darbepoetin 4.5 µg/kg qw sc
Hb target: 13-14 g/dL for women and 13-15 g/dL for men
duration: 12 weeks
Outcomes primary: dose response relationship of darbepoetin in haemoglobin or haematopoietic
response and overall survival
secondary: transfusion
Notes full text publication, study number = 32213
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Unclear
Allocation concealment (selection bias) Low risk yes - central computerized system
Hedenus 2002a
Methods see Hedenus 2002
Participants
Interventions Darbepoetin 1.0 µg/kg qw sc
Outcomes
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Methods see Hedenus 2002
Participants




Methods see Hedenus 2002
Participants




Methods randomised controlled trial, placebo-controlled
Participants N = 349, randomised: ESA = 176, control = 173
disease: lymphoma: Hodgkin disease, NHL, MM, CLL, Waldenstrom´ s disease
treatment: NR, assumed to be chemotherapy without platinum
Hb baseline: 9.5 g/dL
Interventions drug: Darbepoetin alpha
dose: 2.25 mg/kg qw sc
Hb target: 13-14 g/dL (women), 13-15 g/dL (men)
duration: 12 weeks
Outcomes primary: Hb response
secondary: transfusion, Hb change, QoL, safety
Notes full text publication, additional unpublished data were obtained for an individual patient
data meta-analysis study (Bohlius et al 2009, study number = 63455)
Risk of bias
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Hedenus 2003 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk unclear - based on a schedule specified by
Amgen before the start of the study
Allocation concealment (selection bias) Low risk yes - central randomisation
Hedenus 2003 FDA 2007












Methods randomised controlled trial, not placebo-controlled
Participants N = 50, randomised: control = 11; ESAa = 19; ESAb = 14; ESAc = 6; ESAtotal = 39
disease: various solid tumours
treatment: radiotherapy
mean/median baseline Hb: 11.5 g/dL
Interventions drug: Epoetin alpha or beta
dose: ESAa: 150U/kg 3x/week i.v., ESAb: 300U/kg 3x/week i.v., ESAc: 150U/kg 3x/
week s.c.;
Hb target: 14 - 16 g/dL (men) or 13 - 15 g/dL (women)
duration: 8 weeks
Outcomes haematologic response, change in Hb values
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Henke 1999 (Continued)
Notes full text publication, study number = 39895
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Unclear
Allocation concealment (selection bias) Unclear risk Unclear
Henke 1999a
Methods see Henke 1999
Participants n = 19




Methods see Henke 1999
Participants n = 14




Methods see Henke 1999
Participants n= 6
Interventions Epoetin alpha or beta c: 150U/kg 3x/week s.c.
Outcomes
Notes
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Henke 2003
Methods randomised controlled trial, placebo-controlled
Participants N = 351, randomised: ESA = 180, control = 171
disease: advanced (stage III , IV) head and neck cancer
treatment: radiotherapy
baseline Hb: 11.8 g/dL
Interventions drug: Epoetin beta
dose: 300 IU/kg tiw sc
Hb-target: 12-14 g/dL (women), 13-15 g/dL (men)
duration: 7-9 weeks
Outcomes primary: efficacy of radiotherapy, measured as local progression free survival
secondary: survival, progression free survival, Hb, safety, tolerability
Notes full text publication, additional unpublished data were obtained for an individual patient
data meta-analysis study (Bohlius et al 2009, study number = 58106)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk unclear - each centre had numbered pack-
ages per stratum, once randomised the low-
est number had to be assigned. There was a
randomisation list only the statistics centre
had access to. In addition, there were sealed
envelopes for emergencies
Allocation concealment (selection bias) Low risk yes - coded drug packs of identical appear-
ance
Henke 2003 IPD
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Henke 2003 Roche 2004




Notes Data presented by Roche at FDA/ODAC hearing in May 2004
Henry 1995
Methods randomised controlled trial, placebo-controlled
Participants N = 132, randomised: ESA = 67, control = 65
disease: any type of cancer except primary myeloid malignancy or acute leukaemia
treatment: platinum-containing chemotherapy
baseline Hb: 9.5 g/dL
Interventions drug: Epoetin alpha
dose: 150 IU/kg sc TIW
Hb-target: Hct 38%-40%
duration: 12 weeks
Outcomes primary: Hct, transfusion, haematologic response
secondary: correction of anaemia, response, QoL, safety
Notes full text publication, additional unpublished data were obtained for the first Cochrane
review (1985-2001) and an individual patient data meta-analysis study (Bohlius et al
2009, study number = 70332)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk yes - computer generated
Allocation concealment (selection bias) Unclear risk unclear - medication boxes were used, but
without identical appearance
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Henry 1995 IPD




Notes study number = 70332
Henry 1995 J&J 2004




Notes Data presented by J&J at FDA/ODAC hearing in May 2004
Hernandez 2009
Methods randomised controlled trial, placebo-controlled
Participants n = 391, randomised: ESA = 196, control = 195
disease: non-myeloid haematological malignancies, breast, lung, gastrointestinal, geni-
tourinary, gynaecological, other cancer (stage I-IV)
treatment: chemotherapy, 36% receiving platinum
baseline Hb:10.1 g/dL
Interventions drug: Darbepoetin alpha




secondary: Hb target achieved, number of transfusions, safety, QoL
Notes full text publication, additional unpublished data were obtained for an individual patient
data meta-analysis study (Bohlius et al 2009, study number = 37476, Taylor 2005)
Risk of bias
Bias Authors’ judgement Support for judgement
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Hernandez 2009 (Continued)
Random sequence generation (selection
bias)
Unclear risk unclear - no description
Allocation concealment (selection bias) Low risk yes - central randomisation
Hernandez 2009 IPD




Notes study number = 37476
Hoskin 2009
Methods randomised controlled trial, not placebo-controlled
Participants N = 300, randomised: ESA = 151, control = 149
disease: head and neck cancer (stage I-IV)
treatment: radiotherapy, no chemotherapy
baseline Hb: 13.6 g/dL
Interventions drug: Epoetin alpha
dose: if Hb < 12.5 10000 IU sc TIW; if Hb > 12.5 4000 IU sc TIW
Hb-target: 14.5 to 15 g/dL
duration: 12 weeks
Outcomes primary: local disease free survival
secondary: overall survival, QoL, safety
Notes full text publication, additional unpublished data were obtained for an individual patient
data meta-analysis study (Bohlius et al 2009, study number = 81645)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk unclear - central randomisation schedule
stratified by the study site was generated by
the sponsor
Allocation concealment (selection bias) Unclear risk unclear - no description
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Hoskin 2009 GBR-7 FDA 04




Notes unpublished study, data obtained from FDA report for the FDA/ODAC in hearing May 2004
Hoskin 2009 IPD




Notes study number = 81645
Hoskin 2009 J&J 2004






Methods randomised controlled trial, not placebo-controlled
Participants N = 95, randomised: ESA = 48, control = 47
disease: lung, gynaecological, genitourinary, other cancer
treatment: platinum-containing chemotherapy
baseline Hb: not reported, eligibility criterion Hb < 10.5 g/dL, categorized as Hb 10-12
g/dL
Interventions drug: Epoetin alpha
dose: 10,000 IU tiw
Hb-target: 12-14 g/dL
duration: max 28 weeks
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Huddart 2002 (Continued)
Outcomes Hb response, reticulocyte, survival, QoL, safety
Notes abstract, additional unpublished data were obtained for an individual patient data meta-
analysis study (Bohlius et al 2009, study number = 88443)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk unclear - no description
Allocation concealment (selection bias) Unclear risk unclear - no description
Huddart 2002 IPD




Notes study number = 88443
Iconomou 2003
Methods randomised controlled trial, not placebo-controlled
Participants N = 122, randomised: ESA = 57, control = 55
disease: lung, breast, colorectal, ovarian, unknownprimary, kidney, stomach, other cancer
treatment: chemotherapy, platinum & non platinum
baseline Hb: 10.1 g/dL





Notes full text publication, study number = 40799
Risk of bias
Bias Authors’ judgement Support for judgement
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Iconomou 2003 (Continued)
Random sequence generation (selection
bias)
Unclear risk Unclear
Allocation concealment (selection bias) Low risk Randomisation was performed by a tele-
phone call to the registry of the department
of medicine
Italian 1998
Methods randomised controlled trial, placebo-controlled
Participants N = 87, randomised: ESA = 44, control = 43
disease: Myelodysplastic Syndromes
treatment: none
mean/median baseline Hb: 8.2 g/dL;
Interventions drug: Epoetin alpha
dose: 150U/kg 3x/week s.c.
Hb target: not reported
duration: 8 weeks, thereafter Epo for all the patients
Outcomes haematologic response, change in haemoglobin values, adverse events
Notes full text publication, additional unpublished data were obtained for the first Cochrane
review (1985-2001), study number = 46703
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Yes - computer random number generator
Allocation concealment (selection bias) Low risk Yes - central registration by telephone be-
fore treatment assignment
Katakami 2008
Methods randomised controlled trial, placebo-controlled
Participants N = 207, ESA = 103, control = 104
disease: lung and gynaecologic cancer
treatment: platinum-containing chemotherapy
baseline Hb: not reported, eligibility criterion Hb <= 11 g/dL, categorized as Hb 10-12
g/dL
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Katakami 2008 (Continued)
Interventions drug: darbepoetin alfa
dose: 2.25 ug/kg once per week sc
Hb target: 13.0 g/dL (amended to 12.0 g/dL)
duration: 12 weeks
Outcomes proportion of patients reaching transfusion trigger or receiving RBCT, haematologic
endpoints,
adverse events, survival
Notes abstract publication (study id: 13567) additional study reporting exactly the same: Kat-
sumata 2009
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk unclear, not reported
Allocation concealment (selection bias) Unclear risk unclear, not reported
Kotasek 2002
Methods randomised controlled trial, placebo-controlled
Participants N = 161, randomised: ESA = 129, control = 32
disease: lung, breast, gastrointestinal, genitourinary, gynaecological, other cancer (stage
I-IV)
treatment: chemotherapy
baseline Hb: not reported, eligibility criterion Hb <= 11 g/dL, categorized as Hb 10-12
g/dL
Interventions drug: Darbepoetin alpha
dose: a: 9 µg/kg sc Q4W, b: 12 µg/kg sc Q4W, c: 15 µg/kg sc Q4W, d: 18 µg/kg sc Q4W
Hb-target: 13-14 g/dL (women), 13-15 g/dL (men)
duration: 12 weeks
Outcomes primary: safety
secondary: determine effective dose, effect of ESA, QoL feasibility
Notes additional unpublished data were obtained for an individual patient data meta-analysis
study (Bohlius et al 2009, study number = 26117)
Risk of bias
Bias Authors’ judgement Support for judgement
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Kotasek 2002 (Continued)
Random sequence generation (selection
bias)
Unclear risk unclear - no description
Allocation concealment (selection bias) Low risk yes - central randomisation
Kotasek 2002 IPD






Methods randomised controlled trial, placebo-controlled
Participants N = 259, randomised: ESA = 208, control = 51
disease: breast, gynaecological, gastrointestinal, lung, genitourinary, other cancer
treatment: chemotherapy, not reported whether with or without platinum, interpreted
as some patients receiving platinum
baseline Hb: 9.9 g/dL
Interventions drug = Darbepoetin alpha
dose = a: 4.5 µg/kg sc Q3W, b: 6.75 µg/kg sc Q3W, c: 9 µg/kg sc Q3W, d: 12 µg/kg sc
Q3W, e: 13.5 µg/kg sc Q3W, f: 15 µg/kg sc Q3W
Hb-target = 13-14 g/dL (women), 13-15 g/dL (men)
duration = 12 weeks
Outcomes primary: safety
secondary: determine effective dose, effect of ESA, QoL feasibility
Notes full text publication, additional unpublished data were obtained for an individual patient
data meta-analysis study (Bohlius et al 2009, study number = 35466)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk unclear - no description
Allocation concealment (selection bias) Low risk yes - central randomisation
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Kotasek 2003 IPD




Notes study number = 35466
Kotasek 2003a
Methods see Kotasek 2003
Participants N = 32




Methods see Kotasek 2003
Participants N = 17




Methods see Kotasek 2003
Participants N = 46
Interventions Darbepoetin 9 µg/kg Q3W sc
Outcomes
Notes
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Kotasek 2003d
Methods see Kotasek 2003
Participants N = 28




Methods see Kotasek 2003
Participants N = 35




Methods see Kotasek 2003
Participants N = 40




Methods randomised controlled trial, placebo-controlled
Participants N = 313, randomised: ESA a = 104, ESA b = 105, control = 104
disease: lung cancer, gastrointestinal tumour, breast cancer, genitourinary, haematological
and other cancer
treatment: platinum and non-platinum containing chemotherapy
baseline Hb: 9.4 g/dL
Interventions drug: Epoetin delta
dose: a: 150 IU/kg tiw, b: 300 IU/kg tiw
Hb-target: 12 - 14 g/dL
duration: 12 weeks
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Krzakowski 2008 (Continued)
Outcomes primary: Hb, RBC, transfusions
secondary: haematocrit, FACT-An, subgroup analysis for type of cancer/ chemotherapy
Notes full text publication, study number = 49839
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk unclear
Allocation concealment (selection bias) Unclear risk unclear
Krzakowski 2008a
Methods see Krzakowski 2008
Participants ESA a = 104




Methods see Krzakowski 2008
Participants ESA b = 105




Methods randomised controlled trial, placebo-controlled
Participants N = 72, evaluated: 53. randomisation is only given for those:
Epoetin a = 16, Epoetin b = 18, control = 19
disease: NSCLC
treatment: platinum based chemotherapy
baseline Hb: 12.3 g/dL
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Kunikane 2001 (Continued)
Interventions drug: Epoetin beta
dose: 1: 100U/kg 3x/week s.c.; 2: 200U/kg 3x/week s.c.
Hb-target: 14 g/dL in women, 16 g/dL in men
duration: 6 weeks
Outcomes change in Hb values, transfusion requirement, adverse events
Notes full text publication, additional unpublished data obtained for first Cochrane Review,
study number = 51164
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk unclear
Allocation concealment (selection bias) Low risk yes - central registration before treatment
assignment
Kunikane 2001a
Methods see Kunikane 2001
Participants Epoetin 1: n = 16




Methods see Kunikane 2001
Participants
Interventions Epoetin beta 2: 200U/kg 3x/week s.c.
Outcomes
Notes
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Kurz 1997
Methods randomised controlled trial, placebo-controlled
Participants N = 35, randomised: ESA = 23, control = 13
disease: gynaecologic tumours
treatment: platinum based chemotherapy
baseline Hb: 9.9 g/dL
Interventions drug: Epoetin alpha
dose: 150U/kg 3x/week s.c.
Hb-target: no upper target reported
duration: 12 weeks
Outcomes haematologic response, change inHaemoglobin values, transfusion requirement,Quality
of Life, adverse events
Notes full text publication, additional unpublished data were obtained for the first Cochrane
review (1985-2001), study number = 54819
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Yes - random permuted blocks and a cor-
responding randomisation list at the ran-
domisation office
Allocation concealment (selection bias) Low risk Yes - registration of the patients with an
institution seperate from the centre where
patients were recruited before treatment as-
signment
Leyland-Jones 05 J&J 04




Notes Data presented by J&J at FDA/ODAC hearing in May 2004
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Leyland-Jones 2005
Methods randomised controlled trial, placebo-controlled
Participants N = 939, randomised: ESA = 469, control = 470
disease: metastatic breast cancer (stage IV, M1)
treatment: chemotherapy
baseline Hb: 12.5 g/dL
Interventions drug: Epoetin alpha
dose: 40,000 IU qw sc
Hb-target = 12-14 g/dL
duration: 52 weeks
Outcomes primary: overall survival
secondary: Hb, transfusion, tumour control, QoL, time to progression
Notes full text publication, additional unpublished data were obtained for an individual patient
data meta-analysis study (Bohlius et al 2009, study number = 17100)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk yes - computer-generated
Allocation concealment (selection bias) Low risk yes - central randomisation
Leyland-Jones 2005 IPD




Notes study number = 17100
Littlewood 2001
Methods randomised controlled trial, placebo-controlled
Participants N=375, randomised: ESA = 251, control = 124
disease: NHL, MM, HD, CLL, gastrointestinal, other cancer
treatment: chemotherapy without platinum
baseline Hb: 9.8 g/dL
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Littlewood 2001 (Continued)
Interventions drug: Epoetin alpha




secondary: haematologic response, Hb, Hct, reticulocytes, predictors for response, QoL,
adverse events, after protocol amendment also survival
Notes full text publication, additional unpublished data were obtained for the first Cochrane
review (1985-2001) and an individual patient data meta-analysis study (Bohlius et al
2009, study number = 17123)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk yes - computer-generated randomisation
schedule prepared by RWJPRI
Allocation concealment (selection bias) Low risk yes - coded drug packs of identical appear-
ance
Littlewood 2001 IPD




Notes study number = 17123





Notes Data presented by J&J at FDA/ODAC hearing in May 2004
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Machtay 2007
Methods randomised controlled trial, not placebo-controlled
Participants N = 148, randomised: ESA = 77, control = 71
disease: head and neck cancer (stage I-IV)
treatment: radiotherapy, advanced stages received in addition platinum based chemo-
therapy
baseline Hb: 12.1 g/dL
Interventions drug: Epoetin alpha
dose: 40’000 IU sc weekly
Hb-target: 12.5-14 g/dL (women), 13.5-16 g/dL (men)
duration: 8-10 weeks
Outcomes primary: local regional control tumour response
secondary: overall survival, patterns of failure, local-regional progression-free survival,
Hb, toxicity, QoL
Notes full text publication, additional unpublished data were obtained for an individual patient
data meta-analysis study (Bohlius et al 2009, study number = 87660), old publication
was Machtay 2004
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk unclear - no description
Allocation concealment (selection bias) Low risk yes - central randomisation
Machtay 2007 IPD




Notes study number = 87660
112Erythropoietin or darbepoetin for patients with cancer (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Milroy 2003 IPD






Methods randomised controlled trial, not placebo-controlled
Participants N = 424, randomised: ESA = 214, control = 210
disease: NSCLC (stage IIIb or IV, advanced)
treatment: platinum-based chemotherapy
baseline Hb: 12.7 g/dL
Interventions drug: Epoetin alpha
dose: if body weight > 45 kg 10000 IU sc TIW, if body weight < 45 kg 5000 IU sc TIW
Hb-target: 12.5-14 g/dL (women), 13.5-15 g/dL (men)
duration = during chemotherapy
Outcomes primary: QoL
secondary: Hb, tumour response, survival, transfusion
Notes full text publication, additional unpublished data were obtained for an individual patient
data meta-analysis study (Bohlius et al 2009, study number = 67954)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk unclear - no description
Allocation concealment (selection bias) Low risk yes - central randomisation
ML17616 2006
Methods randomised controlled trial, not placebo-controlled
Participants N = 60
disease: MM, NHL and Cll
treatment: chemotherapy, assumed to be without platinum because of hematological
disease
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ML17616 2006 (Continued)
baseline Hb: not reported, eligibility criterion Hb <10 g/dL, categorized as Hb baseline
< 10 g/dL
Interventions drug: epoetin beta
dose: 150 IU/kg TIW
Hb-target: NR
duration: 12 weeks
Outcomes primary: hematologic response
secondary: Hb, transfusions, safety
Notes clinical trial result information, study number = 99765
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk unclear
Allocation concealment (selection bias) Unclear risk unclear
ML17620 2006
Methods randomised controlled trial, not placebo-controlled
Participants N = 121
disease: solid tumours
treatment: platinum-based chemotherapy
baseline Hb: not reported, unclear
Interventions drug: epoetin beta
dose: 150 IU/kg TIW
Hb-target: NR
duration: 12 weeks
Outcomes primary: hematologic response
secondary: Hb, transfusions, Hct, safety, blood pressure
Notes clinical trial result information, study number = 10373
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk unclear
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ML17620 2006 (Continued)
Allocation concealment (selection bias) Unclear risk unclear
Moebus 2007
Methods randomised controlled trial, not placebo-controlled
Participants N = 643, randomised: ESA = 324, control = 319
disease: breast cancer (high risk, stage II/IIIA; M0)
treatment: chemotherapy without platinum
baseline Hb: 12.6 g/dL
Interventions drug: Epoetin alpha
dose: 150 IU/kg sc TIW
Hb-target: 13-14 g/dL
duration: 18 weeks
Outcomes primary: transfusion, Hb
secondary: recurrence free survival, overall survival, relapse, QoL
Notes abstract publication, additional unpublished data were obtained for the first Cochrane
review (1985-2001) and an individual patient data meta-analysis study (Bohlius et al
2009, study number = 22515)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk yes - computer random-number generator
Allocation concealment (selection bias) Low risk yes - central registration of patients before
treatment allocation
Moebus 2007 IPD
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Moebus 2007 J&J 2007






Methods randomised controlled trial, placebo-controlled
Participants N = 100, randomised: ESA = 50, control = 50
disease: pancreatic, genital, colon and lung cancer
treatment: none
baseline Hb: 10.01 g/dL; for ESA group 9.87g/dL for control group 10.15, categorized
as 10-12 g/dL






Notes full text publication, was excluded in the IPD Review, study number = 61315
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk unclear
Allocation concealment (selection bias) Unclear risk unclear
O’Shaughnessy 2005
Methods randomised controlled trial, placebo-controlled
Participants N = 100, randomised: ESA = 51, control = 49
disease: breast cancer, stages I-IIIB
treatment: chemotherapy
baseline Hb: 12.9 g/dL
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O’Shaughnessy 2005 (Continued)
Interventions drug: Epoetin alpha
dose: 40,000 IU qw sc
Hb-target: 13-15 g/dL
duration: 12 weeks
Outcomes primary: cognitive function, fatigue
secondary: QoL
Notes full text publication, additional unpublished data were obtained for an individual patient
data meta-analysis study (Bohlius et al 2009, study number = 40730)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk yes - computer generated
Allocation concealment (selection bias) Low risk yes - coded drug packs of identical appear-
ance
O’Shaugnessy 2005 IPD




Notes study number = 40730
OBE/EPO-INT-03 IPD
Methods randomised controlled trial, not placebo-controlled
Participants N = 72, randomised: ESA = 35, control = 37
disease: MM
treatment: chemotherapy, assumed to be without platinum because of hematological
disease
baseline Hb: not reported, unclear
Interventions drug: Epoetin alpha
dose: 40’000 IU sc weekly
Hb-target: 12-13 g/dL
duration: during chemotherapy
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OBE/EPO-INT-03 IPD (Continued)
Outcomes primary: Hb change
secondary: QoL, Hb response, transfusion, safety
Notes unpublished data were obtained for an individual patient data meta-analysis study
(Bohlius et al 2009, study number = 92503)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk unclear - no description
Allocation concealment (selection bias) Low risk yes - central randomisation
Oberhoff 1998
Methods randomised controlled trial, not placebo-controlled
Participants N = 218, randomised: ESA = 114, control = 104
disease: ovarian, breast, lung, genitourinary, gastrointestinal, other cancer
treatment: platinum containing chemotherapy
baseline Hb: ESA arm 9.6 g/dL, control 10.3 g/dL, categorised as < 10 g/dL
Interventions drug: Epoetin beta




secondary: haematologic response, Hb response, safety
Notes full text publication, additional unpublished data were obtained for the first Cochrane
review (1985-2001) and an individual patient data meta-analysis study (Bohlius et al
2009, study number = 45434)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk unclear - no description
Allocation concealment (selection bias) Low risk yes - central randomisation
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Oberhoff 1998 IPD




Notes study number = 45434
Osterborg 1996
Methods randomised controlled trial, not placebo-controlled
Participants N = 144, randomised: ESA 1 = 47, ESA 2 = 48, control = 49
disease: MM, NHL, chronic lymphocytic lymphoma
treatment: chemotherapy, non-platinum containing
baseline Hb: 8.8 g/dL
Interventions drug: Epoetin beta
dose: a: 10000 IU sc 7x/week, b: 2.000U daily s.c.; increased to 5.000U and 10.000U
daily if no response
Hb-target: 12-13 g/dL (women), 13-14 g/dL (men)
duration: 24 weeks
Outcomes primary: transfusion
secondary: safety, Hb, haematologic response
Notes full text publication, additional unpublished data were obtained for the first Cochrane
review (1985-2001) and an individual patient data meta-analysis study (Bohlius et al
2009, study number = 43680)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk unclear - no description
Allocation concealment (selection bias) Low risk yes - central randomisation
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Osterborg 1996 IPD




Notes study number = 43680
Osterborg 1996a
Methods see Osterborg 1996
Participants




Methods see Osterborg 1996
Participants




Methods randomised controlled trial, placebo-controlled
Participants N = 349, randomised: ESA = 173, control = 176
disease: MM, NHL, CLL;
treatment: chemotherapy, assumed without platinum because of hematological disease
baseline Hb: 9.3 10g/dL
Interventions drug: Epoetin beta
dose: 150U/kg 3x/week s.c.
Hb-target = 13-14 g/dL
duration: 16 weeks
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Osterborg 2002 (Continued)
Outcomes primary: transfusion free survival
secondary: haematologic response, Hb change, time to response, number of blood trans-
fusions, QoL, safety
Notes full text publication, additional unpublished data were obtained for the first Cochrane
review and an individual patient data meta-analysis study (Bohlius et al 2009, study
number = 77914)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk unclear - randomisation program
Allocation concealment (selection bias) Low risk yes - central randomisation
Osterborg 2002 IPD




Notes study number = 77914
Overgaard 2009
Methods randomised controlled trial, not placebo-controlled
Participants N = 515, randomised: ESA = 255, control = 260
disease: head and neck cancer
treatment: radiotherapy
baseline Hb: approximately 13 g/dL
Interventions drug: darbepoetin
dose: 150 mg sc weekly
Hb target: > 15.5 g/dL
duration: 8 to 10 weeks
Outcomes OS, DS, tumour control, adverse events
Notes abstract publication, study number = 62913
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Overgaard 2009 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk not reported
Allocation concealment (selection bias) Low risk central allocation method
P-174 IPD






Methods randomised controlled trial, placebo-controlled
Participants N = 45, randomised: ESA = 33, control = 12
disease: CLL (any stage)
treatment: NR ’other’
baseline Hb category: not reported, unclear
Interventions drug: Epoetin alpha
dose: 150 IU/kg tiw sc
Hct-target: 38% to 40%
duration 12 weeks
Outcomes primary: Hct
secondary: Hb, transfusion, QoL, safety
Notes data presented by J&J at FDA/ODAC hearing in May 2004, additional unpublished
data were obtained for an individual patient data meta-analysis (Bohlius et al, 2009 study
number = 60584)
Risk of bias
Bias Authors’ judgement Support for judgement
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P-174 J&J 2004 (Continued)
Random sequence generation (selection
bias)
Low risk yes - computer-generated
Allocation concealment (selection bias) Unclear risk unclear - no description
Pirker 2008
Methods randomised controlled trial, placebo-controlled
Participants N = 600, randomised: ESA = 299, control = 301
disease: SCLC (untreated, extensive stage)
treatment: platinum-containing chemotherapy
baseline Hb: 11.9 g/dL, ESA arm 12.03 g/dL, control 11.86 g/dL, categorised as 10-12
g/dL
Interventions drug: Darbepoetin alpha
dose: 300 µg sc weekly for weeks 1-4 then 300 µg Q3W starting week 5 onwards
Hb-target: 13-14 g/dL
duration: 19 weeks
Outcomes primary: Hb change, survival
secondary: QoL, progression-free-survival, tumour response, time to progression, trans-
fusion
Notes full text publication, additional unpublished data were obtained for an individual patient
data meta-analysis study (Bohlius et al 2009, study number = 89335)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk unclear - no description
Allocation concealment (selection bias) Low risk yes - central randomisation
Pirker 2008 IPD
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Pronzato 2010
Methods randomised controlled trial, not placebo-controlled
Participants N = 223, randomised ESA=110, control =113
disease: breast cancer (stage I-IV)
treatment: chemotherapy
baseline Hb: 10.7 g/dL
Interventions drug: epoetin alpha
dose: if body weight >45kg 10,000 IU sc TIW, if body weight <45kg 5,000 IU sc TIW
Hb target: 12-14 g/dL
duration: categorized: >20 weeks
Outcomes Primary: QoL (anaemia)
Secondary: hematological response, other QoL, tumour response, OS, number of pa-
tients transfuse
Notes Full-text publication, unpublished data were obtained for an individual patient data
meta-analysis study (Bohlius et al 2009, study number = 22233)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk unclear - no description
Allocation concealment (selection bias) Low risk yes - central randomisation
Pronzato 2010 IPD






Methods randomised controlled trial, placebo-controlled
Participants N = 56, randomised: ESA = 28, control = 28
disease: lung, gynaecological, hematological malignancies, other cancer
treatment: chemotherapy
baseline Hb: 10.8 g/dL
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Quirt 1996 (Continued)
Interventions drug: Epoetin alpha
dose: 150U/kg 3x/week s.c
Hb-target: 12.5-14 g/dL
duration: 16 weeks
Outcomes primary: transfusion, Hb change
secondary: QoL, costs from societal perspective, tumour response
Notes abstract publication, additional unpublished data were obtained for an individual patient
data meta-analysis study (Bohlius et al 2009, study number = 80214)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk unclear - no description
Allocation concealment (selection bias) Unclear risk unclear - no description
Quirt 1996 IPD




Notes study number = 80214
Ray-Coquard 2009
Methods randomised controlled trial, not placebo-controlled
Participants N = 218, randomised: ESA = 110, control = 108
disease: breast, sarcoma, lung, ovarian, other solid cancer and hematological malignancies
treatment: chemotherapy (IPD) full text: NR
baseline Hb: 10.0 g/dL, categorised as 10-12 g/dL
Interventions drug: Epoetin alpha
dose: if body weight < 45 kg 10000 IU sc 2x/week, if body weight 45 kg to < 89 kg
10000 IU sc TIW, if body weight > 89 kg 10000 IU sc 4x/week
Hb-target: 12-14 g/dL
planned ESA duration: 12 weeks
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Ray-Coquard 2009 (Continued)
Outcomes primary: transfusion dependent anaemia
secondary: QoL, Hb response predictors, Hb, toxicity, survival, costs
Notes full text publication, additional unpublished data were obtained for an individual patient
data meta-analysis study (Bohlius et al 2009, study number = 37491)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk yes
Allocation concealment (selection bias) Low risk yes
Ray-Coquard 2009 IPD




Notes abstract publication, IPD data
Razzouk 2004






Methods randomised controlled trial, placebo-controlled
Participants N = 224, randomised ESA: 112, Control: 112
disease: solid tumours, HD, NHL, ALL
treatment: chemotherapy
baseline Hb: 9.7 g/dL
126Erythropoietin or darbepoetin for patients with cancer (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Razzouk 2006 (Continued)
Interventions drug: epoetin alpha
dose: 600 IU/kg iv weekly




Notes Full-text publication, additional unpublished data were obtained for an Individual Pa-
tient Data meta-analysis study (Bohlius et al 2009). Study number: 80515
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk yes- computer generated
Allocation concealment (selection bias) Low risk yes- central randomisation and coded drug
packages of identical appearance
Rose 1994
Methods randomised controlled trial, placebo-controlled
Participants N = 221, ESA = 142, control = 79
disease: CLL (stage III, IV)
treatment: chemo- and radiotherapy, without platinum
baseline Hb: 9.2 g/dL
Interventions drug: Epoetin alpha
dose: 150U/kg 3x/week s.c.
Hb target: Hct 38%-40%
duration: 12 weeks
Outcomes primary: Hct, haematologic response
secondary: transfusion, safety, QoL
Notes Abstract publication, additional unpublished data were obtained for the this Cochrane
review and an individual patient data meta-analysis study (Bohlius et al 2009, study
number = 98358)
Risk of bias
Bias Authors’ judgement Support for judgement
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Rose 1994 (Continued)
Random sequence generation (selection
bias)
Low risk yes - computer-generated
Allocation concealment (selection bias) Unclear risk unclear - no description
Rose 1994 IPD




Notes study number = 98358
Rose 1994 J&J 2004




Notes Data presented by J&J at FDA/ODAC hearing in May 2004
Rosen 2003
Methods randomised controlled trial, not placebo-controlled
Participants N = 90, randomised: ESA = 47, control = 43
disease: head and neck cancer
treatment: radiation therapy and non platinum-containing chemotherapy
baseline Hb: 12.2 g/dL at baseline
Interventions drug: Epo
dose: 40’000 IU per week
Hb-target: NR
duration: 14 weeks
Outcomes primary: response rate, toxicity, disease free and overall survival
secondary: response to Epo treatment
Notes full text publication, was excluded in the IPD review: n = 90, study number = 72003
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Rosen 2003 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk unclear
Allocation concealment (selection bias) Unclear risk unclear
Rosenzweig 2004
Methods randomised controlled trial, not placebo-controlled
Participants N = 27, randomised: ESA = 14, control = 13
disease: metastatic breast cancer
treatment: less than 50% of participants received chemotherapy, some received hor-
mones, categorised as other
baseline Hb: not reported, eligibility criterion Hb < 12 g/dL, categorised as Hb 10-12
g/dL
Interventions drug: Epoetin alpha
dose: 40,000 IU qw sc
Hb target: NR
duration: 12 weeks
Outcomes primary: fatigue, QoL
Notes full text publication, study number = 76065
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk unclear
Allocation concealment (selection bias) Low risk Yes - using sequential, opaque, sealed en-
velopes with the order unknown to the in-
vestigators
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Savonije 2005
Methods randomised controlled trial, not placebo-controlled
Participants N = 315, randomised: ESA = 211, control = 104
disease: NSCLC, gastrointestinal, gynaecological, colorectal, SCLC, other cancer
treatment: platinum based chemotherapy
baseline Hb: 10.7 g/dL
Interventions drug: Epoetin alpha




secondary: Hb, tumour response, QoL, survival
Notes full text publication, additional unpublished data were obtained for an individual patient
data meta-analysis study (Bohlius et al 2009, study number = 70724)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk unclear - randomisation centre generates a
list of subject numbers and randomly allo-
cate numbers to the two treatment groups
using a block size of six
Allocation concealment (selection bias) Low risk Yes - central randomisation
Savonije 2005 IPD




Notes study number = 70724
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Silvestris 1995
Methods randomised controlled trial, not placebo-controlled
Participants N = 54, randomised: ESA = 30, control = 24
disease: MM
treatment: chemotherapy without platinum
baseline Hb: <=8 g/dL
Interventions drug: Epoetin alpha
dose: 150U/kg 3x/week s.c.
Hb target: no target defined
duration: 24 weeks
Outcomes haematologic response, adverse events
Notes full text publication, study number = 76441
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk unclear
Allocation concealment (selection bias) Unclear risk unclear
Smith 2003
Methods randomised controlled trial, placebo-controlled
Participants N = 86, randomised: ESA = 64, control = 22
disease: genitourinary, breast, gastrointestinal, lymphoma: myeloma, CLL, NHL
treatment: none
baseline Hb: 9.995; <10 g/dL for two groups and 10-12 g/dL for the other two, catego-
rized as <10 g/dL
Interventions drug: Darbepoetin alpha
dose: see below
Hb target: 13-14 g/L (women), 13-15 (men) g/dL
duration: 12 weeks
Outcomes primary: haematopoietic response
secondary: time to response, Hb response, Hb change, transfusions, serum darbepoetin
conc. in a subset of patients
Notes full text publication, study number = 76561
Risk of bias
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Smith 2003 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk unclear
Allocation concealment (selection bias) Unclear risk unclear
Smith 2003 Amgen 2007






Methods See Smith 2003
Participants




Methods See Smith 2003
Participants
Interventions dose b: 6.75 µg/kg Q4W sc
Outcomes
Notes
132Erythropoietin or darbepoetin for patients with cancer (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Smith 2003c
Methods See Smith 2003
Participants




Methods randomised controlled trial, placebo-controlled
Participants N = 989, randomised: ESA = 517, control = 472
disease: lung, hematological malignancies, breast, gastrointestinal, genitourinary, other
cancer (stage III-IV)
treatment: none
baseline Hb: 9.5 g/dL
Interventions drug: Darbepoetin alpha




secondary: Hb, QoL, safety
Notes full text publication, additional unpublished data were obtained for an individual patient
data meta-analysis study (Bohlius et al 2009, study number = 81215)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk unclear
Allocation concealment (selection bias) Low risk Yes, adequate
Smith 2008 IPD
Methods see Smith 2008
Participants
Interventions
133Erythropoietin or darbepoetin for patients with cancer (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.




Methods randomised controlled trial, not placebo-controlled
Participants n = 74, randomised: ESA = 34, control = 40
disease: cervical cancer (stage IIB-IVA)
treatment: radio- and platinum-containing chemotherapy
baseline Hb: 11.5 g/dL
Interventions drug: Epoetin beta
dose: 150 IU/kg sc TIW
Hb-target: 14-15 g/dL
duration: 12 weeks
Outcomes primary: tumour control failures
secondary: progression-free survival, overall response rate, relapses/metastases, overall
survival, Hb change, QoL, safety
Notes full text publication, additional unpublished data were obtained for an individual patient
data meta-analysis study (Bohlius et al 2009, study number = 70404)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk unclear - patient randomisation num-
ber were generated without reporting the
method
Allocation concealment (selection bias) Unclear risk unclear - patient randomisation numbers
were to be allocated sequentially in the or-
der in which the patients are enrolled
Strauss 2008 IPD
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Strauss 2008 IPD (Continued)
Notes
Suzuki 2008
Methods randomised controlled trial, placebo-controlled
Participants N=123: ESA: 81, control=42
disease: lymphoma, breast cancer
treatment: chemotherapy
baseline Hb: not reported, eligibility criterion Hb <= 11 g/dL, after amendment <= 10
g/dL, categorized as Hb 10-12 g/dL
Interventions drug: darbepoetin alpha
dose: a) 4.5 ug/kg sc Q3W or b) 6.75 ug/kg sc Q3W
Hb target: <=13.0 g/dL, amended to <=12.0 g/dL
duration: 12 weeks
Outcomes Hb response, safety, QoL, survival
Notes abstract publication, study id: 14688
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk unclear, not reported
Allocation concealment (selection bias) Unclear risk unclear, not reported
Suzuki 2008a
Methods see Suzuki 2008
Participants darbepoetin: 40, placebo: 42
Interventions darbepoetin 4.5 ug/kg sc Q3W vs placebo
Outcomes
Notes
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Suzuki 2008b
Methods see Suzuki 2008
Participants darbepoetin: 41, placebo: 42




Methods randomised controlled trial, not placebo-controlled
Participants N = 48, randomised: ESA = 24, control = 24
disease: breast, lung, prostate and cervix cancer
treatment: chemotherapy for 5 patients, radiotherapy for probably all of the patients
baseline Hb: ESA arm 12.07, control: 10.72 g/dL, categorized as 10-12 g/dL
Interventions drug: Epoetin alfa
dose: 200 IU/kg/d
Hb target: 14 g/dL for women and 15 g/dL for men
duration: 7 weeks
Outcomes Hb, total white blood cell count and platelets, QoL
Notes full text publication, excluded for IPD-Review, study number = 77932
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk computer-generated random numbers in
blocks of 10
Allocation concealment (selection bias) Unclear risk not reported, unclear
Ten Bokkel 1998
Methods randomised controlled trial, not placebo-controlled
Participants N = 122, randomised: ESA = 88, control = 34
disease: ovarian carcinoma (stage II-IV)
treatment: platinum-based chemotherapy
baseline Hb: 11.6 g/dL
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Ten Bokkel 1998 (Continued)
Interventions drug: Epoetin beta
dose: a: 150 IU/kg sc TIW, b: 300 IU/kg sc TIW
Hb-target: 14-15 g/dL
duration = during chemotherapy, 24 weeks
Outcomes primary: transfusion
secondary: Hb, reticulocytes, Hct, safety, tumour response, adverse events
Notes full text publication, additional unpublished data were obtained for the first Cochrane
review (1985-2001) and an individual patient data meta-analysis study (Bohlius et al
2009, study number = 47852)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk unclear - no description
Allocation concealment (selection bias) Low risk yes - central randomisation
Ten Bokkel 1998a
Methods see Ten Bokkel 1998
Participants Epoetin a: N = 45




Methods see Ten Bokkel 1998
Participants Epoetin 2: N = 42
Interventions dose b: 300U/kg 3x/week s.c.
Outcomes
Notes
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Ten Bokkel1998 IPD




Notes study number = 47852
Thatcher 1999
Methods randomised controlled trial, not placebo-controlled
Participants N = 130, randomised: ESA = 86, control = 44
disease: SCLC
treatment: platinum based chemotherapy
baseline Hb: 13.4 g/dL
Interventions drug: Epoetin alpha
dose: ESA a: 150 IU/kg sc TIW; ESAb: 300 IU/kg sc TIW
Hb-target: 13-15 g/dL
duration: 26 weeks
Outcomes change in Hb values, transfusion requirement, QoL, adverse events
Notes full text publication, additional unpublished data were obtained for the first Cochrane
review (1985-2001) and an individual patient data meta-analysis study (Bohlius et al
2009, study number = 65529)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk unclear - upon study entry each patient was
assigned a sequential identification number
which had been randomly assigned to che-
motherapy with or without ESA, blocks of
6, each investigator had to treat at least 6
patients, but preferably 12 patients
Allocation concealment (selection bias) Unclear risk unclear - see randomisation
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Thatcher 1999 IPD




Notes study number = 65529
Thatcher 1999a
Methods See Thatcher 1999
Participants Epoetin a: n = 42




Methods See Thatcher 1999
Participants Epoetin b: N = 44




Methods randomised controlled trial, not placebo-controlled
Participants N = 130, randomised: ESA = 65, control = 65
disease: breast, gastrointestinal, gynaecological, other cancer
treatment: chemotherapy
baseline Hb: 10.6 g/dL
Interventions drug: Epoetin alpha
dose: if body weight > 45 kg 10000 IU sc TIW, if body weight < 45 kg 5000 IU sc TIW
Hb-target: 12-14 g/dL
duration: 12 weeks
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Thomas 2002 (Continued)
Outcomes Hb, QoL, transfusions
Notes abstract publication, additional unpublished data were obtained for an individual patient
data meta-analysis study (Bohlius et al 2009, study number = 84090)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk unclear - no description
Allocation concealment (selection bias) Low risk yes - central randomisation
Thomas 2002 IPD




Notes study number = 84090
Thomas 2008
Methods randomised controlled trial, not placebo-controlled
Participants N = 114 (from IPD), full-text: accrued: 114, 5 found subsequently not eligible ran-
domised: ESA = 57, control = 52; planned were 460, vs IPD, vs 2006
disease: cervical cancer (stage IIB - IV A, M0)
treatment: platinum-based chemotherapy plus radiotherapy
baseline Hb: 10.7 g/dL
Interventions drug: Epoetin alpha
dose: 40000 IU sc weekly
Hb-target: 13-14 g/dL
duration: 8 weeks max, categorised as 6-9 weeks
Outcomes primary: progression-free survival
secondary: OS, local control, distant recurrences, thromboembolic events
Notes full text publication, additional unpublished data were obtained for an individual patient
data meta-analysis study (Bohlius et al 2009, study number = 21481)
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Thomas 2008 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk unclear - no description “eligible patients
were randomised...”
Allocation concealment (selection bias) Low risk yes - central randomisation
Thomas 2008 IPD





Thomas 2008 J&J 2004






Methods randomised controlled trial, placebo-controlled
Participants N = 66, randomised: ESA = 45, control = 21
disease: Myelodysplastic Syndromes
treatment: no chemotherapy, GM-CSF 0.3-5.0 mg/kg daily in both groups
mean/median baseline Hb: 9 g/dL
Interventions drug: Epoetin alpha
dose: 150U/kg 3x/week s.c. +
Hb target: 12 - 13 g/dL
duration: 12 weeks
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Thompson 2000 (Continued)
Outcomes haematologic response, change in Hb values, transfusion requirement, adverse events
Notes full text publication, additional unpublished data were obtained for the first Cochrane
review (1985-2001), study number = 82687
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Yes - computer random-number generator
Allocation concealment (selection bias) Low risk Yes - adequate
Throuvalas 2000
Methods randomised controlled trial, not placebo-controlled
Participants N = 55, randomised: ESA = 28, control = 27
disease: cervix and bladder carcinoma
treatment: platinum-based radiochemotherapy
baseline Hb: 11.3 g/dL
Interventions drug: Epoetin (?)
dose: 10,000U 5x/week s.c.
Hb target: NR
duration: 6 weeks
Outcomes change in Hb values, transfusion requirement, tumour response
Notes abstract publication, additional unpublished data were obtained for the first Cochrane
review (1985-2001), study number = 83700
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk yes - random-number generator
Allocation concealment (selection bias) Low risk yes - central allocation
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Tjulandin 2010
Methods randomised controlled trial, placebo-controlled
Participants N = 223, randomised: Epo theta = 76, Epo beta = 73, control = 74
disease: ovarian cancer, gastric cancer, breast cancer, lung cancer. other solid cancers
treatment: platinum-based chemotherapy
baseline Hb: 9.5 g/dL
Interventions drug a): Epoetin theta, dose: 20’000 IU weekly
drug b): Epoetin beta, dose: 150 IU/kg sc TIW
Hb-target: 13 g/dL
duration: 12 weeks
Outcomes primary: haematological response
secondary: partial Hb response, RBCTs, number of bloods units transfused, safety, QoL
Notes full-text publication, study number = 19632
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk computer-generated allocation schedule
Allocation concealment (selection bias) Unclear risk not reported
Tjulandin 2010a
Methods see Tjulandin 2010
Participants




Methods see Tjulandin 2010
Participants
Interventions Epoetin beta, dose: 150 IU/kg sc TIW
Outcomes
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Methods randomised controlled trial, placebo-controlled
Participants N = 186, randomised: ESA = 95, control = 91
disease: hematological, breast and gastric cancer
treatment: chemotherapy without platinum
baseline Hb: 9.2 g/dL
Interventions drug: Epoetin theta
dose: 20’000 IU weekly
Hb-target: 13 g/dL
duration: 12 weeks
Outcomes primary: haematological response
secondary: partial Hb response, RBCTs, number of bloods units transfused, safety, QoL
Notes full-text publication, study number = 18036
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk computer-generated
Allocation concealment (selection bias) Unclear risk not reported
Tsuboi 2009
Methods randomised controlled trial, placebo-controlled
Participants N = 122, randomised: ESA = 63, control = 59
disease: lung cancer, malignant lymphoma (HL and NHL)
treatment: chemotherapy, both platinum and non-platinum containing, no numbers
given
baseline Hb: 10.2 g/dL
Interventions drug: Epoetin beta
dose: 36’000 IU sc weekly
Hb target: >= 14 g/dL
duration: 8 weeks
Outcomes primary: Hb change
secondary: hematological response, transfusions, Hb, QoL, (survival, cave: retrospective)
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Tsuboi 2009 (Continued)
Notes full text publication, abstract Watanabe 2006 was excluded for the IPD-Review, study
number = 92759
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk unclear
Allocation concealment (selection bias) Low risk yes - central randomisation system
Untch 2008 IPD






Methods randomised controlled trial, not placebo-controlled
Participants N = 733, randomised: ESA = 356, control = 377
disease: breast cancer (M0)
treatment: non platinum-containing chemotherapy
baseline Hb: 13.6 g/dL
Interventions drug: Darbepoetin alpha
dose: 4.5 µg/kg sc Q2W
Hb-target: 12.5-13 g/dL
duration: during chemotherapy, approximately > 20 weeks
Outcomes primary: relapse free survival time, OS
secondary: tumour control, safety and tolerability, transfusion, Hb level, QoL
Notes two full text publications, in addition unpublished data were obtained for the individual
patient data meta-analysis study (Bohlius et al 2009, study number = 66960)
Risk of bias
Bias Authors’ judgement Support for judgement
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Untch 2011˙1 (Continued)
Random sequence generation (selection
bias)
Unclear risk unclear - no description
Allocation concealment (selection bias) Unclear risk unclear - description is unclear
Untch 2011˙2





Vansteenkiste 02 FDA 2004






Methods randomised controlled trial, placebo-controlled
Participants N = 320, randomised: ESA = 159, control = 161
disease: SCLC (limited and extensive), and NSCLC (stage I-IV)
treatment: platinum based chemotherapy
baseline Hb: 10.1 g/dL
Interventions drug: Darbepoetin alpha
dose: 2.25 mg/kg sc weekly
Hb-target: 13-14 g/dL (women), 13-15 g/dL (men)
duration: 12 weeks
Outcomes primary: transfusion
secondary: Hb response, Hb, transfusion timing and quantity, QoL
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Vansteenkiste 2002 (Continued)
Notes full text publication, additional unpublished data were obtained for and an individual
patient data meta-analysis study (Bohlius et al 2009, study number = 49684)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk unclear - based on a schedule specified by
Amgen before the start of the study
Allocation concealment (selection bias) Low risk yes - central randomisation
Vansteenkiste 2002 IPD




Notes study number = 49684
Welch 1995
Methods randomised controlled trial, not placebo-controlled
Participants N = 30, randomised: ESA = 15, control = 15
disease: ovarian carcinoma
treatment: platinum-containing chemotherapy
mean/median baseline Hb: 12.9 g/dL
Interventions drug: Epoetin alpha
dose: 300U/kg 3x/week s.c.
Hb - target: 12-15 g/dL
duration: 24 weeks
Outcomes change in Hb values, transfusion requirement, adverse events
Notes full text publication, study number = 97952
Risk of bias
Bias Authors’ judgement Support for judgement
147Erythropoietin or darbepoetin for patients with cancer (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Welch 1995 (Continued)
Random sequence generation (selection
bias)
Unclear risk unclear
Allocation concealment (selection bias) Unclear risk unclear
Wilkinson 2006
Methods randomised controlled trial, not placebo-controlled
Participants N = 182, randomised: ESA = 121; control = 61
disease: ovarian cancer (stage I-IV)
treatment: chemotherapy
baseline Hb: 10.7 g/dL
Interventions drug: Epoetin alpha
dose: if body weight > 45 kg 10000 IU sc TIW, if < 45 kg 5000 IU sc TIW
Hb-target: 12-14 g/dL
duration: max. 28 weeks
Outcomes primary: Hb response
secondary: QoL, transfusion, tumour response
Notes full text publication, additional unpublished data were obtained for an individual patient
data meta-analysis study (Bohlius et al 2009, study number = 75688)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk unclear - a prospective randomisation pro-
cedure will be employed
Allocation concealment (selection bias) Unclear risk unclear - assigned envelopes, but it is un-
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Winquist 2009
Methods randomised controlled trial, placebo-controlled
Participants N = 56, randomised ESA: 26, control = 30
disease: prostate cancer
treatment: unclear
Baseline Hb: 10.4 g/dL
Interventions drug: epoetin alpha
dose: 40,000 IU sc 3 times /week
Hb target: 14.0 g/dL
duration: 16 weeks
Outcomes primary: QoL
secondary: Hb level, RBCTs, adverse events, survival
Notes letter publication, study number 13321
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk not reported, unclear
Allocation concealment (selection bias) Low risk central telephone
Witzig 2005
Methods randomised controlled trial, placebo-controlled
Participants N = 344, randomised: ESA = 174, control = 170
disease: lung, breast, other cancer (active incurable advanced stage)
treatment: chemotherapy, platinum & non platinum
Hb category: 9.5 g/dL
Interventions drug: Epoetin alpha
dose: 40000 IU sc weekly
Hb-target: 13-15 g/dL
planned ESA duration: 16 weeks
Outcomes primary: transfusions
secondary: Hb change, Hb over time, predictors for response, incidence of nephrotoxi-
city, OS, tumour response, QoL
Notes full text publication, additional unpublished data were obtained for an individual patient
data meta-analysis study (Bohlius et al 2009, study number = 36512)
Risk of bias
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Witzig 2005 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk yes - computer-generated
Allocation concealment (selection bias) Low risk yes - central randomisation and coded drug
packs of identical appearance
Witzig 2005 IPD





Witzig 2005 J&J 2004




Notes Data presented by J&J at FDA/ODAC hearing in May 2004
Wright 2007
Methods randomised controlled trial, placebo-controlled
Participants N = 70, randomised: ESA = 33, control = 37
disease: NSCLC (advanced stage IIIA, B and IV, recurrent disease)
treatment: no anticancer therapy
baseline Hb: 10.3 g/dL
Interventions drug: Epoetin alpha
dose: 40’000 IU sc weekly
Hb-target: 12-14 g/dL
duration = 12 weeks
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Wright 2007 (Continued)
Outcomes primary: QoL
secondary: Hb, Hct, transfusion, safety
Notes full text publication, additional unpublished data were obtained for an individual patient
data meta-analysis study (Bohlius et al 2009, study number = 53572)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk yes - computer-generated
Allocation concealment (selection bias) Low risk yes - central randomisation
Wright 2007 IPD






Methods randomised controlled trial, placebo-controlled
Participants N = 30, randomised: ESA = 16, control = 14
disease: Ewing’s or osteosarcoma
treatment: chemotherapy, some platinum-based
mean/median baseline Hb: 10.8 g/dL
Interventions drug: Epoetin beta
dose: 600U/kg 2x/week i.v.
Hb-target: 11-13.5 g/dL
duration: 20 weeks
Outcomes change in Hb values, transfusion requirement, adverse events
Notes full text publication, no IPD data, study number = 97958
Risk of bias
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Wurnig 1996 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Yes - computer-generated randomisation
code
Allocation concealment (selection bias) Unclear risk Unclear
CLL: Chronic lymphatic leukaemia
D: day
ESA: erythropoiesis stimulating agent
FDA: Food and Drug Administration, USA




IPD: individual patient data
i.v.: intravenous
J&J: Johnson & Johnson Pharmaceuticals Ltd.
MM: multiple myeloma
NHL: non-Hodgkin’s lymphoma
NSCLC: non-small cell lung cancer
NR: not reported
ODAC: Oncology Drug Advisory Committee
OS: overall survival
QoL: Quality of Life
qw: once per week
Q3W: once every three weeks
Q4W: once every four weeks
RBC: red blood cell
s.c.: subcutaneous
SCLC: small cell lung cancer




Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Aagaard 2010 nrct
Aapro 2009 nrct
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(Continued)
Abdelrazik 2007 ineligible patient characteristics: ALL
Abraham 2011 nrct
Adamson 2009 no RCT
Alexopoulos 2004 randomised comparison of epoetin alfa 10,000 IU tiw versus darbepoetin alfa 150 mcg qw, n = 50
Anonymous 2007 no RCT
Anthony 2011 all arms ESAs
Arcasoy 2010 nrct
Arslan 2004 randomised comparison of different usage strategies
Auerbach 2004 randomised comparison of different iron applications
Australian 2010 nrct
Aziz 2001 treatment allocation not concealed
IPD: too small for inclusion
Barosi 1998 nrct
Barosi 2011 nrct
Beggs 2003 randomised comparison of 40,000 IU epoetin alfa versus placebo, study too small for inclusion: n = 21
Bell 2008 no RCT
Bessho 1997 ineligible patient characteristics: only patients with aplastic anaemia included, N = 131
Bindi 2004 unclear whether this a randomised controlled trial, authors have been unsuccesfully contacted
IPD: too small for inclusion
Blayney 2003 study stated to be randomised, experimental arms received darbepoetin alfa, treatment in the control
group not documented, authors were contacted for clarification without success, n = 1173
Boccia 2007 no RCT
Borg 2008 no RCT
Borget 2008 no RCT
Bowen 2004 G-CSF only in one arm
Brower 2008 nrct
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(Continued)
Buchler 2011 nrct
Buyukpamukcu 2002 follow-up study to Varan 1999, does not satisfy allocation concealment requirement
Cabanillas 2012 acute leukaemia
Candelaria 2005 no ESA was given
Canon 2006 compared different ESA dosages
Canon 2011 retrospective analysis of dose-fidning study
Caravita 2009 nrct
Casadevall 2004 randomised controlled study in patients with MDS, comparing erythropoietin PLUS G-CSF versus
supportive care without erythropoietin and without G-CSF
Cazzola 2003 randomised comparison of once weekly 30,000 IU epoetin beta versus three times weekly 10,000 IU
epoetin beta
Chan 1995 very small trial, only 10 evaluable patients per study arm
Cheng 2009 yixuesheng capsule with ESA vs ESA alone
Christodoulakis 2005 ESAs were given in context with surgery
Coiffier 2006 nrct
Coleman 2009 not randomised for epo
Crawford 1997 randomised-controlled trial, placebo controlled, double-blind, included 25 patients with SCLC, as no
sufficient data were available the study was excluded
Crawford 2003 randomised comparison of epootin alfa 40,000 IU per week versus control; patients in the control group
received epoetin alfa when the Hb level decreased below 10g/dL, n = 216
Crawford 2007 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Cremieux 2003 nrct
Dahl 2008 nrct
Daneryd 1998 epoetin only given to the anaemic patients in the treatment arm
Dannemann 2004 compared different ESA dosages
Demetri 1998 community based, non randomised study including 2,370 patients with nonmyeloid malignancies
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Dusenbery 1994 mixed concurrent and historical controls
Elsaid 2001 n too small
Fagnoni 2005 retrospective study design
Ferrero 2009 no RCT
Franchi 2008 no RCT, dose comparing
Freeman 2006 too small for inclusion, n = 14
Fujisaka 2004 single arm study, no RCT
Gabrilove 2001 community based, nonrandomised study including 3,012 participants with nonmyeloid malignancies
Garton 1995 very small trial, only 10 evaluable patrticipants per study arm
Gascon 2008 nrct
Gebbia 1992 n = 19, too small for inclusion
Glaser 1999 noRCT, 37participantswith advanced oral squamous carcinoma receiving neoadjuvant radiochemother-
apy
Glaser 2001 noRCT, 191patientswith advanced oral squamous carcinoma receiving neoadjuvant radiochemotherapy
Glaspy 1997 community study
Glaspy 2001 dose finding study, not randomised
Glaspy 2002 darbepoetin versus erythropoietin, related to Glaspy 2002b
Glaspy 2002b darbepoetin versus erythropoietin, related to Glaspy 2002
Glaspy 2003 darbepoetin versus erythropoietin
Glaspy 2005 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Glaspy 2006 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Glaspy 2011 nrct
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(Continued)
Glimelius 1998 randomised study with two different EPO groups: 2.000 U sc three times per week versus 10.000 U sc
tree times per week
Glossmann 2003 randomised controlled comparison in patietns with relapsed lymphoma undergoing stem-cell supported
high-dose therapy with or without erythropoietin
Goldsmith 2011 nrct
Granetto 2003 randomised comparison of fixed versus weight-based dosing of epoetin alfa
Gregory 2005 nrct
Grigorescu 2006 probably not randomised
Hadland 2009 nrct
Han 2008 randomised trial of amifostine vs epo
Harousseau 2005 nrct
Hellström-Lindberg 1998 G-CSF supplementation only in the control arm
Hellstörm-Lindberg 2010 nrct
Henry 2004 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Henry 2006 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Henry 2007 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Henze 2002 surgery
Hesketh 2004 comparison of different darbepo dosages
Hirsh 2007 CERA
Huggett 2011 not relevant (listed as ”other reasons“ in prisma”)
Hyer 2011 nrct
Itzykson 2009 case report, no RCT
Jacubowski 2003 comparisons of epo versus darbepo, ongoing
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(Continued)
Jadersten 2008 nrct
Jitnuyanont 2001 randomised comparison of erythropoietin versus control in 24 anaemic cancer patients, study was split
into three arms with 10 and less patients per study arm
Johansson 2001 randomised comparison of epeotin beta 1,000 IU versus 5,000 IU three times per week
Jones 2011 nrct
Juan 2006 no RCT




Kettelhack 1998 ESAs were given in context with surgery
Kim 2010 no cancer
Kosmadakis 2003 ESAs were given in context with surgery
Kotasek 2004 compared different ESA dosages
Kotasek 2007 compared different ESA dosages






Leon 1998 historical control group
Lichtin 2008 nrct
Loibl 2006 all patients received ESAs
Ludwig 1995 nrct
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(Continued)
Malik 1998 nrct, N = 23
Mangiameli 2002 randomised controlled study with 5 patients per study arm
Mantovani 2000 nrct
Marinaccio 2003 randomised comparison of epoetin alfa versus control for patients with ovarian cancer undergoing surgery
and chemotherapy, epoetin was administered BEFORE surgery, n = 22
Markman 1993 comparison of two non-randomised trials
Mel 2008 nrct
Merchionne 2009 nrct
Merlano 2001 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
MF4266 ineligible patient characteristics AML
Miller 2004 unclear wether this is a randomised trial
Morishima 2006 compared different ESA dosages
Morrow 2007 nrct
Muravyov 2009 single arm study without control group
Muravyov 2010 nrct
Mustacchi 2006 nrct
Nagel 2011 too many patients in experimental arm did not receive ESAs
NCT00364845 2011 no cancer
Nonoguchi 2009 nrct
Oberhoff 2005 nrct
Olsson 2002 randomised comparison of epeotin beta 1,000 IU versus 5,000 IU three times per week
Opie 2011 nrct
Ots 2008 epoetin vs darbepoetin
Pat 2009 nrct
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(Continued)
Pierelli 1999 randomised-controlled trial, unblinded, not placebo controlled, 50 participants with ovarian carcinoma
were included, as no sufficient data were available, the study was excluded
Poirier 2010 nrct
Policarpo 2007 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Popescu 2010 nrct
Porter 1996 too small for inclusion
Puglisi 2009 subgroup analysis
Rades 2009 nrct
Rath 2010 nrct
Rau 1998 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Rearden 2004 randomised comparison of darbepoetin early and late initiating of treatment




Sakai 2004 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Samper 2002 randomised comparison of erythropoetin alfa 10,000 IU three times per week versus 30,000 IU once
per week
Schwartzberg 2004 darbepo versus epo
Schwartzberg 2005 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Schwartzberg 2007 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Scott 2002 randomised comparison of erythropoietin versus placebo in head and neck cancer patients undergoing
surgery
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(Continued)
Senecal 2005 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Shasha 2003 community study
Shi 2007 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Shord 2009 nrct
Spaeth 2010 nrct
Spicka 2004 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Steensma 2006 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Steensma 2011 all patients EPO
Stein 1991 very small study, fewer than 10 participants per treatment arm




Straus 2002 upfront epo compared to epo if Hb decreased below 9 g/dL
Straus 2006 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Stull 2010 nrct
Suzuki 2008ex single arm study
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(Continued)
Varan 1999 treatment allocation not concealed
IPD: too small for inclusion
Vekeman 2009 nrct
Velilla Millan 2003 randomised comparison of epeotin 10,000 IU tiw versus 40,000 IU qw
Vorvaud 2007 nrct
Wagner 2004 no usable data for any outcome
Walsh 2010 nrct
Waltzman 2004 comment to Glaspy 2003 study
IPD: Darbepoetin compared to erythropoietin
Waltzman 2005 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or




Yilmaz 2004 application of different erythropoietin alfa dosages: 150 IU/kg tiw versus 250 IU/kg tiw in children with
cancer
Yurut-Caloglu 2008 nrct
Zagari 2003 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Zaragoza 2004 n = 17, too small for inclusion
Zhang 2003 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Zhou 2006 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
ALL: acute lymphatic leukaemia
AML: acute myeloid leukaemia
CERA: continuous erythropoietin receptor activator
ESAs: erythropoiesis stimulating agents
G-CSF: granulocyte colony-stimulating factor
Hb: haemoglobin
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nrct: not a randomised controlled trial
RCT: randomised controlled trial
SAA: serum amyloid A
SCLC: small cell lung cancer
sc: subcutaneous
vs: versus
Characteristics of ongoing studies [ordered by study ID]
Blackstock
Trial name or title 1CDR0000069148CCCWFU-62299; NCI-P01-0200; CCCWFU-BG01-193
Methods
Participants Solid - NSCLC Chem + Rad
Interventions Epo, unsure - Epo dose unknown
Outcomes Hb levels, disease progression, tumour response rate, overall survival, QoL, number of RBCT
Starting date January 2002
Contact information AR Blackstock
Notes
Boehrer 2010
Trial name or title GFMAzaEpo-2008-1 trial, NCT01015352
Methods Randomised phase-II trial
Participants Lower Risk Myelodysplastic Syndrome (MDS)
Interventions AZA vs AZA+Epoetin beta
Outcomes Major erythroid responses (HI-Emajor) after 6 courses, according to IWG2000 criteria. Secondary endpoints
included overall IWG 2000 HI-E, including major and minor, after 4 and 6 courses, response duration, IPSS
progression, survival and toxicity
Starting date NR
Contact information
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Boehrer 2010 (Continued)
Notes http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg
Unclear whether it should be included or not.
Broadley
Trial name or title Double-blind randomised placebo controlled trial of the effect of epoetin alfa on symptomatic anaemia and
fatigue in cancer patients receiving ongoing care without planned chemotherapy
Methods
Participants Disease: metastatic breast and prostate cancer;
Treatment: none
Interventions Epoetin alfa vs placebo
Outcomes Change in HB values;
QoL.
Starting date October 1998
Contact information Dr K. Broadley
Palliative Medicine








Trial name or title NRR 2004 Issue 2 Study ID numbers: N0123138194, REC 01/05/53.C
Methods
Participants Haem - MM, Chemotherapy
Interventions Epo alfa vs standard, epo dose unknown
Outcomes Hb Respnse, QoL (FACT-An)
Starting date Jan 2002, Finish date: June 05
Contact information Chapman C
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Trial name or title LNH03-6B GELA Study
Methods Multicentric prospective randomised phase III study
Participants Elderly patients with DLBCL treated by immunochemotherapy
Interventions Darbepoetin vs usual treatment
Outcomes The efficacy of DA in association with chemotherapy (R-CHOP) as measured by the EFS at 2 years, events
being defined as death from any cause, relapse for complete responders and unconfirmed complete responders,
progression during or after treatment and changes of therapy during allocated treatment. Secondary objectives





Trial name or title EPO-CAN-303;NCT00083434R
Methods
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Famoyin 2004
Trial name or title A randomised phase II study of thalidomide with or without erythropoietin (EPO) in metastatic renal cell
carcinoma (RCC)
Methods Randomised phase II study
Participants Metastatic renal cell carcinoma
Interventions Thalidomide with or without EPO
Outcomes Hb, QoL
Starting date
Contact information C. Famoyin, C. Byrnes, S. Roberts, J. Gollob, M. Atkins, J. Mier, Y.-J. Ko, S. Gautam and D. McDemott
Beth Israel Deaconess Medical Center, Boston, MA
Notes Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition).
Vol 22, No 14S (July 15 Supplement), 2004: 4747
Fisch
Trial name or title CDR0000069409; MDA-DM-02331; MDA-DM-0038; NCI-P02-0225; NCI00052221MJ
Methods
Participants Solid tumours, no concomitant anti- malignancy treatment
Interventions Epo alfa vs Placebo
Outcomes Hb response, QoL, Fatigue
Starting date Feb 03
Contact information Fisch S
Notes
Gallagher
Trial name or title The role of epoetin alpha in anaemia and fatigue in cancer patients
Methods
Participants Disease: ovarian and cervical cancer
Treatment: concomitant cisplatin chemotherapy
Interventions Epoetin alpha vs no treatment
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Gallagher (Continued)
Outcomes Changes in HB values;
QoL
Starting date September 1998
Contact information Dr C Gallagher
Medical Oncology Department







Trial name or title Erythropoietin for the prevention of anaemia in neoplastic patients treated with cisplatin
Methods Randomised controlled study
Participants Patients with advanced tumours
Interventions Epoetin alpha versus control
Outcomes Hb, serum epoetin levels
Starting date NR
Contact information T. Gamucci, Department of Medical Oncology, 1, Regina Elena Institute for Cancer Research, Rome, Italy,
Notes Gamucci T, Thorel MF, Frasca AM, Giannarell D, Calabresi F. Erythropoietin for the prevention of anaemia
in neoplastic patients treated with cisplatin. Eur J Cancer. 1993;29A Suppl 2:S13-4. PMID: 8398359
Gascon 2010
Trial name or title Amgen 20070782; ClinicalTrials.gov NCT00858364
Methods Randomized, placebo-controlled trial
Participants Non-small cell lung cancer (NSCLC) patients (pts) with anaemia concomitant with chemotherapy (ACC)
Interventions Darbepoetin vs placebo
Outcomes Noninferiority of ESA to placebo for overall survival (primary endpoint) and progression-free survival (mod-
ified RECIST per investigator; secondary endpoint) will be examined when 2700 deaths occur. Other safety
endpoints include tumour response and thromboembolic events. Transfusion rates are a key efficacy endpoint;
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Gascon 2010 (Continued)
Hb changes will also be reported
Starting date NR
Contact information NR
Notes No results yet; to follow up
Ghavamzadeh 2010
Trial name or title NR
Methods Randomized, double blind, placebo-controlled phase III study





Notes Not retrievable from librarians. unclear whether it would be included or not
H Thomas 1997
Trial name or title Open label comparative evaluation of the effect of epoetin on quality of life and burden of illness in anaemic
patients receiving platinum-containing chemotherapy
Methods
Participants Disease: cancer;
Treatment: concomitant platinum-based chemotherapy
Interventions
Outcomes Changes in Hb values;
QoL
Starting date July 1997
Contact information Dr Hilary Thomas
Department of Clinical Oncology
Imperial College School of Medicine
Hammersmith Hospital
Du Cane Road
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Trial name or title A double blind, randomised, placebo-controlled study to evaluate the impact of maintaining haemoglobin
using epoetin alpha in stage IV breast cancer subjects receiving chemotherapy
Methods
Participants Disease: breast cancer;
Treatment: concomitant chemotherapy
Interventions Epoetin alfa vs placebo





Starting date August 2000
Contact information Prof A. Howell








Trial name or title CDR 0000257189;AGOSG-OVAR-MO16375-MARCH; EI20217; ROCHE-MO16375; ROCH-
RO2053859
Methods
Participants Solid cancers, Cervix ca, undergoing chemo - plat + Rad
Interventions Epo beta vs Standard care , epo dose unknown
Outcomes Hb, AE, TR, Hb response, QoL
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Koelbl (Continued)
Starting date
Contact information H Koelbl
Notes
Lambin 2006
Trial name or title Lambin, was CDR0000068669 and EORTC 22996-24002
Methods A phase III double-blind, randomised, placebo-controlled study of Erythropoietin when used as an adjuvant
to radiation therapy in patients with head and neck squamous cell carcinoma
Participants Head and neck squamous cell carcinoma; Radiation
Interventions Epo once a week +RT +/-chemotherapy versus placebo +RT +/-chemotherapy
Outcomes Loco-regional control, overall survival, Hb levels during radiotherapy, adverse effects
Starting date February 1999
designed for 762 patients
Contact information Dr. P-. Lambin, EORTC, Maastricht/Heerlen, The Netherlands
Dr V. G. Budach
Arbeitsgemeinschaft Radiologische Onkologie
Dr J. Bernier
EORTC Head and Neck Cancer Group
Dr J.-H. Bourhis
Groupe d’Oncologie et Radiothérapie Tête et Cou
Dr J. Denham
Trans-Tasman Radiation Oncological Group Incorporated
Notes
Liang 2009
Trial name or title The clinical study on recombinant human erythropoietin for chemotherapy - related anaemia
Methods Randomised controlled trial, not placebo-controlled




169Erythropoietin or darbepoetin for patients with cancer (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Liang 2009 (Continued)
Interventions Drug: Epo






Notes Liang J,QingB, ShenL,ChengH.The clinical study on recombinant human erythropoietin for chemotherapy
- related anaemia. Clinical Research 2009;29(1):58-60; full text in Chinese, English abstract, study number
= 54993
Nitz 2008
Trial name or title Adjuvant chemotherapy with or without darbepoetin in node-positive breast cancer: a safety analysis from
the phase III ARA plus trial
Methods Randomised controlled trial
Participants Breast cancer patients




Notes Nitz U, Oberhoff C, Reimer T, Schumacher C, Hackmann J, Warm M, Uleer C, Runde V, Gluz O, Zuna
I West German Study Group, Moenchengladbach, Germany; Marienhospital, Essen, Germany; Klinikum
Suedstadt, Rostock, Germany; St. Elisabeth KH, Koeln, Germany; Uni Koeln, Koeln, Germany; HZM
Pharmaservice,Wiesbaden, Germany; Praxis Gyn. Onko.,Hildesheim, Germany;Wilhelm-Anton-H., Goch,
Germany. Adjuvant chemotherapywith or without darbepoetin in node-positive breast cancer: a safety analysis
from the phase III ARA plus trial. San Antonio Breast Cancer Symposium 2008:4100
O´ Brien
Trial name or title Open-label randomised group-comparative evaluation of the effect of epoetin on anaemia and fatigue in lung
cancer patients receiving palliative platinum containing chemotherapy
Methods
Participants Disease: lung cancer
Treatment: concomitant platinum containing chemotherapy
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O´ Brien (Continued)
Interventions Epoetin vs standardised intervention
Outcomes Change in HB values;
QoL;
Response and tolerance to chemotherapy.
Starting date August 1998
Contact information Dr Mary O´ Brien
Medicine Section








Trial name or title Phase III randomised study of epoetin alfa in anaemic patientswith advanced cancer undergoing chemotherapy
Methods
Participants Disease: advanced cancer;
Treatment: concomitant chemotherapy
Interventions Epoetin alfa vs placebo
Outcomes Change in Hb values;
Transfusion requirement;
QoL.
Starting date December 1998
Contact information Dr M. J. O´ Connell
North Central Cancer Treatment Group USA
Notes
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Park 1996
Trial name or title Clinical evaluation of recombinant human erythropoietin (Eprex) in anaemic cancer patients receiving che-
motherapy
Methods Randomised controlled trial
Participants Anaemic cancer patients (lung cancer, stomach cancer, colon cancer)
Interventions Epeotin alpha
Outcomes Haematocrit, RBC transfusion
Starting date NR
Contact information NR
Notes Park HS, Hong DS, Lee SJ, Chung TJ, Choi YM. Clinical evaluation of recombinant human erythropoietin
(Eprex) in anaemic cancer patients receiving chemotherapy. Ann Oncol 1996;7(Suppl 5)
Parliament
Trial name or title Radiation therapy with or without Epoetin alfa in anaemic patients with head and neck cancer
Methods




Outcomes Changes in Hb values; AEs; QoL; local tumour control rate; OS
Starting date






Trial name or title EPREX trial: Open-label comparative-group evaluation of the effect of epoetin alfa on quality of life and
burden of illness in anaemic cancer patients receiving platinum containing chemotherapy
Methods
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R Thomas 2002 (Continued)
Participants Disease: various malignancies;
Treatment: concomitant platinum-based chemotherapy




Change in Hb values.
Starting date June 1997
Contact information Dr R. Thomas
Primrose Oncology Unit







Trial name or title Randomised comparison of epoetin alfa versus control in patients with multiple myeloma, n=91, only interim
analysis available so far, costs reported
Methods Randomised controlled trial
Participants Patients with multiple myeloma




Notes Recasens V, Rubio-Martinez A, Gomez-Barrera M, Rubio-Felix D, Giralt M, Giraldo P. A pharmacoeconom-
ical
analysis comparing Epoetin Alpha vs transfusion in patients with anaemia associated to multiple myeloma.
Blood. 2003;
Vol. 102, issue 11.
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Rexer 2006
Trial name or title Prospektiv offene, randomisierte Phase III Studie zur Evaluation von Darbepoetin Alfa (Aranesp) als Support-
ivtherapie bei Paienten mit ”good/intermediate prognosis“ Keimzelltumoren: PEB versus PEB+ Darbepoetin
alfa (Aranesp”), Leitung: Prof. Bokemeyer, University Hospital Eppendorf, Hamburg, Germany
Methods Randomised controlled trial
Participants Testicular cancer patients
Interventions Darbepoetin versus control
Outcomes Hb, RBC transfusion, QoL, disease progressions, OS.
Starting date NR
Contact information Ina Böhlke, i.boehlke@uke.uni-hamburg.de
Notes Rexer H [Darbepoetin alfa (Aranesp) as supportive therapy in patients with germ cell




Trial name or title Evaluation of epoetin in lung cancer pts. receiving chemotherapy
Methods
Participants Disease: lung cancer;
Treatment: concomitant platinum-based chemotherapy
Interventions Epoetin alpha vs no treatment
Outcomes
Starting date November 1998
Contact information Dr R. M. Rudd
Medical Oncology Department
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Stewart
Trial name or title Open randomised comparative group evaluation of the effect of epoetin alfa on local disease free survival and
quality of life in head and neck cancer patients receiving radical radiotherapy
Methods
Participants Disease: head and neck cancer;
Treatment: concomitant radiotherapy
Interventions




Starting date August 1999









Trial name or title A double-blind, placebo controlled study to assess the effects of early intervention and/or treatment with








Contact information UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London NW1 2DA
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Trial name or title The Effectiveness of a Fixed Low Dose of Erythropoietin (EPO) in Anemic Solid Tumor Patients Receiving
Concomitant Chemotherapy: A Prospective, Randomized, Controlled Study
Methods Randomised controlled trial
Participants Anemic solid tumour patients




Notes Youssef Lama A, Hussien Dilman Haj, Sulaiman Siham. The Effectiveness of a Fixed Low Dose of Ery-
thropoietin (EPO) in Anemic Solid Tumor Patients Receiving Concomitant Chemotherapy: A Prospective,
Randomized, Controlled Study. ASH Annual Meeting Abstracts 2011;118(21):2092
Ziras 2001
Trial name or title Soluble transferrin receptor (sTFR) as a predictor of response to prophylactic epoetin alfa (EPO) treatment
in non-anaemic cancer patients (pts) under chemotherapy (CT). Preliminary results
Methods Randomised controlled trial




Contact information Agii Anargiri Cancer Hospital Athens, Metaxa Cancer Hosptial, Piraeus, Greece
Notes Proc Am Soc Clin Oncol 20:2001 (abstr 2987)
AE: adverse event
AZA: Azacitidine
DLBCL: diffuse large B-cell lymphoma.
EPO: Erythropoietin
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ESA: erythropoiesis stimulating agent
G-CSF: granulocyte colony-stimulating factors
Hb: haemoglobin




QoL: quality of life




RBCT: red blood cell transfusions
RT: radiotherapy
TR: tumour response
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D A T A A N D A N A L Y S E S
Comparison 1. Haematologic response




participants Statistical method Effect size
1 Haematological response -
overall
46 6413 Risk Ratio (M-H, Fixed, 95% CI) 3.39 [3.10, 3.71]
2 Haematologic response - baseline
Hb
46 6413 Risk Ratio (M-H, Fixed, 95% CI) 3.39 [3.10, 3.71]
2.1 Hb <= 10 g/dL 36 4137 Risk Ratio (M-H, Fixed, 95% CI) 3.02 [2.72, 3.35]
2.2 Hb 10 to 12 g/dL 8 1775 Risk Ratio (M-H, Fixed, 95% CI) 4.60 [3.79, 5.58]
2.3 Hb > 12 g/dL 1 380 Risk Ratio (M-H, Fixed, 95% CI) 7.48 [3.00, 18.62]
2.4 Hb category unclear 1 121 Risk Ratio (M-H, Fixed, 95% CI) 2.04 [1.20, 3.46]
3 Haematologic response -
different malignancies
46 6413 Risk Ratio (M-H, Fixed, 95% CI) 3.39 [3.10, 3.71]
3.1 solid tumours 18 3089 Risk Ratio (M-H, Fixed, 95% CI) 3.56 [3.12, 4.07]
3.2 haematological
malignancies
15 1623 Risk Ratio (M-H, Fixed, 95% CI) 3.12 [2.64, 3.69]
3.3 MDS 2 151 Risk Ratio (M-H, Fixed, 95% CI) 4.27 [0.86, 21.19]
3.4 mixed 12 1550 Risk Ratio (M-H, Fixed, 95% CI) 3.38 [2.80, 4.08]
3.5 not reported 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Haematological response- age 46 6413 Risk Ratio (M-H, Fixed, 95% CI) 3.39 [3.10, 3.71]
4.1 children 1 222 Risk Ratio (M-H, Fixed, 95% CI) 1.62 [1.20, 2.18]
4.2 adults 45 6191 Risk Ratio (M-H, Fixed, 95% CI) 3.55 [3.23, 3.90]
5 Haematological response- age
differentiated
46 6413 Risk Ratio (M-H, Fixed, 95% CI) 3.39 [3.10, 3.71]
5.1 only children <18 years 1 222 Risk Ratio (M-H, Fixed, 95% CI) 1.62 [1.20, 2.18]
5.2 adults ≥18 years 43 5623 Risk Ratio (M-H, Fixed, 95% CI) 3.34 [3.03, 3.68]
5.3 >70% non-elderly 18-65
years
2 568 Risk Ratio (M-H, Fixed, 95% CI) 8.26 [5.22, 13.06]
5.4 only non-elderly adults 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.5 >70% elderly >65 years 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.6 only elderly adults 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Haematologic response -
different therapies
46 6413 Risk Ratio (M-H, Fixed, 95% CI) 3.39 [3.10, 3.71]
6.1 chemotherapy 38 5562 Risk Ratio (M-H, Fixed, 95% CI) 3.32 [3.02, 3.64]
6.2 radiotherapy/
radiochemotherapy
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.3 no therapy 7 630 Risk Ratio (M-H, Fixed, 95% CI) 5.50 [3.25, 9.31]




46 6413 Risk Ratio (M-H, Fixed, 95% CI) 3.39 [3.10, 3.71]
7.1 chemotherapy, >70% with
platinum
7 1301 Risk Ratio (M-H, Fixed, 95% CI) 3.12 [2.51, 3.87]
7.2 chemotherapy, <70%
platinum containing
3 659 Risk Ratio (M-H, Fixed, 95% CI) 2.71 [2.16, 3.40]
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7.3 chemotherapy without
platinum (all patients)




8 643 Risk Ratio (M-H, Fixed, 95% CI) 4.05 [2.84, 5.77]
7.5 chemotherapy no details
given
3 345 Risk Ratio (M-H, Fixed, 95% CI) 2.13 [1.59, 2.86]
7.6 radiochemotherapy 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.7 radiotherapy 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.8 no therapy 7 630 Risk Ratio (M-H, Fixed, 95% CI) 5.50 [3.25, 9.31]
7.9 other 1 221 Risk Ratio (M-H, Fixed, 95% CI) 2.87 [1.69, 4.85]
8 Haematologic response - epoetin
versus darbepoetin
46 6413 Risk Ratio (M-H, Fixed, 95% CI) 3.39 [3.10, 3.71]
8.1 Epoetin 30 5270 Risk Ratio (M-H, Fixed, 95% CI) 3.27 [2.97, 3.59]
8.2 Darbepoetin 16 1143 Risk Ratio (M-H, Fixed, 95% CI) 4.22 [3.22, 5.55]
9 Haematologic response -
duration of ESA medication
46 6413 Risk Ratio (M-H, Fixed, 95% CI) 3.39 [3.10, 3.71]
9.1 6 to 9 weeks 6 349 Risk Ratio (M-H, Fixed, 95% CI) 3.74 [1.94, 7.19]
9.2 12 to 16 weeks 34 4574 Risk Ratio (M-H, Fixed, 95% CI) 3.17 [2.87, 3.51]
9.3 more than 17 weeks 6 1490 Risk Ratio (M-H, Fixed, 95% CI) 4.41 [3.52, 5.52]
10 Haematologic response - iron
supplementation
46 6413 Risk Ratio (M-H, Fixed, 95% CI) 3.39 [3.10, 3.71]
10.1 fixed iron
supplementation
2 441 Risk Ratio (M-H, Fixed, 95% CI) 2.43 [1.92, 3.07]
10.2 iron supplementation as
necessary
36 5265 Risk Ratio (M-H, Fixed, 95% CI) 3.63 [3.27, 4.03]
10.3 no explicit statement on
iron supplementation or no
iron given
7 399 Risk Ratio (M-H, Fixed, 95% CI) 4.82 [2.64, 8.81]
10.4 explicitly stated NO
IRON
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.5 iron given differently in
both study arms
1 308 Risk Ratio (M-H, Fixed, 95% CI) 2.22 [1.63, 3.01]
11 Haematologic response -
allocation concealment
46 6413 Risk Ratio (M-H, Fixed, 95% CI) 3.39 [3.10, 3.71]
11.1 adequate 30 4721 Risk Ratio (M-H, Fixed, 95% CI) 3.35 [3.02, 3.72]
11.2 unclear 16 1692 Risk Ratio (M-H, Fixed, 95% CI) 3.50 [2.92, 4.19]
12 Haematologic response -
masking
46 6413 Risk Ratio (M-H, Fixed, 95% CI) 3.39 [3.10, 3.71]
12.1 double-blind 29 3430 Risk Ratio (M-H, Fixed, 95% CI) 3.02 [2.70, 3.37]
12.2 unblinded 17 2983 Risk Ratio (M-H, Fixed, 95% CI) 4.07 [3.49, 4.74]
13 Haematologic response -
intention-to treat
46 6413 Risk Ratio (M-H, Fixed, 95% CI) 3.39 [3.10, 3.71]
13.1 ITT or less than 10%
of participants per study arm
excluded
41 5657 Risk Ratio (M-H, Fixed, 95% CI) 3.32 [3.03, 3.65]
13.2 more than 10% of
participants per study arm
excluded
2 512 Risk Ratio (M-H, Fixed, 95% CI) 6.85 [3.76, 12.48]
13.3 unclear 3 244 Risk Ratio (M-H, Fixed, 95% CI) 3.04 [1.92, 4.80]
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14 Haematologic response -
publication
46 6413 Risk Ratio (M-H, Fixed, 95% CI) 3.39 [3.10, 3.71]
14.1 full text publication 32 5229 Risk Ratio (M-H, Fixed, 95% CI) 3.44 [3.12, 3.80]
14.2 abstract publication 2 123 Risk Ratio (M-H, Fixed, 95% CI) 5.19 [2.23, 12.04]
14.3 unpublished data 10 880 Risk Ratio (M-H, Fixed, 95% CI) 3.44 [2.45, 4.82]
14.4 FDA hearing 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
14.5 clinical trial result
information
2 181 Risk Ratio (M-H, Fixed, 95% CI) 1.98 [1.36, 2.89]
15 Haematological response -
merged experimental arms
31 6413 Risk Ratio (M-H, Fixed, 95% CI) 3.42 [3.12, 3.74]
Comparison 2. Change of haemoglobin level




participants Statistical method Effect size
1 Change in Hb values - overall 75 11609 Mean Difference (IV, Fixed, 95% CI) 1.57 [1.51, 1.62]
2 Change in Hb values - baseline
Hb
75 11609 Mean Difference (IV, Fixed, 95% CI) 1.57 [1.51, 1.62]
2.1 Hb <=10g/dL 41 5092 Mean Difference (IV, Fixed, 95% CI) 1.53 [1.43, 1.62]
2.2 Hb 10 to 12 g/dL 23 3572 Mean Difference (IV, Fixed, 95% CI) 1.79 [1.71, 1.88]
2.3 Hb >12 g/dL 10 2824 Mean Difference (IV, Fixed, 95% CI) 1.12 [0.99, 1.25]
2.4 unclear 1 121 Mean Difference (IV, Fixed, 95% CI) 1.53 [0.91, 2.15]
3 Change in Hb values - different
malignancies
75 11609 Mean Difference (IV, Fixed, 95% CI) 1.57 [1.51, 1.62]
3.1 solid tumours 45 6262 Mean Difference (IV, Fixed, 95% CI) 1.76 [1.68, 1.83]
3.2 haematological
malignancies
14 2391 Mean Difference (IV, Fixed, 95% CI) 1.05 [0.90, 1.19]
3.3 MDS 1 28 Mean Difference (IV, Fixed, 95% CI) 1.87 [0.89, 2.85]
3.4 mixed 15 2928 Mean Difference (IV, Fixed, 95% CI) 1.35 [1.21, 1.48]
3.5 unclear 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Change in Hb values - age 75 11609 Mean Difference (IV, Fixed, 95% CI) 1.57 [1.51, 1.62]
4.1 children 1 222 Mean Difference (IV, Fixed, 95% CI) 0.30 [-0.27, 0.87]
4.2 adults 74 11387 Mean Difference (IV, Fixed, 95% CI) 1.58 [1.52, 1.64]
5 Change in Hb values - age
differentiated
75 11609 Mean Difference (IV, Fixed, 95% CI) 1.57 [1.51, 1.62]
5.1 only children <18 years 1 222 Mean Difference (IV, Fixed, 95% CI) 0.30 [-0.27, 0.87]
5.2 adults ≥18 years 62 8214 Mean Difference (IV, Fixed, 95% CI) 1.57 [1.49, 1.64]
5.3 > 70% non-elderly 18-65
years
9 1136 Mean Difference (IV, Fixed, 95% CI) 1.99 [1.88, 2.10]
5.4 only non-elderly adults 2 1992 Mean Difference (IV, Fixed, 95% CI) 0.76 [0.60, 0.91]
5.5 > 70% elderly >65 years 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.6 only elderly adults 1 45 Mean Difference (IV, Fixed, 95% CI) 2.70 [1.87, 3.53]
6 Change in Hb values - different
therapies
75 11609 Mean Difference (IV, Fixed, 95% CI) 1.57 [1.51, 1.62]
6.1 chemotherapy 58 8956 Mean Difference (IV, Fixed, 95% CI) 1.46 [1.39, 1.52]
6.2 radiotherapy/
radiochemotherapy
8 974 Mean Difference (IV, Fixed, 95% CI) 2.41 [2.24, 2.58]
6.3 no therapy 9 1679 Mean Difference (IV, Fixed, 95% CI) 1.42 [1.25, 1.60]
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7 Change in Hb values - different
therapies differentiated
75 11609 Mean Difference (IV, Fixed, 95% CI) 1.57 [1.51, 1.62]
7.1 chemotherapy, >70% with
platinum
19 2126 Mean Difference (IV, Fixed, 95% CI) 1.68 [1.55, 1.82]
7.2 chemotherapy, <70%
platinum containing
7 1315 Mean Difference (IV, Fixed, 95% CI) 1.84 [1.62, 2.05]
7.3 chemotherapy without
platinum




9 782 Mean Difference (IV, Fixed, 95% CI) 1.37 [1.13, 1.61]
7.5 chemotherapy, no details
given
1 222 Mean Difference (IV, Fixed, 95% CI) 0.30 [-0.27, 0.87]
7.6 radiotherapy 5 696 Mean Difference (IV, Fixed, 95% CI) 2.32 [2.01, 2.63]
7.7 radiochemotherapy 3 278 Mean Difference (IV, Fixed, 95% CI) 2.45 [2.25, 2.65]
7.8 no therapy 9 1679 Mean Difference (IV, Fixed, 95% CI) 1.42 [1.25, 1.60]
8 Change in Hb values - epoetin
vs darbepoetin
75 11609 Mean Difference (IV, Fixed, 95% CI) 1.57 [1.51, 1.62]
8.1 Epoetin 57 8304 Mean Difference (IV, Fixed, 95% CI) 1.69 [1.62, 1.75]
8.2 Darbepoetin 18 3305 Mean Difference (IV, Fixed, 95% CI) 1.13 [1.00, 1.25]
9 Change in Hb values - duration
of ESA medication
75 11609 Mean Difference (IV, Fixed, 95% CI) 1.57 [1.51, 1.62]
9.1 6 to 9 weeks 17 1235 Mean Difference (IV, Fixed, 95% CI) 2.30 [2.16, 2.44]
9.2 12 to 16 weeks 43 6393 Mean Difference (IV, Fixed, 95% CI) 1.62 [1.54, 1.70]
9.3 more than 17 weeks 15 3981 Mean Difference (IV, Fixed, 95% CI) 1.05 [0.95, 1.16]
10 Change in Hb values - iron
supplementation
75 11609 Mean Difference (IV, Fixed, 95% CI) 1.57 [1.51, 1.62]
10.1 fixed iron
supplementation
14 2483 Mean Difference (IV, Fixed, 95% CI) 1.94 [1.81, 2.07]
10.2 iron supplementation as
necessary
53 8807 Mean Difference (IV, Fixed, 95% CI) 1.47 [1.40, 1.53]
10.3 no explicit statement on
iron supplementation or no
iron given
8 319 Mean Difference (IV, Fixed, 95% CI) 1.66 [1.34, 1.99]
10.4 explicitly stated no iron
new
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.5 iron given differently in
both study arms new ongoing
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
11 Change in Hb values -
allocation concealment
75 11609 Mean Difference (IV, Fixed, 95% CI) 1.57 [1.51, 1.62]
11.1 adequate 45 6768 Mean Difference (IV, Fixed, 95% CI) 1.52 [1.45, 1.60]
11.2 unclear 30 4841 Mean Difference (IV, Fixed, 95% CI) 1.62 [1.53, 1.71]
12 Change in Hb values - masking 75 11609 Mean Difference (IV, Fixed, 95% CI) 1.57 [1.51, 1.62]
12.1 double-blind 42 7438 Mean Difference (IV, Fixed, 95% CI) 1.47 [1.40, 1.55]
12.2 unblinded 33 4171 Mean Difference (IV, Fixed, 95% CI) 1.67 [1.59, 1.75]
13 Change in Hb values -
intention-to-treat
75 11609 Mean Difference (IV, Fixed, 95% CI) 1.57 [1.51, 1.62]
13.1 ITT or less than 10%
of participants per study arm
excluded
57 9137 Mean Difference (IV, Fixed, 95% CI) 1.61 [1.55, 1.68]
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13.2 more than 10% of
participants per study arm
excluded
18 2472 Mean Difference (IV, Fixed, 95% CI) 1.28 [1.13, 1.43]
13.3 unclear 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
14 Change in Hb values -
publication
75 11609 Mean Difference (IV, Fixed, 95% CI) 1.57 [1.51, 1.62]
14.1 full text publication 59 10026 Mean Difference (IV, Fixed, 95% CI) 1.54 [1.47, 1.60]
14.2 abstract publication 3 252 Mean Difference (IV, Fixed, 95% CI) 1.70 [1.30, 2.09]
14.3 unpublished data 10 804 Mean Difference (IV, Fixed, 95% CI) 1.56 [1.36, 1.76]
14.4 ODAC documents 1 346 Mean Difference (IV, Fixed, 95% CI) 2.5 [2.14, 2.86]
14.5 Clinical trials results 2 181 Mean Difference (IV, Fixed, 95% CI) 1.48 [0.94, 2.02]
15 Change in Hb values -
experimental arms merged
56 11609 Mean Difference (IV, Fixed, 95% CI) 1.56 [1.51, 1.62]
16 Change in Hb values-
sensitivity analysis
65 8685 Mean Difference (IV, Fixed, 95% CI) 1.66 [1.59, 1.72]
17 Change in Hb values -
publication sensitivity analysis
excluding Henke 2003
74 11263 Mean Difference (IV, Fixed, 95% CI) 1.54 [1.48, 1.60]
17.1 full text publication 58 8723 Mean Difference (IV, Fixed, 95% CI) 1.63 [1.57, 1.70]
17.2 abstract publication 4 1555 Mean Difference (IV, Fixed, 95% CI) 0.87 [0.69, 1.04]
17.3 unpublished data 10 804 Mean Difference (IV, Fixed, 95% CI) 1.56 [1.36, 1.76]
17.4 ODAC documents 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
17.5 clinical study report 2 181 Mean Difference (IV, Fixed, 95% CI) 1.48 [0.94, 2.02]
Comparison 3. Participants receiving red blood cell transfusions




participants Statistical method Effect size
1 Participants receiving red blood
cell transfusions - overall
88 16093 Risk Ratio (M-H, Fixed, 95% CI) 0.65 [0.62, 0.68]
2 Participants receiving red blood
cell transfusions - baseline Hb
88 16093 Risk Ratio (M-H, Fixed, 95% CI) 0.65 [0.62, 0.68]
2.1 Hb <=10 g/dL 42 5605 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.67, 0.76]
2.2 Hb 10 to 12 g/dL 29 5669 Risk Ratio (M-H, Fixed, 95% CI) 0.50 [0.46, 0.55]
2.3 Hb > 12 g/dL 17 4819 Risk Ratio (M-H, Fixed, 95% CI) 0.73 [0.67, 0.78]
2.4 unclear 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Participants receiving red blood
cell transfusions - different
malignancies
88 16093 Risk Ratio (M-H, Fixed, 95% CI) 0.65 [0.62, 0.68]
3.1 solid tumours 53 9305 Risk Ratio (M-H, Fixed, 95% CI) 0.50 [0.46, 0.54]
3.2 haematological
malignancies
15 2852 Risk Ratio (M-H, Fixed, 95% CI) 0.80 [0.75, 0.86]
3.3 MDS 2 151 Risk Ratio (M-H, Fixed, 95% CI) 0.80 [0.68, 0.96]
3.4 mixed 19 3785 Risk Ratio (M-H, Fixed, 95% CI) 0.74 [0.68, 0.80]
3.5 not reported 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Participants receiving red blood
cell transfusions - age
88 16093 Risk Ratio (M-H, Fixed, 95% CI) 0.65 [0.62, 0.68]
4.1 children 1 222 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.71, 0.99]
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4.2 adults 87 15871 Risk Ratio (M-H, Fixed, 95% CI) 0.64 [0.62, 0.67]
5 Participants receiving red
blood cell transfusions - age
differentiated
88 16093 Risk Ratio (M-H, Fixed, 95% CI) 0.65 [0.62, 0.68]
5.1 only children <18 years 1 222 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.71, 0.99]
5.2 adults ≥18 years 70 11556 Risk Ratio (M-H, Fixed, 95% CI) 0.62 [0.59, 0.66]
5.3 >68% non-elderly 18-65
years
11 1343 Risk Ratio (M-H, Fixed, 95% CI) 0.49 [0.41, 0.60]
5.4 only non-elderly adults 5 2927 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.72, 0.84]
5.5 >68% elderly >65 years 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.6 only elderly adults 1 45 Risk Ratio (M-H, Fixed, 95% CI) 0.40 [0.17, 0.94]
6 Participants receiving red blood
cell transfusions - different
therapies
88 16093 Risk Ratio (M-H, Fixed, 95% CI) 0.65 [0.62, 0.68]
6.1 chemotherapy 71 13405 Risk Ratio (M-H, Fixed, 95% CI) 0.64 [0.61, 0.67]
6.2 radio/radiochemotherapy 6 693 Risk Ratio (M-H, Fixed, 95% CI) 0.45 [0.34, 0.58]
6.3 no therapy 10 1774 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.72, 0.91]
6.4 unclear/other 1 221 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.60, 0.99]
7 Participants receiving red blood
cell transfusions - different
therapies differentiated
88 16093 Risk Ratio (M-H, Fixed, 95% CI) 0.65 [0.62, 0.68]
7.1 chemotherapy, > 70%
with platinum
26 3592 Risk Ratio (M-H, Fixed, 95% CI) 0.49 [0.44, 0.54]
7.2 chemotherapy, < 70%
with platinum
10 2043 Risk Ratio (M-H, Fixed, 95% CI) 0.63 [0.55, 0.73]
7.3 chemotherapy without
platinum (all patients)




9 772 Risk Ratio (M-H, Fixed, 95% CI) 0.53 [0.43, 0.65]
7.5 chemotherapy no details
given
3 489 Risk Ratio (M-H, Fixed, 95% CI) 0.73 [0.63, 0.86]
7.6 radiochemotherapy 6 693 Risk Ratio (M-H, Fixed, 95% CI) 0.45 [0.34, 0.58]
7.7 radiotherapy 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.8 no therapy 10 1774 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.72, 0.91]
7.9 unclear/other 1 221 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.60, 0.99]
8 Participants receiving red blood
cell transfusions - epoetin
versus darbepoetin
88 16093 Risk Ratio (M-H, Fixed, 95% CI) 0.65 [0.62, 0.68]
8.1 Epoetin 67 11786 Risk Ratio (M-H, Fixed, 95% CI) 0.65 [0.62, 0.68]
8.2 Darbepoetin 21 4307 Risk Ratio (M-H, Fixed, 95% CI) 0.66 [0.60, 0.72]
9 Participants receiving red blood
cell transfusions - duration of
ESA medication
88 16093 Risk Ratio (M-H, Fixed, 95% CI) 0.65 [0.62, 0.68]
9.1 6 to 9 weeks 13 815 Risk Ratio (M-H, Fixed, 95% CI) 0.60 [0.49, 0.74]
9.2 12 to 16 weeks 52 8413 Risk Ratio (M-H, Fixed, 95% CI) 0.65 [0.61, 0.69]
9.3 more than 17 weeks 23 6865 Risk Ratio (M-H, Fixed, 95% CI) 0.65 [0.61, 0.70]
10 Participants receiving red
blood cell transfusions - iron
supplementation
88 16093 Risk Ratio (M-H, Fixed, 95% CI) 0.65 [0.62, 0.68]
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10.1 fixed iron
supplementation
10 2104 Risk Ratio (M-H, Fixed, 95% CI) 0.58 [0.49, 0.70]
10.2 iron supplementation as
necessary
63 12060 Risk Ratio (M-H, Fixed, 95% CI) 0.68 [0.65, 0.71]
10.3 no explicit statement on
iron supplementation or no
iron given
11 645 Risk Ratio (M-H, Fixed, 95% CI) 0.52 [0.42, 0.65]
10.4 explicitly stated NO
IRON
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.5 iron given differently in
both study arms new
4 1284 Risk Ratio (M-H, Fixed, 95% CI) 0.51 [0.43, 0.61]
11 Participants receiving red blood
cell transfusions - allocation
concealment
88 16093 Risk Ratio (M-H, Fixed, 95% CI) 0.65 [0.62, 0.68]
11.1 adequate 55 10898 Risk Ratio (M-H, Fixed, 95% CI) 0.61 [0.58, 0.65]
11.2 unclear 33 5195 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.67, 0.76]
12 Participants receiving red blood
cell transfusions - masking
88 16093 Risk Ratio (M-H, Fixed, 95% CI) 0.65 [0.62, 0.68]
12.1 double-blind 50 9677 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.68, 0.75]
12.2 unblinded 38 6416 Risk Ratio (M-H, Fixed, 95% CI) 0.52 [0.47, 0.56]
13 Participants receiving red blood
cell transfusions - intention-to
treat
88 16093 Risk Ratio (M-H, Fixed, 95% CI) 0.65 [0.62, 0.68]
13.1 ITT or less than 10%
of participants per study arm
excluded
73 13772 Risk Ratio (M-H, Fixed, 95% CI) 0.66 [0.63, 0.69]
13.2 more than 10% of
participants per study arm
excluded
11 1035 Risk Ratio (M-H, Fixed, 95% CI) 0.48 [0.36, 0.63]
13.3 unclear 4 1286 Risk Ratio (M-H, Fixed, 95% CI) 0.45 [0.33, 0.62]
14 Participants receiving red blood
cell transfusions - publication
88 16093 Risk Ratio (M-H, Fixed, 95% CI) 0.65 [0.62, 0.68]
14.1 fulltext publication 65 12678 Risk Ratio (M-H, Fixed, 95% CI) 0.66 [0.63, 0.70]
14.2 abstract publication 7 1242 Risk Ratio (M-H, Fixed, 95% CI) 0.40 [0.32, 0.49]
14.3 unpublished data 14 1658 Risk Ratio (M-H, Fixed, 95% CI) 0.73 [0.67, 0.80]
14.4 FDA presented data 1 314 Risk Ratio (M-H, Fixed, 95% CI) 0.60 [0.47, 0.78]
14.5 Other 1 201 Risk Ratio (M-H, Fixed, 95% CI) 0.44 [0.26, 0.73]
15 Participants receiving red blood
cell transfusions - first 4 weeks
are...
88 16093 Risk Ratio (M-H, Fixed, 95% CI) 0.65 [0.62, 0.68]
15.1 included in the analysis 32 5319 Risk Ratio (M-H, Fixed, 95% CI) 0.65 [0.61, 0.70]
15.2 excluded from the
analysis
23 3288 Risk Ratio (M-H, Fixed, 95% CI) 0.68 [0.61, 0.75]
15.3 unclear 33 7486 Risk Ratio (M-H, Fixed, 95% CI) 0.64 [0.60, 0.68]
16 Participants receiving red blood
cell transfusions - experimental
arms merged
70 16093 Risk Ratio (M-H, Fixed, 95% CI) 0.65 [0.62, 0.68]
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Comparison 4. Number of red blood cell units transfused per patient




participants Statistical method Effect size
1 Number of RBC units transfused
- overall
25 4715 Mean Difference (IV, Fixed, 95% CI) -0.98 [-1.17, -0.78]
2 Number of RBC units transfused
- baseline Hb
25 4715 Mean Difference (IV, Fixed, 95% CI) -0.98 [-1.17, -0.78]
2.1 Hb < 10g/dL 16 1996 Mean Difference (IV, Fixed, 95% CI) -1.02 [-1.35, -0.68]
2.2 Hb 10 to 12g/dL 5 1096 Mean Difference (IV, Fixed, 95% CI) -0.95 [-1.24, -0.65]
2.3 Hb > 12g/dL 4 1623 Mean Difference (IV, Fixed, 95% CI) -0.97 [-1.41, -0.54]
3 Number of RBC units transfused
- age differentiated
25 4715 Mean Difference (IV, Fixed, 95% CI) -0.98 [-1.17, -0.78]
3.1 only children <18 years 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 adults ≥18 years 21 3093 Mean Difference (IV, Fixed, 95% CI) -0.81 [-1.04, -0.57]
3.3 >68% non-elderly 18-65
years
3 353 Mean Difference (IV, Fixed, 95% CI) -1.25 [-1.72, -0.77]
3.4 only non-elderly adults 1 1269 Mean Difference (IV, Fixed, 95% CI) -1.60 [-2.18, -1.02]
3.5 >68% elderly >65 years 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.6 only elderly > 65 J 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Number of RBC units transfused
- age
25 4715 Mean Difference (IV, Fixed, 95% CI) -0.98 [-1.17, -0.78]
4.1 adults 25 4715 Mean Difference (IV, Fixed, 95% CI) -0.98 [-1.17, -0.78]
5 Number of RBC units transfused
- different malignancies
25 4715 Mean Difference (IV, Fixed, 95% CI) -0.98 [-1.17, -0.78]
5.1 solid tumours 10 1437 Mean Difference (IV, Fixed, 95% CI) -1.07 [-1.34, -0.80]
5.2 haematological
malignancies
10 2254 Mean Difference (IV, Fixed, 95% CI) -1.19 [-1.63, -0.76]
5.3 mixed 5 1024 Mean Difference (IV, Fixed, 95% CI) -0.62 [-1.01, -0.24]
6 Number of RBC units transfused
- different therapies
25 4715 Mean Difference (IV, Fixed, 95% CI) -0.98 [-1.17, -0.78]
6.1 chemotherapy 23 4376 Mean Difference (IV, Fixed, 95% CI) -0.98 [-1.18, -0.78]
6.2 radiotherapy/
radiochemotherapy
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.3 no therapy 1 118 Mean Difference (IV, Fixed, 95% CI) -0.67 [-1.81, 0.47]
6.4 unclear/ other 1 221 Mean Difference (IV, Fixed, 95% CI) -2.2 [-6.44, 2.04]
7 Number of RBC units
transfused - different therapies
differentiated
25 4715 Mean Difference (IV, Fixed, 95% CI) -0.98 [-1.17, -0.78]
7.1 chemotherapy > 70% with
platinum
10 1344 Mean Difference (IV, Fixed, 95% CI) -1.11 [-1.40, -0.83]
7.2 chemotherapy, <70% with
platinum
2 584 Mean Difference (IV, Fixed, 95% CI) -0.52 [-0.93, -0.12]
7.3 chemotherapy without
platinum




2 394 Mean Difference (IV, Fixed, 95% CI) -1.01 [-1.80, -0.21]
7.5 chemotherapy no details
given
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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7.6 radiochemotherapy 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.7 radiotherapy 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.8 no therapy 1 118 Mean Difference (IV, Fixed, 95% CI) -0.67 [-1.81, 0.47]
7.9 unclear/other 1 221 Mean Difference (IV, Fixed, 95% CI) -2.2 [-6.44, 2.04]
8 Number of RBC units transfused
- epoetin versus darbepoetin
25 4715 Mean Difference (IV, Fixed, 95% CI) -0.98 [-1.17, -0.78]
8.1 Epoetin 23 4052 Mean Difference (IV, Fixed, 95% CI) -1.06 [-1.29, -0.82]
8.2 Darbepoetin 2 663 Mean Difference (IV, Fixed, 95% CI) -0.78 [-1.15, -0.42]
9 Number of RBC units transfused
- duration of ESA medication
25 4715 Mean Difference (IV, Fixed, 95% CI) -0.98 [-1.17, -0.78]
9.1 6 to 9 weeks 6 364 Mean Difference (IV, Fixed, 95% CI) -1.25 [-1.75, -0.75]
9.2 12 to 16 weeks 12 2688 Mean Difference (IV, Fixed, 95% CI) -0.78 [-1.03, -0.54]
9.3 more than 17 weeks 7 1663 Mean Difference (IV, Fixed, 95% CI) -1.40 [-1.84, -0.95]
10 Number of RBC
units transfused - iron
supplementation
25 4715 Mean Difference (IV, Fixed, 95% CI) -0.98 [-1.17, -0.78]
10.1 fixed iron
supplementation
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.2 iron supplementation as
necessary
24 4402 Mean Difference (IV, Fixed, 95% CI) -0.92 [-1.13, -0.72]
10.3 no explicit statement on
iron supplementation or no
iron given
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.4 explicitely stated NO
IRON
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.5 iron given differently in
both study arms
1 313 Mean Difference (IV, Fixed, 95% CI) -1.6 [-2.30, -0.90]
11 Number of RBC units
transfused - allocation
concealment
25 4715 Mean Difference (IV, Fixed, 95% CI) -0.98 [-1.17, -0.78]
11.1 adequate 15 2243 Mean Difference (IV, Fixed, 95% CI) -0.93 [-1.19, -0.67]
11.2 unclear 10 2472 Mean Difference (IV, Fixed, 95% CI) -1.04 [-1.35, -0.74]
12 Number of RBC units
transfused - masking
25 4715 Mean Difference (IV, Fixed, 95% CI) -0.98 [-1.17, -0.78]
12.1 double-blind 12 3382 Mean Difference (IV, Fixed, 95% CI) -0.91 [-1.14, -0.69]
12.2 unblinded 13 1333 Mean Difference (IV, Fixed, 95% CI) -1.16 [-1.55, -0.77]
13 Number of RBC units
transfused - intention-to-treat
25 4715 Mean Difference (IV, Fixed, 95% CI) -0.98 [-1.17, -0.78]
13.1 ITT or less than 10%
of participants per study arm
excluded
24 4583 Mean Difference (IV, Fixed, 95% CI) -0.99 [-1.19, -0.79]
13.2 more than 10% of
participants per study arm
excluded
1 132 Mean Difference (IV, Fixed, 95% CI) -0.69 [-1.66, 0.28]
14 Number of RBC units
transfused - publication
25 4715 Mean Difference (IV, Fixed, 95% CI) -0.98 [-1.17, -0.78]
14.1 full text publication 4 1200 Mean Difference (IV, Fixed, 95% CI) -0.77 [-1.06, -0.48]
14.2 abstract publication 1 1269 Mean Difference (IV, Fixed, 95% CI) -1.60 [-2.18, -1.02]
14.3 unpublished data 20 2246 Mean Difference (IV, Fixed, 95% CI) -1.03 [-1.33, -0.73]
14.4 FDA presented data 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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15 Number of RBC units
transfused - first 4 weeks are...
25 4715 Mean Difference (IV, Fixed, 95% CI) -0.98 [-1.17, -0.78]
15.1 included in the analysis 18 2658 Mean Difference (IV, Fixed, 95% CI) -0.99 [-1.23, -0.74]
15.2 excluded from the
analysis
3 623 Mean Difference (IV, Fixed, 95% CI) -0.53 [-0.94, -0.12]
15.3 unclear 4 1434 Mean Difference (IV, Fixed, 95% CI) -1.72 [-2.27, -1.18]
16 Number of RBC units
transfused - experimental arms
merged
19 4715 Mean Difference (IV, Fixed, 95% CI) -0.98 [-1.17, -0.78]
17 Number of RBC units
transfused - age differentiated
sensitivity analysis
25 4715 Mean Difference (IV, Fixed, 95% CI) -0.98 [-1.17, -0.78]
17.1 only children <18 years 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
17.2 adults ≥18 years 21 3093 Mean Difference (IV, Fixed, 95% CI) -0.81 [-1.04, -0.57]
17.3 >68% non-elderly 18-65
years
4 1622 Mean Difference (IV, Fixed, 95% CI) -1.39 [-1.75, -1.02]
17.4 only non-elderly adults 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
17.5 >68% elderly >65 years 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
17.6 only elderly > 65 J 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 5. Overall survival




participants Statistical method Effect size
1 Overall survival - overall 80 19003 Peto Odds Ratio (95% CI) 1.05 [1.00, 1.11]
2 Overall survival updated review
(adjusted results)
80 19003 Peto Odds Ratio (95% CI) 1.05 [1.00, 1.11]
3 Overall survival - baseline Hb 80 19003 Peto Odds Ratio (95% CI) 1.05 [1.00, 1.11]
3.1 Hb < 10 g/dL 29 6144 Peto Odds Ratio (95% CI) 1.06 [0.96, 1.17]
3.2 Hb 10 to 12 g/dL 31 6418 Peto Odds Ratio (95% CI) 1.01 [0.93, 1.10]
3.3 Hb > 12 g/dL 15 5725 Peto Odds Ratio (95% CI) 1.17 [1.06, 1.29]
3.4 unclear 5 716 Peto Odds Ratio (95% CI) 0.83 [0.67, 1.03]
4 Overall survival - different
malignancies
80 19003 Peto Odds Ratio (95% CI) 1.05 [1.00, 1.11]
4.1 solid tumours 50 11704 Peto Odds Ratio (95% CI) 1.06 [1.00, 1.13]
4.2 haematological
malignancies
11 2901 Peto Odds Ratio (95% CI) 1.07 [0.90, 1.26]
4.3 MDS 1 66 Peto Odds Ratio (95% CI) 4.52 [0.38, 53.37]
4.4 mixed 18 4332 Peto Odds Ratio (95% CI) 1.02 [0.91, 1.15]
4.5 not reported 0 0 Peto Odds Ratio (95% CI) 0.0 [0.0, 0.0]
5 Overall survival - age 80 19003 Peto Odds Ratio (95% CI) 1.05 [1.00, 1.11]
5.1 children 1 222 Peto Odds Ratio (95% CI) 0.98 [0.14, 7.03]
5.2 adults 79 18781 Peto Odds Ratio (95% CI) 1.05 [1.00, 1.11]
6 Overall survival - age
differentiated
80 19003 Peto Odds Ratio (95% CI) 1.05 [1.00, 1.11]
6.1 only children < 18 1 222 Peto Odds Ratio (95% CI) 0.98 [0.14, 7.03]
6.2 adults >= 18 62 13975 Peto Odds Ratio (95% CI) 1.07 [1.01, 1.13]
6.3 > 68% non elderly 18-65 11 1611 Peto Odds Ratio (95% CI) 0.86 [0.67, 1.10]
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6.4 only non-elderly adults 4 2916 Peto Odds Ratio (95% CI) 1.02 [0.82, 1.26]
6.5 > 68% elderly > 65 2 279 Peto Odds Ratio (95% CI) 0.77 [0.51, 1.17]
6.6 only elderly > 65 0 0 Peto Odds Ratio (95% CI) 0.0 [0.0, 0.0]
7 Overall survival - different
therapies
80 19003 Peto Odds Ratio (95% CI) 1.05 [1.00, 1.11]
7.1 chemotherapy 55 13800 Peto Odds Ratio (95% CI) 1.04 [0.98, 1.11]
7.2 radiotherapy/
radiochemotherapy
14 2939 Peto Odds Ratio (95% CI) 1.03 [0.92, 1.15]
7.3 no therapy 8 1942 Peto Odds Ratio (95% CI) 1.23 [1.04, 1.45]
7.4 unclear/other 3 322 Peto Odds Ratio (95% CI) 0.79 [0.49, 1.27]
8 Overall survival - different
therapies differentiated
80 19003 Peto Odds Ratio (95% CI) 1.05 [1.00, 1.11]
8.1 chemotherapy, > 70%
with platinum
19 3622 Peto Odds Ratio (95% CI) 1.01 [0.91, 1.12]
8.2 chemotherapy, < 70%
with platinum
7 1812 Peto Odds Ratio (95% CI) 1.14 [0.95, 1.36]
8.3 chemotherapy without
platinum (all patients)
19 6706 Peto Odds Ratio (95% CI) 1.08 [0.98, 1.19]
8.4 chemotherapy, platinum
and non platinum containing,
no numbers given
5 910 Peto Odds Ratio (95% CI) 0.94 [0.65, 1.37]
8.5 chemotherapy no details
given
5 750 Peto Odds Ratio (95% CI) 0.82 [0.61, 1.10]
8.6 radiochemotherapy 8 1193 Peto Odds Ratio (95% CI) 0.92 [0.78, 1.09]
8.7 radiotherapy 6 1746 Peto Odds Ratio (95% CI) 1.12 [0.97, 1.30]
8.8 no therapy 8 1942 Peto Odds Ratio (95% CI) 1.23 [1.04, 1.45]
8.9 unclear/other 3 322 Peto Odds Ratio (95% CI) 0.79 [0.49, 1.27]
9 Overall survival - epoetin vs
darbepoetin
80 19003 Peto Odds Ratio (95% CI) 1.05 [1.00, 1.11]
9.1 Epoetin 67 14047 Peto Odds Ratio (95% CI) 1.04 [0.98, 1.10]
9.2 Darbepoetin 13 4956 Peto Odds Ratio (95% CI) 1.09 [0.99, 1.20]
10 Overall survival - duration of
ESA medication
80 19003 Peto Odds Ratio (95% CI) 1.05 [1.00, 1.11]
10.1 6 to 9 weeks 13 2244 Peto Odds Ratio (95% CI) 1.10 [0.95, 1.27]
10.2 12 to 16 weeks 46 9385 Peto Odds Ratio (95% CI) 1.05 [0.98, 1.13]
10.3 more than 17 weeks 18 6963 Peto Odds Ratio (95% CI) 1.04 [0.95, 1.14]
10.4 not reported 3 411 Peto Odds Ratio (95% CI) 1.10 [0.58, 2.07]
11 Overall survival - iron
supplementation
80 19003 Peto Odds Ratio (95% CI) 1.05 [1.00, 1.11]
11.1 fixed iron
supplementation
10 2348 Peto Odds Ratio (95% CI) 1.15 [0.99, 1.33]
11.2 iron supplementation as
necessary
56 13888 Peto Odds Ratio (95% CI) 1.07 [1.01, 1.14]
11.3 iron handled differently
in the study arms
9 2050 Peto Odds Ratio (95% CI) 0.96 [0.84, 1.11]
11.4 no explicit statement on
iron supplementation or no
iron given
5 717 Peto Odds Ratio (95% CI) 0.56 [0.38, 0.83]
11.5 explicitly stated NO
IRON
0 0 Peto Odds Ratio (95% CI) 0.0 [0.0, 0.0]
12 Overall survival - publication 80 19003 Peto Odds Ratio (95% CI) 1.05 [1.00, 1.11]
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12.1 full text publication 20 4531 Peto Odds Ratio (95% CI) 1.07 [0.92, 1.24]
12.2 abstract publication 3 1020 Peto Odds Ratio (95% CI) 1.09 [0.87, 1.37]
12.3 unpublished data 5 318 Peto Odds Ratio (95% CI) 0.73 [0.17, 3.05]
12.4 Data presented at FDA
hearing
0 0 Peto Odds Ratio (95% CI) 0.0 [0.0, 0.0]
12.5 Data taken from IPD
review (Bohlius 2009)
50 13018 Peto Odds Ratio (95% CI) 1.06 [1.00, 1.12]
12.6 clinical trial result
information
1 60 Peto Odds Ratio (95% CI) 7.39 [0.15, 372.38]
12.7 other 1 56 Peto Odds Ratio (95% CI) 0.58 [0.33, 1.03]
13 Overall survival - time-to-event
or binary mortality data
80 19003 Peto Odds Ratio (95% CI) 1.05 [1.00, 1.11]
13.1 binary mortality data at
end of study
19 1917 Peto Odds Ratio (95% CI) 1.02 [0.66, 1.60]
13.2 Data from IPD review 50 13018 Peto Odds Ratio (95% CI) 1.06 [1.00, 1.12]
13.3 Cox regression analysis,
Hazard ratio, log-rank test,
p-value
7 3141 Peto Odds Ratio (95% CI) 1.07 [0.92, 1.25]
13.4 Survival curve and
p-value
4 927 Peto Odds Ratio (95% CI) 0.99 [0.78, 1.24]
14 Overall survival - allocation
concealment
80 19003 Peto Odds Ratio (95% CI) 1.05 [1.00, 1.11]
14.1 adequate 47 12424 Peto Odds Ratio (95% CI) 1.08 [1.02, 1.14]
14.2 unclear 33 6579 Peto Odds Ratio (95% CI) 0.97 [0.87, 1.09]
15 Overall survival - masking 80 19003 Peto Odds Ratio (95% CI) 1.05 [1.00, 1.11]
15.1 double-blind 42 10525 Peto Odds Ratio (95% CI) 1.06 [0.99, 1.14]
15.2 unblinded 38 8478 Peto Odds Ratio (95% CI) 1.04 [0.96, 1.12]
16 Overall survival -
intention-to-treat
80 19003 Peto Odds Ratio (95% CI) 1.05 [1.00, 1.11]
16.1 ITT or less than 10%
of participants per study arm
excluded
75 18052 Peto Odds Ratio (95% CI) 1.05 [1.00, 1.11]
16.2 more than 10% of
participants per study arm
excluded
2 385 Peto Odds Ratio (95% CI) 1.25 [0.92, 1.71]
16.3 Unclear 3 566 Peto Odds Ratio (95% CI) 0.49 [0.27, 0.89]
17 Overall survival - follow up 80 19003 Peto Odds Ratio (95% CI) 1.05 [1.00, 1.11]
17.1 follow up longer than
on-study mortality
44 13224 Peto Odds Ratio (95% CI) 1.05 [0.99, 1.10]
17.2 Short term follow up 36 5779 Peto Odds Ratio (95% CI) 1.14 [0.95, 1.36]
18 Overall survival - follow up and
design
80 19003 Peto Odds Ratio (95% CI) 1.05 [1.00, 1.11]
18.1 Long term follow up and
designed for long term follow
up
25 9704 Peto Odds Ratio (95% CI) 1.06 [0.99, 1.12]
18.2 Long term follow up but
not designed for long term
follow up
11 2197 Peto Odds Ratio (95% CI) 1.02 [0.89, 1.18]
18.3 Long term follow up and
design unclear
7 1142 Peto Odds Ratio (95% CI) 0.96 [0.79, 1.16]
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18.4 Short term follow up but
designed for long term follow
up
3 1250 Peto Odds Ratio (95% CI) 1.32 [1.05, 1.66]
18.5 Short term follow up
and not designed for long term
follow up
34 4710 Peto Odds Ratio (95% CI) 0.97 [0.76, 1.23]
18.6 short term follow up and
design unclear
0 0 Peto Odds Ratio (95% CI) 0.0 [0.0, 0.0]
19 Overall survival- experimental
arms merged
78 19003 Peto Odds Ratio (95% CI) 1.05 [1.00, 1.11]
20 Overall survival- experimental
arms merged sens pos
76 17551 Peto Odds Ratio (95% CI) 1.04 [0.98, 1.10]
21 Overall survival- experimental
arms merged sens neg
76 18018 Peto Odds Ratio (95% CI) 1.08 [1.02, 1.14]
22 Overall survival - sensitivity
analysis baseline Hb
75 18287 Peto Odds Ratio (95% CI) 1.07 [1.01, 1.13]
22.1 Hb < 10 g/dL 29 6144 Peto Odds Ratio (95% CI) 1.06 [0.96, 1.17]
22.2 Hb 10 to 12 g/dL 31 6418 Peto Odds Ratio (95% CI) 1.01 [0.93, 1.10]
22.3 Hb > 12 g/dL 15 5725 Peto Odds Ratio (95% CI) 1.17 [1.06, 1.29]
23 Overall survival - sensitivity
analysis iron supplementation
75 18286 Peto Odds Ratio (95% CI) 1.07 [1.01, 1.12]
23.1 fixed iron
supplementation
10 2348 Peto Odds Ratio (95% CI) 1.15 [0.99, 1.33]
23.2 iron supplementation as
necessary
56 13888 Peto Odds Ratio (95% CI) 1.07 [1.01, 1.14]
23.3 iron handled differently
in the study arms
9 2050 Peto Odds Ratio (95% CI) 0.96 [0.84, 1.11]
23.4 explicitly stated NO
IRON
0 0 Peto Odds Ratio (95% CI) 0.0 [0.0, 0.0]
24 Overall survival - sensitivity
analysis intention-to-treat
77 18437 Peto Odds Ratio (95% CI) 1.06 [1.01, 1.12]
24.1 ITT or less than 10%
of participants per study arm
excluded
75 18052 Peto Odds Ratio (95% CI) 1.05 [1.00, 1.11]
24.2 more than 10% of
participants per study arm
excluded
2 385 Peto Odds Ratio (95% CI) 1.25 [0.92, 1.71]
Comparison 6. On-study mortality




participants Statistical method Effect size
1 On-study mortality - overall 72 15935 Peto Odds Ratio (95% CI) 1.17 [1.06, 1.29]
2 On-study mortality - baseline
Hb
72 15935 Peto Odds Ratio (95% CI) 1.17 [1.06, 1.29]
2.1 Hb < 10 g/dL 28 5759 Peto Odds Ratio (95% CI) 1.12 [0.96, 1.32]
2.2 Hb 10 to 12 g/dL 26 5537 Peto Odds Ratio (95% CI) 1.09 [0.91, 1.29]
2.3 Hb > 12 g/dL 13 3923 Peto Odds Ratio (95% CI) 1.37 [1.12, 1.68]
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2.4 unclear 5 716 Peto Odds Ratio (95% CI) 1.20 [0.75, 1.93]
3 On-study mortality - different
malignancies
72 15935 Peto Odds Ratio (95% CI) 1.17 [1.06, 1.29]
3.1 solid tumours 44 10056 Peto Odds Ratio (95% CI) 1.21 [1.06, 1.37]
3.2 haematological
malignancies
10 1598 Peto Odds Ratio (95% CI) 1.13 [0.80, 1.59]
3.3 MDS 1 66 Peto Odds Ratio (95% CI) 4.52 [0.38, 53.37]
3.4 mixed 17 4215 Peto Odds Ratio (95% CI) 1.10 [0.92, 1.31]
3.5 not reported 0 0 Peto Odds Ratio (95% CI) 0.0 [0.0, 0.0]
4 On-study mortality - age 72 15935 Peto Odds Ratio (95% CI) 1.17 [1.06, 1.29]
4.1 children 1 222 Peto Odds Ratio (95% CI) 0.98 [0.14, 7.03]
4.2 adults 71 15713 Peto Odds Ratio (95% CI) 1.17 [1.06, 1.29]
5 On-study mortality - age
differentiated
72 15935 Peto Odds Ratio (95% CI) 1.17 [1.06, 1.29]
5.1 children 1 222 Peto Odds Ratio (95% CI) 0.98 [0.14, 7.03]
5.2 adults >= 18 59 13007 Peto Odds Ratio (95% CI) 1.18 [1.07, 1.31]
5.3 > 68% non elderly, 18-65 10 1334 Peto Odds Ratio (95% CI) 0.76 [0.42, 1.35]
5.4 only non elderly adults 2 1372 Peto Odds Ratio (95% CI) 0.0 [0.0, 0.0]
5.5 > 68% elderly > 65 years 0 0 Peto Odds Ratio (95% CI) 0.0 [0.0, 0.0]
5.6 only elderly 0 0 Peto Odds Ratio (95% CI) 0.0 [0.0, 0.0]
6 On-study mortality - different
therapies
72 15935 Peto Odds Ratio (95% CI) 1.17 [1.06, 1.29]
6.1 chemotherapy 52 12058 Peto Odds Ratio (95% CI) 1.10 [0.98, 1.24]
6.2 radiotherapy/
radiochemotherapy
10 1669 Peto Odds Ratio (95% CI) 1.48 [0.96, 2.27]
6.3 no therapy 8 1942 Peto Odds Ratio (95% CI) 1.34 [1.07, 1.66]
6.4 unclear/other 2 266 Peto Odds Ratio (95% CI) 1.48 [0.65, 3.37]
7 On-study mortality - different
therapies differentiated
72 15935 Peto Odds Ratio (95% CI) 1.17 [1.06, 1.29]
7.1 chemotherapy, > 70%
with platinum
19 3622 Peto Odds Ratio (95% CI) 1.04 [0.85, 1.27]
7.2 chemotherapy, <70% with
platinum
6 1475 Peto Odds Ratio (95% CI) 1.06 [0.76, 1.49]
7.3 chemotherapy without
platinum, all patients




4 793 Peto Odds Ratio (95% CI) 0.74 [0.40, 1.38]
7.5 chemotherapy, no details
reported
5 750 Peto Odds Ratio (95% CI) 0.82 [0.50, 1.34]
7.6 radiochemotherapy 6 822 Peto Odds Ratio (95% CI) 1.46 [0.85, 2.51]
7.7 radiotherapy 4 847 Peto Odds Ratio (95% CI) 1.51 [0.75, 3.06]
7.8 no therapy 8 1942 Peto Odds Ratio (95% CI) 1.34 [1.07, 1.66]
7.9 unclear/other 2 266 Peto Odds Ratio (95% CI) 1.48 [0.65, 3.37]
8 On-study mortality - duration of
ESA medication
72 15935 Peto Odds Ratio (95% CI) 1.17 [1.06, 1.29]
8.1 6 to 9 weeks 9 1113 Peto Odds Ratio (95% CI) 0.95 [0.57, 1.59]
8.2 12 to 16 weeks 44 8992 Peto Odds Ratio (95% CI) 1.16 [1.02, 1.33]
8.3 more than 17 weeks 16 5419 Peto Odds Ratio (95% CI) 1.22 [1.04, 1.42]
8.4 not reported 3 411 Peto Odds Ratio (95% CI) 0.82 [0.38, 1.78]
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9 On-study mortality - epoetin vs
darbepoetin
72 15935 Peto Odds Ratio (95% CI) 1.17 [1.06, 1.29]
9.1 Epoetin 60 11478 Peto Odds Ratio (95% CI) 1.16 [1.03, 1.30]
9.2 Darbepoetin 12 4457 Peto Odds Ratio (95% CI) 1.20 [1.00, 1.44]
10 On-study mortality - iron
supplementation
72 15935 Peto Odds Ratio (95% CI) 1.17 [1.06, 1.29]
10.1 fixed iron
supplementation
8 1911 Peto Odds Ratio (95% CI) 1.20 [0.80, 1.81]
10.2 iron supplementation as
necessary
53 11954 Peto Odds Ratio (95% CI) 1.17 [1.05, 1.30]
10.3 no explicit statement on
iron supplementation or no
iron given
3 276 Peto Odds Ratio (95% CI) 2.16 [0.72, 6.46]
10.4 explicitly stated no iron 0 0 Peto Odds Ratio (95% CI) 0.0 [0.0, 0.0]
10.5 iron handled differently
in the study arms
8 1794 Peto Odds Ratio (95% CI) 1.09 [0.74, 1.60]
11 On-study mortality -
publication
72 15935 Peto Odds Ratio (95% CI) 1.17 [1.06, 1.29]
11.1 full text publication 14 1689 Peto Odds Ratio (95% CI) 0.97 [0.60, 1.57]
11.2 abstract publication 2 181 Peto Odds Ratio (95% CI) 7.64 [1.29, 45.03]
11.3 unpublished data 5 318 Peto Odds Ratio (95% CI) 1.65 [0.20, 13.32]
11.4 Data presented at FDA
hearing
0 0 Peto Odds Ratio (95% CI) 0.0 [0.0, 0.0]
11.5 IPD Bohlius 2009 51 13747 Peto Odds Ratio (95% CI) 1.17 [1.06, 1.29]
12 On-study mortality -
time-to-event or binary
mortality data
72 15935 Peto Odds Ratio (95% CI) 1.17 [1.06, 1.29]
12.1 binary mortality data at
end of study
21 2188 Peto Odds Ratio (95% CI) 1.14 [0.73, 1.79]
12.2 Results from IPD review 51 13747 Peto Odds Ratio (95% CI) 1.17 [1.06, 1.29]
12.3 Cox regression analysis,
Hazard ratio, log-rank test, p-
value
0 0 Peto Odds Ratio (95% CI) 0.0 [0.0, 0.0]
12.4 Survival curve and p-
value
0 0 Peto Odds Ratio (95% CI) 0.0 [0.0, 0.0]
13 On-study mortality - allocation
concealment
72 15935 Peto Odds Ratio (95% CI) 1.17 [1.06, 1.29]
13.1 adequate 42 11144 Peto Odds Ratio (95% CI) 1.20 [1.08, 1.34]
13.2 unclear 30 4791 Peto Odds Ratio (95% CI) 1.03 [0.82, 1.30]
14 On-study mortality - masking 72 15935 Peto Odds Ratio (95% CI) 1.17 [1.06, 1.29]
14.1 double-blind 39 9049 Peto Odds Ratio (95% CI) 1.19 [1.06, 1.34]
14.2 unblinded 33 6886 Peto Odds Ratio (95% CI) 1.12 [0.94, 1.34]
15 On-study mortality -
intention-to-treat
72 15935 Peto Odds Ratio (95% CI) 1.17 [1.06, 1.29]
15.1 ITT or less than 10%
of participants per study arm
excluded
69 15706 Peto Odds Ratio (95% CI) 1.16 [1.05, 1.28]
15.2 more than 10% of
participants per study arm
excluded
1 48 Peto Odds Ratio (95% CI) 0.0 [0.0, 0.0]
15.3 Unclear 2 181 Peto Odds Ratio (95% CI) 7.64 [1.29, 45.03]
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16 On-study mortality - sensitivity
analysis - follow-up
80 19018 Peto Odds Ratio (95% CI) 1.16 [1.05, 1.27]
16.1 Short term follow
subgroup
72 15935 Peto Odds Ratio (95% CI) 1.17 [1.06, 1.29]
16.2 Short term from Kaplan
Meier curve
7 2966 Peto Odds Ratio (95% CI) 1.06 [0.60, 1.86]
16.3 Long term follow up 1 117 Peto Odds Ratio (95% CI) 0.94 [0.57, 1.54]
17 On-study mortality - sensitivity
analysis experimental arms
merged
70 15935 Peto Odds Ratio (95% CI) 1.17 [1.06, 1.29]
18 On-study mortality - sensitivity
analysis intention-to-treat
70 15754 Peto Odds Ratio (95% CI) 1.16 [1.05, 1.28]
18.1 ITT or less than 10%
of participants per study arm
excluded
69 15706 Peto Odds Ratio (95% CI) 1.16 [1.05, 1.28]
18.2 more than 10% of
participants per study arm
excluded
1 48 Peto Odds Ratio (95% CI) 0.0 [0.0, 0.0]
19 On-study mortality - sensitivity
analysis excluding Leyland and
Smith
70 14007 Peto Odds Ratio (95% CI) 1.09 [0.97, 1.23]
Comparison 7. Complete tumour response




participants Statistical method Effect size
1 Complete tumour response 19 5012 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.98, 1.06]
2 Tumour-response specific quality
criteria
19 5012 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.98, 1.06]
2.1 high quality 5 2476 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.95, 1.02]
2.2 low quality 14 2536 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [0.98, 1.36]
3 Complete tumour response
- experimental study arms
merged
15 5012 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.98, 1.06]
Comparison 8. Change in FACT-Fatigue 13




participants Statistical method Effect size
1 Change in FACT-Fatigue (13
items) - overall
18 4965 Mean Difference (IV, Fixed, 95% CI) 2.08 [1.43, 2.72]
2 Change in FACT-Fatigue
sensitivity analysis- Tsuboi
18 4967 Mean Difference (IV, Fixed, 95% CI) 2.10 [1.46, 2.75]
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3 Change in FACT-F 13 - baseline
Hb
18 4965 Mean Difference (IV, Fixed, 95% CI) 2.08 [1.43, 2.72]
3.1 Hb <= 10 g/dL 8 2484 Mean Difference (IV, Fixed, 95% CI) 1.66 [0.76, 2.55]
3.2 Hb 10 to 12 g/dL 9 2181 Mean Difference (IV, Fixed, 95% CI) 2.87 [1.89, 3.85]
3.3 Hb > 12 g/dL 1 300 Mean Difference (IV, Fixed, 95% CI) 0.0 [-2.63, 2.63]
3.4 Hb category unclear 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Change in FACT-F 13 - different
malignancies
18 4965 Mean Difference (IV, Fixed, 95% CI) 2.08 [1.43, 2.72]
4.1 solid tumours 9 2459 Mean Difference (IV, Fixed, 95% CI) 2.29 [1.33, 3.25]
4.2 haematological
malignancies
2 566 Mean Difference (IV, Fixed, 95% CI) 1.99 [0.28, 3.69]
4.3 mixed 7 1940 Mean Difference (IV, Fixed, 95% CI) 1.87 [0.87, 2.87]
4.4 unclear 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Change in FACT-F 13 - age 18 4965 Mean Difference (IV, Fixed, 95% CI) 2.08 [1.43, 2.72]
5.1 only children < 18 years 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 adults >= 18 years 17 4627 Mean Difference (IV, Fixed, 95% CI) 1.82 [1.16, 2.49]
5.3 >70% non elderly 18-65
years
1 338 Mean Difference (IV, Fixed, 95% CI) 5.1 [2.79, 7.41]
5.4 only non-elderly adults 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.5 >70% elderly >65 years 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.6 only elderly > 65 years 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Change in FACT-F 13 - different
therapies
18 4965 Mean Difference (IV, Fixed, 95% CI) 2.08 [1.43, 2.72]
6.1 chemotherapy 14 3515 Mean Difference (IV, Fixed, 95% CI) 2.79 [2.03, 3.55]
6.2 radiotherapy 1 300 Mean Difference (IV, Fixed, 95% CI) 0.0 [-2.63, 2.63]
6.3 no therapy 3 1150 Mean Difference (IV, Fixed, 95% CI) 0.42 [-0.91, 1.76]
6.4 unclear 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Change in FACT-F 13 - different
therapies differentiated
18 4965 Mean Difference (IV, Fixed, 95% CI) 2.07 [1.43, 2.72]
7.1 chemotherapy, >70% with
platinum
4 1069 Mean Difference (IV, Fixed, 95% CI) 1.85 [0.41, 3.30]
7.2 chemotherapy, <70%
platinum containing
2 411 Mean Difference (IV, Fixed, 95% CI) 2.53 [-0.01, 5.07]
7.3 chemotherapy without
platinum (all patients)




3 567 Mean Difference (IV, Fixed, 95% CI) 3.27 [1.30, 5.23]
7.5 radiochemotherapy NEW 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.6 radiotherapy 1 300 Mean Difference (IV, Fixed, 95% CI) 0.0 [-2.63, 2.63]
7.7 no therapy 3 1150 Mean Difference (IV, Fixed, 95% CI) 0.42 [-0.91, 1.76]
7.8 unclear 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.9 chemotherapy no details
given
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Change in FACT-F 13 - epoetin
versus darbepoetin
18 4965 Mean Difference (IV, Fixed, 95% CI) 2.08 [1.43, 2.72]
8.1 Epoetin 11 2475 Mean Difference (IV, Fixed, 95% CI) 3.25 [2.33, 4.16]
8.2 Darbepoetin 7 2490 Mean Difference (IV, Fixed, 95% CI) 0.94 [0.04, 1.84]
9 Change in FACT-F 13 -
duration of ESA medication
18 4965 Mean Difference (IV, Fixed, 95% CI) 2.08 [1.43, 2.72]
9.1 6 to 9 weeks 1 115 Mean Difference (IV, Fixed, 95% CI) 3.10 [-0.27, 6.47]
9.2 12 to 16 weeks 15 4076 Mean Difference (IV, Fixed, 95% CI) 1.99 [1.30, 2.69]
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9.3 more than 17 weeks 2 774 Mean Difference (IV, Fixed, 95% CI) 2.35 [0.46, 4.25]
9.4 unclear 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10 Change in FACT-F 13 - iron
supplementation
18 4965 Mean Difference (IV, Fixed, 95% CI) 2.08 [1.43, 2.72]
10.1 fixed iron
supplementation
4 863 Mean Difference (IV, Fixed, 95% CI) 1.64 [-0.01, 3.29]
10.2 iron supplementation as
necessary
13 3881 Mean Difference (IV, Fixed, 95% CI) 2.03 [1.32, 2.74]
10.3 no explicit statement on
iron supplementation or no
iron given
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.4 explicitly stated NO
IRON
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.5 unclear 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.6 iron given differently in
both study arms new
1 221 Mean Difference (IV, Fixed, 95% CI) 5.15 [1.70, 8.60]
11 Change in FACT-F 13 -
allocation concealment
18 4965 Mean Difference (IV, Fixed, 95% CI) 2.08 [1.43, 2.72]
11.1 adequate 16 4493 Mean Difference (IV, Fixed, 95% CI) 2.20 [1.51, 2.89]
11.2 unclear 2 472 Mean Difference (IV, Fixed, 95% CI) 1.20 [-0.61, 3.02]
11.3 unclear wether adequate
or unclear :)
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
12 Change in FACT-F 13 -
masking
18 4965 Mean Difference (IV, Fixed, 95% CI) 2.08 [1.43, 2.72]
12.1 double-blind 11 3384 Mean Difference (IV, Fixed, 95% CI) 1.33 [0.56, 2.10]
12.2 unblinded 7 1581 Mean Difference (IV, Fixed, 95% CI) 3.76 [2.60, 4.92]
13 Change in FACT-F 13 -
intention-to treat
18 4965 Mean Difference (IV, Fixed, 95% CI) 2.08 [1.43, 2.72]
13.1 ITT or less than 10%
of participants per study arm
excluded
4 864 Mean Difference (IV, Fixed, 95% CI) 3.30 [1.89, 4.70]
13.2 more than 10% of
participants per study arm
excluded
12 3689 Mean Difference (IV, Fixed, 95% CI) 1.80 [1.04, 2.56]
13.3 unclear 2 412 Mean Difference (IV, Fixed, 95% CI) 1.34 [-0.95, 3.63]
14 Change in FACT-F 13 -
publication
18 4965 Mean Difference (IV, Fixed, 95% CI) 2.08 [1.43, 2.72]
14.1 full text publication 16 4412 Mean Difference (IV, Fixed, 95% CI) 2.17 [1.49, 2.85]
14.2 abstract publication 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
14.3 unpublished data 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
14.4 FDA hearing 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
14.5 clinical trial result
information
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
14.6 other source 2 553 Mean Difference (IV, Fixed, 95% CI) 1.32 [-0.63, 3.26]
15 Change in FACT-F 13 - type
of data
18 4965 Mean Difference (IV, Fixed, 95% CI) 2.08 [1.43, 2.72]
15.1 Not imputed data 7 2298 Mean Difference (IV, Fixed, 95% CI) 1.88 [0.96, 2.80]
15.2 Imputed data 11 2667 Mean Difference (IV, Fixed, 95% CI) 2.26 [1.36, 3.15]
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Comparison 9. Change in FACT-An 20




participants Statistical method Effect size
1 Change in FACT-An (20 items)
- overall
6 1085 Mean Difference (IV, Fixed, 95% CI) 6.14 [4.55, 7.73]
2 Change in FACT-An 20 -
baseline Hb
6 1085 Mean Difference (IV, Fixed, 95% CI) 6.14 [4.55, 7.73]
2.1 Hb <= 10 g/dL 1 290 Mean Difference (IV, Fixed, 95% CI) 6.6 [3.92, 9.28]
2.2 Hb 10 to 12 g/dL 4 713 Mean Difference (IV, Fixed, 95% CI) 5.82 [3.71, 7.93]
2.3 Hb > 12 g/dL 1 82 Mean Difference (IV, Fixed, 95% CI) 6.4 [0.83, 11.97]
2.4 Hb category unclear 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Change in FACT-An 20 -
different malignancies
6 1085 Mean Difference (IV, Fixed, 95% CI) 6.14 [4.55, 7.73]
3.1 solid tumours 5 795 Mean Difference (IV, Fixed, 95% CI) 5.90 [3.92, 7.87]
3.2 haematological
malignancies
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.3 mixed 1 290 Mean Difference (IV, Fixed, 95% CI) 6.6 [3.92, 9.28]
3.4 unclear 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Change in FACT-An 20 - age 6 1085 Mean Difference (IV, Fixed, 95% CI) 6.14 [4.55, 7.73]
4.1 only children < 18 years 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 adults >= 18 years 5 747 Mean Difference (IV, Fixed, 95% CI) 5.93 [4.00, 7.86]
4.3 >70% non elderly 18-65
years
1 338 Mean Difference (IV, Fixed, 95% CI) 6.59 [3.79, 9.39]
4.4 only non-elderly adults 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.5 >70% elderly >65 years 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.6 only elderly > 65 years 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Change in FACT-An 20 -
different therapies
6 1085 Mean Difference (IV, Fixed, 95% CI) 6.14 [4.55, 7.73]
5.1 chemotherapy 5 1051 Mean Difference (IV, Fixed, 95% CI) 6.21 [4.60, 7.82]
5.2 radiotherapy 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.3 no therapy 1 34 Mean Difference (IV, Fixed, 95% CI) 3.9 [-5.75, 13.55]
5.4 unclear 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Change in FACT-An
20 - different therapies
differentiated
6 1085 Mean Difference (IV, Fixed, 95% CI) 6.14 [4.55, 7.73]
6.1 chemotherapy, >70% with
platinum
2 256 Mean Difference (IV, Fixed, 95% CI) 5.08 [1.12, 9.04]
6.2 chemotherapy, <70%
platinum containing
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.3 chemotherapy without
platinum (all patients)




0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.5 radiochemotherapy NEW 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.6 radiotherapy 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.7 no therapy 1 34 Mean Difference (IV, Fixed, 95% CI) 3.9 [-5.75, 13.55]
6.8 unclear 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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6.9 chemotherapy no details
given
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Change in FACT-An 20 -
epoetin versus darbepoetin
6 1085 Mean Difference (IV, Fixed, 95% CI) 6.14 [4.55, 7.73]
7.1 Epoetin 6 1085 Mean Difference (IV, Fixed, 95% CI) 6.14 [4.55, 7.73]
7.2 Darbepoetin 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Change in FACT-An 20 -
duration of ESA medication
6 1085 Mean Difference (IV, Fixed, 95% CI) 6.14 [4.55, 7.73]
8.1 6 to 9 weeks 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.2 12 to 16 weeks 5 795 Mean Difference (IV, Fixed, 95% CI) 5.90 [3.92, 7.87]
8.3 more than 17 weeks 1 290 Mean Difference (IV, Fixed, 95% CI) 6.6 [3.92, 9.28]
8.4 unclear 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Change in FACT-An 20 - iron
supplementation
6 1085 Mean Difference (IV, Fixed, 95% CI) 6.14 [4.55, 7.73]
9.1 fixed iron supplementation 1 126 Mean Difference (IV, Fixed, 95% CI) 3.53 [-1.90, 8.96]
9.2 iron supplementation as
necessary
4 744 Mean Difference (IV, Fixed, 95% CI) 6.48 [4.68, 8.28]
9.3 no explicit statement on
iron supplementation or no
iron given
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.4 explicitly stated NO
IRON
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.5 unclear 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.6 iron given differently in
both study arms new
1 215 Mean Difference (IV, Fixed, 95% CI) 5.84 [1.47, 10.21]
10 Change in FACT-An 20 -
allocation concealment
6 1085 Mean Difference (IV, Fixed, 95% CI) 6.14 [4.55, 7.73]
10.1 adequate 6 1085 Mean Difference (IV, Fixed, 95% CI) 6.14 [4.55, 7.73]
10.2 unclear 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.3 unclear wether adequate
or unclear :)
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
11 Change in FACT-An 20 -
masking
6 1085 Mean Difference (IV, Fixed, 95% CI) 6.14 [4.55, 7.73]
11.1 double-blind 3 406 Mean Difference (IV, Fixed, 95% CI) 6.41 [4.06, 8.75]
11.2 unblinded 3 679 Mean Difference (IV, Fixed, 95% CI) 5.92 [3.76, 8.08]
12 Change in FACT-An 20 -
intention-to treat
6 1085 Mean Difference (IV, Fixed, 95% CI) 6.14 [4.55, 7.73]
12.1 ITT or less than 10%
of participants per study arm
excluded
1 338 Mean Difference (IV, Fixed, 95% CI) 6.59 [3.79, 9.39]
12.2 more than 10% of
participants per study arm
excluded
5 747 Mean Difference (IV, Fixed, 95% CI) 5.93 [4.00, 7.86]
12.3 unclear 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
13 Change in FACT-An 20 -
publication
6 1085 Mean Difference (IV, Fixed, 95% CI) 6.14 [4.55, 7.73]
13.1 full text publication 6 1085 Mean Difference (IV, Fixed, 95% CI) 6.14 [4.55, 7.73]
13.2 abstract publication 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
13.3 unpublished data 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
13.4 FDA hearing 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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13.5 clinical trial result
information
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
14 Change in FACT-An 20 - data
type
6 1085 Mean Difference (IV, Fixed, 95% CI) 6.14 [4.55, 7.73]
14.1 Not imputed data 3 635 Mean Difference (IV, Fixed, 95% CI) 6.38 [4.20, 8.55]
14.2 Imputed data 3 450 Mean Difference (IV, Fixed, 95% CI) 5.88 [3.54, 8.21]
Comparison 10. Change in FACT-An Total 47




participants Statistical method Effect size
1 Change in FACT-An Total (47
items) - overall
10 1815 Mean Difference (IV, Fixed, 95% CI) 6.92 [4.59, 9.25]
2 Change in FACT-An Total 47-
sensitivity analysis
9 1715 Mean Difference (IV, Fixed, 95% CI) 3.46 [0.96, 5.96]
3 Change in FACT-An Total 47 -
baseline Hb
10 1815 Mean Difference (IV, Fixed, 95% CI) 6.92 [4.59, 9.25]
3.1 Hb <= 10 g/dL 5 978 Mean Difference (IV, Fixed, 95% CI) 2.57 [-0.63, 5.78]
3.2 Hb 10 to 12 g/dL 4 537 Mean Difference (IV, Fixed, 95% CI) 16.22 [12.14, 20.30]
3.3 Hb > 12 g/dL 1 300 Mean Difference (IV, Fixed, 95% CI) 1.90 [-4.19, 7.99]
3.4 Hb category unclear 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Change in FACT-An Total 47 -
different malignancies
10 1815 Mean Difference (IV, Fixed, 95% CI) 6.92 [4.59, 9.25]
4.1 solid tumours 8 1437 Mean Difference (IV, Fixed, 95% CI) 7.21 [4.58, 9.84]
4.2 haematological
malignancies
1 206 Mean Difference (IV, Fixed, 95% CI) 6.10 [-1.67, 13.87]
4.3 mixed 1 172 Mean Difference (IV, Fixed, 95% CI) 5.7 [-0.83, 12.23]
4.4 unclear 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Change in FACT-An Total 47 -
age
10 1815 Mean Difference (IV, Fixed, 95% CI) 6.92 [4.59, 9.25]
5.1 only children < 18 years 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 adults >= 18 years 10 1815 Mean Difference (IV, Fixed, 95% CI) 6.92 [4.59, 9.25]
5.3 >70% non elderly 18-65
years
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.4 only non-elderly adults 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.5 >70% elderly >65 years 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.6 only elderly > 65 years 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Change in FACT-An Total 47 -
different therapies
10 1815 Mean Difference (IV, Fixed, 95% CI) 6.92 [4.59, 9.25]
6.1 chemotherapy 8 1415 Mean Difference (IV, Fixed, 95% CI) 3.77 [1.03, 6.51]
6.2 radiotherapy 1 300 Mean Difference (IV, Fixed, 95% CI) 1.90 [-4.19, 7.99]
6.3 no therapy 1 100 Mean Difference (IV, Fixed, 95% CI) 29.90 [23.46, 36.34]
6.4 unclear 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Change in FACT-An Total
47 - different therapies
differentiated
10 1815 Mean Difference (IV, Fixed, 95% CI) 6.92 [4.59, 9.25]
7.1 chemotherapy, >70% with
platinum
3 352 Mean Difference (IV, Fixed, 95% CI) 6.91 [1.12, 12.70]
198Erythropoietin or darbepoetin for patients with cancer (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
7.2 chemotherapy, <70%
platinum containing
3 600 Mean Difference (IV, Fixed, 95% CI) 0.28 [-3.90, 4.45]
7.3 chemotherapy without
platinum (all patients)




0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.5 radiochemotherapy NEW 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.6 radiotherapy 1 300 Mean Difference (IV, Fixed, 95% CI) 1.90 [-4.19, 7.99]
7.7 no therapy 1 100 Mean Difference (IV, Fixed, 95% CI) 29.90 [23.46, 36.34]
7.8 unclear 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.9 chemotherapy no details
given
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Change in FACT-An Total 47 -
epoetin versus darbepoetin
10 1815 Mean Difference (IV, Fixed, 95% CI) 6.92 [4.59, 9.25]
8.1 Epoetin 10 1815 Mean Difference (IV, Fixed, 95% CI) 6.92 [4.59, 9.25]
8.2 Darbepoetin 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Change in FACT-An Total 47 -
duration of ESA medication
10 1815 Mean Difference (IV, Fixed, 95% CI) 6.92 [4.59, 9.25]
9.1 6 to 9 weeks 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.2 12 to 16 weeks 8 1625 Mean Difference (IV, Fixed, 95% CI) 3.39 [0.83, 5.96]
9.3 more than 17 weeks 2 190 Mean Difference (IV, Fixed, 95% CI) 23.64 [18.05, 29.22]
9.4 unclear 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10 Change in FACT-An Total 47
- iron supplementation
10 1815 Mean Difference (IV, Fixed, 95% CI) 6.92 [4.59, 9.25]
10.1 fixed iron
supplementation
7 1217 Mean Difference (IV, Fixed, 95% CI) 7.14 [4.31, 9.96]
10.2 iron supplementation as
necessary
2 378 Mean Difference (IV, Fixed, 95% CI) 5.87 [0.86, 10.87]
10.3 no explicit statement on
iron supplementation or no
iron given
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.4 explicitly stated NO
IRON
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.5 unclear 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.6 iron given differently in
both study arms new
1 220 Mean Difference (IV, Fixed, 95% CI) 7.67 [0.40, 14.94]
11 Change in FACT-An Total 47
- allocation concealment
10 1815 Mean Difference (IV, Fixed, 95% CI) 6.92 [4.59, 9.25]
11.1 adequate 4 840 Mean Difference (IV, Fixed, 95% CI) 4.69 [0.92, 8.45]
11.2 unclear 6 975 Mean Difference (IV, Fixed, 95% CI) 8.30 [5.33, 11.26]
12 Change in FACT-An Total 47
- masking
10 1815 Mean Difference (IV, Fixed, 95% CI) 6.92 [4.59, 9.25]
12.1 double-blind 6 1078 Mean Difference (IV, Fixed, 95% CI) 8.00 [5.13, 10.87]
12.2 unblinded 4 737 Mean Difference (IV, Fixed, 95% CI) 4.83 [0.84, 8.82]
13 Change in FACT-An Total 47
- intention-to treat
10 1815 Mean Difference (IV, Fixed, 95% CI) 6.92 [4.59, 9.25]
13.1 ITT or less than 10%
of participants per study arm
excluded
4 585 Mean Difference (IV, Fixed, 95% CI) 10.85 [7.29, 14.41]
199Erythropoietin or darbepoetin for patients with cancer (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
13.2 more than 10% of
participants per study arm
excluded
4 840 Mean Difference (IV, Fixed, 95% CI) 4.69 [0.92, 8.45]
13.3 unclear 2 390 Mean Difference (IV, Fixed, 95% CI) 2.54 [-2.81, 7.90]
14 Change in FACT-An Total 47
- publication
10 1815 Mean Difference (IV, Fixed, 95% CI) 6.92 [4.59, 9.25]
14.1 full text publication 9 1725 Mean Difference (IV, Fixed, 95% CI) 7.02 [4.63, 9.40]
14.2 abstract publication 1 90 Mean Difference (IV, Fixed, 95% CI) 4.71 [-6.49, 15.91]
14.3 unpublished data 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
14.4 FDA hearing 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
14.5 clinical trial result
information
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
15 Change in Fact-An Total 47 -
data type
10 1815 Mean Difference (IV, Fixed, 95% CI) 6.92 [4.59, 9.25]
15.1 Not imputed data 7 1101 Mean Difference (IV, Fixed, 95% CI) 9.31 [6.45, 12.17]
15.2 Imputed data 3 714 Mean Difference (IV, Fixed, 95% CI) 2.19 [-1.83, 6.20]
16 FACT-An Total 47 - merged
experimental study arms
9 1815 Mean Difference (IV, Fixed, 95% CI) 6.92 [4.59, 9.25]
Comparison 11. Thrombotic events




participants Statistical method Effect size
1 Thrombotic events - overall 60 15498 Risk Ratio (M-H, Fixed, 95% CI) 1.52 [1.34, 1.74]
2 Thrombotic events - baseline Hb 60 15498 Risk Ratio (M-H, Fixed, 95% CI) 1.52 [1.34, 1.74]
2.1 Hb < 10 g/dL 19 4231 Risk Ratio (M-H, Fixed, 95% CI) 1.41 [1.06, 1.88]
2.2 Hb 10 to 12 g/dL 26 5491 Risk Ratio (M-H, Fixed, 95% CI) 1.64 [1.33, 2.03]
2.3 Hb > 12 g/dL 13 5348 Risk Ratio (M-H, Fixed, 95% CI) 1.44 [1.15, 1.80]
2.4 Hb unclear 2 428 Risk Ratio (M-H, Fixed, 95% CI) 1.64 [1.02, 2.65]
3 Thrombotic events - different
malignancies
60 15498 Risk Ratio (M-H, Fixed, 95% CI) 1.52 [1.34, 1.74]
3.1 solid tumours 36 9121 Risk Ratio (M-H, Fixed, 95% CI) 1.67 [1.41, 1.96]
3.2 haematological
malignancies
8 2531 Risk Ratio (M-H, Fixed, 95% CI) 1.33 [0.93, 1.90]
3.3 mixed 14 3693 Risk Ratio (M-H, Fixed, 95% CI) 1.29 [0.98, 1.69]
3.4 MDS 2 153 Risk Ratio (M-H, Fixed, 95% CI) 2.08 [0.23, 18.84]
3.5 not reported 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Thrombotic events - age 60 15498 Risk Ratio (M-H, Fixed, 95% CI) 1.52 [1.34, 1.74]
4.1 children 1 222 Risk Ratio (M-H, Fixed, 95% CI) 2.95 [0.61, 14.28]
4.2 adults 59 15276 Risk Ratio (M-H, Fixed, 95% CI) 1.52 [1.33, 1.73]
5 Thrombotic events - age
differentiated
60 15498 Risk Ratio (M-H, Fixed, 95% CI) 1.52 [1.34, 1.74]
5.1 children 1 222 Risk Ratio (M-H, Fixed, 95% CI) 2.95 [0.61, 14.28]
5.2 adults >= 18 46 11310 Risk Ratio (M-H, Fixed, 95% CI) 1.60 [1.38, 1.86]
5.3 > 68% non elderly, 18-65 7 1028 Risk Ratio (M-H, Fixed, 95% CI) 1.71 [1.02, 2.86]
5.4 only non elderly 5 2882 Risk Ratio (M-H, Fixed, 95% CI) 1.17 [0.86, 1.60]
5.5 > 68% elderly > 65 years 1 56 Risk Ratio (M-H, Fixed, 95% CI) 0.23 [0.01, 4.58]
5.6 only elderly 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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6 Thrombotic events - different
therapies
60 15498 Risk Ratio (M-H, Fixed, 95% CI) 1.52 [1.34, 1.74]
6.1 chemotherapy 37 10844 Risk Ratio (M-H, Fixed, 95% CI) 1.48 [1.27, 1.73]
6.2 radiotherapy/
radiochemotherapy
11 2384 Risk Ratio (M-H, Fixed, 95% CI) 2.02 [1.44, 2.83]
6.3 no therapy 8 1921 Risk Ratio (M-H, Fixed, 95% CI) 1.25 [0.88, 1.78]
6.4 unclear/other 4 349 Risk Ratio (M-H, Fixed, 95% CI) 2.09 [0.74, 5.93]
7 Thrombotic events - different
therapies differentiated
60 15498 Risk Ratio (M-H, Fixed, 95% CI) 1.52 [1.34, 1.74]
7.1 chemotherapy, > 70%
with platinum
16 3136 Risk Ratio (M-H, Fixed, 95% CI) 1.46 [1.13, 1.89]
7.2 chemotherapy, < 70%
with platinum
3 919 Risk Ratio (M-H, Fixed, 95% CI) 1.63 [0.92, 2.88]
7.3 chemotherapy, without
platinum, all patients
14 6085 Risk Ratio (M-H, Fixed, 95% CI) 1.42 [1.14, 1.76]
7.4 chemotherapy, platinum
and non platinum containing,
no numbers given
2 265 Risk Ratio (M-H, Fixed, 95% CI) 4.56 [0.79, 26.20]
7.5 chemotherapy no details
given
2 439 Risk Ratio (M-H, Fixed, 95% CI) 1.79 [0.67, 4.76]
7.6 radiochemotherapy 7 1097 Risk Ratio (M-H, Fixed, 95% CI) 2.01 [1.37, 2.96]
7.7 radiotherapy 4 1287 Risk Ratio (M-H, Fixed, 95% CI) 2.03 [1.02, 4.07]
7.8 no therapy 8 1921 Risk Ratio (M-H, Fixed, 95% CI) 1.25 [0.88, 1.78]
7.9 unclear/other 4 349 Risk Ratio (M-H, Fixed, 95% CI) 2.09 [0.74, 5.93]
8 Thrombotic events - epoetin
versus darbepoetin
60 15498 Risk Ratio (M-H, Fixed, 95% CI) 1.52 [1.34, 1.74]
8.1 Epoetin 50 11055 Risk Ratio (M-H, Fixed, 95% CI) 1.57 [1.33, 1.85]
8.2 Darbepoetin 10 4443 Risk Ratio (M-H, Fixed, 95% CI) 1.44 [1.16, 1.79]
9 Thrombotic events - duration of
ESA treatment
60 15498 Risk Ratio (M-H, Fixed, 95% CI) 1.52 [1.34, 1.74]
9.1 6 to 9 weeks 10 1719 Risk Ratio (M-H, Fixed, 95% CI) 2.06 [1.17, 3.64]
9.2 12 to 16 weeks 30 7223 Risk Ratio (M-H, Fixed, 95% CI) 1.46 [1.20, 1.77]
9.3 more than 17 weeks 19 6312 Risk Ratio (M-H, Fixed, 95% CI) 1.53 [1.27, 1.84]
9.4 not reported 1 244 Risk Ratio (M-H, Fixed, 95% CI) 1.46 [0.15, 13.85]
10 Thrombotic events - iron
supplementation
60 15498 Risk Ratio (M-H, Fixed, 95% CI) 1.52 [1.34, 1.74]
10.1 fixed iron
supplementation
4 1445 Risk Ratio (M-H, Fixed, 95% CI) 1.53 [0.92, 2.54]
10.2 iron supplementation as
necessary
47 12073 Risk Ratio (M-H, Fixed, 95% CI) 1.51 [1.31, 1.74]
10.3 no explicit statement on
iron supplementation or no
iron given
4 293 Risk Ratio (M-H, Fixed, 95% CI) 1.26 [0.39, 4.06]
10.4 iron handled differently
in the study arms
5 1687 Risk Ratio (M-H, Fixed, 95% CI) 1.69 [1.12, 2.54]
10.5 explicitly stated NO
IRON
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
11 Thrombotic events -
concealment of allocation
60 15498 Risk Ratio (M-H, Fixed, 95% CI) 1.52 [1.34, 1.74]
11.1 adequate 38 10494 Risk Ratio (M-H, Fixed, 95% CI) 1.64 [1.40, 1.92]
11.2 unclear 22 5004 Risk Ratio (M-H, Fixed, 95% CI) 1.31 [1.04, 1.65]
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12 Thrombotic events - masking 60 15498 Risk Ratio (M-H, Fixed, 95% CI) 1.52 [1.34, 1.74]
12.1 double-blind 32 9209 Risk Ratio (M-H, Fixed, 95% CI) 1.40 [1.19, 1.64]
12.2 unblinded 28 6289 Risk Ratio (M-H, Fixed, 95% CI) 1.78 [1.43, 2.23]
13 Thrombotic events -
intention-to-treat
60 15498 Risk Ratio (M-H, Fixed, 95% CI) 1.52 [1.34, 1.74]
13.1 ITT or less than 10%
of participants per study arm
excluded
55 13182 Risk Ratio (M-H, Fixed, 95% CI) 1.50 [1.30, 1.72]
13.2 more than 10% of
participants per study arm
excluded
3 1589 Risk Ratio (M-H, Fixed, 95% CI) 1.59 [0.95, 2.66]
13.3 unclear 2 727 Risk Ratio (M-H, Fixed, 95% CI) 1.82 [1.15, 2.89]
14 Thrombotic events -
publication
60 15498 Risk Ratio (M-H, Fixed, 95% CI) 1.52 [1.34, 1.74]
14.1 full text publication 35 8388 Risk Ratio (M-H, Fixed, 95% CI) 1.57 [1.32, 1.87]
14.2 abstract publication 2 1343 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.70, 1.55]
14.3 unpublished data 1 66 Risk Ratio (M-H, Fixed, 95% CI) 1.43 [0.06, 33.82]
14.4 data presented at ODAC
hearing
21 5645 Risk Ratio (M-H, Fixed, 95% CI) 1.66 [1.33, 2.08]
14.5 other 1 56 Risk Ratio (M-H, Fixed, 95% CI) 0.23 [0.01, 4.58]
15 Thrombotic events -
experimental arms merged
57 15498 Risk Ratio (M-H, Fixed, 95% CI) 1.53 [1.34, 1.74]
Comparison 12. Hypertension




participants Statistical method Effect size
1 Hypertension - overall 37 7228 Risk Ratio (M-H, Fixed, 95% CI) 1.30 [1.08, 1.56]
2 Hypertension - merged
experimental study arms
31 7228 Risk Ratio (M-H, Fixed, 95% CI) 1.31 [1.09, 1.58]
3 Hypertension - sensitivity
analysis Dammacco
37 7228 Risk Ratio (M-H, Fixed, 95% CI) 1.29 [1.10, 1.52]
4 Hypertension - sensitivity
analysis random effects
37 7228 Risk Ratio (M-H, Random, 95% CI) 1.12 [0.94, 1.33]
5 Hypertension - sensitivity
analysis without Rose
36 7007 Risk Ratio (M-H, Fixed, 95% CI) 1.52 [1.18, 1.97]
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Comparison 13. Thrombocytopenia or haemorrhage




participants Statistical method Effect size
1 Thrombocytopenia - overall 24 4507 Risk Ratio (M-H, Fixed, 95% CI) 1.21 [1.04, 1.42]
2 Thrombocytopenia - merged
experimental arms
21 4507 Risk Ratio (M-H, Fixed, 95% CI) 1.21 [1.04, 1.41]
3 Thrombocytopenia - sensitivity
analysis random effects
24 4507 Risk Ratio (M-H, Random, 95% CI) 1.18 [1.02, 1.36]
Comparison 14. Rash




participants Statistical method Effect size
1 Rash - overall 18 2485 Risk Ratio (M-H, Fixed, 95% CI) 1.49 [0.99, 2.24]
2 Rash - merged experimental
arms
16 2485 Risk Ratio (M-H, Fixed, 95% CI) 1.50 [1.00, 2.27]
Comparison 15. Seizure




participants Statistical method Effect size
1 Seizure - overall 8 2890 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.42, 1.41]
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Analysis 1.1. Comparison 1 Haematologic response, Outcome 1 Haematological response - overall.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 1 Haematologic response
Outcome: 1 Haematological response - overall
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Aapro 2008 157/231 32/232 6.6 % 4.93 [ 3.53, 6.88 ]
Abels 1993 20/63 6/55 1.3 % 2.91 [ 1.26, 6.72 ]
Bamias 2003 15/72 2/72 0.4 % 7.50 [ 1.78, 31.62 ]
Boogaerts 2003 63/133 17/129 3.6 % 3.59 [ 2.23, 5.80 ]
Case 1993 46/79 10/74 2.1 % 4.31 [ 2.35, 7.90 ]
Cazzola 1995a 2/31 0/7 0.2 % 1.25 [ 0.07, 23.55 ]
Cazzola 1995b 9/29 1/8 0.3 % 2.48 [ 0.37, 16.80 ]
Cazzola 1995c 19/31 0/7 0.2 % 9.75 [ 0.66, 144.80 ]
Cazzola 1995d 16/26 1/7 0.3 % 4.31 [ 0.68, 27.12 ]
Chang 2005 115/175 11/175 2.3 % 10.45 [ 5.84, 18.71 ]
Charu 2007 150/220 5/55 1.7 % 7.50 [ 3.24, 17.38 ]
Dammacco 2001 38/66 6/66 1.2 % 6.33 [ 2.87, 13.96 ]
Hedenus 2002a 5/11 1/3 0.3 % 1.36 [ 0.24, 7.66 ]
Hedenus 2002b 12/22 0/4 0.2 % 5.43 [ 0.38, 77.40 ]
Hedenus 2002c 14/22 0/4 0.2 % 6.30 [ 0.45, 89.06 ]
Hedenus 2003 104/174 31/170 6.5 % 3.28 [ 2.33, 4.61 ]
Henry 1995 31/64 4/61 0.8 % 7.39 [ 2.77, 19.69 ]
Iconomou 2003 25/57 7/55 1.5 % 3.45 [ 1.62, 7.31 ]
Italian 1998 5/43 0/42 0.1 % 10.75 [ 0.61, 188.54 ]
Kotasek 2003a 8/32 1/8 0.3 % 2.00 [ 0.29, 13.77 ]
Kotasek 2003b 8/17 1/8 0.3 % 3.76 [ 0.56, 25.21 ]
Kotasek 2003c 23/46 2/9 0.7 % 2.25 [ 0.64, 7.90 ]
Kotasek 2003d 17/28 1/8 0.3 % 4.86 [ 0.76, 31.12 ]
Kotasek 2003e 20/35 1/9 0.3 % 5.14 [ 0.79, 33.37 ]
Kotasek 2003f 20/40 1/9 0.3 % 4.50 [ 0.69, 29.30 ]
Littlewood 2001 172/244 22/115 6.2 % 3.68 [ 2.51, 5.41 ]
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(. . . Continued)
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Milroy 2011 37/189 5/191 1.0 % 7.48 [ 3.00, 18.62 ]
ML17616 2006 21/30 11/30 2.3 % 1.91 [ 1.13, 3.23 ]
ML17620 2006 29/61 14/60 2.9 % 2.04 [ 1.20, 3.46 ]
Oberhoff 1998 38/114 7/104 1.5 % 4.95 [ 2.31, 10.60 ]
Osterborg 1996a 21/47 4/24 1.1 % 2.68 [ 1.04, 6.93 ]
Osterborg 1996b 23/48 4/25 1.1 % 2.99 [ 1.16, 7.71 ]
Osterborg 2002 114/170 46/173 9.4 % 2.52 [ 1.93, 3.30 ]
Razzouk 2006 63/111 39/111 8.1 % 1.62 [ 1.20, 2.18 ]
Rose 1994 67/142 13/79 3.5 % 2.87 [ 1.69, 4.85 ]
Savonije 2005 143/208 31/100 8.7 % 2.22 [ 1.63, 3.01 ]
Smith 2003a 12/21 1/7 0.3 % 4.00 [ 0.63, 25.49 ]
Smith 2003b 10/21 0/7 0.2 % 7.64 [ 0.50, 115.83 ]
Smith 2003c 13/22 0/8 0.1 % 10.57 [ 0.70, 159.65 ]
Suzuki 2008a 22/40 3/21 0.8 % 3.85 [ 1.30, 11.39 ]
Suzuki 2008b 28/41 2/21 0.5 % 7.17 [ 1.89, 27.24 ]
Thompson 2000 4/45 1/21 0.3 % 1.87 [ 0.22, 15.70 ]
Tjulandin 2010a 50/76 8/37 2.2 % 3.04 [ 1.61, 5.74 ]
Tjulandin 2010b 52/73 7/37 1.9 % 3.77 [ 1.90, 7.45 ]
Tjulandin 2011 69/95 23/91 4.9 % 2.87 [ 1.98, 4.18 ]
Witzig 2005 120/165 52/164 10.8 % 2.29 [ 1.80, 2.93 ]
Total (95% CI) 3710 2703 100.0 % 3.39 [ 3.10, 3.71 ]
Total events: 2050 (Treatment), 434 (Control)
Heterogeneity: Chi2 = 95.56, df = 45 (P = 0.00002); I2 =53%
Test for overall effect: Z = 26.39 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.2. Comparison 1 Haematologic response, Outcome 2 Haematologic response - baseline Hb.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 1 Haematologic response
Outcome: 2 Haematologic response - baseline Hb
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hb <= 10 g/dL
Abels 1993 20/63 6/55 1.3 % 2.91 [ 1.26, 6.72 ]
Boogaerts 2003 63/133 17/129 3.6 % 3.59 [ 2.23, 5.80 ]
Case 1993 46/79 10/74 2.1 % 4.31 [ 2.35, 7.90 ]
Cazzola 1995a 2/31 0/7 0.2 % 1.25 [ 0.07, 23.55 ]
Cazzola 1995b 9/29 1/8 0.3 % 2.48 [ 0.37, 16.80 ]
Cazzola 1995c 19/31 0/7 0.2 % 9.75 [ 0.66, 144.80 ]
Cazzola 1995d 16/26 1/7 0.3 % 4.31 [ 0.68, 27.12 ]
Dammacco 2001 38/66 6/66 1.2 % 6.33 [ 2.87, 13.96 ]
Hedenus 2002a 5/11 1/3 0.3 % 1.36 [ 0.24, 7.66 ]
Hedenus 2002b 12/22 0/4 0.2 % 5.43 [ 0.38, 77.40 ]
Hedenus 2002c 14/22 0/4 0.2 % 6.30 [ 0.45, 89.06 ]
Hedenus 2003 104/174 31/170 6.5 % 3.28 [ 2.33, 4.61 ]
Henry 1995 31/64 4/61 0.8 % 7.39 [ 2.77, 19.69 ]
Italian 1998 5/43 0/42 0.1 % 10.75 [ 0.61, 188.54 ]
Kotasek 2003a 8/32 1/8 0.3 % 2.00 [ 0.29, 13.77 ]
Kotasek 2003b 8/17 1/8 0.3 % 3.76 [ 0.56, 25.21 ]
Kotasek 2003c 23/46 2/9 0.7 % 2.25 [ 0.64, 7.90 ]
Kotasek 2003d 17/28 1/8 0.3 % 4.86 [ 0.76, 31.12 ]
Kotasek 2003e 20/35 1/9 0.3 % 5.14 [ 0.79, 33.37 ]
Kotasek 2003f 20/40 1/9 0.3 % 4.50 [ 0.69, 29.30 ]
Littlewood 2001 172/244 22/115 6.2 % 3.68 [ 2.51, 5.41 ]
ML17616 2006 21/30 11/30 2.3 % 1.91 [ 1.13, 3.23 ]
Oberhoff 1998 38/114 7/104 1.5 % 4.95 [ 2.31, 10.60 ]
Osterborg 1996a 21/47 4/24 1.1 % 2.68 [ 1.04, 6.93 ]
Osterborg 1996b 23/48 4/25 1.1 % 2.99 [ 1.16, 7.71 ]
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(. . . Continued)
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Osterborg 2002 114/170 46/173 9.4 % 2.52 [ 1.93, 3.30 ]
Razzouk 2006 63/111 39/111 8.1 % 1.62 [ 1.20, 2.18 ]
Rose 1994 67/142 13/79 3.5 % 2.87 [ 1.69, 4.85 ]
Smith 2003a 12/21 1/7 0.3 % 4.00 [ 0.63, 25.49 ]
Smith 2003b 10/21 0/7 0.2 % 7.64 [ 0.50, 115.83 ]
Smith 2003c 13/22 0/8 0.1 % 10.57 [ 0.70, 159.65 ]
Thompson 2000 4/45 1/21 0.3 % 1.87 [ 0.22, 15.70 ]
Tjulandin 2010a 50/76 8/37 2.2 % 3.04 [ 1.61, 5.74 ]
Tjulandin 2010b 52/73 7/37 1.9 % 3.77 [ 1.90, 7.45 ]
Tjulandin 2011 69/95 23/91 4.9 % 2.87 [ 1.98, 4.18 ]
Witzig 2005 120/165 52/164 10.8 % 2.29 [ 1.80, 2.93 ]
Subtotal (95% CI) 2416 1721 73.6 % 3.02 [ 2.72, 3.35 ]
Total events: 1329 (Treatment), 322 (Control)
Heterogeneity: Chi2 = 44.07, df = 35 (P = 0.14); I2 =21%
Test for overall effect: Z = 20.57 (P < 0.00001)
2 Hb 10 to 12 g/dL
Aapro 2008 157/231 32/232 6.6 % 4.93 [ 3.53, 6.88 ]
Bamias 2003 15/72 2/72 0.4 % 7.50 [ 1.78, 31.62 ]
Chang 2005 115/175 11/175 2.3 % 10.45 [ 5.84, 18.71 ]
Charu 2007 150/220 5/55 1.7 % 7.50 [ 3.24, 17.38 ]
Iconomou 2003 25/57 7/55 1.5 % 3.45 [ 1.62, 7.31 ]
Savonije 2005 143/208 31/100 8.7 % 2.22 [ 1.63, 3.01 ]
Suzuki 2008a 22/40 3/21 0.8 % 3.85 [ 1.30, 11.39 ]
Suzuki 2008b 28/41 2/21 0.5 % 7.17 [ 1.89, 27.24 ]
Subtotal (95% CI) 1044 731 22.5 % 4.60 [ 3.79, 5.58 ]
Total events: 655 (Treatment), 93 (Control)
Heterogeneity: Chi2 = 32.40, df = 7 (P = 0.00003); I2 =78%
Test for overall effect: Z = 15.51 (P < 0.00001)
3 Hb > 12 g/dL
Milroy 2011 37/189 5/191 1.0 % 7.48 [ 3.00, 18.62 ]
Subtotal (95% CI) 189 191 1.0 % 7.48 [ 3.00, 18.62 ]
Total events: 37 (Treatment), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 4.32 (P = 0.000015)
4 Hb category unclear
ML17620 2006 29/61 14/60 2.9 % 2.04 [ 1.20, 3.46 ]
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 61 60 2.9 % 2.04 [ 1.20, 3.46 ]
Total events: 29 (Treatment), 14 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.64 (P = 0.0084)
Total (95% CI) 3710 2703 100.0 % 3.39 [ 3.10, 3.71 ]
Total events: 2050 (Treatment), 434 (Control)
Heterogeneity: Chi2 = 95.56, df = 45 (P = 0.00002); I2 =53%
Test for overall effect: Z = 26.39 (P < 0.00001)
Test for subgroup differences: Chi2 = 20.41, df = 3 (P = 0.00), I2 =85%
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Analysis 1.3. Comparison 1 Haematologic response, Outcome 3 Haematologic response - different
malignancies.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 1 Haematologic response
Outcome: 3 Haematologic response - different malignancies
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 solid tumours
Aapro 2008 157/231 32/232 6.6 % 4.93 [ 3.53, 6.88 ]
Bamias 2003 15/72 2/72 0.4 % 7.50 [ 1.78, 31.62 ]
Chang 2005 115/175 11/175 2.3 % 10.45 [ 5.84, 18.71 ]
Iconomou 2003 25/57 7/55 1.5 % 3.45 [ 1.62, 7.31 ]
Kotasek 2003a 8/32 1/8 0.3 % 2.00 [ 0.29, 13.77 ]
Kotasek 2003b 8/17 1/8 0.3 % 3.76 [ 0.56, 25.21 ]
Kotasek 2003c 23/46 2/9 0.7 % 2.25 [ 0.64, 7.90 ]
Kotasek 2003d 17/28 1/8 0.3 % 4.86 [ 0.76, 31.12 ]
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(. . . Continued)
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kotasek 2003e 20/35 1/9 0.3 % 5.14 [ 0.79, 33.37 ]
Kotasek 2003f 20/40 1/9 0.3 % 4.50 [ 0.69, 29.30 ]
Littlewood 2001 87/131 13/61 3.7 % 3.12 [ 1.90, 5.12 ]
Milroy 2011 37/189 5/191 1.0 % 7.48 [ 3.00, 18.62 ]
ML17620 2006 29/61 14/60 2.9 % 2.04 [ 1.20, 3.46 ]
Oberhoff 1998 38/114 7/104 1.5 % 4.95 [ 2.31, 10.60 ]
Savonije 2005 143/208 31/100 8.7 % 2.22 [ 1.63, 3.01 ]
Tjulandin 2010a 50/76 8/37 2.2 % 3.04 [ 1.61, 5.74 ]
Tjulandin 2010b 52/73 7/37 1.9 % 3.77 [ 1.90, 7.45 ]
Witzig 2005 120/165 52/164 10.8 % 2.29 [ 1.80, 2.93 ]
Subtotal (95% CI) 1750 1339 45.9 % 3.56 [ 3.12, 4.07 ]
Total events: 964 (Treatment), 196 (Control)
Heterogeneity: Chi2 = 48.84, df = 17 (P = 0.00006); I2 =65%
Test for overall effect: Z = 18.83 (P < 0.00001)
2 haematological malignancies
Cazzola 1995a 2/31 0/7 0.2 % 1.25 [ 0.07, 23.55 ]
Cazzola 1995b 9/29 1/8 0.3 % 2.48 [ 0.37, 16.80 ]
Cazzola 1995c 19/31 0/7 0.2 % 9.75 [ 0.66, 144.80 ]
Cazzola 1995d 16/26 1/7 0.3 % 4.31 [ 0.68, 27.12 ]
Dammacco 2001 38/66 6/66 1.2 % 6.33 [ 2.87, 13.96 ]
Hedenus 2002a 5/11 1/3 0.3 % 1.36 [ 0.24, 7.66 ]
Hedenus 2002b 12/22 0/4 0.2 % 5.43 [ 0.38, 77.40 ]
Hedenus 2002c 14/22 0/4 0.2 % 6.30 [ 0.45, 89.06 ]
Hedenus 2003 104/174 31/170 6.5 % 3.28 [ 2.33, 4.61 ]
Littlewood 2001 85/113 9/54 2.5 % 4.51 [ 2.46, 8.27 ]
ML17616 2006 21/30 11/30 2.3 % 1.91 [ 1.13, 3.23 ]
Osterborg 1996a 21/47 4/24 1.1 % 2.68 [ 1.04, 6.93 ]
Osterborg 1996b 23/48 4/25 1.1 % 2.99 [ 1.16, 7.71 ]
Osterborg 2002 114/170 46/173 9.4 % 2.52 [ 1.93, 3.30 ]
Rose 1994 67/142 13/79 3.5 % 2.87 [ 1.69, 4.85 ]
Subtotal (95% CI) 962 661 29.3 % 3.12 [ 2.64, 3.69 ]
Total events: 550 (Treatment), 127 (Control)
Heterogeneity: Chi2 = 13.10, df = 14 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 13.32 (P < 0.00001)
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
3 MDS
Italian 1998 5/43 0/42 0.1 % 10.75 [ 0.61, 188.54 ]
Thompson 2000 4/45 1/21 0.3 % 1.87 [ 0.22, 15.70 ]
Subtotal (95% CI) 88 63 0.4 % 4.27 [ 0.86, 21.19 ]
Total events: 9 (Treatment), 1 (Control)
Heterogeneity: Chi2 = 0.98, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 1.78 (P = 0.076)
4 mixed
Abels 1993 20/63 6/55 1.3 % 2.91 [ 1.26, 6.72 ]
Boogaerts 2003 63/133 17/129 3.6 % 3.59 [ 2.23, 5.80 ]
Case 1993 46/79 10/74 2.1 % 4.31 [ 2.35, 7.90 ]
Charu 2007 150/220 5/55 1.7 % 7.50 [ 3.24, 17.38 ]
Henry 1995 31/64 4/61 0.8 % 7.39 [ 2.77, 19.69 ]
Razzouk 2006 63/111 39/111 8.1 % 1.62 [ 1.20, 2.18 ]
Smith 2003a 12/21 1/7 0.3 % 4.00 [ 0.63, 25.49 ]
Smith 2003b 10/21 0/7 0.2 % 7.64 [ 0.50, 115.83 ]
Smith 2003c 13/22 0/8 0.1 % 10.57 [ 0.70, 159.65 ]
Suzuki 2008a 22/40 3/21 0.8 % 3.85 [ 1.30, 11.39 ]
Suzuki 2008b 28/41 2/21 0.5 % 7.17 [ 1.89, 27.24 ]
Tjulandin 2011 69/95 23/91 4.9 % 2.87 [ 1.98, 4.18 ]
Subtotal (95% CI) 910 640 24.5 % 3.38 [ 2.80, 4.08 ]
Total events: 527 (Treatment), 110 (Control)
Heterogeneity: Chi2 = 32.95, df = 11 (P = 0.00054); I2 =67%
Test for overall effect: Z = 12.72 (P < 0.00001)
5 not reported
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (Treatment), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 3710 2703 100.0 % 3.39 [ 3.10, 3.71 ]
Total events: 2050 (Treatment), 434 (Control)
Heterogeneity: Chi2 = 96.35, df = 46 (P = 0.00002); I2 =52%
Test for overall effect: Z = 26.39 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.57, df = 3 (P = 0.67), I2 =0.0%
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Analysis 1.4. Comparison 1 Haematologic response, Outcome 4 Haematological response- age.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 1 Haematologic response
Outcome: 4 Haematological response- age
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 children
Razzouk 2006 63/111 39/111 8.1 % 1.62 [ 1.20, 2.18 ]
Subtotal (95% CI) 111 111 8.1 % 1.62 [ 1.20, 2.18 ]
Total events: 63 (Treatment), 39 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.13 (P = 0.0018)
2 adults
Aapro 2008 157/231 32/232 6.6 % 4.93 [ 3.53, 6.88 ]
Abels 1993 20/63 6/55 1.3 % 2.91 [ 1.26, 6.72 ]
Bamias 2003 15/72 2/72 0.4 % 7.50 [ 1.78, 31.62 ]
Boogaerts 2003 63/133 17/129 3.6 % 3.59 [ 2.23, 5.80 ]
Case 1993 46/79 10/74 2.1 % 4.31 [ 2.35, 7.90 ]
Cazzola 1995a 2/31 0/7 0.2 % 1.25 [ 0.07, 23.55 ]
Cazzola 1995b 9/29 1/8 0.3 % 2.48 [ 0.37, 16.80 ]
Cazzola 1995c 19/31 0/7 0.2 % 9.75 [ 0.66, 144.80 ]
Cazzola 1995d 16/26 1/7 0.3 % 4.31 [ 0.68, 27.12 ]
Chang 2005 115/175 11/175 2.3 % 10.45 [ 5.84, 18.71 ]
Charu 2007 150/220 5/55 1.7 % 7.50 [ 3.24, 17.38 ]
Dammacco 2001 38/66 6/66 1.2 % 6.33 [ 2.87, 13.96 ]
Hedenus 2002a 5/11 1/3 0.3 % 1.36 [ 0.24, 7.66 ]
Hedenus 2002b 12/22 0/4 0.2 % 5.43 [ 0.38, 77.40 ]
Hedenus 2002c 14/22 0/4 0.2 % 6.30 [ 0.45, 89.06 ]
Hedenus 2003 104/174 31/170 6.5 % 3.28 [ 2.33, 4.61 ]
Henry 1995 31/64 4/61 0.8 % 7.39 [ 2.77, 19.69 ]
Iconomou 2003 25/57 7/55 1.5 % 3.45 [ 1.62, 7.31 ]
Italian 1998 5/43 0/42 0.1 % 10.75 [ 0.61, 188.54 ]
Kotasek 2003a 8/32 1/8 0.3 % 2.00 [ 0.29, 13.77 ]
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kotasek 2003b 8/17 1/8 0.3 % 3.76 [ 0.56, 25.21 ]
Kotasek 2003c 23/46 2/9 0.7 % 2.25 [ 0.64, 7.90 ]
Kotasek 2003d 17/28 1/8 0.3 % 4.86 [ 0.76, 31.12 ]
Kotasek 2003e 20/35 1/9 0.3 % 5.14 [ 0.79, 33.37 ]
Kotasek 2003f 20/40 1/9 0.3 % 4.50 [ 0.69, 29.30 ]
Littlewood 2001 172/244 22/115 6.2 % 3.68 [ 2.51, 5.41 ]
Milroy 2011 37/189 5/191 1.0 % 7.48 [ 3.00, 18.62 ]
ML17616 2006 21/30 11/30 2.3 % 1.91 [ 1.13, 3.23 ]
ML17620 2006 29/61 14/60 2.9 % 2.04 [ 1.20, 3.46 ]
Oberhoff 1998 38/114 7/104 1.5 % 4.95 [ 2.31, 10.60 ]
Osterborg 1996a 21/47 4/24 1.1 % 2.68 [ 1.04, 6.93 ]
Osterborg 1996b 23/48 4/25 1.1 % 2.99 [ 1.16, 7.71 ]
Osterborg 2002 114/170 46/173 9.4 % 2.52 [ 1.93, 3.30 ]
Rose 1994 67/142 13/79 3.5 % 2.87 [ 1.69, 4.85 ]
Savonije 2005 143/208 31/100 8.7 % 2.22 [ 1.63, 3.01 ]
Smith 2003a 12/21 1/7 0.3 % 4.00 [ 0.63, 25.49 ]
Smith 2003b 10/21 0/7 0.2 % 7.64 [ 0.50, 115.83 ]
Smith 2003c 13/22 0/8 0.1 % 10.57 [ 0.70, 159.65 ]
Suzuki 2008a 22/40 3/21 0.8 % 3.85 [ 1.30, 11.39 ]
Suzuki 2008b 28/41 2/21 0.5 % 7.17 [ 1.89, 27.24 ]
Thompson 2000 4/45 1/21 0.3 % 1.87 [ 0.22, 15.70 ]
Tjulandin 2010a 50/76 8/37 2.2 % 3.04 [ 1.61, 5.74 ]
Tjulandin 2010b 52/73 7/37 1.9 % 3.77 [ 1.90, 7.45 ]
Tjulandin 2011 69/95 23/91 4.9 % 2.87 [ 1.98, 4.18 ]
Witzig 2005 120/165 52/164 10.8 % 2.29 [ 1.80, 2.93 ]
Subtotal (95% CI) 3599 2592 91.9 % 3.55 [ 3.23, 3.90 ]
Total events: 1987 (Treatment), 395 (Control)
Heterogeneity: Chi2 = 75.87, df = 44 (P = 0.002); I2 =42%
Test for overall effect: Z = 26.17 (P < 0.00001)
Total (95% CI) 3710 2703 100.0 % 3.39 [ 3.10, 3.71 ]
Total events: 2050 (Treatment), 434 (Control)
Heterogeneity: Chi2 = 95.56, df = 45 (P = 0.00002); I2 =53%
Test for overall effect: Z = 26.39 (P < 0.00001)
Test for subgroup differences: Chi2 = 23.94, df = 1 (P = 0.00), I2 =96%
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Analysis 1.5. Comparison 1 Haematologic response, Outcome 5 Haematological response- age
differentiated.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 1 Haematologic response
Outcome: 5 Haematological response- age differentiated
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 only children <18 years
Razzouk 2006 63/111 39/111 8.1 % 1.62 [ 1.20, 2.18 ]
Subtotal (95% CI) 111 111 8.1 % 1.62 [ 1.20, 2.18 ]
Total events: 63 (Treatment), 39 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.13 (P = 0.0018)
2 adults≥18 years
Aapro 2008 157/231 32/232 6.6 % 4.93 [ 3.53, 6.88 ]
Abels 1993 20/63 6/55 1.3 % 2.91 [ 1.26, 6.72 ]
Bamias 2003 15/72 2/72 0.4 % 7.50 [ 1.78, 31.62 ]
Boogaerts 2003 63/133 17/129 3.6 % 3.59 [ 2.23, 5.80 ]
Case 1993 46/79 10/74 2.1 % 4.31 [ 2.35, 7.90 ]
Cazzola 1995a 2/31 0/7 0.2 % 1.25 [ 0.07, 23.55 ]
Cazzola 1995b 9/29 1/8 0.3 % 2.48 [ 0.37, 16.80 ]
Cazzola 1995c 19/31 0/7 0.2 % 9.75 [ 0.66, 144.80 ]
Cazzola 1995d 16/26 1/7 0.3 % 4.31 [ 0.68, 27.12 ]
Charu 2007 150/220 5/55 1.7 % 7.50 [ 3.24, 17.38 ]
Dammacco 2001 38/66 6/66 1.2 % 6.33 [ 2.87, 13.96 ]
Hedenus 2002a 5/11 1/3 0.3 % 1.36 [ 0.24, 7.66 ]
Hedenus 2002b 12/22 0/4 0.2 % 5.43 [ 0.38, 77.40 ]
Hedenus 2002c 14/22 0/4 0.2 % 6.30 [ 0.45, 89.06 ]
Hedenus 2003 104/174 31/170 6.5 % 3.28 [ 2.33, 4.61 ]
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Henry 1995 31/64 4/61 0.8 % 7.39 [ 2.77, 19.69 ]
Iconomou 2003 25/57 7/55 1.5 % 3.45 [ 1.62, 7.31 ]
Italian 1998 5/43 0/42 0.1 % 10.75 [ 0.61, 188.54 ]
Kotasek 2003a 8/32 1/8 0.3 % 2.00 [ 0.29, 13.77 ]
Kotasek 2003b 8/17 1/8 0.3 % 3.76 [ 0.56, 25.21 ]
Kotasek 2003c 23/46 2/9 0.7 % 2.25 [ 0.64, 7.90 ]
Kotasek 2003d 17/28 1/8 0.3 % 4.86 [ 0.76, 31.12 ]
Kotasek 2003e 20/35 1/9 0.3 % 5.14 [ 0.79, 33.37 ]
Kotasek 2003f 20/40 1/9 0.3 % 4.50 [ 0.69, 29.30 ]
Littlewood 2001 172/244 22/115 6.2 % 3.68 [ 2.51, 5.41 ]
Milroy 2011 37/189 5/191 1.0 % 7.48 [ 3.00, 18.62 ]
ML17616 2006 21/30 11/30 2.3 % 1.91 [ 1.13, 3.23 ]
ML17620 2006 29/61 14/60 2.9 % 2.04 [ 1.20, 3.46 ]
Osterborg 1996a 21/47 4/24 1.1 % 2.68 [ 1.04, 6.93 ]
Osterborg 1996b 23/48 4/25 1.1 % 2.99 [ 1.16, 7.71 ]
Osterborg 2002 114/170 46/173 9.4 % 2.52 [ 1.93, 3.30 ]
Rose 1994 67/142 13/79 3.5 % 2.87 [ 1.69, 4.85 ]
Savonije 2005 143/208 31/100 8.7 % 2.22 [ 1.63, 3.01 ]
Smith 2003a 12/21 1/7 0.3 % 4.00 [ 0.63, 25.49 ]
Smith 2003b 10/21 0/7 0.2 % 7.64 [ 0.50, 115.83 ]
Smith 2003c 13/22 0/8 0.1 % 10.57 [ 0.70, 159.65 ]
Suzuki 2008a 22/40 3/21 0.8 % 3.85 [ 1.30, 11.39 ]
Suzuki 2008b 28/41 2/21 0.5 % 7.17 [ 1.89, 27.24 ]
Thompson 2000 4/45 1/21 0.3 % 1.87 [ 0.22, 15.70 ]
Tjulandin 2010a 50/76 8/37 2.2 % 3.04 [ 1.61, 5.74 ]
Tjulandin 2010b 52/73 7/37 1.9 % 3.77 [ 1.90, 7.45 ]
Tjulandin 2011 69/95 23/91 4.9 % 2.87 [ 1.98, 4.18 ]
Witzig 2005 120/165 52/164 10.8 % 2.29 [ 1.80, 2.93 ]
Subtotal (95% CI) 3310 2313 88.1 % 3.34 [ 3.03, 3.68 ]
Total events: 1834 (Treatment), 377 (Control)
Heterogeneity: Chi2 = 55.62, df = 42 (P = 0.08); I2 =24%
Test for overall effect: Z = 24.39 (P < 0.00001)
3 >70% non-elderly 18-65 years
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chang 2005 115/175 11/175 2.3 % 10.45 [ 5.84, 18.71 ]
Oberhoff 1998 38/114 7/104 1.5 % 4.95 [ 2.31, 10.60 ]
Subtotal (95% CI) 289 279 3.8 % 8.26 [ 5.22, 13.06 ]
Total events: 153 (Treatment), 18 (Control)
Heterogeneity: Chi2 = 2.36, df = 1 (P = 0.12); I2 =58%
Test for overall effect: Z = 9.03 (P < 0.00001)
4 only non-elderly adults
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (Treatment), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 >70% elderly >65 years
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (Treatment), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
6 only elderly adults
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (Treatment), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 3710 2703 100.0 % 3.39 [ 3.10, 3.71 ]
Total events: 2050 (Treatment), 434 (Control)
Heterogeneity: Chi2 = 95.56, df = 45 (P = 0.00002); I2 =53%
Test for overall effect: Z = 26.39 (P < 0.00001)
Test for subgroup differences: Chi2 = 37.02, df = 2 (P = 0.00), I2 =95%
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Analysis 1.6. Comparison 1 Haematologic response, Outcome 6 Haematologic response - different
therapies.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 1 Haematologic response
Outcome: 6 Haematologic response - different therapies
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 chemotherapy
Aapro 2008 157/231 32/232 6.6 % 4.93 [ 3.53, 6.88 ]
Bamias 2003 15/72 2/72 0.4 % 7.50 [ 1.78, 31.62 ]
Boogaerts 2003 63/133 17/129 3.6 % 3.59 [ 2.23, 5.80 ]
Case 1993 46/79 10/74 2.1 % 4.31 [ 2.35, 7.90 ]
Cazzola 1995a 2/31 0/7 0.2 % 1.25 [ 0.07, 23.55 ]
Cazzola 1995b 9/29 1/8 0.3 % 2.48 [ 0.37, 16.80 ]
Cazzola 1995c 19/31 0/7 0.2 % 9.75 [ 0.66, 144.80 ]
Cazzola 1995d 16/26 1/7 0.3 % 4.31 [ 0.68, 27.12 ]
Chang 2005 115/175 11/175 2.3 % 10.45 [ 5.84, 18.71 ]
Dammacco 2001 38/66 6/66 1.2 % 6.33 [ 2.87, 13.96 ]
Hedenus 2002a 5/11 1/3 0.3 % 1.36 [ 0.24, 7.66 ]
Hedenus 2002b 12/22 0/4 0.2 % 5.43 [ 0.38, 77.40 ]
Hedenus 2002c 14/22 0/4 0.2 % 6.30 [ 0.45, 89.06 ]
Hedenus 2003 104/174 31/170 6.5 % 3.28 [ 2.33, 4.61 ]
Henry 1995 31/64 4/61 0.8 % 7.39 [ 2.77, 19.69 ]
Iconomou 2003 25/57 7/55 1.5 % 3.45 [ 1.62, 7.31 ]
Kotasek 2003a 8/32 1/8 0.3 % 2.00 [ 0.29, 13.77 ]
Kotasek 2003b 8/17 1/8 0.3 % 3.76 [ 0.56, 25.21 ]
Kotasek 2003c 23/46 2/9 0.7 % 2.25 [ 0.64, 7.90 ]
Kotasek 2003d 17/28 1/8 0.3 % 4.86 [ 0.76, 31.12 ]
Kotasek 2003e 20/35 1/9 0.3 % 5.14 [ 0.79, 33.37 ]
Kotasek 2003f 20/40 1/9 0.3 % 4.50 [ 0.69, 29.30 ]
Littlewood 2001 172/244 22/115 6.2 % 3.68 [ 2.51, 5.41 ]
Milroy 2011 37/189 5/191 1.0 % 7.48 [ 3.00, 18.62 ]
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
ML17616 2006 21/30 11/30 2.3 % 1.91 [ 1.13, 3.23 ]
ML17620 2006 29/61 14/60 2.9 % 2.04 [ 1.20, 3.46 ]
Oberhoff 1998 38/114 7/104 1.5 % 4.95 [ 2.31, 10.60 ]
Osterborg 1996a 21/47 4/24 1.1 % 2.68 [ 1.04, 6.93 ]
Osterborg 1996b 23/48 4/25 1.1 % 2.99 [ 1.16, 7.71 ]
Osterborg 2002 114/170 46/173 9.4 % 2.52 [ 1.93, 3.30 ]
Razzouk 2006 63/111 39/111 8.1 % 1.62 [ 1.20, 2.18 ]
Savonije 2005 143/208 31/100 8.7 % 2.22 [ 1.63, 3.01 ]
Suzuki 2008a 22/40 3/21 0.8 % 3.85 [ 1.30, 11.39 ]
Suzuki 2008b 28/41 2/21 0.5 % 7.17 [ 1.89, 27.24 ]
Tjulandin 2010a 50/76 8/37 2.2 % 3.04 [ 1.61, 5.74 ]
Tjulandin 2010b 52/73 7/37 1.9 % 3.77 [ 1.90, 7.45 ]
Tjulandin 2011 69/95 23/91 4.9 % 2.87 [ 1.98, 4.18 ]
Witzig 2005 120/165 52/164 10.8 % 2.29 [ 1.80, 2.93 ]
Subtotal (95% CI) 3133 2429 92.6 % 3.32 [ 3.02, 3.64 ]
Total events: 1769 (Treatment), 408 (Control)
Heterogeneity: Chi2 = 87.08, df = 37 (P<0.00001); I2 =58%
Test for overall effect: Z = 25.32 (P < 0.00001)
2 radiotherapy/radiochemotherapy
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (Treatment), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 no therapy
Abels 1993 20/63 6/55 1.3 % 2.91 [ 1.26, 6.72 ]
Charu 2007 150/220 5/55 1.7 % 7.50 [ 3.24, 17.38 ]
Italian 1998 5/43 0/42 0.1 % 10.75 [ 0.61, 188.54 ]
Smith 2003a 12/21 1/7 0.3 % 4.00 [ 0.63, 25.49 ]
Smith 2003b 10/21 0/7 0.2 % 7.64 [ 0.50, 115.83 ]
Smith 2003c 13/22 0/8 0.1 % 10.57 [ 0.70, 159.65 ]
Thompson 2000 4/45 1/21 0.3 % 1.87 [ 0.22, 15.70 ]
Subtotal (95% CI) 435 195 4.0 % 5.50 [ 3.25, 9.31 ]
Total events: 214 (Treatment), 13 (Control)
Heterogeneity: Chi2 = 4.34, df = 6 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 6.36 (P < 0.00001)
4 other
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rose 1994 67/142 13/79 3.5 % 2.87 [ 1.69, 4.85 ]
Subtotal (95% CI) 142 79 3.5 % 2.87 [ 1.69, 4.85 ]
Total events: 67 (Treatment), 13 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.92 (P = 0.000088)
Total (95% CI) 3710 2703 100.0 % 3.39 [ 3.10, 3.71 ]
Total events: 2050 (Treatment), 434 (Control)
Heterogeneity: Chi2 = 95.56, df = 45 (P = 0.00002); I2 =53%
Test for overall effect: Z = 26.39 (P < 0.00001)
Test for subgroup differences: Chi2 = 3.80, df = 2 (P = 0.15), I2 =47%
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Analysis 1.7. Comparison 1 Haematologic response, Outcome 7 Haematologic response - different
therapies differentiated.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 1 Haematologic response
Outcome: 7 Haematologic response - different therapies differentiated
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 chemotherapy, >70% with platinum
Bamias 2003 15/72 2/72 0.4 % 7.50 [ 1.78, 31.62 ]
Henry 1995 31/64 4/61 0.8 % 7.39 [ 2.77, 19.69 ]
Milroy 2011 37/189 5/191 1.0 % 7.48 [ 3.00, 18.62 ]
ML17620 2006 29/61 14/60 2.9 % 2.04 [ 1.20, 3.46 ]
Savonije 2005 143/208 31/100 8.7 % 2.22 [ 1.63, 3.01 ]
Tjulandin 2010a 50/76 8/37 2.2 % 3.04 [ 1.61, 5.74 ]
Tjulandin 2010b 52/73 7/37 1.9 % 3.77 [ 1.90, 7.45 ]
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 743 558 18.0 % 3.12 [ 2.51, 3.87 ]
Total events: 357 (Treatment), 71 (Control)
Heterogeneity: Chi2 = 15.48, df = 6 (P = 0.02); I2 =61%
Test for overall effect: Z = 10.31 (P < 0.00001)
2 chemotherapy, <70% platinum containing
Iconomou 2003 25/57 7/55 1.5 % 3.45 [ 1.62, 7.31 ]
Oberhoff 1998 38/114 7/104 1.5 % 4.95 [ 2.31, 10.60 ]
Witzig 2005 120/165 52/164 10.8 % 2.29 [ 1.80, 2.93 ]
Subtotal (95% CI) 336 323 13.8 % 2.71 [ 2.16, 3.40 ]
Total events: 183 (Treatment), 66 (Control)
Heterogeneity: Chi2 = 4.61, df = 2 (P = 0.10); I2 =57%
Test for overall effect: Z = 8.59 (P < 0.00001)
3 chemotherapy without platinum (all patients)
Aapro 2008 157/231 32/232 6.6 % 4.93 [ 3.53, 6.88 ]
Case 1993 46/79 10/74 2.1 % 4.31 [ 2.35, 7.90 ]
Cazzola 1995a 2/31 0/7 0.2 % 1.25 [ 0.07, 23.55 ]
Cazzola 1995b 9/29 1/8 0.3 % 2.48 [ 0.37, 16.80 ]
Cazzola 1995c 19/31 0/7 0.2 % 9.75 [ 0.66, 144.80 ]
Cazzola 1995d 16/26 1/7 0.3 % 4.31 [ 0.68, 27.12 ]
Chang 2005 115/175 11/175 2.3 % 10.45 [ 5.84, 18.71 ]
Hedenus 2002a 5/11 1/3 0.3 % 1.36 [ 0.24, 7.66 ]
Hedenus 2002b 12/22 0/4 0.2 % 5.43 [ 0.38, 77.40 ]
Hedenus 2002c 14/22 0/4 0.2 % 6.30 [ 0.45, 89.06 ]
Hedenus 2003 104/174 31/170 6.5 % 3.28 [ 2.33, 4.61 ]
Littlewood 2001 172/244 22/115 6.2 % 3.68 [ 2.51, 5.41 ]
ML17616 2006 21/30 11/30 2.3 % 1.91 [ 1.13, 3.23 ]
Osterborg 1996a 21/47 4/24 1.1 % 2.68 [ 1.04, 6.93 ]
Osterborg 1996b 23/48 4/25 1.1 % 2.99 [ 1.16, 7.71 ]
Osterborg 2002 114/170 46/173 9.4 % 2.52 [ 1.93, 3.30 ]
Tjulandin 2011 69/95 23/91 4.9 % 2.87 [ 1.98, 4.18 ]
Subtotal (95% CI) 1465 1149 44.2 % 3.73 [ 3.26, 4.26 ]
Total events: 919 (Treatment), 197 (Control)
Heterogeneity: Chi2 = 35.13, df = 16 (P = 0.004); I2 =54%
Test for overall effect: Z = 19.37 (P < 0.00001)
4 chemotherapy, platinum and non-platinum containing, no numbers given
Boogaerts 2003 63/133 17/129 3.6 % 3.59 [ 2.23, 5.80 ]
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dammacco 2001 38/66 6/66 1.2 % 6.33 [ 2.87, 13.96 ]
Kotasek 2003a 8/32 1/8 0.3 % 2.00 [ 0.29, 13.77 ]
Kotasek 2003b 8/17 1/8 0.3 % 3.76 [ 0.56, 25.21 ]
Kotasek 2003c 23/46 2/9 0.7 % 2.25 [ 0.64, 7.90 ]
Kotasek 2003d 17/28 1/8 0.3 % 4.86 [ 0.76, 31.12 ]
Kotasek 2003e 20/35 1/9 0.3 % 5.14 [ 0.79, 33.37 ]
Kotasek 2003f 20/40 1/9 0.3 % 4.50 [ 0.69, 29.30 ]
Subtotal (95% CI) 397 246 7.1 % 4.05 [ 2.84, 5.77 ]
Total events: 197 (Treatment), 30 (Control)
Heterogeneity: Chi2 = 2.94, df = 7 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 7.73 (P < 0.00001)
5 chemotherapy no details given
Razzouk 2006 63/111 39/111 8.1 % 1.62 [ 1.20, 2.18 ]
Suzuki 2008a 22/40 3/21 0.8 % 3.85 [ 1.30, 11.39 ]
Suzuki 2008b 28/41 2/21 0.5 % 7.17 [ 1.89, 27.24 ]
Subtotal (95% CI) 192 153 9.4 % 2.13 [ 1.59, 2.86 ]
Total events: 113 (Treatment), 44 (Control)
Heterogeneity: Chi2 = 7.58, df = 2 (P = 0.02); I2 =74%
Test for overall effect: Z = 5.05 (P < 0.00001)
6 radiochemotherapy
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (Treatment), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
7 radiotherapy
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (Treatment), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
8 no therapy
Abels 1993 20/63 6/55 1.3 % 2.91 [ 1.26, 6.72 ]
Charu 2007 150/220 5/55 1.7 % 7.50 [ 3.24, 17.38 ]
Italian 1998 5/43 0/42 0.1 % 10.75 [ 0.61, 188.54 ]
Smith 2003a 12/21 1/7 0.3 % 4.00 [ 0.63, 25.49 ]
Smith 2003b 10/21 0/7 0.2 % 7.64 [ 0.50, 115.83 ]
Smith 2003c 13/22 0/8 0.1 % 10.57 [ 0.70, 159.65 ]
Thompson 2000 4/45 1/21 0.3 % 1.87 [ 0.22, 15.70 ]
Subtotal (95% CI) 435 195 4.0 % 5.50 [ 3.25, 9.31 ]
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 214 (Treatment), 13 (Control)
Heterogeneity: Chi2 = 4.34, df = 6 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 6.36 (P < 0.00001)
9 other
Rose 1994 67/142 13/79 3.5 % 2.87 [ 1.69, 4.85 ]
Subtotal (95% CI) 142 79 3.5 % 2.87 [ 1.69, 4.85 ]
Total events: 67 (Treatment), 13 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.92 (P = 0.000088)
Total (95% CI) 3710 2703 100.0 % 3.39 [ 3.10, 3.71 ]
Total events: 2050 (Treatment), 434 (Control)
Heterogeneity: Chi2 = 95.56, df = 45 (P = 0.00002); I2 =53%
Test for overall effect: Z = 26.39 (P < 0.00001)
Test for subgroup differences: Chi2 = 20.08, df = 6 (P = 0.00), I2 =70%
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Analysis 1.8. Comparison 1 Haematologic response, Outcome 8 Haematologic response - epoetin versus
darbepoetin.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 1 Haematologic response
Outcome: 8 Haematologic response - epoetin versus darbepoetin
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Epoetin
Aapro 2008 157/231 32/232 6.6 % 4.93 [ 3.53, 6.88 ]
Abels 1993 20/63 6/55 1.3 % 2.91 [ 1.26, 6.72 ]
Bamias 2003 15/72 2/72 0.4 % 7.50 [ 1.78, 31.62 ]
Boogaerts 2003 63/133 17/129 3.6 % 3.59 [ 2.23, 5.80 ]
Case 1993 46/79 10/74 2.1 % 4.31 [ 2.35, 7.90 ]
Cazzola 1995a 2/31 0/7 0.2 % 1.25 [ 0.07, 23.55 ]
Cazzola 1995b 9/29 1/8 0.3 % 2.48 [ 0.37, 16.80 ]
Cazzola 1995c 19/31 0/7 0.2 % 9.75 [ 0.66, 144.80 ]
Cazzola 1995d 16/26 1/7 0.3 % 4.31 [ 0.68, 27.12 ]
Chang 2005 115/175 11/175 2.3 % 10.45 [ 5.84, 18.71 ]
Dammacco 2001 38/66 6/66 1.2 % 6.33 [ 2.87, 13.96 ]
Henry 1995 31/64 4/61 0.8 % 7.39 [ 2.77, 19.69 ]
Iconomou 2003 25/57 7/55 1.5 % 3.45 [ 1.62, 7.31 ]
Italian 1998 5/43 0/42 0.1 % 10.75 [ 0.61, 188.54 ]
Littlewood 2001 172/244 22/115 6.2 % 3.68 [ 2.51, 5.41 ]
Milroy 2011 37/189 5/191 1.0 % 7.48 [ 3.00, 18.62 ]
ML17616 2006 21/30 11/30 2.3 % 1.91 [ 1.13, 3.23 ]
ML17620 2006 29/61 14/60 2.9 % 2.04 [ 1.20, 3.46 ]
Oberhoff 1998 38/114 7/104 1.5 % 4.95 [ 2.31, 10.60 ]
Osterborg 1996a 21/47 4/24 1.1 % 2.68 [ 1.04, 6.93 ]
Osterborg 1996b 23/48 4/25 1.1 % 2.99 [ 1.16, 7.71 ]
Osterborg 2002 114/170 46/173 9.4 % 2.52 [ 1.93, 3.30 ]
Razzouk 2006 63/111 39/111 8.1 % 1.62 [ 1.20, 2.18 ]
Rose 1994 67/142 13/79 3.5 % 2.87 [ 1.69, 4.85 ]
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Savonije 2005 143/208 31/100 8.7 % 2.22 [ 1.63, 3.01 ]
Thompson 2000 4/45 1/21 0.3 % 1.87 [ 0.22, 15.70 ]
Tjulandin 2010a 50/76 8/37 2.2 % 3.04 [ 1.61, 5.74 ]
Tjulandin 2010b 52/73 7/37 1.9 % 3.77 [ 1.90, 7.45 ]
Tjulandin 2011 69/95 23/91 4.9 % 2.87 [ 1.98, 4.18 ]
Witzig 2005 120/165 52/164 10.8 % 2.29 [ 1.80, 2.93 ]
Subtotal (95% CI) 2918 2352 86.9 % 3.27 [ 2.97, 3.59 ]
Total events: 1584 (Treatment), 384 (Control)
Heterogeneity: Chi2 = 82.73, df = 29 (P<0.00001); I2 =65%
Test for overall effect: Z = 24.28 (P < 0.00001)
2 Darbepoetin
Charu 2007 150/220 5/55 1.7 % 7.50 [ 3.24, 17.38 ]
Hedenus 2002a 5/11 1/3 0.3 % 1.36 [ 0.24, 7.66 ]
Hedenus 2002b 12/22 0/4 0.2 % 5.43 [ 0.38, 77.40 ]
Hedenus 2002c 14/22 0/4 0.2 % 6.30 [ 0.45, 89.06 ]
Hedenus 2003 104/174 31/170 6.5 % 3.28 [ 2.33, 4.61 ]
Kotasek 2003a 8/32 1/8 0.3 % 2.00 [ 0.29, 13.77 ]
Kotasek 2003b 8/17 1/8 0.3 % 3.76 [ 0.56, 25.21 ]
Kotasek 2003c 23/46 2/9 0.7 % 2.25 [ 0.64, 7.90 ]
Kotasek 2003d 17/28 1/8 0.3 % 4.86 [ 0.76, 31.12 ]
Kotasek 2003e 20/35 1/9 0.3 % 5.14 [ 0.79, 33.37 ]
Kotasek 2003f 20/40 1/9 0.3 % 4.50 [ 0.69, 29.30 ]
Smith 2003a 12/21 1/7 0.3 % 4.00 [ 0.63, 25.49 ]
Smith 2003b 10/21 0/7 0.2 % 7.64 [ 0.50, 115.83 ]
Smith 2003c 13/22 0/8 0.1 % 10.57 [ 0.70, 159.65 ]
Suzuki 2008a 22/40 3/21 0.8 % 3.85 [ 1.30, 11.39 ]
Suzuki 2008b 28/41 2/21 0.5 % 7.17 [ 1.89, 27.24 ]
Subtotal (95% CI) 792 351 13.1 % 4.22 [ 3.22, 5.55 ]
Total events: 466 (Treatment), 50 (Control)
Heterogeneity: Chi2 = 8.57, df = 15 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 10.36 (P < 0.00001)
Total (95% CI) 3710 2703 100.0 % 3.39 [ 3.10, 3.71 ]
Total events: 2050 (Treatment), 434 (Control)
Heterogeneity: Chi2 = 95.56, df = 45 (P = 0.00002); I2 =53%
Test for overall effect: Z = 26.39 (P < 0.00001)
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Test for subgroup differences: Chi2 = 3.04, df = 1 (P = 0.08), I2 =67%
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Analysis 1.9. Comparison 1 Haematologic response, Outcome 9 Haematologic response - duration of ESA
medication.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 1 Haematologic response
Outcome: 9 Haematologic response - duration of ESA medication
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 6 to 9 weeks
Abels 1993 20/63 6/55 1.3 % 2.91 [ 1.26, 6.72 ]
Cazzola 1995a 2/31 0/7 0.2 % 1.25 [ 0.07, 23.55 ]
Cazzola 1995b 9/29 1/8 0.3 % 2.48 [ 0.37, 16.80 ]
Cazzola 1995c 19/31 0/7 0.2 % 9.75 [ 0.66, 144.80 ]
Cazzola 1995d 16/26 1/7 0.3 % 4.31 [ 0.68, 27.12 ]
Italian 1998 5/43 0/42 0.1 % 10.75 [ 0.61, 188.54 ]
Subtotal (95% CI) 223 126 2.4 % 3.74 [ 1.94, 7.19 ]
Total events: 71 (Treatment), 8 (Control)
Heterogeneity: Chi2 = 2.08, df = 5 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 3.95 (P = 0.000078)
2 12 to 16 weeks
Boogaerts 2003 63/133 17/129 3.6 % 3.59 [ 2.23, 5.80 ]
Case 1993 46/79 10/74 2.1 % 4.31 [ 2.35, 7.90 ]
Chang 2005 115/175 11/175 2.3 % 10.45 [ 5.84, 18.71 ]
Charu 2007 150/220 5/55 1.7 % 7.50 [ 3.24, 17.38 ]
Dammacco 2001 38/66 6/66 1.2 % 6.33 [ 2.87, 13.96 ]
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hedenus 2002a 5/11 1/3 0.3 % 1.36 [ 0.24, 7.66 ]
Hedenus 2002b 12/22 0/4 0.2 % 5.43 [ 0.38, 77.40 ]
Hedenus 2002c 14/22 0/4 0.2 % 6.30 [ 0.45, 89.06 ]
Hedenus 2003 104/174 31/170 6.5 % 3.28 [ 2.33, 4.61 ]
Henry 1995 31/64 4/61 0.8 % 7.39 [ 2.77, 19.69 ]
Iconomou 2003 25/57 7/55 1.5 % 3.45 [ 1.62, 7.31 ]
Kotasek 2003a 8/32 1/8 0.3 % 2.00 [ 0.29, 13.77 ]
Kotasek 2003b 8/17 1/8 0.3 % 3.76 [ 0.56, 25.21 ]
Kotasek 2003c 23/46 2/9 0.7 % 2.25 [ 0.64, 7.90 ]
Kotasek 2003d 17/28 1/8 0.3 % 4.86 [ 0.76, 31.12 ]
Kotasek 2003e 20/35 1/9 0.3 % 5.14 [ 0.79, 33.37 ]
Kotasek 2003f 20/40 1/9 0.3 % 4.50 [ 0.69, 29.30 ]
ML17616 2006 21/30 11/30 2.3 % 1.91 [ 1.13, 3.23 ]
ML17620 2006 29/61 14/60 2.9 % 2.04 [ 1.20, 3.46 ]
Oberhoff 1998 38/114 7/104 1.5 % 4.95 [ 2.31, 10.60 ]
Osterborg 2002 114/170 46/173 9.4 % 2.52 [ 1.93, 3.30 ]
Razzouk 2006 63/111 39/111 8.1 % 1.62 [ 1.20, 2.18 ]
Rose 1994 67/142 13/79 3.5 % 2.87 [ 1.69, 4.85 ]
Savonije 2005 143/208 31/100 8.7 % 2.22 [ 1.63, 3.01 ]
Smith 2003a 12/21 1/7 0.3 % 4.00 [ 0.63, 25.49 ]
Smith 2003b 10/21 0/7 0.2 % 7.64 [ 0.50, 115.83 ]
Smith 2003c 13/22 0/8 0.1 % 10.57 [ 0.70, 159.65 ]
Suzuki 2008a 22/40 3/21 0.8 % 3.85 [ 1.30, 11.39 ]
Suzuki 2008b 28/41 2/21 0.5 % 7.17 [ 1.89, 27.24 ]
Thompson 2000 4/45 1/21 0.3 % 1.87 [ 0.22, 15.70 ]
Tjulandin 2010a 50/76 8/37 2.2 % 3.04 [ 1.61, 5.74 ]
Tjulandin 2010b 52/73 7/37 1.9 % 3.77 [ 1.90, 7.45 ]
Tjulandin 2011 69/95 23/91 4.9 % 2.87 [ 1.98, 4.18 ]
Witzig 2005 120/165 52/164 10.8 % 2.29 [ 1.80, 2.93 ]
Subtotal (95% CI) 2656 1918 81.1 % 3.17 [ 2.87, 3.51 ]
Total events: 1554 (Treatment), 357 (Control)
Heterogeneity: Chi2 = 75.33, df = 33 (P = 0.00004); I2 =56%
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Test for overall effect: Z = 22.63 (P < 0.00001)
3 more than 17 weeks
Aapro 2008 157/231 32/232 6.6 % 4.93 [ 3.53, 6.88 ]
Bamias 2003 15/72 2/72 0.4 % 7.50 [ 1.78, 31.62 ]
Littlewood 2001 172/244 22/115 6.2 % 3.68 [ 2.51, 5.41 ]
Milroy 2011 37/189 5/191 1.0 % 7.48 [ 3.00, 18.62 ]
Osterborg 1996a 21/47 4/24 1.1 % 2.68 [ 1.04, 6.93 ]
Osterborg 1996b 23/48 4/25 1.1 % 2.99 [ 1.16, 7.71 ]
Subtotal (95% CI) 831 659 16.4 % 4.41 [ 3.52, 5.52 ]
Total events: 425 (Treatment), 69 (Control)
Heterogeneity: Chi2 = 4.77, df = 5 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 12.92 (P < 0.00001)
Total (95% CI) 3710 2703 100.0 % 3.39 [ 3.10, 3.71 ]
Total events: 2050 (Treatment), 434 (Control)
Heterogeneity: Chi2 = 95.56, df = 45 (P = 0.00002); I2 =53%
Test for overall effect: Z = 26.39 (P < 0.00001)
Test for subgroup differences: Chi2 = 6.92, df = 2 (P = 0.03), I2 =71%
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Analysis 1.10. Comparison 1 Haematologic response, Outcome 10 Haematologic response - iron
supplementation.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 1 Haematologic response
Outcome: 10 Haematologic response - iron supplementation
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 fixed iron supplementation
Iconomou 2003 25/57 7/55 1.5 % 3.45 [ 1.62, 7.31 ]
Witzig 2005 120/165 52/164 10.8 % 2.29 [ 1.80, 2.93 ]
Subtotal (95% CI) 222 219 12.3 % 2.43 [ 1.92, 3.07 ]
Total events: 145 (Treatment), 59 (Control)
Heterogeneity: Chi2 = 1.05, df = 1 (P = 0.31); I2 =5%
Test for overall effect: Z = 7.44 (P < 0.00001)
2 iron supplementation as necessary
Aapro 2008 157/231 32/232 6.6 % 4.93 [ 3.53, 6.88 ]
Abels 1993 20/63 6/55 1.3 % 2.91 [ 1.26, 6.72 ]
Boogaerts 2003 63/133 17/129 3.6 % 3.59 [ 2.23, 5.80 ]
Case 1993 46/79 10/74 2.1 % 4.31 [ 2.35, 7.90 ]
Cazzola 1995a 2/31 0/7 0.2 % 1.25 [ 0.07, 23.55 ]
Cazzola 1995b 9/29 1/8 0.3 % 2.48 [ 0.37, 16.80 ]
Cazzola 1995c 19/31 0/7 0.2 % 9.75 [ 0.66, 144.80 ]
Cazzola 1995d 16/26 1/7 0.3 % 4.31 [ 0.68, 27.12 ]
Chang 2005 115/175 11/175 2.3 % 10.45 [ 5.84, 18.71 ]
Charu 2007 150/220 5/55 1.7 % 7.50 [ 3.24, 17.38 ]
Dammacco 2001 38/66 6/66 1.2 % 6.33 [ 2.87, 13.96 ]
Hedenus 2003 104/174 31/170 6.5 % 3.28 [ 2.33, 4.61 ]
Henry 1995 31/64 4/61 0.8 % 7.39 [ 2.77, 19.69 ]
Italian 1998 5/43 0/42 0.1 % 10.75 [ 0.61, 188.54 ]
Kotasek 2003a 8/32 1/8 0.3 % 2.00 [ 0.29, 13.77 ]
Kotasek 2003b 8/17 1/8 0.3 % 3.76 [ 0.56, 25.21 ]
Kotasek 2003c 23/46 2/9 0.7 % 2.25 [ 0.64, 7.90 ]
Kotasek 2003d 17/28 1/8 0.3 % 4.86 [ 0.76, 31.12 ]
Kotasek 2003e 20/35 1/9 0.3 % 5.14 [ 0.79, 33.37 ]
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kotasek 2003f 20/40 1/9 0.3 % 4.50 [ 0.69, 29.30 ]
Littlewood 2001 172/244 22/115 6.2 % 3.68 [ 2.51, 5.41 ]
Milroy 2011 37/189 5/191 1.0 % 7.48 [ 3.00, 18.62 ]
ML17616 2006 21/30 11/30 2.3 % 1.91 [ 1.13, 3.23 ]
ML17620 2006 29/61 14/60 2.9 % 2.04 [ 1.20, 3.46 ]
Oberhoff 1998 38/114 7/104 1.5 % 4.95 [ 2.31, 10.60 ]
Osterborg 1996a 21/47 4/24 1.1 % 2.68 [ 1.04, 6.93 ]
Osterborg 1996b 23/48 4/25 1.1 % 2.99 [ 1.16, 7.71 ]
Osterborg 2002 114/170 46/173 9.4 % 2.52 [ 1.93, 3.30 ]
Razzouk 2006 63/111 39/111 8.1 % 1.62 [ 1.20, 2.18 ]
Rose 1994 67/142 13/79 3.5 % 2.87 [ 1.69, 4.85 ]
Smith 2003a 12/21 1/7 0.3 % 4.00 [ 0.63, 25.49 ]
Smith 2003b 10/21 0/7 0.2 % 7.64 [ 0.50, 115.83 ]
Smith 2003c 13/22 0/8 0.1 % 10.57 [ 0.70, 159.65 ]
Tjulandin 2010a 50/76 8/37 2.2 % 3.04 [ 1.61, 5.74 ]
Tjulandin 2010b 52/73 7/37 1.9 % 3.77 [ 1.90, 7.45 ]
Tjulandin 2011 69/95 23/91 4.9 % 2.87 [ 1.98, 4.18 ]
Subtotal (95% CI) 3027 2238 76.3 % 3.63 [ 3.27, 4.03 ]
Total events: 1662 (Treatment), 335 (Control)
Heterogeneity: Chi2 = 78.84, df = 35 (P = 0.00003); I2 =56%
Test for overall effect: Z = 24.20 (P < 0.00001)
3 no explicit statement on iron supplementation or no iron given
Bamias 2003 15/72 2/72 0.4 % 7.50 [ 1.78, 31.62 ]
Hedenus 2002a 5/11 1/3 0.3 % 1.36 [ 0.24, 7.66 ]
Hedenus 2002b 12/22 0/4 0.2 % 5.43 [ 0.38, 77.40 ]
Hedenus 2002c 14/22 0/4 0.2 % 6.30 [ 0.45, 89.06 ]
Suzuki 2008a 22/40 3/21 0.8 % 3.85 [ 1.30, 11.39 ]
Suzuki 2008b 28/41 2/21 0.5 % 7.17 [ 1.89, 27.24 ]
Thompson 2000 4/45 1/21 0.3 % 1.87 [ 0.22, 15.70 ]
Subtotal (95% CI) 253 146 2.7 % 4.82 [ 2.64, 8.81 ]
Total events: 100 (Treatment), 9 (Control)
Heterogeneity: Chi2 = 3.73, df = 6 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 5.12 (P < 0.00001)
4 explicitly stated NO IRON
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (Treatment), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 iron given differently in both study arms
Savonije 2005 143/208 31/100 8.7 % 2.22 [ 1.63, 3.01 ]
Subtotal (95% CI) 208 100 8.7 % 2.22 [ 1.63, 3.01 ]
Total events: 143 (Treatment), 31 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 5.09 (P < 0.00001)
Total (95% CI) 3710 2703 100.0 % 3.39 [ 3.10, 3.71 ]
Total events: 2050 (Treatment), 434 (Control)
Heterogeneity: Chi2 = 95.56, df = 45 (P = 0.00002); I2 =53%
Test for overall effect: Z = 26.39 (P < 0.00001)
Test for subgroup differences: Chi2 = 17.66, df = 3 (P = 0.00), I2 =83%
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Analysis 1.11. Comparison 1 Haematologic response, Outcome 11 Haematologic response - allocation
concealment.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 1 Haematologic response
Outcome: 11 Haematologic response - allocation concealment
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 adequate
Aapro 2008 157/231 32/232 6.6 % 4.93 [ 3.53, 6.88 ]
Boogaerts 2003 63/133 17/129 3.6 % 3.59 [ 2.23, 5.80 ]
Cazzola 1995a 2/31 0/7 0.2 % 1.25 [ 0.07, 23.55 ]
Cazzola 1995b 9/29 1/8 0.3 % 2.48 [ 0.37, 16.80 ]
Cazzola 1995c 19/31 0/7 0.2 % 9.75 [ 0.66, 144.80 ]
Cazzola 1995d 16/26 1/7 0.3 % 4.31 [ 0.68, 27.12 ]
Chang 2005 115/175 11/175 2.3 % 10.45 [ 5.84, 18.71 ]
Charu 2007 150/220 5/55 1.7 % 7.50 [ 3.24, 17.38 ]
Hedenus 2002a 5/11 1/3 0.3 % 1.36 [ 0.24, 7.66 ]
Hedenus 2002b 12/22 0/4 0.2 % 5.43 [ 0.38, 77.40 ]
Hedenus 2002c 14/22 0/4 0.2 % 6.30 [ 0.45, 89.06 ]
Hedenus 2003 104/174 31/170 6.5 % 3.28 [ 2.33, 4.61 ]
Iconomou 2003 25/57 7/55 1.5 % 3.45 [ 1.62, 7.31 ]
Italian 1998 5/43 0/42 0.1 % 10.75 [ 0.61, 188.54 ]
Kotasek 2003a 8/32 1/8 0.3 % 2.00 [ 0.29, 13.77 ]
Kotasek 2003b 8/17 1/8 0.3 % 3.76 [ 0.56, 25.21 ]
Kotasek 2003c 23/46 2/9 0.7 % 2.25 [ 0.64, 7.90 ]
Kotasek 2003d 17/28 1/8 0.3 % 4.86 [ 0.76, 31.12 ]
Kotasek 2003e 20/35 1/9 0.3 % 5.14 [ 0.79, 33.37 ]
Kotasek 2003f 20/40 1/9 0.3 % 4.50 [ 0.69, 29.30 ]
Littlewood 2001 172/244 22/115 6.2 % 3.68 [ 2.51, 5.41 ]
Milroy 2011 37/189 5/191 1.0 % 7.48 [ 3.00, 18.62 ]
Oberhoff 1998 38/114 7/104 1.5 % 4.95 [ 2.31, 10.60 ]
Osterborg 1996a 21/47 4/24 1.1 % 2.68 [ 1.04, 6.93 ]
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Osterborg 1996b 23/48 4/25 1.1 % 2.99 [ 1.16, 7.71 ]
Osterborg 2002 114/170 46/173 9.4 % 2.52 [ 1.93, 3.30 ]
Razzouk 2006 63/111 39/111 8.1 % 1.62 [ 1.20, 2.18 ]
Savonije 2005 143/208 31/100 8.7 % 2.22 [ 1.63, 3.01 ]
Thompson 2000 4/45 1/21 0.3 % 1.87 [ 0.22, 15.70 ]
Witzig 2005 120/165 52/164 10.8 % 2.29 [ 1.80, 2.93 ]
Subtotal (95% CI) 2744 1977 74.4 % 3.35 [ 3.02, 3.72 ]
Total events: 1527 (Treatment), 324 (Control)
Heterogeneity: Chi2 = 75.91, df = 29 (P<0.00001); I2 =62%
Test for overall effect: Z = 22.64 (P < 0.00001)
2 unclear
Abels 1993 20/63 6/55 1.3 % 2.91 [ 1.26, 6.72 ]
Bamias 2003 15/72 2/72 0.4 % 7.50 [ 1.78, 31.62 ]
Case 1993 46/79 10/74 2.1 % 4.31 [ 2.35, 7.90 ]
Dammacco 2001 38/66 6/66 1.2 % 6.33 [ 2.87, 13.96 ]
Henry 1995 31/64 4/61 0.8 % 7.39 [ 2.77, 19.69 ]
ML17616 2006 21/30 11/30 2.3 % 1.91 [ 1.13, 3.23 ]
ML17620 2006 29/61 14/60 2.9 % 2.04 [ 1.20, 3.46 ]
Rose 1994 67/142 13/79 3.5 % 2.87 [ 1.69, 4.85 ]
Smith 2003a 12/21 1/7 0.3 % 4.00 [ 0.63, 25.49 ]
Smith 2003b 10/21 0/7 0.2 % 7.64 [ 0.50, 115.83 ]
Smith 2003c 13/22 0/8 0.1 % 10.57 [ 0.70, 159.65 ]
Suzuki 2008a 22/40 3/21 0.8 % 3.85 [ 1.30, 11.39 ]
Suzuki 2008b 28/41 2/21 0.5 % 7.17 [ 1.89, 27.24 ]
Tjulandin 2010a 50/76 8/37 2.2 % 3.04 [ 1.61, 5.74 ]
Tjulandin 2010b 52/73 7/37 1.9 % 3.77 [ 1.90, 7.45 ]
Tjulandin 2011 69/95 23/91 4.9 % 2.87 [ 1.98, 4.18 ]
Subtotal (95% CI) 966 726 25.6 % 3.50 [ 2.92, 4.19 ]
Total events: 523 (Treatment), 110 (Control)
Heterogeneity: Chi2 = 19.17, df = 15 (P = 0.21); I2 =22%
Test for overall effect: Z = 13.56 (P < 0.00001)
Total (95% CI) 3710 2703 100.0 % 3.39 [ 3.10, 3.71 ]
Total events: 2050 (Treatment), 434 (Control)
Heterogeneity: Chi2 = 95.56, df = 45 (P = 0.00002); I2 =53%
Test for overall effect: Z = 26.39 (P < 0.00001)
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Test for subgroup differences: Chi2 = 0.15, df = 1 (P = 0.70), I2 =0.0%
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Analysis 1.12. Comparison 1 Haematologic response, Outcome 12 Haematologic response - masking.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 1 Haematologic response
Outcome: 12 Haematologic response - masking
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 double-blind
Abels 1993 20/63 6/55 1.3 % 2.91 [ 1.26, 6.72 ]
Case 1993 46/79 10/74 2.1 % 4.31 [ 2.35, 7.90 ]
Dammacco 2001 38/66 6/66 1.2 % 6.33 [ 2.87, 13.96 ]
Hedenus 2002a 5/11 1/3 0.3 % 1.36 [ 0.24, 7.66 ]
Hedenus 2002b 12/22 0/4 0.2 % 5.43 [ 0.38, 77.40 ]
Hedenus 2002c 14/22 0/4 0.2 % 6.30 [ 0.45, 89.06 ]
Hedenus 2003 104/174 31/170 6.5 % 3.28 [ 2.33, 4.61 ]
Henry 1995 31/64 4/61 0.8 % 7.39 [ 2.77, 19.69 ]
Italian 1998 5/43 0/42 0.1 % 10.75 [ 0.61, 188.54 ]
Kotasek 2003a 8/32 1/8 0.3 % 2.00 [ 0.29, 13.77 ]
Kotasek 2003b 8/17 1/8 0.3 % 3.76 [ 0.56, 25.21 ]
Kotasek 2003c 23/46 2/9 0.7 % 2.25 [ 0.64, 7.90 ]
Kotasek 2003d 17/28 1/8 0.3 % 4.86 [ 0.76, 31.12 ]
Kotasek 2003e 20/35 1/9 0.3 % 5.14 [ 0.79, 33.37 ]
Kotasek 2003f 20/40 1/9 0.3 % 4.50 [ 0.69, 29.30 ]
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(. . . Continued)
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Littlewood 2001 172/244 22/115 6.2 % 3.68 [ 2.51, 5.41 ]
Osterborg 2002 114/170 46/173 9.4 % 2.52 [ 1.93, 3.30 ]
Razzouk 2006 63/111 39/111 8.1 % 1.62 [ 1.20, 2.18 ]
Rose 1994 67/142 13/79 3.5 % 2.87 [ 1.69, 4.85 ]
Smith 2003a 12/21 1/7 0.3 % 4.00 [ 0.63, 25.49 ]
Smith 2003b 10/21 0/7 0.2 % 7.64 [ 0.50, 115.83 ]
Smith 2003c 13/22 0/8 0.1 % 10.57 [ 0.70, 159.65 ]
Suzuki 2008a 22/40 3/21 0.8 % 3.85 [ 1.30, 11.39 ]
Suzuki 2008b 28/41 2/21 0.5 % 7.17 [ 1.89, 27.24 ]
Thompson 2000 4/45 1/21 0.3 % 1.87 [ 0.22, 15.70 ]
Tjulandin 2010a 50/76 8/37 2.2 % 3.04 [ 1.61, 5.74 ]
Tjulandin 2010b 52/73 7/37 1.9 % 3.77 [ 1.90, 7.45 ]
Tjulandin 2011 69/95 23/91 4.9 % 2.87 [ 1.98, 4.18 ]
Witzig 2005 120/165 52/164 10.8 % 2.29 [ 1.80, 2.93 ]
Subtotal (95% CI) 2008 1422 64.4 % 3.02 [ 2.70, 3.37 ]
Total events: 1167 (Treatment), 282 (Control)
Heterogeneity: Chi2 = 39.44, df = 28 (P = 0.07); I2 =29%
Test for overall effect: Z = 19.30 (P < 0.00001)
2 unblinded
Aapro 2008 157/231 32/232 6.6 % 4.93 [ 3.53, 6.88 ]
Bamias 2003 15/72 2/72 0.4 % 7.50 [ 1.78, 31.62 ]
Boogaerts 2003 63/133 17/129 3.6 % 3.59 [ 2.23, 5.80 ]
Cazzola 1995a 2/31 0/7 0.2 % 1.25 [ 0.07, 23.55 ]
Cazzola 1995b 9/29 1/8 0.3 % 2.48 [ 0.37, 16.80 ]
Cazzola 1995c 19/31 0/7 0.2 % 9.75 [ 0.66, 144.80 ]
Cazzola 1995d 16/26 1/7 0.3 % 4.31 [ 0.68, 27.12 ]
Chang 2005 115/175 11/175 2.3 % 10.45 [ 5.84, 18.71 ]
Charu 2007 150/220 5/55 1.7 % 7.50 [ 3.24, 17.38 ]
Iconomou 2003 25/57 7/55 1.5 % 3.45 [ 1.62, 7.31 ]
Milroy 2011 37/189 5/191 1.0 % 7.48 [ 3.00, 18.62 ]
ML17616 2006 21/30 11/30 2.3 % 1.91 [ 1.13, 3.23 ]
ML17620 2006 29/61 14/60 2.9 % 2.04 [ 1.20, 3.46 ]
Oberhoff 1998 38/114 7/104 1.5 % 4.95 [ 2.31, 10.60 ]
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(. . . Continued)
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Osterborg 1996a 21/47 4/24 1.1 % 2.68 [ 1.04, 6.93 ]
Osterborg 1996b 23/48 4/25 1.1 % 2.99 [ 1.16, 7.71 ]
Savonije 2005 143/208 31/100 8.7 % 2.22 [ 1.63, 3.01 ]
Subtotal (95% CI) 1702 1281 35.6 % 4.07 [ 3.49, 4.74 ]
Total events: 883 (Treatment), 152 (Control)
Heterogeneity: Chi2 = 48.54, df = 16 (P = 0.00004); I2 =67%
Test for overall effect: Z = 17.91 (P < 0.00001)
Total (95% CI) 3710 2703 100.0 % 3.39 [ 3.10, 3.71 ]
Total events: 2050 (Treatment), 434 (Control)
Heterogeneity: Chi2 = 95.56, df = 45 (P = 0.00002); I2 =53%
Test for overall effect: Z = 26.39 (P < 0.00001)
Test for subgroup differences: Chi2 = 9.54, df = 1 (P = 0.00), I2 =90%
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Analysis 1.13. Comparison 1 Haematologic response, Outcome 13 Haematologic response - intention-to
treat.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 1 Haematologic response
Outcome: 13 Haematologic response - intention-to treat
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ITT or less than 10% of participants per study arm excluded
Aapro 2008 157/231 32/232 6.6 % 4.93 [ 3.53, 6.88 ]
Abels 1993 20/63 6/55 1.3 % 2.91 [ 1.26, 6.72 ]
Bamias 2003 15/72 2/72 0.4 % 7.50 [ 1.78, 31.62 ]
Boogaerts 2003 63/133 17/129 3.6 % 3.59 [ 2.23, 5.80 ]
Case 1993 46/79 10/74 2.1 % 4.31 [ 2.35, 7.90 ]
Cazzola 1995a 2/31 0/7 0.2 % 1.25 [ 0.07, 23.55 ]
Cazzola 1995b 9/29 1/8 0.3 % 2.48 [ 0.37, 16.80 ]
Cazzola 1995c 19/31 0/7 0.2 % 9.75 [ 0.66, 144.80 ]
Cazzola 1995d 16/26 1/7 0.3 % 4.31 [ 0.68, 27.12 ]
Chang 2005 115/175 11/175 2.3 % 10.45 [ 5.84, 18.71 ]
Charu 2007 150/220 5/55 1.7 % 7.50 [ 3.24, 17.38 ]
Hedenus 2002a 5/11 1/3 0.3 % 1.36 [ 0.24, 7.66 ]
Hedenus 2002b 12/22 0/4 0.2 % 5.43 [ 0.38, 77.40 ]
Hedenus 2002c 14/22 0/4 0.2 % 6.30 [ 0.45, 89.06 ]
Hedenus 2003 104/174 31/170 6.5 % 3.28 [ 2.33, 4.61 ]
Henry 1995 31/64 4/61 0.8 % 7.39 [ 2.77, 19.69 ]
Iconomou 2003 25/57 7/55 1.5 % 3.45 [ 1.62, 7.31 ]
Italian 1998 5/43 0/42 0.1 % 10.75 [ 0.61, 188.54 ]
Kotasek 2003a 8/32 1/8 0.3 % 2.00 [ 0.29, 13.77 ]
Kotasek 2003b 8/17 1/8 0.3 % 3.76 [ 0.56, 25.21 ]
Kotasek 2003c 23/46 2/9 0.7 % 2.25 [ 0.64, 7.90 ]
Kotasek 2003d 17/28 1/8 0.3 % 4.86 [ 0.76, 31.12 ]
Kotasek 2003e 20/35 1/9 0.3 % 5.14 [ 0.79, 33.37 ]
Kotasek 2003f 20/40 1/9 0.3 % 4.50 [ 0.69, 29.30 ]
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(. . . Continued)
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Littlewood 2001 172/244 22/115 6.2 % 3.68 [ 2.51, 5.41 ]
ML17616 2006 21/30 11/30 2.3 % 1.91 [ 1.13, 3.23 ]
Oberhoff 1998 38/114 7/104 1.5 % 4.95 [ 2.31, 10.60 ]
Osterborg 1996a 21/47 4/24 1.1 % 2.68 [ 1.04, 6.93 ]
Osterborg 1996b 23/48 4/25 1.1 % 2.99 [ 1.16, 7.71 ]
Osterborg 2002 114/170 46/173 9.4 % 2.52 [ 1.93, 3.30 ]
Razzouk 2006 63/111 39/111 8.1 % 1.62 [ 1.20, 2.18 ]
Rose 1994 67/142 13/79 3.5 % 2.87 [ 1.69, 4.85 ]
Savonije 2005 143/208 31/100 8.7 % 2.22 [ 1.63, 3.01 ]
Smith 2003a 12/21 1/7 0.3 % 4.00 [ 0.63, 25.49 ]
Smith 2003b 10/21 0/7 0.2 % 7.64 [ 0.50, 115.83 ]
Smith 2003c 13/22 0/8 0.1 % 10.57 [ 0.70, 159.65 ]
Thompson 2000 4/45 1/21 0.3 % 1.87 [ 0.22, 15.70 ]
Tjulandin 2010a 50/76 8/37 2.2 % 3.04 [ 1.61, 5.74 ]
Tjulandin 2010b 52/73 7/37 1.9 % 3.77 [ 1.90, 7.45 ]
Tjulandin 2011 69/95 23/91 4.9 % 2.87 [ 1.98, 4.18 ]
Witzig 2005 120/165 52/164 10.8 % 2.29 [ 1.80, 2.93 ]
Subtotal (95% CI) 3313 2344 93.4 % 3.32 [ 3.03, 3.65 ]
Total events: 1896 (Treatment), 404 (Control)
Heterogeneity: Chi2 = 82.99, df = 40 (P = 0.00008); I2 =52%
Test for overall effect: Z = 25.13 (P < 0.00001)
2 more than 10% of participants per study arm excluded
Dammacco 2001 38/66 6/66 1.2 % 6.33 [ 2.87, 13.96 ]
Milroy 2011 37/189 5/191 1.0 % 7.48 [ 3.00, 18.62 ]
Subtotal (95% CI) 255 257 2.3 % 6.85 [ 3.76, 12.48 ]
Total events: 75 (Treatment), 11 (Control)
Heterogeneity: Chi2 = 0.07, df = 1 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 6.29 (P < 0.00001)
3 unclear
ML17620 2006 29/61 14/60 2.9 % 2.04 [ 1.20, 3.46 ]
Suzuki 2008a 22/40 3/21 0.8 % 3.85 [ 1.30, 11.39 ]
Suzuki 2008b 28/41 2/21 0.5 % 7.17 [ 1.89, 27.24 ]
Subtotal (95% CI) 142 102 4.3 % 3.04 [ 1.92, 4.80 ]
Total events: 79 (Treatment), 19 (Control)
Heterogeneity: Chi2 = 3.96, df = 2 (P = 0.14); I2 =50%
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(. . . Continued)
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Test for overall effect: Z = 4.75 (P < 0.00001)
Total (95% CI) 3710 2703 100.0 % 3.39 [ 3.10, 3.71 ]
Total events: 2050 (Treatment), 434 (Control)
Heterogeneity: Chi2 = 95.56, df = 45 (P = 0.00002); I2 =53%
Test for overall effect: Z = 26.39 (P < 0.00001)
Test for subgroup differences: Chi2 = 5.67, df = 2 (P = 0.06), I2 =65%
0.001 0.01 0.1 1 10 100 1000
Favours Control Favours Treatment
Analysis 1.14. Comparison 1 Haematologic response, Outcome 14 Haematologic response - publication.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 1 Haematologic response
Outcome: 14 Haematologic response - publication
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 full text publication
Aapro 2008 157/231 32/232 6.6 % 4.93 [ 3.53, 6.88 ]
Abels 1993 20/63 6/55 1.3 % 2.91 [ 1.26, 6.72 ]
Bamias 2003 15/72 2/72 0.4 % 7.50 [ 1.78, 31.62 ]
Boogaerts 2003 63/133 17/129 3.6 % 3.59 [ 2.23, 5.80 ]
Case 1993 46/79 10/74 2.1 % 4.31 [ 2.35, 7.90 ]
Chang 2005 115/175 11/175 2.3 % 10.45 [ 5.84, 18.71 ]
Charu 2007 150/220 5/55 1.7 % 7.50 [ 3.24, 17.38 ]
Dammacco 2001 38/66 6/66 1.2 % 6.33 [ 2.87, 13.96 ]
Hedenus 2002a 5/11 1/3 0.3 % 1.36 [ 0.24, 7.66 ]
Hedenus 2002b 12/22 0/4 0.2 % 5.43 [ 0.38, 77.40 ]
Hedenus 2002c 14/22 0/4 0.2 % 6.30 [ 0.45, 89.06 ]
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(. . . Continued)
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hedenus 2003 104/174 31/170 6.5 % 3.28 [ 2.33, 4.61 ]
Henry 1995 31/64 4/61 0.8 % 7.39 [ 2.77, 19.69 ]
Iconomou 2003 25/57 7/55 1.5 % 3.45 [ 1.62, 7.31 ]
Kotasek 2003a 8/32 1/8 0.3 % 2.00 [ 0.29, 13.77 ]
Kotasek 2003b 8/17 1/8 0.3 % 3.76 [ 0.56, 25.21 ]
Kotasek 2003c 23/46 2/9 0.7 % 2.25 [ 0.64, 7.90 ]
Kotasek 2003d 17/28 1/8 0.3 % 4.86 [ 0.76, 31.12 ]
Kotasek 2003e 20/35 1/9 0.3 % 5.14 [ 0.79, 33.37 ]
Kotasek 2003f 20/40 1/9 0.3 % 4.50 [ 0.69, 29.30 ]
Littlewood 2001 172/244 22/115 6.2 % 3.68 [ 2.51, 5.41 ]
Milroy 2011 37/189 5/191 1.0 % 7.48 [ 3.00, 18.62 ]
Osterborg 2002 114/170 46/173 9.4 % 2.52 [ 1.93, 3.30 ]
Razzouk 2006 63/111 39/111 8.1 % 1.62 [ 1.20, 2.18 ]
Savonije 2005 143/208 31/100 8.7 % 2.22 [ 1.63, 3.01 ]
Smith 2003a 12/21 1/7 0.3 % 4.00 [ 0.63, 25.49 ]
Smith 2003b 10/21 0/7 0.2 % 7.64 [ 0.50, 115.83 ]
Smith 2003c 13/22 0/8 0.1 % 10.57 [ 0.70, 159.65 ]
Tjulandin 2010a 50/76 8/37 2.2 % 3.04 [ 1.61, 5.74 ]
Tjulandin 2010b 52/73 7/37 1.9 % 3.77 [ 1.90, 7.45 ]
Tjulandin 2011 69/95 23/91 4.9 % 2.87 [ 1.98, 4.18 ]
Witzig 2005 120/165 52/164 10.8 % 2.29 [ 1.80, 2.93 ]
Subtotal (95% CI) 2982 2247 84.9 % 3.44 [ 3.12, 3.80 ]
Total events: 1746 (Treatment), 373 (Control)
Heterogeneity: Chi2 = 83.98, df = 31 (P<0.00001); I2 =63%
Test for overall effect: Z = 24.87 (P < 0.00001)
2 abstract publication
Suzuki 2008a 22/40 3/21 0.8 % 3.85 [ 1.30, 11.39 ]
Suzuki 2008b 28/41 2/21 0.5 % 7.17 [ 1.89, 27.24 ]
Subtotal (95% CI) 81 42 1.4 % 5.19 [ 2.23, 12.04 ]
Total events: 50 (Treatment), 5 (Control)
Heterogeneity: Chi2 = 0.52, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 3.83 (P = 0.00013)
3 unpublished data
Cazzola 1995a 2/31 0/7 0.2 % 1.25 [ 0.07, 23.55 ]
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(. . . Continued)
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cazzola 1995b 9/29 1/8 0.3 % 2.48 [ 0.37, 16.80 ]
Cazzola 1995c 19/31 0/7 0.2 % 9.75 [ 0.66, 144.80 ]
Cazzola 1995d 16/26 1/7 0.3 % 4.31 [ 0.68, 27.12 ]
Italian 1998 5/43 0/42 0.1 % 10.75 [ 0.61, 188.54 ]
Oberhoff 1998 38/114 7/104 1.5 % 4.95 [ 2.31, 10.60 ]
Osterborg 1996a 21/47 4/24 1.1 % 2.68 [ 1.04, 6.93 ]
Osterborg 1996b 23/48 4/25 1.1 % 2.99 [ 1.16, 7.71 ]
Rose 1994 67/142 13/79 3.5 % 2.87 [ 1.69, 4.85 ]
Thompson 2000 4/45 1/21 0.3 % 1.87 [ 0.22, 15.70 ]
Subtotal (95% CI) 556 324 8.5 % 3.44 [ 2.45, 4.82 ]
Total events: 204 (Treatment), 31 (Control)
Heterogeneity: Chi2 = 3.81, df = 9 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 7.16 (P < 0.00001)
4 FDA hearing
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (Treatment), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 clinical trial result information
ML17616 2006 21/30 11/30 2.3 % 1.91 [ 1.13, 3.23 ]
ML17620 2006 29/61 14/60 2.9 % 2.04 [ 1.20, 3.46 ]
Subtotal (95% CI) 91 90 5.2 % 1.98 [ 1.36, 2.89 ]
Total events: 50 (Treatment), 25 (Control)
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 3.56 (P = 0.00038)
Total (95% CI) 3710 2703 100.0 % 3.39 [ 3.10, 3.71 ]
Total events: 2050 (Treatment), 434 (Control)
Heterogeneity: Chi2 = 95.56, df = 45 (P = 0.00002); I2 =53%
Test for overall effect: Z = 26.39 (P < 0.00001)
Test for subgroup differences: Chi2 = 8.83, df = 3 (P = 0.03), I2 =66%
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Analysis 1.15. Comparison 1 Haematologic response, Outcome 15 Haematological response - merged
experimental arms.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 1 Haematologic response
Outcome: 15 Haematological response - merged experimental arms
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Aapro 2008 157/231 32/232 6.7 % 4.93 [ 3.53, 6.88 ]
Abels 1993 20/63 6/55 1.3 % 2.91 [ 1.26, 6.72 ]
Bamias 2003 15/72 2/72 0.4 % 7.50 [ 1.78, 31.62 ]
Boogaerts 2003 63/133 17/129 3.6 % 3.59 [ 2.23, 5.80 ]
Case 1993 46/79 10/74 2.2 % 4.31 [ 2.35, 7.90 ]
Cazzola 1995 46/117 2/29 0.7 % 5.70 [ 1.47, 22.12 ]
Chang 2005 115/175 11/175 2.3 % 10.45 [ 5.84, 18.71 ]
Charu 2007 150/220 5/55 1.7 % 7.50 [ 3.24, 17.38 ]
Dammacco 2001 38/66 6/66 1.3 % 6.33 [ 2.87, 13.96 ]
Hedenus 2002 31/55 1/11 0.3 % 6.20 [ 0.94, 40.76 ]
Hedenus 2003 104/174 31/170 6.6 % 3.28 [ 2.33, 4.61 ]
Henry 1995 31/64 4/61 0.9 % 7.39 [ 2.77, 19.69 ]
Iconomou 2003 25/57 7/55 1.5 % 3.45 [ 1.62, 7.31 ]
Italian 1998 5/43 0/42 0.1 % 10.75 [ 0.61, 188.54 ]
Kotasek 2003 96/198 7/51 2.3 % 3.53 [ 1.75, 7.13 ]
Littlewood 2001 172/244 22/115 6.3 % 3.68 [ 2.51, 5.41 ]
Milroy 2011 37/189 5/191 1.0 % 7.48 [ 3.00, 18.62 ]
ML17616 2006 21/30 11/30 2.3 % 1.91 [ 1.13, 3.23 ]
ML17620 2006 29/61 14/60 3.0 % 2.04 [ 1.20, 3.46 ]
Oberhoff 1998 38/114 7/104 1.5 % 4.95 [ 2.31, 10.60 ]
Osterborg 1996 44/95 8/49 2.2 % 2.84 [ 1.45, 5.54 ]
Osterborg 2002 114/170 46/173 9.5 % 2.52 [ 1.93, 3.30 ]
Razzouk 2006 63/111 39/111 8.2 % 1.62 [ 1.20, 2.18 ]
Rose 1994 67/142 13/79 3.5 % 2.87 [ 1.69, 4.85 ]
Savonije 2005 143/208 31/100 8.8 % 2.22 [ 1.63, 3.01 ]
0.001 0.01 0.1 1 10 100 1000
Favours control Favours treatment
(Continued . . . )
240Erythropoietin or darbepoetin for patients with cancer (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Smith 2003 35/64 1/22 0.3 % 12.03 [ 1.75, 82.71 ]
Suzuki 2008 50/81 5/42 1.4 % 5.19 [ 2.24, 12.02 ]
Thompson 2000 4/45 1/21 0.3 % 1.87 [ 0.22, 15.70 ]
Tjulandin 2010 102/149 15/74 4.2 % 3.38 [ 2.12, 5.38 ]
Tjulandin 2011 69/95 23/91 4.9 % 2.87 [ 1.98, 4.18 ]
Witzig 2005 120/165 52/164 10.9 % 2.29 [ 1.80, 2.93 ]
Total (95% CI) 3710 2703 100.0 % 3.42 [ 3.12, 3.74 ]
Total events: 2050 (Treatment), 434 (Control)
Heterogeneity: Chi2 = 93.78, df = 30 (P<0.00001); I2 =68%
Test for overall effect: Z = 26.41 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Change of haemoglobin level, Outcome 1 Change in Hb values - overall.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 2 Change of haemoglobin level
Outcome: 1 Change in Hb values - overall





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Abels 1993 63 0.952 (2.142) 55 -0.03 (1.36) 0.8 % 0.99 [ 0.35, 1.63 ]
Aravantinos 2003 24 2.31 (1.22) 23 1.23 (1.59) 0.5 % 1.08 [ 0.27, 1.89 ]
Bamias 2003 72 0.57 (2.12) 72 -0.49 (1.36) 1.0 % 1.06 [ 0.48, 1.64 ]
Boogaerts 2003 133 2.1 (1.83) 129 0.9 (1.5) 2.0 % 1.20 [ 0.80, 1.60 ]
Carabantes 1999 20 1 (1.56) 15 -1.7 (1.22) 0.4 % 2.70 [ 1.78, 3.62 ]
Cascinu 1994 50 1.88 (0.83) 49 -0.61 (0.95) 2.7 % 2.49 [ 2.14, 2.84 ]
Case 1993 79 2.346 (2.04) 74 0.37 (1.46) 1.1 % 1.97 [ 1.41, 2.53 ]
Cazzola 1995a 31 -0.1 (2.23) 7 -0.04 (2.05) 0.1 % -0.06 [ -1.77, 1.65 ]
Cazzola 1995b 29 0.17 (1.72) 8 -0.04 (2.05) 0.1 % 0.21 [ -1.34, 1.76 ]
Cazzola 1995c 31 0.3 (2.9) 7 -0.04 (2.05) 0.1 % 0.34 [ -1.49, 2.17 ]
Cazzola 1995d 26 0.44 (2.29) 7 -0.04 (2.05) 0.1 % 0.48 [ -1.28, 2.24 ]
Chang 2005 175 1.14 (0.8) 175 -0.58 (0.73) 12.9 % 1.72 [ 1.56, 1.88 ]
Charu 2007 220 2.1 (1.854) 55 0.1 (0.927) 2.8 % 2.00 [ 1.65, 2.35 ]
Christodoulou 2009 167 2.74 (13.62) 170 0.52 (4.18) 0.1 % 2.22 [ 0.06, 4.38 ]
Dammacco 2001 69 1.8 (2.11) 76 -0.2 (1.31) 1.0 % 2.00 [ 1.42, 2.58 ]
Del Mastro 1997 28 -0.8 (1.4) 24 -3.05 (1) 0.8 % 2.25 [ 1.60, 2.90 ]
Engert 2009 648 -1.88 (1.78) 655 -2.55 (1.78) 8.9 % 0.67 [ 0.48, 0.86 ]
Fujisaka 2011 89 1.84 (1.33) 92 0.02 (1.12) 2.6 % 1.82 [ 1.46, 2.18 ]
Gebbia 2003 22 -2.4 (1.5) 23 -5.1 (1.33) 0.5 % 2.70 [ 1.87, 3.53 ]
Gordon 2008 139 1.3 (1.4) 49 0.2 (1) 2.5 % 1.10 [ 0.74, 1.46 ]
Grote 2005 64 -0.2 (1.38) 58 -2.9 (1.53) 1.2 % 2.70 [ 2.18, 3.22 ]
Gupta 2009 58 1.55 (0.74) 57 -1.5 (0.61) 5.4 % 3.05 [ 2.80, 3.30 ]
Hedenus 2002a 5 1.56 (1.93) 2 1 (0.56) 0.1 % 0.56 [ -1.30, 2.42 ]
Hedenus 2002b 17 1.64 (1.25) 2 1 (0.56) 0.3 % 0.64 [ -0.34, 1.62 ]
Hedenus 2002c 14 2.46 (1.49) 2 1 (0.56) 0.3 % 1.46 [ 0.36, 2.56 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Hedenus 2003 174 1.8 (2.24) 170 0.19 (1.3) 2.2 % 1.61 [ 1.22, 2.00 ]
Henke 1999a 19 3.2 (1.6) 3 0.6 (1.4) 0.1 % 2.60 [ 0.86, 4.34 ]
Henke 1999b 14 3.5 (1.2) 4 0.6 (1.4) 0.1 % 2.90 [ 1.39, 4.41 ]
Henke 1999c 6 3.9 (2.1) 4 0.6 (1.4) 0.1 % 3.30 [ 1.13, 5.47 ]
Henke 2003 Roche 2004 178 3.4 (1.7) 168 0.9 (1.7) 2.6 % 2.50 [ 2.14, 2.86 ]
Henry 1995 63 2.04 (2.38) 61 0.44 (1.7) 0.6 % 1.60 [ 0.87, 2.33 ]
Hoskin 2009 151 0.625 (3.5) 149 -0.47 (3.48) 0.5 % 1.09 [ 0.30, 1.88 ]
Huddart 2002 45 2.6 (2) 45 1.2 (1.46) 0.6 % 1.40 [ 0.68, 2.12 ]
Iconomou 2003 57 1.7 (1.6) 55 0.3 (1.4) 1.1 % 1.40 [ 0.84, 1.96 ]
Italian 1998 17 1.73 (1.56) 11 -0.14 (1.09) 0.3 % 1.87 [ 0.89, 2.85 ]
Kotasek 2003a 32 0.54 (1.24) 8 -0.02 (1.43) 0.3 % 0.56 [ -0.52, 1.64 ]
Kotasek 2003b 17 0.86 (1.57) 8 -0.02 (1.43) 0.2 % 0.88 [ -0.36, 2.12 ]
Kotasek 2003c 46 0.9 (1.63) 9 -0.02 (1.43) 0.3 % 0.92 [ -0.13, 1.97 ]
Kotasek 2003d 28 1.63 (2.01) 8 -0.02 (1.43) 0.2 % 1.65 [ 0.41, 2.89 ]
Kotasek 2003e 35 1.45 (1.42) 8 -0.02 (1.43) 0.3 % 1.47 [ 0.37, 2.57 ]
Kotasek 2003f 40 1.21 (1.9) 9 -0.02 (1.43) 0.3 % 1.23 [ 0.13, 2.33 ]
Krzakowski 2008a 104 2.5 (2.4) 52 0.6 (1.7) 0.8 % 1.90 [ 1.25, 2.55 ]
Krzakowski 2008b 105 2.5 (2.6) 52 0.6 (1.7) 0.7 % 1.90 [ 1.22, 2.58 ]
Kunikane 2001a 16 0.89 (1.72) 10 -0.65 (1.31) 0.2 % 1.54 [ 0.37, 2.71 ]
Kunikane 2001b 18 1.72 (1.1) 9 -0.65 (1.31) 0.3 % 2.37 [ 1.37, 3.37 ]
Kurz 1997 23 3.26 (1.98) 12 0.25 (1.66) 0.2 % 3.01 [ 1.77, 4.25 ]
Leyland-Jones 2005 81 0.34 (1.73) 86 0.14 (1.7) 1.2 % 0.20 [ -0.32, 0.72 ]
Littlewood 2001 244 2.2 (2.18) 115 0.5 (1.79) 1.8 % 1.70 [ 1.27, 2.13 ]
ML17616 2006 30 3.09 (2.08) 30 1.76 (2.28) 0.3 % 1.33 [ 0.23, 2.43 ]
ML17620 2006 61 2.12 (1.64) 60 0.59 (1.83) 0.9 % 1.53 [ 0.91, 2.15 ]
Mystakidou 2005 50 2.4 (1.3) 50 -0.1 (1.02) 1.6 % 2.50 [ 2.04, 2.96 ]
O’Shaughnessy 2005 47 0.8 (1.2) 46 -2.1 (1.4) 1.2 % 2.90 [ 2.37, 3.43 ]
Oberhoff 1998 59 2.24 (2) 47 0.6 (1.43) 0.8 % 1.64 [ 0.99, 2.29 ]
Osterborg 1996a 17 2.6 (1.74) 13 1.02 (1.28) 0.3 % 1.58 [ 0.50, 2.66 ]
Osterborg 1996b 27 1.71 (1.67) 14 1.02 (1.28) 0.4 % 0.69 [ -0.23, 1.61 ]
Osterborg 2002 138 2.48 (1.74) 142 0.82 (1.4) 2.4 % 1.66 [ 1.29, 2.03 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Pirker 2008 270 -1.13 (1.93) 279 -1.98 (1.87) 3.3 % 0.85 [ 0.53, 1.17 ]
Pronzato 2010 107 1.7 (1.35) 109 0.4 (1.24) 2.8 % 1.30 [ 0.95, 1.65 ]
Razzouk 2006 111 1.3 (2.38) 111 1 (1.9) 1.0 % 0.30 [ -0.27, 0.87 ]
Smith 2003a 21 1.18 (2.01) 7 0 (0.91) 0.3 % 1.18 [ 0.09, 2.27 ]
Smith 2003b 21 1.22 (1.62) 7 0 (0.91) 0.4 % 1.22 [ 0.25, 2.19 ]
Smith 2003c 22 1.7 (1.93) 8 0 (0.91) 0.3 % 1.70 [ 0.68, 2.72 ]
Smith 2008 437 0.79 (2.83) 447 0.29 (2.8) 2.4 % 0.50 [ 0.13, 0.87 ]
Ten Bokkel 1998a 34 0.66 (1.76) 12 -0.57 (1.16) 0.4 % 1.23 [ 0.35, 2.11 ]
Ten Bokkel 1998b 27 1.04 (1.73) 12 -0.57 (1.16) 0.4 % 1.61 [ 0.68, 2.54 ]
Thomas 2002 62 1.9 (1.74) 65 0.39 (1.38) 1.1 % 1.51 [ 0.96, 2.06 ]
Thomas 2008 52 1.72 (1.79) 57 0.09 (1.23) 1.0 % 1.63 [ 1.05, 2.21 ]
Throuvalas 2000 28 0.7 (0.95) 26 -0.5 (0.56) 1.9 % 1.20 [ 0.79, 1.61 ]
Tjulandin 2010a 76 1.6 (1.42) 37 0.2 (1.74) 0.8 % 1.40 [ 0.75, 2.05 ]
Tjulandin 2010b 73 1.9 (1.74) 37 0.2 (1.74) 0.7 % 1.70 [ 1.01, 2.39 ]
Tjulandin 2011 95 2.1 (1.3) 91 0.65 (1.94) 1.5 % 1.45 [ 0.97, 1.93 ]
Tsuboi 2009 61 1.4 (1.9) 56 -0.8 (1.5) 0.9 % 2.20 [ 1.58, 2.82 ]
Untch 2011˙1 330 -0.07 (2) 359 -0.98 (1.33) 5.1 % 0.91 [ 0.65, 1.17 ]
Wilkinson 2006 114 1.6 (1.5) 59 0.3 (1.3) 1.8 % 1.30 [ 0.87, 1.73 ]
Witzig 2005 166 2.8 (1.62) 164 0.9 (1.52) 2.9 % 1.90 [ 1.56, 2.24 ]
Total (95% CI) 6322 5287 100.0 % 1.57 [ 1.51, 1.62 ]
Heterogeneity: Chi2 = 564.37, df = 74 (P<0.00001); I2 =87%
Test for overall effect: Z = 53.27 (P < 0.00001)
Test for subgroup differences: Not applicable
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Hb <=10g/dL
Abels 1993 63 0.952 (2.142) 55 -0.03 (1.36) 0.8 % 0.99 [ 0.35, 1.63 ]
Aravantinos 2003 24 2.31 (1.22) 23 1.23 (1.59) 0.5 % 1.08 [ 0.27, 1.89 ]
Boogaerts 2003 133 2.1 (1.83) 129 0.9 (1.5) 2.0 % 1.20 [ 0.80, 1.60 ]
Cascinu 1994 50 1.88 (0.83) 49 -0.61 (0.95) 2.7 % 2.49 [ 2.14, 2.84 ]
Case 1993 79 2.346 (2.04) 74 0.37 (1.46) 1.1 % 1.97 [ 1.41, 2.53 ]
Cazzola 1995a 31 -0.1 (2.23) 7 -0.04 (2.05) 0.1 % -0.06 [ -1.77, 1.65 ]
Cazzola 1995b 29 0.17 (1.72) 8 -0.04 (2.05) 0.1 % 0.21 [ -1.34, 1.76 ]
Cazzola 1995c 31 0.3 (2.9) 7 -0.04 (2.05) 0.1 % 0.34 [ -1.49, 2.17 ]
Cazzola 1995d 26 0.44 (2.29) 7 -0.04 (2.05) 0.1 % 0.48 [ -1.28, 2.24 ]
Dammacco 2001 69 1.8 (2.11) 76 -0.2 (1.31) 1.0 % 2.00 [ 1.42, 2.58 ]
Fujisaka 2011 89 1.84 (1.33) 92 0.02 (1.12) 2.6 % 1.82 [ 1.46, 2.18 ]
Hedenus 2002a 5 1.56 (1.93) 2 1 (0.56) 0.1 % 0.56 [ -1.30, 2.42 ]
Hedenus 2002b 17 1.64 (1.25) 2 1 (0.56) 0.3 % 0.64 [ -0.34, 1.62 ]
Hedenus 2002c 14 2.46 (1.49) 2 1 (0.56) 0.3 % 1.46 [ 0.36, 2.56 ]
Hedenus 2003 174 1.8 (2.24) 170 0.19 (1.3) 2.2 % 1.61 [ 1.22, 2.00 ]
Henry 1995 63 2.04 (2.38) 61 0.44 (1.7) 0.6 % 1.60 [ 0.87, 2.33 ]
Italian 1998 17 1.73 (1.56) 11 -0.14 (1.09) 0.3 % 1.87 [ 0.89, 2.85 ]
Kotasek 2003a 32 0.54 (1.24) 8 -0.02 (1.43) 0.3 % 0.56 [ -0.52, 1.64 ]
Kotasek 2003b 17 0.86 (1.57) 8 -0.02 (1.43) 0.2 % 0.88 [ -0.36, 2.12 ]
Kotasek 2003c 46 0.9 (1.63) 9 -0.02 (1.43) 0.3 % 0.92 [ -0.13, 1.97 ]
Kotasek 2003d 28 1.63 (2.01) 8 -0.02 (1.43) 0.2 % 1.65 [ 0.41, 2.89 ]
Kotasek 2003e 35 1.45 (1.42) 8 -0.02 (1.43) 0.3 % 1.47 [ 0.37, 2.57 ]
Kotasek 2003f 40 1.21 (1.9) 9 -0.02 (1.43) 0.3 % 1.23 [ 0.13, 2.33 ]
Krzakowski 2008a 104 2.5 (2.4) 52 0.6 (1.7) 0.8 % 1.90 [ 1.25, 2.55 ]
-10 -5 0 5 10
Favours Control Favours Treatment
(Continued . . . )
245Erythropoietin or darbepoetin for patients with cancer (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Krzakowski 2008b 105 2.5 (2.6) 52 0.6 (1.7) 0.7 % 1.90 [ 1.22, 2.58 ]
Kurz 1997 23 3.26 (1.98) 12 0.25 (1.66) 0.2 % 3.01 [ 1.77, 4.25 ]
Littlewood 2001 244 2.2 (2.18) 115 0.5 (1.79) 1.8 % 1.70 [ 1.27, 2.13 ]
ML17616 2006 30 3.09 (2.08) 30 1.76 (2.28) 0.3 % 1.33 [ 0.23, 2.43 ]
Oberhoff 1998 59 2.24 (2) 47 0.6 (1.43) 0.8 % 1.64 [ 0.99, 2.29 ]
Osterborg 1996a 17 2.6 (1.74) 13 1.02 (1.28) 0.3 % 1.58 [ 0.50, 2.66 ]
Osterborg 1996b 27 1.71 (1.67) 14 1.02 (1.28) 0.4 % 0.69 [ -0.23, 1.61 ]
Osterborg 2002 138 2.48 (1.74) 142 0.82 (1.4) 2.4 % 1.66 [ 1.29, 2.03 ]
Razzouk 2006 111 1.3 (2.38) 111 1 (1.9) 1.0 % 0.30 [ -0.27, 0.87 ]
Smith 2003a 21 1.18 (2.01) 7 0 (0.91) 0.3 % 1.18 [ 0.09, 2.27 ]
Smith 2003b 21 1.22 (1.62) 7 0 (0.91) 0.4 % 1.22 [ 0.25, 2.19 ]
Smith 2003c 22 1.7 (1.93) 8 0 (0.91) 0.3 % 1.70 [ 0.68, 2.72 ]
Smith 2008 437 0.79 (2.83) 447 0.29 (2.8) 2.4 % 0.50 [ 0.13, 0.87 ]
Tjulandin 2010a 76 1.6 (1.42) 37 0.2 (1.74) 0.8 % 1.40 [ 0.75, 2.05 ]
Tjulandin 2010b 73 1.9 (1.74) 37 0.2 (1.74) 0.7 % 1.70 [ 1.01, 2.39 ]
Tjulandin 2011 95 2.1 (1.3) 91 0.65 (1.94) 1.5 % 1.45 [ 0.97, 1.93 ]
Witzig 2005 166 2.8 (1.62) 164 0.9 (1.52) 2.9 % 1.90 [ 1.56, 2.24 ]
Subtotal (95% CI) 2881 2211 34.5 % 1.53 [ 1.43, 1.62 ]
Heterogeneity: Chi2 = 128.41, df = 40 (P<0.00001); I2 =69%
Test for overall effect: Z = 30.50 (P < 0.00001)
2 Hb 10 to 12 g/dL
Bamias 2003 72 0.57 (2.12) 72 -0.49 (1.36) 1.0 % 1.06 [ 0.48, 1.64 ]
Carabantes 1999 20 1 (1.56) 15 -1.7 (1.22) 0.4 % 2.70 [ 1.78, 3.62 ]
Chang 2005 175 1.14 (0.8) 175 -0.58 (0.73) 12.9 % 1.72 [ 1.56, 1.88 ]
Charu 2007 220 2.1 (1.854) 55 0.1 (0.927) 2.8 % 2.00 [ 1.65, 2.35 ]
Christodoulou 2009 167 2.74 (13.62) 170 0.52 (4.18) 0.1 % 2.22 [ 0.06, 4.38 ]
Gordon 2008 139 1.3 (1.4) 49 0.2 (1) 2.5 % 1.10 [ 0.74, 1.46 ]
Gupta 2009 58 1.55 (0.74) 57 -1.5 (0.61) 5.4 % 3.05 [ 2.80, 3.30 ]
Henke 1999a 19 3.2 (1.6) 3 0.6 (1.4) 0.1 % 2.60 [ 0.86, 4.34 ]
Henke 1999b 14 3.5 (1.2) 4 0.6 (1.4) 0.1 % 2.90 [ 1.39, 4.41 ]
Henke 1999c 6 3.9 (2.1) 4 0.6 (1.4) 0.1 % 3.30 [ 1.13, 5.47 ]
Henke 2003 Roche 2004 178 3.4 (1.7) 168 0.9 (1.7) 2.6 % 2.50 [ 2.14, 2.86 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Huddart 2002 45 2.6 (2) 45 1.2 (1.46) 0.6 % 1.40 [ 0.68, 2.12 ]
Iconomou 2003 57 1.7 (1.6) 55 0.3 (1.4) 1.1 % 1.40 [ 0.84, 1.96 ]
Mystakidou 2005 50 2.4 (1.3) 50 -0.1 (1.02) 1.6 % 2.50 [ 2.04, 2.96 ]
Pirker 2008 270 -1.13 (1.93) 279 -1.98 (1.87) 3.3 % 0.85 [ 0.53, 1.17 ]
Pronzato 2010 107 1.7 (1.35) 109 0.4 (1.24) 2.8 % 1.30 [ 0.95, 1.65 ]
Ten Bokkel 1998a 34 0.66 (1.76) 12 -0.57 (1.16) 0.4 % 1.23 [ 0.35, 2.11 ]
Ten Bokkel 1998b 27 1.04 (1.73) 12 -0.57 (1.16) 0.4 % 1.61 [ 0.68, 2.54 ]
Thomas 2002 62 1.9 (1.74) 65 0.39 (1.38) 1.1 % 1.51 [ 0.96, 2.06 ]
Thomas 2008 52 1.72 (1.79) 57 0.09 (1.23) 1.0 % 1.63 [ 1.05, 2.21 ]
Throuvalas 2000 28 0.7 (0.95) 26 -0.5 (0.56) 1.9 % 1.20 [ 0.79, 1.61 ]
Tsuboi 2009 61 1.4 (1.9) 56 -0.8 (1.5) 0.9 % 2.20 [ 1.58, 2.82 ]
Wilkinson 2006 114 1.6 (1.5) 59 0.3 (1.3) 1.8 % 1.30 [ 0.87, 1.73 ]
Subtotal (95% CI) 1975 1597 44.7 % 1.79 [ 1.71, 1.88 ]
Heterogeneity: Chi2 = 216.14, df = 22 (P<0.00001); I2 =90%
Test for overall effect: Z = 40.85 (P < 0.00001)
3 Hb >12 g/dL
Del Mastro 1997 28 -0.8 (1.4) 24 -3.05 (1) 0.8 % 2.25 [ 1.60, 2.90 ]
Engert 2009 648 -1.88 (1.78) 655 -2.55 (1.78) 8.9 % 0.67 [ 0.48, 0.86 ]
Gebbia 2003 22 -2.4 (1.5) 23 -5.1 (1.33) 0.5 % 2.70 [ 1.87, 3.53 ]
Grote 2005 64 -0.2 (1.38) 58 -2.9 (1.53) 1.2 % 2.70 [ 2.18, 3.22 ]
Hoskin 2009 151 0.625 (3.5) 149 -0.47 (3.48) 0.5 % 1.09 [ 0.30, 1.88 ]
Kunikane 2001a 16 0.89 (1.72) 10 -0.65 (1.31) 0.2 % 1.54 [ 0.37, 2.71 ]
Kunikane 2001b 18 1.72 (1.1) 9 -0.65 (1.31) 0.3 % 2.37 [ 1.37, 3.37 ]
Leyland-Jones 2005 81 0.34 (1.73) 86 0.14 (1.7) 1.2 % 0.20 [ -0.32, 0.72 ]
O’Shaughnessy 2005 47 0.8 (1.2) 46 -2.1 (1.4) 1.2 % 2.90 [ 2.37, 3.43 ]
Untch 2011˙1 330 -0.07 (2) 359 -0.98 (1.33) 5.1 % 0.91 [ 0.65, 1.17 ]
Subtotal (95% CI) 1405 1419 19.9 % 1.12 [ 0.99, 1.25 ]
Heterogeneity: Chi2 = 146.19, df = 9 (P<0.00001); I2 =94%
Test for overall effect: Z = 17.02 (P < 0.00001)
4 unclear
ML17620 2006 61 2.12 (1.64) 60 0.59 (1.83) 0.9 % 1.53 [ 0.91, 2.15 ]
Subtotal (95% CI) 61 60 0.9 % 1.53 [ 0.91, 2.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.84 (P < 0.00001)
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Total (95% CI) 6322 5287 100.0 % 1.57 [ 1.51, 1.62 ]
Heterogeneity: Chi2 = 564.37, df = 74 (P<0.00001); I2 =87%
Test for overall effect: Z = 53.27 (P < 0.00001)
Test for subgroup differences: Chi2 = 73.63, df = 3 (P = 0.00), I2 =96%
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Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 2 Change of haemoglobin level
Outcome: 3 Change in Hb values - different malignancies





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 solid tumours
Aravantinos 2003 24 2.31 (1.22) 23 1.23 (1.59) 0.5 % 1.08 [ 0.27, 1.89 ]
Bamias 2003 72 0.57 (2.12) 72 -0.49 (1.36) 1.0 % 1.06 [ 0.48, 1.64 ]
Carabantes 1999 20 1 (1.56) 15 -1.7 (1.22) 0.4 % 2.70 [ 1.78, 3.62 ]
Cascinu 1994 50 1.88 (0.83) 49 -0.61 (0.95) 2.7 % 2.49 [ 2.14, 2.84 ]
Chang 2005 175 1.14 (0.8) 175 -0.58 (0.73) 12.9 % 1.72 [ 1.56, 1.88 ]
Christodoulou 2009 167 2.74 (13.62) 170 0.52 (4.18) 0.1 % 2.22 [ 0.06, 4.38 ]
Del Mastro 1997 28 -0.8 (1.4) 24 -3.05 (1) 0.8 % 2.25 [ 1.60, 2.90 ]
Fujisaka 2011 89 1.84 (1.33) 92 0.02 (1.12) 2.6 % 1.82 [ 1.46, 2.18 ]
Gebbia 2003 22 -2.4 (1.5) 23 -5.1 (1.33) 0.5 % 2.70 [ 1.87, 3.53 ]
Grote 2005 64 -0.2 (1.38) 58 -2.9 (1.53) 1.2 % 2.70 [ 2.18, 3.22 ]
Gupta 2009 58 1.55 (0.74) 57 -1.5 (0.61) 5.4 % 3.05 [ 2.80, 3.30 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Henke 1999a 19 3.2 (1.6) 3 0.6 (1.4) 0.1 % 2.60 [ 0.86, 4.34 ]
Henke 1999b 14 3.5 (1.2) 4 0.6 (1.4) 0.1 % 2.90 [ 1.39, 4.41 ]
Henke 1999c 6 3.9 (2.1) 4 0.6 (1.4) 0.1 % 3.30 [ 1.13, 5.47 ]
Henke 2003 Roche 2004 178 3.4 (1.7) 168 0.9 (1.7) 2.6 % 2.50 [ 2.14, 2.86 ]
Hoskin 2009 151 0.625 (3.5) 149 -0.47 (3.48) 0.5 % 1.09 [ 0.30, 1.88 ]
Huddart 2002 45 2.6 (2) 45 1.2 (1.46) 0.6 % 1.40 [ 0.68, 2.12 ]
Iconomou 2003 57 1.7 (1.6) 55 0.3 (1.4) 1.1 % 1.40 [ 0.84, 1.96 ]
Kotasek 2003a 32 0.54 (1.24) 8 -0.02 (1.43) 0.3 % 0.56 [ -0.52, 1.64 ]
Kotasek 2003b 17 0.86 (1.57) 8 -0.02 (1.43) 0.2 % 0.88 [ -0.36, 2.12 ]
Kotasek 2003c 46 0.9 (1.63) 9 -0.02 (1.43) 0.3 % 0.92 [ -0.13, 1.97 ]
Kotasek 2003d 28 1.63 (2.01) 8 -0.02 (1.43) 0.2 % 1.65 [ 0.41, 2.89 ]
Kotasek 2003e 35 1.45 (1.42) 8 -0.02 (1.43) 0.3 % 1.47 [ 0.37, 2.57 ]
Kotasek 2003f 40 1.21 (1.9) 9 -0.02 (1.43) 0.3 % 1.23 [ 0.13, 2.33 ]
Kunikane 2001a 16 0.89 (1.72) 10 -0.65 (1.31) 0.2 % 1.54 [ 0.37, 2.71 ]
Kunikane 2001b 18 1.72 (1.1) 9 -0.65 (1.31) 0.3 % 2.37 [ 1.37, 3.37 ]
Kurz 1997 23 3.26 (1.98) 12 0.25 (1.66) 0.2 % 3.01 [ 1.77, 4.25 ]
Leyland-Jones 2005 81 0.34 (1.73) 86 0.14 (1.7) 1.2 % 0.20 [ -0.32, 0.72 ]
Littlewood 2001 244 2.2 (2.18) 115 0.5 (1.79) 1.8 % 1.70 [ 1.27, 2.13 ]
ML17620 2006 61 2.12 (1.64) 60 0.59 (1.83) 0.9 % 1.53 [ 0.91, 2.15 ]
Mystakidou 2005 50 2.4 (1.3) 50 -0.1 (1.02) 1.6 % 2.50 [ 2.04, 2.96 ]
O’Shaughnessy 2005 47 0.8 (1.2) 46 -2.1 (1.4) 1.2 % 2.90 [ 2.37, 3.43 ]
Oberhoff 1998 59 2.24 (2) 47 0.6 (1.43) 0.8 % 1.64 [ 0.99, 2.29 ]
Pirker 2008 270 -1.13 (1.93) 279 -1.98 (1.87) 3.3 % 0.85 [ 0.53, 1.17 ]
Pronzato 2010 107 1.7 (1.35) 109 0.4 (1.24) 2.8 % 1.30 [ 0.95, 1.65 ]
Ten Bokkel 1998a 34 0.66 (1.76) 12 -0.57 (1.16) 0.4 % 1.23 [ 0.35, 2.11 ]
Ten Bokkel 1998b 27 1.04 (1.73) 12 -0.57 (1.16) 0.4 % 1.61 [ 0.68, 2.54 ]
Thomas 2002 62 1.9 (1.74) 65 0.39 (1.38) 1.1 % 1.51 [ 0.96, 2.06 ]
Thomas 2008 52 1.72 (1.79) 57 0.09 (1.23) 1.0 % 1.63 [ 1.05, 2.21 ]
Throuvalas 2000 28 0.7 (0.95) 26 -0.5 (0.56) 1.9 % 1.20 [ 0.79, 1.61 ]
Tjulandin 2010a 76 1.6 (1.42) 37 0.2 (1.74) 0.8 % 1.40 [ 0.75, 2.05 ]
Tjulandin 2010b 73 1.9 (1.74) 37 0.2 (1.74) 0.7 % 1.70 [ 1.01, 2.39 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Untch 2011˙1 330 -0.07 (2) 359 -0.98 (1.33) 5.1 % 0.91 [ 0.65, 1.17 ]
Wilkinson 2006 114 1.6 (1.5) 59 0.3 (1.3) 1.8 % 1.30 [ 0.87, 1.73 ]
Witzig 2005 166 2.8 (1.62) 164 0.9 (1.52) 2.9 % 1.90 [ 1.56, 2.24 ]
Subtotal (95% CI) 3375 2887 65.0 % 1.76 [ 1.68, 1.83 ]
Heterogeneity: Chi2 = 355.14, df = 44 (P<0.00001); I2 =88%
Test for overall effect: Z = 48.21 (P < 0.00001)
2 haematological malignancies
Cazzola 1995a 31 -0.1 (2.23) 7 -0.04 (2.05) 0.1 % -0.06 [ -1.77, 1.65 ]
Cazzola 1995b 29 0.17 (1.72) 8 -0.04 (2.05) 0.1 % 0.21 [ -1.34, 1.76 ]
Cazzola 1995c 31 0.3 (2.9) 7 -0.04 (2.05) 0.1 % 0.34 [ -1.49, 2.17 ]
Cazzola 1995d 26 0.44 (2.29) 7 -0.04 (2.05) 0.1 % 0.48 [ -1.28, 2.24 ]
Dammacco 2001 69 1.8 (2.11) 76 -0.2 (1.31) 1.0 % 2.00 [ 1.42, 2.58 ]
Engert 2009 648 -1.88 (1.78) 655 -2.55 (1.78) 8.9 % 0.67 [ 0.48, 0.86 ]
Hedenus 2002a 5 1.56 (1.93) 2 1 (0.56) 0.1 % 0.56 [ -1.30, 2.42 ]
Hedenus 2002b 17 1.64 (1.25) 2 1 (0.56) 0.3 % 0.64 [ -0.34, 1.62 ]
Hedenus 2002c 14 2.46 (1.49) 2 1 (0.56) 0.3 % 1.46 [ 0.36, 2.56 ]
Hedenus 2003 174 1.8 (2.24) 170 0.19 (1.3) 2.2 % 1.61 [ 1.22, 2.00 ]
ML17616 2006 30 3.09 (2.08) 30 1.76 (2.28) 0.3 % 1.33 [ 0.23, 2.43 ]
Osterborg 1996a 17 2.6 (1.74) 13 1.02 (1.28) 0.3 % 1.58 [ 0.50, 2.66 ]
Osterborg 1996b 27 1.71 (1.67) 14 1.02 (1.28) 0.4 % 0.69 [ -0.23, 1.61 ]
Osterborg 2002 138 2.48 (1.74) 142 0.82 (1.4) 2.4 % 1.66 [ 1.29, 2.03 ]
Subtotal (95% CI) 1256 1135 16.6 % 1.05 [ 0.90, 1.19 ]
Heterogeneity: Chi2 = 50.66, df = 13 (P<0.00001); I2 =74%
Test for overall effect: Z = 14.51 (P < 0.00001)
3 MDS
Italian 1998 17 1.73 (1.56) 11 -0.14 (1.09) 0.3 % 1.87 [ 0.89, 2.85 ]
Subtotal (95% CI) 17 11 0.3 % 1.87 [ 0.89, 2.85 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.73 (P = 0.00019)
4 mixed
Abels 1993 63 0.952 (2.142) 55 -0.03 (1.36) 0.8 % 0.99 [ 0.35, 1.63 ]
Boogaerts 2003 133 2.1 (1.83) 129 0.9 (1.5) 2.0 % 1.20 [ 0.80, 1.60 ]
Case 1993 79 2.346 (2.04) 74 0.37 (1.46) 1.1 % 1.97 [ 1.41, 2.53 ]
Charu 2007 220 2.1 (1.854) 55 0.1 (0.927) 2.8 % 2.00 [ 1.65, 2.35 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Gordon 2008 139 1.3 (1.4) 49 0.2 (1) 2.5 % 1.10 [ 0.74, 1.46 ]
Henry 1995 63 2.04 (2.38) 61 0.44 (1.7) 0.6 % 1.60 [ 0.87, 2.33 ]
Krzakowski 2008a 104 2.5 (2.4) 52 0.6 (1.7) 0.8 % 1.90 [ 1.25, 2.55 ]
Krzakowski 2008b 105 2.5 (2.6) 52 0.6 (1.7) 0.7 % 1.90 [ 1.22, 2.58 ]
Razzouk 2006 111 1.3 (2.38) 111 1 (1.9) 1.0 % 0.30 [ -0.27, 0.87 ]
Smith 2003a 21 1.18 (2.01) 7 0 (0.91) 0.3 % 1.18 [ 0.09, 2.27 ]
Smith 2003b 21 1.22 (1.62) 7 0 (0.91) 0.4 % 1.22 [ 0.25, 2.19 ]
Smith 2003c 22 1.7 (1.93) 8 0 (0.91) 0.3 % 1.70 [ 0.68, 2.72 ]
Smith 2008 437 0.79 (2.83) 447 0.29 (2.8) 2.4 % 0.50 [ 0.13, 0.87 ]
Tjulandin 2011 95 2.1 (1.3) 91 0.65 (1.94) 1.5 % 1.45 [ 0.97, 1.93 ]
Tsuboi 2009 61 1.4 (1.9) 56 -0.8 (1.5) 0.9 % 2.20 [ 1.58, 2.82 ]
Subtotal (95% CI) 1674 1254 18.0 % 1.35 [ 1.21, 1.48 ]
Heterogeneity: Chi2 = 68.95, df = 14 (P<0.00001); I2 =80%
Test for overall effect: Z = 19.48 (P < 0.00001)
5 unclear
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 6322 5287 100.0 % 1.57 [ 1.51, 1.62 ]
Heterogeneity: Chi2 = 564.37, df = 74 (P<0.00001); I2 =87%
Test for overall effect: Z = 53.27 (P < 0.00001)
Test for subgroup differences: Chi2 = 89.61, df = 3 (P = 0.00), I2 =97%
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Analysis 2.4. Comparison 2 Change of haemoglobin level, Outcome 4 Change in Hb values - age.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 2 Change of haemoglobin level
Outcome: 4 Change in Hb values - age





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 children
Razzouk 2006 111 1.3 (2.38) 111 1 (1.9) 1.0 % 0.30 [ -0.27, 0.87 ]
Subtotal (95% CI) 111 111 1.0 % 0.30 [ -0.27, 0.87 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
2 adults
Abels 1993 63 0.952 (2.142) 55 -0.03 (1.36) 0.8 % 0.99 [ 0.35, 1.63 ]
Aravantinos 2003 24 2.31 (1.22) 23 1.23 (1.59) 0.5 % 1.08 [ 0.27, 1.89 ]
Bamias 2003 72 0.57 (2.12) 72 -0.49 (1.36) 1.0 % 1.06 [ 0.48, 1.64 ]
Boogaerts 2003 133 2.1 (1.83) 129 0.9 (1.5) 2.0 % 1.20 [ 0.80, 1.60 ]
Carabantes 1999 20 1 (1.56) 15 -1.7 (1.22) 0.4 % 2.70 [ 1.78, 3.62 ]
Cascinu 1994 50 1.88 (0.83) 49 -0.61 (0.95) 2.7 % 2.49 [ 2.14, 2.84 ]
Case 1993 79 2.346 (2.04) 74 0.37 (1.46) 1.1 % 1.97 [ 1.41, 2.53 ]
Cazzola 1995a 31 -0.1 (2.23) 7 -0.04 (2.05) 0.1 % -0.06 [ -1.77, 1.65 ]
Cazzola 1995b 29 0.17 (1.72) 8 -0.04 (2.05) 0.1 % 0.21 [ -1.34, 1.76 ]
Cazzola 1995c 31 0.3 (2.9) 7 -0.04 (2.05) 0.1 % 0.34 [ -1.49, 2.17 ]
Cazzola 1995d 26 0.44 (2.29) 7 -0.04 (2.05) 0.1 % 0.48 [ -1.28, 2.24 ]
Chang 2005 175 1.14 (0.8) 175 -0.58 (0.73) 12.9 % 1.72 [ 1.56, 1.88 ]
Charu 2007 220 2.1 (1.854) 55 0.1 (0.927) 2.8 % 2.00 [ 1.65, 2.35 ]
Christodoulou 2009 167 2.74 (13.62) 170 0.52 (4.18) 0.1 % 2.22 [ 0.06, 4.38 ]
Dammacco 2001 69 1.8 (2.11) 76 -0.2 (1.31) 1.0 % 2.00 [ 1.42, 2.58 ]
Del Mastro 1997 28 -0.8 (1.4) 24 -3.05 (1) 0.8 % 2.25 [ 1.60, 2.90 ]
Engert 2009 648 -1.88 (1.78) 655 -2.55 (1.78) 8.9 % 0.67 [ 0.48, 0.86 ]
Fujisaka 2011 89 1.84 (1.33) 92 0.02 (1.12) 2.6 % 1.82 [ 1.46, 2.18 ]
Gebbia 2003 22 -2.4 (1.5) 23 -5.1 (1.33) 0.5 % 2.70 [ 1.87, 3.53 ]
Gordon 2008 139 1.3 (1.4) 49 0.2 (1) 2.5 % 1.10 [ 0.74, 1.46 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Grote 2005 64 -0.2 (1.38) 58 -2.9 (1.53) 1.2 % 2.70 [ 2.18, 3.22 ]
Gupta 2009 58 1.55 (0.74) 57 -1.5 (0.61) 5.4 % 3.05 [ 2.80, 3.30 ]
Hedenus 2002a 5 1.56 (1.93) 2 1 (0.56) 0.1 % 0.56 [ -1.30, 2.42 ]
Hedenus 2002b 17 1.64 (1.25) 2 1 (0.56) 0.3 % 0.64 [ -0.34, 1.62 ]
Hedenus 2002c 14 2.46 (1.49) 2 1 (0.56) 0.3 % 1.46 [ 0.36, 2.56 ]
Hedenus 2003 174 1.8 (2.24) 170 0.19 (1.3) 2.2 % 1.61 [ 1.22, 2.00 ]
Henke 1999a 19 3.2 (1.6) 3 0.6 (1.4) 0.1 % 2.60 [ 0.86, 4.34 ]
Henke 1999b 14 3.5 (1.2) 4 0.6 (1.4) 0.1 % 2.90 [ 1.39, 4.41 ]
Henke 1999c 6 3.9 (2.1) 4 0.6 (1.4) 0.1 % 3.30 [ 1.13, 5.47 ]
Henke 2003 Roche 2004 178 3.4 (1.7) 168 0.9 (1.7) 2.6 % 2.50 [ 2.14, 2.86 ]
Henry 1995 63 2.04 (2.38) 61 0.44 (1.7) 0.6 % 1.60 [ 0.87, 2.33 ]
Hoskin 2009 151 0.625 (3.5) 149 -0.47 (3.48) 0.5 % 1.09 [ 0.30, 1.88 ]
Huddart 2002 45 2.6 (2) 45 1.2 (1.46) 0.6 % 1.40 [ 0.68, 2.12 ]
Iconomou 2003 57 1.7 (1.6) 55 0.3 (1.4) 1.1 % 1.40 [ 0.84, 1.96 ]
Italian 1998 17 1.73 (1.56) 11 -0.14 (1.09) 0.3 % 1.87 [ 0.89, 2.85 ]
Kotasek 2003a 32 0.54 (1.24) 8 -0.02 (1.43) 0.3 % 0.56 [ -0.52, 1.64 ]
Kotasek 2003b 17 0.86 (1.57) 8 -0.02 (1.43) 0.2 % 0.88 [ -0.36, 2.12 ]
Kotasek 2003c 46 0.9 (1.63) 9 -0.02 (1.43) 0.3 % 0.92 [ -0.13, 1.97 ]
Kotasek 2003d 28 1.63 (2.01) 8 -0.02 (1.43) 0.2 % 1.65 [ 0.41, 2.89 ]
Kotasek 2003e 35 1.45 (1.42) 8 -0.02 (1.43) 0.3 % 1.47 [ 0.37, 2.57 ]
Kotasek 2003f 40 1.21 (1.9) 9 -0.02 (1.43) 0.3 % 1.23 [ 0.13, 2.33 ]
Krzakowski 2008a 104 2.5 (2.4) 52 0.6 (1.7) 0.8 % 1.90 [ 1.25, 2.55 ]
Krzakowski 2008b 105 2.5 (2.6) 52 0.6 (1.7) 0.7 % 1.90 [ 1.22, 2.58 ]
Kunikane 2001a 16 0.89 (1.72) 10 -0.65 (1.31) 0.2 % 1.54 [ 0.37, 2.71 ]
Kunikane 2001b 18 1.72 (1.1) 9 -0.65 (1.31) 0.3 % 2.37 [ 1.37, 3.37 ]
Kurz 1997 23 3.26 (1.98) 12 0.25 (1.66) 0.2 % 3.01 [ 1.77, 4.25 ]
Leyland-Jones 2005 81 0.34 (1.73) 86 0.14 (1.7) 1.2 % 0.20 [ -0.32, 0.72 ]
Littlewood 2001 244 2.2 (2.18) 115 0.5 (1.79) 1.8 % 1.70 [ 1.27, 2.13 ]
ML17616 2006 30 3.09 (2.08) 30 1.76 (2.28) 0.3 % 1.33 [ 0.23, 2.43 ]
ML17620 2006 61 2.12 (1.64) 60 0.59 (1.83) 0.9 % 1.53 [ 0.91, 2.15 ]
Mystakidou 2005 50 2.4 (1.3) 50 -0.1 (1.02) 1.6 % 2.50 [ 2.04, 2.96 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
O’Shaughnessy 2005 47 0.8 (1.2) 46 -2.1 (1.4) 1.2 % 2.90 [ 2.37, 3.43 ]
Oberhoff 1998 59 2.24 (2) 47 0.6 (1.43) 0.8 % 1.64 [ 0.99, 2.29 ]
Osterborg 1996a 17 2.6 (1.74) 13 1.02 (1.28) 0.3 % 1.58 [ 0.50, 2.66 ]
Osterborg 1996b 27 1.71 (1.67) 14 1.02 (1.28) 0.4 % 0.69 [ -0.23, 1.61 ]
Osterborg 2002 138 2.48 (1.74) 142 0.82 (1.4) 2.4 % 1.66 [ 1.29, 2.03 ]
Pirker 2008 270 -1.13 (1.93) 279 -1.98 (1.87) 3.3 % 0.85 [ 0.53, 1.17 ]
Pronzato 2010 107 1.7 (1.35) 109 0.4 (1.24) 2.8 % 1.30 [ 0.95, 1.65 ]
Smith 2003a 21 1.18 (2.01) 7 0 (0.91) 0.3 % 1.18 [ 0.09, 2.27 ]
Smith 2003b 21 1.22 (1.62) 7 0 (0.91) 0.4 % 1.22 [ 0.25, 2.19 ]
Smith 2003c 22 1.7 (1.93) 8 0 (0.91) 0.3 % 1.70 [ 0.68, 2.72 ]
Smith 2008 437 0.79 (2.83) 447 0.29 (2.8) 2.4 % 0.50 [ 0.13, 0.87 ]
Ten Bokkel 1998a 34 0.66 (1.76) 12 -0.57 (1.16) 0.4 % 1.23 [ 0.35, 2.11 ]
Ten Bokkel 1998b 27 1.04 (1.73) 12 -0.57 (1.16) 0.4 % 1.61 [ 0.68, 2.54 ]
Thomas 2002 62 1.9 (1.74) 65 0.39 (1.38) 1.1 % 1.51 [ 0.96, 2.06 ]
Thomas 2008 52 1.72 (1.79) 57 0.09 (1.23) 1.0 % 1.63 [ 1.05, 2.21 ]
Throuvalas 2000 28 0.7 (0.95) 26 -0.5 (0.56) 1.9 % 1.20 [ 0.79, 1.61 ]
Tjulandin 2010a 76 1.6 (1.42) 37 0.2 (1.74) 0.8 % 1.40 [ 0.75, 2.05 ]
Tjulandin 2010b 73 1.9 (1.74) 37 0.2 (1.74) 0.7 % 1.70 [ 1.01, 2.39 ]
Tjulandin 2011 95 2.1 (1.3) 91 0.65 (1.94) 1.5 % 1.45 [ 0.97, 1.93 ]
Tsuboi 2009 61 1.4 (1.9) 56 -0.8 (1.5) 0.9 % 2.20 [ 1.58, 2.82 ]
Untch 2011˙1 330 -0.07 (2) 359 -0.98 (1.33) 5.1 % 0.91 [ 0.65, 1.17 ]
Wilkinson 2006 114 1.6 (1.5) 59 0.3 (1.3) 1.8 % 1.30 [ 0.87, 1.73 ]
Witzig 2005 166 2.8 (1.62) 164 0.9 (1.52) 2.9 % 1.90 [ 1.56, 2.24 ]
Subtotal (95% CI) 6211 5176 99.0 % 1.58 [ 1.52, 1.64 ]
Heterogeneity: Chi2 = 545.01, df = 73 (P<0.00001); I2 =87%
Test for overall effect: Z = 53.45 (P < 0.00001)
Total (95% CI) 6322 5287 100.0 % 1.57 [ 1.51, 1.62 ]
Heterogeneity: Chi2 = 564.37, df = 74 (P<0.00001); I2 =87%
Test for overall effect: Z = 53.27 (P < 0.00001)
Test for subgroup differences: Chi2 = 19.35, df = 1 (P = 0.00), I2 =95%
-10 -5 0 5 10
Favours control Favours treatment
254Erythropoietin or darbepoetin for patients with cancer (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.5. Comparison 2 Change of haemoglobin level, Outcome 5 Change in Hb values - age
differentiated.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 2 Change of haemoglobin level
Outcome: 5 Change in Hb values - age differentiated





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 only children <18 years
Razzouk 2006 111 1.3 (2.38) 111 1 (1.9) 1.0 % 0.30 [ -0.27, 0.87 ]
Subtotal (95% CI) 111 111 1.0 % 0.30 [ -0.27, 0.87 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
2 adults≥18 years
Abels 1993 63 0.952 (2.142) 55 -0.03 (1.36) 0.8 % 0.99 [ 0.35, 1.63 ]
Aravantinos 2003 24 2.31 (1.22) 23 1.23 (1.59) 0.5 % 1.08 [ 0.27, 1.89 ]
Bamias 2003 72 0.57 (2.12) 72 -0.49 (1.36) 1.0 % 1.06 [ 0.48, 1.64 ]
Boogaerts 2003 133 2.1 (1.83) 129 0.9 (1.5) 2.0 % 1.20 [ 0.80, 1.60 ]
Carabantes 1999 20 1 (1.56) 15 -1.7 (1.22) 0.4 % 2.70 [ 1.78, 3.62 ]
Case 1993 79 2.346 (2.04) 74 0.37 (1.46) 1.1 % 1.97 [ 1.41, 2.53 ]
Cazzola 1995a 31 -0.1 (2.23) 7 -0.04 (2.05) 0.1 % -0.06 [ -1.77, 1.65 ]
Cazzola 1995b 29 0.17 (1.72) 8 -0.04 (2.05) 0.1 % 0.21 [ -1.34, 1.76 ]
Cazzola 1995c 31 0.3 (2.9) 7 -0.04 (2.05) 0.1 % 0.34 [ -1.49, 2.17 ]
Cazzola 1995d 26 0.44 (2.29) 7 -0.04 (2.05) 0.1 % 0.48 [ -1.28, 2.24 ]
Charu 2007 220 2.1 (1.854) 55 0.1 (0.927) 2.8 % 2.00 [ 1.65, 2.35 ]
Christodoulou 2009 167 2.74 (13.62) 170 0.52 (4.18) 0.1 % 2.22 [ 0.06, 4.38 ]
Dammacco 2001 69 1.8 (2.11) 76 -0.2 (1.31) 1.0 % 2.00 [ 1.42, 2.58 ]
Fujisaka 2011 89 1.84 (1.33) 92 0.02 (1.12) 2.6 % 1.82 [ 1.46, 2.18 ]
Gordon 2008 139 1.3 (1.4) 49 0.2 (1) 2.5 % 1.10 [ 0.74, 1.46 ]
Grote 2005 64 -0.2 (1.38) 58 -2.9 (1.53) 1.2 % 2.70 [ 2.18, 3.22 ]
Hedenus 2002a 5 1.56 (1.93) 2 1 (0.56) 0.1 % 0.56 [ -1.30, 2.42 ]
Hedenus 2002b 17 1.64 (1.25) 2 1 (0.56) 0.3 % 0.64 [ -0.34, 1.62 ]
Hedenus 2002c 14 2.46 (1.49) 2 1 (0.56) 0.3 % 1.46 [ 0.36, 2.56 ]
Hedenus 2003 174 1.8 (2.24) 170 0.19 (1.3) 2.2 % 1.61 [ 1.22, 2.00 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Henke 1999a 19 3.2 (1.6) 3 0.6 (1.4) 0.1 % 2.60 [ 0.86, 4.34 ]
Henke 1999b 14 3.5 (1.2) 4 0.6 (1.4) 0.1 % 2.90 [ 1.39, 4.41 ]
Henke 1999c 6 3.9 (2.1) 4 0.6 (1.4) 0.1 % 3.30 [ 1.13, 5.47 ]
Henke 2003 Roche 2004 178 3.4 (1.7) 168 0.9 (1.7) 2.6 % 2.50 [ 2.14, 2.86 ]
Henry 1995 63 2.04 (2.38) 61 0.44 (1.7) 0.6 % 1.60 [ 0.87, 2.33 ]
Hoskin 2009 151 0.625 (3.5) 149 -0.47 (3.48) 0.5 % 1.09 [ 0.30, 1.88 ]
Huddart 2002 45 2.6 (2) 45 1.2 (1.46) 0.6 % 1.40 [ 0.68, 2.12 ]
Iconomou 2003 57 1.7 (1.6) 55 0.3 (1.4) 1.1 % 1.40 [ 0.84, 1.96 ]
Italian 1998 17 1.73 (1.56) 11 -0.14 (1.09) 0.3 % 1.87 [ 0.89, 2.85 ]
Kotasek 2003a 32 0.54 (1.24) 8 -0.02 (1.43) 0.3 % 0.56 [ -0.52, 1.64 ]
Kotasek 2003b 17 0.86 (1.57) 8 -0.02 (1.43) 0.2 % 0.88 [ -0.36, 2.12 ]
Kotasek 2003c 46 0.9 (1.63) 9 -0.02 (1.43) 0.3 % 0.92 [ -0.13, 1.97 ]
Kotasek 2003d 28 1.63 (2.01) 8 -0.02 (1.43) 0.2 % 1.65 [ 0.41, 2.89 ]
Kotasek 2003e 35 1.45 (1.42) 8 -0.02 (1.43) 0.3 % 1.47 [ 0.37, 2.57 ]
Kotasek 2003f 40 1.21 (1.9) 9 -0.02 (1.43) 0.3 % 1.23 [ 0.13, 2.33 ]
Krzakowski 2008a 104 2.5 (2.4) 52 0.6 (1.7) 0.8 % 1.90 [ 1.25, 2.55 ]
Krzakowski 2008b 105 2.5 (2.6) 52 0.6 (1.7) 0.7 % 1.90 [ 1.22, 2.58 ]
Kunikane 2001a 16 0.89 (1.72) 10 -0.65 (1.31) 0.2 % 1.54 [ 0.37, 2.71 ]
Kunikane 2001b 18 1.72 (1.1) 9 -0.65 (1.31) 0.3 % 2.37 [ 1.37, 3.37 ]
Leyland-Jones 2005 81 0.34 (1.73) 86 0.14 (1.7) 1.2 % 0.20 [ -0.32, 0.72 ]
Littlewood 2001 244 2.2 (2.18) 115 0.5 (1.79) 1.8 % 1.70 [ 1.27, 2.13 ]
ML17616 2006 30 3.09 (2.08) 30 1.76 (2.28) 0.3 % 1.33 [ 0.23, 2.43 ]
ML17620 2006 61 2.12 (1.64) 60 0.59 (1.83) 0.9 % 1.53 [ 0.91, 2.15 ]
Mystakidou 2005 50 2.4 (1.3) 50 -0.1 (1.02) 1.6 % 2.50 [ 2.04, 2.96 ]
O’Shaughnessy 2005 47 0.8 (1.2) 46 -2.1 (1.4) 1.2 % 2.90 [ 2.37, 3.43 ]
Osterborg 1996a 17 2.6 (1.74) 13 1.02 (1.28) 0.3 % 1.58 [ 0.50, 2.66 ]
Osterborg 1996b 27 1.71 (1.67) 14 1.02 (1.28) 0.4 % 0.69 [ -0.23, 1.61 ]
Osterborg 2002 138 2.48 (1.74) 142 0.82 (1.4) 2.4 % 1.66 [ 1.29, 2.03 ]
Pirker 2008 270 -1.13 (1.93) 279 -1.98 (1.87) 3.3 % 0.85 [ 0.53, 1.17 ]
Smith 2003a 21 1.18 (2.01) 7 0 (0.91) 0.3 % 1.18 [ 0.09, 2.27 ]
Smith 2003b 21 1.22 (1.62) 7 0 (0.91) 0.4 % 1.22 [ 0.25, 2.19 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Smith 2003c 22 1.7 (1.93) 8 0 (0.91) 0.3 % 1.70 [ 0.68, 2.72 ]
Smith 2008 437 0.79 (2.83) 447 0.29 (2.8) 2.4 % 0.50 [ 0.13, 0.87 ]
Ten Bokkel 1998a 34 0.66 (1.76) 12 -0.57 (1.16) 0.4 % 1.23 [ 0.35, 2.11 ]
Ten Bokkel 1998b 27 1.04 (1.73) 12 -0.57 (1.16) 0.4 % 1.61 [ 0.68, 2.54 ]
Thomas 2002 62 1.9 (1.74) 65 0.39 (1.38) 1.1 % 1.51 [ 0.96, 2.06 ]
Tjulandin 2010a 76 1.6 (1.42) 37 0.2 (1.74) 0.8 % 1.40 [ 0.75, 2.05 ]
Tjulandin 2010b 73 1.9 (1.74) 37 0.2 (1.74) 0.7 % 1.70 [ 1.01, 2.39 ]
Tjulandin 2011 95 2.1 (1.3) 91 0.65 (1.94) 1.5 % 1.45 [ 0.97, 1.93 ]
Tsuboi 2009 61 1.4 (1.9) 56 -0.8 (1.5) 0.9 % 2.20 [ 1.58, 2.82 ]
Wilkinson 2006 114 1.6 (1.5) 59 0.3 (1.3) 1.8 % 1.30 [ 0.87, 1.73 ]
Witzig 2005 166 2.8 (1.62) 164 0.9 (1.52) 2.9 % 1.90 [ 1.56, 2.24 ]
Subtotal (95% CI) 4631 3583 56.1 % 1.57 [ 1.49, 1.64 ]
Heterogeneity: Chi2 = 247.47, df = 61 (P<0.00001); I2 =75%
Test for overall effect: Z = 39.91 (P < 0.00001)
3 > 70% non-elderly 18-65 years
Cascinu 1994 50 1.88 (0.83) 49 -0.61 (0.95) 2.7 % 2.49 [ 2.14, 2.84 ]
Chang 2005 175 1.14 (0.8) 175 -0.58 (0.73) 12.9 % 1.72 [ 1.56, 1.88 ]
Del Mastro 1997 28 -0.8 (1.4) 24 -3.05 (1) 0.8 % 2.25 [ 1.60, 2.90 ]
Gupta 2009 58 1.55 (0.74) 57 -1.5 (0.61) 5.4 % 3.05 [ 2.80, 3.30 ]
Kurz 1997 23 3.26 (1.98) 12 0.25 (1.66) 0.2 % 3.01 [ 1.77, 4.25 ]
Oberhoff 1998 59 2.24 (2) 47 0.6 (1.43) 0.8 % 1.64 [ 0.99, 2.29 ]
Pronzato 2010 107 1.7 (1.35) 109 0.4 (1.24) 2.8 % 1.30 [ 0.95, 1.65 ]
Thomas 2008 52 1.72 (1.79) 57 0.09 (1.23) 1.0 % 1.63 [ 1.05, 2.21 ]
Throuvalas 2000 28 0.7 (0.95) 26 -0.5 (0.56) 1.9 % 1.20 [ 0.79, 1.61 ]
Subtotal (95% CI) 580 556 28.4 % 1.99 [ 1.88, 2.10 ]
Heterogeneity: Chi2 = 124.16, df = 8 (P<0.00001); I2 =94%
Test for overall effect: Z = 36.07 (P < 0.00001)
4 only non-elderly adults
Engert 2009 648 -1.88 (1.78) 655 -2.55 (1.78) 8.9 % 0.67 [ 0.48, 0.86 ]
Untch 2011˙1 330 -0.07 (2) 359 -0.98 (1.33) 5.1 % 0.91 [ 0.65, 1.17 ]
Subtotal (95% CI) 978 1014 13.9 % 0.76 [ 0.60, 0.91 ]
Heterogeneity: Chi2 = 2.15, df = 1 (P = 0.14); I2 =54%
Test for overall effect: Z = 9.62 (P < 0.00001)
5 > 70% elderly >65 years
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
6 only elderly adults
Gebbia 2003 22 -2.4 (1.5) 23 -5.1 (1.33) 0.5 % 2.70 [ 1.87, 3.53 ]
Subtotal (95% CI) 22 23 0.5 % 2.70 [ 1.87, 3.53 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.38 (P < 0.00001)
Total (95% CI) 6322 5287 100.0 % 1.57 [ 1.51, 1.62 ]
Heterogeneity: Chi2 = 564.37, df = 74 (P<0.00001); I2 =87%
Test for overall effect: Z = 53.27 (P < 0.00001)
Test for subgroup differences: Chi2 = 190.59, df = 4 (P = 0.00), I2 =98%
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Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 2 Change of haemoglobin level
Outcome: 6 Change in Hb values - different therapies





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 chemotherapy
Aravantinos 2003 24 2.31 (1.22) 23 1.23 (1.59) 0.5 % 1.08 [ 0.27, 1.89 ]
Bamias 2003 72 0.57 (2.12) 72 -0.49 (1.36) 1.0 % 1.06 [ 0.48, 1.64 ]
Boogaerts 2003 133 2.1 (1.83) 129 0.9 (1.5) 2.0 % 1.20 [ 0.80, 1.60 ]
Carabantes 1999 20 1 (1.56) 15 -1.7 (1.22) 0.4 % 2.70 [ 1.78, 3.62 ]
Cascinu 1994 50 1.88 (0.83) 49 -0.61 (0.95) 2.7 % 2.49 [ 2.14, 2.84 ]
Case 1993 79 2.346 (2.04) 74 0.37 (1.46) 1.1 % 1.97 [ 1.41, 2.53 ]
Cazzola 1995a 31 -0.1 (2.23) 7 -0.04 (2.05) 0.1 % -0.06 [ -1.77, 1.65 ]
Cazzola 1995b 29 0.17 (1.72) 8 -0.04 (2.05) 0.1 % 0.21 [ -1.34, 1.76 ]
Cazzola 1995c 31 0.3 (2.9) 7 -0.04 (2.05) 0.1 % 0.34 [ -1.49, 2.17 ]
Cazzola 1995d 26 0.44 (2.29) 7 -0.04 (2.05) 0.1 % 0.48 [ -1.28, 2.24 ]
Chang 2005 175 1.14 (0.8) 175 -0.58 (0.73) 12.9 % 1.72 [ 1.56, 1.88 ]
Christodoulou 2009 167 2.74 (13.62) 170 0.52 (4.18) 0.1 % 2.22 [ 0.06, 4.38 ]
Dammacco 2001 69 1.8 (2.11) 76 -0.2 (1.31) 1.0 % 2.00 [ 1.42, 2.58 ]
Del Mastro 1997 28 -0.8 (1.4) 24 -3.05 (1) 0.8 % 2.25 [ 1.60, 2.90 ]
Engert 2009 648 -1.88 (1.78) 655 -2.55 (1.78) 8.9 % 0.67 [ 0.48, 0.86 ]
Fujisaka 2011 89 1.84 (1.33) 92 0.02 (1.12) 2.6 % 1.82 [ 1.46, 2.18 ]
Gebbia 2003 22 -2.4 (1.5) 23 -5.1 (1.33) 0.5 % 2.70 [ 1.87, 3.53 ]
Grote 2005 64 -0.2 (1.38) 58 -2.9 (1.53) 1.2 % 2.70 [ 2.18, 3.22 ]
Hedenus 2002a 5 1.56 (1.93) 2 1 (0.56) 0.1 % 0.56 [ -1.30, 2.42 ]
Hedenus 2002b 17 1.64 (1.25) 2 1 (0.56) 0.3 % 0.64 [ -0.34, 1.62 ]
Hedenus 2002c 14 2.46 (1.49) 2 1 (0.56) 0.3 % 1.46 [ 0.36, 2.56 ]
Hedenus 2003 174 1.8 (2.24) 170 0.19 (1.3) 2.2 % 1.61 [ 1.22, 2.00 ]
Henry 1995 63 2.04 (2.38) 61 0.44 (1.7) 0.6 % 1.60 [ 0.87, 2.33 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Huddart 2002 45 2.6 (2) 45 1.2 (1.46) 0.6 % 1.40 [ 0.68, 2.12 ]
Iconomou 2003 57 1.7 (1.6) 55 0.3 (1.4) 1.1 % 1.40 [ 0.84, 1.96 ]
Kotasek 2003a 32 0.54 (1.24) 8 -0.02 (1.43) 0.3 % 0.56 [ -0.52, 1.64 ]
Kotasek 2003b 17 0.86 (1.57) 8 -0.02 (1.43) 0.2 % 0.88 [ -0.36, 2.12 ]
Kotasek 2003c 46 0.9 (1.63) 9 -0.02 (1.43) 0.3 % 0.92 [ -0.13, 1.97 ]
Kotasek 2003d 28 1.63 (2.01) 8 -0.02 (1.43) 0.2 % 1.65 [ 0.41, 2.89 ]
Kotasek 2003e 35 1.45 (1.42) 8 -0.02 (1.43) 0.3 % 1.47 [ 0.37, 2.57 ]
Kotasek 2003f 40 1.21 (1.9) 9 -0.02 (1.43) 0.3 % 1.23 [ 0.13, 2.33 ]
Krzakowski 2008a 104 2.5 (2.4) 52 0.6 (1.7) 0.8 % 1.90 [ 1.25, 2.55 ]
Krzakowski 2008b 105 2.5 (2.6) 52 0.6 (1.7) 0.7 % 1.90 [ 1.22, 2.58 ]
Kunikane 2001a 16 0.89 (1.72) 10 -0.65 (1.31) 0.2 % 1.54 [ 0.37, 2.71 ]
Kunikane 2001b 18 1.72 (1.1) 9 -0.65 (1.31) 0.3 % 2.37 [ 1.37, 3.37 ]
Kurz 1997 23 3.26 (1.98) 12 0.25 (1.66) 0.2 % 3.01 [ 1.77, 4.25 ]
Leyland-Jones 2005 81 0.34 (1.73) 86 0.14 (1.7) 1.2 % 0.20 [ -0.32, 0.72 ]
Littlewood 2001 244 2.2 (2.18) 115 0.5 (1.79) 1.8 % 1.70 [ 1.27, 2.13 ]
ML17616 2006 30 3.09 (2.08) 30 1.76 (2.28) 0.3 % 1.33 [ 0.23, 2.43 ]
ML17620 2006 61 2.12 (1.64) 60 0.59 (1.83) 0.9 % 1.53 [ 0.91, 2.15 ]
O’Shaughnessy 2005 47 0.8 (1.2) 46 -2.1 (1.4) 1.2 % 2.90 [ 2.37, 3.43 ]
Oberhoff 1998 59 2.24 (2) 47 0.6 (1.43) 0.8 % 1.64 [ 0.99, 2.29 ]
Osterborg 1996a 17 2.6 (1.74) 13 1.02 (1.28) 0.3 % 1.58 [ 0.50, 2.66 ]
Osterborg 1996b 27 1.71 (1.67) 14 1.02 (1.28) 0.4 % 0.69 [ -0.23, 1.61 ]
Osterborg 2002 138 2.48 (1.74) 142 0.82 (1.4) 2.4 % 1.66 [ 1.29, 2.03 ]
Pirker 2008 270 -1.13 (1.93) 279 -1.98 (1.87) 3.3 % 0.85 [ 0.53, 1.17 ]
Pronzato 2010 107 1.7 (1.35) 109 0.4 (1.24) 2.8 % 1.30 [ 0.95, 1.65 ]
Razzouk 2006 111 1.3 (2.38) 111 1 (1.9) 1.0 % 0.30 [ -0.27, 0.87 ]
Ten Bokkel 1998a 34 0.66 (1.76) 12 -0.57 (1.16) 0.4 % 1.23 [ 0.35, 2.11 ]
Ten Bokkel 1998b 27 1.04 (1.73) 12 -0.57 (1.16) 0.4 % 1.61 [ 0.68, 2.54 ]
Thomas 2002 62 1.9 (1.74) 65 0.39 (1.38) 1.1 % 1.51 [ 0.96, 2.06 ]
Tjulandin 2010a 76 1.6 (1.42) 37 0.2 (1.74) 0.8 % 1.40 [ 0.75, 2.05 ]
Tjulandin 2010b 73 1.9 (1.74) 37 0.2 (1.74) 0.7 % 1.70 [ 1.01, 2.39 ]
Tjulandin 2011 95 2.1 (1.3) 91 0.65 (1.94) 1.5 % 1.45 [ 0.97, 1.93 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Tsuboi 2009 61 1.4 (1.9) 56 -0.8 (1.5) 0.9 % 2.20 [ 1.58, 2.82 ]
Untch 2011˙1 330 -0.07 (2) 359 -0.98 (1.33) 5.1 % 0.91 [ 0.65, 1.17 ]
Wilkinson 2006 114 1.6 (1.5) 59 0.3 (1.3) 1.8 % 1.30 [ 0.87, 1.73 ]
Witzig 2005 166 2.8 (1.62) 164 0.9 (1.52) 2.9 % 1.90 [ 1.56, 2.24 ]
Subtotal (95% CI) 4826 4130 76.9 % 1.46 [ 1.39, 1.52 ]
Heterogeneity: Chi2 = 313.83, df = 57 (P<0.00001); I2 =82%
Test for overall effect: Z = 43.46 (P < 0.00001)
2 radiotherapy/radiochemotherapy
Gupta 2009 58 1.55 (0.74) 57 -1.5 (0.61) 5.4 % 3.05 [ 2.80, 3.30 ]
Henke 1999a 19 3.2 (1.6) 3 0.6 (1.4) 0.1 % 2.60 [ 0.86, 4.34 ]
Henke 1999b 14 3.5 (1.2) 4 0.6 (1.4) 0.1 % 2.90 [ 1.39, 4.41 ]
Henke 1999c 6 3.9 (2.1) 4 0.6 (1.4) 0.1 % 3.30 [ 1.13, 5.47 ]
Henke 2003 Roche 2004 178 3.4 (1.7) 168 0.9 (1.7) 2.6 % 2.50 [ 2.14, 2.86 ]
Hoskin 2009 151 0.625 (3.5) 149 -0.47 (3.48) 0.5 % 1.09 [ 0.30, 1.88 ]
Thomas 2008 52 1.72 (1.79) 57 0.09 (1.23) 1.0 % 1.63 [ 1.05, 2.21 ]
Throuvalas 2000 28 0.7 (0.95) 26 -0.5 (0.56) 1.9 % 1.20 [ 0.79, 1.61 ]
Subtotal (95% CI) 506 468 11.8 % 2.41 [ 2.24, 2.58 ]
Heterogeneity: Chi2 = 77.61, df = 7 (P<0.00001); I2 =91%
Test for overall effect: Z = 28.17 (P < 0.00001)
3 no therapy
Abels 1993 63 0.952 (2.142) 55 -0.03 (1.36) 0.8 % 0.99 [ 0.35, 1.63 ]
Charu 2007 220 2.1 (1.854) 55 0.1 (0.927) 2.8 % 2.00 [ 1.65, 2.35 ]
Gordon 2008 139 1.3 (1.4) 49 0.2 (1) 2.5 % 1.10 [ 0.74, 1.46 ]
Italian 1998 17 1.73 (1.56) 11 -0.14 (1.09) 0.3 % 1.87 [ 0.89, 2.85 ]
Mystakidou 2005 50 2.4 (1.3) 50 -0.1 (1.02) 1.6 % 2.50 [ 2.04, 2.96 ]
Smith 2003a 21 1.18 (2.01) 7 0 (0.91) 0.3 % 1.18 [ 0.09, 2.27 ]
Smith 2003b 21 1.22 (1.62) 7 0 (0.91) 0.4 % 1.22 [ 0.25, 2.19 ]
Smith 2003c 22 1.7 (1.93) 8 0 (0.91) 0.3 % 1.70 [ 0.68, 2.72 ]
Smith 2008 437 0.79 (2.83) 447 0.29 (2.8) 2.4 % 0.50 [ 0.13, 0.87 ]
Subtotal (95% CI) 990 689 11.4 % 1.42 [ 1.25, 1.60 ]
Heterogeneity: Chi2 = 61.90, df = 8 (P<0.00001); I2 =87%
Test for overall effect: Z = 16.34 (P < 0.00001)
Total (95% CI) 6322 5287 100.0 % 1.57 [ 1.51, 1.62 ]
Heterogeneity: Chi2 = 564.37, df = 74 (P<0.00001); I2 =87%
Test for overall effect: Z = 53.27 (P < 0.00001)
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Test for subgroup differences: Chi2 = 111.03, df = 2 (P = 0.00), I2 =98%
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Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 2 Change of haemoglobin level
Outcome: 7 Change in Hb values - different therapies differentiated





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 chemotherapy, >70% with platinum
Aravantinos 2003 24 2.31 (1.22) 23 1.23 (1.59) 0.5 % 1.08 [ 0.27, 1.89 ]
Bamias 2003 72 0.57 (2.12) 72 -0.49 (1.36) 1.0 % 1.06 [ 0.48, 1.64 ]
Carabantes 1999 20 1 (1.56) 15 -1.7 (1.22) 0.4 % 2.70 [ 1.78, 3.62 ]
Cascinu 1994 50 1.88 (0.83) 49 -0.61 (0.95) 2.7 % 2.49 [ 2.14, 2.84 ]
Fujisaka 2011 89 1.84 (1.33) 92 0.02 (1.12) 2.6 % 1.82 [ 1.46, 2.18 ]
Gebbia 2003 22 -2.4 (1.5) 23 -5.1 (1.33) 0.5 % 2.70 [ 1.87, 3.53 ]
Grote 2005 64 -0.2 (1.38) 58 -2.9 (1.53) 1.2 % 2.70 [ 2.18, 3.22 ]
Henry 1995 63 2.04 (2.38) 61 0.44 (1.7) 0.6 % 1.60 [ 0.87, 2.33 ]
Huddart 2002 45 2.6 (2) 45 1.2 (1.46) 0.6 % 1.40 [ 0.68, 2.12 ]
Kunikane 2001a 16 0.89 (1.72) 10 -0.65 (1.31) 0.2 % 1.54 [ 0.37, 2.71 ]
Kunikane 2001b 18 1.72 (1.1) 9 -0.65 (1.31) 0.3 % 2.37 [ 1.37, 3.37 ]
Kurz 1997 23 3.26 (1.98) 12 0.25 (1.66) 0.2 % 3.01 [ 1.77, 4.25 ]
ML17620 2006 61 2.12 (1.64) 60 0.59 (1.83) 0.9 % 1.53 [ 0.91, 2.15 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Pirker 2008 270 -1.13 (1.93) 279 -1.98 (1.87) 3.3 % 0.85 [ 0.53, 1.17 ]
Ten Bokkel 1998a 34 0.66 (1.76) 12 -0.57 (1.16) 0.4 % 1.23 [ 0.35, 2.11 ]
Ten Bokkel 1998b 27 1.04 (1.73) 12 -0.57 (1.16) 0.4 % 1.61 [ 0.68, 2.54 ]
Tjulandin 2010a 76 1.6 (1.42) 37 0.2 (1.74) 0.8 % 1.40 [ 0.75, 2.05 ]
Tjulandin 2010b 73 1.9 (1.74) 37 0.2 (1.74) 0.7 % 1.70 [ 1.01, 2.39 ]
Wilkinson 2006 114 1.6 (1.5) 59 0.3 (1.3) 1.8 % 1.30 [ 0.87, 1.73 ]
Subtotal (95% CI) 1161 965 19.1 % 1.68 [ 1.55, 1.82 ]
Heterogeneity: Chi2 = 90.83, df = 18 (P<0.00001); I2 =80%
Test for overall effect: Z = 25.07 (P < 0.00001)
2 chemotherapy, <70% platinum containing
Christodoulou 2009 167 2.74 (13.62) 170 0.52 (4.18) 0.1 % 2.22 [ 0.06, 4.38 ]
Iconomou 2003 57 1.7 (1.6) 55 0.3 (1.4) 1.1 % 1.40 [ 0.84, 1.96 ]
Krzakowski 2008a 104 2.5 (2.4) 52 0.6 (1.7) 0.8 % 1.90 [ 1.25, 2.55 ]
Krzakowski 2008b 105 2.5 (2.6) 52 0.6 (1.7) 0.7 % 1.90 [ 1.22, 2.58 ]
Oberhoff 1998 59 2.24 (2) 47 0.6 (1.43) 0.8 % 1.64 [ 0.99, 2.29 ]
Tsuboi 2009 61 1.4 (1.9) 56 -0.8 (1.5) 0.9 % 2.20 [ 1.58, 2.82 ]
Witzig 2005 166 2.8 (1.62) 164 0.9 (1.52) 2.9 % 1.90 [ 1.56, 2.24 ]
Subtotal (95% CI) 719 596 7.2 % 1.84 [ 1.62, 2.05 ]
Heterogeneity: Chi2 = 4.37, df = 6 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 16.74 (P < 0.00001)
3 chemotherapy without platinum
Case 1993 79 2.346 (2.04) 74 0.37 (1.46) 1.1 % 1.97 [ 1.41, 2.53 ]
Cazzola 1995a 31 -0.1 (2.23) 7 -0.04 (2.05) 0.1 % -0.06 [ -1.77, 1.65 ]
Cazzola 1995b 29 0.17 (1.72) 8 -0.04 (2.05) 0.1 % 0.21 [ -1.34, 1.76 ]
Cazzola 1995c 31 0.3 (2.9) 7 -0.04 (2.05) 0.1 % 0.34 [ -1.49, 2.17 ]
Cazzola 1995d 26 0.44 (2.29) 7 -0.04 (2.05) 0.1 % 0.48 [ -1.28, 2.24 ]
Chang 2005 175 1.14 (0.8) 175 -0.58 (0.73) 12.9 % 1.72 [ 1.56, 1.88 ]
Del Mastro 1997 28 -0.8 (1.4) 24 -3.05 (1) 0.8 % 2.25 [ 1.60, 2.90 ]
Engert 2009 648 -1.88 (1.78) 655 -2.55 (1.78) 8.9 % 0.67 [ 0.48, 0.86 ]
Hedenus 2002a 5 1.56 (1.93) 2 1 (0.56) 0.1 % 0.56 [ -1.30, 2.42 ]
Hedenus 2002b 17 1.64 (1.25) 2 1 (0.56) 0.3 % 0.64 [ -0.34, 1.62 ]
Hedenus 2002c 14 2.46 (1.49) 2 1 (0.56) 0.3 % 1.46 [ 0.36, 2.56 ]
Hedenus 2003 174 1.8 (2.24) 170 0.19 (1.3) 2.2 % 1.61 [ 1.22, 2.00 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Leyland-Jones 2005 81 0.34 (1.73) 86 0.14 (1.7) 1.2 % 0.20 [ -0.32, 0.72 ]
Littlewood 2001 244 2.2 (2.18) 115 0.5 (1.79) 1.8 % 1.70 [ 1.27, 2.13 ]
ML17616 2006 30 3.09 (2.08) 30 1.76 (2.28) 0.3 % 1.33 [ 0.23, 2.43 ]
O’Shaughnessy 2005 47 0.8 (1.2) 46 -2.1 (1.4) 1.2 % 2.90 [ 2.37, 3.43 ]
Osterborg 1996a 17 2.6 (1.74) 13 1.02 (1.28) 0.3 % 1.58 [ 0.50, 2.66 ]
Osterborg 1996b 27 1.71 (1.67) 14 1.02 (1.28) 0.4 % 0.69 [ -0.23, 1.61 ]
Osterborg 2002 138 2.48 (1.74) 142 0.82 (1.4) 2.4 % 1.66 [ 1.29, 2.03 ]
Pronzato 2010 107 1.7 (1.35) 109 0.4 (1.24) 2.8 % 1.30 [ 0.95, 1.65 ]
Tjulandin 2011 95 2.1 (1.3) 91 0.65 (1.94) 1.5 % 1.45 [ 0.97, 1.93 ]
Untch 2011˙1 330 -0.07 (2) 359 -0.98 (1.33) 5.1 % 0.91 [ 0.65, 1.17 ]
Subtotal (95% CI) 2373 2138 43.9 % 1.33 [ 1.25, 1.42 ]
Heterogeneity: Chi2 = 161.70, df = 21 (P<0.00001); I2 =87%
Test for overall effect: Z = 30.05 (P < 0.00001)
4 chemotherapy, platinum and non-platinum containing, no numbers given
Boogaerts 2003 133 2.1 (1.83) 129 0.9 (1.5) 2.0 % 1.20 [ 0.80, 1.60 ]
Dammacco 2001 69 1.8 (2.11) 76 -0.2 (1.31) 1.0 % 2.00 [ 1.42, 2.58 ]
Kotasek 2003a 32 0.54 (1.24) 8 -0.02 (1.43) 0.3 % 0.56 [ -0.52, 1.64 ]
Kotasek 2003b 17 0.86 (1.57) 8 -0.02 (1.43) 0.2 % 0.88 [ -0.36, 2.12 ]
Kotasek 2003c 46 0.9 (1.63) 9 -0.02 (1.43) 0.3 % 0.92 [ -0.13, 1.97 ]
Kotasek 2003d 28 1.63 (2.01) 8 -0.02 (1.43) 0.2 % 1.65 [ 0.41, 2.89 ]
Kotasek 2003e 35 1.45 (1.42) 8 -0.02 (1.43) 0.3 % 1.47 [ 0.37, 2.57 ]
Kotasek 2003f 40 1.21 (1.9) 9 -0.02 (1.43) 0.3 % 1.23 [ 0.13, 2.33 ]
Thomas 2002 62 1.9 (1.74) 65 0.39 (1.38) 1.1 % 1.51 [ 0.96, 2.06 ]
Subtotal (95% CI) 462 320 5.7 % 1.37 [ 1.13, 1.61 ]
Heterogeneity: Chi2 = 9.25, df = 8 (P = 0.32); I2 =13%
Test for overall effect: Z = 11.14 (P < 0.00001)
5 chemotherapy, no details given
Razzouk 2006 111 1.3 (2.38) 111 1 (1.9) 1.0 % 0.30 [ -0.27, 0.87 ]
Subtotal (95% CI) 111 111 1.0 % 0.30 [ -0.27, 0.87 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
6 radiotherapy
Henke 1999a 19 3.2 (1.6) 3 0.6 (1.4) 0.1 % 2.60 [ 0.86, 4.34 ]
Henke 1999b 14 3.5 (1.2) 4 0.6 (1.4) 0.1 % 2.90 [ 1.39, 4.41 ]
-10 -5 0 5 10
Favours Control Favours Treatment
(Continued . . . )
264Erythropoietin or darbepoetin for patients with cancer (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Henke 1999c 6 3.9 (2.1) 4 0.6 (1.4) 0.1 % 3.30 [ 1.13, 5.47 ]
Henke 2003 Roche 2004 178 3.4 (1.7) 168 0.9 (1.7) 2.6 % 2.50 [ 2.14, 2.86 ]
Hoskin 2009 151 0.625 (3.5) 149 -0.47 (3.48) 0.5 % 1.09 [ 0.30, 1.88 ]
Subtotal (95% CI) 368 328 3.4 % 2.32 [ 2.01, 2.63 ]
Heterogeneity: Chi2 = 11.68, df = 4 (P = 0.02); I2 =66%
Test for overall effect: Z = 14.64 (P < 0.00001)
7 radiochemotherapy
Gupta 2009 58 1.55 (0.74) 57 -1.5 (0.61) 5.4 % 3.05 [ 2.80, 3.30 ]
Thomas 2008 52 1.72 (1.79) 57 0.09 (1.23) 1.0 % 1.63 [ 1.05, 2.21 ]
Throuvalas 2000 28 0.7 (0.95) 26 -0.5 (0.56) 1.9 % 1.20 [ 0.79, 1.61 ]
Subtotal (95% CI) 138 140 8.3 % 2.45 [ 2.25, 2.65 ]
Heterogeneity: Chi2 = 65.45, df = 2 (P<0.00001); I2 =97%
Test for overall effect: Z = 24.08 (P < 0.00001)
8 no therapy
Abels 1993 63 0.952 (2.142) 55 -0.03 (1.36) 0.8 % 0.99 [ 0.35, 1.63 ]
Charu 2007 220 2.1 (1.854) 55 0.1 (0.927) 2.8 % 2.00 [ 1.65, 2.35 ]
Gordon 2008 139 1.3 (1.4) 49 0.2 (1) 2.5 % 1.10 [ 0.74, 1.46 ]
Italian 1998 17 1.73 (1.56) 11 -0.14 (1.09) 0.3 % 1.87 [ 0.89, 2.85 ]
Mystakidou 2005 50 2.4 (1.3) 50 -0.1 (1.02) 1.6 % 2.50 [ 2.04, 2.96 ]
Smith 2003a 21 1.18 (2.01) 7 0 (0.91) 0.3 % 1.18 [ 0.09, 2.27 ]
Smith 2003b 21 1.22 (1.62) 7 0 (0.91) 0.4 % 1.22 [ 0.25, 2.19 ]
Smith 2003c 22 1.7 (1.93) 8 0 (0.91) 0.3 % 1.70 [ 0.68, 2.72 ]
Smith 2008 437 0.79 (2.83) 447 0.29 (2.8) 2.4 % 0.50 [ 0.13, 0.87 ]
Subtotal (95% CI) 990 689 11.4 % 1.42 [ 1.25, 1.60 ]
Heterogeneity: Chi2 = 61.90, df = 8 (P<0.00001); I2 =87%
Test for overall effect: Z = 16.34 (P < 0.00001)
Total (95% CI) 6322 5287 100.0 % 1.57 [ 1.51, 1.62 ]
Heterogeneity: Chi2 = 564.37, df = 74 (P<0.00001); I2 =87%
Test for overall effect: Z = 53.27 (P < 0.00001)
Test for subgroup differences: Chi2 = 159.20, df = 7 (P = 0.00), I2 =96%
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Analysis 2.8. Comparison 2 Change of haemoglobin level, Outcome 8 Change in Hb values - epoetin vs
darbepoetin.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 2 Change of haemoglobin level
Outcome: 8 Change in Hb values - epoetin vs darbepoetin





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Epoetin
Abels 1993 63 0.952 (2.142) 55 -0.03 (1.36) 0.8 % 0.99 [ 0.35, 1.63 ]
Aravantinos 2003 24 2.31 (1.22) 23 1.23 (1.59) 0.5 % 1.08 [ 0.27, 1.89 ]
Bamias 2003 72 0.57 (2.12) 72 -0.49 (1.36) 1.0 % 1.06 [ 0.48, 1.64 ]
Boogaerts 2003 133 2.1 (1.83) 129 0.9 (1.5) 2.0 % 1.20 [ 0.80, 1.60 ]
Carabantes 1999 20 1 (1.56) 15 -1.7 (1.22) 0.4 % 2.70 [ 1.78, 3.62 ]
Cascinu 1994 50 1.88 (0.83) 49 -0.61 (0.95) 2.7 % 2.49 [ 2.14, 2.84 ]
Case 1993 79 2.346 (2.04) 74 0.37 (1.46) 1.1 % 1.97 [ 1.41, 2.53 ]
Cazzola 1995a 31 -0.1 (2.23) 7 -0.04 (2.05) 0.1 % -0.06 [ -1.77, 1.65 ]
Cazzola 1995b 29 0.17 (1.72) 8 -0.04 (2.05) 0.1 % 0.21 [ -1.34, 1.76 ]
Cazzola 1995c 31 0.3 (2.9) 7 -0.04 (2.05) 0.1 % 0.34 [ -1.49, 2.17 ]
Cazzola 1995d 26 0.44 (2.29) 7 -0.04 (2.05) 0.1 % 0.48 [ -1.28, 2.24 ]
Chang 2005 175 1.14 (0.8) 175 -0.58 (0.73) 12.9 % 1.72 [ 1.56, 1.88 ]
Christodoulou 2009 167 2.74 (13.62) 170 0.52 (4.18) 0.1 % 2.22 [ 0.06, 4.38 ]
Dammacco 2001 69 1.8 (2.11) 76 -0.2 (1.31) 1.0 % 2.00 [ 1.42, 2.58 ]
Del Mastro 1997 28 -0.8 (1.4) 24 -3.05 (1) 0.8 % 2.25 [ 1.60, 2.90 ]
Engert 2009 648 -1.88 (1.78) 655 -2.55 (1.78) 8.9 % 0.67 [ 0.48, 0.86 ]
Fujisaka 2011 89 1.84 (1.33) 92 0.02 (1.12) 2.6 % 1.82 [ 1.46, 2.18 ]
Gebbia 2003 22 -2.4 (1.5) 23 -5.1 (1.33) 0.5 % 2.70 [ 1.87, 3.53 ]
Grote 2005 64 -0.2 (1.38) 58 -2.9 (1.53) 1.2 % 2.70 [ 2.18, 3.22 ]
Gupta 2009 58 1.55 (0.74) 57 -1.5 (0.61) 5.4 % 3.05 [ 2.80, 3.30 ]
Henke 1999a 19 3.2 (1.6) 3 0.6 (1.4) 0.1 % 2.60 [ 0.86, 4.34 ]
Henke 1999b 14 3.5 (1.2) 4 0.6 (1.4) 0.1 % 2.90 [ 1.39, 4.41 ]
Henke 1999c 6 3.9 (2.1) 4 0.6 (1.4) 0.1 % 3.30 [ 1.13, 5.47 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Henke 2003 Roche 2004 178 3.4 (1.7) 168 0.9 (1.7) 2.6 % 2.50 [ 2.14, 2.86 ]
Henry 1995 63 2.04 (2.38) 61 0.44 (1.7) 0.6 % 1.60 [ 0.87, 2.33 ]
Hoskin 2009 151 0.625 (3.5) 149 -0.47 (3.48) 0.5 % 1.09 [ 0.30, 1.88 ]
Huddart 2002 45 2.6 (2) 45 1.2 (1.46) 0.6 % 1.40 [ 0.68, 2.12 ]
Iconomou 2003 57 1.7 (1.6) 55 0.3 (1.4) 1.1 % 1.40 [ 0.84, 1.96 ]
Italian 1998 17 1.73 (1.56) 11 -0.14 (1.09) 0.3 % 1.87 [ 0.89, 2.85 ]
Krzakowski 2008a 104 2.5 (2.4) 52 0.6 (1.7) 0.8 % 1.90 [ 1.25, 2.55 ]
Krzakowski 2008b 105 2.5 (2.6) 52 0.6 (1.7) 0.7 % 1.90 [ 1.22, 2.58 ]
Kunikane 2001a 16 0.89 (1.72) 10 -0.65 (1.31) 0.2 % 1.54 [ 0.37, 2.71 ]
Kunikane 2001b 18 1.72 (1.1) 9 -0.65 (1.31) 0.3 % 2.37 [ 1.37, 3.37 ]
Kurz 1997 23 3.26 (1.98) 12 0.25 (1.66) 0.2 % 3.01 [ 1.77, 4.25 ]
Leyland-Jones 2005 81 0.34 (1.73) 86 0.14 (1.7) 1.2 % 0.20 [ -0.32, 0.72 ]
Littlewood 2001 244 2.2 (2.18) 115 0.5 (1.79) 1.8 % 1.70 [ 1.27, 2.13 ]
ML17616 2006 30 3.09 (2.08) 30 1.76 (2.28) 0.3 % 1.33 [ 0.23, 2.43 ]
ML17620 2006 61 2.12 (1.64) 60 0.59 (1.83) 0.9 % 1.53 [ 0.91, 2.15 ]
Mystakidou 2005 50 2.4 (1.3) 50 -0.1 (1.02) 1.6 % 2.50 [ 2.04, 2.96 ]
O’Shaughnessy 2005 47 0.8 (1.2) 46 -2.1 (1.4) 1.2 % 2.90 [ 2.37, 3.43 ]
Oberhoff 1998 59 2.24 (2) 47 0.6 (1.43) 0.8 % 1.64 [ 0.99, 2.29 ]
Osterborg 1996a 17 2.6 (1.74) 13 1.02 (1.28) 0.3 % 1.58 [ 0.50, 2.66 ]
Osterborg 1996b 27 1.71 (1.67) 14 1.02 (1.28) 0.4 % 0.69 [ -0.23, 1.61 ]
Osterborg 2002 138 2.48 (1.74) 142 0.82 (1.4) 2.4 % 1.66 [ 1.29, 2.03 ]
Pronzato 2010 107 1.7 (1.35) 109 0.4 (1.24) 2.8 % 1.30 [ 0.95, 1.65 ]
Razzouk 2006 111 1.3 (2.38) 111 1 (1.9) 1.0 % 0.30 [ -0.27, 0.87 ]
Ten Bokkel 1998a 34 0.66 (1.76) 12 -0.57 (1.16) 0.4 % 1.23 [ 0.35, 2.11 ]
Ten Bokkel 1998b 27 1.04 (1.73) 12 -0.57 (1.16) 0.4 % 1.61 [ 0.68, 2.54 ]
Thomas 2002 62 1.9 (1.74) 65 0.39 (1.38) 1.1 % 1.51 [ 0.96, 2.06 ]
Thomas 2008 52 1.72 (1.79) 57 0.09 (1.23) 1.0 % 1.63 [ 1.05, 2.21 ]
Throuvalas 2000 28 0.7 (0.95) 26 -0.5 (0.56) 1.9 % 1.20 [ 0.79, 1.61 ]
Tjulandin 2010a 76 1.6 (1.42) 37 0.2 (1.74) 0.8 % 1.40 [ 0.75, 2.05 ]
Tjulandin 2010b 73 1.9 (1.74) 37 0.2 (1.74) 0.7 % 1.70 [ 1.01, 2.39 ]
Tjulandin 2011 95 2.1 (1.3) 91 0.65 (1.94) 1.5 % 1.45 [ 0.97, 1.93 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Tsuboi 2009 61 1.4 (1.9) 56 -0.8 (1.5) 0.9 % 2.20 [ 1.58, 2.82 ]
Wilkinson 2006 114 1.6 (1.5) 59 0.3 (1.3) 1.8 % 1.30 [ 0.87, 1.73 ]
Witzig 2005 166 2.8 (1.62) 164 0.9 (1.52) 2.9 % 1.90 [ 1.56, 2.24 ]
Subtotal (95% CI) 4454 3850 78.5 % 1.69 [ 1.62, 1.75 ]
Heterogeneity: Chi2 = 450.63, df = 56 (P<0.00001); I2 =88%
Test for overall effect: Z = 50.84 (P < 0.00001)
2 Darbepoetin
Charu 2007 220 2.1 (1.854) 55 0.1 (0.927) 2.8 % 2.00 [ 1.65, 2.35 ]
Gordon 2008 139 1.3 (1.4) 49 0.2 (1) 2.5 % 1.10 [ 0.74, 1.46 ]
Hedenus 2002a 5 1.56 (1.93) 2 1 (0.56) 0.1 % 0.56 [ -1.30, 2.42 ]
Hedenus 2002b 17 1.64 (1.25) 2 1 (0.56) 0.3 % 0.64 [ -0.34, 1.62 ]
Hedenus 2002c 14 2.46 (1.49) 2 1 (0.56) 0.3 % 1.46 [ 0.36, 2.56 ]
Hedenus 2003 174 1.8 (2.24) 170 0.19 (1.3) 2.2 % 1.61 [ 1.22, 2.00 ]
Kotasek 2003a 32 0.54 (1.24) 8 -0.02 (1.43) 0.3 % 0.56 [ -0.52, 1.64 ]
Kotasek 2003b 17 0.86 (1.57) 8 -0.02 (1.43) 0.2 % 0.88 [ -0.36, 2.12 ]
Kotasek 2003c 46 0.9 (1.63) 9 -0.02 (1.43) 0.3 % 0.92 [ -0.13, 1.97 ]
Kotasek 2003d 28 1.63 (2.01) 8 -0.02 (1.43) 0.2 % 1.65 [ 0.41, 2.89 ]
Kotasek 2003e 35 1.45 (1.42) 8 -0.02 (1.43) 0.3 % 1.47 [ 0.37, 2.57 ]
Kotasek 2003f 40 1.21 (1.9) 9 -0.02 (1.43) 0.3 % 1.23 [ 0.13, 2.33 ]
Pirker 2008 270 -1.13 (1.93) 279 -1.98 (1.87) 3.3 % 0.85 [ 0.53, 1.17 ]
Smith 2003a 21 1.18 (2.01) 7 0 (0.91) 0.3 % 1.18 [ 0.09, 2.27 ]
Smith 2003b 21 1.22 (1.62) 7 0 (0.91) 0.4 % 1.22 [ 0.25, 2.19 ]
Smith 2003c 22 1.7 (1.93) 8 0 (0.91) 0.3 % 1.70 [ 0.68, 2.72 ]
Smith 2008 437 0.79 (2.83) 447 0.29 (2.8) 2.4 % 0.50 [ 0.13, 0.87 ]
Untch 2011˙1 330 -0.07 (2) 359 -0.98 (1.33) 5.1 % 0.91 [ 0.65, 1.17 ]
Subtotal (95% CI) 1868 1437 21.5 % 1.13 [ 1.00, 1.25 ]
Heterogeneity: Chi2 = 52.43, df = 17 (P = 0.00002); I2 =68%
Test for overall effect: Z = 17.74 (P < 0.00001)
Total (95% CI) 6322 5287 100.0 % 1.57 [ 1.51, 1.62 ]
Heterogeneity: Chi2 = 564.37, df = 74 (P<0.00001); I2 =87%
Test for overall effect: Z = 53.27 (P < 0.00001)
Test for subgroup differences: Chi2 = 61.31, df = 1 (P = 0.00), I2 =98%
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Analysis 2.9. Comparison 2 Change of haemoglobin level, Outcome 9 Change in Hb values - duration of
ESA medication.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 2 Change of haemoglobin level
Outcome: 9 Change in Hb values - duration of ESA medication





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 6 to 9 weeks
Abels 1993 63 0.952 (2.142) 55 -0.03 (1.36) 0.8 % 0.99 [ 0.35, 1.63 ]
Cascinu 1994 50 1.88 (0.83) 49 -0.61 (0.95) 2.7 % 2.49 [ 2.14, 2.84 ]
Cazzola 1995a 31 -0.1 (2.23) 7 -0.04 (2.05) 0.1 % -0.06 [ -1.77, 1.65 ]
Cazzola 1995b 29 0.17 (1.72) 8 -0.04 (2.05) 0.1 % 0.21 [ -1.34, 1.76 ]
Cazzola 1995c 31 0.3 (2.9) 7 -0.04 (2.05) 0.1 % 0.34 [ -1.49, 2.17 ]
Cazzola 1995d 26 0.44 (2.29) 7 -0.04 (2.05) 0.1 % 0.48 [ -1.28, 2.24 ]
Gupta 2009 58 1.55 (0.74) 57 -1.5 (0.61) 5.4 % 3.05 [ 2.80, 3.30 ]
Henke 1999a 19 3.2 (1.6) 3 0.6 (1.4) 0.1 % 2.60 [ 0.86, 4.34 ]
Henke 1999b 14 3.5 (1.2) 4 0.6 (1.4) 0.1 % 2.90 [ 1.39, 4.41 ]
Henke 1999c 6 3.9 (2.1) 4 0.6 (1.4) 0.1 % 3.30 [ 1.13, 5.47 ]
Henke 2003 Roche 2004 178 3.4 (1.7) 168 0.9 (1.7) 2.6 % 2.50 [ 2.14, 2.86 ]
Italian 1998 17 1.73 (1.56) 11 -0.14 (1.09) 0.3 % 1.87 [ 0.89, 2.85 ]
Kunikane 2001a 16 0.89 (1.72) 10 -0.65 (1.31) 0.2 % 1.54 [ 0.37, 2.71 ]
Kunikane 2001b 18 1.72 (1.1) 9 -0.65 (1.31) 0.3 % 2.37 [ 1.37, 3.37 ]
Thomas 2008 52 1.72 (1.79) 57 0.09 (1.23) 1.0 % 1.63 [ 1.05, 2.21 ]
Throuvalas 2000 28 0.7 (0.95) 26 -0.5 (0.56) 1.9 % 1.20 [ 0.79, 1.61 ]
Tsuboi 2009 61 1.4 (1.9) 56 -0.8 (1.5) 0.9 % 2.20 [ 1.58, 2.82 ]
Subtotal (95% CI) 697 538 17.0 % 2.30 [ 2.16, 2.44 ]
Heterogeneity: Chi2 = 113.00, df = 16 (P<0.00001); I2 =86%
Test for overall effect: Z = 32.31 (P < 0.00001)
2 12 to 16 weeks
Aravantinos 2003 24 2.31 (1.22) 23 1.23 (1.59) 0.5 % 1.08 [ 0.27, 1.89 ]
Boogaerts 2003 133 2.1 (1.83) 129 0.9 (1.5) 2.0 % 1.20 [ 0.80, 1.60 ]
Case 1993 79 2.346 (2.04) 74 0.37 (1.46) 1.1 % 1.97 [ 1.41, 2.53 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Chang 2005 175 1.14 (0.8) 175 -0.58 (0.73) 12.9 % 1.72 [ 1.56, 1.88 ]
Charu 2007 220 2.1 (1.854) 55 0.1 (0.927) 2.8 % 2.00 [ 1.65, 2.35 ]
Christodoulou 2009 167 2.74 (13.62) 170 0.52 (4.18) 0.1 % 2.22 [ 0.06, 4.38 ]
Dammacco 2001 69 1.8 (2.11) 76 -0.2 (1.31) 1.0 % 2.00 [ 1.42, 2.58 ]
Del Mastro 1997 28 -0.8 (1.4) 24 -3.05 (1) 0.8 % 2.25 [ 1.60, 2.90 ]
Fujisaka 2011 89 1.84 (1.33) 92 0.02 (1.12) 2.6 % 1.82 [ 1.46, 2.18 ]
Gebbia 2003 22 -2.4 (1.5) 23 -5.1 (1.33) 0.5 % 2.70 [ 1.87, 3.53 ]
Gordon 2008 139 1.3 (1.4) 49 0.2 (1) 2.5 % 1.10 [ 0.74, 1.46 ]
Grote 2005 64 -0.2 (1.38) 58 -2.9 (1.53) 1.2 % 2.70 [ 2.18, 3.22 ]
Hedenus 2002a 5 1.56 (1.93) 2 1 (0.56) 0.1 % 0.56 [ -1.30, 2.42 ]
Hedenus 2002b 17 1.64 (1.25) 2 1 (0.56) 0.3 % 0.64 [ -0.34, 1.62 ]
Hedenus 2002c 14 2.46 (1.49) 2 1 (0.56) 0.3 % 1.46 [ 0.36, 2.56 ]
Hedenus 2003 174 1.8 (2.24) 170 0.19 (1.3) 2.2 % 1.61 [ 1.22, 2.00 ]
Henry 1995 63 2.04 (2.38) 61 0.44 (1.7) 0.6 % 1.60 [ 0.87, 2.33 ]
Hoskin 2009 151 0.625 (3.5) 149 -0.47 (3.48) 0.5 % 1.09 [ 0.30, 1.88 ]
Iconomou 2003 57 1.7 (1.6) 55 0.3 (1.4) 1.1 % 1.40 [ 0.84, 1.96 ]
Kotasek 2003a 32 0.54 (1.24) 8 -0.02 (1.43) 0.3 % 0.56 [ -0.52, 1.64 ]
Kotasek 2003b 17 0.86 (1.57) 8 -0.02 (1.43) 0.2 % 0.88 [ -0.36, 2.12 ]
Kotasek 2003c 46 0.9 (1.63) 9 -0.02 (1.43) 0.3 % 0.92 [ -0.13, 1.97 ]
Kotasek 2003d 28 1.63 (2.01) 8 -0.02 (1.43) 0.2 % 1.65 [ 0.41, 2.89 ]
Kotasek 2003e 35 1.45 (1.42) 8 -0.02 (1.43) 0.3 % 1.47 [ 0.37, 2.57 ]
Kotasek 2003f 40 1.21 (1.9) 9 -0.02 (1.43) 0.3 % 1.23 [ 0.13, 2.33 ]
Krzakowski 2008a 104 2.5 (2.4) 52 0.6 (1.7) 0.8 % 1.90 [ 1.25, 2.55 ]
Krzakowski 2008b 105 2.5 (2.6) 52 0.6 (1.7) 0.7 % 1.90 [ 1.22, 2.58 ]
Kurz 1997 23 3.26 (1.98) 12 0.25 (1.66) 0.2 % 3.01 [ 1.77, 4.25 ]
ML17616 2006 30 3.09 (2.08) 30 1.76 (2.28) 0.3 % 1.33 [ 0.23, 2.43 ]
ML17620 2006 61 2.12 (1.64) 60 0.59 (1.83) 0.9 % 1.53 [ 0.91, 2.15 ]
O’Shaughnessy 2005 47 0.8 (1.2) 46 -2.1 (1.4) 1.2 % 2.90 [ 2.37, 3.43 ]
Oberhoff 1998 59 2.24 (2) 47 0.6 (1.43) 0.8 % 1.64 [ 0.99, 2.29 ]
Osterborg 2002 138 2.48 (1.74) 142 0.82 (1.4) 2.4 % 1.66 [ 1.29, 2.03 ]
Razzouk 2006 111 1.3 (2.38) 111 1 (1.9) 1.0 % 0.30 [ -0.27, 0.87 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Smith 2003a 21 1.18 (2.01) 7 0 (0.91) 0.3 % 1.18 [ 0.09, 2.27 ]
Smith 2003b 21 1.22 (1.62) 7 0 (0.91) 0.4 % 1.22 [ 0.25, 2.19 ]
Smith 2003c 22 1.7 (1.93) 8 0 (0.91) 0.3 % 1.70 [ 0.68, 2.72 ]
Smith 2008 437 0.79 (2.83) 447 0.29 (2.8) 2.4 % 0.50 [ 0.13, 0.87 ]
Thomas 2002 62 1.9 (1.74) 65 0.39 (1.38) 1.1 % 1.51 [ 0.96, 2.06 ]
Tjulandin 2010a 76 1.6 (1.42) 37 0.2 (1.74) 0.8 % 1.40 [ 0.75, 2.05 ]
Tjulandin 2010b 73 1.9 (1.74) 37 0.2 (1.74) 0.7 % 1.70 [ 1.01, 2.39 ]
Tjulandin 2011 95 2.1 (1.3) 91 0.65 (1.94) 1.5 % 1.45 [ 0.97, 1.93 ]
Witzig 2005 166 2.8 (1.62) 164 0.9 (1.52) 2.9 % 1.90 [ 1.56, 2.24 ]
Subtotal (95% CI) 3539 2854 53.1 % 1.62 [ 1.54, 1.70 ]
Heterogeneity: Chi2 = 155.84, df = 42 (P<0.00001); I2 =73%
Test for overall effect: Z = 40.16 (P < 0.00001)
3 more than 17 weeks
Bamias 2003 72 0.57 (2.12) 72 -0.49 (1.36) 1.0 % 1.06 [ 0.48, 1.64 ]
Carabantes 1999 20 1 (1.56) 15 -1.7 (1.22) 0.4 % 2.70 [ 1.78, 3.62 ]
Engert 2009 648 -1.88 (1.78) 655 -2.55 (1.78) 8.9 % 0.67 [ 0.48, 0.86 ]
Huddart 2002 45 2.6 (2) 45 1.2 (1.46) 0.6 % 1.40 [ 0.68, 2.12 ]
Leyland-Jones 2005 81 0.34 (1.73) 86 0.14 (1.7) 1.2 % 0.20 [ -0.32, 0.72 ]
Littlewood 2001 244 2.2 (2.18) 115 0.5 (1.79) 1.8 % 1.70 [ 1.27, 2.13 ]
Mystakidou 2005 50 2.4 (1.3) 50 -0.1 (1.02) 1.6 % 2.50 [ 2.04, 2.96 ]
Osterborg 1996a 17 2.6 (1.74) 13 1.02 (1.28) 0.3 % 1.58 [ 0.50, 2.66 ]
Osterborg 1996b 27 1.71 (1.67) 14 1.02 (1.28) 0.4 % 0.69 [ -0.23, 1.61 ]
Pirker 2008 270 -1.13 (1.93) 279 -1.98 (1.87) 3.3 % 0.85 [ 0.53, 1.17 ]
Pronzato 2010 107 1.7 (1.35) 109 0.4 (1.24) 2.8 % 1.30 [ 0.95, 1.65 ]
Ten Bokkel 1998a 34 0.66 (1.76) 12 -0.57 (1.16) 0.4 % 1.23 [ 0.35, 2.11 ]
Ten Bokkel 1998b 27 1.04 (1.73) 12 -0.57 (1.16) 0.4 % 1.61 [ 0.68, 2.54 ]
Untch 2011˙1 330 -0.07 (2) 359 -0.98 (1.33) 5.1 % 0.91 [ 0.65, 1.17 ]
Wilkinson 2006 114 1.6 (1.5) 59 0.3 (1.3) 1.8 % 1.30 [ 0.87, 1.73 ]
Subtotal (95% CI) 2086 1895 29.9 % 1.05 [ 0.95, 1.16 ]
Heterogeneity: Chi2 = 94.78, df = 14 (P<0.00001); I2 =85%
Test for overall effect: Z = 19.55 (P < 0.00001)
Total (95% CI) 6322 5287 100.0 % 1.57 [ 1.51, 1.62 ]
Heterogeneity: Chi2 = 564.37, df = 74 (P<0.00001); I2 =87%
Test for overall effect: Z = 53.27 (P < 0.00001)
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Test for subgroup differences: Chi2 = 200.75, df = 2 (P = 0.00), I2 =99%
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Analysis 2.10. Comparison 2 Change of haemoglobin level, Outcome 10 Change in Hb values - iron
supplementation.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 2 Change of haemoglobin level
Outcome: 10 Change in Hb values - iron supplementation





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 fixed iron supplementation
Aravantinos 2003 24 2.31 (1.22) 23 1.23 (1.59) 0.5 % 1.08 [ 0.27, 1.89 ]
Christodoulou 2009 167 2.74 (13.62) 170 0.52 (4.18) 0.1 % 2.22 [ 0.06, 4.38 ]
Gupta 2009 58 1.55 (0.74) 57 -1.5 (0.61) 5.4 % 3.05 [ 2.80, 3.30 ]
Henke 1999a 19 3.2 (1.6) 3 0.6 (1.4) 0.1 % 2.60 [ 0.86, 4.34 ]
Henke 1999b 14 3.5 (1.2) 4 0.6 (1.4) 0.1 % 2.90 [ 1.39, 4.41 ]
Henke 1999c 6 3.9 (2.1) 4 0.6 (1.4) 0.1 % 3.30 [ 1.13, 5.47 ]
Hoskin 2009 151 0.625 (3.5) 149 -0.47 (3.48) 0.5 % 1.09 [ 0.30, 1.88 ]
Huddart 2002 45 2.6 (2) 45 1.2 (1.46) 0.6 % 1.40 [ 0.68, 2.12 ]
Iconomou 2003 57 1.7 (1.6) 55 0.3 (1.4) 1.1 % 1.40 [ 0.84, 1.96 ]
Krzakowski 2008a 104 2.5 (2.4) 52 0.6 (1.7) 0.8 % 1.90 [ 1.25, 2.55 ]
Krzakowski 2008b 105 2.5 (2.6) 52 0.6 (1.7) 0.7 % 1.90 [ 1.22, 2.58 ]
Mystakidou 2005 50 2.4 (1.3) 50 -0.1 (1.02) 1.6 % 2.50 [ 2.04, 2.96 ]
Untch 2011˙1 330 -0.07 (2) 359 -0.98 (1.33) 5.1 % 0.91 [ 0.65, 1.17 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Witzig 2005 166 2.8 (1.62) 164 0.9 (1.52) 2.9 % 1.90 [ 1.56, 2.24 ]
Subtotal (95% CI) 1296 1187 19.6 % 1.94 [ 1.81, 2.07 ]
Heterogeneity: Chi2 = 163.36, df = 13 (P<0.00001); I2 =92%
Test for overall effect: Z = 29.23 (P < 0.00001)
2 iron supplementation as necessary
Abels 1993 63 0.952 (2.142) 55 -0.03 (1.36) 0.8 % 0.99 [ 0.35, 1.63 ]
Boogaerts 2003 133 2.1 (1.83) 129 0.9 (1.5) 2.0 % 1.20 [ 0.80, 1.60 ]
Cascinu 1994 50 1.88 (0.83) 49 -0.61 (0.95) 2.7 % 2.49 [ 2.14, 2.84 ]
Case 1993 79 2.346 (2.04) 74 0.37 (1.46) 1.1 % 1.97 [ 1.41, 2.53 ]
Cazzola 1995a 31 -0.1 (2.23) 7 -0.04 (2.05) 0.1 % -0.06 [ -1.77, 1.65 ]
Cazzola 1995b 29 0.17 (1.72) 8 -0.04 (2.05) 0.1 % 0.21 [ -1.34, 1.76 ]
Cazzola 1995c 31 0.3 (2.9) 7 -0.04 (2.05) 0.1 % 0.34 [ -1.49, 2.17 ]
Cazzola 1995d 26 0.44 (2.29) 7 -0.04 (2.05) 0.1 % 0.48 [ -1.28, 2.24 ]
Chang 2005 175 1.14 (0.8) 175 -0.58 (0.73) 12.9 % 1.72 [ 1.56, 1.88 ]
Charu 2007 220 2.1 (1.854) 55 0.1 (0.927) 2.8 % 2.00 [ 1.65, 2.35 ]
Dammacco 2001 69 1.8 (2.11) 76 -0.2 (1.31) 1.0 % 2.00 [ 1.42, 2.58 ]
Del Mastro 1997 28 -0.8 (1.4) 24 -3.05 (1) 0.8 % 2.25 [ 1.60, 2.90 ]
Engert 2009 648 -1.88 (1.78) 655 -2.55 (1.78) 8.9 % 0.67 [ 0.48, 0.86 ]
Fujisaka 2011 89 1.84 (1.33) 92 0.02 (1.12) 2.6 % 1.82 [ 1.46, 2.18 ]
Gordon 2008 139 1.3 (1.4) 49 0.2 (1) 2.5 % 1.10 [ 0.74, 1.46 ]
Grote 2005 64 -0.2 (1.38) 58 -2.9 (1.53) 1.2 % 2.70 [ 2.18, 3.22 ]
Hedenus 2003 174 1.8 (2.24) 170 0.19 (1.3) 2.2 % 1.61 [ 1.22, 2.00 ]
Henke 2003 Roche 2004 178 3.4 (1.7) 168 0.9 (1.7) 2.6 % 2.50 [ 2.14, 2.86 ]
Henry 1995 63 2.04 (2.38) 61 0.44 (1.7) 0.6 % 1.60 [ 0.87, 2.33 ]
Italian 1998 17 1.73 (1.56) 11 -0.14 (1.09) 0.3 % 1.87 [ 0.89, 2.85 ]
Kotasek 2003a 32 0.54 (1.24) 8 -0.02 (1.43) 0.3 % 0.56 [ -0.52, 1.64 ]
Kotasek 2003b 17 0.86 (1.57) 8 -0.02 (1.43) 0.2 % 0.88 [ -0.36, 2.12 ]
Kotasek 2003c 46 0.9 (1.63) 9 -0.02 (1.43) 0.3 % 0.92 [ -0.13, 1.97 ]
Kotasek 2003d 28 1.63 (2.01) 8 -0.02 (1.43) 0.2 % 1.65 [ 0.41, 2.89 ]
Kotasek 2003e 35 1.45 (1.42) 8 -0.02 (1.43) 0.3 % 1.47 [ 0.37, 2.57 ]
Kotasek 2003f 40 1.21 (1.9) 9 -0.02 (1.43) 0.3 % 1.23 [ 0.13, 2.33 ]
Kurz 1997 23 3.26 (1.98) 12 0.25 (1.66) 0.2 % 3.01 [ 1.77, 4.25 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Leyland-Jones 2005 81 0.34 (1.73) 86 0.14 (1.7) 1.2 % 0.20 [ -0.32, 0.72 ]
Littlewood 2001 244 2.2 (2.18) 115 0.5 (1.79) 1.8 % 1.70 [ 1.27, 2.13 ]
ML17616 2006 30 3.09 (2.08) 30 1.76 (2.28) 0.3 % 1.33 [ 0.23, 2.43 ]
ML17620 2006 61 2.12 (1.64) 60 0.59 (1.83) 0.9 % 1.53 [ 0.91, 2.15 ]
O’Shaughnessy 2005 47 0.8 (1.2) 46 -2.1 (1.4) 1.2 % 2.90 [ 2.37, 3.43 ]
Oberhoff 1998 59 2.24 (2) 47 0.6 (1.43) 0.8 % 1.64 [ 0.99, 2.29 ]
Osterborg 1996a 17 2.6 (1.74) 13 1.02 (1.28) 0.3 % 1.58 [ 0.50, 2.66 ]
Osterborg 1996b 27 1.71 (1.67) 14 1.02 (1.28) 0.4 % 0.69 [ -0.23, 1.61 ]
Osterborg 2002 138 2.48 (1.74) 142 0.82 (1.4) 2.4 % 1.66 [ 1.29, 2.03 ]
Pirker 2008 270 -1.13 (1.93) 279 -1.98 (1.87) 3.3 % 0.85 [ 0.53, 1.17 ]
Pronzato 2010 107 1.7 (1.35) 109 0.4 (1.24) 2.8 % 1.30 [ 0.95, 1.65 ]
Razzouk 2006 111 1.3 (2.38) 111 1 (1.9) 1.0 % 0.30 [ -0.27, 0.87 ]
Smith 2003a 21 1.18 (2.01) 7 0 (0.91) 0.3 % 1.18 [ 0.09, 2.27 ]
Smith 2003b 21 1.22 (1.62) 7 0 (0.91) 0.4 % 1.22 [ 0.25, 2.19 ]
Smith 2003c 22 1.7 (1.93) 8 0 (0.91) 0.3 % 1.70 [ 0.68, 2.72 ]
Smith 2008 437 0.79 (2.83) 447 0.29 (2.8) 2.4 % 0.50 [ 0.13, 0.87 ]
Ten Bokkel 1998a 34 0.66 (1.76) 12 -0.57 (1.16) 0.4 % 1.23 [ 0.35, 2.11 ]
Ten Bokkel 1998b 27 1.04 (1.73) 12 -0.57 (1.16) 0.4 % 1.61 [ 0.68, 2.54 ]
Thomas 2002 62 1.9 (1.74) 65 0.39 (1.38) 1.1 % 1.51 [ 0.96, 2.06 ]
Thomas 2008 52 1.72 (1.79) 57 0.09 (1.23) 1.0 % 1.63 [ 1.05, 2.21 ]
Throuvalas 2000 28 0.7 (0.95) 26 -0.5 (0.56) 1.9 % 1.20 [ 0.79, 1.61 ]
Tjulandin 2010a 76 1.6 (1.42) 37 0.2 (1.74) 0.8 % 1.40 [ 0.75, 2.05 ]
Tjulandin 2010b 73 1.9 (1.74) 37 0.2 (1.74) 0.7 % 1.70 [ 1.01, 2.39 ]
Tjulandin 2011 95 2.1 (1.3) 91 0.65 (1.94) 1.5 % 1.45 [ 0.97, 1.93 ]
Tsuboi 2009 61 1.4 (1.9) 56 -0.8 (1.5) 0.9 % 2.20 [ 1.58, 2.82 ]
Wilkinson 2006 114 1.6 (1.5) 59 0.3 (1.3) 1.8 % 1.30 [ 0.87, 1.73 ]
Subtotal (95% CI) 4842 3965 77.3 % 1.47 [ 1.40, 1.53 ]
Heterogeneity: Chi2 = 337.12, df = 52 (P<0.00001); I2 =85%
Test for overall effect: Z = 43.87 (P < 0.00001)
3 no explicit statement on iron supplementation or no iron given
Bamias 2003 72 0.57 (2.12) 72 -0.49 (1.36) 1.0 % 1.06 [ 0.48, 1.64 ]
Carabantes 1999 20 1 (1.56) 15 -1.7 (1.22) 0.4 % 2.70 [ 1.78, 3.62 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Gebbia 2003 22 -2.4 (1.5) 23 -5.1 (1.33) 0.5 % 2.70 [ 1.87, 3.53 ]
Hedenus 2002a 5 1.56 (1.93) 2 1 (0.56) 0.1 % 0.56 [ -1.30, 2.42 ]
Hedenus 2002b 17 1.64 (1.25) 2 1 (0.56) 0.3 % 0.64 [ -0.34, 1.62 ]
Hedenus 2002c 14 2.46 (1.49) 2 1 (0.56) 0.3 % 1.46 [ 0.36, 2.56 ]
Kunikane 2001a 16 0.89 (1.72) 10 -0.65 (1.31) 0.2 % 1.54 [ 0.37, 2.71 ]
Kunikane 2001b 18 1.72 (1.1) 9 -0.65 (1.31) 0.3 % 2.37 [ 1.37, 3.37 ]
Subtotal (95% CI) 184 135 3.1 % 1.66 [ 1.34, 1.99 ]
Heterogeneity: Chi2 = 22.66, df = 7 (P = 0.002); I2 =69%
Test for overall effect: Z = 10.05 (P < 0.00001)
4 explicitly stated no iron new
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
5 iron given differently in both study arms new ongoing
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 6322 5287 100.0 % 1.57 [ 1.51, 1.62 ]
Heterogeneity: Chi2 = 564.37, df = 74 (P<0.00001); I2 =87%
Test for overall effect: Z = 53.27 (P < 0.00001)
Test for subgroup differences: Chi2 = 41.22, df = 2 (P = 0.00), I2 =95%
-10 -5 0 5 10
Favours Control Favours Treatment
275Erythropoietin or darbepoetin for patients with cancer (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.11. Comparison 2 Change of haemoglobin level, Outcome 11 Change in Hb values - allocation
concealment.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 2 Change of haemoglobin level
Outcome: 11 Change in Hb values - allocation concealment





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 adequate
Boogaerts 2003 133 2.1 (1.83) 129 0.9 (1.5) 2.0 % 1.20 [ 0.80, 1.60 ]
Cazzola 1995a 31 -0.1 (2.23) 7 -0.04 (2.05) 0.1 % -0.06 [ -1.77, 1.65 ]
Cazzola 1995b 29 0.17 (1.72) 8 -0.04 (2.05) 0.1 % 0.21 [ -1.34, 1.76 ]
Cazzola 1995c 31 0.3 (2.9) 7 -0.04 (2.05) 0.1 % 0.34 [ -1.49, 2.17 ]
Cazzola 1995d 26 0.44 (2.29) 7 -0.04 (2.05) 0.1 % 0.48 [ -1.28, 2.24 ]
Chang 2005 175 1.14 (0.8) 175 -0.58 (0.73) 12.9 % 1.72 [ 1.56, 1.88 ]
Charu 2007 220 2.1 (1.854) 55 0.1 (0.927) 2.8 % 2.00 [ 1.65, 2.35 ]
Christodoulou 2009 167 2.74 (13.62) 170 0.52 (4.18) 0.1 % 2.22 [ 0.06, 4.38 ]
Del Mastro 1997 28 -0.8 (1.4) 24 -3.05 (1) 0.8 % 2.25 [ 1.60, 2.90 ]
Fujisaka 2011 89 1.84 (1.33) 92 0.02 (1.12) 2.6 % 1.82 [ 1.46, 2.18 ]
Gordon 2008 139 1.3 (1.4) 49 0.2 (1) 2.5 % 1.10 [ 0.74, 1.46 ]
Hedenus 2002a 5 1.56 (1.93) 2 1 (0.56) 0.1 % 0.56 [ -1.30, 2.42 ]
Hedenus 2002b 17 1.64 (1.25) 2 1 (0.56) 0.3 % 0.64 [ -0.34, 1.62 ]
Hedenus 2002c 14 2.46 (1.49) 2 1 (0.56) 0.3 % 1.46 [ 0.36, 2.56 ]
Hedenus 2003 174 1.8 (2.24) 170 0.19 (1.3) 2.2 % 1.61 [ 1.22, 2.00 ]
Henke 2003 Roche 2004 178 3.4 (1.7) 168 0.9 (1.7) 2.6 % 2.50 [ 2.14, 2.86 ]
Iconomou 2003 57 1.7 (1.6) 55 0.3 (1.4) 1.1 % 1.40 [ 0.84, 1.96 ]
Italian 1998 17 1.73 (1.56) 11 -0.14 (1.09) 0.3 % 1.87 [ 0.89, 2.85 ]
Kotasek 2003a 32 0.54 (1.24) 8 -0.02 (1.43) 0.3 % 0.56 [ -0.52, 1.64 ]
Kotasek 2003b 17 0.86 (1.57) 8 -0.02 (1.43) 0.2 % 0.88 [ -0.36, 2.12 ]
Kotasek 2003c 46 0.9 (1.63) 9 -0.02 (1.43) 0.3 % 0.92 [ -0.13, 1.97 ]
Kotasek 2003d 28 1.63 (2.01) 8 -0.02 (1.43) 0.2 % 1.65 [ 0.41, 2.89 ]
Kotasek 2003e 35 1.45 (1.42) 8 -0.02 (1.43) 0.3 % 1.47 [ 0.37, 2.57 ]
Kotasek 2003f 40 1.21 (1.9) 9 -0.02 (1.43) 0.3 % 1.23 [ 0.13, 2.33 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Kunikane 2001a 16 0.89 (1.72) 10 -0.65 (1.31) 0.2 % 1.54 [ 0.37, 2.71 ]
Kunikane 2001b 18 1.72 (1.1) 9 -0.65 (1.31) 0.3 % 2.37 [ 1.37, 3.37 ]
Kurz 1997 23 3.26 (1.98) 12 0.25 (1.66) 0.2 % 3.01 [ 1.77, 4.25 ]
Leyland-Jones 2005 81 0.34 (1.73) 86 0.14 (1.7) 1.2 % 0.20 [ -0.32, 0.72 ]
Littlewood 2001 244 2.2 (2.18) 115 0.5 (1.79) 1.8 % 1.70 [ 1.27, 2.13 ]
O’Shaughnessy 2005 47 0.8 (1.2) 46 -2.1 (1.4) 1.2 % 2.90 [ 2.37, 3.43 ]
Oberhoff 1998 59 2.24 (2) 47 0.6 (1.43) 0.8 % 1.64 [ 0.99, 2.29 ]
Osterborg 1996a 17 2.6 (1.74) 13 1.02 (1.28) 0.3 % 1.58 [ 0.50, 2.66 ]
Osterborg 1996b 27 1.71 (1.67) 14 1.02 (1.28) 0.4 % 0.69 [ -0.23, 1.61 ]
Osterborg 2002 138 2.48 (1.74) 142 0.82 (1.4) 2.4 % 1.66 [ 1.29, 2.03 ]
Pirker 2008 270 -1.13 (1.93) 279 -1.98 (1.87) 3.3 % 0.85 [ 0.53, 1.17 ]
Pronzato 2010 107 1.7 (1.35) 109 0.4 (1.24) 2.8 % 1.30 [ 0.95, 1.65 ]
Razzouk 2006 111 1.3 (2.38) 111 1 (1.9) 1.0 % 0.30 [ -0.27, 0.87 ]
Smith 2008 437 0.79 (2.83) 447 0.29 (2.8) 2.4 % 0.50 [ 0.13, 0.87 ]
Ten Bokkel 1998a 34 0.66 (1.76) 12 -0.57 (1.16) 0.4 % 1.23 [ 0.35, 2.11 ]
Ten Bokkel 1998b 27 1.04 (1.73) 12 -0.57 (1.16) 0.4 % 1.61 [ 0.68, 2.54 ]
Thomas 2002 62 1.9 (1.74) 65 0.39 (1.38) 1.1 % 1.51 [ 0.96, 2.06 ]
Thomas 2008 52 1.72 (1.79) 57 0.09 (1.23) 1.0 % 1.63 [ 1.05, 2.21 ]
Throuvalas 2000 28 0.7 (0.95) 26 -0.5 (0.56) 1.9 % 1.20 [ 0.79, 1.61 ]
Tsuboi 2009 61 1.4 (1.9) 56 -0.8 (1.5) 0.9 % 2.20 [ 1.58, 2.82 ]
Witzig 2005 166 2.8 (1.62) 164 0.9 (1.52) 2.9 % 1.90 [ 1.56, 2.24 ]
Subtotal (95% CI) 3753 3015 59.5 % 1.52 [ 1.45, 1.60 ]
Heterogeneity: Chi2 = 218.40, df = 44 (P<0.00001); I2 =80%
Test for overall effect: Z = 40.04 (P < 0.00001)
2 unclear
Abels 1993 63 0.952 (2.142) 55 -0.03 (1.36) 0.8 % 0.99 [ 0.35, 1.63 ]
Aravantinos 2003 24 2.31 (1.22) 23 1.23 (1.59) 0.5 % 1.08 [ 0.27, 1.89 ]
Bamias 2003 72 0.57 (2.12) 72 -0.49 (1.36) 1.0 % 1.06 [ 0.48, 1.64 ]
Carabantes 1999 20 1 (1.56) 15 -1.7 (1.22) 0.4 % 2.70 [ 1.78, 3.62 ]
Cascinu 1994 50 1.88 (0.83) 49 -0.61 (0.95) 2.7 % 2.49 [ 2.14, 2.84 ]
Case 1993 79 2.346 (2.04) 74 0.37 (1.46) 1.1 % 1.97 [ 1.41, 2.53 ]
Dammacco 2001 69 1.8 (2.11) 76 -0.2 (1.31) 1.0 % 2.00 [ 1.42, 2.58 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Engert 2009 648 -1.88 (1.78) 655 -2.55 (1.78) 8.9 % 0.67 [ 0.48, 0.86 ]
Gebbia 2003 22 -2.4 (1.5) 23 -5.1 (1.33) 0.5 % 2.70 [ 1.87, 3.53 ]
Grote 2005 64 -0.2 (1.38) 58 -2.9 (1.53) 1.2 % 2.70 [ 2.18, 3.22 ]
Gupta 2009 58 1.55 (0.74) 57 -1.5 (0.61) 5.4 % 3.05 [ 2.80, 3.30 ]
Henke 1999a 19 3.2 (1.6) 3 0.6 (1.4) 0.1 % 2.60 [ 0.86, 4.34 ]
Henke 1999b 14 3.5 (1.2) 4 0.6 (1.4) 0.1 % 2.90 [ 1.39, 4.41 ]
Henke 1999c 6 3.9 (2.1) 4 0.6 (1.4) 0.1 % 3.30 [ 1.13, 5.47 ]
Henry 1995 63 2.04 (2.38) 61 0.44 (1.7) 0.6 % 1.60 [ 0.87, 2.33 ]
Hoskin 2009 151 0.625 (3.5) 149 -0.47 (3.48) 0.5 % 1.09 [ 0.30, 1.88 ]
Huddart 2002 45 2.6 (2) 45 1.2 (1.46) 0.6 % 1.40 [ 0.68, 2.12 ]
Krzakowski 2008a 104 2.5 (2.4) 52 0.6 (1.7) 0.8 % 1.90 [ 1.25, 2.55 ]
Krzakowski 2008b 105 2.5 (2.6) 52 0.6 (1.7) 0.7 % 1.90 [ 1.22, 2.58 ]
ML17616 2006 30 3.09 (2.08) 30 1.76 (2.28) 0.3 % 1.33 [ 0.23, 2.43 ]
ML17620 2006 61 2.12 (1.64) 60 0.59 (1.83) 0.9 % 1.53 [ 0.91, 2.15 ]
Mystakidou 2005 50 2.4 (1.3) 50 -0.1 (1.02) 1.6 % 2.50 [ 2.04, 2.96 ]
Smith 2003a 21 1.18 (2.01) 7 0 (0.91) 0.3 % 1.18 [ 0.09, 2.27 ]
Smith 2003b 21 1.22 (1.62) 7 0 (0.91) 0.4 % 1.22 [ 0.25, 2.19 ]
Smith 2003c 22 1.7 (1.93) 8 0 (0.91) 0.3 % 1.70 [ 0.68, 2.72 ]
Tjulandin 2010a 76 1.6 (1.42) 37 0.2 (1.74) 0.8 % 1.40 [ 0.75, 2.05 ]
Tjulandin 2010b 73 1.9 (1.74) 37 0.2 (1.74) 0.7 % 1.70 [ 1.01, 2.39 ]
Tjulandin 2011 95 2.1 (1.3) 91 0.65 (1.94) 1.5 % 1.45 [ 0.97, 1.93 ]
Untch 2011˙1 330 -0.07 (2) 359 -0.98 (1.33) 5.1 % 0.91 [ 0.65, 1.17 ]
Wilkinson 2006 114 1.6 (1.5) 59 0.3 (1.3) 1.8 % 1.30 [ 0.87, 1.73 ]
Subtotal (95% CI) 2569 2272 40.5 % 1.62 [ 1.53, 1.71 ]
Heterogeneity: Chi2 = 343.18, df = 29 (P<0.00001); I2 =92%
Test for overall effect: Z = 35.18 (P < 0.00001)
Total (95% CI) 6322 5287 100.0 % 1.57 [ 1.51, 1.62 ]
Heterogeneity: Chi2 = 564.37, df = 74 (P<0.00001); I2 =87%
Test for overall effect: Z = 53.27 (P < 0.00001)
Test for subgroup differences: Chi2 = 2.78, df = 1 (P = 0.10), I2 =64%
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Analysis 2.12. Comparison 2 Change of haemoglobin level, Outcome 12 Change in Hb values - masking.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 2 Change of haemoglobin level
Outcome: 12 Change in Hb values - masking





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 double-blind
Abels 1993 63 0.952 (2.142) 55 -0.03 (1.36) 0.8 % 0.99 [ 0.35, 1.63 ]
Cascinu 1994 50 1.88 (0.83) 49 -0.61 (0.95) 2.7 % 2.49 [ 2.14, 2.84 ]
Case 1993 79 2.346 (2.04) 74 0.37 (1.46) 1.1 % 1.97 [ 1.41, 2.53 ]
Dammacco 2001 69 1.8 (2.11) 76 -0.2 (1.31) 1.0 % 2.00 [ 1.42, 2.58 ]
Engert 2009 648 -1.88 (1.78) 655 -2.55 (1.78) 8.9 % 0.67 [ 0.48, 0.86 ]
Fujisaka 2011 89 1.84 (1.33) 92 0.02 (1.12) 2.6 % 1.82 [ 1.46, 2.18 ]
Gordon 2008 139 1.3 (1.4) 49 0.2 (1) 2.5 % 1.10 [ 0.74, 1.46 ]
Grote 2005 64 -0.2 (1.38) 58 -2.9 (1.53) 1.2 % 2.70 [ 2.18, 3.22 ]
Hedenus 2002a 5 1.56 (1.93) 2 1 (0.56) 0.1 % 0.56 [ -1.30, 2.42 ]
Hedenus 2002b 17 1.64 (1.25) 2 1 (0.56) 0.3 % 0.64 [ -0.34, 1.62 ]
Hedenus 2002c 14 2.46 (1.49) 2 1 (0.56) 0.3 % 1.46 [ 0.36, 2.56 ]
Hedenus 2003 174 1.8 (2.24) 170 0.19 (1.3) 2.2 % 1.61 [ 1.22, 2.00 ]
Henke 2003 Roche 2004 178 3.4 (1.7) 168 0.9 (1.7) 2.6 % 2.50 [ 2.14, 2.86 ]
Henry 1995 63 2.04 (2.38) 61 0.44 (1.7) 0.6 % 1.60 [ 0.87, 2.33 ]
Italian 1998 17 1.73 (1.56) 11 -0.14 (1.09) 0.3 % 1.87 [ 0.89, 2.85 ]
Kotasek 2003a 32 0.54 (1.24) 8 -0.02 (1.43) 0.3 % 0.56 [ -0.52, 1.64 ]
Kotasek 2003b 17 0.86 (1.57) 8 -0.02 (1.43) 0.2 % 0.88 [ -0.36, 2.12 ]
Kotasek 2003c 46 0.9 (1.63) 9 -0.02 (1.43) 0.3 % 0.92 [ -0.13, 1.97 ]
Kotasek 2003d 28 1.63 (2.01) 8 -0.02 (1.43) 0.2 % 1.65 [ 0.41, 2.89 ]
Kotasek 2003e 35 1.45 (1.42) 8 -0.02 (1.43) 0.3 % 1.47 [ 0.37, 2.57 ]
Kotasek 2003f 40 1.21 (1.9) 9 -0.02 (1.43) 0.3 % 1.23 [ 0.13, 2.33 ]
Krzakowski 2008a 104 2.5 (2.4) 52 0.6 (1.7) 0.8 % 1.90 [ 1.25, 2.55 ]
Krzakowski 2008b 105 2.5 (2.6) 52 0.6 (1.7) 0.7 % 1.90 [ 1.22, 2.58 ]
Kunikane 2001a 16 0.89 (1.72) 10 -0.65 (1.31) 0.2 % 1.54 [ 0.37, 2.71 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Kunikane 2001b 18 1.72 (1.1) 9 -0.65 (1.31) 0.3 % 2.37 [ 1.37, 3.37 ]
Kurz 1997 23 3.26 (1.98) 12 0.25 (1.66) 0.2 % 3.01 [ 1.77, 4.25 ]
Leyland-Jones 2005 81 0.34 (1.73) 86 0.14 (1.7) 1.2 % 0.20 [ -0.32, 0.72 ]
Littlewood 2001 244 2.2 (2.18) 115 0.5 (1.79) 1.8 % 1.70 [ 1.27, 2.13 ]
Mystakidou 2005 50 2.4 (1.3) 50 -0.1 (1.02) 1.6 % 2.50 [ 2.04, 2.96 ]
O’Shaughnessy 2005 47 0.8 (1.2) 46 -2.1 (1.4) 1.2 % 2.90 [ 2.37, 3.43 ]
Osterborg 2002 138 2.48 (1.74) 142 0.82 (1.4) 2.4 % 1.66 [ 1.29, 2.03 ]
Pirker 2008 270 -1.13 (1.93) 279 -1.98 (1.87) 3.3 % 0.85 [ 0.53, 1.17 ]
Razzouk 2006 111 1.3 (2.38) 111 1 (1.9) 1.0 % 0.30 [ -0.27, 0.87 ]
Smith 2003a 21 1.18 (2.01) 7 0 (0.91) 0.3 % 1.18 [ 0.09, 2.27 ]
Smith 2003b 21 1.22 (1.62) 7 0 (0.91) 0.4 % 1.22 [ 0.25, 2.19 ]
Smith 2003c 22 1.7 (1.93) 8 0 (0.91) 0.3 % 1.70 [ 0.68, 2.72 ]
Smith 2008 437 0.79 (2.83) 447 0.29 (2.8) 2.4 % 0.50 [ 0.13, 0.87 ]
Tjulandin 2010a 76 1.6 (1.42) 37 0.2 (1.74) 0.8 % 1.40 [ 0.75, 2.05 ]
Tjulandin 2010b 73 1.9 (1.74) 37 0.2 (1.74) 0.7 % 1.70 [ 1.01, 2.39 ]
Tjulandin 2011 95 2.1 (1.3) 91 0.65 (1.94) 1.5 % 1.45 [ 0.97, 1.93 ]
Tsuboi 2009 61 1.4 (1.9) 56 -0.8 (1.5) 0.9 % 2.20 [ 1.58, 2.82 ]
Witzig 2005 166 2.8 (1.62) 164 0.9 (1.52) 2.9 % 1.90 [ 1.56, 2.24 ]
Subtotal (95% CI) 4046 3392 53.7 % 1.47 [ 1.40, 1.55 ]
Heterogeneity: Chi2 = 332.01, df = 41 (P<0.00001); I2 =88%
Test for overall effect: Z = 36.77 (P < 0.00001)
2 unblinded
Aravantinos 2003 24 2.31 (1.22) 23 1.23 (1.59) 0.5 % 1.08 [ 0.27, 1.89 ]
Bamias 2003 72 0.57 (2.12) 72 -0.49 (1.36) 1.0 % 1.06 [ 0.48, 1.64 ]
Boogaerts 2003 133 2.1 (1.83) 129 0.9 (1.5) 2.0 % 1.20 [ 0.80, 1.60 ]
Carabantes 1999 20 1 (1.56) 15 -1.7 (1.22) 0.4 % 2.70 [ 1.78, 3.62 ]
Cazzola 1995a 31 -0.1 (2.23) 7 -0.04 (2.05) 0.1 % -0.06 [ -1.77, 1.65 ]
Cazzola 1995b 29 0.17 (1.72) 8 -0.04 (2.05) 0.1 % 0.21 [ -1.34, 1.76 ]
Cazzola 1995c 31 0.3 (2.9) 7 -0.04 (2.05) 0.1 % 0.34 [ -1.49, 2.17 ]
Cazzola 1995d 26 0.44 (2.29) 7 -0.04 (2.05) 0.1 % 0.48 [ -1.28, 2.24 ]
Chang 2005 175 1.14 (0.8) 175 -0.58 (0.73) 12.9 % 1.72 [ 1.56, 1.88 ]
Charu 2007 220 2.1 (1.854) 55 0.1 (0.927) 2.8 % 2.00 [ 1.65, 2.35 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Christodoulou 2009 167 2.74 (13.62) 170 0.52 (4.18) 0.1 % 2.22 [ 0.06, 4.38 ]
Del Mastro 1997 28 -0.8 (1.4) 24 -3.05 (1) 0.8 % 2.25 [ 1.60, 2.90 ]
Gebbia 2003 22 -2.4 (1.5) 23 -5.1 (1.33) 0.5 % 2.70 [ 1.87, 3.53 ]
Gupta 2009 58 1.55 (0.74) 57 -1.5 (0.61) 5.4 % 3.05 [ 2.80, 3.30 ]
Henke 1999a 19 3.2 (1.6) 3 0.6 (1.4) 0.1 % 2.60 [ 0.86, 4.34 ]
Henke 1999b 14 3.5 (1.2) 4 0.6 (1.4) 0.1 % 2.90 [ 1.39, 4.41 ]
Henke 1999c 6 3.9 (2.1) 4 0.6 (1.4) 0.1 % 3.30 [ 1.13, 5.47 ]
Hoskin 2009 151 0.625 (3.5) 149 -0.47 (3.48) 0.5 % 1.09 [ 0.30, 1.88 ]
Huddart 2002 45 2.6 (2) 45 1.2 (1.46) 0.6 % 1.40 [ 0.68, 2.12 ]
Iconomou 2003 57 1.7 (1.6) 55 0.3 (1.4) 1.1 % 1.40 [ 0.84, 1.96 ]
ML17616 2006 30 3.09 (2.08) 30 1.76 (2.28) 0.3 % 1.33 [ 0.23, 2.43 ]
ML17620 2006 61 2.12 (1.64) 60 0.59 (1.83) 0.9 % 1.53 [ 0.91, 2.15 ]
Oberhoff 1998 59 2.24 (2) 47 0.6 (1.43) 0.8 % 1.64 [ 0.99, 2.29 ]
Osterborg 1996a 17 2.6 (1.74) 13 1.02 (1.28) 0.3 % 1.58 [ 0.50, 2.66 ]
Osterborg 1996b 27 1.71 (1.67) 14 1.02 (1.28) 0.4 % 0.69 [ -0.23, 1.61 ]
Pronzato 2010 107 1.7 (1.35) 109 0.4 (1.24) 2.8 % 1.30 [ 0.95, 1.65 ]
Ten Bokkel 1998a 34 0.66 (1.76) 12 -0.57 (1.16) 0.4 % 1.23 [ 0.35, 2.11 ]
Ten Bokkel 1998b 27 1.04 (1.73) 12 -0.57 (1.16) 0.4 % 1.61 [ 0.68, 2.54 ]
Thomas 2002 62 1.9 (1.74) 65 0.39 (1.38) 1.1 % 1.51 [ 0.96, 2.06 ]
Thomas 2008 52 1.72 (1.79) 57 0.09 (1.23) 1.0 % 1.63 [ 1.05, 2.21 ]
Throuvalas 2000 28 0.7 (0.95) 26 -0.5 (0.56) 1.9 % 1.20 [ 0.79, 1.61 ]
Untch 2011˙1 330 -0.07 (2) 359 -0.98 (1.33) 5.1 % 0.91 [ 0.65, 1.17 ]
Wilkinson 2006 114 1.6 (1.5) 59 0.3 (1.3) 1.8 % 1.30 [ 0.87, 1.73 ]
Subtotal (95% CI) 2276 1895 46.3 % 1.67 [ 1.59, 1.75 ]
Heterogeneity: Chi2 = 221.32, df = 32 (P<0.00001); I2 =86%
Test for overall effect: Z = 38.70 (P < 0.00001)
Total (95% CI) 6322 5287 100.0 % 1.57 [ 1.51, 1.62 ]
Heterogeneity: Chi2 = 564.37, df = 74 (P<0.00001); I2 =87%
Test for overall effect: Z = 53.27 (P < 0.00001)
Test for subgroup differences: Chi2 = 11.04, df = 1 (P = 0.00), I2 =91%
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Analysis 2.13. Comparison 2 Change of haemoglobin level, Outcome 13 Change in Hb values - intention-to-
treat.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 2 Change of haemoglobin level
Outcome: 13 Change in Hb values - intention-to-treat





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ITT or less than 10% of participants per study arm excluded
Abels 1993 63 0.952 (2.142) 55 -0.03 (1.36) 0.8 % 0.99 [ 0.35, 1.63 ]
Aravantinos 2003 24 2.31 (1.22) 23 1.23 (1.59) 0.5 % 1.08 [ 0.27, 1.89 ]
Bamias 2003 72 0.57 (2.12) 72 -0.49 (1.36) 1.0 % 1.06 [ 0.48, 1.64 ]
Boogaerts 2003 133 2.1 (1.83) 129 0.9 (1.5) 2.0 % 1.20 [ 0.80, 1.60 ]
Carabantes 1999 20 1 (1.56) 15 -1.7 (1.22) 0.4 % 2.70 [ 1.78, 3.62 ]
Cascinu 1994 50 1.88 (0.83) 49 -0.61 (0.95) 2.7 % 2.49 [ 2.14, 2.84 ]
Case 1993 79 2.346 (2.04) 74 0.37 (1.46) 1.1 % 1.97 [ 1.41, 2.53 ]
Cazzola 1995a 31 -0.1 (2.23) 7 -0.04 (2.05) 0.1 % -0.06 [ -1.77, 1.65 ]
Cazzola 1995b 29 0.17 (1.72) 8 -0.04 (2.05) 0.1 % 0.21 [ -1.34, 1.76 ]
Cazzola 1995c 31 0.3 (2.9) 7 -0.04 (2.05) 0.1 % 0.34 [ -1.49, 2.17 ]
Cazzola 1995d 26 0.44 (2.29) 7 -0.04 (2.05) 0.1 % 0.48 [ -1.28, 2.24 ]
Chang 2005 175 1.14 (0.8) 175 -0.58 (0.73) 12.9 % 1.72 [ 1.56, 1.88 ]
Charu 2007 220 2.1 (1.854) 55 0.1 (0.927) 2.8 % 2.00 [ 1.65, 2.35 ]
Dammacco 2001 69 1.8 (2.11) 76 -0.2 (1.31) 1.0 % 2.00 [ 1.42, 2.58 ]
Del Mastro 1997 28 -0.8 (1.4) 24 -3.05 (1) 0.8 % 2.25 [ 1.60, 2.90 ]
Engert 2009 648 -1.88 (1.78) 655 -2.55 (1.78) 8.9 % 0.67 [ 0.48, 0.86 ]
Fujisaka 2011 89 1.84 (1.33) 92 0.02 (1.12) 2.6 % 1.82 [ 1.46, 2.18 ]
Gebbia 2003 22 -2.4 (1.5) 23 -5.1 (1.33) 0.5 % 2.70 [ 1.87, 3.53 ]
Gupta 2009 58 1.55 (0.74) 57 -1.5 (0.61) 5.4 % 3.05 [ 2.80, 3.30 ]
Hedenus 2003 174 1.8 (2.24) 170 0.19 (1.3) 2.2 % 1.61 [ 1.22, 2.00 ]
Henke 1999a 19 3.2 (1.6) 3 0.6 (1.4) 0.1 % 2.60 [ 0.86, 4.34 ]
Henke 1999b 14 3.5 (1.2) 4 0.6 (1.4) 0.1 % 2.90 [ 1.39, 4.41 ]
Henke 1999c 6 3.9 (2.1) 4 0.6 (1.4) 0.1 % 3.30 [ 1.13, 5.47 ]
Henke 2003 Roche 2004 178 3.4 (1.7) 168 0.9 (1.7) 2.6 % 2.50 [ 2.14, 2.86 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Henry 1995 63 2.04 (2.38) 61 0.44 (1.7) 0.6 % 1.60 [ 0.87, 2.33 ]
Hoskin 2009 151 0.625 (3.5) 149 -0.47 (3.48) 0.5 % 1.09 [ 0.30, 1.88 ]
Huddart 2002 45 2.6 (2) 45 1.2 (1.46) 0.6 % 1.40 [ 0.68, 2.12 ]
Iconomou 2003 57 1.7 (1.6) 55 0.3 (1.4) 1.1 % 1.40 [ 0.84, 1.96 ]
Kotasek 2003a 32 0.54 (1.24) 8 -0.02 (1.43) 0.3 % 0.56 [ -0.52, 1.64 ]
Kotasek 2003b 17 0.86 (1.57) 8 -0.02 (1.43) 0.2 % 0.88 [ -0.36, 2.12 ]
Kotasek 2003c 46 0.9 (1.63) 9 -0.02 (1.43) 0.3 % 0.92 [ -0.13, 1.97 ]
Kotasek 2003d 28 1.63 (2.01) 8 -0.02 (1.43) 0.2 % 1.65 [ 0.41, 2.89 ]
Kotasek 2003e 35 1.45 (1.42) 8 -0.02 (1.43) 0.3 % 1.47 [ 0.37, 2.57 ]
Kotasek 2003f 40 1.21 (1.9) 9 -0.02 (1.43) 0.3 % 1.23 [ 0.13, 2.33 ]
Krzakowski 2008a 104 2.5 (2.4) 52 0.6 (1.7) 0.8 % 1.90 [ 1.25, 2.55 ]
Krzakowski 2008b 105 2.5 (2.6) 52 0.6 (1.7) 0.7 % 1.90 [ 1.22, 2.58 ]
Kurz 1997 23 3.26 (1.98) 12 0.25 (1.66) 0.2 % 3.01 [ 1.77, 4.25 ]
Littlewood 2001 244 2.2 (2.18) 115 0.5 (1.79) 1.8 % 1.70 [ 1.27, 2.13 ]
ML17616 2006 30 3.09 (2.08) 30 1.76 (2.28) 0.3 % 1.33 [ 0.23, 2.43 ]
ML17620 2006 61 2.12 (1.64) 60 0.59 (1.83) 0.9 % 1.53 [ 0.91, 2.15 ]
Mystakidou 2005 50 2.4 (1.3) 50 -0.1 (1.02) 1.6 % 2.50 [ 2.04, 2.96 ]
O’Shaughnessy 2005 47 0.8 (1.2) 46 -2.1 (1.4) 1.2 % 2.90 [ 2.37, 3.43 ]
Pirker 2008 270 -1.13 (1.93) 279 -1.98 (1.87) 3.3 % 0.85 [ 0.53, 1.17 ]
Pronzato 2010 107 1.7 (1.35) 109 0.4 (1.24) 2.8 % 1.30 [ 0.95, 1.65 ]
Razzouk 2006 111 1.3 (2.38) 111 1 (1.9) 1.0 % 0.30 [ -0.27, 0.87 ]
Smith 2003a 21 1.18 (2.01) 7 0 (0.91) 0.3 % 1.18 [ 0.09, 2.27 ]
Smith 2003b 21 1.22 (1.62) 7 0 (0.91) 0.4 % 1.22 [ 0.25, 2.19 ]
Smith 2003c 22 1.7 (1.93) 8 0 (0.91) 0.3 % 1.70 [ 0.68, 2.72 ]
Thomas 2002 62 1.9 (1.74) 65 0.39 (1.38) 1.1 % 1.51 [ 0.96, 2.06 ]
Throuvalas 2000 28 0.7 (0.95) 26 -0.5 (0.56) 1.9 % 1.20 [ 0.79, 1.61 ]
Tjulandin 2010a 76 1.6 (1.42) 37 0.2 (1.74) 0.8 % 1.40 [ 0.75, 2.05 ]
Tjulandin 2010b 73 1.9 (1.74) 37 0.2 (1.74) 0.7 % 1.70 [ 1.01, 2.39 ]
Tjulandin 2011 95 2.1 (1.3) 91 0.65 (1.94) 1.5 % 1.45 [ 0.97, 1.93 ]
Tsuboi 2009 61 1.4 (1.9) 56 -0.8 (1.5) 0.9 % 2.20 [ 1.58, 2.82 ]
Untch 2011˙1 330 -0.07 (2) 359 -0.98 (1.33) 5.1 % 0.91 [ 0.65, 1.17 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Wilkinson 2006 114 1.6 (1.5) 59 0.3 (1.3) 1.8 % 1.30 [ 0.87, 1.73 ]
Witzig 2005 166 2.8 (1.62) 164 0.9 (1.52) 2.9 % 1.90 [ 1.56, 2.24 ]
Subtotal (95% CI) 4993 4144 85.3 % 1.61 [ 1.55, 1.68 ]
Heterogeneity: Chi2 = 467.14, df = 56 (P<0.00001); I2 =88%
Test for overall effect: Z = 50.72 (P < 0.00001)
2 more than 10% of participants per study arm excluded
Christodoulou 2009 167 2.74 (13.62) 170 0.52 (4.18) 0.1 % 2.22 [ 0.06, 4.38 ]
Gordon 2008 139 1.3 (1.4) 49 0.2 (1) 2.5 % 1.10 [ 0.74, 1.46 ]
Grote 2005 64 -0.2 (1.38) 58 -2.9 (1.53) 1.2 % 2.70 [ 2.18, 3.22 ]
Hedenus 2002a 5 1.56 (1.93) 2 1 (0.56) 0.1 % 0.56 [ -1.30, 2.42 ]
Hedenus 2002b 17 1.64 (1.25) 2 1 (0.56) 0.3 % 0.64 [ -0.34, 1.62 ]
Hedenus 2002c 14 2.46 (1.49) 2 1 (0.56) 0.3 % 1.46 [ 0.36, 2.56 ]
Italian 1998 17 1.73 (1.56) 11 -0.14 (1.09) 0.3 % 1.87 [ 0.89, 2.85 ]
Kunikane 2001a 16 0.89 (1.72) 10 -0.65 (1.31) 0.2 % 1.54 [ 0.37, 2.71 ]
Kunikane 2001b 18 1.72 (1.1) 9 -0.65 (1.31) 0.3 % 2.37 [ 1.37, 3.37 ]
Leyland-Jones 2005 81 0.34 (1.73) 86 0.14 (1.7) 1.2 % 0.20 [ -0.32, 0.72 ]
Oberhoff 1998 59 2.24 (2) 47 0.6 (1.43) 0.8 % 1.64 [ 0.99, 2.29 ]
Osterborg 1996a 17 2.6 (1.74) 13 1.02 (1.28) 0.3 % 1.58 [ 0.50, 2.66 ]
Osterborg 1996b 27 1.71 (1.67) 14 1.02 (1.28) 0.4 % 0.69 [ -0.23, 1.61 ]
Osterborg 2002 138 2.48 (1.74) 142 0.82 (1.4) 2.4 % 1.66 [ 1.29, 2.03 ]
Smith 2008 437 0.79 (2.83) 447 0.29 (2.8) 2.4 % 0.50 [ 0.13, 0.87 ]
Ten Bokkel 1998a 34 0.66 (1.76) 12 -0.57 (1.16) 0.4 % 1.23 [ 0.35, 2.11 ]
Ten Bokkel 1998b 27 1.04 (1.73) 12 -0.57 (1.16) 0.4 % 1.61 [ 0.68, 2.54 ]
Thomas 2008 52 1.72 (1.79) 57 0.09 (1.23) 1.0 % 1.63 [ 1.05, 2.21 ]
Subtotal (95% CI) 1329 1143 14.7 % 1.28 [ 1.13, 1.43 ]
Heterogeneity: Chi2 = 81.39, df = 17 (P<0.00001); I2 =79%
Test for overall effect: Z = 16.77 (P < 0.00001)
3 unclear
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 6322 5287 100.0 % 1.57 [ 1.51, 1.62 ]
Heterogeneity: Chi2 = 564.37, df = 74 (P<0.00001); I2 =87%
Test for overall effect: Z = 53.27 (P < 0.00001)
Test for subgroup differences: Chi2 = 15.84, df = 1 (P = 0.00), I2 =94%
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Analysis 2.14. Comparison 2 Change of haemoglobin level, Outcome 14 Change in Hb values - publication.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 2 Change of haemoglobin level
Outcome: 14 Change in Hb values - publication





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 full text publication
Abels 1993 63 0.952 (2.142) 55 -0.03 (1.36) 0.8 % 0.99 [ 0.35, 1.63 ]
Aravantinos 2003 24 2.31 (1.22) 23 1.23 (1.59) 0.5 % 1.08 [ 0.27, 1.89 ]
Bamias 2003 72 0.57 (2.12) 72 -0.49 (1.36) 1.0 % 1.06 [ 0.48, 1.64 ]
Boogaerts 2003 133 2.1 (1.83) 129 0.9 (1.5) 2.0 % 1.20 [ 0.80, 1.60 ]
Cascinu 1994 50 1.88 (0.83) 49 -0.61 (0.95) 2.7 % 2.49 [ 2.14, 2.84 ]
Case 1993 79 2.346 (2.04) 74 0.37 (1.46) 1.1 % 1.97 [ 1.41, 2.53 ]
Cazzola 1995a 31 -0.1 (2.23) 7 -0.04 (2.05) 0.1 % -0.06 [ -1.77, 1.65 ]
Cazzola 1995b 29 0.17 (1.72) 8 -0.04 (2.05) 0.1 % 0.21 [ -1.34, 1.76 ]
Cazzola 1995c 31 0.3 (2.9) 7 -0.04 (2.05) 0.1 % 0.34 [ -1.49, 2.17 ]
Cazzola 1995d 26 0.44 (2.29) 7 -0.04 (2.05) 0.1 % 0.48 [ -1.28, 2.24 ]
Chang 2005 175 1.14 (0.8) 175 -0.58 (0.73) 12.9 % 1.72 [ 1.56, 1.88 ]
Charu 2007 220 2.1 (1.854) 55 0.1 (0.927) 2.8 % 2.00 [ 1.65, 2.35 ]
Christodoulou 2009 167 2.74 (13.62) 170 0.52 (4.18) 0.1 % 2.22 [ 0.06, 4.38 ]
Del Mastro 1997 28 -0.8 (1.4) 24 -3.05 (1) 0.8 % 2.25 [ 1.60, 2.90 ]
Engert 2009 648 -1.88 (1.78) 655 -2.55 (1.78) 8.9 % 0.67 [ 0.48, 0.86 ]
Fujisaka 2011 89 1.84 (1.33) 92 0.02 (1.12) 2.6 % 1.82 [ 1.46, 2.18 ]
Gebbia 2003 22 -2.4 (1.5) 23 -5.1 (1.33) 0.5 % 2.70 [ 1.87, 3.53 ]
Gordon 2008 139 1.3 (1.4) 49 0.2 (1) 2.5 % 1.10 [ 0.74, 1.46 ]
Grote 2005 64 -0.2 (1.38) 58 -2.9 (1.53) 1.2 % 2.70 [ 2.18, 3.22 ]
Gupta 2009 58 1.55 (0.74) 57 -1.5 (0.61) 5.4 % 3.05 [ 2.80, 3.30 ]
Hedenus 2002a 5 1.56 (1.93) 2 1 (0.56) 0.1 % 0.56 [ -1.30, 2.42 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Hedenus 2002b 17 1.64 (1.25) 2 1 (0.56) 0.3 % 0.64 [ -0.34, 1.62 ]
Hedenus 2002c 14 2.46 (1.49) 2 1 (0.56) 0.3 % 1.46 [ 0.36, 2.56 ]
Hedenus 2003 174 1.8 (2.24) 170 0.19 (1.3) 2.2 % 1.61 [ 1.22, 2.00 ]
Henke 1999a 19 3.2 (1.6) 3 0.6 (1.4) 0.1 % 2.60 [ 0.86, 4.34 ]
Henke 1999b 14 3.5 (1.2) 4 0.6 (1.4) 0.1 % 2.90 [ 1.39, 4.41 ]
Henke 1999c 6 3.9 (2.1) 4 0.6 (1.4) 0.1 % 3.30 [ 1.13, 5.47 ]
Henry 1995 63 2.04 (2.38) 61 0.44 (1.7) 0.6 % 1.60 [ 0.87, 2.33 ]
Hoskin 2009 151 0.625 (3.5) 149 -0.47 (3.48) 0.5 % 1.09 [ 0.30, 1.88 ]
Iconomou 2003 57 1.7 (1.6) 55 0.3 (1.4) 1.1 % 1.40 [ 0.84, 1.96 ]
Kotasek 2003a 32 0.54 (1.24) 8 -0.02 (1.43) 0.3 % 0.56 [ -0.52, 1.64 ]
Kotasek 2003b 17 0.86 (1.57) 8 -0.02 (1.43) 0.2 % 0.88 [ -0.36, 2.12 ]
Kotasek 2003c 46 0.9 (1.63) 9 -0.02 (1.43) 0.3 % 0.92 [ -0.13, 1.97 ]
Kotasek 2003d 28 1.63 (2.01) 8 -0.02 (1.43) 0.2 % 1.65 [ 0.41, 2.89 ]
Kotasek 2003e 35 1.45 (1.42) 8 -0.02 (1.43) 0.3 % 1.47 [ 0.37, 2.57 ]
Kotasek 2003f 40 1.21 (1.9) 9 -0.02 (1.43) 0.3 % 1.23 [ 0.13, 2.33 ]
Krzakowski 2008a 104 2.5 (2.4) 52 0.6 (1.7) 0.8 % 1.90 [ 1.25, 2.55 ]
Krzakowski 2008b 105 2.5 (2.6) 52 0.6 (1.7) 0.7 % 1.90 [ 1.22, 2.58 ]
Kunikane 2001a 16 0.89 (1.72) 10 -0.65 (1.31) 0.2 % 1.54 [ 0.37, 2.71 ]
Kunikane 2001b 18 1.72 (1.1) 9 -0.65 (1.31) 0.3 % 2.37 [ 1.37, 3.37 ]
Leyland-Jones 2005 81 0.34 (1.73) 86 0.14 (1.7) 1.2 % 0.20 [ -0.32, 0.72 ]
Littlewood 2001 244 2.2 (2.18) 115 0.5 (1.79) 1.8 % 1.70 [ 1.27, 2.13 ]
Mystakidou 2005 50 2.4 (1.3) 50 -0.1 (1.02) 1.6 % 2.50 [ 2.04, 2.96 ]
O’Shaughnessy 2005 47 0.8 (1.2) 46 -2.1 (1.4) 1.2 % 2.90 [ 2.37, 3.43 ]
Pirker 2008 270 -1.13 (1.93) 279 -1.98 (1.87) 3.3 % 0.85 [ 0.53, 1.17 ]
Pronzato 2010 107 1.7 (1.35) 109 0.4 (1.24) 2.8 % 1.30 [ 0.95, 1.65 ]
Razzouk 2006 111 1.3 (2.38) 111 1 (1.9) 1.0 % 0.30 [ -0.27, 0.87 ]
Smith 2003a 21 1.18 (2.01) 7 0 (0.91) 0.3 % 1.18 [ 0.09, 2.27 ]
Smith 2003b 21 1.22 (1.62) 7 0 (0.91) 0.4 % 1.22 [ 0.25, 2.19 ]
Smith 2003c 22 1.7 (1.93) 8 0 (0.91) 0.3 % 1.70 [ 0.68, 2.72 ]
Smith 2008 437 0.79 (2.83) 447 0.29 (2.8) 2.4 % 0.50 [ 0.13, 0.87 ]
Thomas 2008 52 1.72 (1.79) 57 0.09 (1.23) 1.0 % 1.63 [ 1.05, 2.21 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Tjulandin 2010a 76 1.6 (1.42) 37 0.2 (1.74) 0.8 % 1.40 [ 0.75, 2.05 ]
Tjulandin 2010b 73 1.9 (1.74) 37 0.2 (1.74) 0.7 % 1.70 [ 1.01, 2.39 ]
Tjulandin 2011 95 2.1 (1.3) 91 0.65 (1.94) 1.5 % 1.45 [ 0.97, 1.93 ]
Tsuboi 2009 61 1.4 (1.9) 56 -0.8 (1.5) 0.9 % 2.20 [ 1.58, 2.82 ]
Untch 2011˙1 330 -0.07 (2) 359 -0.98 (1.33) 5.1 % 0.91 [ 0.65, 1.17 ]
Wilkinson 2006 114 1.6 (1.5) 59 0.3 (1.3) 1.8 % 1.30 [ 0.87, 1.73 ]
Witzig 2005 166 2.8 (1.62) 164 0.9 (1.52) 2.9 % 1.90 [ 1.56, 2.24 ]
Subtotal (95% CI) 5487 4539 86.0 % 1.54 [ 1.47, 1.60 ]
Heterogeneity: Chi2 = 515.98, df = 58 (P<0.00001); I2 =89%
Test for overall effect: Z = 48.46 (P < 0.00001)
2 abstract publication
Carabantes 1999 20 1 (1.56) 15 -1.7 (1.22) 0.4 % 2.70 [ 1.78, 3.62 ]
Huddart 2002 45 2.6 (2) 45 1.2 (1.46) 0.6 % 1.40 [ 0.68, 2.12 ]
Thomas 2002 62 1.9 (1.74) 65 0.39 (1.38) 1.1 % 1.51 [ 0.96, 2.06 ]
Subtotal (95% CI) 127 125 2.1 % 1.70 [ 1.30, 2.09 ]
Heterogeneity: Chi2 = 5.65, df = 2 (P = 0.06); I2 =65%
Test for overall effect: Z = 8.42 (P < 0.00001)
3 unpublished data
Dammacco 2001 69 1.8 (2.11) 76 -0.2 (1.31) 1.0 % 2.00 [ 1.42, 2.58 ]
Italian 1998 17 1.73 (1.56) 11 -0.14 (1.09) 0.3 % 1.87 [ 0.89, 2.85 ]
Kurz 1997 23 3.26 (1.98) 12 0.25 (1.66) 0.2 % 3.01 [ 1.77, 4.25 ]
Oberhoff 1998 59 2.24 (2) 47 0.6 (1.43) 0.8 % 1.64 [ 0.99, 2.29 ]
Osterborg 1996a 17 2.6 (1.74) 13 1.02 (1.28) 0.3 % 1.58 [ 0.50, 2.66 ]
Osterborg 1996b 27 1.71 (1.67) 14 1.02 (1.28) 0.4 % 0.69 [ -0.23, 1.61 ]
Osterborg 2002 138 2.48 (1.74) 142 0.82 (1.4) 2.4 % 1.66 [ 1.29, 2.03 ]
Ten Bokkel 1998a 34 0.66 (1.76) 12 -0.57 (1.16) 0.4 % 1.23 [ 0.35, 2.11 ]
Ten Bokkel 1998b 27 1.04 (1.73) 12 -0.57 (1.16) 0.4 % 1.61 [ 0.68, 2.54 ]
Throuvalas 2000 28 0.7 (0.95) 26 -0.5 (0.56) 1.9 % 1.20 [ 0.79, 1.61 ]
Subtotal (95% CI) 439 365 8.2 % 1.56 [ 1.36, 1.76 ]
Heterogeneity: Chi2 = 15.11, df = 9 (P = 0.09); I2 =40%
Test for overall effect: Z = 15.19 (P < 0.00001)
4 ODAC documents
Henke 2003 Roche 2004 178 3.4 (1.7) 168 0.9 (1.7) 2.6 % 2.50 [ 2.14, 2.86 ]
Subtotal (95% CI) 178 168 2.6 % 2.50 [ 2.14, 2.86 ]
Heterogeneity: not applicable
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Test for overall effect: Z = 13.67 (P < 0.00001)
5 Clinical trials results
ML17616 2006 30 3.09 (2.08) 30 1.76 (2.28) 0.3 % 1.33 [ 0.23, 2.43 ]
ML17620 2006 61 2.12 (1.64) 60 0.59 (1.83) 0.9 % 1.53 [ 0.91, 2.15 ]
Subtotal (95% CI) 91 90 1.1 % 1.48 [ 0.94, 2.02 ]
Heterogeneity: Chi2 = 0.10, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 5.38 (P < 0.00001)
Total (95% CI) 6322 5287 100.0 % 1.57 [ 1.51, 1.62 ]
Heterogeneity: Chi2 = 564.37, df = 74 (P<0.00001); I2 =87%
Test for overall effect: Z = 53.27 (P < 0.00001)
Test for subgroup differences: Chi2 = 27.54, df = 4 (P = 0.00), I2 =85%
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Analysis 2.15. Comparison 2 Change of haemoglobin level, Outcome 15 Change in Hb values -
experimental arms merged.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 2 Change of haemoglobin level
Outcome: 15 Change in Hb values - experimental arms merged





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Abels 1993 63 0.952 (2.142) 55 -0.03 (1.36) 0.8 % 0.99 [ 0.35, 1.63 ]
Aravantinos 2003 24 2.31 (1.22) 23 1.23 (1.59) 0.5 % 1.08 [ 0.27, 1.89 ]
Bamias 2003 72 0.57 (2.12) 72 -0.49 (1.36) 1.0 % 1.06 [ 0.48, 1.64 ]
Boogaerts 2003 133 2.1 (1.83) 129 0.9 (1.5) 2.0 % 1.20 [ 0.80, 1.60 ]
Carabantes 1999 20 1 (1.56) 15 -1.7 (1.22) 0.4 % 2.70 [ 1.78, 3.62 ]
Cascinu 1994 50 1.88 (0.83) 49 -0.61 (0.95) 2.7 % 2.49 [ 2.14, 2.84 ]
Case 1993 79 2.346 (2.04) 74 0.37 (1.46) 1.1 % 1.97 [ 1.41, 2.53 ]
Cazzola 1995 117 0.19 (2.31) 29 -0.04 (2.05) 0.5 % 0.23 [ -0.63, 1.09 ]
Chang 2005 175 1.14 (0.8) 175 -0.58 (0.73) 12.9 % 1.72 [ 1.56, 1.88 ]
Charu 2007 220 2.1 (1.854) 55 0.1 (0.927) 2.8 % 2.00 [ 1.65, 2.35 ]
Christodoulou 2009 167 2.74 (13.62) 170 0.52 (4.18) 0.1 % 2.22 [ 0.06, 4.38 ]
Dammacco 2001 69 1.8 (2.11) 76 -0.2 (1.31) 1.0 % 2.00 [ 1.42, 2.58 ]
Del Mastro 1997 28 -0.8 (1.4) 24 -3.05 (1) 0.8 % 2.25 [ 1.60, 2.90 ]
Engert 2009 648 -1.88 (1.78) 655 -2.55 (1.78) 8.9 % 0.67 [ 0.48, 0.86 ]
Fujisaka 2011 89 1.84 (1.33) 92 0.02 (1.12) 2.6 % 1.82 [ 1.46, 2.18 ]
Gebbia 2003 22 -2.4 (1.5) 23 -5.1 (1.33) 0.5 % 2.70 [ 1.87, 3.53 ]
Gordon 2008 139 1.3 (1.4) 49 0.2 (1) 2.5 % 1.10 [ 0.74, 1.46 ]
Grote 2005 64 -0.2 (1.38) 58 -2.9 (1.53) 1.2 % 2.70 [ 2.18, 3.22 ]
Gupta 2009 58 1.55 (0.74) 57 -1.5 (0.61) 5.4 % 3.05 [ 2.80, 3.30 ]
Hedenus 2002 36 1.94 (1.46) 6 1 (0.56) 0.8 % 0.94 [ 0.29, 1.59 ]
Hedenus 2003 174 1.8 (2.24) 170 0.19 (1.3) 2.2 % 1.61 [ 1.22, 2.00 ]
Henke 1999 39 3.42 (1.53) 11 0.6 (1.4) 0.4 % 2.82 [ 1.86, 3.78 ]
Henke 2003 Roche 2004 178 3.4 (1.7) 168 0.9 (1.7) 2.6 % 2.50 [ 2.14, 2.86 ]
Henry 1995 63 2.04 (2.38) 61 0.44 (1.7) 0.6 % 1.60 [ 0.87, 2.33 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Hoskin 2009 151 0.625 (3.5) 149 -0.47 (3.48) 0.5 % 1.09 [ 0.30, 1.88 ]
Huddart 2002 45 2.6 (2) 45 1.2 (1.46) 0.6 % 1.40 [ 0.68, 2.12 ]
Iconomou 2003 57 1.7 (1.6) 55 0.3 (1.4) 1.1 % 1.40 [ 0.84, 1.96 ]
Italian 1998 17 1.73 (1.56) 11 -0.14 (1.09) 0.3 % 1.87 [ 0.89, 2.85 ]
Kotasek 2003 198 1.1 (1.67) 50 -0.02 (1.43) 1.6 % 1.12 [ 0.66, 1.58 ]
Krzakowski 2008 209 2.5 (2.5) 104 0.6 (1.7) 1.5 % 1.90 [ 1.43, 2.37 ]
Kunikane 2001 34 1.33 (1.46) 19 -0.65 (1.31) 0.6 % 1.98 [ 1.21, 2.75 ]
Kurz 1997 23 3.26 (1.98) 12 0.25 (1.66) 0.2 % 3.01 [ 1.77, 4.25 ]
Leyland-Jones 2005 81 0.34 (1.73) 86 0.14 (1.7) 1.2 % 0.20 [ -0.32, 0.72 ]
Littlewood 2001 244 2.2 (2.18) 115 0.5 (1.79) 1.8 % 1.70 [ 1.27, 2.13 ]
ML17616 2006 30 3.09 (2.08) 30 1.76 (2.28) 0.3 % 1.33 [ 0.23, 2.43 ]
ML17620 2006 61 2.12 (1.64) 60 0.59 (1.83) 0.9 % 1.53 [ 0.91, 2.15 ]
Mystakidou 2005 50 2.4 (1.3) 50 -0.1 (1.02) 1.6 % 2.50 [ 2.04, 2.96 ]
O’Shaughnessy 2005 47 0.8 (1.2) 46 -2.1 (1.4) 1.2 % 2.90 [ 2.37, 3.43 ]
Oberhoff 1998 59 2.24 (2) 47 0.6 (1.43) 0.8 % 1.64 [ 0.99, 2.29 ]
Osterborg 1996 44 2.05 (1.73) 27 1.02 (1.28) 0.7 % 1.03 [ 0.33, 1.73 ]
Osterborg 2002 138 2.48 (1.74) 142 0.82 (1.4) 2.4 % 1.66 [ 1.29, 2.03 ]
Pirker 2008 270 -1.13 (1.93) 279 -1.98 (1.87) 3.3 % 0.85 [ 0.53, 1.17 ]
Pronzato 2010 107 1.7 (1.35) 109 0.4 (1.24) 2.8 % 1.30 [ 0.95, 1.65 ]
Razzouk 2006 111 1.3 (2.38) 111 1 (1.9) 1.0 % 0.30 [ -0.27, 0.87 ]
Smith 2003 64 1.37 (1.75) 22 0 (0.91) 1.0 % 1.37 [ 0.80, 1.94 ]
Smith 2008 437 0.79 (2.83) 447 0.29 (2.8) 2.4 % 0.50 [ 0.13, 0.87 ]
Ten Bokkel 1998 61 0.83 (1.74) 24 -0.57 (1.16) 0.8 % 1.40 [ 0.76, 2.04 ]
Thomas 2002 62 1.9 (1.74) 65 0.39 (1.38) 1.1 % 1.51 [ 0.96, 2.06 ]
Thomas 2008 52 1.72 (1.79) 57 0.09 (1.23) 1.0 % 1.63 [ 1.05, 2.21 ]
Throuvalas 2000 28 0.7 (0.95) 26 -0.5 (0.56) 1.9 % 1.20 [ 0.79, 1.61 ]
Tjulandin 2010 149 1.75 (1.59) 74 0.2 (1.74) 1.5 % 1.55 [ 1.08, 2.02 ]
Tjulandin 2011 95 2.1 (1.3) 91 0.65 (1.94) 1.5 % 1.45 [ 0.97, 1.93 ]
Tsuboi 2009 61 1.4 (1.9) 56 -0.8 (1.5) 0.9 % 2.20 [ 1.58, 2.82 ]
Untch 2011˙1 330 -0.07 (2) 359 -0.98 (1.33) 5.1 % 0.91 [ 0.65, 1.17 ]
Wilkinson 2006 114 1.6 (1.5) 59 0.3 (1.3) 1.8 % 1.30 [ 0.87, 1.73 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Witzig 2005 166 2.8 (1.62) 164 0.9 (1.52) 2.9 % 1.90 [ 1.56, 2.24 ]
Total (95% CI) 6322 5287 100.0 % 1.56 [ 1.51, 1.62 ]
Heterogeneity: Chi2 = 556.15, df = 55 (P<0.00001); I2 =90%
Test for overall effect: Z = 53.30 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.16. Comparison 2 Change of haemoglobin level, Outcome 16 Change in Hb values- sensitivity
analysis.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 2 Change of haemoglobin level
Outcome: 16 Change in Hb values- sensitivity analysis





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Abels 1993 63 0.952 (2.142) 55 -0.03 (1.36) 1.1 % 0.99 [ 0.35, 1.63 ]
Boogaerts 2003 133 2.1 (1.83) 129 0.9 (1.5) 2.8 % 1.20 [ 0.80, 1.60 ]
Carabantes 1999 20 1 (1.56) 15 -1.7 (1.22) 0.5 % 2.70 [ 1.78, 3.62 ]
Cascinu 1994 50 1.88 (0.83) 49 -0.61 (0.95) 3.7 % 2.49 [ 2.14, 2.84 ]
Case 1993 79 2.346 (2.04) 74 0.37 (1.46) 1.5 % 1.97 [ 1.41, 2.53 ]
Cazzola 1995a 31 -0.1 (2.23) 7 -0.04 (2.05) 0.2 % -0.06 [ -1.77, 1.65 ]
Cazzola 1995b 29 0.17 (1.72) 8 -0.04 (2.05) 0.2 % 0.21 [ -1.34, 1.76 ]
Cazzola 1995c 31 0.3 (2.9) 7 -0.04 (2.05) 0.1 % 0.34 [ -1.49, 2.17 ]
Cazzola 1995d 26 0.44 (2.29) 7 -0.04 (2.05) 0.1 % 0.48 [ -1.28, 2.24 ]
Charu 2007 220 2.1 (1.854) 55 0.1 (0.927) 3.8 % 2.00 [ 1.65, 2.35 ]
Dammacco 2001 69 1.8 (2.11) 76 -0.2 (1.31) 1.4 % 2.00 [ 1.42, 2.58 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Del Mastro 1997 28 -0.8 (1.4) 24 -3.05 (1) 1.1 % 2.25 [ 1.60, 2.90 ]
Fujisaka 2011 89 1.84 (1.33) 92 0.02 (1.12) 3.6 % 1.82 [ 1.46, 2.18 ]
Gordon 2008 139 1.3 (1.4) 49 0.2 (1) 3.5 % 1.10 [ 0.74, 1.46 ]
Gupta 2009 58 1.55 (0.74) 57 -1.5 (0.61) 7.5 % 3.05 [ 2.80, 3.30 ]
Hedenus 2002a 5 1.56 (1.93) 2 1 (0.56) 0.1 % 0.56 [ -1.30, 2.42 ]
Hedenus 2002b 17 1.64 (1.25) 2 1 (0.56) 0.5 % 0.64 [ -0.34, 1.62 ]
Hedenus 2002c 14 2.46 (1.49) 2 1 (0.56) 0.4 % 1.46 [ 0.36, 2.56 ]
Hedenus 2003 174 1.8 (2.24) 170 0.19 (1.3) 3.1 % 1.61 [ 1.22, 2.00 ]
Henke 1999a 19 3.2 (1.6) 3 0.6 (1.4) 0.2 % 2.60 [ 0.86, 4.34 ]
Henke 1999b 14 3.5 (1.2) 4 0.6 (1.4) 0.2 % 2.90 [ 1.39, 4.41 ]
Henke 1999c 6 3.9 (2.1) 4 0.6 (1.4) 0.1 % 3.30 [ 1.13, 5.47 ]
Henke 2003 Roche 2004 178 3.4 (1.7) 168 0.9 (1.7) 3.6 % 2.50 [ 2.14, 2.86 ]
Henry 1995 63 2.04 (2.38) 61 0.44 (1.7) 0.9 % 1.60 [ 0.87, 2.33 ]
Huddart 2002 45 2.6 (2) 45 1.2 (1.46) 0.9 % 1.40 [ 0.68, 2.12 ]
Iconomou 2003 57 1.7 (1.6) 55 0.3 (1.4) 1.5 % 1.40 [ 0.84, 1.96 ]
Italian 1998 17 1.73 (1.56) 11 -0.14 (1.09) 0.5 % 1.87 [ 0.89, 2.85 ]
Kotasek 2003a 32 0.54 (1.24) 8 -0.02 (1.43) 0.4 % 0.56 [ -0.52, 1.64 ]
Kotasek 2003b 17 0.86 (1.57) 8 -0.02 (1.43) 0.3 % 0.88 [ -0.36, 2.12 ]
Kotasek 2003c 46 0.9 (1.63) 9 -0.02 (1.43) 0.4 % 0.92 [ -0.13, 1.97 ]
Kotasek 2003d 28 1.63 (2.01) 8 -0.02 (1.43) 0.3 % 1.65 [ 0.41, 2.89 ]
Kotasek 2003e 35 1.45 (1.42) 8 -0.02 (1.43) 0.4 % 1.47 [ 0.37, 2.57 ]
Kotasek 2003f 40 1.21 (1.9) 9 -0.02 (1.43) 0.4 % 1.23 [ 0.13, 2.33 ]
Krzakowski 2008a 104 2.5 (2.4) 52 0.6 (1.7) 1.1 % 1.90 [ 1.25, 2.55 ]
Krzakowski 2008b 105 2.5 (2.6) 52 0.6 (1.7) 1.0 % 1.90 [ 1.22, 2.58 ]
Kunikane 2001a 16 0.89 (1.72) 10 -0.65 (1.31) 0.3 % 1.54 [ 0.37, 2.71 ]
Kunikane 2001b 18 1.72 (1.1) 9 -0.65 (1.31) 0.5 % 2.37 [ 1.37, 3.37 ]
Kurz 1997 23 3.26 (1.98) 12 0.25 (1.66) 0.3 % 3.01 [ 1.77, 4.25 ]
Littlewood 2001 244 2.2 (2.18) 115 0.5 (1.79) 2.5 % 1.70 [ 1.27, 2.13 ]
ML17616 2006 30 3.09 (2.08) 30 1.76 (2.28) 0.4 % 1.33 [ 0.23, 2.43 ]
ML17620 2006 61 2.12 (1.64) 60 0.59 (1.83) 1.2 % 1.53 [ 0.91, 2.15 ]
Mystakidou 2005 50 2.4 (1.3) 50 -0.1 (1.02) 2.2 % 2.50 [ 2.04, 2.96 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
O’Shaughnessy 2005 47 0.8 (1.2) 46 -2.1 (1.4) 1.6 % 2.90 [ 2.37, 3.43 ]
Oberhoff 1998 59 2.24 (2) 47 0.6 (1.43) 1.1 % 1.64 [ 0.99, 2.29 ]
Osterborg 1996a 17 2.6 (1.74) 13 1.02 (1.28) 0.4 % 1.58 [ 0.50, 2.66 ]
Osterborg 1996b 27 1.71 (1.67) 14 1.02 (1.28) 0.5 % 0.69 [ -0.23, 1.61 ]
Osterborg 2002 138 2.48 (1.74) 142 0.82 (1.4) 3.3 % 1.66 [ 1.29, 2.03 ]
Pirker 2008 270 -1.13 (1.93) 279 -1.98 (1.87) 4.5 % 0.85 [ 0.53, 1.17 ]
Pronzato 2010 107 1.7 (1.35) 109 0.4 (1.24) 3.8 % 1.30 [ 0.95, 1.65 ]
Razzouk 2006 111 1.3 (2.38) 111 1 (1.9) 1.4 % 0.30 [ -0.27, 0.87 ]
Smith 2003a 21 1.18 (2.01) 7 0 (0.91) 0.4 % 1.18 [ 0.09, 2.27 ]
Smith 2003b 21 1.22 (1.62) 7 0 (0.91) 0.5 % 1.22 [ 0.25, 2.19 ]
Smith 2003c 22 1.7 (1.93) 8 0 (0.91) 0.4 % 1.70 [ 0.68, 2.72 ]
Smith 2008 437 0.79 (2.83) 447 0.29 (2.8) 3.3 % 0.50 [ 0.13, 0.87 ]
Ten Bokkel 1998a 34 0.66 (1.76) 12 -0.57 (1.16) 0.6 % 1.23 [ 0.35, 2.11 ]
Ten Bokkel 1998b 27 1.04 (1.73) 12 -0.57 (1.16) 0.5 % 1.61 [ 0.68, 2.54 ]
Thomas 2002 62 1.9 (1.74) 65 0.39 (1.38) 1.5 % 1.51 [ 0.96, 2.06 ]
Throuvalas 2000 28 0.7 (0.95) 26 -0.5 (0.56) 2.7 % 1.20 [ 0.79, 1.61 ]
Tjulandin 2010a 76 1.6 (1.42) 37 0.2 (1.74) 1.1 % 1.40 [ 0.75, 2.05 ]
Tjulandin 2010b 73 1.9 (1.74) 37 0.2 (1.74) 1.0 % 1.70 [ 1.01, 2.39 ]
Tjulandin 2011 95 2.1 (1.3) 91 0.65 (1.94) 2.0 % 1.45 [ 0.97, 1.93 ]
Tsuboi 2009 61 1.4 (1.9) 56 -0.8 (1.5) 1.2 % 2.20 [ 1.58, 2.82 ]
Untch 2011˙1 330 -0.07 (2) 359 -0.98 (1.33) 7.0 % 0.91 [ 0.65, 1.17 ]
Wilkinson 2006 114 1.6 (1.5) 59 0.3 (1.3) 2.5 % 1.30 [ 0.87, 1.73 ]
Witzig 2005 166 2.8 (1.62) 164 0.9 (1.52) 4.0 % 1.90 [ 1.56, 2.24 ]
Total (95% CI) 4866 3819 100.0 % 1.66 [ 1.59, 1.72 ]
Heterogeneity: Chi2 = 413.54, df = 64 (P<0.00001); I2 =85%
Test for overall effect: Z = 47.91 (P < 0.00001)
Test for subgroup differences: Not applicable
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Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 2 Change of haemoglobin level
Outcome: 17 Change in Hb values - publication sensitivity analysis excluding Henke 2003





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 full text publication
Abels 1993 63 0.952 (2.142) 55 -0.03 (1.36) 0.8 % 0.99 [ 0.35, 1.63 ]
Aravantinos 2003 24 2.31 (1.22) 23 1.23 (1.59) 0.5 % 1.08 [ 0.27, 1.89 ]
Bamias 2003 72 0.57 (2.12) 72 -0.49 (1.36) 1.0 % 1.06 [ 0.48, 1.64 ]
Boogaerts 2003 133 2.1 (1.83) 129 0.9 (1.5) 2.1 % 1.20 [ 0.80, 1.60 ]
Cascinu 1994 50 1.88 (0.83) 49 -0.61 (0.95) 2.8 % 2.49 [ 2.14, 2.84 ]
Case 1993 79 2.346 (2.04) 74 0.37 (1.46) 1.1 % 1.97 [ 1.41, 2.53 ]
Cazzola 1995a 31 -0.1 (2.23) 7 -0.04 (2.05) 0.1 % -0.06 [ -1.77, 1.65 ]
Cazzola 1995b 29 0.17 (1.72) 8 -0.04 (2.05) 0.1 % 0.21 [ -1.34, 1.76 ]
Cazzola 1995c 31 0.3 (2.9) 7 -0.04 (2.05) 0.1 % 0.34 [ -1.49, 2.17 ]
Cazzola 1995d 26 0.44 (2.29) 7 -0.04 (2.05) 0.1 % 0.48 [ -1.28, 2.24 ]
Chang 2005 175 1.14 (0.8) 175 -0.58 (0.73) 13.2 % 1.72 [ 1.56, 1.88 ]
Charu 2007 220 2.1 (1.854) 55 0.1 (0.927) 2.8 % 2.00 [ 1.65, 2.35 ]
Christodoulou 2009 167 2.74 (13.62) 170 0.52 (4.18) 0.1 % 2.22 [ 0.06, 4.38 ]
Del Mastro 1997 28 -0.8 (1.4) 24 -3.05 (1) 0.8 % 2.25 [ 1.60, 2.90 ]
Fujisaka 2011 89 1.84 (1.33) 92 0.02 (1.12) 2.6 % 1.82 [ 1.46, 2.18 ]
Gebbia 2003 22 -2.4 (1.5) 23 -5.1 (1.33) 0.5 % 2.70 [ 1.87, 3.53 ]
Gordon 2008 139 1.3 (1.4) 49 0.2 (1) 2.6 % 1.10 [ 0.74, 1.46 ]
Grote 2005 64 -0.2 (1.38) 58 -2.9 (1.53) 1.3 % 2.70 [ 2.18, 3.22 ]
Gupta 2009 58 1.55 (0.74) 57 -1.5 (0.61) 5.5 % 3.05 [ 2.80, 3.30 ]
Hedenus 2002a 5 1.56 (1.93) 2 1 (0.56) 0.1 % 0.56 [ -1.30, 2.42 ]
Hedenus 2002b 17 1.64 (1.25) 2 1 (0.56) 0.4 % 0.64 [ -0.34, 1.62 ]
Hedenus 2002c 14 2.46 (1.49) 2 1 (0.56) 0.3 % 1.46 [ 0.36, 2.56 ]
Hedenus 2003 174 1.8 (2.24) 170 0.19 (1.3) 2.3 % 1.61 [ 1.22, 2.00 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Henke 1999a 19 3.2 (1.6) 3 0.6 (1.4) 0.1 % 2.60 [ 0.86, 4.34 ]
Henke 1999b 14 3.5 (1.2) 4 0.6 (1.4) 0.1 % 2.90 [ 1.39, 4.41 ]
Henke 1999c 6 3.9 (2.1) 4 0.6 (1.4) 0.1 % 3.30 [ 1.13, 5.47 ]
Henry 1995 63 2.04 (2.38) 61 0.44 (1.7) 0.6 % 1.60 [ 0.87, 2.33 ]
Hoskin 2009 151 0.625 (3.5) 149 -0.47 (3.48) 0.5 % 1.09 [ 0.30, 1.88 ]
Iconomou 2003 57 1.7 (1.6) 55 0.3 (1.4) 1.1 % 1.40 [ 0.84, 1.96 ]
Kotasek 2003a 32 0.54 (1.24) 8 -0.02 (1.43) 0.3 % 0.56 [ -0.52, 1.64 ]
Kotasek 2003b 17 0.86 (1.57) 8 -0.02 (1.43) 0.2 % 0.88 [ -0.36, 2.12 ]
Kotasek 2003c 46 0.9 (1.63) 9 -0.02 (1.43) 0.3 % 0.92 [ -0.13, 1.97 ]
Kotasek 2003d 28 1.63 (2.01) 8 -0.02 (1.43) 0.2 % 1.65 [ 0.41, 2.89 ]
Kotasek 2003e 35 1.45 (1.42) 8 -0.02 (1.43) 0.3 % 1.47 [ 0.37, 2.57 ]
Kotasek 2003f 40 1.21 (1.9) 9 -0.02 (1.43) 0.3 % 1.23 [ 0.13, 2.33 ]
Krzakowski 2008a 104 2.5 (2.4) 52 0.6 (1.7) 0.8 % 1.90 [ 1.25, 2.55 ]
Krzakowski 2008b 105 2.5 (2.6) 52 0.6 (1.7) 0.7 % 1.90 [ 1.22, 2.58 ]
Kunikane 2001a 16 0.89 (1.72) 10 -0.65 (1.31) 0.2 % 1.54 [ 0.37, 2.71 ]
Kunikane 2001b 18 1.72 (1.1) 9 -0.65 (1.31) 0.3 % 2.37 [ 1.37, 3.37 ]
Leyland-Jones 2005 81 0.34 (1.73) 86 0.14 (1.7) 1.3 % 0.20 [ -0.32, 0.72 ]
Littlewood 2001 244 2.2 (2.18) 115 0.5 (1.79) 1.9 % 1.70 [ 1.27, 2.13 ]
Mystakidou 2005 50 2.4 (1.3) 50 -0.1 (1.02) 1.6 % 2.50 [ 2.04, 2.96 ]
O’Shaughnessy 2005 47 0.8 (1.2) 46 -2.1 (1.4) 1.2 % 2.90 [ 2.37, 3.43 ]
Pirker 2008 270 -1.13 (1.93) 279 -1.98 (1.87) 3.4 % 0.85 [ 0.53, 1.17 ]
Pronzato 2010 107 1.7 (1.35) 109 0.4 (1.24) 2.8 % 1.30 [ 0.95, 1.65 ]
Razzouk 2006 111 1.3 (2.38) 111 1 (1.9) 1.1 % 0.30 [ -0.27, 0.87 ]
Smith 2003a 21 1.18 (2.01) 7 0 (0.91) 0.3 % 1.18 [ 0.09, 2.27 ]
Smith 2003b 21 1.22 (1.62) 7 0 (0.91) 0.4 % 1.22 [ 0.25, 2.19 ]
Smith 2003c 22 1.7 (1.93) 8 0 (0.91) 0.3 % 1.70 [ 0.68, 2.72 ]
Smith 2008 437 0.79 (2.83) 447 0.29 (2.8) 2.5 % 0.50 [ 0.13, 0.87 ]
Thomas 2008 52 1.72 (1.79) 57 0.09 (1.23) 1.0 % 1.63 [ 1.05, 2.21 ]
Tjulandin 2010a 76 1.6 (1.42) 37 0.2 (1.74) 0.8 % 1.40 [ 0.75, 2.05 ]
Tjulandin 2010b 73 1.9 (1.74) 37 0.2 (1.74) 0.7 % 1.70 [ 1.01, 2.39 ]
Tjulandin 2011 95 2.1 (1.3) 91 0.65 (1.94) 1.5 % 1.45 [ 0.97, 1.93 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Tsuboi 2009 61 1.4 (1.9) 56 -0.8 (1.5) 0.9 % 2.20 [ 1.58, 2.82 ]
Untch 2011˙1 330 -0.07 (2) 359 -0.98 (1.33) 5.2 % 0.91 [ 0.65, 1.17 ]
Wilkinson 2006 114 1.6 (1.5) 59 0.3 (1.3) 1.8 % 1.30 [ 0.87, 1.73 ]
Witzig 2005 166 2.8 (1.62) 164 0.9 (1.52) 3.0 % 1.90 [ 1.56, 2.24 ]
Subtotal (95% CI) 4839 3884 79.1 % 1.63 [ 1.57, 1.70 ]
Heterogeneity: Chi2 = 430.14, df = 57 (P<0.00001); I2 =87%
Test for overall effect: Z = 48.87 (P < 0.00001)
2 abstract publication
Carabantes 1999 20 1 (1.56) 15 -1.7 (1.22) 0.4 % 2.70 [ 1.78, 3.62 ]
Engert 2009 648 -1.88 (1.78) 655 -2.55 (1.78) 9.1 % 0.67 [ 0.48, 0.86 ]
Huddart 2002 45 2.6 (2) 45 1.2 (1.46) 0.7 % 1.40 [ 0.68, 2.12 ]
Thomas 2002 62 1.9 (1.74) 65 0.39 (1.38) 1.1 % 1.51 [ 0.96, 2.06 ]
Subtotal (95% CI) 775 780 11.3 % 0.87 [ 0.69, 1.04 ]
Heterogeneity: Chi2 = 26.58, df = 3 (P<0.00001); I2 =89%
Test for overall effect: Z = 9.81 (P < 0.00001)
3 unpublished data
Dammacco 2001 69 1.8 (2.11) 76 -0.2 (1.31) 1.0 % 2.00 [ 1.42, 2.58 ]
Italian 1998 17 1.73 (1.56) 11 -0.14 (1.09) 0.4 % 1.87 [ 0.89, 2.85 ]
Kurz 1997 23 3.26 (1.98) 12 0.25 (1.66) 0.2 % 3.01 [ 1.77, 4.25 ]
Oberhoff 1998 59 2.24 (2) 47 0.6 (1.43) 0.8 % 1.64 [ 0.99, 2.29 ]
Osterborg 1996a 17 2.6 (1.74) 13 1.02 (1.28) 0.3 % 1.58 [ 0.50, 2.66 ]
Osterborg 1996b 27 1.71 (1.67) 14 1.02 (1.28) 0.4 % 0.69 [ -0.23, 1.61 ]
Osterborg 2002 138 2.48 (1.74) 142 0.82 (1.4) 2.5 % 1.66 [ 1.29, 2.03 ]
Ten Bokkel 1998a 34 0.66 (1.76) 12 -0.57 (1.16) 0.4 % 1.23 [ 0.35, 2.11 ]
Ten Bokkel 1998b 27 1.04 (1.73) 12 -0.57 (1.16) 0.4 % 1.61 [ 0.68, 2.54 ]
Throuvalas 2000 28 0.7 (0.95) 26 -0.5 (0.56) 2.0 % 1.20 [ 0.79, 1.61 ]
Subtotal (95% CI) 439 365 8.4 % 1.56 [ 1.36, 1.76 ]
Heterogeneity: Chi2 = 15.11, df = 9 (P = 0.09); I2 =40%
Test for overall effect: Z = 15.19 (P < 0.00001)
4 ODAC documents
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
5 clinical study report
ML17616 2006 30 3.09 (2.08) 30 1.76 (2.28) 0.3 % 1.33 [ 0.23, 2.43 ]
ML17620 2006 61 2.12 (1.64) 60 0.59 (1.83) 0.9 % 1.53 [ 0.91, 2.15 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Subtotal (95% CI) 91 90 1.2 % 1.48 [ 0.94, 2.02 ]
Heterogeneity: Chi2 = 0.10, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 5.38 (P < 0.00001)
Total (95% CI) 6144 5119 100.0 % 1.54 [ 1.48, 1.60 ]
Heterogeneity: Chi2 = 537.53, df = 73 (P<0.00001); I2 =86%
Test for overall effect: Z = 51.75 (P < 0.00001)
Test for subgroup differences: Chi2 = 65.62, df = 3 (P = 0.00), I2 =95%
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Analysis 3.1. Comparison 3 Participants receiving red blood cell transfusions, Outcome 1 Participants
receiving red blood cell transfusions - overall.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 3 Participants receiving red blood cell transfusions
Outcome: 1 Participants receiving red blood cell transfusions - overall
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Aapro 2008 33/231 63/232 2.1 % 0.53 [ 0.36, 0.77 ]
Abels 1993 21/63 21/55 0.7 % 0.87 [ 0.54, 1.42 ]
Aravantinos 2003 9/24 23/23 0.8 % 0.39 [ 0.23, 0.64 ]
Bamias 2003 11/72 24/72 0.8 % 0.46 [ 0.24, 0.86 ]
Blohmer 2011 14/127 38/129 1.2 % 0.37 [ 0.21, 0.66 ]
Boogaerts 2003 43/133 67/129 2.2 % 0.62 [ 0.46, 0.84 ]
Carabantes 1999 4/20 13/15 0.5 % 0.23 [ 0.09, 0.57 ]
Cascinu 1994 10/50 28/50 0.9 % 0.36 [ 0.19, 0.65 ]
Case 1993 32/79 36/74 1.2 % 0.83 [ 0.58, 1.19 ]
Cazzola 1995a 7/31 2/7 0.1 % 0.79 [ 0.21, 3.02 ]
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cazzola 1995b 5/29 2/8 0.1 % 0.69 [ 0.16, 2.91 ]
Cazzola 1995c 6/31 2/7 0.1 % 0.68 [ 0.17, 2.68 ]
Cazzola 1995d 4/26 2/7 0.1 % 0.54 [ 0.12, 2.36 ]
Chang 2005 15/175 40/175 1.3 % 0.38 [ 0.22, 0.65 ]
Charu 2007 27/226 13/59 0.7 % 0.54 [ 0.30, 0.98 ]
Christodoulou 2009 16/167 36/170 1.2 % 0.45 [ 0.26, 0.78 ]
Dammacco 2001 19/69 36/76 1.1 % 0.58 [ 0.37, 0.91 ]
Del Mastro 1997 0/31 2/31 0.1 % 0.20 [ 0.01, 4.00 ]
Dunphy 1999 2/13 5/14 0.2 % 0.43 [ 0.10, 1.85 ]
Engert 2010 405/640 467/643 15.3 % 0.87 [ 0.81, 0.94 ]
EPO-INT-3 J%J 2004 21/136 23/65 1.0 % 0.44 [ 0.26, 0.73 ]
Fujisaka 2011 4/89 18/92 0.6 % 0.23 [ 0.08, 0.65 ]
Gebbia 2003 5/22 13/23 0.4 % 0.40 [ 0.17, 0.94 ]
Gordon 2008 18/162 6/56 0.3 % 1.04 [ 0.43, 2.48 ]
Goss 2005 8/52 27/52 0.9 % 0.30 [ 0.15, 0.59 ]
Grote 2005 26/109 42/115 1.3 % 0.65 [ 0.43, 0.99 ]
Gupta 2009 9/58 25/57 0.8 % 0.35 [ 0.18, 0.69 ]
Hedenus 2002a 3/11 2/3 0.1 % 0.41 [ 0.12, 1.43 ]
Hedenus 2002b 6/22 2/4 0.1 % 0.55 [ 0.17, 1.80 ]
Hedenus 2002c 3/22 1/4 0.1 % 0.55 [ 0.07, 4.02 ]
Hedenus 2003 52/167 79/165 2.6 % 0.65 [ 0.49, 0.86 ]
Henry 1995 34/64 42/61 1.4 % 0.77 [ 0.58, 1.03 ]
Hernandez 2009 58/193 91/193 3.0 % 0.64 [ 0.49, 0.83 ]
Huddart 2002 18/45 32/45 1.1 % 0.56 [ 0.38, 0.84 ]
Iconomou 2003 9/57 14/55 0.5 % 0.62 [ 0.29, 1.31 ]
Italian 1998 28/43 35/42 1.2 % 0.78 [ 0.60, 1.01 ]
Katakami 2008 7/103 20/104 0.7 % 0.35 [ 0.16, 0.80 ]
Kotasek 2003a 8/30 4/8 0.2 % 0.53 [ 0.21, 1.33 ]
Kotasek 2003b 5/17 4/8 0.2 % 0.59 [ 0.21, 1.62 ]
Kotasek 2003c 12/41 4/9 0.2 % 0.66 [ 0.28, 1.57 ]
Kotasek 2003d 7/27 4/8 0.2 % 0.52 [ 0.20, 1.33 ]
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kotasek 2003e 9/35 3/8 0.2 % 0.69 [ 0.24, 1.97 ]
Kotasek 2003f 7/38 4/9 0.2 % 0.41 [ 0.15, 1.12 ]
Krzakowski 2008a 27/104 14/52 0.6 % 0.96 [ 0.55, 1.68 ]
Krzakowski 2008b 23/105 14/52 0.6 % 0.81 [ 0.46, 1.45 ]
Kunikane 2001a 1/16 0/9 0.0 % 1.76 [ 0.08, 39.32 ]
Kunikane 2001b 2/18 0/10 0.0 % 2.89 [ 0.15, 54.98 ]
Kurz 1997 5/23 8/12 0.3 % 0.33 [ 0.14, 0.78 ]
Leyland-Jones 2005 47/469 66/470 2.2 % 0.71 [ 0.50, 1.01 ]
Littlewood 2001 62/251 49/124 2.2 % 0.63 [ 0.46, 0.85 ]
Milroy 2011 16/189 43/191 1.4 % 0.38 [ 0.22, 0.64 ]
Moebus 2007 41/320 86/305 2.9 % 0.45 [ 0.32, 0.64 ]
O’Shaughnessy 2005 0/47 4/47 0.1 % 0.11 [ 0.01, 2.01 ]
Oberhoff 1998 32/114 44/104 1.5 % 0.66 [ 0.46, 0.96 ]
Osterborg 1996a 33/47 19/24 0.8 % 0.89 [ 0.67, 1.17 ]
Osterborg 1996b 39/48 20/25 0.9 % 1.02 [ 0.80, 1.29 ]
Osterborg 2002 65/169 90/173 2.9 % 0.74 [ 0.58, 0.94 ]
Pirker 2008 52/298 116/298 3.8 % 0.45 [ 0.34, 0.60 ]
Pronzato 2010 8/107 18/109 0.6 % 0.45 [ 0.21, 1.00 ]
Quirt 1996 4/27 8/27 0.3 % 0.50 [ 0.17, 1.47 ]
Ray-Coquard 2009 39/108 61/105 2.0 % 0.62 [ 0.46, 0.84 ]
Razzouk 2006 72/111 86/111 2.8 % 0.84 [ 0.71, 0.99 ]
Rose 1994 65/142 47/79 2.0 % 0.77 [ 0.60, 0.99 ]
Rosen 2003 19/47 24/43 0.8 % 0.72 [ 0.47, 1.12 ]
Savonije 2005 77/211 66/102 2.9 % 0.56 [ 0.45, 0.71 ]
Smith 2003a 3/20 1/6 0.1 % 0.90 [ 0.11, 7.14 ]
Smith 2003b 1/20 1/7 0.0 % 0.35 [ 0.03, 4.88 ]
Smith 2003c 2/21 2/7 0.1 % 0.33 [ 0.06, 1.94 ]
Smith 2008 176/419 215/432 7.0 % 0.84 [ 0.73, 0.98 ]
Strauss 2008 9/34 12/40 0.4 % 0.88 [ 0.42, 1.84 ]
Ten Bokkel 1998a 2/45 7/17 0.3 % 0.11 [ 0.02, 0.47 ]
Ten Bokkel 1998b 6/42 6/16 0.3 % 0.38 [ 0.14, 1.01 ]
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Thatcher 1999a 19/42 13/22 0.6 % 0.77 [ 0.47, 1.24 ]
Thatcher 1999b 9/44 13/22 0.6 % 0.35 [ 0.18, 0.68 ]
Thomas 2002 7/62 31/65 1.0 % 0.24 [ 0.11, 0.50 ]
Thompson 2000 34/45 19/21 0.9 % 0.84 [ 0.67, 1.04 ]
Throuvalas 2000 2/28 10/26 0.3 % 0.19 [ 0.04, 0.77 ]
Tjulandin 2010a 8/76 9/37 0.4 % 0.43 [ 0.18, 1.03 ]
Tjulandin 2010b 9/73 9/37 0.4 % 0.51 [ 0.22, 1.17 ]
Tjulandin 2011 13/95 23/91 0.8 % 0.54 [ 0.29, 1.00 ]
Tsuboi 2009 7/61 7/56 0.2 % 0.92 [ 0.34, 2.45 ]
Untch 2011˙1 1/356 0/377 0.0 % 3.18 [ 0.13, 77.72 ]
Vansteenkiste 02 FDA 2004 53/156 89/158 2.9 % 0.60 [ 0.47, 0.78 ]
Welch 1995 4/15 8/15 0.3 % 0.50 [ 0.19, 1.31 ]
Wilkinson 2006 9/114 18/59 0.8 % 0.26 [ 0.12, 0.54 ]
Witzig 2005 42/166 65/164 2.2 % 0.64 [ 0.46, 0.88 ]
Wright 2007 5/33 10/37 0.3 % 0.56 [ 0.21, 1.47 ]
Wurnig 1996 8/15 14/14 0.5 % 0.55 [ 0.34, 0.88 ]
Total (95% CI) 8733 7360 100.0 % 0.65 [ 0.62, 0.68 ]
Total events: 2198 (Treatment), 2880 (Control)
Heterogeneity: Chi2 = 217.08, df = 87 (P<0.00001); I2 =60%
Test for overall effect: Z = 19.89 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 Participants receiving red blood cell transfusions, Outcome 2 Participants
receiving red blood cell transfusions - baseline Hb.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 3 Participants receiving red blood cell transfusions
Outcome: 2 Participants receiving red blood cell transfusions - baseline Hb
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hb <=10 g/dL
Abels 1993 21/63 21/55 0.7 % 0.87 [ 0.54, 1.42 ]
Aravantinos 2003 9/24 23/23 0.8 % 0.39 [ 0.23, 0.64 ]
Boogaerts 2003 43/133 67/129 2.2 % 0.62 [ 0.46, 0.84 ]
Cascinu 1994 10/50 28/50 0.9 % 0.36 [ 0.19, 0.65 ]
Case 1993 32/79 36/74 1.2 % 0.83 [ 0.58, 1.19 ]
Cazzola 1995a 7/31 2/7 0.1 % 0.79 [ 0.21, 3.02 ]
Cazzola 1995b 5/29 2/8 0.1 % 0.69 [ 0.16, 2.91 ]
Cazzola 1995c 6/31 2/7 0.1 % 0.68 [ 0.17, 2.68 ]
Cazzola 1995d 4/26 2/7 0.1 % 0.54 [ 0.12, 2.36 ]
Dammacco 2001 19/69 36/76 1.1 % 0.58 [ 0.37, 0.91 ]
Fujisaka 2011 4/89 18/92 0.6 % 0.23 [ 0.08, 0.65 ]
Hedenus 2002a 3/11 2/3 0.1 % 0.41 [ 0.12, 1.43 ]
Hedenus 2002b 6/22 2/4 0.1 % 0.55 [ 0.17, 1.80 ]
Hedenus 2002c 3/22 1/4 0.1 % 0.55 [ 0.07, 4.02 ]
Hedenus 2003 52/167 79/165 2.6 % 0.65 [ 0.49, 0.86 ]
Henry 1995 34/64 42/61 1.4 % 0.77 [ 0.58, 1.03 ]
Italian 1998 28/43 35/42 1.2 % 0.78 [ 0.60, 1.01 ]
Kotasek 2003a 8/30 4/8 0.2 % 0.53 [ 0.21, 1.33 ]
Kotasek 2003b 5/17 4/8 0.2 % 0.59 [ 0.21, 1.62 ]
Kotasek 2003c 12/41 4/9 0.2 % 0.66 [ 0.28, 1.57 ]
Kotasek 2003d 7/27 4/8 0.2 % 0.52 [ 0.20, 1.33 ]
Kotasek 2003e 9/35 3/8 0.2 % 0.69 [ 0.24, 1.97 ]
Kotasek 2003f 7/38 4/9 0.2 % 0.41 [ 0.15, 1.12 ]
Krzakowski 2008a 27/104 14/52 0.6 % 0.96 [ 0.55, 1.68 ]
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Krzakowski 2008b 23/105 14/52 0.6 % 0.81 [ 0.46, 1.45 ]
Kurz 1997 5/23 8/12 0.3 % 0.33 [ 0.14, 0.78 ]
Littlewood 2001 62/251 49/124 2.2 % 0.63 [ 0.46, 0.85 ]
Oberhoff 1998 32/114 44/104 1.5 % 0.66 [ 0.46, 0.96 ]
Osterborg 1996a 33/47 19/24 0.8 % 0.89 [ 0.67, 1.17 ]
Osterborg 1996b 39/48 20/25 0.9 % 1.02 [ 0.80, 1.29 ]
Osterborg 2002 65/169 90/173 2.9 % 0.74 [ 0.58, 0.94 ]
Razzouk 2006 72/111 86/111 2.8 % 0.84 [ 0.71, 0.99 ]
Rose 1994 65/142 47/79 2.0 % 0.77 [ 0.60, 0.99 ]
Smith 2003a 3/20 1/6 0.1 % 0.90 [ 0.11, 7.14 ]
Smith 2003b 1/20 1/7 0.0 % 0.35 [ 0.03, 4.88 ]
Smith 2003c 2/21 2/7 0.1 % 0.33 [ 0.06, 1.94 ]
Smith 2008 176/419 215/432 7.0 % 0.84 [ 0.73, 0.98 ]
Thompson 2000 34/45 19/21 0.9 % 0.84 [ 0.67, 1.04 ]
Tjulandin 2010a 8/76 9/37 0.4 % 0.43 [ 0.18, 1.03 ]
Tjulandin 2010b 9/73 9/37 0.4 % 0.51 [ 0.22, 1.17 ]
Tjulandin 2011 13/95 23/91 0.8 % 0.54 [ 0.29, 1.00 ]
Witzig 2005 42/166 65/164 2.2 % 0.64 [ 0.46, 0.88 ]
Subtotal (95% CI) 3190 2415 41.1 % 0.71 [ 0.67, 0.76 ]
Total events: 1045 (Treatment), 1156 (Control)
Heterogeneity: Chi2 = 53.76, df = 41 (P = 0.09); I2 =24%
Test for overall effect: Z = 10.54 (P < 0.00001)
2 Hb 10 to 12 g/dL
Aapro 2008 33/231 63/232 2.1 % 0.53 [ 0.36, 0.77 ]
Bamias 2003 11/72 24/72 0.8 % 0.46 [ 0.24, 0.86 ]
Blohmer 2011 14/127 38/129 1.2 % 0.37 [ 0.21, 0.66 ]
Carabantes 1999 4/20 13/15 0.5 % 0.23 [ 0.09, 0.57 ]
Chang 2005 15/175 40/175 1.3 % 0.38 [ 0.22, 0.65 ]
Charu 2007 27/226 13/59 0.7 % 0.54 [ 0.30, 0.98 ]
Christodoulou 2009 16/167 36/170 1.2 % 0.45 [ 0.26, 0.78 ]
EPO-INT-3 J%J 2004 21/136 23/65 1.0 % 0.44 [ 0.26, 0.73 ]
Gordon 2008 18/162 6/56 0.3 % 1.04 [ 0.43, 2.48 ]
Gupta 2009 9/58 25/57 0.8 % 0.35 [ 0.18, 0.69 ]
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hernandez 2009 58/193 91/193 3.0 % 0.64 [ 0.49, 0.83 ]
Huddart 2002 18/45 32/45 1.1 % 0.56 [ 0.38, 0.84 ]
Iconomou 2003 9/57 14/55 0.5 % 0.62 [ 0.29, 1.31 ]
Katakami 2008 7/103 20/104 0.7 % 0.35 [ 0.16, 0.80 ]
Pirker 2008 52/298 116/298 3.8 % 0.45 [ 0.34, 0.60 ]
Pronzato 2010 8/107 18/109 0.6 % 0.45 [ 0.21, 1.00 ]
Quirt 1996 4/27 8/27 0.3 % 0.50 [ 0.17, 1.47 ]
Ray-Coquard 2009 39/108 61/105 2.0 % 0.62 [ 0.46, 0.84 ]
Savonije 2005 77/211 66/102 2.9 % 0.56 [ 0.45, 0.71 ]
Strauss 2008 9/34 12/40 0.4 % 0.88 [ 0.42, 1.84 ]
Ten Bokkel 1998a 2/45 7/17 0.3 % 0.11 [ 0.02, 0.47 ]
Ten Bokkel 1998b 6/42 6/16 0.3 % 0.38 [ 0.14, 1.01 ]
Thomas 2002 7/62 31/65 1.0 % 0.24 [ 0.11, 0.50 ]
Throuvalas 2000 2/28 10/26 0.3 % 0.19 [ 0.04, 0.77 ]
Tsuboi 2009 7/61 7/56 0.2 % 0.92 [ 0.34, 2.45 ]
Vansteenkiste 02 FDA 2004 53/156 89/158 2.9 % 0.60 [ 0.47, 0.78 ]
Wilkinson 2006 9/114 18/59 0.8 % 0.26 [ 0.12, 0.54 ]
Wright 2007 5/33 10/37 0.3 % 0.56 [ 0.21, 1.47 ]
Wurnig 1996 8/15 14/14 0.5 % 0.55 [ 0.34, 0.88 ]
Subtotal (95% CI) 3113 2556 31.8 % 0.50 [ 0.46, 0.55 ]
Total events: 548 (Treatment), 911 (Control)
Heterogeneity: Chi2 = 36.86, df = 28 (P = 0.12); I2 =24%
Test for overall effect: Z = 15.03 (P < 0.00001)
3 Hb > 12 g/dL
Del Mastro 1997 0/31 2/31 0.1 % 0.20 [ 0.01, 4.00 ]
Dunphy 1999 2/13 5/14 0.2 % 0.43 [ 0.10, 1.85 ]
Engert 2010 405/640 467/643 15.3 % 0.87 [ 0.81, 0.94 ]
Gebbia 2003 5/22 13/23 0.4 % 0.40 [ 0.17, 0.94 ]
Goss 2005 8/52 27/52 0.9 % 0.30 [ 0.15, 0.59 ]
Grote 2005 26/109 42/115 1.3 % 0.65 [ 0.43, 0.99 ]
Kunikane 2001a 1/16 0/9 0.0 % 1.76 [ 0.08, 39.32 ]
Kunikane 2001b 2/18 0/10 0.0 % 2.89 [ 0.15, 54.98 ]
Leyland-Jones 2005 47/469 66/470 2.2 % 0.71 [ 0.50, 1.01 ]
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Milroy 2011 16/189 43/191 1.4 % 0.38 [ 0.22, 0.64 ]
Moebus 2007 41/320 86/305 2.9 % 0.45 [ 0.32, 0.64 ]
O’Shaughnessy 2005 0/47 4/47 0.1 % 0.11 [ 0.01, 2.01 ]
Rosen 2003 19/47 24/43 0.8 % 0.72 [ 0.47, 1.12 ]
Thatcher 1999a 19/42 13/22 0.6 % 0.77 [ 0.47, 1.24 ]
Thatcher 1999b 9/44 13/22 0.6 % 0.35 [ 0.18, 0.68 ]
Untch 2011˙1 1/356 0/377 0.0 % 3.18 [ 0.13, 77.72 ]
Welch 1995 4/15 8/15 0.3 % 0.50 [ 0.19, 1.31 ]
Subtotal (95% CI) 2430 2389 27.1 % 0.73 [ 0.67, 0.78 ]
Total events: 605 (Treatment), 813 (Control)
Heterogeneity: Chi2 = 54.28, df = 16 (P<0.00001); I2 =71%
Test for overall effect: Z = 8.52 (P < 0.00001)
4 unclear
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (Treatment), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 8733 7360 100.0 % 0.65 [ 0.62, 0.68 ]
Total events: 2198 (Treatment), 2880 (Control)
Heterogeneity: Chi2 = 217.08, df = 87 (P<0.00001); I2 =60%
Test for overall effect: Z = 19.89 (P < 0.00001)
Test for subgroup differences: Chi2 = 48.26, df = 2 (P = 0.00), I2 =96%
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Analysis 3.3. Comparison 3 Participants receiving red blood cell transfusions, Outcome 3 Participants
receiving red blood cell transfusions - different malignancies.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 3 Participants receiving red blood cell transfusions
Outcome: 3 Participants receiving red blood cell transfusions - different malignancies
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 solid tumours
Aapro 2008 33/231 63/232 2.1 % 0.53 [ 0.36, 0.77 ]
Aravantinos 2003 9/24 23/23 0.8 % 0.39 [ 0.23, 0.64 ]
Bamias 2003 11/72 24/72 0.8 % 0.46 [ 0.24, 0.86 ]
Blohmer 2011 14/127 38/129 1.2 % 0.37 [ 0.21, 0.66 ]
Carabantes 1999 4/20 13/15 0.5 % 0.23 [ 0.09, 0.57 ]
Cascinu 1994 10/50 28/50 0.9 % 0.36 [ 0.19, 0.65 ]
Chang 2005 15/175 40/175 1.3 % 0.38 [ 0.22, 0.65 ]
Christodoulou 2009 16/167 36/170 1.2 % 0.45 [ 0.26, 0.78 ]
Del Mastro 1997 0/31 2/31 0.1 % 0.20 [ 0.01, 4.00 ]
Dunphy 1999 2/13 5/14 0.2 % 0.43 [ 0.10, 1.85 ]
Fujisaka 2011 4/89 18/92 0.6 % 0.23 [ 0.08, 0.65 ]
Gebbia 2003 5/22 13/23 0.4 % 0.40 [ 0.17, 0.94 ]
Goss 2005 8/52 27/52 0.9 % 0.30 [ 0.15, 0.59 ]
Grote 2005 26/109 42/115 1.3 % 0.65 [ 0.43, 0.99 ]
Gupta 2009 9/58 25/57 0.8 % 0.35 [ 0.18, 0.69 ]
Huddart 2002 18/45 32/45 1.1 % 0.56 [ 0.38, 0.84 ]
Iconomou 2003 9/57 14/55 0.5 % 0.62 [ 0.29, 1.31 ]
Katakami 2008 7/103 20/104 0.7 % 0.35 [ 0.16, 0.80 ]
Kotasek 2003a 8/30 4/8 0.2 % 0.53 [ 0.21, 1.33 ]
Kotasek 2003b 5/17 4/8 0.2 % 0.59 [ 0.21, 1.62 ]
Kotasek 2003c 12/41 4/9 0.2 % 0.66 [ 0.28, 1.57 ]
Kotasek 2003d 7/27 4/8 0.2 % 0.52 [ 0.20, 1.33 ]
Kotasek 2003e 9/35 3/8 0.2 % 0.69 [ 0.24, 1.97 ]
Kotasek 2003f 7/38 4/9 0.2 % 0.41 [ 0.15, 1.12 ]
0.01 0.1 1 10 100
Favours Treatment Favours Control
(Continued . . . )
305Erythropoietin or darbepoetin for patients with cancer (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kunikane 2001a 1/16 0/9 0.0 % 1.76 [ 0.08, 39.32 ]
Kunikane 2001b 2/18 0/10 0.0 % 2.89 [ 0.15, 54.98 ]
Kurz 1997 5/23 8/12 0.3 % 0.33 [ 0.14, 0.78 ]
Leyland-Jones 2005 47/469 66/470 2.2 % 0.71 [ 0.50, 1.01 ]
Littlewood 2001 33/136 24/66 1.1 % 0.67 [ 0.43, 1.03 ]
Milroy 2011 16/189 43/191 1.4 % 0.38 [ 0.22, 0.64 ]
Moebus 2007 41/320 86/305 2.9 % 0.45 [ 0.32, 0.64 ]
O’Shaughnessy 2005 0/47 4/47 0.1 % 0.11 [ 0.01, 2.01 ]
Oberhoff 1998 32/114 44/104 1.5 % 0.66 [ 0.46, 0.96 ]
Pirker 2008 52/298 116/298 3.8 % 0.45 [ 0.34, 0.60 ]
Pronzato 2010 8/107 18/109 0.6 % 0.45 [ 0.21, 1.00 ]
Rosen 2003 19/47 24/43 0.8 % 0.72 [ 0.47, 1.12 ]
Savonije 2005 77/211 66/102 2.9 % 0.56 [ 0.45, 0.71 ]
Strauss 2008 9/34 12/40 0.4 % 0.88 [ 0.42, 1.84 ]
Ten Bokkel 1998a 2/45 7/17 0.3 % 0.11 [ 0.02, 0.47 ]
Ten Bokkel 1998b 6/42 6/16 0.3 % 0.38 [ 0.14, 1.01 ]
Thatcher 1999a 19/42 13/22 0.6 % 0.77 [ 0.47, 1.24 ]
Thatcher 1999b 9/44 13/22 0.6 % 0.35 [ 0.18, 0.68 ]
Thomas 2002 7/62 31/65 1.0 % 0.24 [ 0.11, 0.50 ]
Throuvalas 2000 2/28 10/26 0.3 % 0.19 [ 0.04, 0.77 ]
Tjulandin 2010a 8/76 9/37 0.4 % 0.43 [ 0.18, 1.03 ]
Tjulandin 2010b 9/73 9/37 0.4 % 0.51 [ 0.22, 1.17 ]
Untch 2011˙1 1/356 0/377 0.0 % 3.18 [ 0.13, 77.72 ]
Vansteenkiste 02 FDA 2004 53/156 89/158 2.9 % 0.60 [ 0.47, 0.78 ]
Welch 1995 4/15 8/15 0.3 % 0.50 [ 0.19, 1.31 ]
Wilkinson 2006 9/114 18/59 0.8 % 0.26 [ 0.12, 0.54 ]
Witzig 2005 42/166 65/164 2.2 % 0.64 [ 0.46, 0.88 ]
Wright 2007 5/33 10/37 0.3 % 0.56 [ 0.21, 1.47 ]
Wurnig 1996 8/15 14/14 0.5 % 0.55 [ 0.34, 0.88 ]
Subtotal (95% CI) 4929 4376 45.4 % 0.50 [ 0.46, 0.54 ]
Total events: 774 (Treatment), 1299 (Control)
Heterogeneity: Chi2 = 60.78, df = 52 (P = 0.19); I2 =14%
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Test for overall effect: Z = 17.82 (P < 0.00001)
2 haematological malignancies
Cazzola 1995a 7/31 2/7 0.1 % 0.79 [ 0.21, 3.02 ]
Cazzola 1995b 5/29 2/8 0.1 % 0.69 [ 0.16, 2.91 ]
Cazzola 1995c 6/31 2/7 0.1 % 0.68 [ 0.17, 2.68 ]
Cazzola 1995d 4/26 2/7 0.1 % 0.54 [ 0.12, 2.36 ]
Dammacco 2001 19/69 36/76 1.1 % 0.58 [ 0.37, 0.91 ]
Engert 2010 405/640 467/643 15.3 % 0.87 [ 0.81, 0.94 ]
Hedenus 2002a 3/11 2/3 0.1 % 0.41 [ 0.12, 1.43 ]
Hedenus 2002b 6/22 2/4 0.1 % 0.55 [ 0.17, 1.80 ]
Hedenus 2002c 3/22 1/4 0.1 % 0.55 [ 0.07, 4.02 ]
Hedenus 2003 52/167 79/165 2.6 % 0.65 [ 0.49, 0.86 ]
Littlewood 2001 29/115 25/58 1.1 % 0.59 [ 0.38, 0.90 ]
Osterborg 1996a 33/47 19/24 0.8 % 0.89 [ 0.67, 1.17 ]
Osterborg 1996b 39/48 20/25 0.9 % 1.02 [ 0.80, 1.29 ]
Osterborg 2002 65/169 90/173 2.9 % 0.74 [ 0.58, 0.94 ]
Rose 1994 65/142 47/79 2.0 % 0.77 [ 0.60, 0.99 ]
Subtotal (95% CI) 1569 1283 27.5 % 0.80 [ 0.75, 0.86 ]
Total events: 741 (Treatment), 796 (Control)
Heterogeneity: Chi2 = 17.50, df = 14 (P = 0.23); I2 =20%
Test for overall effect: Z = 6.64 (P < 0.00001)
3 MDS
Italian 1998 28/43 35/42 1.2 % 0.78 [ 0.60, 1.01 ]
Thompson 2000 34/45 19/21 0.9 % 0.84 [ 0.67, 1.04 ]
Subtotal (95% CI) 88 63 2.0 % 0.80 [ 0.68, 0.96 ]
Total events: 62 (Treatment), 54 (Control)
Heterogeneity: Chi2 = 0.16, df = 1 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 2.46 (P = 0.014)
4 mixed
Abels 1993 21/63 21/55 0.7 % 0.87 [ 0.54, 1.42 ]
Boogaerts 2003 43/133 67/129 2.2 % 0.62 [ 0.46, 0.84 ]
Case 1993 32/79 36/74 1.2 % 0.83 [ 0.58, 1.19 ]
Charu 2007 27/226 13/59 0.7 % 0.54 [ 0.30, 0.98 ]
EPO-INT-3 J%J 2004 21/136 23/65 1.0 % 0.44 [ 0.26, 0.73 ]
Gordon 2008 18/162 6/56 0.3 % 1.04 [ 0.43, 2.48 ]
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Henry 1995 34/64 42/61 1.4 % 0.77 [ 0.58, 1.03 ]
Hernandez 2009 58/193 91/193 3.0 % 0.64 [ 0.49, 0.83 ]
Krzakowski 2008a 27/104 14/52 0.6 % 0.96 [ 0.55, 1.68 ]
Krzakowski 2008b 23/105 14/52 0.6 % 0.81 [ 0.46, 1.45 ]
Quirt 1996 4/27 8/27 0.3 % 0.50 [ 0.17, 1.47 ]
Ray-Coquard 2009 39/108 61/105 2.0 % 0.62 [ 0.46, 0.84 ]
Razzouk 2006 72/111 86/111 2.8 % 0.84 [ 0.71, 0.99 ]
Smith 2003a 3/20 1/6 0.1 % 0.90 [ 0.11, 7.14 ]
Smith 2003b 1/20 1/7 0.0 % 0.35 [ 0.03, 4.88 ]
Smith 2003c 2/21 2/7 0.1 % 0.33 [ 0.06, 1.94 ]
Smith 2008 176/419 215/432 7.0 % 0.84 [ 0.73, 0.98 ]
Tjulandin 2011 13/95 23/91 0.8 % 0.54 [ 0.29, 1.00 ]
Tsuboi 2009 7/61 7/56 0.2 % 0.92 [ 0.34, 2.45 ]
Subtotal (95% CI) 2147 1638 25.1 % 0.74 [ 0.68, 0.80 ]
Total events: 621 (Treatment), 731 (Control)
Heterogeneity: Chi2 = 19.35, df = 18 (P = 0.37); I2 =7%
Test for overall effect: Z = 7.20 (P < 0.00001)
5 not reported
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (Treatment), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 8733 7360 100.0 % 0.65 [ 0.62, 0.68 ]
Total events: 2198 (Treatment), 2880 (Control)
Heterogeneity: Chi2 = 217.26, df = 88 (P<0.00001); I2 =59%
Test for overall effect: Z = 19.89 (P < 0.00001)
Test for subgroup differences: Chi2 = 97.22, df = 3 (P = 0.0), I2 =97%
0.01 0.1 1 10 100
Favours Treatment Favours Control
308Erythropoietin or darbepoetin for patients with cancer (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.4. Comparison 3 Participants receiving red blood cell transfusions, Outcome 4 Participants
receiving red blood cell transfusions - age.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 3 Participants receiving red blood cell transfusions
Outcome: 4 Participants receiving red blood cell transfusions - age
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 children
Razzouk 2006 72/111 86/111 2.8 % 0.84 [ 0.71, 0.99 ]
Subtotal (95% CI) 111 111 2.8 % 0.84 [ 0.71, 0.99 ]
Total events: 72 (Treatment), 86 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.05 (P = 0.040)
2 adults
Aapro 2008 33/231 63/232 2.1 % 0.53 [ 0.36, 0.77 ]
Abels 1993 21/63 21/55 0.7 % 0.87 [ 0.54, 1.42 ]
Aravantinos 2003 9/24 23/23 0.8 % 0.39 [ 0.23, 0.64 ]
Bamias 2003 11/72 24/72 0.8 % 0.46 [ 0.24, 0.86 ]
Blohmer 2011 14/127 38/129 1.2 % 0.37 [ 0.21, 0.66 ]
Boogaerts 2003 43/133 67/129 2.2 % 0.62 [ 0.46, 0.84 ]
Carabantes 1999 4/20 13/15 0.5 % 0.23 [ 0.09, 0.57 ]
Cascinu 1994 10/50 28/50 0.9 % 0.36 [ 0.19, 0.65 ]
Case 1993 32/79 36/74 1.2 % 0.83 [ 0.58, 1.19 ]
Cazzola 1995a 7/31 2/7 0.1 % 0.79 [ 0.21, 3.02 ]
Cazzola 1995b 5/29 2/8 0.1 % 0.69 [ 0.16, 2.91 ]
Cazzola 1995c 6/31 2/7 0.1 % 0.68 [ 0.17, 2.68 ]
Cazzola 1995d 4/26 2/7 0.1 % 0.54 [ 0.12, 2.36 ]
Chang 2005 15/175 40/175 1.3 % 0.38 [ 0.22, 0.65 ]
Charu 2007 27/226 13/59 0.7 % 0.54 [ 0.30, 0.98 ]
Christodoulou 2009 16/167 36/170 1.2 % 0.45 [ 0.26, 0.78 ]
Dammacco 2001 19/69 36/76 1.1 % 0.58 [ 0.37, 0.91 ]
Del Mastro 1997 0/31 2/31 0.1 % 0.20 [ 0.01, 4.00 ]
Dunphy 1999 2/13 5/14 0.2 % 0.43 [ 0.10, 1.85 ]
Engert 2010 405/640 467/643 15.3 % 0.87 [ 0.81, 0.94 ]
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
EPO-INT-3 J%J 2004 21/136 23/65 1.0 % 0.44 [ 0.26, 0.73 ]
Fujisaka 2011 4/89 18/92 0.6 % 0.23 [ 0.08, 0.65 ]
Gebbia 2003 5/22 13/23 0.4 % 0.40 [ 0.17, 0.94 ]
Gordon 2008 18/162 6/56 0.3 % 1.04 [ 0.43, 2.48 ]
Goss 2005 8/52 27/52 0.9 % 0.30 [ 0.15, 0.59 ]
Grote 2005 26/109 42/115 1.3 % 0.65 [ 0.43, 0.99 ]
Gupta 2009 9/58 25/57 0.8 % 0.35 [ 0.18, 0.69 ]
Hedenus 2002a 3/11 2/3 0.1 % 0.41 [ 0.12, 1.43 ]
Hedenus 2002b 6/22 2/4 0.1 % 0.55 [ 0.17, 1.80 ]
Hedenus 2002c 3/22 1/4 0.1 % 0.55 [ 0.07, 4.02 ]
Hedenus 2003 52/167 79/165 2.6 % 0.65 [ 0.49, 0.86 ]
Henry 1995 34/64 42/61 1.4 % 0.77 [ 0.58, 1.03 ]
Hernandez 2009 58/193 91/193 3.0 % 0.64 [ 0.49, 0.83 ]
Huddart 2002 18/45 32/45 1.1 % 0.56 [ 0.38, 0.84 ]
Iconomou 2003 9/57 14/55 0.5 % 0.62 [ 0.29, 1.31 ]
Italian 1998 28/43 35/42 1.2 % 0.78 [ 0.60, 1.01 ]
Katakami 2008 7/103 20/104 0.7 % 0.35 [ 0.16, 0.80 ]
Kotasek 2003a 8/30 4/8 0.2 % 0.53 [ 0.21, 1.33 ]
Kotasek 2003b 5/17 4/8 0.2 % 0.59 [ 0.21, 1.62 ]
Kotasek 2003c 12/41 4/9 0.2 % 0.66 [ 0.28, 1.57 ]
Kotasek 2003d 7/27 4/8 0.2 % 0.52 [ 0.20, 1.33 ]
Kotasek 2003e 9/35 3/8 0.2 % 0.69 [ 0.24, 1.97 ]
Kotasek 2003f 7/38 4/9 0.2 % 0.41 [ 0.15, 1.12 ]
Krzakowski 2008a 27/104 14/52 0.6 % 0.96 [ 0.55, 1.68 ]
Krzakowski 2008b 23/105 14/52 0.6 % 0.81 [ 0.46, 1.45 ]
Kunikane 2001a 1/16 0/9 0.0 % 1.76 [ 0.08, 39.32 ]
Kunikane 2001b 2/18 0/10 0.0 % 2.89 [ 0.15, 54.98 ]
Kurz 1997 5/23 8/12 0.3 % 0.33 [ 0.14, 0.78 ]
Leyland-Jones 2005 47/469 66/470 2.2 % 0.71 [ 0.50, 1.01 ]
Littlewood 2001 62/251 49/124 2.2 % 0.63 [ 0.46, 0.85 ]
Milroy 2011 16/189 43/191 1.4 % 0.38 [ 0.22, 0.64 ]
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Moebus 2007 41/320 86/305 2.9 % 0.45 [ 0.32, 0.64 ]
O’Shaughnessy 2005 0/47 4/47 0.1 % 0.11 [ 0.01, 2.01 ]
Oberhoff 1998 32/114 44/104 1.5 % 0.66 [ 0.46, 0.96 ]
Osterborg 1996a 33/47 19/24 0.8 % 0.89 [ 0.67, 1.17 ]
Osterborg 1996b 39/48 20/25 0.9 % 1.02 [ 0.80, 1.29 ]
Osterborg 2002 65/169 90/173 2.9 % 0.74 [ 0.58, 0.94 ]
Pirker 2008 52/298 116/298 3.8 % 0.45 [ 0.34, 0.60 ]
Pronzato 2010 8/107 18/109 0.6 % 0.45 [ 0.21, 1.00 ]
Quirt 1996 4/27 8/27 0.3 % 0.50 [ 0.17, 1.47 ]
Ray-Coquard 2009 39/108 61/105 2.0 % 0.62 [ 0.46, 0.84 ]
Rose 1994 65/142 47/79 2.0 % 0.77 [ 0.60, 0.99 ]
Rosen 2003 19/47 24/43 0.8 % 0.72 [ 0.47, 1.12 ]
Savonije 2005 77/211 66/102 2.9 % 0.56 [ 0.45, 0.71 ]
Smith 2003a 3/20 1/6 0.1 % 0.90 [ 0.11, 7.14 ]
Smith 2003b 1/20 1/7 0.0 % 0.35 [ 0.03, 4.88 ]
Smith 2003c 2/21 2/7 0.1 % 0.33 [ 0.06, 1.94 ]
Smith 2008 176/419 215/432 7.0 % 0.84 [ 0.73, 0.98 ]
Strauss 2008 9/34 12/40 0.4 % 0.88 [ 0.42, 1.84 ]
Ten Bokkel 1998a 2/45 7/17 0.3 % 0.11 [ 0.02, 0.47 ]
Ten Bokkel 1998b 6/42 6/16 0.3 % 0.38 [ 0.14, 1.01 ]
Thatcher 1999a 19/42 13/22 0.6 % 0.77 [ 0.47, 1.24 ]
Thatcher 1999b 9/44 13/22 0.6 % 0.35 [ 0.18, 0.68 ]
Thomas 2002 7/62 31/65 1.0 % 0.24 [ 0.11, 0.50 ]
Thompson 2000 34/45 19/21 0.9 % 0.84 [ 0.67, 1.04 ]
Throuvalas 2000 2/28 10/26 0.3 % 0.19 [ 0.04, 0.77 ]
Tjulandin 2010a 8/76 9/37 0.4 % 0.43 [ 0.18, 1.03 ]
Tjulandin 2010b 9/73 9/37 0.4 % 0.51 [ 0.22, 1.17 ]
Tjulandin 2011 13/95 23/91 0.8 % 0.54 [ 0.29, 1.00 ]
Tsuboi 2009 7/61 7/56 0.2 % 0.92 [ 0.34, 2.45 ]
Untch 2011˙1 1/356 0/377 0.0 % 3.18 [ 0.13, 77.72 ]
Vansteenkiste 02 FDA 2004 53/156 89/158 2.9 % 0.60 [ 0.47, 0.78 ]
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Welch 1995 4/15 8/15 0.3 % 0.50 [ 0.19, 1.31 ]
Wilkinson 2006 9/114 18/59 0.8 % 0.26 [ 0.12, 0.54 ]
Witzig 2005 42/166 65/164 2.2 % 0.64 [ 0.46, 0.88 ]
Wright 2007 5/33 10/37 0.3 % 0.56 [ 0.21, 1.47 ]
Wurnig 1996 8/15 14/14 0.5 % 0.55 [ 0.34, 0.88 ]
Subtotal (95% CI) 8622 7249 97.2 % 0.64 [ 0.62, 0.67 ]
Total events: 2126 (Treatment), 2794 (Control)
Heterogeneity: Chi2 = 211.91, df = 86 (P<0.00001); I2 =59%
Test for overall effect: Z = 19.79 (P < 0.00001)
Total (95% CI) 8733 7360 100.0 % 0.65 [ 0.62, 0.68 ]
Total events: 2198 (Treatment), 2880 (Control)
Heterogeneity: Chi2 = 217.08, df = 87 (P<0.00001); I2 =60%
Test for overall effect: Z = 19.89 (P < 0.00001)
Test for subgroup differences: Chi2 = 8.64, df = 1 (P = 0.00), I2 =88%
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Analysis 3.5. Comparison 3 Participants receiving red blood cell transfusions, Outcome 5 Participants
receiving red blood cell transfusions - age differentiated.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 3 Participants receiving red blood cell transfusions
Outcome: 5 Participants receiving red blood cell transfusions - age differentiated
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 only children <18 years
Razzouk 2006 72/111 86/111 2.8 % 0.84 [ 0.71, 0.99 ]
Subtotal (95% CI) 111 111 2.8 % 0.84 [ 0.71, 0.99 ]
Total events: 72 (Treatment), 86 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.05 (P = 0.040)
2 adults≥18 years
Aapro 2008 33/231 63/232 2.1 % 0.53 [ 0.36, 0.77 ]
Abels 1993 21/63 21/55 0.7 % 0.87 [ 0.54, 1.42 ]
Aravantinos 2003 9/24 23/23 0.8 % 0.39 [ 0.23, 0.64 ]
Bamias 2003 11/72 24/72 0.8 % 0.46 [ 0.24, 0.86 ]
Boogaerts 2003 43/133 67/129 2.2 % 0.62 [ 0.46, 0.84 ]
Carabantes 1999 4/20 13/15 0.5 % 0.23 [ 0.09, 0.57 ]
Case 1993 32/79 36/74 1.2 % 0.83 [ 0.58, 1.19 ]
Cazzola 1995a 7/31 2/7 0.1 % 0.79 [ 0.21, 3.02 ]
Cazzola 1995b 5/29 2/8 0.1 % 0.69 [ 0.16, 2.91 ]
Cazzola 1995c 6/31 2/7 0.1 % 0.68 [ 0.17, 2.68 ]
Cazzola 1995d 4/26 2/7 0.1 % 0.54 [ 0.12, 2.36 ]
Charu 2007 27/226 13/59 0.7 % 0.54 [ 0.30, 0.98 ]
Christodoulou 2009 16/167 36/170 1.2 % 0.45 [ 0.26, 0.78 ]
Dammacco 2001 19/69 36/76 1.1 % 0.58 [ 0.37, 0.91 ]
Dunphy 1999 2/13 5/14 0.2 % 0.43 [ 0.10, 1.85 ]
EPO-INT-3 J%J 2004 21/136 23/65 1.0 % 0.44 [ 0.26, 0.73 ]
Fujisaka 2011 4/89 18/92 0.6 % 0.23 [ 0.08, 0.65 ]
Gordon 2008 18/162 6/56 0.3 % 1.04 [ 0.43, 2.48 ]
Goss 2005 8/52 27/52 0.9 % 0.30 [ 0.15, 0.59 ]
Grote 2005 26/109 42/115 1.3 % 0.65 [ 0.43, 0.99 ]
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hedenus 2002a 3/11 2/3 0.1 % 0.41 [ 0.12, 1.43 ]
Hedenus 2002b 6/22 2/4 0.1 % 0.55 [ 0.17, 1.80 ]
Hedenus 2002c 3/22 1/4 0.1 % 0.55 [ 0.07, 4.02 ]
Hedenus 2003 52/167 79/165 2.6 % 0.65 [ 0.49, 0.86 ]
Henry 1995 34/64 42/61 1.4 % 0.77 [ 0.58, 1.03 ]
Hernandez 2009 58/193 91/193 3.0 % 0.64 [ 0.49, 0.83 ]
Huddart 2002 18/45 32/45 1.1 % 0.56 [ 0.38, 0.84 ]
Iconomou 2003 9/57 14/55 0.5 % 0.62 [ 0.29, 1.31 ]
Italian 1998 28/43 35/42 1.2 % 0.78 [ 0.60, 1.01 ]
Katakami 2008 7/103 20/104 0.7 % 0.35 [ 0.16, 0.80 ]
Kotasek 2003a 8/30 4/8 0.2 % 0.53 [ 0.21, 1.33 ]
Kotasek 2003b 5/17 4/8 0.2 % 0.59 [ 0.21, 1.62 ]
Kotasek 2003c 12/41 4/9 0.2 % 0.66 [ 0.28, 1.57 ]
Kotasek 2003d 7/27 4/8 0.2 % 0.52 [ 0.20, 1.33 ]
Kotasek 2003e 9/35 3/8 0.2 % 0.69 [ 0.24, 1.97 ]
Kotasek 2003f 7/38 4/9 0.2 % 0.41 [ 0.15, 1.12 ]
Krzakowski 2008a 27/104 14/52 0.6 % 0.96 [ 0.55, 1.68 ]
Krzakowski 2008b 23/105 14/52 0.6 % 0.81 [ 0.46, 1.45 ]
Kunikane 2001a 1/16 0/9 0.0 % 1.76 [ 0.08, 39.32 ]
Kunikane 2001b 2/18 0/10 0.0 % 2.89 [ 0.15, 54.98 ]
Leyland-Jones 2005 47/469 66/470 2.2 % 0.71 [ 0.50, 1.01 ]
Littlewood 2001 62/251 49/124 2.2 % 0.63 [ 0.46, 0.85 ]
Milroy 2011 16/189 43/191 1.4 % 0.38 [ 0.22, 0.64 ]
O’Shaughnessy 2005 0/47 4/47 0.1 % 0.11 [ 0.01, 2.01 ]
Osterborg 1996a 33/47 19/24 0.8 % 0.89 [ 0.67, 1.17 ]
Osterborg 1996b 39/48 20/25 0.9 % 1.02 [ 0.80, 1.29 ]
Osterborg 2002 65/169 90/173 2.9 % 0.74 [ 0.58, 0.94 ]
Pirker 2008 52/298 116/298 3.8 % 0.45 [ 0.34, 0.60 ]
Quirt 1996 4/27 8/27 0.3 % 0.50 [ 0.17, 1.47 ]
Ray-Coquard 2009 39/108 61/105 2.0 % 0.62 [ 0.46, 0.84 ]
Rose 1994 65/142 47/79 2.0 % 0.77 [ 0.60, 0.99 ]
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Savonije 2005 77/211 66/102 2.9 % 0.56 [ 0.45, 0.71 ]
Smith 2003a 3/20 1/6 0.1 % 0.90 [ 0.11, 7.14 ]
Smith 2003b 1/20 1/7 0.0 % 0.35 [ 0.03, 4.88 ]
Smith 2003c 2/21 2/7 0.1 % 0.33 [ 0.06, 1.94 ]
Smith 2008 176/419 215/432 7.0 % 0.84 [ 0.73, 0.98 ]
Ten Bokkel 1998a 2/45 7/17 0.3 % 0.11 [ 0.02, 0.47 ]
Ten Bokkel 1998b 6/42 6/16 0.3 % 0.38 [ 0.14, 1.01 ]
Thatcher 1999a 19/42 13/22 0.6 % 0.77 [ 0.47, 1.24 ]
Thatcher 1999b 9/44 13/22 0.6 % 0.35 [ 0.18, 0.68 ]
Thomas 2002 7/62 31/65 1.0 % 0.24 [ 0.11, 0.50 ]
Thompson 2000 34/45 19/21 0.9 % 0.84 [ 0.67, 1.04 ]
Tjulandin 2010a 8/76 9/37 0.4 % 0.43 [ 0.18, 1.03 ]
Tjulandin 2010b 9/73 9/37 0.4 % 0.51 [ 0.22, 1.17 ]
Tjulandin 2011 13/95 23/91 0.8 % 0.54 [ 0.29, 1.00 ]
Tsuboi 2009 7/61 7/56 0.2 % 0.92 [ 0.34, 2.45 ]
Vansteenkiste 02 FDA 2004 53/156 89/158 2.9 % 0.60 [ 0.47, 0.78 ]
Wilkinson 2006 9/114 18/59 0.8 % 0.26 [ 0.12, 0.54 ]
Witzig 2005 42/166 65/164 2.2 % 0.64 [ 0.46, 0.88 ]
Wright 2007 5/33 10/37 0.3 % 0.56 [ 0.21, 1.47 ]
Subtotal (95% CI) 6460 5096 69.4 % 0.62 [ 0.59, 0.66 ]
Total events: 1539 (Treatment), 1957 (Control)
Heterogeneity: Chi2 = 126.97, df = 69 (P = 0.00003); I2 =46%
Test for overall effect: Z = 17.19 (P < 0.00001)
3 >68% non-elderly 18-65 years
Cascinu 1994 10/50 28/50 0.9 % 0.36 [ 0.19, 0.65 ]
Chang 2005 15/175 40/175 1.3 % 0.38 [ 0.22, 0.65 ]
Del Mastro 1997 0/31 2/31 0.1 % 0.20 [ 0.01, 4.00 ]
Gupta 2009 9/58 25/57 0.8 % 0.35 [ 0.18, 0.69 ]
Kurz 1997 5/23 8/12 0.3 % 0.33 [ 0.14, 0.78 ]
Oberhoff 1998 32/114 44/104 1.5 % 0.66 [ 0.46, 0.96 ]
Pronzato 2010 8/107 18/109 0.6 % 0.45 [ 0.21, 1.00 ]
Rosen 2003 19/47 24/43 0.8 % 0.72 [ 0.47, 1.12 ]
Strauss 2008 9/34 12/40 0.4 % 0.88 [ 0.42, 1.84 ]
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Throuvalas 2000 2/28 10/26 0.3 % 0.19 [ 0.04, 0.77 ]
Wurnig 1996 8/15 14/14 0.5 % 0.55 [ 0.34, 0.88 ]
Subtotal (95% CI) 682 661 7.6 % 0.49 [ 0.41, 0.60 ]
Total events: 117 (Treatment), 225 (Control)
Heterogeneity: Chi2 = 14.06, df = 10 (P = 0.17); I2 =29%
Test for overall effect: Z = 7.40 (P < 0.00001)
4 only non-elderly adults
Blohmer 2011 14/127 38/129 1.2 % 0.37 [ 0.21, 0.66 ]
Engert 2010 405/640 467/643 15.3 % 0.87 [ 0.81, 0.94 ]
Moebus 2007 41/320 86/305 2.9 % 0.45 [ 0.32, 0.64 ]
Untch 2011˙1 1/356 0/377 0.0 % 3.18 [ 0.13, 77.72 ]
Welch 1995 4/15 8/15 0.3 % 0.50 [ 0.19, 1.31 ]
Subtotal (95% CI) 1458 1469 19.8 % 0.78 [ 0.72, 0.84 ]
Total events: 465 (Treatment), 599 (Control)
Heterogeneity: Chi2 = 26.71, df = 4 (P = 0.00002); I2 =85%
Test for overall effect: Z = 6.40 (P < 0.00001)
5 >68% elderly >65 years
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (Treatment), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
6 only elderly adults
Gebbia 2003 5/22 13/23 0.4 % 0.40 [ 0.17, 0.94 ]
Subtotal (95% CI) 22 23 0.4 % 0.40 [ 0.17, 0.94 ]
Total events: 5 (Treatment), 13 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.10 (P = 0.036)
Total (95% CI) 8733 7360 100.0 % 0.65 [ 0.62, 0.68 ]
Total events: 2198 (Treatment), 2880 (Control)
Heterogeneity: Chi2 = 217.08, df = 87 (P<0.00001); I2 =60%
Test for overall effect: Z = 19.89 (P < 0.00001)
Test for subgroup differences: Chi2 = 38.54, df = 4 (P = 0.00), I2 =90%
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Analysis 3.6. Comparison 3 Participants receiving red blood cell transfusions, Outcome 6 Participants
receiving red blood cell transfusions - different therapies.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 3 Participants receiving red blood cell transfusions
Outcome: 6 Participants receiving red blood cell transfusions - different therapies
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 chemotherapy
Aapro 2008 33/231 63/232 2.1 % 0.53 [ 0.36, 0.77 ]
Aravantinos 2003 9/24 23/23 0.8 % 0.39 [ 0.23, 0.64 ]
Bamias 2003 11/72 24/72 0.8 % 0.46 [ 0.24, 0.86 ]
Boogaerts 2003 43/133 67/129 2.2 % 0.62 [ 0.46, 0.84 ]
Carabantes 1999 4/20 13/15 0.5 % 0.23 [ 0.09, 0.57 ]
Cascinu 1994 10/50 28/50 0.9 % 0.36 [ 0.19, 0.65 ]
Case 1993 32/79 36/74 1.2 % 0.83 [ 0.58, 1.19 ]
Cazzola 1995a 7/31 2/7 0.1 % 0.79 [ 0.21, 3.02 ]
Cazzola 1995b 5/29 2/8 0.1 % 0.69 [ 0.16, 2.91 ]
Cazzola 1995c 6/31 2/7 0.1 % 0.68 [ 0.17, 2.68 ]
Cazzola 1995d 4/26 2/7 0.1 % 0.54 [ 0.12, 2.36 ]
Chang 2005 15/175 40/175 1.3 % 0.38 [ 0.22, 0.65 ]
Christodoulou 2009 16/167 36/170 1.2 % 0.45 [ 0.26, 0.78 ]
Dammacco 2001 19/69 36/76 1.1 % 0.58 [ 0.37, 0.91 ]
Del Mastro 1997 0/31 2/31 0.1 % 0.20 [ 0.01, 4.00 ]
Dunphy 1999 2/13 5/14 0.2 % 0.43 [ 0.10, 1.85 ]
Engert 2010 405/640 467/643 15.3 % 0.87 [ 0.81, 0.94 ]
EPO-INT-3 J%J 2004 21/136 23/65 1.0 % 0.44 [ 0.26, 0.73 ]
Fujisaka 2011 4/89 18/92 0.6 % 0.23 [ 0.08, 0.65 ]
Gebbia 2003 5/22 13/23 0.4 % 0.40 [ 0.17, 0.94 ]
Grote 2005 26/109 42/115 1.3 % 0.65 [ 0.43, 0.99 ]
Hedenus 2002a 3/11 2/3 0.1 % 0.41 [ 0.12, 1.43 ]
Hedenus 2002b 6/22 2/4 0.1 % 0.55 [ 0.17, 1.80 ]
Hedenus 2002c 3/22 1/4 0.1 % 0.55 [ 0.07, 4.02 ]
0.01 0.1 1 10 100
Favours Treatment Favours Control
(Continued . . . )
317Erythropoietin or darbepoetin for patients with cancer (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hedenus 2003 52/167 79/165 2.6 % 0.65 [ 0.49, 0.86 ]
Henry 1995 34/64 42/61 1.4 % 0.77 [ 0.58, 1.03 ]
Hernandez 2009 58/193 91/193 3.0 % 0.64 [ 0.49, 0.83 ]
Huddart 2002 18/45 32/45 1.1 % 0.56 [ 0.38, 0.84 ]
Iconomou 2003 9/57 14/55 0.5 % 0.62 [ 0.29, 1.31 ]
Katakami 2008 7/103 20/104 0.7 % 0.35 [ 0.16, 0.80 ]
Kotasek 2003a 8/30 4/8 0.2 % 0.53 [ 0.21, 1.33 ]
Kotasek 2003b 5/17 4/8 0.2 % 0.59 [ 0.21, 1.62 ]
Kotasek 2003c 12/41 4/9 0.2 % 0.66 [ 0.28, 1.57 ]
Kotasek 2003d 7/27 4/8 0.2 % 0.52 [ 0.20, 1.33 ]
Kotasek 2003e 9/35 3/8 0.2 % 0.69 [ 0.24, 1.97 ]
Kotasek 2003f 7/38 4/9 0.2 % 0.41 [ 0.15, 1.12 ]
Krzakowski 2008a 27/104 14/52 0.6 % 0.96 [ 0.55, 1.68 ]
Krzakowski 2008b 23/105 14/52 0.6 % 0.81 [ 0.46, 1.45 ]
Kunikane 2001a 1/16 0/9 0.0 % 1.76 [ 0.08, 39.32 ]
Kunikane 2001b 2/18 0/10 0.0 % 2.89 [ 0.15, 54.98 ]
Kurz 1997 5/23 8/12 0.3 % 0.33 [ 0.14, 0.78 ]
Leyland-Jones 2005 47/469 66/470 2.2 % 0.71 [ 0.50, 1.01 ]
Littlewood 2001 62/251 49/124 2.2 % 0.63 [ 0.46, 0.85 ]
Milroy 2011 16/189 43/191 1.4 % 0.38 [ 0.22, 0.64 ]
Moebus 2007 41/320 86/305 2.9 % 0.45 [ 0.32, 0.64 ]
O’Shaughnessy 2005 0/47 4/47 0.1 % 0.11 [ 0.01, 2.01 ]
Oberhoff 1998 32/114 44/104 1.5 % 0.66 [ 0.46, 0.96 ]
Osterborg 1996a 33/47 19/24 0.8 % 0.89 [ 0.67, 1.17 ]
Osterborg 1996b 39/48 20/25 0.9 % 1.02 [ 0.80, 1.29 ]
Osterborg 2002 65/169 90/173 2.9 % 0.74 [ 0.58, 0.94 ]
Pirker 2008 52/298 116/298 3.8 % 0.45 [ 0.34, 0.60 ]
Pronzato 2010 8/107 18/109 0.6 % 0.45 [ 0.21, 1.00 ]
Quirt 1996 4/27 8/27 0.3 % 0.50 [ 0.17, 1.47 ]
Ray-Coquard 2009 39/108 61/105 2.0 % 0.62 [ 0.46, 0.84 ]
Razzouk 2006 72/111 86/111 2.8 % 0.84 [ 0.71, 0.99 ]
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Savonije 2005 77/211 66/102 2.9 % 0.56 [ 0.45, 0.71 ]
Ten Bokkel 1998a 2/45 7/17 0.3 % 0.11 [ 0.02, 0.47 ]
Ten Bokkel 1998b 6/42 6/16 0.3 % 0.38 [ 0.14, 1.01 ]
Thatcher 1999a 19/42 13/22 0.6 % 0.77 [ 0.47, 1.24 ]
Thatcher 1999b 9/44 13/22 0.6 % 0.35 [ 0.18, 0.68 ]
Thomas 2002 7/62 31/65 1.0 % 0.24 [ 0.11, 0.50 ]
Tjulandin 2010a 8/76 9/37 0.4 % 0.43 [ 0.18, 1.03 ]
Tjulandin 2010b 9/73 9/37 0.4 % 0.51 [ 0.22, 1.17 ]
Tjulandin 2011 13/95 23/91 0.8 % 0.54 [ 0.29, 1.00 ]
Tsuboi 2009 7/61 7/56 0.2 % 0.92 [ 0.34, 2.45 ]
Untch 2011˙1 1/356 0/377 0.0 % 3.18 [ 0.13, 77.72 ]
Vansteenkiste 02 FDA 2004 53/156 89/158 2.9 % 0.60 [ 0.47, 0.78 ]
Welch 1995 4/15 8/15 0.3 % 0.50 [ 0.19, 1.31 ]
Wilkinson 2006 9/114 18/59 0.8 % 0.26 [ 0.12, 0.54 ]
Witzig 2005 42/166 65/164 2.2 % 0.64 [ 0.46, 0.88 ]
Wurnig 1996 8/15 14/14 0.5 % 0.55 [ 0.34, 0.88 ]
Subtotal (95% CI) 7193 6212 82.3 % 0.64 [ 0.61, 0.67 ]
Total events: 1757 (Treatment), 2374 (Control)
Heterogeneity: Chi2 = 183.91, df = 70 (P<0.00001); I2 =62%
Test for overall effect: Z = 18.80 (P < 0.00001)
2 radio/radiochemotherapy
Blohmer 2011 14/127 38/129 1.2 % 0.37 [ 0.21, 0.66 ]
Goss 2005 8/52 27/52 0.9 % 0.30 [ 0.15, 0.59 ]
Gupta 2009 9/58 25/57 0.8 % 0.35 [ 0.18, 0.69 ]
Rosen 2003 19/47 24/43 0.8 % 0.72 [ 0.47, 1.12 ]
Strauss 2008 9/34 12/40 0.4 % 0.88 [ 0.42, 1.84 ]
Throuvalas 2000 2/28 10/26 0.3 % 0.19 [ 0.04, 0.77 ]
Subtotal (95% CI) 346 347 4.5 % 0.45 [ 0.34, 0.58 ]
Total events: 61 (Treatment), 136 (Control)
Heterogeneity: Chi2 = 11.69, df = 5 (P = 0.04); I2 =57%
Test for overall effect: Z = 6.11 (P < 0.00001)
3 no therapy
Abels 1993 21/63 21/55 0.7 % 0.87 [ 0.54, 1.42 ]
Charu 2007 27/226 13/59 0.7 % 0.54 [ 0.30, 0.98 ]
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gordon 2008 18/162 6/56 0.3 % 1.04 [ 0.43, 2.48 ]
Italian 1998 28/43 35/42 1.2 % 0.78 [ 0.60, 1.01 ]
Smith 2003a 3/20 1/6 0.1 % 0.90 [ 0.11, 7.14 ]
Smith 2003b 1/20 1/7 0.0 % 0.35 [ 0.03, 4.88 ]
Smith 2003c 2/21 2/7 0.1 % 0.33 [ 0.06, 1.94 ]
Smith 2008 176/419 215/432 7.0 % 0.84 [ 0.73, 0.98 ]
Thompson 2000 34/45 19/21 0.9 % 0.84 [ 0.67, 1.04 ]
Wright 2007 5/33 10/37 0.3 % 0.56 [ 0.21, 1.47 ]
Subtotal (95% CI) 1052 722 11.2 % 0.81 [ 0.72, 0.91 ]
Total events: 315 (Treatment), 323 (Control)
Heterogeneity: Chi2 = 4.51, df = 9 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 3.59 (P = 0.00033)
4 unclear/other
Rose 1994 65/142 47/79 2.0 % 0.77 [ 0.60, 0.99 ]
Subtotal (95% CI) 142 79 2.0 % 0.77 [ 0.60, 0.99 ]
Total events: 65 (Treatment), 47 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.01 (P = 0.044)
Total (95% CI) 8733 7360 100.0 % 0.65 [ 0.62, 0.68 ]
Total events: 2198 (Treatment), 2880 (Control)
Heterogeneity: Chi2 = 217.08, df = 87 (P<0.00001); I2 =60%
Test for overall effect: Z = 19.89 (P < 0.00001)
Test for subgroup differences: Chi2 = 25.04, df = 3 (P = 0.00), I2 =88%
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Analysis 3.7. Comparison 3 Participants receiving red blood cell transfusions, Outcome 7 Participants
receiving red blood cell transfusions - different therapies differentiated.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 3 Participants receiving red blood cell transfusions
Outcome: 7 Participants receiving red blood cell transfusions - different therapies differentiated
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 chemotherapy, > 70% with platinum
Aravantinos 2003 9/24 23/23 0.8 % 0.39 [ 0.23, 0.64 ]
Bamias 2003 11/72 24/72 0.8 % 0.46 [ 0.24, 0.86 ]
Carabantes 1999 4/20 13/15 0.5 % 0.23 [ 0.09, 0.57 ]
Cascinu 1994 10/50 28/50 0.9 % 0.36 [ 0.19, 0.65 ]
Dunphy 1999 2/13 5/14 0.2 % 0.43 [ 0.10, 1.85 ]
Fujisaka 2011 4/89 18/92 0.6 % 0.23 [ 0.08, 0.65 ]
Gebbia 2003 5/22 13/23 0.4 % 0.40 [ 0.17, 0.94 ]
Grote 2005 26/109 42/115 1.3 % 0.65 [ 0.43, 0.99 ]
Henry 1995 34/64 42/61 1.4 % 0.77 [ 0.58, 1.03 ]
Huddart 2002 18/45 32/45 1.1 % 0.56 [ 0.38, 0.84 ]
Katakami 2008 7/103 20/104 0.7 % 0.35 [ 0.16, 0.80 ]
Kunikane 2001a 1/16 0/9 0.0 % 1.76 [ 0.08, 39.32 ]
Kunikane 2001b 2/18 0/10 0.0 % 2.89 [ 0.15, 54.98 ]
Kurz 1997 5/23 8/12 0.3 % 0.33 [ 0.14, 0.78 ]
Milroy 2011 16/189 43/191 1.4 % 0.38 [ 0.22, 0.64 ]
Pirker 2008 52/298 116/298 3.8 % 0.45 [ 0.34, 0.60 ]
Savonije 2005 77/211 66/102 2.9 % 0.56 [ 0.45, 0.71 ]
Ten Bokkel 1998a 2/45 7/17 0.3 % 0.11 [ 0.02, 0.47 ]
Ten Bokkel 1998b 6/42 6/16 0.3 % 0.38 [ 0.14, 1.01 ]
Thatcher 1999a 19/42 13/22 0.6 % 0.77 [ 0.47, 1.24 ]
Thatcher 1999b 9/44 13/22 0.6 % 0.35 [ 0.18, 0.68 ]
Tjulandin 2010a 8/76 9/37 0.4 % 0.43 [ 0.18, 1.03 ]
Tjulandin 2010b 9/73 9/37 0.4 % 0.51 [ 0.22, 1.17 ]
Vansteenkiste 02 FDA 2004 53/156 89/158 2.9 % 0.60 [ 0.47, 0.78 ]
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Welch 1995 4/15 8/15 0.3 % 0.50 [ 0.19, 1.31 ]
Wilkinson 2006 9/114 18/59 0.8 % 0.26 [ 0.12, 0.54 ]
Subtotal (95% CI) 1973 1619 23.7 % 0.49 [ 0.44, 0.54 ]
Total events: 402 (Treatment), 665 (Control)
Heterogeneity: Chi2 = 39.20, df = 25 (P = 0.04); I2 =36%
Test for overall effect: Z = 13.83 (P < 0.00001)
2 chemotherapy, < 70% with platinum
Christodoulou 2009 16/167 36/170 1.2 % 0.45 [ 0.26, 0.78 ]
EPO-INT-3 J%J 2004 21/136 23/65 1.0 % 0.44 [ 0.26, 0.73 ]
Hernandez 2009 58/193 91/193 3.0 % 0.64 [ 0.49, 0.83 ]
Iconomou 2003 9/57 14/55 0.5 % 0.62 [ 0.29, 1.31 ]
Krzakowski 2008a 27/104 14/52 0.6 % 0.96 [ 0.55, 1.68 ]
Krzakowski 2008b 23/105 14/52 0.6 % 0.81 [ 0.46, 1.45 ]
Oberhoff 1998 32/114 44/104 1.5 % 0.66 [ 0.46, 0.96 ]
Tsuboi 2009 7/61 7/56 0.2 % 0.92 [ 0.34, 2.45 ]
Witzig 2005 42/166 65/164 2.2 % 0.64 [ 0.46, 0.88 ]
Wurnig 1996 8/15 14/14 0.5 % 0.55 [ 0.34, 0.88 ]
Subtotal (95% CI) 1118 925 11.3 % 0.63 [ 0.55, 0.73 ]
Total events: 243 (Treatment), 322 (Control)
Heterogeneity: Chi2 = 7.39, df = 9 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 6.40 (P < 0.00001)
3 chemotherapy without platinum (all patients)
Aapro 2008 33/231 63/232 2.1 % 0.53 [ 0.36, 0.77 ]
Case 1993 32/79 36/74 1.2 % 0.83 [ 0.58, 1.19 ]
Cazzola 1995a 7/31 2/7 0.1 % 0.79 [ 0.21, 3.02 ]
Cazzola 1995b 5/29 2/8 0.1 % 0.69 [ 0.16, 2.91 ]
Cazzola 1995c 6/31 2/7 0.1 % 0.68 [ 0.17, 2.68 ]
Cazzola 1995d 4/26 2/7 0.1 % 0.54 [ 0.12, 2.36 ]
Chang 2005 15/175 40/175 1.3 % 0.38 [ 0.22, 0.65 ]
Del Mastro 1997 0/31 2/31 0.1 % 0.20 [ 0.01, 4.00 ]
Engert 2010 405/640 467/643 15.3 % 0.87 [ 0.81, 0.94 ]
Hedenus 2002a 3/11 2/3 0.1 % 0.41 [ 0.12, 1.43 ]
Hedenus 2002b 6/22 2/4 0.1 % 0.55 [ 0.17, 1.80 ]
Hedenus 2002c 3/22 1/4 0.1 % 0.55 [ 0.07, 4.02 ]
0.01 0.1 1 10 100
Favours Treatment Favours Control
(Continued . . . )
322Erythropoietin or darbepoetin for patients with cancer (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hedenus 2003 52/167 79/165 2.6 % 0.65 [ 0.49, 0.86 ]
Leyland-Jones 2005 47/469 66/470 2.2 % 0.71 [ 0.50, 1.01 ]
Littlewood 2001 62/251 49/124 2.2 % 0.63 [ 0.46, 0.85 ]
Moebus 2007 41/320 86/305 2.9 % 0.45 [ 0.32, 0.64 ]
O’Shaughnessy 2005 0/47 4/47 0.1 % 0.11 [ 0.01, 2.01 ]
Osterborg 1996a 33/47 19/24 0.8 % 0.89 [ 0.67, 1.17 ]
Osterborg 1996b 39/48 20/25 0.9 % 1.02 [ 0.80, 1.29 ]
Osterborg 2002 65/169 90/173 2.9 % 0.74 [ 0.58, 0.94 ]
Pronzato 2010 8/107 18/109 0.6 % 0.45 [ 0.21, 1.00 ]
Tjulandin 2011 13/95 23/91 0.8 % 0.54 [ 0.29, 1.00 ]
Untch 2011˙1 1/356 0/377 0.0 % 3.18 [ 0.13, 77.72 ]
Subtotal (95% CI) 3404 3105 36.7 % 0.73 [ 0.69, 0.78 ]
Total events: 880 (Treatment), 1075 (Control)
Heterogeneity: Chi2 = 54.87, df = 22 (P = 0.00012); I2 =60%
Test for overall effect: Z = 9.49 (P < 0.00001)
4 chemotherapy, platinum and non-platinum containing, no numbers given
Boogaerts 2003 43/133 67/129 2.2 % 0.62 [ 0.46, 0.84 ]
Dammacco 2001 19/69 36/76 1.1 % 0.58 [ 0.37, 0.91 ]
Kotasek 2003a 8/30 4/8 0.2 % 0.53 [ 0.21, 1.33 ]
Kotasek 2003b 5/17 4/8 0.2 % 0.59 [ 0.21, 1.62 ]
Kotasek 2003c 12/41 4/9 0.2 % 0.66 [ 0.28, 1.57 ]
Kotasek 2003d 7/27 4/8 0.2 % 0.52 [ 0.20, 1.33 ]
Kotasek 2003e 9/35 3/8 0.2 % 0.69 [ 0.24, 1.97 ]
Kotasek 2003f 7/38 4/9 0.2 % 0.41 [ 0.15, 1.12 ]
Thomas 2002 7/62 31/65 1.0 % 0.24 [ 0.11, 0.50 ]
Subtotal (95% CI) 452 320 5.5 % 0.53 [ 0.43, 0.65 ]
Total events: 117 (Treatment), 157 (Control)
Heterogeneity: Chi2 = 6.53, df = 8 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 6.10 (P < 0.00001)
5 chemotherapy no details given
Quirt 1996 4/27 8/27 0.3 % 0.50 [ 0.17, 1.47 ]
Ray-Coquard 2009 39/108 61/105 2.0 % 0.62 [ 0.46, 0.84 ]
Razzouk 2006 72/111 86/111 2.8 % 0.84 [ 0.71, 0.99 ]
Subtotal (95% CI) 246 243 5.1 % 0.73 [ 0.63, 0.86 ]
Total events: 115 (Treatment), 155 (Control)
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: Chi2 = 3.98, df = 2 (P = 0.14); I2 =50%
Test for overall effect: Z = 3.91 (P = 0.000093)
6 radiochemotherapy
Blohmer 2011 14/127 38/129 1.2 % 0.37 [ 0.21, 0.66 ]
Goss 2005 8/52 27/52 0.9 % 0.30 [ 0.15, 0.59 ]
Gupta 2009 9/58 25/57 0.8 % 0.35 [ 0.18, 0.69 ]
Rosen 2003 19/47 24/43 0.8 % 0.72 [ 0.47, 1.12 ]
Strauss 2008 9/34 12/40 0.4 % 0.88 [ 0.42, 1.84 ]
Throuvalas 2000 2/28 10/26 0.3 % 0.19 [ 0.04, 0.77 ]
Subtotal (95% CI) 346 347 4.5 % 0.45 [ 0.34, 0.58 ]
Total events: 61 (Treatment), 136 (Control)
Heterogeneity: Chi2 = 11.69, df = 5 (P = 0.04); I2 =57%
Test for overall effect: Z = 6.11 (P < 0.00001)
7 radiotherapy
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (Treatment), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
8 no therapy
Abels 1993 21/63 21/55 0.7 % 0.87 [ 0.54, 1.42 ]
Charu 2007 27/226 13/59 0.7 % 0.54 [ 0.30, 0.98 ]
Gordon 2008 18/162 6/56 0.3 % 1.04 [ 0.43, 2.48 ]
Italian 1998 28/43 35/42 1.2 % 0.78 [ 0.60, 1.01 ]
Smith 2003a 3/20 1/6 0.1 % 0.90 [ 0.11, 7.14 ]
Smith 2003b 1/20 1/7 0.0 % 0.35 [ 0.03, 4.88 ]
Smith 2003c 2/21 2/7 0.1 % 0.33 [ 0.06, 1.94 ]
Smith 2008 176/419 215/432 7.0 % 0.84 [ 0.73, 0.98 ]
Thompson 2000 34/45 19/21 0.9 % 0.84 [ 0.67, 1.04 ]
Wright 2007 5/33 10/37 0.3 % 0.56 [ 0.21, 1.47 ]
Subtotal (95% CI) 1052 722 11.2 % 0.81 [ 0.72, 0.91 ]
Total events: 315 (Treatment), 323 (Control)
Heterogeneity: Chi2 = 4.51, df = 9 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 3.59 (P = 0.00033)
9 unclear/other
Rose 1994 65/142 47/79 2.0 % 0.77 [ 0.60, 0.99 ]
Subtotal (95% CI) 142 79 2.0 % 0.77 [ 0.60, 0.99 ]
Total events: 65 (Treatment), 47 (Control)
Heterogeneity: not applicable
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Test for overall effect: Z = 2.01 (P = 0.044)
Total (95% CI) 8733 7360 100.0 % 0.65 [ 0.62, 0.68 ]
Total events: 2198 (Treatment), 2880 (Control)
Heterogeneity: Chi2 = 217.08, df = 87 (P<0.00001); I2 =60%
Test for overall effect: Z = 19.89 (P < 0.00001)
Test for subgroup differences: Chi2 = 71.88, df = 7 (P = 0.00), I2 =90%
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Analysis 3.8. Comparison 3 Participants receiving red blood cell transfusions, Outcome 8 Participants
receiving red blood cell transfusions - epoetin versus darbepoetin.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 3 Participants receiving red blood cell transfusions
Outcome: 8 Participants receiving red blood cell transfusions - epoetin versus darbepoetin
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Epoetin
Aapro 2008 33/231 63/232 2.1 % 0.53 [ 0.36, 0.77 ]
Abels 1993 21/63 21/55 0.7 % 0.87 [ 0.54, 1.42 ]
Aravantinos 2003 9/24 23/23 0.8 % 0.39 [ 0.23, 0.64 ]
Bamias 2003 11/72 24/72 0.8 % 0.46 [ 0.24, 0.86 ]
Blohmer 2011 14/127 38/129 1.2 % 0.37 [ 0.21, 0.66 ]
Boogaerts 2003 43/133 67/129 2.2 % 0.62 [ 0.46, 0.84 ]
Carabantes 1999 4/20 13/15 0.5 % 0.23 [ 0.09, 0.57 ]
Cascinu 1994 10/50 28/50 0.9 % 0.36 [ 0.19, 0.65 ]
Case 1993 32/79 36/74 1.2 % 0.83 [ 0.58, 1.19 ]
Cazzola 1995a 7/31 2/7 0.1 % 0.79 [ 0.21, 3.02 ]
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cazzola 1995b 5/29 2/8 0.1 % 0.69 [ 0.16, 2.91 ]
Cazzola 1995c 6/31 2/7 0.1 % 0.68 [ 0.17, 2.68 ]
Cazzola 1995d 4/26 2/7 0.1 % 0.54 [ 0.12, 2.36 ]
Chang 2005 15/175 40/175 1.3 % 0.38 [ 0.22, 0.65 ]
Christodoulou 2009 16/167 36/170 1.2 % 0.45 [ 0.26, 0.78 ]
Dammacco 2001 19/69 36/76 1.1 % 0.58 [ 0.37, 0.91 ]
Del Mastro 1997 0/31 2/31 0.1 % 0.20 [ 0.01, 4.00 ]
Dunphy 1999 2/13 5/14 0.2 % 0.43 [ 0.10, 1.85 ]
Engert 2010 405/640 467/643 15.3 % 0.87 [ 0.81, 0.94 ]
EPO-INT-3 J%J 2004 21/136 23/65 1.0 % 0.44 [ 0.26, 0.73 ]
Fujisaka 2011 4/89 18/92 0.6 % 0.23 [ 0.08, 0.65 ]
Gebbia 2003 5/22 13/23 0.4 % 0.40 [ 0.17, 0.94 ]
Goss 2005 8/52 27/52 0.9 % 0.30 [ 0.15, 0.59 ]
Grote 2005 26/109 42/115 1.3 % 0.65 [ 0.43, 0.99 ]
Gupta 2009 9/58 25/57 0.8 % 0.35 [ 0.18, 0.69 ]
Henry 1995 34/64 42/61 1.4 % 0.77 [ 0.58, 1.03 ]
Huddart 2002 18/45 32/45 1.1 % 0.56 [ 0.38, 0.84 ]
Iconomou 2003 9/57 14/55 0.5 % 0.62 [ 0.29, 1.31 ]
Italian 1998 28/43 35/42 1.2 % 0.78 [ 0.60, 1.01 ]
Krzakowski 2008a 27/104 14/52 0.6 % 0.96 [ 0.55, 1.68 ]
Krzakowski 2008b 23/105 14/52 0.6 % 0.81 [ 0.46, 1.45 ]
Kunikane 2001a 1/16 0/9 0.0 % 1.76 [ 0.08, 39.32 ]
Kunikane 2001b 2/18 0/10 0.0 % 2.89 [ 0.15, 54.98 ]
Kurz 1997 5/23 8/12 0.3 % 0.33 [ 0.14, 0.78 ]
Leyland-Jones 2005 47/469 66/470 2.2 % 0.71 [ 0.50, 1.01 ]
Littlewood 2001 62/251 49/124 2.2 % 0.63 [ 0.46, 0.85 ]
Milroy 2011 16/189 43/191 1.4 % 0.38 [ 0.22, 0.64 ]
Moebus 2007 41/320 86/305 2.9 % 0.45 [ 0.32, 0.64 ]
O’Shaughnessy 2005 0/47 4/47 0.1 % 0.11 [ 0.01, 2.01 ]
Oberhoff 1998 32/114 44/104 1.5 % 0.66 [ 0.46, 0.96 ]
Osterborg 1996a 33/47 19/24 0.8 % 0.89 [ 0.67, 1.17 ]
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Osterborg 1996b 39/48 20/25 0.9 % 1.02 [ 0.80, 1.29 ]
Osterborg 2002 65/169 90/173 2.9 % 0.74 [ 0.58, 0.94 ]
Pronzato 2010 8/107 18/109 0.6 % 0.45 [ 0.21, 1.00 ]
Quirt 1996 4/27 8/27 0.3 % 0.50 [ 0.17, 1.47 ]
Ray-Coquard 2009 39/108 61/105 2.0 % 0.62 [ 0.46, 0.84 ]
Razzouk 2006 72/111 86/111 2.8 % 0.84 [ 0.71, 0.99 ]
Rose 1994 65/142 47/79 2.0 % 0.77 [ 0.60, 0.99 ]
Rosen 2003 19/47 24/43 0.8 % 0.72 [ 0.47, 1.12 ]
Savonije 2005 77/211 66/102 2.9 % 0.56 [ 0.45, 0.71 ]
Strauss 2008 9/34 12/40 0.4 % 0.88 [ 0.42, 1.84 ]
Ten Bokkel 1998a 2/45 7/17 0.3 % 0.11 [ 0.02, 0.47 ]
Ten Bokkel 1998b 6/42 6/16 0.3 % 0.38 [ 0.14, 1.01 ]
Thatcher 1999a 19/42 13/22 0.6 % 0.77 [ 0.47, 1.24 ]
Thatcher 1999b 9/44 13/22 0.6 % 0.35 [ 0.18, 0.68 ]
Thomas 2002 7/62 31/65 1.0 % 0.24 [ 0.11, 0.50 ]
Thompson 2000 34/45 19/21 0.9 % 0.84 [ 0.67, 1.04 ]
Throuvalas 2000 2/28 10/26 0.3 % 0.19 [ 0.04, 0.77 ]
Tjulandin 2010a 8/76 9/37 0.4 % 0.43 [ 0.18, 1.03 ]
Tjulandin 2010b 9/73 9/37 0.4 % 0.51 [ 0.22, 1.17 ]
Tjulandin 2011 13/95 23/91 0.8 % 0.54 [ 0.29, 1.00 ]
Tsuboi 2009 7/61 7/56 0.2 % 0.92 [ 0.34, 2.45 ]
Welch 1995 4/15 8/15 0.3 % 0.50 [ 0.19, 1.31 ]
Wilkinson 2006 9/114 18/59 0.8 % 0.26 [ 0.12, 0.54 ]
Witzig 2005 42/166 65/164 2.2 % 0.64 [ 0.46, 0.88 ]
Wright 2007 5/33 10/37 0.3 % 0.56 [ 0.21, 1.47 ]
Wurnig 1996 8/15 14/14 0.5 % 0.55 [ 0.34, 0.88 ]
Subtotal (95% CI) 6349 5437 77.4 % 0.65 [ 0.62, 0.68 ]
Total events: 1688 (Treatment), 2219 (Control)
Heterogeneity: Chi2 = 191.91, df = 66 (P<0.00001); I2 =66%
Test for overall effect: Z = 17.85 (P < 0.00001)
2 Darbepoetin
Charu 2007 27/226 13/59 0.7 % 0.54 [ 0.30, 0.98 ]
Gordon 2008 18/162 6/56 0.3 % 1.04 [ 0.43, 2.48 ]
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hedenus 2002a 3/11 2/3 0.1 % 0.41 [ 0.12, 1.43 ]
Hedenus 2002b 6/22 2/4 0.1 % 0.55 [ 0.17, 1.80 ]
Hedenus 2002c 3/22 1/4 0.1 % 0.55 [ 0.07, 4.02 ]
Hedenus 2003 52/167 79/165 2.6 % 0.65 [ 0.49, 0.86 ]
Hernandez 2009 58/193 91/193 3.0 % 0.64 [ 0.49, 0.83 ]
Katakami 2008 7/103 20/104 0.7 % 0.35 [ 0.16, 0.80 ]
Kotasek 2003a 8/30 4/8 0.2 % 0.53 [ 0.21, 1.33 ]
Kotasek 2003b 5/17 4/8 0.2 % 0.59 [ 0.21, 1.62 ]
Kotasek 2003c 12/41 4/9 0.2 % 0.66 [ 0.28, 1.57 ]
Kotasek 2003d 7/27 4/8 0.2 % 0.52 [ 0.20, 1.33 ]
Kotasek 2003e 9/35 3/8 0.2 % 0.69 [ 0.24, 1.97 ]
Kotasek 2003f 7/38 4/9 0.2 % 0.41 [ 0.15, 1.12 ]
Pirker 2008 52/298 116/298 3.8 % 0.45 [ 0.34, 0.60 ]
Smith 2003a 3/20 1/6 0.1 % 0.90 [ 0.11, 7.14 ]
Smith 2003b 1/20 1/7 0.0 % 0.35 [ 0.03, 4.88 ]
Smith 2003c 2/21 2/7 0.1 % 0.33 [ 0.06, 1.94 ]
Smith 2008 176/419 215/432 7.0 % 0.84 [ 0.73, 0.98 ]
Untch 2011˙1 1/356 0/377 0.0 % 3.18 [ 0.13, 77.72 ]
Vansteenkiste 02 FDA 2004 53/156 89/158 2.9 % 0.60 [ 0.47, 0.78 ]
Subtotal (95% CI) 2384 1923 22.6 % 0.66 [ 0.60, 0.72 ]
Total events: 510 (Treatment), 661 (Control)
Heterogeneity: Chi2 = 26.07, df = 20 (P = 0.16); I2 =23%
Test for overall effect: Z = 8.87 (P < 0.00001)
Total (95% CI) 8733 7360 100.0 % 0.65 [ 0.62, 0.68 ]
Total events: 2198 (Treatment), 2880 (Control)
Heterogeneity: Chi2 = 217.08, df = 87 (P<0.00001); I2 =60%
Test for overall effect: Z = 19.89 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.05, df = 1 (P = 0.83), I2 =0.0%
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Analysis 3.9. Comparison 3 Participants receiving red blood cell transfusions, Outcome 9 Participants
receiving red blood cell transfusions - duration of ESA medication.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 3 Participants receiving red blood cell transfusions
Outcome: 9 Participants receiving red blood cell transfusions - duration of ESA medication
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 6 to 9 weeks
Abels 1993 21/63 21/55 0.7 % 0.87 [ 0.54, 1.42 ]
Cascinu 1994 10/50 28/50 0.9 % 0.36 [ 0.19, 0.65 ]
Cazzola 1995a 7/31 2/7 0.1 % 0.79 [ 0.21, 3.02 ]
Cazzola 1995b 5/29 2/8 0.1 % 0.69 [ 0.16, 2.91 ]
Cazzola 1995c 6/31 2/7 0.1 % 0.68 [ 0.17, 2.68 ]
Cazzola 1995d 4/26 2/7 0.1 % 0.54 [ 0.12, 2.36 ]
Dunphy 1999 2/13 5/14 0.2 % 0.43 [ 0.10, 1.85 ]
Gupta 2009 9/58 25/57 0.8 % 0.35 [ 0.18, 0.69 ]
Italian 1998 28/43 35/42 1.2 % 0.78 [ 0.60, 1.01 ]
Kunikane 2001a 1/16 0/9 0.0 % 1.76 [ 0.08, 39.32 ]
Kunikane 2001b 2/18 0/10 0.0 % 2.89 [ 0.15, 54.98 ]
Throuvalas 2000 2/28 10/26 0.3 % 0.19 [ 0.04, 0.77 ]
Tsuboi 2009 7/61 7/56 0.2 % 0.92 [ 0.34, 2.45 ]
Subtotal (95% CI) 467 348 4.9 % 0.60 [ 0.49, 0.74 ]
Total events: 104 (Treatment), 139 (Control)
Heterogeneity: Chi2 = 16.94, df = 12 (P = 0.15); I2 =29%
Test for overall effect: Z = 4.88 (P < 0.00001)
2 12 to 16 weeks
Aravantinos 2003 9/24 23/23 0.8 % 0.39 [ 0.23, 0.64 ]
Boogaerts 2003 43/133 67/129 2.2 % 0.62 [ 0.46, 0.84 ]
Case 1993 32/79 36/74 1.2 % 0.83 [ 0.58, 1.19 ]
Chang 2005 15/175 40/175 1.3 % 0.38 [ 0.22, 0.65 ]
Charu 2007 27/226 13/59 0.7 % 0.54 [ 0.30, 0.98 ]
Christodoulou 2009 16/167 36/170 1.2 % 0.45 [ 0.26, 0.78 ]
Dammacco 2001 19/69 36/76 1.1 % 0.58 [ 0.37, 0.91 ]
Del Mastro 1997 0/31 2/31 0.1 % 0.20 [ 0.01, 4.00 ]
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
EPO-INT-3 J%J 2004 21/136 23/65 1.0 % 0.44 [ 0.26, 0.73 ]
Fujisaka 2011 4/89 18/92 0.6 % 0.23 [ 0.08, 0.65 ]
Gebbia 2003 5/22 13/23 0.4 % 0.40 [ 0.17, 0.94 ]
Gordon 2008 18/162 6/56 0.3 % 1.04 [ 0.43, 2.48 ]
Grote 2005 26/109 42/115 1.3 % 0.65 [ 0.43, 0.99 ]
Hedenus 2002a 3/11 2/3 0.1 % 0.41 [ 0.12, 1.43 ]
Hedenus 2002b 6/22 2/4 0.1 % 0.55 [ 0.17, 1.80 ]
Hedenus 2002c 3/22 1/4 0.1 % 0.55 [ 0.07, 4.02 ]
Hedenus 2003 52/167 79/165 2.6 % 0.65 [ 0.49, 0.86 ]
Henry 1995 34/64 42/61 1.4 % 0.77 [ 0.58, 1.03 ]
Hernandez 2009 58/193 91/193 3.0 % 0.64 [ 0.49, 0.83 ]
Iconomou 2003 9/57 14/55 0.5 % 0.62 [ 0.29, 1.31 ]
Katakami 2008 7/103 20/104 0.7 % 0.35 [ 0.16, 0.80 ]
Kotasek 2003a 8/30 4/8 0.2 % 0.53 [ 0.21, 1.33 ]
Kotasek 2003b 5/17 4/8 0.2 % 0.59 [ 0.21, 1.62 ]
Kotasek 2003c 12/41 4/9 0.2 % 0.66 [ 0.28, 1.57 ]
Kotasek 2003d 7/27 4/8 0.2 % 0.52 [ 0.20, 1.33 ]
Kotasek 2003e 9/35 3/8 0.2 % 0.69 [ 0.24, 1.97 ]
Kotasek 2003f 7/38 4/9 0.2 % 0.41 [ 0.15, 1.12 ]
Krzakowski 2008a 27/104 14/52 0.6 % 0.96 [ 0.55, 1.68 ]
Krzakowski 2008b 23/105 14/52 0.6 % 0.81 [ 0.46, 1.45 ]
Kurz 1997 5/23 8/12 0.3 % 0.33 [ 0.14, 0.78 ]
O’Shaughnessy 2005 0/47 4/47 0.1 % 0.11 [ 0.01, 2.01 ]
Oberhoff 1998 32/114 44/104 1.5 % 0.66 [ 0.46, 0.96 ]
Osterborg 2002 65/169 90/173 2.9 % 0.74 [ 0.58, 0.94 ]
Quirt 1996 4/27 8/27 0.3 % 0.50 [ 0.17, 1.47 ]
Ray-Coquard 2009 39/108 61/105 2.0 % 0.62 [ 0.46, 0.84 ]
Razzouk 2006 72/111 86/111 2.8 % 0.84 [ 0.71, 0.99 ]
Rose 1994 65/142 47/79 2.0 % 0.77 [ 0.60, 0.99 ]
Rosen 2003 19/47 24/43 0.8 % 0.72 [ 0.47, 1.12 ]
Savonije 2005 77/211 66/102 2.9 % 0.56 [ 0.45, 0.71 ]
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Smith 2003a 3/20 1/6 0.1 % 0.90 [ 0.11, 7.14 ]
Smith 2003b 1/20 1/7 0.0 % 0.35 [ 0.03, 4.88 ]
Smith 2003c 2/21 2/7 0.1 % 0.33 [ 0.06, 1.94 ]
Smith 2008 176/419 215/432 7.0 % 0.84 [ 0.73, 0.98 ]
Strauss 2008 9/34 12/40 0.4 % 0.88 [ 0.42, 1.84 ]
Thomas 2002 7/62 31/65 1.0 % 0.24 [ 0.11, 0.50 ]
Thompson 2000 34/45 19/21 0.9 % 0.84 [ 0.67, 1.04 ]
Tjulandin 2010a 8/76 9/37 0.4 % 0.43 [ 0.18, 1.03 ]
Tjulandin 2010b 9/73 9/37 0.4 % 0.51 [ 0.22, 1.17 ]
Tjulandin 2011 13/95 23/91 0.8 % 0.54 [ 0.29, 1.00 ]
Vansteenkiste 02 FDA 2004 53/156 89/158 2.9 % 0.60 [ 0.47, 0.78 ]
Witzig 2005 42/166 65/164 2.2 % 0.64 [ 0.46, 0.88 ]
Wright 2007 5/33 10/37 0.3 % 0.56 [ 0.21, 1.47 ]
Subtotal (95% CI) 4677 3736 55.2 % 0.65 [ 0.61, 0.69 ]
Total events: 1245 (Treatment), 1581 (Control)
Heterogeneity: Chi2 = 73.75, df = 51 (P = 0.02); I2 =31%
Test for overall effect: Z = 14.42 (P < 0.00001)
3 more than 17 weeks
Aapro 2008 33/231 63/232 2.1 % 0.53 [ 0.36, 0.77 ]
Bamias 2003 11/72 24/72 0.8 % 0.46 [ 0.24, 0.86 ]
Blohmer 2011 14/127 38/129 1.2 % 0.37 [ 0.21, 0.66 ]
Carabantes 1999 4/20 13/15 0.5 % 0.23 [ 0.09, 0.57 ]
Engert 2010 405/640 467/643 15.3 % 0.87 [ 0.81, 0.94 ]
Goss 2005 8/52 27/52 0.9 % 0.30 [ 0.15, 0.59 ]
Huddart 2002 18/45 32/45 1.1 % 0.56 [ 0.38, 0.84 ]
Leyland-Jones 2005 47/469 66/470 2.2 % 0.71 [ 0.50, 1.01 ]
Littlewood 2001 62/251 49/124 2.2 % 0.63 [ 0.46, 0.85 ]
Milroy 2011 16/189 43/191 1.4 % 0.38 [ 0.22, 0.64 ]
Moebus 2007 41/320 86/305 2.9 % 0.45 [ 0.32, 0.64 ]
Osterborg 1996a 33/47 19/24 0.8 % 0.89 [ 0.67, 1.17 ]
Osterborg 1996b 39/48 20/25 0.9 % 1.02 [ 0.80, 1.29 ]
Pirker 2008 52/298 116/298 3.8 % 0.45 [ 0.34, 0.60 ]
Pronzato 2010 8/107 18/109 0.6 % 0.45 [ 0.21, 1.00 ]
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ten Bokkel 1998a 2/45 7/17 0.3 % 0.11 [ 0.02, 0.47 ]
Ten Bokkel 1998b 6/42 6/16 0.3 % 0.38 [ 0.14, 1.01 ]
Thatcher 1999a 19/42 13/22 0.6 % 0.77 [ 0.47, 1.24 ]
Thatcher 1999b 9/44 13/22 0.6 % 0.35 [ 0.18, 0.68 ]
Untch 2011˙1 1/356 0/377 0.0 % 3.18 [ 0.13, 77.72 ]
Welch 1995 4/15 8/15 0.3 % 0.50 [ 0.19, 1.31 ]
Wilkinson 2006 9/114 18/59 0.8 % 0.26 [ 0.12, 0.54 ]
Wurnig 1996 8/15 14/14 0.5 % 0.55 [ 0.34, 0.88 ]
Subtotal (95% CI) 3589 3276 39.9 % 0.65 [ 0.61, 0.70 ]
Total events: 849 (Treatment), 1160 (Control)
Heterogeneity: Chi2 = 126.00, df = 22 (P<0.00001); I2 =83%
Test for overall effect: Z = 12.84 (P < 0.00001)
Total (95% CI) 8733 7360 100.0 % 0.65 [ 0.62, 0.68 ]
Total events: 2198 (Treatment), 2880 (Control)
Heterogeneity: Chi2 = 217.08, df = 87 (P<0.00001); I2 =60%
Test for overall effect: Z = 19.89 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.61, df = 2 (P = 0.74), I2 =0.0%
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Analysis 3.10. Comparison 3 Participants receiving red blood cell transfusions, Outcome 10 Participants
receiving red blood cell transfusions - iron supplementation.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 3 Participants receiving red blood cell transfusions
Outcome: 10 Participants receiving red blood cell transfusions - iron supplementation
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 fixed iron supplementation
Aravantinos 2003 9/24 23/23 0.8 % 0.39 [ 0.23, 0.64 ]
Christodoulou 2009 16/167 36/170 1.2 % 0.45 [ 0.26, 0.78 ]
Dunphy 1999 2/13 5/14 0.2 % 0.43 [ 0.10, 1.85 ]
Gupta 2009 9/58 25/57 0.8 % 0.35 [ 0.18, 0.69 ]
Huddart 2002 18/45 32/45 1.1 % 0.56 [ 0.38, 0.84 ]
Iconomou 2003 9/57 14/55 0.5 % 0.62 [ 0.29, 1.31 ]
Krzakowski 2008a 27/104 14/52 0.6 % 0.96 [ 0.55, 1.68 ]
Krzakowski 2008b 23/105 14/52 0.6 % 0.81 [ 0.46, 1.45 ]
Untch 2011˙1 1/356 0/377 0.0 % 3.18 [ 0.13, 77.72 ]
Witzig 2005 42/166 65/164 2.2 % 0.64 [ 0.46, 0.88 ]
Subtotal (95% CI) 1095 1009 7.9 % 0.58 [ 0.49, 0.70 ]
Total events: 156 (Treatment), 228 (Control)
Heterogeneity: Chi2 = 11.55, df = 9 (P = 0.24); I2 =22%
Test for overall effect: Z = 6.07 (P < 0.00001)
2 iron supplementation as necessary
Aapro 2008 33/231 63/232 2.1 % 0.53 [ 0.36, 0.77 ]
Abels 1993 21/63 21/55 0.7 % 0.87 [ 0.54, 1.42 ]
Boogaerts 2003 43/133 67/129 2.2 % 0.62 [ 0.46, 0.84 ]
Cascinu 1994 10/50 28/50 0.9 % 0.36 [ 0.19, 0.65 ]
Case 1993 32/79 36/74 1.2 % 0.83 [ 0.58, 1.19 ]
Cazzola 1995a 7/31 2/7 0.1 % 0.79 [ 0.21, 3.02 ]
Cazzola 1995b 5/29 2/8 0.1 % 0.69 [ 0.16, 2.91 ]
Cazzola 1995c 6/31 2/7 0.1 % 0.68 [ 0.17, 2.68 ]
Cazzola 1995d 4/26 2/7 0.1 % 0.54 [ 0.12, 2.36 ]
Chang 2005 15/175 40/175 1.3 % 0.38 [ 0.22, 0.65 ]
Charu 2007 27/226 13/59 0.7 % 0.54 [ 0.30, 0.98 ]
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dammacco 2001 19/69 36/76 1.1 % 0.58 [ 0.37, 0.91 ]
Del Mastro 1997 0/31 2/31 0.1 % 0.20 [ 0.01, 4.00 ]
Engert 2010 405/640 467/643 15.3 % 0.87 [ 0.81, 0.94 ]
EPO-INT-3 J%J 2004 21/136 23/65 1.0 % 0.44 [ 0.26, 0.73 ]
Fujisaka 2011 4/89 18/92 0.6 % 0.23 [ 0.08, 0.65 ]
Gordon 2008 18/162 6/56 0.3 % 1.04 [ 0.43, 2.48 ]
Goss 2005 8/52 27/52 0.9 % 0.30 [ 0.15, 0.59 ]
Grote 2005 26/109 42/115 1.3 % 0.65 [ 0.43, 0.99 ]
Hedenus 2003 52/167 79/165 2.6 % 0.65 [ 0.49, 0.86 ]
Henry 1995 34/64 42/61 1.4 % 0.77 [ 0.58, 1.03 ]
Hernandez 2009 58/193 91/193 3.0 % 0.64 [ 0.49, 0.83 ]
Italian 1998 28/43 35/42 1.2 % 0.78 [ 0.60, 1.01 ]
Kotasek 2003a 8/30 4/8 0.2 % 0.53 [ 0.21, 1.33 ]
Kotasek 2003b 5/17 4/8 0.2 % 0.59 [ 0.21, 1.62 ]
Kotasek 2003c 12/41 4/9 0.2 % 0.66 [ 0.28, 1.57 ]
Kotasek 2003d 7/27 4/8 0.2 % 0.52 [ 0.20, 1.33 ]
Kotasek 2003e 9/35 3/8 0.2 % 0.69 [ 0.24, 1.97 ]
Kotasek 2003f 7/38 4/9 0.2 % 0.41 [ 0.15, 1.12 ]
Kurz 1997 5/23 8/12 0.3 % 0.33 [ 0.14, 0.78 ]
Leyland-Jones 2005 47/469 66/470 2.2 % 0.71 [ 0.50, 1.01 ]
Littlewood 2001 62/251 49/124 2.2 % 0.63 [ 0.46, 0.85 ]
Milroy 2011 16/189 43/191 1.4 % 0.38 [ 0.22, 0.64 ]
O’Shaughnessy 2005 0/47 4/47 0.1 % 0.11 [ 0.01, 2.01 ]
Oberhoff 1998 32/114 44/104 1.5 % 0.66 [ 0.46, 0.96 ]
Osterborg 1996a 33/47 19/24 0.8 % 0.89 [ 0.67, 1.17 ]
Osterborg 1996b 39/48 20/25 0.9 % 1.02 [ 0.80, 1.29 ]
Osterborg 2002 65/169 90/173 2.9 % 0.74 [ 0.58, 0.94 ]
Pirker 2008 52/298 116/298 3.8 % 0.45 [ 0.34, 0.60 ]
Pronzato 2010 8/107 18/109 0.6 % 0.45 [ 0.21, 1.00 ]
Quirt 1996 4/27 8/27 0.3 % 0.50 [ 0.17, 1.47 ]
Ray-Coquard 2009 39/108 61/105 2.0 % 0.62 [ 0.46, 0.84 ]
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Razzouk 2006 72/111 86/111 2.8 % 0.84 [ 0.71, 0.99 ]
Rose 1994 65/142 47/79 2.0 % 0.77 [ 0.60, 0.99 ]
Smith 2003a 3/20 1/6 0.1 % 0.90 [ 0.11, 7.14 ]
Smith 2003b 1/20 1/7 0.0 % 0.35 [ 0.03, 4.88 ]
Smith 2003c 2/21 2/7 0.1 % 0.33 [ 0.06, 1.94 ]
Smith 2008 176/419 215/432 7.0 % 0.84 [ 0.73, 0.98 ]
Strauss 2008 9/34 12/40 0.4 % 0.88 [ 0.42, 1.84 ]
Ten Bokkel 1998a 2/45 7/17 0.3 % 0.11 [ 0.02, 0.47 ]
Ten Bokkel 1998b 6/42 6/16 0.3 % 0.38 [ 0.14, 1.01 ]
Thatcher 1999a 19/42 13/22 0.6 % 0.77 [ 0.47, 1.24 ]
Thatcher 1999b 9/44 13/22 0.6 % 0.35 [ 0.18, 0.68 ]
Thomas 2002 7/62 31/65 1.0 % 0.24 [ 0.11, 0.50 ]
Throuvalas 2000 2/28 10/26 0.3 % 0.19 [ 0.04, 0.77 ]
Tjulandin 2010a 8/76 9/37 0.4 % 0.43 [ 0.18, 1.03 ]
Tjulandin 2010b 9/73 9/37 0.4 % 0.51 [ 0.22, 1.17 ]
Tjulandin 2011 13/95 23/91 0.8 % 0.54 [ 0.29, 1.00 ]
Tsuboi 2009 7/61 7/56 0.2 % 0.92 [ 0.34, 2.45 ]
Vansteenkiste 02 FDA 2004 53/156 89/158 2.9 % 0.60 [ 0.47, 0.78 ]
Welch 1995 4/15 8/15 0.3 % 0.50 [ 0.19, 1.31 ]
Wilkinson 2006 9/114 18/59 0.8 % 0.26 [ 0.12, 0.54 ]
Wright 2007 5/33 10/37 0.3 % 0.56 [ 0.21, 1.47 ]
Subtotal (95% CI) 6567 5493 80.2 % 0.68 [ 0.65, 0.71 ]
Total events: 1807 (Treatment), 2330 (Control)
Heterogeneity: Chi2 = 158.97, df = 62 (P<0.00001); I2 =61%
Test for overall effect: Z = 16.62 (P < 0.00001)
3 no explicit statement on iron supplementation or no iron given
Bamias 2003 11/72 24/72 0.8 % 0.46 [ 0.24, 0.86 ]
Carabantes 1999 4/20 13/15 0.5 % 0.23 [ 0.09, 0.57 ]
Gebbia 2003 5/22 13/23 0.4 % 0.40 [ 0.17, 0.94 ]
Hedenus 2002a 3/11 2/3 0.1 % 0.41 [ 0.12, 1.43 ]
Hedenus 2002b 6/22 2/4 0.1 % 0.55 [ 0.17, 1.80 ]
Hedenus 2002c 3/22 1/4 0.1 % 0.55 [ 0.07, 4.02 ]
Katakami 2008 7/103 20/104 0.7 % 0.35 [ 0.16, 0.80 ]
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kunikane 2001a 1/16 0/9 0.0 % 1.76 [ 0.08, 39.32 ]
Kunikane 2001b 2/18 0/10 0.0 % 2.89 [ 0.15, 54.98 ]
Thompson 2000 34/45 19/21 0.9 % 0.84 [ 0.67, 1.04 ]
Wurnig 1996 8/15 14/14 0.5 % 0.55 [ 0.34, 0.88 ]
Subtotal (95% CI) 366 279 4.0 % 0.52 [ 0.42, 0.65 ]
Total events: 84 (Treatment), 108 (Control)
Heterogeneity: Chi2 = 24.91, df = 10 (P = 0.01); I2 =60%
Test for overall effect: Z = 5.77 (P < 0.00001)
4 explicitly stated NO IRON
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (Treatment), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 iron given differently in both study arms new
Blohmer 2011 14/127 38/129 1.2 % 0.37 [ 0.21, 0.66 ]
Moebus 2007 41/320 86/305 2.9 % 0.45 [ 0.32, 0.64 ]
Rosen 2003 19/47 24/43 0.8 % 0.72 [ 0.47, 1.12 ]
Savonije 2005 77/211 66/102 2.9 % 0.56 [ 0.45, 0.71 ]
Subtotal (95% CI) 705 579 7.9 % 0.51 [ 0.43, 0.61 ]
Total events: 151 (Treatment), 214 (Control)
Heterogeneity: Chi2 = 4.82, df = 3 (P = 0.19); I2 =38%
Test for overall effect: Z = 7.57 (P < 0.00001)
Total (95% CI) 8733 7360 100.0 % 0.65 [ 0.62, 0.68 ]
Total events: 2198 (Treatment), 2880 (Control)
Heterogeneity: Chi2 = 217.08, df = 87 (P<0.00001); I2 =60%
Test for overall effect: Z = 19.89 (P < 0.00001)
Test for subgroup differences: Chi2 = 15.34, df = 3 (P = 0.00), I2 =80%
0.001 0.01 0.1 1 10 100 1000
Favours Treatment Favours Control
336Erythropoietin or darbepoetin for patients with cancer (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.11. Comparison 3 Participants receiving red blood cell transfusions, Outcome 11 Participants
receiving red blood cell transfusions - allocation concealment.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 3 Participants receiving red blood cell transfusions
Outcome: 11 Participants receiving red blood cell transfusions - allocation concealment
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 adequate
Aapro 2008 33/231 63/232 2.1 % 0.53 [ 0.36, 0.77 ]
Blohmer 2011 14/127 38/129 1.2 % 0.37 [ 0.21, 0.66 ]
Boogaerts 2003 43/133 67/129 2.2 % 0.62 [ 0.46, 0.84 ]
Cazzola 1995a 7/31 2/7 0.1 % 0.79 [ 0.21, 3.02 ]
Cazzola 1995b 5/29 2/8 0.1 % 0.69 [ 0.16, 2.91 ]
Cazzola 1995c 6/31 2/7 0.1 % 0.68 [ 0.17, 2.68 ]
Cazzola 1995d 4/26 2/7 0.1 % 0.54 [ 0.12, 2.36 ]
Chang 2005 15/175 40/175 1.3 % 0.38 [ 0.22, 0.65 ]
Charu 2007 27/226 13/59 0.7 % 0.54 [ 0.30, 0.98 ]
Christodoulou 2009 16/167 36/170 1.2 % 0.45 [ 0.26, 0.78 ]
Del Mastro 1997 0/31 2/31 0.1 % 0.20 [ 0.01, 4.00 ]
EPO-INT-3 J%J 2004 21/136 23/65 1.0 % 0.44 [ 0.26, 0.73 ]
Fujisaka 2011 4/89 18/92 0.6 % 0.23 [ 0.08, 0.65 ]
Gordon 2008 18/162 6/56 0.3 % 1.04 [ 0.43, 2.48 ]
Goss 2005 8/52 27/52 0.9 % 0.30 [ 0.15, 0.59 ]
Hedenus 2002a 3/11 2/3 0.1 % 0.41 [ 0.12, 1.43 ]
Hedenus 2002b 6/22 2/4 0.1 % 0.55 [ 0.17, 1.80 ]
Hedenus 2002c 3/22 1/4 0.1 % 0.55 [ 0.07, 4.02 ]
Hedenus 2003 52/167 79/165 2.6 % 0.65 [ 0.49, 0.86 ]
Hernandez 2009 58/193 91/193 3.0 % 0.64 [ 0.49, 0.83 ]
Iconomou 2003 9/57 14/55 0.5 % 0.62 [ 0.29, 1.31 ]
Italian 1998 28/43 35/42 1.2 % 0.78 [ 0.60, 1.01 ]
Kotasek 2003a 8/30 4/8 0.2 % 0.53 [ 0.21, 1.33 ]
Kotasek 2003b 5/17 4/8 0.2 % 0.59 [ 0.21, 1.62 ]
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kotasek 2003c 12/41 4/9 0.2 % 0.66 [ 0.28, 1.57 ]
Kotasek 2003d 7/27 4/8 0.2 % 0.52 [ 0.20, 1.33 ]
Kotasek 2003e 9/35 3/8 0.2 % 0.69 [ 0.24, 1.97 ]
Kotasek 2003f 7/38 4/9 0.2 % 0.41 [ 0.15, 1.12 ]
Kunikane 2001a 1/16 0/9 0.0 % 1.76 [ 0.08, 39.32 ]
Kunikane 2001b 2/18 0/10 0.0 % 2.89 [ 0.15, 54.98 ]
Kurz 1997 5/23 8/12 0.3 % 0.33 [ 0.14, 0.78 ]
Leyland-Jones 2005 47/469 66/470 2.2 % 0.71 [ 0.50, 1.01 ]
Littlewood 2001 62/251 49/124 2.2 % 0.63 [ 0.46, 0.85 ]
Milroy 2011 16/189 43/191 1.4 % 0.38 [ 0.22, 0.64 ]
Moebus 2007 41/320 86/305 2.9 % 0.45 [ 0.32, 0.64 ]
O’Shaughnessy 2005 0/47 4/47 0.1 % 0.11 [ 0.01, 2.01 ]
Oberhoff 1998 32/114 44/104 1.5 % 0.66 [ 0.46, 0.96 ]
Osterborg 1996a 33/47 19/24 0.8 % 0.89 [ 0.67, 1.17 ]
Osterborg 1996b 39/48 20/25 0.9 % 1.02 [ 0.80, 1.29 ]
Osterborg 2002 65/169 90/173 2.9 % 0.74 [ 0.58, 0.94 ]
Pirker 2008 52/298 116/298 3.8 % 0.45 [ 0.34, 0.60 ]
Pronzato 2010 8/107 18/109 0.6 % 0.45 [ 0.21, 1.00 ]
Ray-Coquard 2009 39/108 61/105 2.0 % 0.62 [ 0.46, 0.84 ]
Razzouk 2006 72/111 86/111 2.8 % 0.84 [ 0.71, 0.99 ]
Savonije 2005 77/211 66/102 2.9 % 0.56 [ 0.45, 0.71 ]
Smith 2008 176/419 215/432 7.0 % 0.84 [ 0.73, 0.98 ]
Ten Bokkel 1998a 2/45 7/17 0.3 % 0.11 [ 0.02, 0.47 ]
Ten Bokkel 1998b 6/42 6/16 0.3 % 0.38 [ 0.14, 1.01 ]
Thomas 2002 7/62 31/65 1.0 % 0.24 [ 0.11, 0.50 ]
Thompson 2000 34/45 19/21 0.9 % 0.84 [ 0.67, 1.04 ]
Throuvalas 2000 2/28 10/26 0.3 % 0.19 [ 0.04, 0.77 ]
Tsuboi 2009 7/61 7/56 0.2 % 0.92 [ 0.34, 2.45 ]
Vansteenkiste 02 FDA 2004 53/156 89/158 2.9 % 0.60 [ 0.47, 0.78 ]
Witzig 2005 42/166 65/164 2.2 % 0.64 [ 0.46, 0.88 ]
Wright 2007 5/33 10/37 0.3 % 0.56 [ 0.21, 1.47 ]
0.01 0.1 1 10 100
Favours Treatment Favours Control
(Continued . . . )
338Erythropoietin or darbepoetin for patients with cancer (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 5952 4946 63.6 % 0.61 [ 0.58, 0.65 ]
Total events: 1353 (Treatment), 1823 (Control)
Heterogeneity: Chi2 = 123.69, df = 54 (P<0.00001); I2 =56%
Test for overall effect: Z = 16.90 (P < 0.00001)
2 unclear
Abels 1993 21/63 21/55 0.7 % 0.87 [ 0.54, 1.42 ]
Aravantinos 2003 9/24 23/23 0.8 % 0.39 [ 0.23, 0.64 ]
Bamias 2003 11/72 24/72 0.8 % 0.46 [ 0.24, 0.86 ]
Carabantes 1999 4/20 13/15 0.5 % 0.23 [ 0.09, 0.57 ]
Cascinu 1994 10/50 28/50 0.9 % 0.36 [ 0.19, 0.65 ]
Case 1993 32/79 36/74 1.2 % 0.83 [ 0.58, 1.19 ]
Dammacco 2001 19/69 36/76 1.1 % 0.58 [ 0.37, 0.91 ]
Dunphy 1999 2/13 5/14 0.2 % 0.43 [ 0.10, 1.85 ]
Engert 2010 405/640 467/643 15.3 % 0.87 [ 0.81, 0.94 ]
Gebbia 2003 5/22 13/23 0.4 % 0.40 [ 0.17, 0.94 ]
Grote 2005 26/109 42/115 1.3 % 0.65 [ 0.43, 0.99 ]
Gupta 2009 9/58 25/57 0.8 % 0.35 [ 0.18, 0.69 ]
Henry 1995 34/64 42/61 1.4 % 0.77 [ 0.58, 1.03 ]
Huddart 2002 18/45 32/45 1.1 % 0.56 [ 0.38, 0.84 ]
Katakami 2008 7/103 20/104 0.7 % 0.35 [ 0.16, 0.80 ]
Krzakowski 2008a 27/104 14/52 0.6 % 0.96 [ 0.55, 1.68 ]
Krzakowski 2008b 23/105 14/52 0.6 % 0.81 [ 0.46, 1.45 ]
Quirt 1996 4/27 8/27 0.3 % 0.50 [ 0.17, 1.47 ]
Rose 1994 65/142 47/79 2.0 % 0.77 [ 0.60, 0.99 ]
Rosen 2003 19/47 24/43 0.8 % 0.72 [ 0.47, 1.12 ]
Smith 2003a 3/20 1/6 0.1 % 0.90 [ 0.11, 7.14 ]
Smith 2003b 1/20 1/7 0.0 % 0.35 [ 0.03, 4.88 ]
Smith 2003c 2/21 2/7 0.1 % 0.33 [ 0.06, 1.94 ]
Strauss 2008 9/34 12/40 0.4 % 0.88 [ 0.42, 1.84 ]
Thatcher 1999a 19/42 13/22 0.6 % 0.77 [ 0.47, 1.24 ]
Thatcher 1999b 9/44 13/22 0.6 % 0.35 [ 0.18, 0.68 ]
Tjulandin 2010a 8/76 9/37 0.4 % 0.43 [ 0.18, 1.03 ]
Tjulandin 2010b 9/73 9/37 0.4 % 0.51 [ 0.22, 1.17 ]
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tjulandin 2011 13/95 23/91 0.8 % 0.54 [ 0.29, 1.00 ]
Untch 2011˙1 1/356 0/377 0.0 % 3.18 [ 0.13, 77.72 ]
Welch 1995 4/15 8/15 0.3 % 0.50 [ 0.19, 1.31 ]
Wilkinson 2006 9/114 18/59 0.8 % 0.26 [ 0.12, 0.54 ]
Wurnig 1996 8/15 14/14 0.5 % 0.55 [ 0.34, 0.88 ]
Subtotal (95% CI) 2781 2414 36.4 % 0.71 [ 0.67, 0.76 ]
Total events: 845 (Treatment), 1057 (Control)
Heterogeneity: Chi2 = 79.13, df = 32 (P<0.00001); I2 =60%
Test for overall effect: Z = 10.50 (P < 0.00001)
Total (95% CI) 8733 7360 100.0 % 0.65 [ 0.62, 0.68 ]
Total events: 2198 (Treatment), 2880 (Control)
Heterogeneity: Chi2 = 217.08, df = 87 (P<0.00001); I2 =60%
Test for overall effect: Z = 19.89 (P < 0.00001)
Test for subgroup differences: Chi2 = 12.21, df = 1 (P = 0.00), I2 =92%
0.01 0.1 1 10 100
Favours Treatment Favours Control
340Erythropoietin or darbepoetin for patients with cancer (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.12. Comparison 3 Participants receiving red blood cell transfusions, Outcome 12 Participants
receiving red blood cell transfusions - masking.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 3 Participants receiving red blood cell transfusions
Outcome: 12 Participants receiving red blood cell transfusions - masking
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 double-blind
Abels 1993 21/63 21/55 0.7 % 0.87 [ 0.54, 1.42 ]
Cascinu 1994 10/50 28/50 0.9 % 0.36 [ 0.19, 0.65 ]
Case 1993 32/79 36/74 1.2 % 0.83 [ 0.58, 1.19 ]
Dammacco 2001 19/69 36/76 1.1 % 0.58 [ 0.37, 0.91 ]
Engert 2010 405/640 467/643 15.3 % 0.87 [ 0.81, 0.94 ]
EPO-INT-3 J%J 2004 21/136 23/65 1.0 % 0.44 [ 0.26, 0.73 ]
Fujisaka 2011 4/89 18/92 0.6 % 0.23 [ 0.08, 0.65 ]
Gordon 2008 18/162 6/56 0.3 % 1.04 [ 0.43, 2.48 ]
Goss 2005 8/52 27/52 0.9 % 0.30 [ 0.15, 0.59 ]
Grote 2005 26/109 42/115 1.3 % 0.65 [ 0.43, 0.99 ]
Hedenus 2002a 3/11 2/3 0.1 % 0.41 [ 0.12, 1.43 ]
Hedenus 2002b 6/22 2/4 0.1 % 0.55 [ 0.17, 1.80 ]
Hedenus 2002c 3/22 1/4 0.1 % 0.55 [ 0.07, 4.02 ]
Hedenus 2003 52/167 79/165 2.6 % 0.65 [ 0.49, 0.86 ]
Henry 1995 34/64 42/61 1.4 % 0.77 [ 0.58, 1.03 ]
Hernandez 2009 58/193 91/193 3.0 % 0.64 [ 0.49, 0.83 ]
Italian 1998 28/43 35/42 1.2 % 0.78 [ 0.60, 1.01 ]
Katakami 2008 7/103 20/104 0.7 % 0.35 [ 0.16, 0.80 ]
Kotasek 2003a 8/30 4/8 0.2 % 0.53 [ 0.21, 1.33 ]
Kotasek 2003b 5/17 4/8 0.2 % 0.59 [ 0.21, 1.62 ]
Kotasek 2003c 12/41 4/9 0.2 % 0.66 [ 0.28, 1.57 ]
Kotasek 2003d 7/27 4/8 0.2 % 0.52 [ 0.20, 1.33 ]
Kotasek 2003e 9/35 3/8 0.2 % 0.69 [ 0.24, 1.97 ]
Kotasek 2003f 7/38 4/9 0.2 % 0.41 [ 0.15, 1.12 ]
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Krzakowski 2008a 27/104 14/52 0.6 % 0.96 [ 0.55, 1.68 ]
Krzakowski 2008b 23/105 14/52 0.6 % 0.81 [ 0.46, 1.45 ]
Kunikane 2001a 1/16 0/9 0.0 % 1.76 [ 0.08, 39.32 ]
Kunikane 2001b 2/18 0/10 0.0 % 2.89 [ 0.15, 54.98 ]
Kurz 1997 5/23 8/12 0.3 % 0.33 [ 0.14, 0.78 ]
Leyland-Jones 2005 47/469 66/470 2.2 % 0.71 [ 0.50, 1.01 ]
Littlewood 2001 62/251 49/124 2.2 % 0.63 [ 0.46, 0.85 ]
O’Shaughnessy 2005 0/47 4/47 0.1 % 0.11 [ 0.01, 2.01 ]
Osterborg 2002 65/169 90/173 2.9 % 0.74 [ 0.58, 0.94 ]
Pirker 2008 52/298 116/298 3.8 % 0.45 [ 0.34, 0.60 ]
Quirt 1996 4/27 8/27 0.3 % 0.50 [ 0.17, 1.47 ]
Razzouk 2006 72/111 86/111 2.8 % 0.84 [ 0.71, 0.99 ]
Rose 1994 65/142 47/79 2.0 % 0.77 [ 0.60, 0.99 ]
Smith 2003a 3/20 1/6 0.1 % 0.90 [ 0.11, 7.14 ]
Smith 2003b 1/20 1/7 0.0 % 0.35 [ 0.03, 4.88 ]
Smith 2003c 2/21 2/7 0.1 % 0.33 [ 0.06, 1.94 ]
Smith 2008 176/419 215/432 7.0 % 0.84 [ 0.73, 0.98 ]
Thompson 2000 34/45 19/21 0.9 % 0.84 [ 0.67, 1.04 ]
Tjulandin 2010a 8/76 9/37 0.4 % 0.43 [ 0.18, 1.03 ]
Tjulandin 2010b 9/73 9/37 0.4 % 0.51 [ 0.22, 1.17 ]
Tjulandin 2011 13/95 23/91 0.8 % 0.54 [ 0.29, 1.00 ]
Tsuboi 2009 7/61 7/56 0.2 % 0.92 [ 0.34, 2.45 ]
Vansteenkiste 02 FDA 2004 53/156 89/158 2.9 % 0.60 [ 0.47, 0.78 ]
Witzig 2005 42/166 65/164 2.2 % 0.64 [ 0.46, 0.88 ]
Wright 2007 5/33 10/37 0.3 % 0.56 [ 0.21, 1.47 ]
Wurnig 1996 8/15 14/14 0.5 % 0.55 [ 0.34, 0.88 ]
Subtotal (95% CI) 5242 4435 67.4 % 0.71 [ 0.68, 0.75 ]
Total events: 1589 (Treatment), 1965 (Control)
Heterogeneity: Chi2 = 94.05, df = 49 (P = 0.00012); I2 =48%
Test for overall effect: Z = 13.57 (P < 0.00001)
2 unblinded
Aapro 2008 33/231 63/232 2.1 % 0.53 [ 0.36, 0.77 ]
Aravantinos 2003 9/24 23/23 0.8 % 0.39 [ 0.23, 0.64 ]
0.01 0.1 1 10 100
Favours Treatment Favours Control
(Continued . . . )
342Erythropoietin or darbepoetin for patients with cancer (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bamias 2003 11/72 24/72 0.8 % 0.46 [ 0.24, 0.86 ]
Blohmer 2011 14/127 38/129 1.2 % 0.37 [ 0.21, 0.66 ]
Boogaerts 2003 43/133 67/129 2.2 % 0.62 [ 0.46, 0.84 ]
Carabantes 1999 4/20 13/15 0.5 % 0.23 [ 0.09, 0.57 ]
Cazzola 1995a 7/31 2/7 0.1 % 0.79 [ 0.21, 3.02 ]
Cazzola 1995b 5/29 2/8 0.1 % 0.69 [ 0.16, 2.91 ]
Cazzola 1995c 6/31 2/7 0.1 % 0.68 [ 0.17, 2.68 ]
Cazzola 1995d 4/26 2/7 0.1 % 0.54 [ 0.12, 2.36 ]
Chang 2005 15/175 40/175 1.3 % 0.38 [ 0.22, 0.65 ]
Charu 2007 27/226 13/59 0.7 % 0.54 [ 0.30, 0.98 ]
Christodoulou 2009 16/167 36/170 1.2 % 0.45 [ 0.26, 0.78 ]
Del Mastro 1997 0/31 2/31 0.1 % 0.20 [ 0.01, 4.00 ]
Dunphy 1999 2/13 5/14 0.2 % 0.43 [ 0.10, 1.85 ]
Gebbia 2003 5/22 13/23 0.4 % 0.40 [ 0.17, 0.94 ]
Gupta 2009 9/58 25/57 0.8 % 0.35 [ 0.18, 0.69 ]
Huddart 2002 18/45 32/45 1.1 % 0.56 [ 0.38, 0.84 ]
Iconomou 2003 9/57 14/55 0.5 % 0.62 [ 0.29, 1.31 ]
Milroy 2011 16/189 43/191 1.4 % 0.38 [ 0.22, 0.64 ]
Moebus 2007 41/320 86/305 2.9 % 0.45 [ 0.32, 0.64 ]
Oberhoff 1998 32/114 44/104 1.5 % 0.66 [ 0.46, 0.96 ]
Osterborg 1996a 33/47 19/24 0.8 % 0.89 [ 0.67, 1.17 ]
Osterborg 1996b 39/48 20/25 0.9 % 1.02 [ 0.80, 1.29 ]
Pronzato 2010 8/107 18/109 0.6 % 0.45 [ 0.21, 1.00 ]
Ray-Coquard 2009 39/108 61/105 2.0 % 0.62 [ 0.46, 0.84 ]
Rosen 2003 19/47 24/43 0.8 % 0.72 [ 0.47, 1.12 ]
Savonije 2005 77/211 66/102 2.9 % 0.56 [ 0.45, 0.71 ]
Strauss 2008 9/34 12/40 0.4 % 0.88 [ 0.42, 1.84 ]
Ten Bokkel 1998a 2/45 7/17 0.3 % 0.11 [ 0.02, 0.47 ]
Ten Bokkel 1998b 6/42 6/16 0.3 % 0.38 [ 0.14, 1.01 ]
Thatcher 1999a 19/42 13/22 0.6 % 0.77 [ 0.47, 1.24 ]
Thatcher 1999b 9/44 13/22 0.6 % 0.35 [ 0.18, 0.68 ]
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Thomas 2002 7/62 31/65 1.0 % 0.24 [ 0.11, 0.50 ]
Throuvalas 2000 2/28 10/26 0.3 % 0.19 [ 0.04, 0.77 ]
Untch 2011˙1 1/356 0/377 0.0 % 3.18 [ 0.13, 77.72 ]
Welch 1995 4/15 8/15 0.3 % 0.50 [ 0.19, 1.31 ]
Wilkinson 2006 9/114 18/59 0.8 % 0.26 [ 0.12, 0.54 ]
Subtotal (95% CI) 3491 2925 32.6 % 0.52 [ 0.47, 0.56 ]
Total events: 609 (Treatment), 915 (Control)
Heterogeneity: Chi2 = 86.98, df = 37 (P<0.00001); I2 =57%
Test for overall effect: Z = 15.06 (P < 0.00001)
Total (95% CI) 8733 7360 100.0 % 0.65 [ 0.62, 0.68 ]
Total events: 2198 (Treatment), 2880 (Control)
Heterogeneity: Chi2 = 217.08, df = 87 (P<0.00001); I2 =60%
Test for overall effect: Z = 19.89 (P < 0.00001)
Test for subgroup differences: Chi2 = 40.95, df = 1 (P = 0.00), I2 =98%
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Analysis 3.13. Comparison 3 Participants receiving red blood cell transfusions, Outcome 13 Participants
receiving red blood cell transfusions - intention-to treat.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 3 Participants receiving red blood cell transfusions
Outcome: 13 Participants receiving red blood cell transfusions - intention-to treat
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ITT or less than 10% of participants per study arm excluded
Aapro 2008 33/231 63/232 2.1 % 0.53 [ 0.36, 0.77 ]
Abels 1993 21/63 21/55 0.7 % 0.87 [ 0.54, 1.42 ]
Aravantinos 2003 9/24 23/23 0.8 % 0.39 [ 0.23, 0.64 ]
Bamias 2003 11/72 24/72 0.8 % 0.46 [ 0.24, 0.86 ]
Boogaerts 2003 43/133 67/129 2.2 % 0.62 [ 0.46, 0.84 ]
Carabantes 1999 4/20 13/15 0.5 % 0.23 [ 0.09, 0.57 ]
Cascinu 1994 10/50 28/50 0.9 % 0.36 [ 0.19, 0.65 ]
Case 1993 32/79 36/74 1.2 % 0.83 [ 0.58, 1.19 ]
Cazzola 1995a 7/31 2/7 0.1 % 0.79 [ 0.21, 3.02 ]
Cazzola 1995b 5/29 2/8 0.1 % 0.69 [ 0.16, 2.91 ]
Cazzola 1995c 6/31 2/7 0.1 % 0.68 [ 0.17, 2.68 ]
Cazzola 1995d 4/26 2/7 0.1 % 0.54 [ 0.12, 2.36 ]
Chang 2005 15/175 40/175 1.3 % 0.38 [ 0.22, 0.65 ]
Charu 2007 27/226 13/59 0.7 % 0.54 [ 0.30, 0.98 ]
Dammacco 2001 19/69 36/76 1.1 % 0.58 [ 0.37, 0.91 ]
Del Mastro 1997 0/31 2/31 0.1 % 0.20 [ 0.01, 4.00 ]
Engert 2010 405/640 467/643 15.3 % 0.87 [ 0.81, 0.94 ]
EPO-INT-3 J%J 2004 21/136 23/65 1.0 % 0.44 [ 0.26, 0.73 ]
Fujisaka 2011 4/89 18/92 0.6 % 0.23 [ 0.08, 0.65 ]
Gebbia 2003 5/22 13/23 0.4 % 0.40 [ 0.17, 0.94 ]
Gordon 2008 18/162 6/56 0.3 % 1.04 [ 0.43, 2.48 ]
Goss 2005 8/52 27/52 0.9 % 0.30 [ 0.15, 0.59 ]
Grote 2005 26/109 42/115 1.3 % 0.65 [ 0.43, 0.99 ]
Gupta 2009 9/58 25/57 0.8 % 0.35 [ 0.18, 0.69 ]
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hedenus 2002a 3/11 2/3 0.1 % 0.41 [ 0.12, 1.43 ]
Hedenus 2002b 6/22 2/4 0.1 % 0.55 [ 0.17, 1.80 ]
Hedenus 2002c 3/22 1/4 0.1 % 0.55 [ 0.07, 4.02 ]
Hedenus 2003 52/167 79/165 2.6 % 0.65 [ 0.49, 0.86 ]
Henry 1995 34/64 42/61 1.4 % 0.77 [ 0.58, 1.03 ]
Hernandez 2009 58/193 91/193 3.0 % 0.64 [ 0.49, 0.83 ]
Iconomou 2003 9/57 14/55 0.5 % 0.62 [ 0.29, 1.31 ]
Italian 1998 28/43 35/42 1.2 % 0.78 [ 0.60, 1.01 ]
Krzakowski 2008a 27/104 14/52 0.6 % 0.96 [ 0.55, 1.68 ]
Krzakowski 2008b 23/105 14/52 0.6 % 0.81 [ 0.46, 1.45 ]
Kurz 1997 5/23 8/12 0.3 % 0.33 [ 0.14, 0.78 ]
Leyland-Jones 2005 47/469 66/470 2.2 % 0.71 [ 0.50, 1.01 ]
Littlewood 2001 62/251 49/124 2.2 % 0.63 [ 0.46, 0.85 ]
Moebus 2007 41/320 86/305 2.9 % 0.45 [ 0.32, 0.64 ]
O’Shaughnessy 2005 0/47 4/47 0.1 % 0.11 [ 0.01, 2.01 ]
Oberhoff 1998 32/114 44/104 1.5 % 0.66 [ 0.46, 0.96 ]
Osterborg 1996a 33/47 19/24 0.8 % 0.89 [ 0.67, 1.17 ]
Osterborg 1996b 39/48 20/25 0.9 % 1.02 [ 0.80, 1.29 ]
Osterborg 2002 65/169 90/173 2.9 % 0.74 [ 0.58, 0.94 ]
Pirker 2008 52/298 116/298 3.8 % 0.45 [ 0.34, 0.60 ]
Pronzato 2010 8/107 18/109 0.6 % 0.45 [ 0.21, 1.00 ]
Quirt 1996 4/27 8/27 0.3 % 0.50 [ 0.17, 1.47 ]
Ray-Coquard 2009 39/108 61/105 2.0 % 0.62 [ 0.46, 0.84 ]
Razzouk 2006 72/111 86/111 2.8 % 0.84 [ 0.71, 0.99 ]
Rose 1994 65/142 47/79 2.0 % 0.77 [ 0.60, 0.99 ]
Rosen 2003 19/47 24/43 0.8 % 0.72 [ 0.47, 1.12 ]
Savonije 2005 77/211 66/102 2.9 % 0.56 [ 0.45, 0.71 ]
Smith 2003a 3/20 1/6 0.1 % 0.90 [ 0.11, 7.14 ]
Smith 2003b 1/20 1/7 0.0 % 0.35 [ 0.03, 4.88 ]
Smith 2003c 2/21 2/7 0.1 % 0.33 [ 0.06, 1.94 ]
Smith 2008 176/419 215/432 7.0 % 0.84 [ 0.73, 0.98 ]
0.01 0.1 1 10 100
Favours Treatment Favours Control
(Continued . . . )
346Erythropoietin or darbepoetin for patients with cancer (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Strauss 2008 9/34 12/40 0.4 % 0.88 [ 0.42, 1.84 ]
Ten Bokkel 1998a 2/45 7/17 0.3 % 0.11 [ 0.02, 0.47 ]
Ten Bokkel 1998b 6/42 6/16 0.3 % 0.38 [ 0.14, 1.01 ]
Thatcher 1999a 19/42 13/22 0.6 % 0.77 [ 0.47, 1.24 ]
Thatcher 1999b 9/44 13/22 0.6 % 0.35 [ 0.18, 0.68 ]
Thomas 2002 7/62 31/65 1.0 % 0.24 [ 0.11, 0.50 ]
Thompson 2000 34/45 19/21 0.9 % 0.84 [ 0.67, 1.04 ]
Throuvalas 2000 2/28 10/26 0.3 % 0.19 [ 0.04, 0.77 ]
Tjulandin 2010a 8/76 9/37 0.4 % 0.43 [ 0.18, 1.03 ]
Tjulandin 2010b 9/73 9/37 0.4 % 0.51 [ 0.22, 1.17 ]
Tjulandin 2011 13/95 23/91 0.8 % 0.54 [ 0.29, 1.00 ]
Tsuboi 2009 7/61 7/56 0.2 % 0.92 [ 0.34, 2.45 ]
Vansteenkiste 02 FDA 2004 53/156 89/158 2.9 % 0.60 [ 0.47, 0.78 ]
Welch 1995 4/15 8/15 0.3 % 0.50 [ 0.19, 1.31 ]
Wilkinson 2006 9/114 18/59 0.8 % 0.26 [ 0.12, 0.54 ]
Witzig 2005 42/166 65/164 2.2 % 0.64 [ 0.46, 0.88 ]
Wright 2007 5/33 10/37 0.3 % 0.56 [ 0.21, 1.47 ]
Wurnig 1996 8/15 14/14 0.5 % 0.55 [ 0.34, 0.88 ]
Subtotal (95% CI) 7511 6261 93.1 % 0.66 [ 0.63, 0.69 ]
Total events: 2073 (Treatment), 2683 (Control)
Heterogeneity: Chi2 = 191.64, df = 72 (P<0.00001); I2 =62%
Test for overall effect: Z = 18.58 (P < 0.00001)
2 more than 10% of participants per study arm excluded
Christodoulou 2009 16/167 36/170 1.2 % 0.45 [ 0.26, 0.78 ]
Dunphy 1999 2/13 5/14 0.2 % 0.43 [ 0.10, 1.85 ]
Kotasek 2003a 8/30 4/8 0.2 % 0.53 [ 0.21, 1.33 ]
Kotasek 2003b 5/17 4/8 0.2 % 0.59 [ 0.21, 1.62 ]
Kotasek 2003c 12/41 4/9 0.2 % 0.66 [ 0.28, 1.57 ]
Kotasek 2003d 7/27 4/8 0.2 % 0.52 [ 0.20, 1.33 ]
Kotasek 2003e 9/35 3/8 0.2 % 0.69 [ 0.24, 1.97 ]
Kotasek 2003f 7/38 4/9 0.2 % 0.41 [ 0.15, 1.12 ]
Kunikane 2001a 1/16 0/9 0.0 % 1.76 [ 0.08, 39.32 ]
Kunikane 2001b 2/18 0/10 0.0 % 2.89 [ 0.15, 54.98 ]
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Milroy 2011 16/189 43/191 1.4 % 0.38 [ 0.22, 0.64 ]
Subtotal (95% CI) 591 444 4.0 % 0.48 [ 0.36, 0.63 ]
Total events: 85 (Treatment), 107 (Control)
Heterogeneity: Chi2 = 4.24, df = 10 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 5.29 (P < 0.00001)
3 unclear
Blohmer 2011 14/127 38/129 1.2 % 0.37 [ 0.21, 0.66 ]
Huddart 2002 18/45 32/45 1.1 % 0.56 [ 0.38, 0.84 ]
Katakami 2008 7/103 20/104 0.7 % 0.35 [ 0.16, 0.80 ]
Untch 2011˙1 1/356 0/377 0.0 % 3.18 [ 0.13, 77.72 ]
Subtotal (95% CI) 631 655 3.0 % 0.45 [ 0.33, 0.62 ]
Total events: 40 (Treatment), 90 (Control)
Heterogeneity: Chi2 = 3.34, df = 3 (P = 0.34); I2 =10%
Test for overall effect: Z = 4.95 (P < 0.00001)
Total (95% CI) 8733 7360 100.0 % 0.65 [ 0.62, 0.68 ]
Total events: 2198 (Treatment), 2880 (Control)
Heterogeneity: Chi2 = 217.08, df = 87 (P<0.00001); I2 =60%
Test for overall effect: Z = 19.89 (P < 0.00001)
Test for subgroup differences: Chi2 = 10.80, df = 2 (P = 0.00), I2 =81%
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Analysis 3.14. Comparison 3 Participants receiving red blood cell transfusions, Outcome 14 Participants
receiving red blood cell transfusions - publication.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 3 Participants receiving red blood cell transfusions
Outcome: 14 Participants receiving red blood cell transfusions - publication
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 fulltext publication
Aapro 2008 33/231 63/232 2.1 % 0.53 [ 0.36, 0.77 ]
Abels 1993 21/63 21/55 0.7 % 0.87 [ 0.54, 1.42 ]
Aravantinos 2003 9/24 23/23 0.8 % 0.39 [ 0.23, 0.64 ]
Bamias 2003 11/72 24/72 0.8 % 0.46 [ 0.24, 0.86 ]
Blohmer 2011 14/127 38/129 1.2 % 0.37 [ 0.21, 0.66 ]
Boogaerts 2003 43/133 67/129 2.2 % 0.62 [ 0.46, 0.84 ]
Cascinu 1994 10/50 28/50 0.9 % 0.36 [ 0.19, 0.65 ]
Cazzola 1995a 7/31 2/7 0.1 % 0.79 [ 0.21, 3.02 ]
Cazzola 1995b 5/29 2/8 0.1 % 0.69 [ 0.16, 2.91 ]
Cazzola 1995c 6/31 2/7 0.1 % 0.68 [ 0.17, 2.68 ]
Cazzola 1995d 4/26 2/7 0.1 % 0.54 [ 0.12, 2.36 ]
Chang 2005 15/175 40/175 1.3 % 0.38 [ 0.22, 0.65 ]
Charu 2007 27/226 13/59 0.7 % 0.54 [ 0.30, 0.98 ]
Christodoulou 2009 16/167 36/170 1.2 % 0.45 [ 0.26, 0.78 ]
Dammacco 2001 19/69 36/76 1.1 % 0.58 [ 0.37, 0.91 ]
Del Mastro 1997 0/31 2/31 0.1 % 0.20 [ 0.01, 4.00 ]
Dunphy 1999 2/13 5/14 0.2 % 0.43 [ 0.10, 1.85 ]
Engert 2010 405/640 467/643 15.3 % 0.87 [ 0.81, 0.94 ]
Fujisaka 2011 4/89 18/92 0.6 % 0.23 [ 0.08, 0.65 ]
Gebbia 2003 5/22 13/23 0.4 % 0.40 [ 0.17, 0.94 ]
Gordon 2008 18/162 6/56 0.3 % 1.04 [ 0.43, 2.48 ]
Grote 2005 26/109 42/115 1.3 % 0.65 [ 0.43, 0.99 ]
Gupta 2009 9/58 25/57 0.8 % 0.35 [ 0.18, 0.69 ]
Hedenus 2002a 3/11 2/3 0.1 % 0.41 [ 0.12, 1.43 ]
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hedenus 2002b 6/22 2/4 0.1 % 0.55 [ 0.17, 1.80 ]
Hedenus 2002c 3/22 1/4 0.1 % 0.55 [ 0.07, 4.02 ]
Hedenus 2003 52/167 79/165 2.6 % 0.65 [ 0.49, 0.86 ]
Hernandez 2009 58/193 91/193 3.0 % 0.64 [ 0.49, 0.83 ]
Iconomou 2003 9/57 14/55 0.5 % 0.62 [ 0.29, 1.31 ]
Kotasek 2003a 8/30 4/8 0.2 % 0.53 [ 0.21, 1.33 ]
Kotasek 2003b 5/17 4/8 0.2 % 0.59 [ 0.21, 1.62 ]
Kotasek 2003c 12/41 4/9 0.2 % 0.66 [ 0.28, 1.57 ]
Kotasek 2003d 7/27 4/8 0.2 % 0.52 [ 0.20, 1.33 ]
Kotasek 2003e 9/35 3/8 0.2 % 0.69 [ 0.24, 1.97 ]
Kotasek 2003f 7/38 4/9 0.2 % 0.41 [ 0.15, 1.12 ]
Krzakowski 2008a 27/104 14/52 0.6 % 0.96 [ 0.55, 1.68 ]
Krzakowski 2008b 23/105 14/52 0.6 % 0.81 [ 0.46, 1.45 ]
Kunikane 2001a 1/16 0/9 0.0 % 1.76 [ 0.08, 39.32 ]
Kunikane 2001b 2/18 0/10 0.0 % 2.89 [ 0.15, 54.98 ]
Kurz 1997 5/23 8/12 0.3 % 0.33 [ 0.14, 0.78 ]
Leyland-Jones 2005 47/469 66/470 2.2 % 0.71 [ 0.50, 1.01 ]
Littlewood 2001 62/251 49/124 2.2 % 0.63 [ 0.46, 0.85 ]
Milroy 2011 16/189 43/191 1.4 % 0.38 [ 0.22, 0.64 ]
O’Shaughnessy 2005 0/47 4/47 0.1 % 0.11 [ 0.01, 2.01 ]
Pirker 2008 52/298 116/298 3.8 % 0.45 [ 0.34, 0.60 ]
Pronzato 2010 8/107 18/109 0.6 % 0.45 [ 0.21, 1.00 ]
Ray-Coquard 2009 39/108 61/105 2.0 % 0.62 [ 0.46, 0.84 ]
Razzouk 2006 72/111 86/111 2.8 % 0.84 [ 0.71, 0.99 ]
Rosen 2003 19/47 24/43 0.8 % 0.72 [ 0.47, 1.12 ]
Savonije 2005 77/211 66/102 2.9 % 0.56 [ 0.45, 0.71 ]
Smith 2003a 3/20 1/6 0.1 % 0.90 [ 0.11, 7.14 ]
Smith 2003b 1/20 1/7 0.0 % 0.35 [ 0.03, 4.88 ]
Smith 2003c 2/21 2/7 0.1 % 0.33 [ 0.06, 1.94 ]
Smith 2008 176/419 215/432 7.0 % 0.84 [ 0.73, 0.98 ]
Strauss 2008 9/34 12/40 0.4 % 0.88 [ 0.42, 1.84 ]
0.01 0.1 1 10 100
Favours Treatment Favours Control
(Continued . . . )
350Erythropoietin or darbepoetin for patients with cancer (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tjulandin 2010a 8/76 9/37 0.4 % 0.43 [ 0.18, 1.03 ]
Tjulandin 2010b 9/73 9/37 0.4 % 0.51 [ 0.22, 1.17 ]
Tjulandin 2011 13/95 23/91 0.8 % 0.54 [ 0.29, 1.00 ]
Tsuboi 2009 7/61 7/56 0.2 % 0.92 [ 0.34, 2.45 ]
Untch 2011˙1 1/356 0/377 0.0 % 3.18 [ 0.13, 77.72 ]
Welch 1995 4/15 8/15 0.3 % 0.50 [ 0.19, 1.31 ]
Wilkinson 2006 9/114 18/59 0.8 % 0.26 [ 0.12, 0.54 ]
Witzig 2005 42/166 65/164 2.2 % 0.64 [ 0.46, 0.88 ]
Wright 2007 5/33 10/37 0.3 % 0.56 [ 0.21, 1.47 ]
Wurnig 1996 8/15 14/14 0.5 % 0.55 [ 0.34, 0.88 ]
Subtotal (95% CI) 6860 5818 73.9 % 0.66 [ 0.63, 0.70 ]
Total events: 1635 (Treatment), 2150 (Control)
Heterogeneity: Chi2 = 138.73, df = 64 (P<0.00001); I2 =54%
Test for overall effect: Z = 16.31 (P < 0.00001)
2 abstract publication
Carabantes 1999 4/20 13/15 0.5 % 0.23 [ 0.09, 0.57 ]
Goss 2005 8/52 27/52 0.9 % 0.30 [ 0.15, 0.59 ]
Huddart 2002 18/45 32/45 1.1 % 0.56 [ 0.38, 0.84 ]
Katakami 2008 7/103 20/104 0.7 % 0.35 [ 0.16, 0.80 ]
Moebus 2007 41/320 86/305 2.9 % 0.45 [ 0.32, 0.64 ]
Quirt 1996 4/27 8/27 0.3 % 0.50 [ 0.17, 1.47 ]
Thomas 2002 7/62 31/65 1.0 % 0.24 [ 0.11, 0.50 ]
Subtotal (95% CI) 629 613 7.2 % 0.40 [ 0.32, 0.49 ]
Total events: 89 (Treatment), 217 (Control)
Heterogeneity: Chi2 = 7.67, df = 6 (P = 0.26); I2 =22%
Test for overall effect: Z = 8.41 (P < 0.00001)
3 unpublished data
Case 1993 32/79 36/74 1.2 % 0.83 [ 0.58, 1.19 ]
Henry 1995 34/64 42/61 1.4 % 0.77 [ 0.58, 1.03 ]
Italian 1998 28/43 35/42 1.2 % 0.78 [ 0.60, 1.01 ]
Oberhoff 1998 32/114 44/104 1.5 % 0.66 [ 0.46, 0.96 ]
Osterborg 1996a 33/47 19/24 0.8 % 0.89 [ 0.67, 1.17 ]
Osterborg 1996b 39/48 20/25 0.9 % 1.02 [ 0.80, 1.29 ]
Osterborg 2002 65/169 90/173 2.9 % 0.74 [ 0.58, 0.94 ]
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rose 1994 65/142 47/79 2.0 % 0.77 [ 0.60, 0.99 ]
Ten Bokkel 1998a 2/45 7/17 0.3 % 0.11 [ 0.02, 0.47 ]
Ten Bokkel 1998b 6/42 6/16 0.3 % 0.38 [ 0.14, 1.01 ]
Thatcher 1999a 19/42 13/22 0.6 % 0.77 [ 0.47, 1.24 ]
Thatcher 1999b 9/44 13/22 0.6 % 0.35 [ 0.18, 0.68 ]
Thompson 2000 34/45 19/21 0.9 % 0.84 [ 0.67, 1.04 ]
Throuvalas 2000 2/28 10/26 0.3 % 0.19 [ 0.04, 0.77 ]
Subtotal (95% CI) 952 706 14.9 % 0.73 [ 0.67, 0.80 ]
Total events: 400 (Treatment), 401 (Control)
Heterogeneity: Chi2 = 28.40, df = 13 (P = 0.01); I2 =54%
Test for overall effect: Z = 6.48 (P < 0.00001)
4 FDA presented data
Vansteenkiste 02 FDA 2004 53/156 89/158 2.9 % 0.60 [ 0.47, 0.78 ]
Subtotal (95% CI) 156 158 2.9 % 0.60 [ 0.47, 0.78 ]
Total events: 53 (Treatment), 89 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.84 (P = 0.00012)
5 Other
EPO-INT-3 J%J 2004 21/136 23/65 1.0 % 0.44 [ 0.26, 0.73 ]
Subtotal (95% CI) 136 65 1.0 % 0.44 [ 0.26, 0.73 ]
Total events: 21 (Treatment), 23 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.17 (P = 0.0015)
Total (95% CI) 8733 7360 100.0 % 0.65 [ 0.62, 0.68 ]
Total events: 2198 (Treatment), 2880 (Control)
Heterogeneity: Chi2 = 217.08, df = 87 (P<0.00001); I2 =60%
Test for overall effect: Z = 19.89 (P < 0.00001)
Test for subgroup differences: Chi2 = 28.83, df = 4 (P = 0.00), I2 =86%
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Analysis 3.15. Comparison 3 Participants receiving red blood cell transfusions, Outcome 15 Participants
receiving red blood cell transfusions - first 4 weeks are....
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 3 Participants receiving red blood cell transfusions
Outcome: 15 Participants receiving red blood cell transfusions - first 4 weeks are...
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 included in the analysis
Abels 1993 21/63 21/55 0.7 % 0.87 [ 0.54, 1.42 ]
Aravantinos 2003 9/24 23/23 0.8 % 0.39 [ 0.23, 0.64 ]
Bamias 2003 11/72 24/72 0.8 % 0.46 [ 0.24, 0.86 ]
Boogaerts 2003 43/133 67/129 2.2 % 0.62 [ 0.46, 0.84 ]
Cascinu 1994 10/50 28/50 0.9 % 0.36 [ 0.19, 0.65 ]
Case 1993 32/79 36/74 1.2 % 0.83 [ 0.58, 1.19 ]
Cazzola 1995a 7/31 2/7 0.1 % 0.79 [ 0.21, 3.02 ]
Cazzola 1995b 5/29 2/8 0.1 % 0.69 [ 0.16, 2.91 ]
Cazzola 1995c 6/31 2/7 0.1 % 0.68 [ 0.17, 2.68 ]
Cazzola 1995d 4/26 2/7 0.1 % 0.54 [ 0.12, 2.36 ]
Charu 2007 27/226 13/59 0.7 % 0.54 [ 0.30, 0.98 ]
Dunphy 1999 2/13 5/14 0.2 % 0.43 [ 0.10, 1.85 ]
Gordon 2008 18/162 6/56 0.3 % 1.04 [ 0.43, 2.48 ]
Grote 2005 26/109 42/115 1.3 % 0.65 [ 0.43, 0.99 ]
Hernandez 2009 58/193 91/193 3.0 % 0.64 [ 0.49, 0.83 ]
Huddart 2002 18/45 32/45 1.1 % 0.56 [ 0.38, 0.84 ]
Iconomou 2003 9/57 14/55 0.5 % 0.62 [ 0.29, 1.31 ]
Milroy 2011 16/189 43/191 1.4 % 0.38 [ 0.22, 0.64 ]
Oberhoff 1998 32/114 44/104 1.5 % 0.66 [ 0.46, 0.96 ]
Osterborg 1996a 33/47 19/24 0.8 % 0.89 [ 0.67, 1.17 ]
Osterborg 1996b 39/48 20/25 0.9 % 1.02 [ 0.80, 1.29 ]
Osterborg 2002 65/169 90/173 2.9 % 0.74 [ 0.58, 0.94 ]
Pronzato 2010 8/107 18/109 0.6 % 0.45 [ 0.21, 1.00 ]
Razzouk 2006 72/111 86/111 2.8 % 0.84 [ 0.71, 0.99 ]
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
(Continued . . . )
353Erythropoietin or darbepoetin for patients with cancer (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rose 1994 65/142 47/79 2.0 % 0.77 [ 0.60, 0.99 ]
Savonije 2005 77/211 66/102 2.9 % 0.56 [ 0.45, 0.71 ]
Ten Bokkel 1998a 2/45 7/17 0.3 % 0.11 [ 0.02, 0.47 ]
Ten Bokkel 1998b 6/42 6/16 0.3 % 0.38 [ 0.14, 1.01 ]
Tsuboi 2009 7/61 7/56 0.2 % 0.92 [ 0.34, 2.45 ]
Vansteenkiste 02 FDA 2004 53/156 89/158 2.9 % 0.60 [ 0.47, 0.78 ]
Witzig 2005 42/166 65/164 2.2 % 0.64 [ 0.46, 0.88 ]
Wright 2007 5/33 10/37 0.3 % 0.56 [ 0.21, 1.47 ]
Subtotal (95% CI) 2984 2335 36.2 % 0.65 [ 0.61, 0.70 ]
Total events: 828 (Treatment), 1027 (Control)
Heterogeneity: Chi2 = 58.44, df = 31 (P = 0.002); I2 =47%
Test for overall effect: Z = 11.94 (P < 0.00001)
2 excluded from the analysis
Dammacco 2001 19/69 36/76 1.1 % 0.58 [ 0.37, 0.91 ]
EPO-INT-3 J%J 2004 21/136 23/65 1.0 % 0.44 [ 0.26, 0.73 ]
Fujisaka 2011 4/89 18/92 0.6 % 0.23 [ 0.08, 0.65 ]
Hedenus 2002a 3/11 2/3 0.1 % 0.41 [ 0.12, 1.43 ]
Hedenus 2002b 6/22 2/4 0.1 % 0.55 [ 0.17, 1.80 ]
Hedenus 2002c 3/22 1/4 0.1 % 0.55 [ 0.07, 4.02 ]
Hedenus 2003 52/167 79/165 2.6 % 0.65 [ 0.49, 0.86 ]
Henry 1995 34/64 42/61 1.4 % 0.77 [ 0.58, 1.03 ]
Katakami 2008 7/103 20/104 0.7 % 0.35 [ 0.16, 0.80 ]
Kotasek 2003a 8/30 4/8 0.2 % 0.53 [ 0.21, 1.33 ]
Kotasek 2003b 5/17 4/8 0.2 % 0.59 [ 0.21, 1.62 ]
Kotasek 2003c 12/41 4/9 0.2 % 0.66 [ 0.28, 1.57 ]
Kotasek 2003d 7/27 4/8 0.2 % 0.52 [ 0.20, 1.33 ]
Kotasek 2003e 9/35 3/8 0.2 % 0.69 [ 0.24, 1.97 ]
Kotasek 2003f 7/38 4/9 0.2 % 0.41 [ 0.15, 1.12 ]
Krzakowski 2008a 27/104 14/52 0.6 % 0.96 [ 0.55, 1.68 ]
Krzakowski 2008b 23/105 14/52 0.6 % 0.81 [ 0.46, 1.45 ]
Littlewood 2001 62/251 49/124 2.2 % 0.63 [ 0.46, 0.85 ]
Smith 2003a 3/20 1/6 0.1 % 0.90 [ 0.11, 7.14 ]
Smith 2003b 1/20 1/7 0.0 % 0.35 [ 0.03, 4.88 ]
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Smith 2003c 2/21 2/7 0.1 % 0.33 [ 0.06, 1.94 ]
Smith 2008 176/419 215/432 7.0 % 0.84 [ 0.73, 0.98 ]
Wilkinson 2006 9/114 18/59 0.8 % 0.26 [ 0.12, 0.54 ]
Subtotal (95% CI) 1925 1363 20.2 % 0.68 [ 0.61, 0.75 ]
Total events: 500 (Treatment), 560 (Control)
Heterogeneity: Chi2 = 31.44, df = 22 (P = 0.09); I2 =30%
Test for overall effect: Z = 7.96 (P < 0.00001)
3 unclear
Aapro 2008 33/231 63/232 2.1 % 0.53 [ 0.36, 0.77 ]
Blohmer 2011 14/127 38/129 1.2 % 0.37 [ 0.21, 0.66 ]
Carabantes 1999 4/20 13/15 0.5 % 0.23 [ 0.09, 0.57 ]
Chang 2005 15/175 40/175 1.3 % 0.38 [ 0.22, 0.65 ]
Christodoulou 2009 16/167 36/170 1.2 % 0.45 [ 0.26, 0.78 ]
Del Mastro 1997 0/31 2/31 0.1 % 0.20 [ 0.01, 4.00 ]
Engert 2010 405/640 467/643 15.3 % 0.87 [ 0.81, 0.94 ]
Gebbia 2003 5/22 13/23 0.4 % 0.40 [ 0.17, 0.94 ]
Goss 2005 8/52 27/52 0.9 % 0.30 [ 0.15, 0.59 ]
Gupta 2009 9/58 25/57 0.8 % 0.35 [ 0.18, 0.69 ]
Italian 1998 28/43 35/42 1.2 % 0.78 [ 0.60, 1.01 ]
Kunikane 2001a 1/16 0/9 0.0 % 1.76 [ 0.08, 39.32 ]
Kunikane 2001b 2/18 0/10 0.0 % 2.89 [ 0.15, 54.98 ]
Kurz 1997 5/23 8/12 0.3 % 0.33 [ 0.14, 0.78 ]
Leyland-Jones 2005 47/469 66/470 2.2 % 0.71 [ 0.50, 1.01 ]
Moebus 2007 41/320 86/305 2.9 % 0.45 [ 0.32, 0.64 ]
O’Shaughnessy 2005 0/47 4/47 0.1 % 0.11 [ 0.01, 2.01 ]
Pirker 2008 52/298 116/298 3.8 % 0.45 [ 0.34, 0.60 ]
Quirt 1996 4/27 8/27 0.3 % 0.50 [ 0.17, 1.47 ]
Ray-Coquard 2009 39/108 61/105 2.0 % 0.62 [ 0.46, 0.84 ]
Rosen 2003 19/47 24/43 0.8 % 0.72 [ 0.47, 1.12 ]
Strauss 2008 9/34 12/40 0.4 % 0.88 [ 0.42, 1.84 ]
Thatcher 1999a 19/42 13/22 0.6 % 0.77 [ 0.47, 1.24 ]
Thatcher 1999b 9/44 13/22 0.6 % 0.35 [ 0.18, 0.68 ]
Thomas 2002 7/62 31/65 1.0 % 0.24 [ 0.11, 0.50 ]
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Thompson 2000 34/45 19/21 0.9 % 0.84 [ 0.67, 1.04 ]
Throuvalas 2000 2/28 10/26 0.3 % 0.19 [ 0.04, 0.77 ]
Tjulandin 2010a 8/76 9/37 0.4 % 0.43 [ 0.18, 1.03 ]
Tjulandin 2010b 9/73 9/37 0.4 % 0.51 [ 0.22, 1.17 ]
Tjulandin 2011 13/95 23/91 0.8 % 0.54 [ 0.29, 1.00 ]
Untch 2011˙1 1/356 0/377 0.0 % 3.18 [ 0.13, 77.72 ]
Welch 1995 4/15 8/15 0.3 % 0.50 [ 0.19, 1.31 ]
Wurnig 1996 8/15 14/14 0.5 % 0.55 [ 0.34, 0.88 ]
Subtotal (95% CI) 3824 3662 43.6 % 0.64 [ 0.60, 0.68 ]
Total events: 870 (Treatment), 1293 (Control)
Heterogeneity: Chi2 = 131.29, df = 32 (P<0.00001); I2 =76%
Test for overall effect: Z = 13.86 (P < 0.00001)
Total (95% CI) 8733 7360 100.0 % 0.65 [ 0.62, 0.68 ]
Total events: 2198 (Treatment), 2880 (Control)
Heterogeneity: Chi2 = 217.08, df = 87 (P<0.00001); I2 =60%
Test for overall effect: Z = 19.89 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.14, df = 2 (P = 0.57), I2 =0.0%
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Analysis 3.16. Comparison 3 Participants receiving red blood cell transfusions, Outcome 16 Participants
receiving red blood cell transfusions - experimental arms merged.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 3 Participants receiving red blood cell transfusions
Outcome: 16 Participants receiving red blood cell transfusions - experimental arms merged
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Aapro 2008 33/231 63/232 2.1 % 0.53 [ 0.36, 0.77 ]
Abels 1993 21/63 21/55 0.7 % 0.87 [ 0.54, 1.42 ]
Aravantinos 2003 9/24 23/23 0.8 % 0.39 [ 0.23, 0.64 ]
Bamias 2003 11/72 24/72 0.8 % 0.46 [ 0.24, 0.86 ]
Blohmer 2011 14/127 38/129 1.2 % 0.37 [ 0.21, 0.66 ]
Boogaerts 2003 43/133 67/129 2.2 % 0.62 [ 0.46, 0.84 ]
Carabantes 1999 4/20 13/15 0.5 % 0.23 [ 0.09, 0.57 ]
Cascinu 1994 10/50 28/50 0.9 % 0.36 [ 0.19, 0.65 ]
Case 1993 32/79 36/74 1.2 % 0.83 [ 0.58, 1.19 ]
Cazzola 1995 22/117 8/29 0.4 % 0.68 [ 0.34, 1.37 ]
Chang 2005 15/175 40/175 1.3 % 0.38 [ 0.22, 0.65 ]
Charu 2007 27/226 13/59 0.7 % 0.54 [ 0.30, 0.98 ]
Christodoulou 2009 16/167 36/170 1.2 % 0.45 [ 0.26, 0.78 ]
Dammacco 2001 19/69 36/76 1.1 % 0.58 [ 0.37, 0.91 ]
Del Mastro 1997 0/31 2/31 0.1 % 0.20 [ 0.01, 4.00 ]
Dunphy 1999 2/13 5/14 0.2 % 0.43 [ 0.10, 1.85 ]
Engert 2010 405/640 467/643 15.3 % 0.87 [ 0.81, 0.94 ]
EPO-INT-3 J%J 2004 21/136 23/65 1.0 % 0.44 [ 0.26, 0.73 ]
Fujisaka 2011 4/89 18/92 0.6 % 0.23 [ 0.08, 0.65 ]
Gebbia 2003 5/22 13/23 0.4 % 0.40 [ 0.17, 0.94 ]
Gordon 2008 18/162 6/56 0.3 % 1.04 [ 0.43, 2.48 ]
Goss 2005 8/52 27/52 0.9 % 0.30 [ 0.15, 0.59 ]
Grote 2005 26/109 42/115 1.3 % 0.65 [ 0.43, 0.99 ]
Gupta 2009 9/58 25/57 0.8 % 0.35 [ 0.18, 0.69 ]
Hedenus 2002 12/55 5/11 0.3 % 0.48 [ 0.21, 1.09 ]
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hedenus 2003 52/167 79/165 2.6 % 0.65 [ 0.49, 0.86 ]
Henry 1995 34/64 42/61 1.4 % 0.77 [ 0.58, 1.03 ]
Hernandez 2009 58/193 91/193 3.0 % 0.64 [ 0.49, 0.83 ]
Huddart 2002 18/45 32/45 1.1 % 0.56 [ 0.38, 0.84 ]
Iconomou 2003 9/57 14/55 0.5 % 0.62 [ 0.29, 1.31 ]
Italian 1998 28/43 35/42 1.2 % 0.78 [ 0.60, 1.01 ]
Katakami 2008 7/103 20/104 0.7 % 0.35 [ 0.16, 0.80 ]
Kotasek 2003 48/188 23/50 1.2 % 0.56 [ 0.38, 0.82 ]
Krzakowski 2008 50/209 28/104 1.2 % 0.89 [ 0.60, 1.32 ]
Kunikane 2001 3/34 0/19 0.0 % 4.00 [ 0.22, 73.56 ]
Kurz 1997 5/23 8/12 0.3 % 0.33 [ 0.14, 0.78 ]
Leyland-Jones 2005 47/469 66/470 2.2 % 0.71 [ 0.50, 1.01 ]
Littlewood 2001 62/251 49/124 2.2 % 0.63 [ 0.46, 0.85 ]
Milroy 2011 16/189 43/191 1.4 % 0.38 [ 0.22, 0.64 ]
Moebus 2007 41/320 86/305 2.9 % 0.45 [ 0.32, 0.64 ]
O’Shaughnessy 2005 0/47 4/47 0.1 % 0.11 [ 0.01, 2.01 ]
Oberhoff 1998 32/114 44/104 1.5 % 0.66 [ 0.46, 0.96 ]
Osterborg 1996 72/95 39/49 1.7 % 0.95 [ 0.79, 1.14 ]
Osterborg 2002 65/169 90/173 2.9 % 0.74 [ 0.58, 0.94 ]
Pirker 2008 52/298 116/298 3.8 % 0.45 [ 0.34, 0.60 ]
Pronzato 2010 8/107 18/109 0.6 % 0.45 [ 0.21, 1.00 ]
Quirt 1996 4/27 8/27 0.3 % 0.50 [ 0.17, 1.47 ]
Ray-Coquard 2009 39/108 61/105 2.0 % 0.62 [ 0.46, 0.84 ]
Razzouk 2006 72/111 86/111 2.8 % 0.84 [ 0.71, 0.99 ]
Rose 1994 65/142 47/79 2.0 % 0.77 [ 0.60, 0.99 ]
Rosen 2003 19/47 24/43 0.8 % 0.72 [ 0.47, 1.12 ]
Savonije 2005 77/211 66/102 2.9 % 0.56 [ 0.45, 0.71 ]
Smith 2003 6/61 4/20 0.2 % 0.49 [ 0.15, 1.57 ]
Smith 2008 176/419 215/432 7.0 % 0.84 [ 0.73, 0.98 ]
Strauss 2008 9/34 12/40 0.4 % 0.88 [ 0.42, 1.84 ]
Ten Bokkel 1998 8/87 13/33 0.6 % 0.23 [ 0.11, 0.51 ]
0.02 0.1 1 10 50
Favours treatment Favours control
(Continued . . . )
358Erythropoietin or darbepoetin for patients with cancer (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Thatcher 1999 28/86 26/44 1.1 % 0.55 [ 0.37, 0.81 ]
Thomas 2002 7/62 31/65 1.0 % 0.24 [ 0.11, 0.50 ]
Thompson 2000 34/45 19/21 0.9 % 0.84 [ 0.67, 1.04 ]
Throuvalas 2000 2/28 10/26 0.3 % 0.19 [ 0.04, 0.77 ]
Tjulandin 2010 17/149 18/74 0.8 % 0.47 [ 0.26, 0.86 ]
Tjulandin 2011 13/95 23/91 0.8 % 0.54 [ 0.29, 1.00 ]
Tsuboi 2009 7/61 7/56 0.2 % 0.92 [ 0.34, 2.45 ]
Untch 2011˙1 1/356 0/377 0.0 % 3.18 [ 0.13, 77.72 ]
Vansteenkiste 02 FDA 2004 53/156 89/158 2.9 % 0.60 [ 0.47, 0.78 ]
Welch 1995 4/15 8/15 0.3 % 0.50 [ 0.19, 1.31 ]
Wilkinson 2006 9/114 18/59 0.8 % 0.26 [ 0.12, 0.54 ]
Witzig 2005 42/166 65/164 2.2 % 0.64 [ 0.46, 0.88 ]
Wright 2007 5/33 10/37 0.3 % 0.56 [ 0.21, 1.47 ]
Wurnig 1996 8/15 14/14 0.5 % 0.55 [ 0.34, 0.88 ]
Total (95% CI) 8733 7360 100.0 % 0.65 [ 0.62, 0.68 ]
Total events: 2198 (Treatment), 2880 (Control)
Heterogeneity: Chi2 = 210.83, df = 69 (P<0.00001); I2 =67%
Test for overall effect: Z = 19.90 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 4.1. Comparison 4 Number of red blood cell units transfused per patient, Outcome 1 Number of
RBC units transfused - overall.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 4 Number of red blood cell units transfused per patient
Outcome: 1 Number of RBC units transfused - overall





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Abels 1993 63 1.52 (2.61) 55 2.19 (3.57) 3.0 % -0.67 [ -1.81, 0.47 ]
Boogaerts 2003 133 2.11 (4.97) 129 3.78 (6.53) 2.0 % -1.67 [ -3.08, -0.26 ]
Cascinu 1994 50 0.3 (0.07) 50 1.8 (2.12) 11.3 % -1.50 [ -2.09, -0.91 ]
Case 1993 79 2.03 (3.88) 74 2.75 (4.15) 2.4 % -0.72 [ -2.00, 0.56 ]
Cazzola 1995a 31 1.19 (2.69) 7 1.55 (4.31) 0.4 % -0.36 [ -3.69, 2.97 ]
Cazzola 1995b 29 1.45 (4.57) 8 1.55 (4.31) 0.3 % -0.10 [ -3.52, 3.32 ]
Cazzola 1995c 31 0.97 (2.64) 7 1.55 (4.31) 0.4 % -0.58 [ -3.91, 2.75 ]
Cazzola 1995d 26 0.81 (2.3) 7 1.55 (4.31) 0.4 % -0.74 [ -4.05, 2.57 ]
Dammacco 2001 66 1.49 (2.73) 66 2.18 (2.95) 4.2 % -0.69 [ -1.66, 0.28 ]
Engert 2009 637 3.7 (4.8) 632 5.3 (5.7) 11.6 % -1.60 [ -2.18, -1.02 ]
Grote 2005 109 0.5 (3.6) 115 0.4 (0.7) 8.2 % 0.10 [ -0.59, 0.79 ]
Henry 1995 64 3.56 (7.01) 61 4.01 (4.87) 0.9 % -0.45 [ -2.56, 1.66 ]
Hernandez 2009 181 1 (2) 185 1.5 (2.5) 18.2 % -0.50 [ -0.96, -0.04 ]
Kurz 1997 23 1.43 (3.8) 12 3.7 (3.09) 0.7 % -2.27 [ -4.61, 0.07 ]
Oberhoff 1998 114 1.32 (3.04) 104 1.91 (3.28) 5.5 % -0.59 [ -1.43, 0.25 ]
Osterborg 1996a 47 6.8 (10.1) 24 9.3 (9.2) 0.2 % -2.50 [ -7.18, 2.18 ]
Osterborg 1996b 48 8.7 (9.6) 25 9.3 (9.2) 0.2 % -0.60 [ -5.11, 3.91 ]
Osterborg 2002 169 2.66 (5.56) 173 3.22 (5.17) 3.0 % -0.56 [ -1.70, 0.58 ]
Rose 1994 142 5.8 (10.7) 79 8 (17.5) 0.2 % -2.20 [ -6.44, 2.04 ]
Savonije 2005 211 1.5 (2.6) 102 3.1 (3.1) 8.0 % -1.60 [ -2.30, -0.90 ]
Ten Bokkel 1998a 45 0.33 (1.6) 17 1.27 (1.97) 3.6 % -0.94 [ -1.99, 0.11 ]
Ten Bokkel 1998b 42 0.43 (1.23) 16 1.27 (1.97) 3.6 % -0.84 [ -1.87, 0.19 ]
Thatcher 1999a 42 3.8 (5.58) 22 6.13 (7.13) 0.3 % -2.33 [ -5.75, 1.09 ]
Thatcher 1999b 44 2.1 (4.6) 22 6.13 (7.13) 0.4 % -4.03 [ -7.30, -0.76 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Vansteenkiste 2002 148 0.67 (1.7) 149 1.92 (3.27) 11.1 % -1.25 [ -1.84, -0.66 ]
Total (95% CI) 2574 2141 100.0 % -0.98 [ -1.17, -0.78 ]
Heterogeneity: Chi2 = 34.52, df = 24 (P = 0.08); I2 =30%
Test for overall effect: Z = 9.69 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 4.2. Comparison 4 Number of red blood cell units transfused per patient, Outcome 2 Number of
RBC units transfused - baseline Hb.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 4 Number of red blood cell units transfused per patient
Outcome: 2 Number of RBC units transfused - baseline Hb





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Hb < 10g/dL
Abels 1993 63 1.52 (2.61) 55 2.19 (3.57) 3.0 % -0.67 [ -1.81, 0.47 ]
Boogaerts 2003 133 2.11 (4.97) 129 3.78 (6.53) 2.0 % -1.67 [ -3.08, -0.26 ]
Cascinu 1994 50 0.3 (0.07) 50 1.8 (2.12) 11.3 % -1.50 [ -2.09, -0.91 ]
Case 1993 79 2.03 (3.88) 74 2.75 (4.15) 2.4 % -0.72 [ -2.00, 0.56 ]
Cazzola 1995a 31 1.19 (2.69) 7 1.55 (4.31) 0.4 % -0.36 [ -3.69, 2.97 ]
Cazzola 1995b 29 1.45 (4.57) 8 1.55 (4.31) 0.3 % -0.10 [ -3.52, 3.32 ]
Cazzola 1995c 31 0.97 (2.64) 7 1.55 (4.31) 0.4 % -0.58 [ -3.91, 2.75 ]
Cazzola 1995d 26 0.81 (2.3) 7 1.55 (4.31) 0.4 % -0.74 [ -4.05, 2.57 ]
Dammacco 2001 66 1.49 (2.73) 66 2.18 (2.95) 4.2 % -0.69 [ -1.66, 0.28 ]
Henry 1995 64 3.56 (7.01) 61 4.01 (4.87) 0.9 % -0.45 [ -2.56, 1.66 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Kurz 1997 23 1.43 (3.8) 12 3.7 (3.09) 0.7 % -2.27 [ -4.61, 0.07 ]
Oberhoff 1998 114 1.32 (3.04) 104 1.91 (3.28) 5.5 % -0.59 [ -1.43, 0.25 ]
Osterborg 1996a 47 6.8 (10.1) 24 9.3 (9.2) 0.2 % -2.50 [ -7.18, 2.18 ]
Osterborg 1996b 48 8.7 (9.6) 25 9.3 (9.2) 0.2 % -0.60 [ -5.11, 3.91 ]
Osterborg 2002 169 2.66 (5.56) 173 3.22 (5.17) 3.0 % -0.56 [ -1.70, 0.58 ]
Rose 1994 142 5.8 (10.7) 79 8 (17.5) 0.2 % -2.20 [ -6.44, 2.04 ]
Subtotal (95% CI) 1115 881 34.9 % -1.02 [ -1.35, -0.68 ]
Heterogeneity: Chi2 = 8.64, df = 15 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 5.95 (P < 0.00001)
2 Hb 10 to 12g/dL
Hernandez 2009 181 1 (2) 185 1.5 (2.5) 18.2 % -0.50 [ -0.96, -0.04 ]
Savonije 2005 211 1.5 (2.6) 102 3.1 (3.1) 8.0 % -1.60 [ -2.30, -0.90 ]
Ten Bokkel 1998a 45 0.33 (1.6) 17 1.27 (1.97) 3.6 % -0.94 [ -1.99, 0.11 ]
Ten Bokkel 1998b 42 0.43 (1.23) 16 1.27 (1.97) 3.6 % -0.84 [ -1.87, 0.19 ]
Vansteenkiste 2002 148 0.67 (1.7) 149 1.92 (3.27) 11.1 % -1.25 [ -1.84, -0.66 ]
Subtotal (95% CI) 627 469 44.6 % -0.95 [ -1.24, -0.65 ]
Heterogeneity: Chi2 = 8.00, df = 4 (P = 0.09); I2 =50%
Test for overall effect: Z = 6.28 (P < 0.00001)
3 Hb > 12g/dL
Engert 2009 637 3.7 (4.8) 632 5.3 (5.7) 11.6 % -1.60 [ -2.18, -1.02 ]
Grote 2005 109 0.5 (3.6) 115 0.4 (0.7) 8.2 % 0.10 [ -0.59, 0.79 ]
Thatcher 1999a 42 3.8 (5.58) 22 6.13 (7.13) 0.3 % -2.33 [ -5.75, 1.09 ]
Thatcher 1999b 44 2.1 (4.6) 22 6.13 (7.13) 0.4 % -4.03 [ -7.30, -0.76 ]
Subtotal (95% CI) 832 791 20.5 % -0.97 [ -1.41, -0.54 ]
Heterogeneity: Chi2 = 17.79, df = 3 (P = 0.00049); I2 =83%
Test for overall effect: Z = 4.37 (P = 0.000012)
Total (95% CI) 2574 2141 100.0 % -0.98 [ -1.17, -0.78 ]
Heterogeneity: Chi2 = 34.52, df = 24 (P = 0.08); I2 =30%
Test for overall effect: Z = 9.69 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.09, df = 2 (P = 0.96), I2 =0.0%
-10 -5 0 5 10
Favours treatment Favours control
362Erythropoietin or darbepoetin for patients with cancer (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 4.3. Comparison 4 Number of red blood cell units transfused per patient, Outcome 3 Number of
RBC units transfused - age differentiated.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 4 Number of red blood cell units transfused per patient
Outcome: 3 Number of RBC units transfused - age differentiated





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 only children <18 years
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
2 adults≥18 years
Abels 1993 63 1.52 (2.61) 55 2.19 (3.57) 3.0 % -0.67 [ -1.81, 0.47 ]
Boogaerts 2003 133 2.11 (4.97) 129 3.78 (6.53) 2.0 % -1.67 [ -3.08, -0.26 ]
Case 1993 79 2.03 (3.88) 74 2.75 (4.15) 2.4 % -0.72 [ -2.00, 0.56 ]
Cazzola 1995a 31 1.19 (2.69) 7 1.55 (4.31) 0.4 % -0.36 [ -3.69, 2.97 ]
Cazzola 1995b 29 1.45 (4.57) 8 1.55 (4.31) 0.3 % -0.10 [ -3.52, 3.32 ]
Cazzola 1995c 31 0.97 (2.64) 7 1.55 (4.31) 0.4 % -0.58 [ -3.91, 2.75 ]
Cazzola 1995d 26 0.81 (2.3) 7 1.55 (4.31) 0.4 % -0.74 [ -4.05, 2.57 ]
Dammacco 2001 66 1.49 (2.73) 66 2.18 (2.95) 4.2 % -0.69 [ -1.66, 0.28 ]
Grote 2005 109 0.5 (3.6) 115 0.4 (0.7) 8.2 % 0.10 [ -0.59, 0.79 ]
Henry 1995 64 3.56 (7.01) 61 4.01 (4.87) 0.9 % -0.45 [ -2.56, 1.66 ]
Hernandez 2009 181 1 (2) 185 1.5 (2.5) 18.2 % -0.50 [ -0.96, -0.04 ]
Osterborg 1996a 47 6.8 (10.1) 24 9.3 (9.2) 0.2 % -2.50 [ -7.18, 2.18 ]
Osterborg 1996b 48 8.7 (9.6) 25 9.3 (9.2) 0.2 % -0.60 [ -5.11, 3.91 ]
Osterborg 2002 169 2.66 (5.56) 173 3.22 (5.17) 3.0 % -0.56 [ -1.70, 0.58 ]
Rose 1994 142 5.8 (10.7) 79 8 (17.5) 0.2 % -2.20 [ -6.44, 2.04 ]
Savonije 2005 211 1.5 (2.6) 102 3.1 (3.1) 8.0 % -1.60 [ -2.30, -0.90 ]
Ten Bokkel 1998a 45 0.33 (1.6) 17 1.27 (1.97) 3.6 % -0.94 [ -1.99, 0.11 ]
Ten Bokkel 1998b 42 0.43 (1.23) 16 1.27 (1.97) 3.6 % -0.84 [ -1.87, 0.19 ]
Thatcher 1999a 42 3.8 (5.58) 22 6.13 (7.13) 0.3 % -2.33 [ -5.75, 1.09 ]
Thatcher 1999b 44 2.1 (4.6) 22 6.13 (7.13) 0.4 % -4.03 [ -7.30, -0.76 ]
Vansteenkiste 2002 148 0.67 (1.7) 149 1.92 (3.27) 11.1 % -1.25 [ -1.84, -0.66 ]
-10 -5 0 5 10
Favours treatment Favours control
(Continued . . . )
363Erythropoietin or darbepoetin for patients with cancer (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Subtotal (95% CI) 1750 1343 70.9 % -0.81 [ -1.04, -0.57 ]
Heterogeneity: Chi2 = 23.08, df = 20 (P = 0.28); I2 =13%
Test for overall effect: Z = 6.76 (P < 0.00001)
3 >68% non-elderly 18-65 years
Cascinu 1994 50 0.3 (0.07) 50 1.8 (2.12) 11.3 % -1.50 [ -2.09, -0.91 ]
Kurz 1997 23 1.43 (3.8) 12 3.7 (3.09) 0.7 % -2.27 [ -4.61, 0.07 ]
Oberhoff 1998 114 1.32 (3.04) 104 1.91 (3.28) 5.5 % -0.59 [ -1.43, 0.25 ]
Subtotal (95% CI) 187 166 17.5 % -1.25 [ -1.72, -0.77 ]
Heterogeneity: Chi2 = 3.79, df = 2 (P = 0.15); I2 =47%
Test for overall effect: Z = 5.17 (P < 0.00001)
4 only non-elderly adults
Engert 2009 637 3.7 (4.8) 632 5.3 (5.7) 11.6 % -1.60 [ -2.18, -1.02 ]
Subtotal (95% CI) 637 632 11.6 % -1.60 [ -2.18, -1.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.41 (P < 0.00001)
5 >68% elderly >65 years
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
6 only elderly > 65 J
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 2574 2141 100.0 % -0.98 [ -1.17, -0.78 ]
Heterogeneity: Chi2 = 34.52, df = 24 (P = 0.08); I2 =30%
Test for overall effect: Z = 9.69 (P < 0.00001)
Test for subgroup differences: Chi2 = 7.65, df = 2 (P = 0.02), I2 =74%
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Analysis 4.4. Comparison 4 Number of red blood cell units transfused per patient, Outcome 4 Number of
RBC units transfused - age.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 4 Number of red blood cell units transfused per patient
Outcome: 4 Number of RBC units transfused - age





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 adults
Abels 1993 63 1.52 (2.61) 55 2.19 (3.57) 3.0 % -0.67 [ -1.81, 0.47 ]
Boogaerts 2003 133 2.11 (4.97) 129 3.78 (6.53) 2.0 % -1.67 [ -3.08, -0.26 ]
Cascinu 1994 50 0.3 (0.07) 50 1.8 (2.12) 11.3 % -1.50 [ -2.09, -0.91 ]
Case 1993 79 2.03 (3.88) 74 2.75 (4.15) 2.4 % -0.72 [ -2.00, 0.56 ]
Cazzola 1995a 31 1.19 (2.69) 7 1.55 (4.31) 0.4 % -0.36 [ -3.69, 2.97 ]
Cazzola 1995b 29 1.45 (4.57) 8 1.55 (4.31) 0.3 % -0.10 [ -3.52, 3.32 ]
Cazzola 1995c 31 0.97 (2.64) 7 1.55 (4.31) 0.4 % -0.58 [ -3.91, 2.75 ]
Cazzola 1995d 26 0.81 (2.3) 7 1.55 (4.31) 0.4 % -0.74 [ -4.05, 2.57 ]
Dammacco 2001 66 1.49 (2.73) 66 2.18 (2.95) 4.2 % -0.69 [ -1.66, 0.28 ]
Engert 2009 637 3.7 (4.8) 632 5.3 (5.7) 11.6 % -1.60 [ -2.18, -1.02 ]
Grote 2005 109 0.5 (3.6) 115 0.4 (0.7) 8.2 % 0.10 [ -0.59, 0.79 ]
Henry 1995 64 3.56 (7.01) 61 4.01 (4.87) 0.9 % -0.45 [ -2.56, 1.66 ]
Hernandez 2009 181 1 (2) 185 1.5 (2.5) 18.2 % -0.50 [ -0.96, -0.04 ]
Kurz 1997 23 1.43 (3.8) 12 3.7 (3.09) 0.7 % -2.27 [ -4.61, 0.07 ]
Oberhoff 1998 114 1.32 (3.04) 104 1.91 (3.28) 5.5 % -0.59 [ -1.43, 0.25 ]
Osterborg 1996a 47 6.8 (10.1) 24 9.3 (9.2) 0.2 % -2.50 [ -7.18, 2.18 ]
Osterborg 1996b 48 8.7 (9.6) 25 9.3 (9.2) 0.2 % -0.60 [ -5.11, 3.91 ]
Osterborg 2002 169 2.66 (5.56) 173 3.22 (5.17) 3.0 % -0.56 [ -1.70, 0.58 ]
Rose 1994 142 5.8 (10.7) 79 8 (17.5) 0.2 % -2.20 [ -6.44, 2.04 ]
Savonije 2005 211 1.5 (2.6) 102 3.1 (3.1) 8.0 % -1.60 [ -2.30, -0.90 ]
Ten Bokkel 1998a 45 0.33 (1.6) 17 1.27 (1.97) 3.6 % -0.94 [ -1.99, 0.11 ]
Ten Bokkel 1998b 42 0.43 (1.23) 16 1.27 (1.97) 3.6 % -0.84 [ -1.87, 0.19 ]
Thatcher 1999a 42 3.8 (5.58) 22 6.13 (7.13) 0.3 % -2.33 [ -5.75, 1.09 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Thatcher 1999b 44 2.1 (4.6) 22 6.13 (7.13) 0.4 % -4.03 [ -7.30, -0.76 ]
Vansteenkiste 2002 148 0.67 (1.7) 149 1.92 (3.27) 11.1 % -1.25 [ -1.84, -0.66 ]
Total (95% CI) 2574 2141 100.0 % -0.98 [ -1.17, -0.78 ]
Heterogeneity: Chi2 = 34.52, df = 24 (P = 0.08); I2 =30%
Test for overall effect: Z = 9.69 (P < 0.00001)
Test for subgroup differences: Not applicable
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RBC units transfused - different malignancies.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 4 Number of red blood cell units transfused per patient
Outcome: 5 Number of RBC units transfused - different malignancies





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 solid tumours
Cascinu 1994 50 0.3 (0.07) 50 1.8 (2.12) 11.3 % -1.50 [ -2.09, -0.91 ]
Grote 2005 109 0.5 (3.6) 115 0.4 (0.7) 8.2 % 0.10 [ -0.59, 0.79 ]
Kurz 1997 23 1.43 (3.8) 12 3.7 (3.09) 0.7 % -2.27 [ -4.61, 0.07 ]
Oberhoff 1998 114 1.32 (3.04) 104 1.91 (3.28) 5.5 % -0.59 [ -1.43, 0.25 ]
Savonije 2005 211 1.5 (2.6) 102 3.1 (3.1) 8.0 % -1.60 [ -2.30, -0.90 ]
Ten Bokkel 1998a 45 0.33 (1.6) 17 1.27 (1.97) 3.6 % -0.94 [ -1.99, 0.11 ]
Ten Bokkel 1998b 42 0.43 (1.23) 16 1.27 (1.97) 3.6 % -0.84 [ -1.87, 0.19 ]
Thatcher 1999a 42 3.8 (5.58) 22 6.13 (7.13) 0.3 % -2.33 [ -5.75, 1.09 ]
Thatcher 1999b 44 2.1 (4.6) 22 6.13 (7.13) 0.4 % -4.03 [ -7.30, -0.76 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Vansteenkiste 2002 148 0.67 (1.7) 149 1.92 (3.27) 11.1 % -1.25 [ -1.84, -0.66 ]
Subtotal (95% CI) 828 609 52.8 % -1.07 [ -1.34, -0.80 ]
Heterogeneity: Chi2 = 21.92, df = 9 (P = 0.01); I2 =59%
Test for overall effect: Z = 7.70 (P < 0.00001)
2 haematological malignancies
Cazzola 1995a 31 1.19 (2.69) 7 1.55 (4.31) 0.4 % -0.36 [ -3.69, 2.97 ]
Cazzola 1995b 29 1.45 (4.57) 8 1.55 (4.31) 0.3 % -0.10 [ -3.52, 3.32 ]
Cazzola 1995c 31 0.97 (2.64) 7 1.55 (4.31) 0.4 % -0.58 [ -3.91, 2.75 ]
Cazzola 1995d 26 0.81 (2.3) 7 1.55 (4.31) 0.4 % -0.74 [ -4.05, 2.57 ]
Dammacco 2001 66 1.49 (2.73) 66 2.18 (2.95) 4.2 % -0.69 [ -1.66, 0.28 ]
Engert 2009 637 3.7 (4.8) 632 5.3 (5.7) 11.6 % -1.60 [ -2.18, -1.02 ]
Osterborg 1996a 47 6.8 (10.1) 24 9.3 (9.2) 0.2 % -2.50 [ -7.18, 2.18 ]
Osterborg 1996b 48 8.7 (9.6) 25 9.3 (9.2) 0.2 % -0.60 [ -5.11, 3.91 ]
Osterborg 2002 169 2.66 (5.56) 173 3.22 (5.17) 3.0 % -0.56 [ -1.70, 0.58 ]
Rose 1994 142 5.8 (10.7) 79 8 (17.5) 0.2 % -2.20 [ -6.44, 2.04 ]
Subtotal (95% CI) 1226 1028 20.7 % -1.19 [ -1.63, -0.76 ]
Heterogeneity: Chi2 = 5.53, df = 9 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 5.40 (P < 0.00001)
3 mixed
Abels 1993 63 1.52 (2.61) 55 2.19 (3.57) 3.0 % -0.67 [ -1.81, 0.47 ]
Boogaerts 2003 133 2.11 (4.97) 129 3.78 (6.53) 2.0 % -1.67 [ -3.08, -0.26 ]
Case 1993 79 2.03 (3.88) 74 2.75 (4.15) 2.4 % -0.72 [ -2.00, 0.56 ]
Henry 1995 64 3.56 (7.01) 61 4.01 (4.87) 0.9 % -0.45 [ -2.56, 1.66 ]
Hernandez 2009 181 1 (2) 185 1.5 (2.5) 18.2 % -0.50 [ -0.96, -0.04 ]
Subtotal (95% CI) 520 504 26.4 % -0.62 [ -1.01, -0.24 ]
Heterogeneity: Chi2 = 2.45, df = 4 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 3.19 (P = 0.0014)
Total (95% CI) 2574 2141 100.0 % -0.98 [ -1.17, -0.78 ]
Heterogeneity: Chi2 = 34.52, df = 24 (P = 0.08); I2 =30%
Test for overall effect: Z = 9.69 (P < 0.00001)
Test for subgroup differences: Chi2 = 4.62, df = 2 (P = 0.10), I2 =57%
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Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 4 Number of red blood cell units transfused per patient
Outcome: 6 Number of RBC units transfused - different therapies





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 chemotherapy
Boogaerts 2003 133 2.11 (4.97) 129 3.78 (6.53) 2.0 % -1.67 [ -3.08, -0.26 ]
Cascinu 1994 50 0.3 (0.07) 50 1.8 (2.12) 11.3 % -1.50 [ -2.09, -0.91 ]
Case 1993 79 2.03 (3.88) 74 2.75 (4.15) 2.4 % -0.72 [ -2.00, 0.56 ]
Cazzola 1995a 31 1.19 (2.69) 7 1.55 (4.31) 0.4 % -0.36 [ -3.69, 2.97 ]
Cazzola 1995b 29 1.45 (4.57) 8 1.55 (4.31) 0.3 % -0.10 [ -3.52, 3.32 ]
Cazzola 1995c 31 0.97 (2.64) 7 1.55 (4.31) 0.4 % -0.58 [ -3.91, 2.75 ]
Cazzola 1995d 26 0.81 (2.3) 7 1.55 (4.31) 0.4 % -0.74 [ -4.05, 2.57 ]
Dammacco 2001 66 1.49 (2.73) 66 2.18 (2.95) 4.2 % -0.69 [ -1.66, 0.28 ]
Engert 2009 637 3.7 (4.8) 632 5.3 (5.7) 11.6 % -1.60 [ -2.18, -1.02 ]
Grote 2005 109 0.5 (3.6) 115 0.4 (0.7) 8.2 % 0.10 [ -0.59, 0.79 ]
Henry 1995 64 3.56 (7.01) 61 4.01 (4.87) 0.9 % -0.45 [ -2.56, 1.66 ]
Hernandez 2009 181 1 (2) 185 1.5 (2.5) 18.2 % -0.50 [ -0.96, -0.04 ]
Kurz 1997 23 1.43 (3.8) 12 3.7 (3.09) 0.7 % -2.27 [ -4.61, 0.07 ]
Oberhoff 1998 114 1.32 (3.04) 104 1.91 (3.28) 5.5 % -0.59 [ -1.43, 0.25 ]
Osterborg 1996a 47 6.8 (10.1) 24 9.3 (9.2) 0.2 % -2.50 [ -7.18, 2.18 ]
Osterborg 1996b 48 8.7 (9.6) 25 9.3 (9.2) 0.2 % -0.60 [ -5.11, 3.91 ]
Osterborg 2002 169 2.66 (5.56) 173 3.22 (5.17) 3.0 % -0.56 [ -1.70, 0.58 ]
Savonije 2005 211 1.5 (2.6) 102 3.1 (3.1) 8.0 % -1.60 [ -2.30, -0.90 ]
Ten Bokkel 1998a 45 0.33 (1.6) 17 1.27 (1.97) 3.6 % -0.94 [ -1.99, 0.11 ]
Ten Bokkel 1998b 42 0.43 (1.23) 16 1.27 (1.97) 3.6 % -0.84 [ -1.87, 0.19 ]
Thatcher 1999a 42 3.8 (5.58) 22 6.13 (7.13) 0.3 % -2.33 [ -5.75, 1.09 ]
Thatcher 1999b 44 2.1 (4.6) 22 6.13 (7.13) 0.4 % -4.03 [ -7.30, -0.76 ]
Vansteenkiste 2002 148 0.67 (1.7) 149 1.92 (3.27) 11.1 % -1.25 [ -1.84, -0.66 ]
-10 -5 0 5 10
Favours treatment Favours control
(Continued . . . )
368Erythropoietin or darbepoetin for patients with cancer (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Subtotal (95% CI) 2369 2007 96.8 % -0.98 [ -1.18, -0.78 ]
Heterogeneity: Chi2 = 33.92, df = 22 (P = 0.05); I2 =35%
Test for overall effect: Z = 9.60 (P < 0.00001)
2 radiotherapy/radiochemotherapy
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
3 no therapy
Abels 1993 63 1.52 (2.61) 55 2.19 (3.57) 3.0 % -0.67 [ -1.81, 0.47 ]
Subtotal (95% CI) 63 55 3.0 % -0.67 [ -1.81, 0.47 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.15 (P = 0.25)
4 unclear/ other
Rose 1994 142 5.8 (10.7) 79 8 (17.5) 0.2 % -2.20 [ -6.44, 2.04 ]
Subtotal (95% CI) 142 79 0.2 % -2.20 [ -6.44, 2.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
Total (95% CI) 2574 2141 100.0 % -0.98 [ -1.17, -0.78 ]
Heterogeneity: Chi2 = 34.52, df = 24 (P = 0.08); I2 =30%
Test for overall effect: Z = 9.69 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.60, df = 2 (P = 0.74), I2 =0.0%
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Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 4 Number of red blood cell units transfused per patient
Outcome: 7 Number of RBC units transfused - different therapies differentiated





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 chemotherapy > 70% with platinum
Cascinu 1994 50 0.3 (0.07) 50 1.8 (2.12) 11.3 % -1.50 [ -2.09, -0.91 ]
Grote 2005 109 0.5 (3.6) 115 0.4 (0.7) 8.2 % 0.10 [ -0.59, 0.79 ]
Henry 1995 64 3.56 (7.01) 61 4.01 (4.87) 0.9 % -0.45 [ -2.56, 1.66 ]
Kurz 1997 23 1.43 (3.8) 12 3.7 (3.09) 0.7 % -2.27 [ -4.61, 0.07 ]
Savonije 2005 211 1.5 (2.6) 102 3.1 (3.1) 8.0 % -1.60 [ -2.30, -0.90 ]
Ten Bokkel 1998a 45 0.33 (1.6) 17 1.27 (1.97) 3.6 % -0.94 [ -1.99, 0.11 ]
Ten Bokkel 1998b 42 0.43 (1.23) 16 1.27 (1.97) 3.6 % -0.84 [ -1.87, 0.19 ]
Thatcher 1999a 42 3.8 (5.58) 22 6.13 (7.13) 0.3 % -2.33 [ -5.75, 1.09 ]
Thatcher 1999b 44 2.1 (4.6) 22 6.13 (7.13) 0.4 % -4.03 [ -7.30, -0.76 ]
Vansteenkiste 2002 148 0.67 (1.7) 149 1.92 (3.27) 11.1 % -1.25 [ -1.84, -0.66 ]
Subtotal (95% CI) 778 566 48.2 % -1.11 [ -1.40, -0.83 ]
Heterogeneity: Chi2 = 20.92, df = 9 (P = 0.01); I2 =57%
Test for overall effect: Z = 7.65 (P < 0.00001)
2 chemotherapy, <70% with platinum
Hernandez 2009 181 1 (2) 185 1.5 (2.5) 18.2 % -0.50 [ -0.96, -0.04 ]
Oberhoff 1998 114 1.32 (3.04) 104 1.91 (3.28) 5.5 % -0.59 [ -1.43, 0.25 ]
Subtotal (95% CI) 295 289 23.7 % -0.52 [ -0.93, -0.12 ]
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 2.52 (P = 0.012)
3 chemotherapy without platinum
Case 1993 79 2.03 (3.88) 74 2.75 (4.15) 2.4 % -0.72 [ -2.00, 0.56 ]
Cazzola 1995a 31 1.19 (2.69) 7 1.55 (4.31) 0.4 % -0.36 [ -3.69, 2.97 ]
Cazzola 1995b 29 1.45 (4.57) 8 1.55 (4.31) 0.3 % -0.10 [ -3.52, 3.32 ]
Cazzola 1995c 31 0.97 (2.64) 7 1.55 (4.31) 0.4 % -0.58 [ -3.91, 2.75 ]
Cazzola 1995d 26 0.81 (2.3) 7 1.55 (4.31) 0.4 % -0.74 [ -4.05, 2.57 ]
Engert 2009 637 3.7 (4.8) 632 5.3 (5.7) 11.6 % -1.60 [ -2.18, -1.02 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Osterborg 1996a 47 6.8 (10.1) 24 9.3 (9.2) 0.2 % -2.50 [ -7.18, 2.18 ]
Osterborg 1996b 48 8.7 (9.6) 25 9.3 (9.2) 0.2 % -0.60 [ -5.11, 3.91 ]
Osterborg 2002 169 2.66 (5.56) 173 3.22 (5.17) 3.0 % -0.56 [ -1.70, 0.58 ]
Subtotal (95% CI) 1097 957 18.8 % -1.23 [ -1.69, -0.78 ]
Heterogeneity: Chi2 = 4.78, df = 8 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 5.30 (P < 0.00001)
4 chemotherapy, platinum and non-platinum containing, no numbers given
Boogaerts 2003 133 2.11 (4.97) 129 3.78 (6.53) 2.0 % -1.67 [ -3.08, -0.26 ]
Dammacco 2001 66 1.49 (2.73) 66 2.18 (2.95) 4.2 % -0.69 [ -1.66, 0.28 ]
Subtotal (95% CI) 199 195 6.1 % -1.01 [ -1.80, -0.21 ]
Heterogeneity: Chi2 = 1.26, df = 1 (P = 0.26); I2 =21%
Test for overall effect: Z = 2.47 (P = 0.014)
5 chemotherapy no details given
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
6 radiochemotherapy
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
7 radiotherapy
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
8 no therapy
Abels 1993 63 1.52 (2.61) 55 2.19 (3.57) 3.0 % -0.67 [ -1.81, 0.47 ]
Subtotal (95% CI) 63 55 3.0 % -0.67 [ -1.81, 0.47 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.15 (P = 0.25)
9 unclear/other
Rose 1994 142 5.8 (10.7) 79 8 (17.5) 0.2 % -2.20 [ -6.44, 2.04 ]
Subtotal (95% CI) 142 79 0.2 % -2.20 [ -6.44, 2.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
Total (95% CI) 2574 2141 100.0 % -0.98 [ -1.17, -0.78 ]
Heterogeneity: Chi2 = 34.52, df = 24 (P = 0.08); I2 =30%
Test for overall effect: Z = 9.69 (P < 0.00001)
Test for subgroup differences: Chi2 = 7.52, df = 5 (P = 0.18), I2 =34%
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Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 4 Number of red blood cell units transfused per patient
Outcome: 8 Number of RBC units transfused - epoetin versus darbepoetin





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Epoetin
Abels 1993 63 1.52 (2.61) 55 2.19 (3.57) 3.0 % -0.67 [ -1.81, 0.47 ]
Boogaerts 2003 133 2.11 (4.97) 129 3.78 (6.53) 2.0 % -1.67 [ -3.08, -0.26 ]
Cascinu 1994 50 0.3 (0.07) 50 1.8 (2.12) 11.3 % -1.50 [ -2.09, -0.91 ]
Case 1993 79 2.03 (3.88) 74 2.75 (4.15) 2.4 % -0.72 [ -2.00, 0.56 ]
Cazzola 1995a 31 1.19 (2.69) 7 1.55 (4.31) 0.4 % -0.36 [ -3.69, 2.97 ]
Cazzola 1995b 29 1.45 (4.57) 8 1.55 (4.31) 0.3 % -0.10 [ -3.52, 3.32 ]
Cazzola 1995c 31 0.97 (2.64) 7 1.55 (4.31) 0.4 % -0.58 [ -3.91, 2.75 ]
Cazzola 1995d 26 0.81 (2.3) 7 1.55 (4.31) 0.4 % -0.74 [ -4.05, 2.57 ]
Dammacco 2001 66 1.49 (2.73) 66 2.18 (2.95) 4.2 % -0.69 [ -1.66, 0.28 ]
Engert 2009 637 3.7 (4.8) 632 5.3 (5.7) 11.6 % -1.60 [ -2.18, -1.02 ]
Grote 2005 109 0.5 (3.6) 115 0.4 (0.7) 8.2 % 0.10 [ -0.59, 0.79 ]
Henry 1995 64 3.56 (7.01) 61 4.01 (4.87) 0.9 % -0.45 [ -2.56, 1.66 ]
Kurz 1997 23 1.43 (3.8) 12 3.7 (3.09) 0.7 % -2.27 [ -4.61, 0.07 ]
Oberhoff 1998 114 1.32 (3.04) 104 1.91 (3.28) 5.5 % -0.59 [ -1.43, 0.25 ]
Osterborg 1996a 47 6.8 (10.1) 24 9.3 (9.2) 0.2 % -2.50 [ -7.18, 2.18 ]
Osterborg 1996b 48 8.7 (9.6) 25 9.3 (9.2) 0.2 % -0.60 [ -5.11, 3.91 ]
Osterborg 2002 169 2.66 (5.56) 173 3.22 (5.17) 3.0 % -0.56 [ -1.70, 0.58 ]
Rose 1994 142 5.8 (10.7) 79 8 (17.5) 0.2 % -2.20 [ -6.44, 2.04 ]
Savonije 2005 211 1.5 (2.6) 102 3.1 (3.1) 8.0 % -1.60 [ -2.30, -0.90 ]
Ten Bokkel 1998a 45 0.33 (1.6) 17 1.27 (1.97) 3.6 % -0.94 [ -1.99, 0.11 ]
Ten Bokkel 1998b 42 0.43 (1.23) 16 1.27 (1.97) 3.6 % -0.84 [ -1.87, 0.19 ]
Thatcher 1999a 42 3.8 (5.58) 22 6.13 (7.13) 0.3 % -2.33 [ -5.75, 1.09 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Thatcher 1999b 44 2.1 (4.6) 22 6.13 (7.13) 0.4 % -4.03 [ -7.30, -0.76 ]
Subtotal (95% CI) 2245 1807 70.7 % -1.06 [ -1.29, -0.82 ]
Heterogeneity: Chi2 = 29.19, df = 22 (P = 0.14); I2 =25%
Test for overall effect: Z = 8.81 (P < 0.00001)
2 Darbepoetin
Hernandez 2009 181 1 (2) 185 1.5 (2.5) 18.2 % -0.50 [ -0.96, -0.04 ]
Vansteenkiste 2002 148 0.67 (1.7) 149 1.92 (3.27) 11.1 % -1.25 [ -1.84, -0.66 ]
Subtotal (95% CI) 329 334 29.3 % -0.78 [ -1.15, -0.42 ]
Heterogeneity: Chi2 = 3.82, df = 1 (P = 0.05); I2 =74%
Test for overall effect: Z = 4.22 (P = 0.000025)
Total (95% CI) 2574 2141 100.0 % -0.98 [ -1.17, -0.78 ]
Heterogeneity: Chi2 = 34.52, df = 24 (P = 0.08); I2 =30%
Test for overall effect: Z = 9.69 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.51, df = 1 (P = 0.22), I2 =34%
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Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 4 Number of red blood cell units transfused per patient
Outcome: 9 Number of RBC units transfused - duration of ESA medication





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 6 to 9 weeks
Abels 1993 63 1.52 (2.61) 55 2.19 (3.57) 3.0 % -0.67 [ -1.81, 0.47 ]
Cascinu 1994 50 0.3 (0.07) 50 1.8 (2.12) 11.3 % -1.50 [ -2.09, -0.91 ]
Cazzola 1995a 31 1.19 (2.69) 7 1.55 (4.31) 0.4 % -0.36 [ -3.69, 2.97 ]
Cazzola 1995b 29 1.45 (4.57) 8 1.55 (4.31) 0.3 % -0.10 [ -3.52, 3.32 ]
Cazzola 1995c 31 0.97 (2.64) 7 1.55 (4.31) 0.4 % -0.58 [ -3.91, 2.75 ]
Cazzola 1995d 26 0.81 (2.3) 7 1.55 (4.31) 0.4 % -0.74 [ -4.05, 2.57 ]
Subtotal (95% CI) 230 134 15.7 % -1.25 [ -1.75, -0.75 ]
Heterogeneity: Chi2 = 2.64, df = 5 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 4.90 (P < 0.00001)
2 12 to 16 weeks
Boogaerts 2003 133 2.11 (4.97) 129 3.78 (6.53) 2.0 % -1.67 [ -3.08, -0.26 ]
Case 1993 79 2.03 (3.88) 74 2.75 (4.15) 2.4 % -0.72 [ -2.00, 0.56 ]
Dammacco 2001 66 1.49 (2.73) 66 2.18 (2.95) 4.2 % -0.69 [ -1.66, 0.28 ]
Grote 2005 109 0.5 (3.6) 115 0.4 (0.7) 8.2 % 0.10 [ -0.59, 0.79 ]
Henry 1995 64 3.56 (7.01) 61 4.01 (4.87) 0.9 % -0.45 [ -2.56, 1.66 ]
Hernandez 2009 181 1 (2) 185 1.5 (2.5) 18.2 % -0.50 [ -0.96, -0.04 ]
Kurz 1997 23 1.43 (3.8) 12 3.7 (3.09) 0.7 % -2.27 [ -4.61, 0.07 ]
Oberhoff 1998 114 1.32 (3.04) 104 1.91 (3.28) 5.5 % -0.59 [ -1.43, 0.25 ]
Osterborg 2002 169 2.66 (5.56) 173 3.22 (5.17) 3.0 % -0.56 [ -1.70, 0.58 ]
Rose 1994 142 5.8 (10.7) 79 8 (17.5) 0.2 % -2.20 [ -6.44, 2.04 ]
Savonije 2005 211 1.5 (2.6) 102 3.1 (3.1) 8.0 % -1.60 [ -2.30, -0.90 ]
Vansteenkiste 2002 148 0.67 (1.7) 149 1.92 (3.27) 11.1 % -1.25 [ -1.84, -0.66 ]
Subtotal (95% CI) 1439 1249 64.4 % -0.78 [ -1.03, -0.54 ]
Heterogeneity: Chi2 = 19.44, df = 11 (P = 0.05); I2 =43%
Test for overall effect: Z = 6.22 (P < 0.00001)
3 more than 17 weeks
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Engert 2009 637 3.7 (4.8) 632 5.3 (5.7) 11.6 % -1.60 [ -2.18, -1.02 ]
Osterborg 1996a 47 6.8 (10.1) 24 9.3 (9.2) 0.2 % -2.50 [ -7.18, 2.18 ]
Osterborg 1996b 48 8.7 (9.6) 25 9.3 (9.2) 0.2 % -0.60 [ -5.11, 3.91 ]
Ten Bokkel 1998a 45 0.33 (1.6) 17 1.27 (1.97) 3.6 % -0.94 [ -1.99, 0.11 ]
Ten Bokkel 1998b 42 0.43 (1.23) 16 1.27 (1.97) 3.6 % -0.84 [ -1.87, 0.19 ]
Thatcher 1999a 42 3.8 (5.58) 22 6.13 (7.13) 0.3 % -2.33 [ -5.75, 1.09 ]
Thatcher 1999b 44 2.1 (4.6) 22 6.13 (7.13) 0.4 % -4.03 [ -7.30, -0.76 ]
Subtotal (95% CI) 905 758 19.9 % -1.40 [ -1.84, -0.95 ]
Heterogeneity: Chi2 = 5.42, df = 6 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 6.18 (P < 0.00001)
Total (95% CI) 2574 2141 100.0 % -0.98 [ -1.17, -0.78 ]
Heterogeneity: Chi2 = 34.52, df = 24 (P = 0.08); I2 =30%
Test for overall effect: Z = 9.69 (P < 0.00001)
Test for subgroup differences: Chi2 = 7.02, df = 2 (P = 0.03), I2 =72%
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Analysis 4.10. Comparison 4 Number of red blood cell units transfused per patient, Outcome 10 Number
of RBC units transfused - iron supplementation.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 4 Number of red blood cell units transfused per patient
Outcome: 10 Number of RBC units transfused - iron supplementation





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 fixed iron supplementation
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
2 iron supplementation as necessary
Abels 1993 63 1.52 (2.61) 55 2.19 (3.57) 3.0 % -0.67 [ -1.81, 0.47 ]
Boogaerts 2003 133 2.11 (4.97) 129 3.78 (6.53) 2.0 % -1.67 [ -3.08, -0.26 ]
Cascinu 1994 50 0.3 (0.07) 50 1.8 (2.12) 11.3 % -1.50 [ -2.09, -0.91 ]
Case 1993 79 2.03 (3.88) 74 2.75 (4.15) 2.4 % -0.72 [ -2.00, 0.56 ]
Cazzola 1995a 31 1.19 (2.69) 7 1.55 (4.31) 0.4 % -0.36 [ -3.69, 2.97 ]
Cazzola 1995b 29 1.45 (4.57) 8 1.55 (4.31) 0.3 % -0.10 [ -3.52, 3.32 ]
Cazzola 1995c 31 0.97 (2.64) 7 1.55 (4.31) 0.4 % -0.58 [ -3.91, 2.75 ]
Cazzola 1995d 26 0.81 (2.3) 7 1.55 (4.31) 0.4 % -0.74 [ -4.05, 2.57 ]
Dammacco 2001 66 1.49 (2.73) 66 2.18 (2.95) 4.2 % -0.69 [ -1.66, 0.28 ]
Engert 2009 637 3.7 (4.8) 632 5.3 (5.7) 11.6 % -1.60 [ -2.18, -1.02 ]
Grote 2005 109 0.5 (3.6) 115 0.4 (0.7) 8.2 % 0.10 [ -0.59, 0.79 ]
Henry 1995 64 3.56 (7.01) 61 4.01 (4.87) 0.9 % -0.45 [ -2.56, 1.66 ]
Hernandez 2009 181 1 (2) 185 1.5 (2.5) 18.2 % -0.50 [ -0.96, -0.04 ]
Kurz 1997 23 1.43 (3.8) 12 3.7 (3.09) 0.7 % -2.27 [ -4.61, 0.07 ]
Oberhoff 1998 114 1.32 (3.04) 104 1.91 (3.28) 5.5 % -0.59 [ -1.43, 0.25 ]
Osterborg 1996a 47 6.8 (10.1) 24 9.3 (9.2) 0.2 % -2.50 [ -7.18, 2.18 ]
Osterborg 1996b 48 8.7 (9.6) 25 9.3 (9.2) 0.2 % -0.60 [ -5.11, 3.91 ]
Osterborg 2002 169 2.66 (5.56) 173 3.22 (5.17) 3.0 % -0.56 [ -1.70, 0.58 ]
Rose 1994 142 5.8 (10.7) 79 8 (17.5) 0.2 % -2.20 [ -6.44, 2.04 ]
Ten Bokkel 1998a 45 0.33 (1.6) 17 1.27 (1.97) 3.6 % -0.94 [ -1.99, 0.11 ]
Ten Bokkel 1998b 42 0.43 (1.23) 16 1.27 (1.97) 3.6 % -0.84 [ -1.87, 0.19 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Thatcher 1999a 42 3.8 (5.58) 22 6.13 (7.13) 0.3 % -2.33 [ -5.75, 1.09 ]
Thatcher 1999b 44 2.1 (4.6) 22 6.13 (7.13) 0.4 % -4.03 [ -7.30, -0.76 ]
Vansteenkiste 2002 148 0.67 (1.7) 149 1.92 (3.27) 11.1 % -1.25 [ -1.84, -0.66 ]
Subtotal (95% CI) 2363 2039 92.0 % -0.92 [ -1.13, -0.72 ]
Heterogeneity: Chi2 = 31.17, df = 23 (P = 0.12); I2 =26%
Test for overall effect: Z = 8.78 (P < 0.00001)
3 no explicit statement on iron supplementation or no iron given
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
4 explicitely stated NO IRON
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
5 iron given differently in both study arms
Savonije 2005 211 1.5 (2.6) 102 3.1 (3.1) 8.0 % -1.60 [ -2.30, -0.90 ]
Subtotal (95% CI) 211 102 8.0 % -1.60 [ -2.30, -0.90 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.50 (P < 0.00001)
Total (95% CI) 2574 2141 100.0 % -0.98 [ -1.17, -0.78 ]
Heterogeneity: Chi2 = 34.52, df = 24 (P = 0.08); I2 =30%
Test for overall effect: Z = 9.69 (P < 0.00001)
Test for subgroup differences: Chi2 = 3.34, df = 1 (P = 0.07), I2 =70%
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Analysis 4.11. Comparison 4 Number of red blood cell units transfused per patient, Outcome 11 Number
of RBC units transfused - allocation concealment.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 4 Number of red blood cell units transfused per patient
Outcome: 11 Number of RBC units transfused - allocation concealment





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 adequate
Boogaerts 2003 133 2.11 (4.97) 129 3.78 (6.53) 2.0 % -1.67 [ -3.08, -0.26 ]
Cazzola 1995a 31 1.19 (2.69) 7 1.55 (4.31) 0.4 % -0.36 [ -3.69, 2.97 ]
Cazzola 1995b 29 1.45 (4.57) 8 1.55 (4.31) 0.3 % -0.10 [ -3.52, 3.32 ]
Cazzola 1995c 31 0.97 (2.64) 7 1.55 (4.31) 0.4 % -0.58 [ -3.91, 2.75 ]
Cazzola 1995d 26 0.81 (2.3) 7 1.55 (4.31) 0.4 % -0.74 [ -4.05, 2.57 ]
Hernandez 2009 181 1 (2) 185 1.5 (2.5) 18.2 % -0.50 [ -0.96, -0.04 ]
Kurz 1997 23 1.43 (3.8) 12 3.7 (3.09) 0.7 % -2.27 [ -4.61, 0.07 ]
Oberhoff 1998 114 1.32 (3.04) 104 1.91 (3.28) 5.5 % -0.59 [ -1.43, 0.25 ]
Osterborg 1996a 47 6.8 (10.1) 24 9.3 (9.2) 0.2 % -2.50 [ -7.18, 2.18 ]
Osterborg 1996b 48 8.7 (9.6) 25 9.3 (9.2) 0.2 % -0.60 [ -5.11, 3.91 ]
Osterborg 2002 169 2.66 (5.56) 173 3.22 (5.17) 3.0 % -0.56 [ -1.70, 0.58 ]
Savonije 2005 211 1.5 (2.6) 102 3.1 (3.1) 8.0 % -1.60 [ -2.30, -0.90 ]
Ten Bokkel 1998a 45 0.33 (1.6) 17 1.27 (1.97) 3.6 % -0.94 [ -1.99, 0.11 ]
Ten Bokkel 1998b 42 0.43 (1.23) 16 1.27 (1.97) 3.6 % -0.84 [ -1.87, 0.19 ]
Vansteenkiste 2002 148 0.67 (1.7) 149 1.92 (3.27) 11.1 % -1.25 [ -1.84, -0.66 ]
Subtotal (95% CI) 1278 965 57.5 % -0.93 [ -1.19, -0.67 ]
Heterogeneity: Chi2 = 12.22, df = 14 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 6.97 (P < 0.00001)
2 unclear
Abels 1993 63 1.52 (2.61) 55 2.19 (3.57) 3.0 % -0.67 [ -1.81, 0.47 ]
Cascinu 1994 50 0.3 (0.07) 50 1.8 (2.12) 11.3 % -1.50 [ -2.09, -0.91 ]
Case 1993 79 2.03 (3.88) 74 2.75 (4.15) 2.4 % -0.72 [ -2.00, 0.56 ]
Dammacco 2001 66 1.49 (2.73) 66 2.18 (2.95) 4.2 % -0.69 [ -1.66, 0.28 ]
Engert 2009 637 3.7 (4.8) 632 5.3 (5.7) 11.6 % -1.60 [ -2.18, -1.02 ]
Grote 2005 109 0.5 (3.6) 115 0.4 (0.7) 8.2 % 0.10 [ -0.59, 0.79 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Henry 1995 64 3.56 (7.01) 61 4.01 (4.87) 0.9 % -0.45 [ -2.56, 1.66 ]
Rose 1994 142 5.8 (10.7) 79 8 (17.5) 0.2 % -2.20 [ -6.44, 2.04 ]
Thatcher 1999a 42 3.8 (5.58) 22 6.13 (7.13) 0.3 % -2.33 [ -5.75, 1.09 ]
Thatcher 1999b 44 2.1 (4.6) 22 6.13 (7.13) 0.4 % -4.03 [ -7.30, -0.76 ]
Subtotal (95% CI) 1296 1176 42.5 % -1.04 [ -1.35, -0.74 ]
Heterogeneity: Chi2 = 21.96, df = 9 (P = 0.01); I2 =59%
Test for overall effect: Z = 6.76 (P < 0.00001)
Total (95% CI) 2574 2141 100.0 % -0.98 [ -1.17, -0.78 ]
Heterogeneity: Chi2 = 34.52, df = 24 (P = 0.08); I2 =30%
Test for overall effect: Z = 9.69 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.34, df = 1 (P = 0.56), I2 =0.0%
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Analysis 4.12. Comparison 4 Number of red blood cell units transfused per patient, Outcome 12 Number
of RBC units transfused - masking.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 4 Number of red blood cell units transfused per patient
Outcome: 12 Number of RBC units transfused - masking





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 double-blind
Abels 1993 63 1.52 (2.61) 55 2.19 (3.57) 3.0 % -0.67 [ -1.81, 0.47 ]
Cascinu 1994 50 0.3 (0.07) 50 1.8 (2.12) 11.3 % -1.50 [ -2.09, -0.91 ]
Case 1993 79 2.03 (3.88) 74 2.75 (4.15) 2.4 % -0.72 [ -2.00, 0.56 ]
Dammacco 2001 66 1.49 (2.73) 66 2.18 (2.95) 4.2 % -0.69 [ -1.66, 0.28 ]
Engert 2009 637 3.7 (4.8) 632 5.3 (5.7) 11.6 % -1.60 [ -2.18, -1.02 ]
Grote 2005 109 0.5 (3.6) 115 0.4 (0.7) 8.2 % 0.10 [ -0.59, 0.79 ]
Henry 1995 64 3.56 (7.01) 61 4.01 (4.87) 0.9 % -0.45 [ -2.56, 1.66 ]
Hernandez 2009 181 1 (2) 185 1.5 (2.5) 18.2 % -0.50 [ -0.96, -0.04 ]
Kurz 1997 23 1.43 (3.8) 12 3.7 (3.09) 0.7 % -2.27 [ -4.61, 0.07 ]
Osterborg 2002 169 2.66 (5.56) 173 3.22 (5.17) 3.0 % -0.56 [ -1.70, 0.58 ]
Rose 1994 142 5.8 (10.7) 79 8 (17.5) 0.2 % -2.20 [ -6.44, 2.04 ]
Vansteenkiste 2002 148 0.67 (1.7) 149 1.92 (3.27) 11.1 % -1.25 [ -1.84, -0.66 ]
Subtotal (95% CI) 1731 1651 74.8 % -0.91 [ -1.14, -0.69 ]
Heterogeneity: Chi2 = 24.51, df = 11 (P = 0.01); I2 =55%
Test for overall effect: Z = 7.85 (P < 0.00001)
2 unblinded
Boogaerts 2003 133 2.11 (4.97) 129 3.78 (6.53) 2.0 % -1.67 [ -3.08, -0.26 ]
Cazzola 1995a 31 1.19 (2.69) 7 1.55 (4.31) 0.4 % -0.36 [ -3.69, 2.97 ]
Cazzola 1995b 29 1.45 (4.57) 8 1.55 (4.31) 0.3 % -0.10 [ -3.52, 3.32 ]
Cazzola 1995c 31 0.97 (2.64) 7 1.55 (4.31) 0.4 % -0.58 [ -3.91, 2.75 ]
Cazzola 1995d 26 0.81 (2.3) 7 1.55 (4.31) 0.4 % -0.74 [ -4.05, 2.57 ]
Oberhoff 1998 114 1.32 (3.04) 104 1.91 (3.28) 5.5 % -0.59 [ -1.43, 0.25 ]
Osterborg 1996a 47 6.8 (10.1) 24 9.3 (9.2) 0.2 % -2.50 [ -7.18, 2.18 ]
Osterborg 1996b 48 8.7 (9.6) 25 9.3 (9.2) 0.2 % -0.60 [ -5.11, 3.91 ]
Savonije 2005 211 1.5 (2.6) 102 3.1 (3.1) 8.0 % -1.60 [ -2.30, -0.90 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Ten Bokkel 1998a 45 0.33 (1.6) 17 1.27 (1.97) 3.6 % -0.94 [ -1.99, 0.11 ]
Ten Bokkel 1998b 42 0.43 (1.23) 16 1.27 (1.97) 3.6 % -0.84 [ -1.87, 0.19 ]
Thatcher 1999a 42 3.8 (5.58) 22 6.13 (7.13) 0.3 % -2.33 [ -5.75, 1.09 ]
Thatcher 1999b 44 2.1 (4.6) 22 6.13 (7.13) 0.4 % -4.03 [ -7.30, -0.76 ]
Subtotal (95% CI) 843 490 25.2 % -1.16 [ -1.55, -0.77 ]
Heterogeneity: Chi2 = 8.88, df = 12 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 5.78 (P < 0.00001)
Total (95% CI) 2574 2141 100.0 % -0.98 [ -1.17, -0.78 ]
Heterogeneity: Chi2 = 34.52, df = 24 (P = 0.08); I2 =30%
Test for overall effect: Z = 9.69 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.13, df = 1 (P = 0.29), I2 =11%
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Analysis 4.13. Comparison 4 Number of red blood cell units transfused per patient, Outcome 13 Number
of RBC units transfused - intention-to-treat.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 4 Number of red blood cell units transfused per patient
Outcome: 13 Number of RBC units transfused - intention-to-treat





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ITT or less than 10% of participants per study arm excluded
Abels 1993 63 1.52 (2.61) 55 2.19 (3.57) 3.0 % -0.67 [ -1.81, 0.47 ]
Boogaerts 2003 133 2.11 (4.97) 129 3.78 (6.53) 2.0 % -1.67 [ -3.08, -0.26 ]
Cascinu 1994 50 0.3 (0.07) 50 1.8 (2.12) 11.3 % -1.50 [ -2.09, -0.91 ]
Case 1993 79 2.03 (3.88) 74 2.75 (4.15) 2.4 % -0.72 [ -2.00, 0.56 ]
Cazzola 1995a 31 1.19 (2.69) 7 1.55 (4.31) 0.4 % -0.36 [ -3.69, 2.97 ]
Cazzola 1995b 29 1.45 (4.57) 8 1.55 (4.31) 0.3 % -0.10 [ -3.52, 3.32 ]
Cazzola 1995c 31 0.97 (2.64) 7 1.55 (4.31) 0.4 % -0.58 [ -3.91, 2.75 ]
Cazzola 1995d 26 0.81 (2.3) 7 1.55 (4.31) 0.4 % -0.74 [ -4.05, 2.57 ]
Engert 2009 637 3.7 (4.8) 632 5.3 (5.7) 11.6 % -1.60 [ -2.18, -1.02 ]
Grote 2005 109 0.5 (3.6) 115 0.4 (0.7) 8.2 % 0.10 [ -0.59, 0.79 ]
Henry 1995 64 3.56 (7.01) 61 4.01 (4.87) 0.9 % -0.45 [ -2.56, 1.66 ]
Hernandez 2009 181 1 (2) 185 1.5 (2.5) 18.2 % -0.50 [ -0.96, -0.04 ]
Kurz 1997 23 1.43 (3.8) 12 3.7 (3.09) 0.7 % -2.27 [ -4.61, 0.07 ]
Oberhoff 1998 114 1.32 (3.04) 104 1.91 (3.28) 5.5 % -0.59 [ -1.43, 0.25 ]
Osterborg 1996a 47 6.8 (10.1) 24 9.3 (9.2) 0.2 % -2.50 [ -7.18, 2.18 ]
Osterborg 1996b 48 8.7 (9.6) 25 9.3 (9.2) 0.2 % -0.60 [ -5.11, 3.91 ]
Osterborg 2002 169 2.66 (5.56) 173 3.22 (5.17) 3.0 % -0.56 [ -1.70, 0.58 ]
Rose 1994 142 5.8 (10.7) 79 8 (17.5) 0.2 % -2.20 [ -6.44, 2.04 ]
Savonije 2005 211 1.5 (2.6) 102 3.1 (3.1) 8.0 % -1.60 [ -2.30, -0.90 ]
Ten Bokkel 1998a 45 0.33 (1.6) 17 1.27 (1.97) 3.6 % -0.94 [ -1.99, 0.11 ]
Ten Bokkel 1998b 42 0.43 (1.23) 16 1.27 (1.97) 3.6 % -0.84 [ -1.87, 0.19 ]
Thatcher 1999a 42 3.8 (5.58) 22 6.13 (7.13) 0.3 % -2.33 [ -5.75, 1.09 ]
Thatcher 1999b 44 2.1 (4.6) 22 6.13 (7.13) 0.4 % -4.03 [ -7.30, -0.76 ]
Vansteenkiste 2002 148 0.67 (1.7) 149 1.92 (3.27) 11.1 % -1.25 [ -1.84, -0.66 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Subtotal (95% CI) 2508 2075 95.8 % -0.99 [ -1.19, -0.79 ]
Heterogeneity: Chi2 = 34.17, df = 23 (P = 0.06); I2 =33%
Test for overall effect: Z = 9.61 (P < 0.00001)
2 more than 10% of participants per study arm excluded
Dammacco 2001 66 1.49 (2.73) 66 2.18 (2.95) 4.2 % -0.69 [ -1.66, 0.28 ]
Subtotal (95% CI) 66 66 4.2 % -0.69 [ -1.66, 0.28 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.39 (P = 0.16)
Total (95% CI) 2574 2141 100.0 % -0.98 [ -1.17, -0.78 ]
Heterogeneity: Chi2 = 34.52, df = 24 (P = 0.08); I2 =30%
Test for overall effect: Z = 9.69 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.35, df = 1 (P = 0.55), I2 =0.0%
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Analysis 4.14. Comparison 4 Number of red blood cell units transfused per patient, Outcome 14 Number
of RBC units transfused - publication.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 4 Number of red blood cell units transfused per patient
Outcome: 14 Number of RBC units transfused - publication





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 full text publication
Grote 2005 109 0.5 (3.6) 115 0.4 (0.7) 8.2 % 0.10 [ -0.59, 0.79 ]
Hernandez 2009 181 1 (2) 185 1.5 (2.5) 18.2 % -0.50 [ -0.96, -0.04 ]
Savonije 2005 211 1.5 (2.6) 102 3.1 (3.1) 8.0 % -1.60 [ -2.30, -0.90 ]
Vansteenkiste 2002 148 0.67 (1.7) 149 1.92 (3.27) 11.1 % -1.25 [ -1.84, -0.66 ]
Subtotal (95% CI) 649 551 45.6 % -0.77 [ -1.06, -0.48 ]
Heterogeneity: Chi2 = 15.43, df = 3 (P = 0.001); I2 =81%
Test for overall effect: Z = 5.15 (P < 0.00001)
2 abstract publication
Engert 2009 637 3.7 (4.8) 632 5.3 (5.7) 11.6 % -1.60 [ -2.18, -1.02 ]
Subtotal (95% CI) 637 632 11.6 % -1.60 [ -2.18, -1.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.41 (P < 0.00001)
3 unpublished data
Abels 1993 63 1.52 (2.61) 55 2.19 (3.57) 3.0 % -0.67 [ -1.81, 0.47 ]
Boogaerts 2003 133 2.11 (4.97) 129 3.78 (6.53) 2.0 % -1.67 [ -3.08, -0.26 ]
Cascinu 1994 50 0.3 (0.07) 50 1.8 (2.12) 11.3 % -1.50 [ -2.09, -0.91 ]
Case 1993 79 2.03 (3.88) 74 2.75 (4.15) 2.4 % -0.72 [ -2.00, 0.56 ]
Cazzola 1995a 31 1.19 (2.69) 7 1.55 (4.31) 0.4 % -0.36 [ -3.69, 2.97 ]
Cazzola 1995b 29 1.45 (4.57) 8 1.55 (4.31) 0.3 % -0.10 [ -3.52, 3.32 ]
Cazzola 1995c 31 0.97 (2.64) 7 1.55 (4.31) 0.4 % -0.58 [ -3.91, 2.75 ]
Cazzola 1995d 26 0.81 (2.3) 7 1.55 (4.31) 0.4 % -0.74 [ -4.05, 2.57 ]
Dammacco 2001 66 1.49 (2.73) 66 2.18 (2.95) 4.2 % -0.69 [ -1.66, 0.28 ]
Henry 1995 64 3.56 (7.01) 61 4.01 (4.87) 0.9 % -0.45 [ -2.56, 1.66 ]
Kurz 1997 23 1.43 (3.8) 12 3.7 (3.09) 0.7 % -2.27 [ -4.61, 0.07 ]
Oberhoff 1998 114 1.32 (3.04) 104 1.91 (3.28) 5.5 % -0.59 [ -1.43, 0.25 ]
Osterborg 1996a 47 6.8 (10.1) 24 9.3 (9.2) 0.2 % -2.50 [ -7.18, 2.18 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Osterborg 1996b 48 8.7 (9.6) 25 9.3 (9.2) 0.2 % -0.60 [ -5.11, 3.91 ]
Osterborg 2002 169 2.66 (5.56) 173 3.22 (5.17) 3.0 % -0.56 [ -1.70, 0.58 ]
Rose 1994 142 5.8 (10.7) 79 8 (17.5) 0.2 % -2.20 [ -6.44, 2.04 ]
Ten Bokkel 1998a 45 0.33 (1.6) 17 1.27 (1.97) 3.6 % -0.94 [ -1.99, 0.11 ]
Ten Bokkel 1998b 42 0.43 (1.23) 16 1.27 (1.97) 3.6 % -0.84 [ -1.87, 0.19 ]
Thatcher 1999a 42 3.8 (5.58) 22 6.13 (7.13) 0.3 % -2.33 [ -5.75, 1.09 ]
Thatcher 1999b 44 2.1 (4.6) 22 6.13 (7.13) 0.4 % -4.03 [ -7.30, -0.76 ]
Subtotal (95% CI) 1288 958 42.8 % -1.03 [ -1.33, -0.73 ]
Heterogeneity: Chi2 = 12.59, df = 19 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 6.69 (P < 0.00001)
4 FDA presented data
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 2574 2141 100.0 % -0.98 [ -1.17, -0.78 ]
Heterogeneity: Chi2 = 34.52, df = 24 (P = 0.08); I2 =30%
Test for overall effect: Z = 9.69 (P < 0.00001)
Test for subgroup differences: Chi2 = 6.50, df = 2 (P = 0.04), I2 =69%
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Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 4 Number of red blood cell units transfused per patient
Outcome: 15 Number of RBC units transfused - first 4 weeks are...





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 included in the analysis
Abels 1993 63 1.52 (2.61) 55 2.19 (3.57) 3.0 % -0.67 [ -1.81, 0.47 ]
Boogaerts 2003 133 2.11 (4.97) 129 3.78 (6.53) 2.0 % -1.67 [ -3.08, -0.26 ]
Cascinu 1994 50 0.3 (0.07) 50 1.8 (2.12) 11.3 % -1.50 [ -2.09, -0.91 ]
Case 1993 79 2.03 (3.88) 74 2.75 (4.15) 2.4 % -0.72 [ -2.00, 0.56 ]
Cazzola 1995a 31 1.19 (2.69) 7 1.55 (4.31) 0.4 % -0.36 [ -3.69, 2.97 ]
Cazzola 1995b 29 1.45 (4.57) 8 1.55 (4.31) 0.3 % -0.10 [ -3.52, 3.32 ]
Cazzola 1995c 31 0.97 (2.64) 7 1.55 (4.31) 0.4 % -0.58 [ -3.91, 2.75 ]
Cazzola 1995d 26 0.81 (2.3) 7 1.55 (4.31) 0.4 % -0.74 [ -4.05, 2.57 ]
Grote 2005 109 0.5 (3.6) 115 0.4 (0.7) 8.2 % 0.10 [ -0.59, 0.79 ]
Oberhoff 1998 114 1.32 (3.04) 104 1.91 (3.28) 5.5 % -0.59 [ -1.43, 0.25 ]
Osterborg 1996a 47 6.8 (10.1) 24 9.3 (9.2) 0.2 % -2.50 [ -7.18, 2.18 ]
Osterborg 1996b 48 8.7 (9.6) 25 9.3 (9.2) 0.2 % -0.60 [ -5.11, 3.91 ]
Osterborg 2002 169 2.66 (5.56) 173 3.22 (5.17) 3.0 % -0.56 [ -1.70, 0.58 ]
Rose 1994 142 5.8 (10.7) 79 8 (17.5) 0.2 % -2.20 [ -6.44, 2.04 ]
Savonije 2005 211 1.5 (2.6) 102 3.1 (3.1) 8.0 % -1.60 [ -2.30, -0.90 ]
Ten Bokkel 1998a 45 0.33 (1.6) 17 1.27 (1.97) 3.6 % -0.94 [ -1.99, 0.11 ]
Ten Bokkel 1998b 42 0.43 (1.23) 16 1.27 (1.97) 3.6 % -0.84 [ -1.87, 0.19 ]
Vansteenkiste 2002 148 0.67 (1.7) 149 1.92 (3.27) 11.1 % -1.25 [ -1.84, -0.66 ]
Subtotal (95% CI) 1517 1141 63.8 % -0.99 [ -1.23, -0.74 ]
Heterogeneity: Chi2 = 20.32, df = 17 (P = 0.26); I2 =16%
Test for overall effect: Z = 7.82 (P < 0.00001)
2 excluded from the analysis
Dammacco 2001 66 1.49 (2.73) 66 2.18 (2.95) 4.2 % -0.69 [ -1.66, 0.28 ]
Henry 1995 64 3.56 (7.01) 61 4.01 (4.87) 0.9 % -0.45 [ -2.56, 1.66 ]
Hernandez 2009 181 1 (2) 185 1.5 (2.5) 18.2 % -0.50 [ -0.96, -0.04 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Subtotal (95% CI) 311 312 23.2 % -0.53 [ -0.94, -0.12 ]
Heterogeneity: Chi2 = 0.13, df = 2 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 2.54 (P = 0.011)
3 unclear
Engert 2009 637 3.7 (4.8) 632 5.3 (5.7) 11.6 % -1.60 [ -2.18, -1.02 ]
Kurz 1997 23 1.43 (3.8) 12 3.7 (3.09) 0.7 % -2.27 [ -4.61, 0.07 ]
Thatcher 1999a 42 3.8 (5.58) 22 6.13 (7.13) 0.3 % -2.33 [ -5.75, 1.09 ]
Thatcher 1999b 44 2.1 (4.6) 22 6.13 (7.13) 0.4 % -4.03 [ -7.30, -0.76 ]
Subtotal (95% CI) 746 688 13.0 % -1.72 [ -2.27, -1.18 ]
Heterogeneity: Chi2 = 2.41, df = 3 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 6.17 (P < 0.00001)
Total (95% CI) 2574 2141 100.0 % -0.98 [ -1.17, -0.78 ]
Heterogeneity: Chi2 = 34.52, df = 24 (P = 0.08); I2 =30%
Test for overall effect: Z = 9.69 (P < 0.00001)
Test for subgroup differences: Chi2 = 11.66, df = 2 (P = 0.00), I2 =83%
-10 -5 0 5 10
Favours treatment Favours control
387Erythropoietin or darbepoetin for patients with cancer (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 4.16. Comparison 4 Number of red blood cell units transfused per patient, Outcome 16 Number
of RBC units transfused - experimental arms merged.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 4 Number of red blood cell units transfused per patient
Outcome: 16 Number of RBC units transfused - experimental arms merged





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Abels 1993 63 1.52 (2.61) 55 2.19 (3.57) 3.0 % -0.67 [ -1.81, 0.47 ]
Boogaerts 2003 133 2.11 (4.97) 129 3.78 (6.53) 2.0 % -1.67 [ -3.08, -0.26 ]
Cascinu 1994 50 0.3 (0.07) 50 1.8 (2.12) 11.3 % -1.50 [ -2.09, -0.91 ]
Case 1993 79 2.03 (3.88) 74 2.75 (4.15) 2.4 % -0.72 [ -2.00, 0.56 ]
Cazzola 1995 117 1.105 (3.05) 29 1.55 (4.31) 1.4 % -0.45 [ -2.11, 1.22 ]
Dammacco 2001 66 1.49 (2.73) 66 2.18 (2.95) 4.2 % -0.69 [ -1.66, 0.28 ]
Engert 2009 637 3.7 (4.8) 632 5.3 (5.7) 11.6 % -1.60 [ -2.18, -1.02 ]
Grote 2005 109 0.5 (3.6) 115 0.4 (0.7) 8.2 % 0.10 [ -0.59, 0.79 ]
Henry 1995 64 3.56 (7.01) 61 4.01 (4.87) 0.9 % -0.45 [ -2.56, 1.66 ]
Hernandez 2009 181 1 (2) 185 1.5 (2.5) 18.2 % -0.50 [ -0.96, -0.04 ]
Kurz 1997 23 1.43 (3.8) 12 3.7 (3.09) 0.7 % -2.27 [ -4.61, 0.07 ]
Oberhoff 1998 114 1.32 (3.04) 104 1.91 (3.28) 5.5 % -0.59 [ -1.43, 0.25 ]
Osterborg 1996 95 7.76 (9.85) 49 9.3 (9.2) 0.4 % -1.54 [ -4.79, 1.71 ]
Osterborg 2002 169 2.66 (5.56) 173 3.22 (5.17) 3.0 % -0.56 [ -1.70, 0.58 ]
Rose 1994 142 5.8 (10.7) 79 8 (17.5) 0.2 % -2.20 [ -6.44, 2.04 ]
Savonije 2005 211 1.5 (2.6) 102 3.1 (3.1) 8.0 % -1.60 [ -2.30, -0.90 ]
Ten Bokkel 1998 87 0.38 (1.43) 33 1.27 (1.97) 7.2 % -0.89 [ -1.63, -0.15 ]
Thatcher 1999 86 2.93 (5.1) 44 6.13 (7.13) 0.7 % -3.20 [ -5.57, -0.83 ]
Vansteenkiste 2002 148 0.67 (1.7) 149 1.92 (3.27) 11.1 % -1.25 [ -1.84, -0.66 ]
Total (95% CI) 2574 2141 100.0 % -0.98 [ -1.17, -0.78 ]
Heterogeneity: Chi2 = 33.56, df = 18 (P = 0.01); I2 =46%
Test for overall effect: Z = 9.69 (P < 0.00001)
Test for subgroup differences: Not applicable
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Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 4 Number of red blood cell units transfused per patient
Outcome: 17 Number of RBC units transfused - age differentiated sensitivity analysis





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 only children <18 years
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
2 adults≥18 years
Abels 1993 63 1.52 (2.61) 55 2.19 (3.57) 3.0 % -0.67 [ -1.81, 0.47 ]
Boogaerts 2003 133 2.11 (4.97) 129 3.78 (6.53) 2.0 % -1.67 [ -3.08, -0.26 ]
Case 1993 79 2.03 (3.88) 74 2.75 (4.15) 2.4 % -0.72 [ -2.00, 0.56 ]
Cazzola 1995a 31 1.19 (2.69) 7 1.55 (4.31) 0.4 % -0.36 [ -3.69, 2.97 ]
Cazzola 1995b 29 1.45 (4.57) 8 1.55 (4.31) 0.3 % -0.10 [ -3.52, 3.32 ]
Cazzola 1995c 31 0.97 (2.64) 7 1.55 (4.31) 0.4 % -0.58 [ -3.91, 2.75 ]
Cazzola 1995d 26 0.81 (2.3) 7 1.55 (4.31) 0.4 % -0.74 [ -4.05, 2.57 ]
Dammacco 2001 66 1.49 (2.73) 66 2.18 (2.95) 4.2 % -0.69 [ -1.66, 0.28 ]
Grote 2005 109 0.5 (3.6) 115 0.4 (0.7) 8.2 % 0.10 [ -0.59, 0.79 ]
Henry 1995 64 3.56 (7.01) 61 4.01 (4.87) 0.9 % -0.45 [ -2.56, 1.66 ]
Hernandez 2009 181 1 (2) 185 1.5 (2.5) 18.2 % -0.50 [ -0.96, -0.04 ]
Osterborg 1996a 47 6.8 (10.1) 24 9.3 (9.2) 0.2 % -2.50 [ -7.18, 2.18 ]
Osterborg 1996b 48 8.7 (9.6) 25 9.3 (9.2) 0.2 % -0.60 [ -5.11, 3.91 ]
Osterborg 2002 169 2.66 (5.56) 173 3.22 (5.17) 3.0 % -0.56 [ -1.70, 0.58 ]
Rose 1994 142 5.8 (10.7) 79 8 (17.5) 0.2 % -2.20 [ -6.44, 2.04 ]
Savonije 2005 211 1.5 (2.6) 102 3.1 (3.1) 8.0 % -1.60 [ -2.30, -0.90 ]
Ten Bokkel 1998a 45 0.33 (1.6) 17 1.27 (1.97) 3.6 % -0.94 [ -1.99, 0.11 ]
Ten Bokkel 1998b 42 0.43 (1.23) 16 1.27 (1.97) 3.6 % -0.84 [ -1.87, 0.19 ]
Thatcher 1999a 42 3.8 (5.58) 22 6.13 (7.13) 0.3 % -2.33 [ -5.75, 1.09 ]
Thatcher 1999b 44 2.1 (4.6) 22 6.13 (7.13) 0.4 % -4.03 [ -7.30, -0.76 ]
Vansteenkiste 2002 148 0.67 (1.7) 149 1.92 (3.27) 11.1 % -1.25 [ -1.84, -0.66 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Subtotal (95% CI) 1750 1343 70.9 % -0.81 [ -1.04, -0.57 ]
Heterogeneity: Chi2 = 23.08, df = 20 (P = 0.28); I2 =13%
Test for overall effect: Z = 6.76 (P < 0.00001)
3 >68% non-elderly 18-65 years
Cascinu 1994 50 0.3 (0.07) 50 1.8 (2.12) 11.3 % -1.50 [ -2.09, -0.91 ]
Engert 2009 637 3.7 (4.8) 632 5.3 (5.7) 11.6 % -1.60 [ -2.18, -1.02 ]
Kurz 1997 23 1.43 (3.8) 12 3.7 (3.09) 0.7 % -2.27 [ -4.61, 0.07 ]
Oberhoff 1998 114 1.32 (3.04) 104 1.91 (3.28) 5.5 % -0.59 [ -1.43, 0.25 ]
Subtotal (95% CI) 824 798 29.1 % -1.39 [ -1.75, -1.02 ]
Heterogeneity: Chi2 = 4.65, df = 3 (P = 0.20); I2 =35%
Test for overall effect: Z = 7.42 (P < 0.00001)
4 only non-elderly adults
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
5 >68% elderly >65 years
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
6 only elderly > 65 J
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 2574 2141 100.0 % -0.98 [ -1.17, -0.78 ]
Heterogeneity: Chi2 = 34.52, df = 24 (P = 0.08); I2 =30%
Test for overall effect: Z = 9.69 (P < 0.00001)
Test for subgroup differences: Chi2 = 6.78, df = 1 (P = 0.01), I2 =85%
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Analysis 5.1. Comparison 5 Overall survival, Outcome 1 Overall survival - overall.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 5 Overall survival
Outcome: 1 Overall survival - overall












Aapro 2008 IPD 169/231 169/232 1.07 [ 0.87, 1.32 ]
Abels 1993 IPD 13/65 12/59 0.96 [ 0.44, 2.10 ]
Antonadou 2001 10/190 30/195 0.35 [ 0.19, 0.66 ]
Bamias 2003 7/72 4/72 1.80 [ 0.53, 6.12 ]
Blohmer 2011 25/127 29/129 0.88 [ 0.51, 1.51 ]
Boogaerts 2003 IPD 16/132 12/127 1.53 [ 0.72, 3.26 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Case 1993 IPD 10/81 9/76 1.11 [ 0.45, 2.73 ]
Cazzola 1995 IPD 5/114 3/29 0.69 [ 0.13, 3.57 ]
Chang 2005 IPD 27/176 28/178 0.94 [ 0.55, 1.60 ]
Charu 2007 IPD 8/228 2/59 0.89 [ 0.19, 4.18 ]
Christodoulou 2009 71/167 87/170 1.25 [ 0.92, 1.71 ]
Dammacco 2001 IPD 1/69 7/76 0.23 [ 0.06, 0.90 ]
Debus 2006 IPD 146/195 159/190 0.81 [ 0.64, 1.02 ]
Del Mastro 1997 1/31 3/31 0.36 [ 0.05, 2.53 ]
Dunphy 1999 0/15 1/15 0.14 [ 0.00, 6.82 ]
Engert 2010 27/648 36/655 0.74 [ 0.45, 1.22 ]
EPO-GER-20 IPD 7/48 8/45 0.71 [ 0.26, 1.95 ]
EPO-INT-1 IPD 11/165 3/81 1.88 [ 0.63, 5.64 ]
EPO-INT-3 IPD 9/135 3/65 1.55 [ 0.47, 5.10 ]
Fujisaka 2011 37/89 34/92 1.15 [ 0.72, 1.85 ]
Gordon 2008 IPD 11/164 5/56 0.74 [ 0.26, 2.14 ]
Goss 2005 IPD 28/52 29/52 1.13 [ 0.67, 1.91 ]
Grote 2005 IPD 100/109 101/115 1.17 [ 0.89, 1.54 ]
Gupta 2009 17/58 14/57 0.90 [ 0.51, 1.59 ]
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Hedenus 2002 0/55 0/11 0.0 [ 0.0, 0.0 ]
Hedenus 2003 IPD 101/176 82/173 1.32 [ 0.98, 1.77 ]
Henke 2003 IPD 109/180 89/171 1.27 [ 0.96, 1.68 ]
Henry 1995 IPD 7/67 10/65 0.68 [ 0.26, 1.77 ]
Hernandez 2009 IPD 17/196 20/195 0.84 [ 0.44, 1.60 ]
Hoskin 2009 IPD 74/151 75/149 1.04 [ 0.75, 1.44 ]
Huddart 2002 IPD 8/48 8/47 1.19 [ 0.44, 3.21 ]
Kotasek 2002 IPD 4/129 0/32 3.49 [ 0.30, 40.45 ]
Kotasek 2003 IPD 4/208 1/51 0.99 [ 0.11, 8.84 ]
Krzakowski 2008a 6/104 2/52 1.48 [ 0.33, 6.67 ]
Krzakowski 2008b 10/105 3/52 1.64 [ 0.49, 5.44 ]
Kurz 1997 0/23 0/12 0.0 [ 0.0, 0.0 ]
Leyland-Jones 2005 IPD 121/469 91/470 1.41 [ 1.08, 1.85 ]
Littlewood 2001 IPD 155/251 82/124 0.80 [ 0.61, 1.05 ]
Machtay 2007 IPD 37/77 32/71 1.19 [ 0.74, 1.91 ]
Milroy 2003 IPD 136/214 126/210 1.13 [ 0.88, 1.45 ]
ML17616 2006 1/30 0/30 7.39 [ 0.15, 372.38 ]
ML17620 2006 4/61 0/60 7.70 [ 1.05, 56.33 ]
Moebus 2007 IPD 59/324 56/319 1.01 [ 0.70, 1.46 ]
Mystakidou 2005 1/50 2/50 0.50 [ 0.05, 5.00 ]
O’Shaugnessy 2005 IPD 1/51 0/49 7.69 [ 0.15, 387.58 ]
OBE/EPO-INT-03 IPD 5/35 6/37 1.07 [ 0.32, 3.56 ]
Oberhoff 1998 IPD 9/116 10/111 0.62 [ 0.24, 1.59 ]
Osterborg 1996 IPD 26/99 14/49 0.94 [ 0.49, 1.81 ]
Osterborg 2002 IPD 110/173 109/176 1.04 [ 0.80, 1.36 ]
Overgaard 2009 144/255 119/259 1.26 [ 0.99, 1.61 ]
P-174 IPD 1/33 1/12 0.44 [ 0.03, 7.27 ]
Pirker 2008 IPD 243/299 254/301 0.94 [ 0.78, 1.13 ]
Pronzato 2010 IPD 23/110 20/113 1.05 [ 0.58, 1.91 ]
Quirt 1996 IPD 2/28 0/28 5.90 [ 0.36, 97.07 ]
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Ray-Coquard 2009 IPD 75/110 84/108 0.79 [ 0.58, 1.08 ]
Razzouk 2004 2/112 2/110 0.98 [ 0.14, 7.03 ]
Rose 1994 IPD 16/142 6/79 1.66 [ 0.70, 3.92 ]
Rosen 2003 19/47 23/43 1.19 [ 0.65, 2.18 ]
Savonije 2005 IPD 132/211 61/104 1.14 [ 0.85, 1.53 ]
Smith 2003 3/64 0/22 3.96 [ 0.29, 54.28 ]
Smith 2008 IPD 250/517 216/472 1.22 [ 1.02, 1.47 ]
Strauss 2008 IPD 8/34 5/40 2.00 [ 0.65, 6.13 ]
Sweeney 1998 0/24 0/24 0.0 [ 0.0, 0.0 ]
Ten Bokkel1998 IPD 6/87 2/33 1.27 [ 0.26, 6.34 ]
Thatcher 1999 IPD 7/86 3/44 1.13 [ 0.29, 4.36 ]
Thomas 2002 IPD 4/65 5/65 0.79 [ 0.21, 2.95 ]
Thomas 2008 IPD 22/58 17/56 1.28 [ 0.68, 2.40 ]
Thompson 2000 3/45 0/21 4.52 [ 0.38, 53.37 ]
Throuvalas 2000 0/28 1/27 0.13 [ 0.00, 6.55 ]
Tjulandin 2010a 5/76 6/37 0.28 [ 0.07, 1.08 ]
Tjulandin 2010b 4/73 6/37 0.34 [ 0.09, 1.26 ]
Tjulandin 2011 6/95 5/91 1.16 [ 0.34, 3.90 ]
Tsuboi 2009 21/61 19/56 0.94 [ 0.57, 1.54 ]
Untch 2011˙2 59/345 48/369 1.33 [ 0.91, 1.95 ]
Vansteenkiste 2002 IPD 101/159 118/161 0.79 [ 0.60, 1.04 ]
Wilkinson 2006 IPD 3/121 0/61 4.48 [ 0.40, 50.03 ]
Winquist 2009 24/26 27/30 0.58 [ 0.33, 1.03 ]
Witzig 2005 IPD 121/174 119/170 1.13 [ 0.87, 1.46 ]
Wright 2007 IPD 32/33 34/37 1.55 [ 0.94, 2.54 ]
Total (95% CI) 1.05 [ 1.00, 1.11 ]
Heterogeneity: Chi2 = 95.40, df = 75 (P = 0.06); I2 =21%
Test for overall effect: Z = 1.97 (P = 0.048)
Test for subgroup differences: Not applicable
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Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 5 Overall survival
Outcome: 2 Overall survival updated review (adjusted results)












Aapro 2008 IPD 169/231 169/232 1.07 [ 0.87, 1.32 ]
Abels 1993 IPD 13/65 12/59 0.96 [ 0.44, 2.10 ]
Antonadou 2001 10/190 30/195 0.35 [ 0.19, 0.66 ]
Bamias 2003 7/72 4/72 1.80 [ 0.53, 6.12 ]
Blohmer 2011 25/127 29/129 0.88 [ 0.51, 1.51 ]
Boogaerts 2003 IPD 16/132 12/127 1.53 [ 0.72, 3.26 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Case 1993 IPD 10/81 9/76 1.11 [ 0.45, 2.73 ]
Cazzola 1995 IPD 5/114 3/29 0.69 [ 0.13, 3.57 ]
Chang 2005 IPD 27/176 28/178 0.94 [ 0.55, 1.60 ]
Charu 2007 IPD 8/228 2/59 0.89 [ 0.19, 4.18 ]
Christodoulou 2009 71/167 87/170 1.25 [ 0.92, 1.71 ]
Dammacco 2001 IPD 1/69 7/76 0.23 [ 0.06, 0.90 ]
Debus 2006 IPD 146/195 159/190 0.81 [ 0.64, 1.02 ]
Del Mastro 1997 1/31 3/31 0.36 [ 0.05, 2.53 ]
Dunphy 1999 0/15 1/15 0.14 [ 0.00, 6.82 ]
Engert 2010 27/648 36/655 0.74 [ 0.45, 1.22 ]
EPO-GER-20 IPD 7/48 8/45 0.71 [ 0.26, 1.95 ]
EPO-INT-1 IPD 11/165 3/81 1.88 [ 0.63, 5.64 ]
EPO-INT-3 IPD 9/135 3/65 1.55 [ 0.47, 5.10 ]
Fujisaka 2011 37/89 34/92 1.15 [ 0.72, 1.85 ]
Gordon 2008 IPD 11/164 5/56 0.74 [ 0.26, 2.14 ]
Goss 2005 IPD 28/52 29/52 1.13 [ 0.67, 1.91 ]
Grote 2005 IPD 100/109 101/115 1.17 [ 0.89, 1.54 ]
Gupta 2009 17/58 14/57 0.90 [ 0.51, 1.59 ]
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Hedenus 2002 0/55 0/11 0.0 [ 0.0, 0.0 ]
Hedenus 2003 IPD 101/176 82/173 1.32 [ 0.98, 1.77 ]
Henke 2003 109/180 89/171 1.39 [ 1.05, 1.84 ]
Henry 1995 IPD 7/67 10/65 0.68 [ 0.26, 1.77 ]
Hernandez 2009 IPD 17/196 20/195 0.84 [ 0.44, 1.60 ]
Hoskin 2009 IPD 74/151 75/149 1.04 [ 0.75, 1.44 ]
Huddart 2002 IPD 8/48 8/47 1.19 [ 0.44, 3.21 ]
Kotasek 2002 IPD 4/129 0/32 3.49 [ 0.30, 40.45 ]
Kotasek 2003 IPD 4/208 1/51 0.99 [ 0.11, 8.84 ]
Krzakowski 2008a 6/104 2/52 1.48 [ 0.33, 6.67 ]
Krzakowski 2008b 10/105 3/52 1.64 [ 0.49, 5.44 ]
Kurz 1997 0/23 0/12 0.0 [ 0.0, 0.0 ]
Leyland-Jones 2005 IPD 121/469 91/470 1.41 [ 1.08, 1.85 ]
Littlewood 2001 155/251 82/124 0.76 [ 0.58, 1.00 ]
Machtay 2007 IPD 37/77 32/71 1.19 [ 0.74, 1.91 ]
Milroy 2003 IPD 136/214 126/210 1.13 [ 0.88, 1.45 ]
ML17616 2006 1/30 0/30 7.39 [ 0.15, 372.38 ]
ML17620 2006 4/61 0/60 7.70 [ 1.05, 56.33 ]
Moebus 2007 IPD 59/324 56/319 1.01 [ 0.70, 1.46 ]
Mystakidou 2005 1/50 2/50 0.50 [ 0.05, 5.00 ]
O’Shaugnessy 2005 IPD 1/51 0/49 7.69 [ 0.15, 387.58 ]
OBE/EPO-INT-03 IPD 5/35 6/37 1.07 [ 0.32, 3.56 ]
Oberhoff 1998 IPD 9/116 10/111 0.62 [ 0.24, 1.59 ]
Osterborg 1996 IPD 26/99 14/49 0.94 [ 0.49, 1.81 ]
Osterborg 2002 IPD 110/173 109/176 1.04 [ 0.80, 1.36 ]
Overgaard 2009 144/255 119/259 1.26 [ 0.99, 1.61 ]
P-174 IPD 1/33 1/12 0.44 [ 0.03, 7.27 ]
Pirker 2008 IPD 243/299 254/301 0.94 [ 0.78, 1.13 ]
Pronzato 2010 IPD 23/110 20/113 1.05 [ 0.58, 1.91 ]
Quirt 1996 IPD 2/28 0/28 5.90 [ 0.36, 97.07 ]
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Ray-Coquard 2009 IPD 75/110 84/108 0.79 [ 0.58, 1.08 ]
Razzouk 2004 2/112 2/110 0.98 [ 0.14, 7.03 ]
Rose 1994 IPD 16/142 6/79 1.66 [ 0.70, 3.92 ]
Rosen 2003 19/47 23/43 1.19 [ 0.65, 2.18 ]
Savonije 2005 IPD 132/211 61/104 1.14 [ 0.85, 1.53 ]
Smith 2003 3/64 0/22 3.96 [ 0.29, 54.28 ]
Smith 2008 IPD 250/517 216/472 1.22 [ 1.02, 1.47 ]
Strauss 2008 IPD 8/34 5/40 2.00 [ 0.65, 6.13 ]
Sweeney 1998 0/24 0/24 0.0 [ 0.0, 0.0 ]
Ten Bokkel1998 IPD 6/87 2/33 1.27 [ 0.26, 6.34 ]
Thatcher 1999 IPD 7/86 3/44 1.13 [ 0.29, 4.36 ]
Thomas 2002 IPD 4/65 5/65 0.79 [ 0.21, 2.95 ]
Thomas 2008 IPD 22/58 17/56 1.28 [ 0.68, 2.40 ]
Thompson 2000 3/45 0/21 4.52 [ 0.38, 53.37 ]
Throuvalas 2000 0/28 1/27 0.13 [ 0.00, 6.55 ]
Tjulandin 2010a 5/76 6/37 0.28 [ 0.07, 1.08 ]
Tjulandin 2010b 4/73 6/37 0.34 [ 0.09, 1.26 ]
Tjulandin 2011 6/95 5/91 1.16 [ 0.34, 3.90 ]
Tsuboi 2009 21/61 19/56 0.94 [ 0.57, 1.54 ]
Untch 2011˙2 59/345 48/369 1.33 [ 0.91, 1.95 ]
Vansteenkiste 2002 IPD 101/159 118/161 0.79 [ 0.60, 1.04 ]
Wilkinson 2006 IPD 3/121 0/61 4.48 [ 0.40, 50.03 ]
Winquist 2009 24/26 27/30 0.58 [ 0.33, 1.03 ]
Witzig 2005 IPD 121/174 119/170 1.13 [ 0.87, 1.46 ]
Wright 2007 IPD 32/33 34/37 1.55 [ 0.94, 2.54 ]
Total (95% CI) 1.05 [ 1.00, 1.11 ]
Heterogeneity: Chi2 = 99.00, df = 75 (P = 0.03); I2 =24%
Test for overall effect: Z = 2.01 (P = 0.044)
Test for subgroup differences: Not applicable
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Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 5 Overall survival
Outcome: 3 Overall survival - baseline Hb












1 Hb < 10 g/dL
Abels 1993 IPD 13/65 12/59 0.96 [ 0.44, 2.10 ]
Antonadou 2001 10/190 30/195 0.35 [ 0.19, 0.66 ]
Boogaerts 2003 IPD 16/132 12/127 1.53 [ 0.72, 3.26 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Case 1993 IPD 10/81 9/76 1.11 [ 0.45, 2.73 ]
Cazzola 1995 IPD 5/114 3/29 0.69 [ 0.13, 3.57 ]
Dammacco 2001 IPD 1/69 7/76 0.23 [ 0.06, 0.90 ]
Fujisaka 2011 37/89 34/92 1.15 [ 0.72, 1.85 ]
Hedenus 2002 0/55 0/11 0.0 [ 0.0, 0.0 ]
Hedenus 2003 IPD 101/176 82/173 1.32 [ 0.98, 1.76 ]
Henry 1995 IPD 7/67 10/65 0.68 [ 0.26, 1.77 ]
Kotasek 2003 IPD 4/208 1/51 0.99 [ 0.11, 8.84 ]
Krzakowski 2008a 6/104 2/52 1.48 [ 0.33, 6.67 ]
Krzakowski 2008b 10/105 3/52 1.64 [ 0.49, 5.44 ]
Kurz 1997 0/23 0/12 0.0 [ 0.0, 0.0 ]
Littlewood 2001 IPD 155/251 82/124 0.80 [ 0.61, 1.05 ]
ML17616 2006 1/30 0/30 7.39 [ 0.15, 372.38 ]
Oberhoff 1998 IPD 9/116 10/111 0.62 [ 0.24, 1.59 ]
Osterborg 1996 IPD 26/99 14/49 0.94 [ 0.49, 1.81 ]
Osterborg 2002 IPD 110/173 109/176 1.04 [ 0.80, 1.36 ]
Razzouk 2004 2/112 2/110 0.98 [ 0.14, 7.03 ]
Rose 1994 IPD 16/142 6/79 1.66 [ 0.70, 3.92 ]
Smith 2003 3/64 0/22 3.96 [ 0.29, 54.28 ]
Smith 2008 IPD 250/517 216/472 1.22 [ 1.02, 1.47 ]
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Thompson 2000 3/45 0/21 4.52 [ 0.38, 53.37 ]
Tjulandin 2010a 5/76 6/37 0.28 [ 0.07, 1.08 ]
Tjulandin 2010b 4/73 6/37 0.34 [ 0.09, 1.26 ]
Tjulandin 2011 6/95 5/91 1.16 [ 0.34, 3.90 ]
Witzig 2005 IPD 121/174 119/170 1.13 [ 0.87, 1.46 ]
Subtotal (95% CI) 3495 2649 1.06 [ 0.96, 1.17 ]
Heterogeneity: Chi2 = 40.70, df = 25 (P = 0.02); I2 =39%
Test for overall effect: Z = 1.13 (P = 0.26)
2 Hb 10 to 12 g/dL
Aapro 2008 IPD 169/231 169/232 1.07 [ 0.87, 1.32 ]
Bamias 2003 7/72 4/72 1.80 [ 0.53, 6.12 ]
Blohmer 2011 25/127 29/129 0.88 [ 0.51, 1.51 ]
Chang 2005 IPD 27/176 28/178 0.94 [ 0.55, 1.60 ]
Charu 2007 IPD 8/228 2/59 0.89 [ 0.19, 4.18 ]
Christodoulou 2009 71/167 87/170 1.25 [ 0.92, 1.71 ]
EPO-INT-1 IPD 11/165 3/81 1.88 [ 0.63, 5.64 ]
EPO-INT-3 IPD 9/135 3/65 1.55 [ 0.47, 5.10 ]
Gordon 2008 IPD 11/164 5/56 0.74 [ 0.26, 2.14 ]
Gupta 2009 17/58 14/57 0.90 [ 0.51, 1.59 ]
Henke 2003 IPD 109/180 89/171 1.27 [ 0.96, 1.68 ]
Hernandez 2009 IPD 17/196 20/195 0.84 [ 0.44, 1.60 ]
Huddart 2002 IPD 8/48 8/47 1.19 [ 0.44, 3.21 ]
Kotasek 2002 IPD 4/129 0/32 3.49 [ 0.30, 40.45 ]
Mystakidou 2005 1/50 2/50 0.50 [ 0.05, 5.00 ]
Pirker 2008 IPD 243/299 254/301 0.94 [ 0.78, 1.13 ]
Pronzato 2010 IPD 23/110 20/113 1.05 [ 0.58, 1.91 ]
Quirt 1996 IPD 2/28 0/28 5.90 [ 0.36, 97.07 ]
Ray-Coquard 2009 IPD 75/110 84/108 0.79 [ 0.58, 1.08 ]
Savonije 2005 IPD 132/211 61/104 1.14 [ 0.85, 1.53 ]
Strauss 2008 IPD 8/34 5/40 2.00 [ 0.65, 6.13 ]
Sweeney 1998 0/24 0/24 0.0 [ 0.0, 0.0 ]
Ten Bokkel1998 IPD 6/87 2/33 1.27 [ 0.26, 6.34 ]
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Thomas 2002 IPD 4/65 5/65 0.79 [ 0.21, 2.95 ]
Thomas 2008 IPD 22/58 17/56 1.28 [ 0.68, 2.40 ]
Throuvalas 2000 0/28 1/27 0.13 [ 0.00, 6.55 ]
Tsuboi 2009 21/61 19/56 0.94 [ 0.57, 1.54 ]
Vansteenkiste 2002 IPD 101/159 118/161 0.79 [ 0.60, 1.04 ]
Wilkinson 2006 IPD 3/121 0/61 4.48 [ 0.40, 50.03 ]
Winquist 2009 24/26 27/30 0.58 [ 0.33, 1.03 ]
Wright 2007 IPD 32/33 34/37 1.55 [ 0.94, 2.54 ]
Subtotal (95% CI) 3580 2838 1.01 [ 0.93, 1.10 ]
Heterogeneity: Chi2 = 29.34, df = 29 (P = 0.45); I2 =1%
Test for overall effect: Z = 0.33 (P = 0.74)
3 Hb > 12 g/dL
Del Mastro 1997 1/31 3/31 0.36 [ 0.05, 2.53 ]
Dunphy 1999 0/15 1/15 0.14 [ 0.00, 6.82 ]
Engert 2010 27/648 36/655 0.74 [ 0.45, 1.22 ]
Goss 2005 IPD 28/52 29/52 1.13 [ 0.67, 1.91 ]
Grote 2005 IPD 100/109 101/115 1.17 [ 0.89, 1.54 ]
Hoskin 2009 IPD 74/151 75/149 1.04 [ 0.75, 1.44 ]
Leyland-Jones 2005 IPD 121/469 91/470 1.41 [ 1.08, 1.85 ]
Machtay 2007 IPD 37/77 32/71 1.19 [ 0.74, 1.91 ]
Milroy 2003 IPD 136/214 126/210 1.13 [ 0.88, 1.45 ]
Moebus 2007 IPD 59/324 56/319 1.01 [ 0.70, 1.46 ]
O’Shaugnessy 2005 IPD 1/51 0/49 7.69 [ 0.15, 387.58 ]
Overgaard 2009 144/255 119/259 1.26 [ 0.99, 1.61 ]
Rosen 2003 19/47 23/43 1.19 [ 0.65, 2.18 ]
Thatcher 1999 IPD 7/86 3/44 1.13 [ 0.29, 4.36 ]
Untch 2011˙2 59/345 48/369 1.33 [ 0.91, 1.95 ]
Subtotal (95% CI) 2874 2851 1.17 [ 1.06, 1.29 ]
Heterogeneity: Chi2 = 10.57, df = 14 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 3.02 (P = 0.0025)
4 unclear
Debus 2006 IPD 146/195 159/190 0.81 [ 0.64, 1.02 ]
EPO-GER-20 IPD 7/48 8/45 0.71 [ 0.26, 1.95 ]
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ML17620 2006 4/61 0/60 7.70 [ 1.05, 56.33 ]
OBE/EPO-INT-03 IPD 5/35 6/37 1.07 [ 0.32, 3.56 ]
P-174 IPD 1/33 1/12 0.44 [ 0.03, 7.27 ]
Subtotal (95% CI) 372 344 0.83 [ 0.67, 1.03 ]
Heterogeneity: Chi2 = 5.32, df = 4 (P = 0.26); I2 =25%
Test for overall effect: Z = 1.67 (P = 0.095)
Total (95% CI) 1.05 [ 1.00, 1.11 ]
Heterogeneity: Chi2 = 95.36, df = 75 (P = 0.06); I2 =21%
Test for overall effect: Z = 1.97 (P = 0.048)
Test for subgroup differences: Chi2 = 9.43, df = 3 (P = 0.02), I2 =68%
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Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 5 Overall survival
Outcome: 4 Overall survival - different malignancies













Aapro 2008 IPD 169/231 169/232 1.07 [ 0.87, 1.32 ]
Antonadou 2001 10/190 30/195 0.35 [ 0.19, 0.66 ]
Bamias 2003 7/72 4/72 1.80 [ 0.53, 6.12 ]
Blohmer 2011 25/127 29/129 0.88 [ 0.51, 1.51 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Chang 2005 IPD 27/176 28/178 0.94 [ 0.55, 1.60 ]
Christodoulou 2009 71/167 87/170 1.25 [ 0.92, 1.71 ]
Debus 2006 IPD 146/195 159/190 0.81 [ 0.64, 1.02 ]
Del Mastro 1997 1/31 3/31 0.36 [ 0.05, 2.53 ]
Dunphy 1999 0/15 1/15 0.14 [ 0.00, 6.82 ]
EPO-GER-20 IPD 7/48 8/45 0.71 [ 0.26, 1.95 ]
EPO-INT-1 IPD 11/165 3/81 1.88 [ 0.63, 5.64 ]
Fujisaka 2011 37/89 34/92 1.15 [ 0.72, 1.85 ]
Goss 2005 IPD 28/52 29/52 1.13 [ 0.67, 1.91 ]
Grote 2005 IPD 100/109 101/115 1.17 [ 0.89, 1.54 ]
Gupta 2009 17/58 14/57 0.90 [ 0.51, 1.59 ]
Henke 2003 IPD 109/180 89/171 1.27 [ 0.96, 1.68 ]
Hoskin 2009 IPD 74/151 75/149 1.04 [ 0.75, 1.44 ]
Huddart 2002 IPD 8/48 8/47 1.19 [ 0.44, 3.21 ]
Kotasek 2002 IPD 4/129 0/32 3.49 [ 0.30, 40.45 ]
Kotasek 2003 IPD 4/208 1/51 0.99 [ 0.11, 8.84 ]
Kurz 1997 0/23 0/12 0.0 [ 0.0, 0.0 ]
Leyland-Jones 2005 IPD 121/469 91/470 1.41 [ 1.08, 1.85 ]
Machtay 2007 IPD 37/77 32/71 1.19 [ 0.74, 1.91 ]
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Milroy 2003 IPD 136/214 126/210 1.13 [ 0.88, 1.45 ]
ML17620 2006 4/61 0/60 7.70 [ 1.05, 56.33 ]
Moebus 2007 IPD 59/324 56/319 1.01 [ 0.70, 1.46 ]
Mystakidou 2005 1/50 2/50 0.50 [ 0.05, 5.00 ]
O’Shaugnessy 2005 IPD 1/51 0/49 7.69 [ 0.15, 387.58 ]
Oberhoff 1998 IPD 9/116 10/111 0.62 [ 0.24, 1.59 ]
Overgaard 2009 144/255 119/259 1.26 [ 0.99, 1.61 ]
Pirker 2008 IPD 243/299 254/301 0.94 [ 0.78, 1.13 ]
Pronzato 2010 IPD 23/110 20/113 1.05 [ 0.58, 1.91 ]
Rosen 2003 19/47 23/43 1.19 [ 0.65, 2.18 ]
Savonije 2005 IPD 132/211 61/104 1.14 [ 0.85, 1.53 ]
Strauss 2008 IPD 8/34 5/40 2.00 [ 0.65, 6.13 ]
Sweeney 1998 0/24 0/24 0.0 [ 0.0, 0.0 ]
Ten Bokkel1998 IPD 6/87 2/33 1.27 [ 0.26, 6.34 ]
Thatcher 1999 IPD 7/86 3/44 1.13 [ 0.29, 4.36 ]
Thomas 2002 IPD 4/65 5/65 0.79 [ 0.21, 2.95 ]
Thomas 2008 IPD 22/58 17/56 1.28 [ 0.68, 2.40 ]
Throuvalas 2000 0/28 1/27 0.13 [ 0.00, 6.55 ]
Tjulandin 2010a 5/76 6/37 0.28 [ 0.07, 1.08 ]
Tjulandin 2010b 4/73 6/37 0.34 [ 0.09, 1.26 ]
Untch 2011˙2 59/345 48/369 1.33 [ 0.91, 1.95 ]
Vansteenkiste 2002 IPD 101/159 118/161 0.79 [ 0.60, 1.04 ]
Wilkinson 2006 IPD 3/121 0/61 4.48 [ 0.40, 50.03 ]
Winquist 2009 24/26 27/30 0.58 [ 0.33, 1.03 ]
Witzig 2005 IPD 121/174 119/170 1.13 [ 0.87, 1.46 ]
Wright 2007 IPD 32/33 34/37 1.55 [ 0.94, 2.54 ]
Subtotal (95% CI) 6187 5517 1.06 [ 1.00, 1.13 ]
Heterogeneity: Chi2 = 66.13, df = 46 (P = 0.03); I2 =30%
Test for overall effect: Z = 1.86 (P = 0.062)
2 haematological malignancies
Cazzola 1995 IPD 5/114 3/29 0.69 [ 0.13, 3.57 ]
Dammacco 2001 IPD 1/69 7/76 0.23 [ 0.06, 0.90 ]
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Engert 2010 27/648 36/655 0.74 [ 0.45, 1.22 ]
Hedenus 2002 0/55 0/11 0.0 [ 0.0, 0.0 ]
Hedenus 2003 IPD 101/176 82/173 1.32 [ 0.98, 1.77 ]
ML17616 2006 1/30 0/30 7.39 [ 0.15, 372.38 ]
OBE/EPO-INT-03 IPD 5/35 6/37 1.07 [ 0.32, 3.56 ]
Osterborg 1996 IPD 26/99 14/49 0.94 [ 0.49, 1.81 ]
Osterborg 2002 IPD 110/173 109/176 1.04 [ 0.80, 1.36 ]
P-174 IPD 1/33 1/12 0.44 [ 0.03, 7.27 ]
Rose 1994 IPD 16/142 6/79 1.66 [ 0.70, 3.92 ]
Subtotal (95% CI) 1574 1327 1.07 [ 0.90, 1.26 ]
Heterogeneity: Chi2 = 11.73, df = 9 (P = 0.23); I2 =23%
Test for overall effect: Z = 0.75 (P = 0.45)
3 MDS
Thompson 2000 3/45 0/21 4.52 [ 0.38, 53.37 ]
Subtotal (95% CI) 45 21 4.52 [ 0.38, 53.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.20 (P = 0.23)
4 mixed
Abels 1993 IPD 13/65 12/59 0.96 [ 0.44, 2.10 ]
Boogaerts 2003 IPD 16/132 12/127 1.53 [ 0.72, 3.26 ]
Case 1993 IPD 10/81 9/76 1.11 [ 0.45, 2.73 ]
Charu 2007 IPD 8/228 2/59 0.89 [ 0.19, 4.18 ]
EPO-INT-3 IPD 9/135 3/65 1.55 [ 0.47, 5.10 ]
Gordon 2008 IPD 11/164 5/56 0.74 [ 0.26, 2.14 ]
Henry 1995 IPD 7/67 10/65 0.68 [ 0.26, 1.77 ]
Hernandez 2009 IPD 17/196 20/195 0.84 [ 0.44, 1.60 ]
Krzakowski 2008a 6/104 2/52 1.48 [ 0.33, 6.67 ]
Krzakowski 2008b 10/105 3/52 1.64 [ 0.49, 5.44 ]
Littlewood 2001 IPD 155/251 82/124 0.80 [ 0.61, 1.05 ]
Quirt 1996 IPD 2/28 0/28 5.90 [ 0.36, 97.07 ]
Ray-Coquard 2009 IPD 75/110 84/108 0.79 [ 0.58, 1.08 ]
Razzouk 2004 2/112 2/110 0.98 [ 0.14, 7.03 ]
Smith 2003 3/64 0/22 3.96 [ 0.29, 54.28 ]
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Smith 2008 IPD 250/517 216/472 1.22 [ 1.02, 1.47 ]
Tjulandin 2011 6/95 5/91 1.16 [ 0.34, 3.90 ]
Tsuboi 2009 21/61 19/56 0.94 [ 0.57, 1.54 ]
Subtotal (95% CI) 2515 1817 1.02 [ 0.91, 1.15 ]
Heterogeneity: Chi2 = 15.87, df = 17 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 0.32 (P = 0.75)
5 not reported
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 1.05 [ 1.00, 1.11 ]
Heterogeneity: Chi2 = 95.40, df = 75 (P = 0.06); I2 =21%
Test for overall effect: Z = 1.97 (P = 0.048)
Test for subgroup differences: Chi2 = 1.67, df = 3 (P = 0.64), I2 =0.0%
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Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 5 Overall survival
Outcome: 5 Overall survival - age













Razzouk 2004 2/112 2/110 0.98 [ 0.14, 7.03 ]
Subtotal (95% CI) 112 110 0.98 [ 0.14, 7.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.98)
2 adults
Aapro 2008 IPD 169/231 169/232 1.07 [ 0.87, 1.32 ]
Abels 1993 IPD 13/65 12/59 0.96 [ 0.44, 2.10 ]
Antonadou 2001 10/190 30/195 0.35 [ 0.19, 0.66 ]
Bamias 2003 7/72 4/72 1.80 [ 0.53, 6.12 ]
Blohmer 2011 25/127 29/129 0.88 [ 0.51, 1.51 ]
Boogaerts 2003 IPD 16/132 12/127 1.53 [ 0.72, 3.26 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Case 1993 IPD 10/81 9/76 1.11 [ 0.45, 2.73 ]
Cazzola 1995 IPD 5/114 3/29 0.69 [ 0.13, 3.57 ]
Chang 2005 IPD 27/176 28/178 0.94 [ 0.55, 1.60 ]
Charu 2007 IPD 8/228 2/59 0.89 [ 0.19, 4.18 ]
Christodoulou 2009 71/167 87/170 1.25 [ 0.92, 1.71 ]
Dammacco 2001 IPD 1/69 7/76 0.23 [ 0.06, 0.90 ]
Debus 2006 IPD 146/195 159/190 0.81 [ 0.64, 1.02 ]
Del Mastro 1997 1/31 3/31 0.36 [ 0.05, 2.53 ]
Dunphy 1999 0/15 1/15 0.14 [ 0.00, 6.82 ]
Engert 2010 27/648 36/655 0.74 [ 0.45, 1.22 ]
EPO-GER-20 IPD 7/48 8/45 0.71 [ 0.26, 1.95 ]
EPO-INT-1 IPD 11/165 3/81 1.88 [ 0.63, 5.64 ]
EPO-INT-3 IPD 9/135 3/65 1.55 [ 0.47, 5.10 ]
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Fujisaka 2011 37/89 34/92 1.15 [ 0.72, 1.85 ]
Gordon 2008 IPD 11/164 5/56 0.74 [ 0.26, 2.14 ]
Goss 2005 IPD 28/52 29/52 1.13 [ 0.67, 1.91 ]
Grote 2005 IPD 100/109 101/115 1.17 [ 0.89, 1.54 ]
Gupta 2009 17/58 14/57 0.90 [ 0.51, 1.59 ]
Hedenus 2002 0/55 0/11 0.0 [ 0.0, 0.0 ]
Hedenus 2003 IPD 101/176 82/173 1.32 [ 0.98, 1.77 ]
Henke 2003 IPD 109/180 89/171 1.27 [ 0.96, 1.68 ]
Henry 1995 IPD 7/67 10/65 0.68 [ 0.26, 1.77 ]
Hernandez 2009 IPD 17/196 20/195 0.84 [ 0.44, 1.60 ]
Hoskin 2009 IPD 74/151 75/149 1.04 [ 0.75, 1.44 ]
Huddart 2002 IPD 8/48 8/47 1.19 [ 0.44, 3.21 ]
Kotasek 2002 IPD 4/129 0/32 3.49 [ 0.30, 40.45 ]
Kotasek 2003 IPD 4/208 1/51 0.99 [ 0.11, 8.84 ]
Krzakowski 2008a 6/104 2/52 1.48 [ 0.33, 6.67 ]
Krzakowski 2008b 10/105 3/52 1.64 [ 0.49, 5.44 ]
Kurz 1997 0/23 0/12 0.0 [ 0.0, 0.0 ]
Leyland-Jones 2005 IPD 121/469 91/470 1.41 [ 1.08, 1.85 ]
Littlewood 2001 IPD 155/251 82/124 0.80 [ 0.61, 1.05 ]
Machtay 2007 IPD 37/77 32/71 1.19 [ 0.74, 1.91 ]
Milroy 2003 IPD 136/214 126/210 1.13 [ 0.88, 1.45 ]
ML17616 2006 1/30 0/30 7.39 [ 0.15, 372.38 ]
ML17620 2006 4/61 0/60 7.70 [ 1.05, 56.33 ]
Moebus 2007 IPD 59/324 56/319 1.01 [ 0.70, 1.46 ]
Mystakidou 2005 1/50 2/50 0.50 [ 0.05, 5.00 ]
O’Shaugnessy 2005 IPD 1/51 0/49 7.69 [ 0.15, 387.58 ]
OBE/EPO-INT-03 IPD 5/35 6/37 1.07 [ 0.32, 3.56 ]
Oberhoff 1998 IPD 9/116 10/111 0.62 [ 0.24, 1.59 ]
Osterborg 1996 IPD 26/99 14/49 0.94 [ 0.49, 1.81 ]
Osterborg 2002 IPD 110/173 109/176 1.04 [ 0.80, 1.36 ]
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Overgaard 2009 144/255 119/259 1.26 [ 0.99, 1.61 ]
P-174 IPD 1/33 1/12 0.44 [ 0.03, 7.27 ]
Pirker 2008 IPD 243/299 254/301 0.94 [ 0.78, 1.13 ]
Pronzato 2010 IPD 23/110 20/113 1.05 [ 0.58, 1.91 ]
Quirt 1996 IPD 2/28 0/28 5.90 [ 0.36, 97.07 ]
Ray-Coquard 2009 IPD 75/110 84/108 0.79 [ 0.58, 1.08 ]
Rose 1994 IPD 16/142 6/79 1.66 [ 0.70, 3.92 ]
Rosen 2003 19/47 23/43 1.19 [ 0.65, 2.18 ]
Savonije 2005 IPD 132/211 61/104 1.14 [ 0.85, 1.53 ]
Smith 2003 3/64 0/22 3.96 [ 0.29, 54.28 ]
Smith 2008 IPD 250/517 216/472 1.22 [ 1.02, 1.47 ]
Strauss 2008 IPD 8/34 5/40 2.00 [ 0.65, 6.13 ]
Sweeney 1998 0/24 0/24 0.0 [ 0.0, 0.0 ]
Ten Bokkel1998 IPD 6/87 2/33 1.27 [ 0.26, 6.34 ]
Thatcher 1999 IPD 7/86 3/44 1.13 [ 0.29, 4.36 ]
Thomas 2002 IPD 4/65 5/65 0.79 [ 0.21, 2.95 ]
Thomas 2008 IPD 22/58 17/56 1.28 [ 0.68, 2.40 ]
Thompson 2000 3/45 0/21 4.52 [ 0.38, 53.37 ]
Throuvalas 2000 0/28 1/27 0.13 [ 0.00, 6.55 ]
Tjulandin 2010a 5/76 6/37 0.28 [ 0.07, 1.08 ]
Tjulandin 2010b 4/73 6/37 0.34 [ 0.09, 1.26 ]
Tjulandin 2011 6/95 5/91 1.16 [ 0.34, 3.90 ]
Tsuboi 2009 21/61 19/56 0.94 [ 0.57, 1.54 ]
Untch 2011˙2 59/345 48/369 1.33 [ 0.91, 1.95 ]
Vansteenkiste 2002 IPD 101/159 118/161 0.79 [ 0.60, 1.04 ]
Wilkinson 2006 IPD 3/121 0/61 4.48 [ 0.40, 50.03 ]
Winquist 2009 24/26 27/30 0.58 [ 0.33, 1.03 ]
Witzig 2005 IPD 121/174 119/170 1.13 [ 0.87, 1.46 ]
Wright 2007 IPD 32/33 34/37 1.55 [ 0.94, 2.54 ]
Subtotal (95% CI) 10209 8572 1.05 [ 1.00, 1.11 ]
Heterogeneity: Chi2 = 95.39, df = 74 (P = 0.05); I2 =22%
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Test for overall effect: Z = 1.98 (P = 0.048)
Total (95% CI) 1.05 [ 1.00, 1.11 ]
Heterogeneity: Chi2 = 95.40, df = 75 (P = 0.06); I2 =21%
Test for overall effect: Z = 1.97 (P = 0.048)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.94), I2 =0.0%
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Comparison: 5 Overall survival
Outcome: 6 Overall survival - age differentiated












1 only children < 18
Razzouk 2004 2/112 2/110 0.98 [ 0.14, 7.03 ]
Subtotal (95% CI) 112 110 0.98 [ 0.14, 7.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.98)
2 adults >= 18
Aapro 2008 IPD 169/231 169/232 1.07 [ 0.87, 1.32 ]
Abels 1993 IPD 13/65 12/59 0.96 [ 0.44, 2.10 ]
Bamias 2003 7/72 4/72 1.80 [ 0.53, 6.12 ]
Boogaerts 2003 IPD 16/132 12/127 1.53 [ 0.72, 3.26 ]
Case 1993 IPD 10/81 9/76 1.11 [ 0.45, 2.73 ]
Cazzola 1995 IPD 5/114 3/29 0.69 [ 0.13, 3.57 ]
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Charu 2007 IPD 8/228 2/59 0.89 [ 0.19, 4.18 ]
Christodoulou 2009 71/167 87/170 1.25 [ 0.92, 1.71 ]
Dammacco 2001 IPD 1/69 7/76 0.15 [ 0.02, 1.20 ]
Debus 2006 IPD 146/195 159/190 0.81 [ 0.64, 1.01 ]
Dunphy 1999 0/15 1/15 0.14 [ 0.00, 6.82 ]
EPO-GER-20 IPD 7/48 8/45 0.71 [ 0.26, 1.95 ]
EPO-INT-1 IPD 11/165 3/81 2.07 [ 0.57, 7.45 ]
EPO-INT-3 IPD 9/135 3/65 1.62 [ 0.44, 5.97 ]
Fujisaka 2011 37/89 34/92 1.15 [ 0.72, 1.85 ]
Gordon 2008 IPD 11/164 5/56 0.74 [ 0.26, 2.14 ]
Goss 2005 IPD 28/52 29/52 1.13 [ 0.67, 1.90 ]
Grote 2005 IPD 100/109 101/115 1.17 [ 0.89, 1.55 ]
Hedenus 2002 0/55 0/11 0.0 [ 0.0, 0.0 ]
Hedenus 2003 IPD 101/176 82/173 1.32 [ 0.98, 1.76 ]
Henke 2003 IPD 109/180 89/171 1.27 [ 0.96, 1.69 ]
Henry 1995 IPD 7/67 10/65 0.68 [ 0.26, 1.79 ]
Hernandez 2009 IPD 17/196 20/195 0.83 [ 0.44, 1.59 ]
Hoskin 2009 IPD 74/151 75/149 1.04 [ 0.75, 1.43 ]
Huddart 2002 IPD 8/48 8/47 1.19 [ 0.44, 3.21 ]
Kotasek 2002 IPD 4/129 0/32 3.49 [ 0.30, 40.45 ]
Kotasek 2003 IPD 4/208 1/51 1.01 [ 0.11, 9.06 ]
Krzakowski 2008a 6/104 2/52 1.48 [ 0.33, 6.67 ]
Krzakowski 2008b 10/105 3/52 1.64 [ 0.49, 5.44 ]
Leyland-Jones 2005 IPD 121/469 91/470 1.42 [ 1.08, 1.86 ]
Littlewood 2001 IPD 155/251 82/124 0.81 [ 0.62, 1.06 ]
Machtay 2007 IPD 37/77 32/71 1.19 [ 0.74, 1.91 ]
Milroy 2003 IPD 136/214 126/210 1.13 [ 0.88, 1.43 ]
ML17616 2006 1/30 0/30 7.39 [ 0.15, 372.38 ]
ML17620 2006 4/61 0/60 7.70 [ 1.05, 56.33 ]
Mystakidou 2005 1/50 2/50 0.50 [ 0.05, 5.00 ]
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O’Shaugnessy 2005 IPD 1/51 0/49 7.69 [ 0.15, 387.58 ]
OBE/EPO-INT-03 IPD 5/35 6/37 1.07 [ 0.32, 3.56 ]
Osterborg 1996 IPD 26/99 14/49 0.94 [ 0.49, 1.81 ]
Osterborg 2002 IPD 110/173 109/176 1.04 [ 0.80, 1.36 ]
Overgaard 2009 144/255 119/259 1.26 [ 0.99, 1.61 ]
P-174 IPD 1/33 1/12 0.44 [ 0.03, 7.27 ]
Pirker 2008 IPD 243/299 254/301 0.94 [ 0.78, 1.12 ]
Quirt 1996 IPD 2/28 0/28 5.90 [ 0.36, 97.07 ]
Ray-Coquard 2009 IPD 75/110 84/108 0.79 [ 0.58, 1.08 ]
Rose 1994 IPD 16/142 6/79 1.73 [ 0.67, 4.42 ]
Savonije 2005 IPD 132/211 61/104 1.15 [ 0.85, 1.55 ]
Smith 2003 3/64 0/22 3.96 [ 0.29, 54.28 ]
Smith 2008 IPD 250/517 216/472 1.22 [ 1.02, 1.47 ]
Sweeney 1998 0/24 0/24 0.0 [ 0.0, 0.0 ]
Ten Bokkel1998 IPD 6/87 2/33 1.27 [ 0.26, 6.34 ]
Thatcher 1999 IPD 7/86 3/44 1.13 [ 0.29, 4.36 ]
Thomas 2002 IPD 4/65 5/65 0.79 [ 0.21, 2.96 ]
Thompson 2000 3/45 0/21 4.52 [ 0.38, 53.37 ]
Tjulandin 2010a 5/76 6/37 0.28 [ 0.07, 1.08 ]
Tjulandin 2010b 4/73 6/37 0.34 [ 0.09, 1.26 ]
Tjulandin 2011 6/95 5/91 1.16 [ 0.34, 3.90 ]
Tsuboi 2009 21/61 19/56 0.94 [ 0.57, 1.54 ]
Vansteenkiste 2002 IPD 101/159 118/161 0.79 [ 0.60, 1.03 ]
Wilkinson 2006 IPD 3/121 0/61 0.0 [ 0.0, 0.0 ]
Witzig 2005 IPD 121/174 119/170 1.13 [ 0.87, 1.46 ]
Wright 2007 IPD 32/33 34/37 1.55 [ 0.94, 2.54 ]
Subtotal (95% CI) 7818 6157 1.07 [ 1.01, 1.13 ]
Heterogeneity: Chi2 = 67.27, df = 58 (P = 0.19); I2 =14%
Test for overall effect: Z = 2.42 (P = 0.015)
3 > 68% non elderly 18-65
Antonadou 2001 10/190 30/195 0.35 [ 0.19, 0.66 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
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Chang 2005 IPD 27/176 28/178 0.94 [ 0.55, 1.60 ]
Del Mastro 1997 1/31 3/31 0.36 [ 0.05, 2.53 ]
Gupta 2009 17/58 14/57 0.90 [ 0.51, 1.59 ]
Kurz 1997 0/23 0/12 0.0 [ 0.0, 0.0 ]
Oberhoff 1998 IPD 9/116 10/111 0.62 [ 0.25, 1.58 ]
Rosen 2003 19/47 23/43 1.19 [ 0.65, 2.18 ]
Strauss 2008 IPD 8/34 5/40 2.00 [ 0.65, 6.13 ]
Thomas 2008 IPD 22/58 17/56 1.28 [ 0.68, 2.42 ]
Throuvalas 2000 0/28 1/27 0.13 [ 0.00, 6.55 ]
Subtotal (95% CI) 811 800 0.86 [ 0.67, 1.10 ]
Heterogeneity: Chi2 = 15.01, df = 8 (P = 0.06); I2 =47%
Test for overall effect: Z = 1.22 (P = 0.22)
4 only non-elderly adults
Blohmer 2011 25/127 29/129 0.88 [ 0.51, 1.51 ]
Engert 2010 27/648 36/655 0.74 [ 0.45, 1.22 ]
Moebus 2007 IPD 59/324 56/319 1.01 [ 0.70, 1.46 ]
Untch 2011˙2 59/345 48/369 1.33 [ 0.91, 1.95 ]
Subtotal (95% CI) 1444 1472 1.02 [ 0.82, 1.26 ]
Heterogeneity: Chi2 = 3.74, df = 3 (P = 0.29); I2 =20%
Test for overall effect: Z = 0.18 (P = 0.86)
5 > 68% elderly > 65
Pronzato 2010 IPD 23/110 20/113 1.05 [ 0.58, 1.92 ]
Winquist 2009 24/26 27/30 0.58 [ 0.33, 1.03 ]
Subtotal (95% CI) 136 143 0.77 [ 0.51, 1.17 ]
Heterogeneity: Chi2 = 1.97, df = 1 (P = 0.16); I2 =49%
Test for overall effect: Z = 1.21 (P = 0.23)
6 only elderly > 65
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 1.05 [ 1.00, 1.11 ]
Heterogeneity: Chi2 = 93.19, df = 74 (P = 0.07); I2 =21%
Test for overall effect: Z = 1.91 (P = 0.056)
Test for subgroup differences: Chi2 = 5.20, df = 4 (P = 0.27), I2 =23%
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Aapro 2008 IPD 169/231 169/232 1.07 [ 0.87, 1.32 ]
Bamias 2003 7/72 4/72 1.80 [ 0.53, 6.12 ]
Boogaerts 2003 IPD 16/132 12/127 1.53 [ 0.72, 3.26 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Case 1993 IPD 10/81 9/76 1.11 [ 0.45, 2.73 ]
Cazzola 1995 IPD 5/114 3/29 0.69 [ 0.13, 3.57 ]
Chang 2005 IPD 27/176 28/178 0.94 [ 0.55, 1.60 ]
Christodoulou 2009 71/167 87/170 1.25 [ 0.92, 1.71 ]
Dammacco 2001 IPD 1/69 7/76 0.23 [ 0.06, 0.90 ]
Del Mastro 1997 1/31 3/31 0.36 [ 0.05, 2.53 ]
Dunphy 1999 0/15 1/15 0.14 [ 0.00, 6.82 ]
Engert 2009 27/648 36/655 0.70 [ 0.45, 1.08 ]
EPO-GER-20 IPD 7/48 8/45 0.71 [ 0.26, 1.95 ]
EPO-INT-1 IPD 11/165 3/81 1.88 [ 0.63, 5.64 ]
EPO-INT-3 IPD 9/135 3/65 1.55 [ 0.47, 5.10 ]
Fujisaka 2011 37/89 34/92 1.15 [ 0.72, 1.85 ]
Grote 2005 IPD 100/109 101/115 1.17 [ 0.89, 1.54 ]
Hedenus 2002 0/55 0/11 0.0 [ 0.0, 0.0 ]
Hedenus 2003 IPD 101/176 82/173 1.32 [ 0.98, 1.77 ]
Henry 1995 IPD 7/67 10/65 0.68 [ 0.26, 1.77 ]
Hernandez 2009 IPD 17/196 20/195 0.84 [ 0.44, 1.60 ]
Huddart 2002 IPD 8/48 8/47 1.19 [ 0.44, 3.21 ]
Kotasek 2002 IPD 4/129 0/32 3.49 [ 0.30, 40.45 ]
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Kotasek 2003 IPD 4/208 1/51 0.99 [ 0.11, 8.84 ]
Krzakowski 2008a 6/104 2/52 1.48 [ 0.33, 6.67 ]
Krzakowski 2008b 10/105 3/52 1.64 [ 0.49, 5.44 ]
Kurz 1997 0/23 0/12 0.0 [ 0.0, 0.0 ]
Leyland-Jones 2005 IPD 121/469 91/470 1.41 [ 1.08, 1.85 ]
Littlewood 2001 IPD 155/251 82/124 0.80 [ 0.61, 1.05 ]
Milroy 2003 IPD 136/214 126/210 1.13 [ 0.88, 1.45 ]
ML17616 2006 1/30 0/30 7.39 [ 0.15, 372.38 ]
ML17620 2006 4/61 0/60 7.70 [ 1.05, 56.33 ]
Moebus 2007 IPD 59/324 56/319 1.01 [ 0.70, 1.46 ]
O’Shaugnessy 2005 IPD 1/51 0/49 7.69 [ 0.15, 387.58 ]
OBE/EPO-INT-03 IPD 5/35 6/37 1.07 [ 0.32, 3.56 ]
Oberhoff 1998 IPD 9/116 10/111 0.62 [ 0.24, 1.59 ]
Osterborg 1996 IPD 26/99 14/49 0.94 [ 0.49, 1.81 ]
Osterborg 2002 IPD 110/173 109/176 1.04 [ 0.80, 1.36 ]
Pirker 2008 IPD 243/299 254/301 0.94 [ 0.78, 1.13 ]
Pronzato 2010 IPD 23/110 20/113 1.05 [ 0.58, 1.91 ]
Quirt 1996 IPD 2/28 0/28 5.90 [ 0.36, 97.07 ]
Ray-Coquard 2009 IPD 75/110 84/108 0.79 [ 0.58, 1.08 ]
Razzouk 2004 2/112 2/110 0.98 [ 0.14, 7.03 ]
Savonije 2005 IPD 132/211 61/104 1.14 [ 0.85, 1.53 ]
Ten Bokkel1998 IPD 6/87 2/33 1.27 [ 0.26, 6.34 ]
Thatcher 1999 IPD 7/86 3/44 1.13 [ 0.29, 4.36 ]
Thomas 2002 IPD 4/65 5/65 0.79 [ 0.21, 2.95 ]
Tjulandin 2010a 5/76 6/37 0.28 [ 0.07, 1.08 ]
Tjulandin 2010b 4/73 6/37 0.34 [ 0.09, 1.26 ]
Tjulandin 2011 6/95 5/91 1.16 [ 0.34, 3.90 ]
Tsuboi 2009 21/61 19/56 0.94 [ 0.57, 1.54 ]
Untch 2011˙2 59/345 48/369 1.33 [ 0.91, 1.95 ]
Vansteenkiste 2002 IPD 101/159 118/161 0.79 [ 0.60, 1.04 ]
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Wilkinson 2006 IPD 3/121 0/61 4.48 [ 0.40, 50.03 ]
Witzig 2005 IPD 121/174 119/170 1.13 [ 0.87, 1.46 ]
Subtotal (95% CI) 7478 6322 1.04 [ 0.98, 1.11 ]
Heterogeneity: Chi2 = 58.28, df = 51 (P = 0.23); I2 =12%
Test for overall effect: Z = 1.19 (P = 0.24)
2 radiotherapy/radiochemotherapy
Antonadou 2001 10/190 30/195 0.35 [ 0.19, 0.66 ]
Blohmer 2011 25/127 29/129 0.88 [ 0.51, 1.51 ]
Debus 2006 IPD 146/195 159/190 0.81 [ 0.64, 1.02 ]
Goss 2005 IPD 28/52 29/52 1.13 [ 0.67, 1.91 ]
Gupta 2009 17/58 14/57 0.90 [ 0.51, 1.59 ]
Henke 2003 IPD 109/180 89/171 1.27 [ 0.96, 1.68 ]
Hoskin 2009 IPD 74/151 75/149 1.04 [ 0.75, 1.44 ]
Machtay 2007 IPD 37/77 32/71 1.19 [ 0.74, 1.91 ]
Overgaard 2009 144/255 119/259 1.26 [ 0.99, 1.61 ]
Rosen 2003 19/47 23/43 1.19 [ 0.65, 2.18 ]
Strauss 2008 IPD 8/34 5/40 2.00 [ 0.65, 6.13 ]
Sweeney 1998 0/24 0/24 0.0 [ 0.0, 0.0 ]
Thomas 2008 IPD 22/58 17/56 1.28 [ 0.68, 2.40 ]
Throuvalas 2000 0/28 1/27 0.13 [ 0.00, 6.55 ]
Subtotal (95% CI) 1476 1463 1.03 [ 0.92, 1.15 ]
Heterogeneity: Chi2 = 24.60, df = 12 (P = 0.02); I2 =51%
Test for overall effect: Z = 0.55 (P = 0.58)
3 no therapy
Abels 1993 IPD 13/65 12/59 0.96 [ 0.44, 2.10 ]
Charu 2007 IPD 8/228 2/59 0.89 [ 0.19, 4.18 ]
Gordon 2008 IPD 11/164 5/56 0.74 [ 0.26, 2.14 ]
Mystakidou 2005 1/50 2/50 0.50 [ 0.05, 5.00 ]
Smith 2003 3/64 0/22 3.96 [ 0.29, 54.28 ]
Smith 2008 IPD 250/517 216/472 1.22 [ 1.02, 1.47 ]
Thompson 2000 3/45 0/21 4.52 [ 0.38, 53.37 ]
Wright 2007 IPD 32/33 34/37 1.55 [ 0.94, 2.54 ]
Subtotal (95% CI) 1166 776 1.23 [ 1.04, 1.45 ]
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Heterogeneity: Chi2 = 4.67, df = 7 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 2.47 (P = 0.014)
4 unclear/other
P-174 IPD 1/33 1/12 0.44 [ 0.03, 7.27 ]
Rose 1994 IPD 16/142 6/79 1.66 [ 0.70, 3.92 ]
Winquist 2009 24/26 27/30 0.58 [ 0.33, 1.03 ]
Subtotal (95% CI) 201 121 0.79 [ 0.49, 1.27 ]
Heterogeneity: Chi2 = 4.12, df = 2 (P = 0.13); I2 =51%
Test for overall effect: Z = 0.97 (P = 0.33)
Total (95% CI) 1.05 [ 1.00, 1.11 ]
Heterogeneity: Chi2 = 96.80, df = 75 (P = 0.05); I2 =23%
Test for overall effect: Z = 1.90 (P = 0.057)
Test for subgroup differences: Chi2 = 5.12, df = 3 (P = 0.16), I2 =41%
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Comparison: 5 Overall survival
Outcome: 8 Overall survival - different therapies differentiated












1 chemotherapy, > 70% with platinum
Bamias 2003 7/72 4/72 1.80 [ 0.53, 6.12 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Dunphy 1999 0/15 1/15 0.14 [ 0.00, 6.82 ]
EPO-INT-1 IPD 11/165 3/81 1.88 [ 0.63, 5.64 ]
Fujisaka 2011 37/89 34/92 1.15 [ 0.72, 1.85 ]
Grote 2005 IPD 100/109 101/115 1.17 [ 0.89, 1.54 ]
Henry 1995 IPD 7/67 10/65 0.68 [ 0.26, 1.77 ]
Huddart 2002 IPD 8/48 8/47 1.19 [ 0.44, 3.21 ]
Kurz 1997 0/23 0/12 0.0 [ 0.0, 0.0 ]
Milroy 2003 IPD 136/214 126/210 1.13 [ 0.88, 1.45 ]
ML17620 2006 4/61 0/60 7.70 [ 1.05, 56.33 ]
Pirker 2008 IPD 243/299 254/301 0.94 [ 0.78, 1.13 ]
Savonije 2005 IPD 132/211 61/104 1.14 [ 0.85, 1.53 ]
Ten Bokkel1998 IPD 6/87 2/33 1.27 [ 0.26, 6.34 ]
Thatcher 1999 IPD 7/86 3/44 1.13 [ 0.29, 4.36 ]
Tjulandin 2010a 5/76 6/37 0.28 [ 0.07, 1.08 ]
Tjulandin 2010b 4/73 6/37 0.34 [ 0.09, 1.26 ]
Vansteenkiste 2002 IPD 101/159 118/161 0.79 [ 0.60, 1.04 ]
Wilkinson 2006 IPD 3/121 0/61 4.48 [ 0.40, 50.03 ]
Subtotal (95% CI) 2025 1597 1.01 [ 0.91, 1.12 ]
Heterogeneity: Chi2 = 22.11, df = 16 (P = 0.14); I2 =28%
Test for overall effect: Z = 0.24 (P = 0.81)
2 chemotherapy, < 70% with platinum
Christodoulou 2009 71/167 87/170 1.25 [ 0.92, 1.71 ]
EPO-INT-3 IPD 9/135 3/65 1.55 [ 0.47, 5.10 ]
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Hernandez 2009 IPD 17/196 20/195 0.84 [ 0.44, 1.60 ]
Krzakowski 2008a 6/104 2/52 1.48 [ 0.33, 6.67 ]
Krzakowski 2008b 10/105 3/52 1.64 [ 0.49, 5.44 ]
Oberhoff 1998 IPD 9/116 10/111 0.62 [ 0.24, 1.59 ]
Witzig 2005 IPD 121/174 119/170 1.13 [ 0.87, 1.46 ]
Subtotal (95% CI) 997 815 1.14 [ 0.95, 1.36 ]
Heterogeneity: Chi2 = 3.54, df = 6 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 1.41 (P = 0.16)
3 chemotherapy without platinum (all patients)
Aapro 2008 IPD 169/231 169/232 1.07 [ 0.87, 1.32 ]
Case 1993 IPD 10/81 9/76 1.11 [ 0.45, 2.73 ]
Cazzola 1995 IPD 5/114 3/29 0.69 [ 0.13, 3.57 ]
Chang 2005 IPD 27/176 28/178 0.94 [ 0.55, 1.60 ]
Del Mastro 1997 1/31 3/31 0.36 [ 0.05, 2.53 ]
Engert 2010 27/648 36/655 0.74 [ 0.45, 1.22 ]
Hedenus 2002 0/55 0/11 0.0 [ 0.0, 0.0 ]
Hedenus 2003 IPD 101/176 82/173 1.32 [ 0.98, 1.77 ]
Leyland-Jones 2005 IPD 121/469 91/470 1.41 [ 1.08, 1.85 ]
Littlewood 2001 IPD 155/251 82/124 0.80 [ 0.61, 1.05 ]
ML17616 2006 1/30 0/30 7.39 [ 0.15, 372.38 ]
Moebus 2007 IPD 59/324 56/319 1.01 [ 0.70, 1.46 ]
O’Shaugnessy 2005 IPD 1/51 0/49 7.69 [ 0.15, 387.58 ]
OBE/EPO-INT-03 IPD 5/35 6/37 1.07 [ 0.32, 3.56 ]
Osterborg 1996 IPD 26/99 14/49 0.94 [ 0.49, 1.81 ]
Osterborg 2002 IPD 110/173 109/176 1.04 [ 0.80, 1.36 ]
Pronzato 2010 IPD 23/110 20/113 1.05 [ 0.58, 1.91 ]
Tjulandin 2011 6/95 5/91 1.16 [ 0.34, 3.90 ]
Untch 2011˙2 59/345 48/369 1.33 [ 0.91, 1.95 ]
Subtotal (95% CI) 3494 3212 1.08 [ 0.98, 1.19 ]
Heterogeneity: Chi2 = 17.52, df = 17 (P = 0.42); I2 =3%
Test for overall effect: Z = 1.50 (P = 0.13)
4 chemotherapy, platinum and non platinum containing, no numbers given
Boogaerts 2003 IPD 16/132 12/127 1.53 [ 0.72, 3.26 ]
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Dammacco 2001 IPD 1/69 7/76 0.23 [ 0.06, 0.90 ]
Kotasek 2003 IPD 4/208 1/51 0.99 [ 0.11, 8.84 ]
Thomas 2002 IPD 4/65 5/65 0.79 [ 0.21, 2.95 ]
Tsuboi 2009 21/61 19/56 0.94 [ 0.57, 1.54 ]
Subtotal (95% CI) 535 375 0.94 [ 0.65, 1.37 ]
Heterogeneity: Chi2 = 5.75, df = 4 (P = 0.22); I2 =30%
Test for overall effect: Z = 0.32 (P = 0.75)
5 chemotherapy no details given
EPO-GER-20 IPD 7/48 8/45 0.71 [ 0.26, 1.95 ]
Kotasek 2002 IPD 4/129 0/32 3.49 [ 0.30, 40.45 ]
Quirt 1996 IPD 2/28 0/28 5.90 [ 0.36, 97.07 ]
Ray-Coquard 2009 IPD 75/110 84/108 0.79 [ 0.58, 1.08 ]
Razzouk 2004 2/112 2/110 0.98 [ 0.14, 7.03 ]
Subtotal (95% CI) 427 323 0.82 [ 0.61, 1.10 ]
Heterogeneity: Chi2 = 3.42, df = 4 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 1.34 (P = 0.18)
6 radiochemotherapy
Blohmer 2011 25/127 29/129 0.88 [ 0.51, 1.51 ]
Debus 2006 IPD 146/195 159/190 0.81 [ 0.64, 1.02 ]
Goss 2005 IPD 28/52 29/52 1.13 [ 0.67, 1.91 ]
Gupta 2009 17/58 14/57 0.90 [ 0.51, 1.59 ]
Rosen 2003 19/47 23/43 1.19 [ 0.65, 2.18 ]
Strauss 2008 IPD 8/34 5/40 2.00 [ 0.65, 6.13 ]
Thomas 2008 IPD 22/58 17/56 1.28 [ 0.68, 2.40 ]
Throuvalas 2000 0/28 1/27 0.13 [ 0.00, 6.55 ]
Subtotal (95% CI) 599 594 0.92 [ 0.78, 1.09 ]
Heterogeneity: Chi2 = 6.37, df = 7 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 0.94 (P = 0.35)
7 radiotherapy
Antonadou 2001 10/190 30/195 0.35 [ 0.19, 0.66 ]
Henke 2003 IPD 109/180 89/171 1.27 [ 0.96, 1.68 ]
Hoskin 2009 IPD 74/151 75/149 1.04 [ 0.75, 1.44 ]
Machtay 2007 IPD 37/77 32/71 1.19 [ 0.74, 1.91 ]
Overgaard 2009 144/255 119/259 1.26 [ 0.99, 1.61 ]
0.01 0.1 1 10 100
Favours Treatment Favours Control
(Continued . . . )
418Erythropoietin or darbepoetin for patients with cancer (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)












Sweeney 1998 0/24 0/24 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 877 869 1.12 [ 0.97, 1.30 ]
Heterogeneity: Chi2 = 15.24, df = 4 (P = 0.004); I2 =74%
Test for overall effect: Z = 1.56 (P = 0.12)
8 no therapy
Abels 1993 IPD 13/65 12/59 0.96 [ 0.44, 2.10 ]
Charu 2007 IPD 8/228 2/59 0.89 [ 0.19, 4.18 ]
Gordon 2008 IPD 11/164 5/56 0.74 [ 0.26, 2.14 ]
Mystakidou 2005 1/50 2/50 0.50 [ 0.05, 5.00 ]
Smith 2003 3/64 0/22 3.96 [ 0.29, 54.28 ]
Smith 2008 IPD 250/517 216/472 1.22 [ 1.02, 1.47 ]
Thompson 2000 3/45 0/21 4.52 [ 0.38, 53.37 ]
Wright 2007 IPD 32/33 34/37 1.55 [ 0.94, 2.54 ]
Subtotal (95% CI) 1166 776 1.23 [ 1.04, 1.45 ]
Heterogeneity: Chi2 = 4.67, df = 7 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 2.47 (P = 0.014)
9 unclear/other
P-174 IPD 1/33 1/12 0.44 [ 0.03, 7.27 ]
Rose 1994 IPD 16/142 6/79 1.66 [ 0.70, 3.92 ]
Winquist 2009 24/26 27/30 0.58 [ 0.33, 1.03 ]
Subtotal (95% CI) 201 121 0.79 [ 0.49, 1.27 ]
Heterogeneity: Chi2 = 4.12, df = 2 (P = 0.13); I2 =51%
Test for overall effect: Z = 0.97 (P = 0.33)
Total (95% CI) 1.05 [ 1.00, 1.11 ]
Heterogeneity: Chi2 = 95.40, df = 75 (P = 0.06); I2 =21%
Test for overall effect: Z = 1.97 (P = 0.048)
Test for subgroup differences: Chi2 = 12.64, df = 8 (P = 0.12), I2 =37%
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Analysis 5.9. Comparison 5 Overall survival, Outcome 9 Overall survival - epoetin vs darbepoetin.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 5 Overall survival
Outcome: 9 Overall survival - epoetin vs darbepoetin













Aapro 2008 IPD 169/231 169/232 1.07 [ 0.87, 1.32 ]
Abels 1993 IPD 13/65 12/59 0.96 [ 0.44, 2.10 ]
Antonadou 2001 10/190 30/195 0.35 [ 0.19, 0.66 ]
Bamias 2003 7/72 4/72 1.80 [ 0.53, 6.12 ]
Blohmer 2011 25/127 29/129 0.88 [ 0.51, 1.51 ]
Boogaerts 2003 IPD 16/132 12/127 1.53 [ 0.72, 3.26 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Case 1993 IPD 10/81 9/76 1.11 [ 0.45, 2.73 ]
Cazzola 1995 IPD 5/114 3/29 0.69 [ 0.13, 3.57 ]
Chang 2005 IPD 27/176 28/178 0.94 [ 0.55, 1.60 ]
Christodoulou 2009 71/167 87/170 1.25 [ 0.92, 1.71 ]
Dammacco 2001 IPD 1/69 7/76 0.23 [ 0.06, 0.90 ]
Debus 2006 IPD 146/195 159/190 0.81 [ 0.64, 1.02 ]
Del Mastro 1997 1/31 3/31 0.36 [ 0.05, 2.53 ]
Dunphy 1999 0/15 1/15 0.14 [ 0.00, 6.82 ]
Engert 2010 27/648 36/655 0.74 [ 0.45, 1.22 ]
EPO-GER-20 IPD 7/48 8/45 0.71 [ 0.26, 1.95 ]
EPO-INT-1 IPD 11/165 3/81 1.88 [ 0.63, 5.64 ]
EPO-INT-3 IPD 9/135 3/65 1.55 [ 0.47, 5.10 ]
Fujisaka 2011 37/89 34/92 1.15 [ 0.72, 1.85 ]
Goss 2005 IPD 28/52 29/52 1.13 [ 0.67, 1.91 ]
Grote 2005 IPD 100/109 101/115 1.17 [ 0.89, 1.54 ]
Gupta 2009 17/58 14/57 0.90 [ 0.51, 1.59 ]
Henke 2003 IPD 109/180 89/171 1.27 [ 0.96, 1.68 ]
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Henry 1995 IPD 7/67 10/65 0.68 [ 0.26, 1.77 ]
Hoskin 2009 IPD 74/151 75/149 1.04 [ 0.75, 1.44 ]
Huddart 2002 IPD 8/48 8/47 1.19 [ 0.44, 3.21 ]
Krzakowski 2008a 6/104 2/52 1.48 [ 0.33, 6.67 ]
Krzakowski 2008b 10/105 3/52 1.64 [ 0.49, 5.44 ]
Kurz 1997 0/23 0/12 0.0 [ 0.0, 0.0 ]
Leyland-Jones 2005 IPD 121/469 91/470 1.41 [ 1.08, 1.85 ]
Littlewood 2001 IPD 155/251 82/124 0.80 [ 0.61, 1.05 ]
Machtay 2007 IPD 37/77 32/71 1.19 [ 0.74, 1.91 ]
Milroy 2003 IPD 136/214 126/210 1.13 [ 0.88, 1.45 ]
ML17616 2006 1/30 0/30 7.39 [ 0.15, 372.38 ]
ML17620 2006 4/61 0/60 7.70 [ 1.05, 56.33 ]
Moebus 2007 IPD 59/324 56/319 1.01 [ 0.70, 1.46 ]
Mystakidou 2005 1/50 2/50 0.50 [ 0.05, 5.00 ]
O’Shaugnessy 2005 IPD 1/51 0/49 7.69 [ 0.15, 387.58 ]
OBE/EPO-INT-03 IPD 5/35 6/37 1.07 [ 0.32, 3.56 ]
Oberhoff 1998 IPD 9/116 10/111 0.62 [ 0.24, 1.59 ]
Osterborg 1996 IPD 26/99 14/49 0.94 [ 0.49, 1.81 ]
Osterborg 2002 IPD 110/173 109/176 1.04 [ 0.80, 1.36 ]
P-174 IPD 1/33 1/12 0.44 [ 0.03, 7.27 ]
Pronzato 2010 IPD 23/110 20/113 1.05 [ 0.58, 1.91 ]
Quirt 1996 IPD 2/28 0/28 5.90 [ 0.36, 97.07 ]
Ray-Coquard 2009 IPD 75/110 84/108 0.79 [ 0.58, 1.08 ]
Razzouk 2004 2/112 2/110 0.98 [ 0.14, 7.03 ]
Rose 1994 IPD 16/142 6/79 1.66 [ 0.70, 3.92 ]
Rosen 2003 19/47 23/43 1.19 [ 0.65, 2.18 ]
Savonije 2005 IPD 132/211 61/104 1.14 [ 0.85, 1.53 ]
Strauss 2008 IPD 8/34 5/40 2.00 [ 0.65, 6.13 ]
Sweeney 1998 0/24 0/24 0.0 [ 0.0, 0.0 ]
Ten Bokkel1998 IPD 6/87 2/33 1.27 [ 0.26, 6.34 ]
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Thatcher 1999 IPD 7/86 3/44 1.13 [ 0.29, 4.36 ]
Thomas 2002 IPD 4/65 5/65 0.79 [ 0.21, 2.95 ]
Thomas 2008 IPD 22/58 17/56 1.28 [ 0.68, 2.40 ]
Thompson 2000 3/45 0/21 4.52 [ 0.38, 53.37 ]
Throuvalas 2000 0/28 1/27 0.13 [ 0.00, 6.55 ]
Tjulandin 2010a 5/76 6/37 0.28 [ 0.07, 1.08 ]
Tjulandin 2010b 4/73 6/37 0.34 [ 0.09, 1.26 ]
Tjulandin 2011 6/95 5/91 1.16 [ 0.34, 3.90 ]
Tsuboi 2009 21/61 19/56 0.94 [ 0.57, 1.54 ]
Wilkinson 2006 IPD 3/121 0/61 4.48 [ 0.40, 50.03 ]
Winquist 2009 24/26 27/30 0.58 [ 0.33, 1.03 ]
Witzig 2005 IPD 121/174 119/170 1.13 [ 0.87, 1.46 ]
Wright 2007 IPD 32/33 34/37 1.55 [ 0.94, 2.54 ]
Subtotal (95% CI) 7526 6521 1.04 [ 0.98, 1.10 ]
Heterogeneity: Chi2 = 78.15, df = 63 (P = 0.09); I2 =19%
Test for overall effect: Z = 1.19 (P = 0.23)
2 Darbepoetin
Charu 2007 IPD 8/228 2/59 0.89 [ 0.19, 4.18 ]
Gordon 2008 IPD 11/164 5/56 0.74 [ 0.26, 2.14 ]
Hedenus 2002 0/55 0/11 0.0 [ 0.0, 0.0 ]
Hedenus 2003 IPD 101/176 82/173 1.32 [ 0.98, 1.77 ]
Hernandez 2009 IPD 17/196 20/195 0.84 [ 0.44, 1.60 ]
Kotasek 2002 IPD 4/129 0/32 3.49 [ 0.30, 40.45 ]
Kotasek 2003 IPD 4/208 1/51 0.99 [ 0.11, 8.84 ]
Overgaard 2009 144/255 119/259 1.26 [ 0.99, 1.61 ]
Pirker 2008 IPD 243/299 254/301 0.94 [ 0.78, 1.13 ]
Smith 2003 3/64 0/22 3.96 [ 0.29, 54.28 ]
Smith 2008 IPD 250/517 216/472 1.22 [ 1.02, 1.47 ]
Untch 2011˙2 59/345 48/369 1.33 [ 0.91, 1.95 ]
Vansteenkiste 2002 IPD 101/159 118/161 0.79 [ 0.60, 1.04 ]
Subtotal (95% CI) 2795 2161 1.09 [ 0.99, 1.20 ]
Heterogeneity: Chi2 = 16.57, df = 11 (P = 0.12); I2 =34%
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Test for overall effect: Z = 1.77 (P = 0.076)
Total (95% CI) 1.05 [ 1.00, 1.11 ]
Heterogeneity: Chi2 = 95.40, df = 75 (P = 0.06); I2 =21%
Test for overall effect: Z = 1.97 (P = 0.048)
Test for subgroup differences: Chi2 = 0.67, df = 1 (P = 0.41), I2 =0.0%
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Analysis 5.10. Comparison 5 Overall survival, Outcome 10 Overall survival - duration of ESA medication.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 5 Overall survival
Outcome: 10 Overall survival - duration of ESA medication












1 6 to 9 weeks
Abels 1993 IPD 13/65 12/59 0.96 [ 0.44, 2.10 ]
Antonadou 2001 10/190 30/195 0.35 [ 0.19, 0.66 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Cazzola 1995 IPD 5/114 3/29 0.69 [ 0.13, 3.57 ]
Dunphy 1999 0/15 1/15 0.14 [ 0.00, 6.82 ]
Gupta 2009 17/58 14/57 0.90 [ 0.51, 1.59 ]
Henke 2003 IPD 109/180 89/171 1.27 [ 0.96, 1.68 ]
Machtay 2007 IPD 37/77 32/71 1.19 [ 0.74, 1.91 ]
Overgaard 2009 144/255 119/259 1.26 [ 0.99, 1.61 ]
Sweeney 1998 0/24 0/24 0.0 [ 0.0, 0.0 ]
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Thomas 2008 IPD 22/58 17/56 1.28 [ 0.68, 2.40 ]
Throuvalas 2000 0/28 1/27 0.13 [ 0.00, 6.55 ]
Tsuboi 2009 21/61 19/56 0.94 [ 0.57, 1.54 ]
Subtotal (95% CI) 1175 1069 1.10 [ 0.95, 1.27 ]
Heterogeneity: Chi2 = 18.96, df = 10 (P = 0.04); I2 =47%
Test for overall effect: Z = 1.30 (P = 0.20)
2 12 to 16 weeks
Boogaerts 2003 IPD 16/132 12/127 1.53 [ 0.72, 3.26 ]
Case 1993 IPD 10/81 9/76 1.11 [ 0.45, 2.73 ]
Chang 2005 IPD 27/176 28/178 0.94 [ 0.55, 1.60 ]
Charu 2007 IPD 8/228 2/59 0.89 [ 0.19, 4.18 ]
Christodoulou 2009 71/167 87/170 1.25 [ 0.92, 1.71 ]
Dammacco 2001 IPD 1/69 7/76 0.23 [ 0.06, 0.90 ]
Debus 2006 IPD 146/195 159/190 0.81 [ 0.64, 1.02 ]
Del Mastro 1997 1/31 3/31 0.36 [ 0.05, 2.53 ]
EPO-INT-3 IPD 9/135 3/65 1.55 [ 0.47, 5.10 ]
Fujisaka 2011 37/89 34/92 1.15 [ 0.72, 1.85 ]
Gordon 2008 IPD 11/164 5/56 0.74 [ 0.26, 2.14 ]
Grote 2005 IPD 100/109 101/115 1.17 [ 0.89, 1.54 ]
Hedenus 2002 0/55 0/11 0.0 [ 0.0, 0.0 ]
Hedenus 2003 IPD 101/176 82/173 1.32 [ 0.98, 1.77 ]
Henry 1995 IPD 7/67 10/65 0.68 [ 0.26, 1.77 ]
Hernandez 2009 IPD 17/196 20/195 0.84 [ 0.44, 1.60 ]
Hoskin 2009 IPD 74/151 75/149 1.04 [ 0.75, 1.44 ]
Kotasek 2002 IPD 4/129 0/32 3.49 [ 0.30, 40.45 ]
Kotasek 2003 IPD 4/208 1/51 0.99 [ 0.11, 8.84 ]
Krzakowski 2008a 6/104 2/52 1.48 [ 0.33, 6.67 ]
Krzakowski 2008b 10/105 3/52 1.64 [ 0.49, 5.44 ]
Kurz 1997 0/23 0/12 0.0 [ 0.0, 0.0 ]
ML17616 2006 1/30 0/30 7.39 [ 0.15, 372.38 ]
ML17620 2006 4/61 0/60 7.70 [ 1.05, 56.33 ]
O’Shaugnessy 2005 IPD 1/51 0/49 7.69 [ 0.15, 387.58 ]
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
(Continued . . . )
424Erythropoietin or darbepoetin for patients with cancer (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)












Oberhoff 1998 IPD 9/116 10/111 0.62 [ 0.24, 1.59 ]
Osterborg 2002 IPD 110/173 109/176 1.04 [ 0.80, 1.36 ]
P-174 IPD 1/33 1/12 0.44 [ 0.03, 7.27 ]
Quirt 1996 IPD 2/28 0/28 5.90 [ 0.36, 97.07 ]
Ray-Coquard 2009 IPD 75/110 84/108 0.79 [ 0.58, 1.08 ]
Razzouk 2004 2/112 2/110 0.98 [ 0.14, 7.03 ]
Rose 1994 IPD 16/142 6/79 1.66 [ 0.70, 3.92 ]
Rosen 2003 19/47 23/43 1.19 [ 0.65, 2.18 ]
Savonije 2005 IPD 132/211 61/104 1.14 [ 0.85, 1.53 ]
Smith 2003 3/64 0/22 3.96 [ 0.29, 54.28 ]
Smith 2008 IPD 250/517 216/472 1.22 [ 1.02, 1.47 ]
Strauss 2008 IPD 8/34 5/40 2.00 [ 0.65, 6.13 ]
Thomas 2002 IPD 4/65 5/65 0.79 [ 0.21, 2.95 ]
Thompson 2000 3/45 0/21 4.52 [ 0.38, 53.37 ]
Tjulandin 2010a 5/76 6/37 0.28 [ 0.07, 1.08 ]
Tjulandin 2010b 4/73 6/37 0.34 [ 0.09, 1.26 ]
Tjulandin 2011 6/95 5/91 1.16 [ 0.34, 3.90 ]
Vansteenkiste 2002 IPD 101/159 118/161 0.79 [ 0.60, 1.04 ]
Winquist 2009 24/26 27/30 0.58 [ 0.33, 1.03 ]
Witzig 2005 IPD 121/174 119/170 1.13 [ 0.87, 1.46 ]
Wright 2007 IPD 32/33 34/37 1.55 [ 0.94, 2.54 ]
Subtotal (95% CI) 5265 4120 1.05 [ 0.98, 1.13 ]
Heterogeneity: Chi2 = 57.58, df = 43 (P = 0.07); I2 =25%
Test for overall effect: Z = 1.34 (P = 0.18)
3 more than 17 weeks
Aapro 2008 IPD 169/231 169/232 1.07 [ 0.87, 1.32 ]
Bamias 2003 7/72 4/72 1.80 [ 0.53, 6.12 ]
Blohmer 2011 25/127 29/129 0.88 [ 0.51, 1.51 ]
Engert 2010 27/648 36/655 0.74 [ 0.45, 1.22 ]
Goss 2005 IPD 28/52 29/52 1.13 [ 0.67, 1.91 ]
Huddart 2002 IPD 8/48 8/47 1.19 [ 0.44, 3.21 ]
Leyland-Jones 2005 IPD 121/469 91/470 1.41 [ 1.08, 1.85 ]
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
(Continued . . . )
425Erythropoietin or darbepoetin for patients with cancer (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)












Littlewood 2001 IPD 155/251 82/124 0.80 [ 0.61, 1.05 ]
Milroy 2003 IPD 136/214 126/210 1.13 [ 0.88, 1.45 ]
Moebus 2007 IPD 59/324 56/319 1.01 [ 0.70, 1.46 ]
Mystakidou 2005 1/50 2/50 0.50 [ 0.05, 5.00 ]
Osterborg 1996 IPD 26/99 14/49 0.94 [ 0.49, 1.81 ]
Pirker 2008 IPD 243/299 254/301 0.94 [ 0.78, 1.13 ]
Pronzato 2010 IPD 23/110 20/113 1.05 [ 0.58, 1.91 ]
Ten Bokkel1998 IPD 6/87 2/33 1.27 [ 0.26, 6.34 ]
Thatcher 1999 IPD 7/86 3/44 1.13 [ 0.29, 4.36 ]
Untch 2011˙2 59/345 48/369 1.33 [ 0.91, 1.95 ]
Wilkinson 2006 IPD 3/121 0/61 4.48 [ 0.40, 50.03 ]
Subtotal (95% CI) 3633 3330 1.04 [ 0.95, 1.14 ]
Heterogeneity: Chi2 = 16.75, df = 17 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 0.88 (P = 0.38)
4 not reported
EPO-GER-20 IPD 7/48 8/45 0.71 [ 0.26, 1.95 ]
EPO-INT-1 IPD 11/165 3/81 1.88 [ 0.63, 5.64 ]
OBE/EPO-INT-03 IPD 5/35 6/37 1.07 [ 0.32, 3.56 ]
Subtotal (95% CI) 248 163 1.10 [ 0.58, 2.07 ]
Heterogeneity: Chi2 = 1.66, df = 2 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.29 (P = 0.77)
Total (95% CI) 1.05 [ 1.00, 1.11 ]
Heterogeneity: Chi2 = 95.40, df = 75 (P = 0.06); I2 =21%
Test for overall effect: Z = 1.97 (P = 0.048)
Test for subgroup differences: Chi2 = 0.44, df = 3 (P = 0.93), I2 =0.0%
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Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 5 Overall survival
Outcome: 11 Overall survival - iron supplementation












1 fixed iron supplementation
Christodoulou 2009 71/167 87/170 1.25 [ 0.92, 1.71 ]
Dunphy 1999 0/15 1/15 0.14 [ 0.00, 6.82 ]
Gupta 2009 17/58 14/57 0.90 [ 0.51, 1.59 ]
Hoskin 2009 IPD 74/151 75/149 1.04 [ 0.75, 1.44 ]
Huddart 2002 IPD 8/48 8/47 1.19 [ 0.44, 3.21 ]
Krzakowski 2008a 6/104 2/52 1.48 [ 0.33, 6.67 ]
Krzakowski 2008b 10/105 3/52 1.64 [ 0.49, 5.44 ]
Mystakidou 2005 1/50 2/50 0.50 [ 0.05, 5.00 ]
Untch 2011˙2 59/345 48/369 1.33 [ 0.91, 1.95 ]
Witzig 2005 IPD 121/174 119/170 1.13 [ 0.87, 1.46 ]
Subtotal (95% CI) 1217 1131 1.15 [ 0.99, 1.33 ]
Heterogeneity: Chi2 = 4.02, df = 9 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 1.87 (P = 0.061)
2 iron supplementation as necessary
Aapro 2008 IPD 169/231 169/232 1.07 [ 0.87, 1.32 ]
Abels 1993 IPD 13/65 12/59 0.96 [ 0.44, 2.10 ]
Boogaerts 2003 IPD 16/132 12/127 1.53 [ 0.72, 3.26 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Case 1993 IPD 10/81 9/76 1.11 [ 0.45, 2.73 ]
Cazzola 1995 IPD 5/114 3/29 0.69 [ 0.13, 3.57 ]
Chang 2005 IPD 27/176 28/178 0.94 [ 0.55, 1.60 ]
Charu 2007 IPD 8/228 2/59 0.89 [ 0.19, 4.18 ]
Dammacco 2001 IPD 1/69 7/76 0.23 [ 0.06, 0.90 ]
Del Mastro 1997 1/31 3/31 0.36 [ 0.05, 2.53 ]
Engert 2010 27/648 36/655 0.74 [ 0.45, 1.22 ]
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EPO-INT-1 IPD 11/165 3/81 1.88 [ 0.63, 5.64 ]
EPO-INT-3 IPD 9/135 3/65 1.55 [ 0.47, 5.10 ]
Fujisaka 2011 37/89 34/92 1.15 [ 0.72, 1.85 ]
Gordon 2008 IPD 11/164 5/56 0.74 [ 0.26, 2.14 ]
Goss 2005 IPD 28/52 29/52 1.13 [ 0.67, 1.91 ]
Grote 2005 IPD 100/109 101/115 1.17 [ 0.89, 1.54 ]
Hedenus 2003 IPD 101/176 82/173 1.32 [ 0.98, 1.77 ]
Henke 2003 IPD 109/180 89/171 1.27 [ 0.96, 1.68 ]
Henry 1995 IPD 7/67 10/65 0.68 [ 0.26, 1.77 ]
Hernandez 2009 IPD 17/196 20/195 0.84 [ 0.44, 1.60 ]
Kotasek 2002 IPD 4/129 0/32 3.49 [ 0.30, 40.45 ]
Kotasek 2003 IPD 4/208 1/51 0.99 [ 0.11, 8.84 ]
Kurz 1997 0/23 0/12 0.0 [ 0.0, 0.0 ]
Leyland-Jones 2005 IPD 121/469 91/470 1.41 [ 1.08, 1.85 ]
Littlewood 2001 IPD 155/251 82/124 0.80 [ 0.61, 1.05 ]
Milroy 2003 IPD 136/214 126/210 1.13 [ 0.88, 1.45 ]
ML17616 2006 1/30 0/30 7.39 [ 0.15, 372.38 ]
ML17620 2006 4/61 0/60 7.70 [ 1.05, 56.33 ]
O’Shaugnessy 2005 IPD 1/51 0/49 7.69 [ 0.15, 387.58 ]
Oberhoff 1998 IPD 9/116 10/111 0.62 [ 0.24, 1.59 ]
Osterborg 1996 IPD 26/99 14/49 0.94 [ 0.49, 1.81 ]
Osterborg 2002 IPD 110/173 109/176 1.04 [ 0.80, 1.36 ]
Overgaard 2009 144/255 119/259 1.26 [ 0.99, 1.61 ]
P-174 IPD 1/33 1/12 0.44 [ 0.03, 7.27 ]
Pirker 2008 IPD 243/299 254/301 0.94 [ 0.78, 1.13 ]
Pronzato 2010 IPD 23/110 20/113 1.05 [ 0.58, 1.91 ]
Quirt 1996 IPD 2/28 0/28 5.90 [ 0.36, 97.07 ]
Ray-Coquard 2009 IPD 75/110 84/108 0.79 [ 0.58, 1.08 ]
Razzouk 2004 2/112 2/110 0.98 [ 0.14, 7.03 ]
Rose 1994 IPD 16/142 6/79 1.66 [ 0.70, 3.92 ]
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Smith 2003 3/64 0/22 3.96 [ 0.29, 54.28 ]
Smith 2008 IPD 250/517 216/472 1.22 [ 1.02, 1.47 ]
Strauss 2008 IPD 8/34 5/40 2.00 [ 0.65, 6.13 ]
Ten Bokkel1998 IPD 6/87 2/33 1.27 [ 0.26, 6.34 ]
Thatcher 1999 IPD 7/86 3/44 1.13 [ 0.29, 4.36 ]
Thomas 2002 IPD 4/65 5/65 0.79 [ 0.21, 2.95 ]
Thomas 2008 IPD 22/58 17/56 1.28 [ 0.68, 2.40 ]
Throuvalas 2000 0/28 1/27 0.13 [ 0.00, 6.55 ]
Tjulandin 2010a 5/76 6/37 0.28 [ 0.07, 1.08 ]
Tjulandin 2010b 4/73 6/37 0.34 [ 0.09, 1.26 ]
Tjulandin 2011 6/95 5/91 1.16 [ 0.34, 3.90 ]
Tsuboi 2009 21/61 19/56 0.94 [ 0.57, 1.54 ]
Vansteenkiste 2002 IPD 101/159 118/161 0.79 [ 0.60, 1.04 ]
Wilkinson 2006 IPD 3/121 0/61 4.48 [ 0.40, 50.03 ]
Wright 2007 IPD 32/33 34/37 1.55 [ 0.94, 2.54 ]
Subtotal (95% CI) 7628 6260 1.07 [ 1.01, 1.14 ]
Heterogeneity: Chi2 = 64.77, df = 53 (P = 0.13); I2 =18%
Test for overall effect: Z = 2.21 (P = 0.027)
3 iron handled differently in the study arms
Blohmer 2011 25/127 29/129 0.88 [ 0.51, 1.51 ]
Debus 2006 IPD 146/195 159/190 0.81 [ 0.64, 1.02 ]
EPO-GER-20 IPD 7/48 8/45 0.71 [ 0.26, 1.95 ]
Machtay 2007 IPD 37/77 32/71 1.19 [ 0.74, 1.91 ]
Moebus 2007 IPD 59/324 56/319 1.01 [ 0.70, 1.46 ]
OBE/EPO-INT-03 IPD 5/35 6/37 1.07 [ 0.32, 3.56 ]
Rosen 2003 19/47 23/43 1.19 [ 0.65, 2.18 ]
Savonije 2005 IPD 132/211 61/104 1.14 [ 0.85, 1.53 ]
Sweeney 1998 0/24 0/24 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 1088 962 0.96 [ 0.84, 1.11 ]
Heterogeneity: Chi2 = 5.27, df = 7 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.54 (P = 0.59)
4 no explicit statement on iron supplementation or no iron given
Antonadou 2001 10/190 30/195 0.35 [ 0.19, 0.66 ]
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Bamias 2003 7/72 4/72 1.80 [ 0.53, 6.12 ]
Hedenus 2002 0/55 0/11 0.0 [ 0.0, 0.0 ]
Thompson 2000 3/45 0/21 4.52 [ 0.38, 53.37 ]
Winquist 2009 24/26 27/30 0.58 [ 0.33, 1.03 ]
Subtotal (95% CI) 388 329 0.56 [ 0.38, 0.83 ]
Heterogeneity: Chi2 = 8.36, df = 3 (P = 0.04); I2 =64%
Test for overall effect: Z = 2.86 (P = 0.0042)
5 explicitly stated NO IRON
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 1.05 [ 1.00, 1.11 ]
Heterogeneity: Chi2 = 95.40, df = 75 (P = 0.06); I2 =21%
Test for overall effect: Z = 1.97 (P = 0.048)
Test for subgroup differences: Chi2 = 12.99, df = 3 (P = 0.00), I2 =77%
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Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 5 Overall survival
Outcome: 12 Overall survival - publication












1 full text publication
Bamias 2003 7/72 4/72 1.80 [ 0.53, 6.12 ]
Blohmer 2011 25/127 29/129 0.88 [ 0.51, 1.51 ]
Christodoulou 2009 71/167 87/170 1.25 [ 0.92, 1.71 ]
Dunphy 1999 0/15 1/15 0.14 [ 0.00, 6.82 ]
Engert 2010 27/648 36/655 0.74 [ 0.45, 1.22 ]
Fujisaka 2011 37/89 34/92 1.15 [ 0.72, 1.85 ]
Gupta 2009 17/58 14/57 0.90 [ 0.51, 1.59 ]
Hedenus 2002 0/55 0/11 0.0 [ 0.0, 0.0 ]
Krzakowski 2008a 6/104 2/52 1.48 [ 0.33, 6.67 ]
Krzakowski 2008b 10/105 3/52 1.64 [ 0.49, 5.44 ]
Mystakidou 2005 1/50 2/50 0.50 [ 0.05, 5.00 ]
Razzouk 2004 2/112 2/110 0.98 [ 0.14, 7.03 ]
Rosen 2003 19/47 23/43 1.19 [ 0.65, 2.18 ]
Smith 2003 3/64 0/22 3.96 [ 0.29, 54.28 ]
Sweeney 1998 0/24 0/24 0.0 [ 0.0, 0.0 ]
Tjulandin 2010a 5/76 6/37 0.28 [ 0.07, 1.08 ]
Tjulandin 2010b 4/73 6/37 0.34 [ 0.09, 1.26 ]
Tjulandin 2011 6/95 5/91 1.16 [ 0.34, 3.90 ]
Tsuboi 2009 21/61 19/56 0.94 [ 0.57, 1.54 ]
Untch 2011˙2 59/345 48/369 1.33 [ 0.91, 1.95 ]
Subtotal (95% CI) 2387 2144 1.07 [ 0.92, 1.24 ]
Heterogeneity: Chi2 = 16.16, df = 17 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.82 (P = 0.41)
2 abstract publication
Antonadou 2001 10/190 30/195 0.35 [ 0.19, 0.66 ]
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ML17620 2006 4/61 0/60 7.70 [ 1.05, 56.33 ]
Overgaard 2009 144/255 119/259 1.26 [ 0.99, 1.61 ]
Subtotal (95% CI) 506 514 1.09 [ 0.87, 1.37 ]
Heterogeneity: Chi2 = 17.76, df = 2 (P = 0.00014); I2 =89%
Test for overall effect: Z = 0.76 (P = 0.45)
3 unpublished data
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Del Mastro 1997 1/31 3/31 0.36 [ 0.05, 2.53 ]
Kurz 1997 0/23 0/12 0.0 [ 0.0, 0.0 ]
Thompson 2000 3/45 0/21 4.52 [ 0.38, 53.37 ]
Throuvalas 2000 0/28 1/27 0.13 [ 0.00, 6.55 ]
Subtotal (95% CI) 177 141 0.73 [ 0.17, 3.05 ]
Heterogeneity: Chi2 = 3.35, df = 2 (P = 0.19); I2 =40%
Test for overall effect: Z = 0.43 (P = 0.67)
4 Data presented at FDA hearing
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Data taken from IPD review (Bohlius 2009)
Aapro 2008 IPD 169/231 169/232 1.07 [ 0.87, 1.32 ]
Abels 1993 IPD 13/65 12/59 0.96 [ 0.44, 2.10 ]
Boogaerts 2003 IPD 16/132 12/127 1.53 [ 0.72, 3.26 ]
Case 1993 IPD 10/81 9/76 1.11 [ 0.45, 2.73 ]
Cazzola 1995 IPD 5/114 3/29 0.69 [ 0.13, 3.57 ]
Chang 2005 IPD 27/176 28/178 0.94 [ 0.55, 1.60 ]
Charu 2007 IPD 8/228 2/59 0.89 [ 0.19, 4.18 ]
Dammacco 2001 IPD 1/69 7/76 0.23 [ 0.06, 0.90 ]
Debus 2006 IPD 146/195 159/190 0.81 [ 0.64, 1.02 ]
EPO-GER-20 IPD 7/48 8/45 0.71 [ 0.26, 1.95 ]
EPO-INT-1 IPD 11/165 3/81 1.88 [ 0.63, 5.64 ]
EPO-INT-3 IPD 9/135 3/65 1.55 [ 0.47, 5.10 ]
Gordon 2008 IPD 11/164 5/56 0.74 [ 0.26, 2.14 ]
Goss 2005 IPD 28/52 29/52 1.13 [ 0.67, 1.91 ]
Grote 2005 IPD 100/109 101/115 1.17 [ 0.89, 1.54 ]
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Hedenus 2003 IPD 101/176 82/173 1.32 [ 0.98, 1.77 ]
Henke 2003 IPD 109/180 89/171 1.27 [ 0.96, 1.68 ]
Henry 1995 IPD 7/67 10/65 0.68 [ 0.26, 1.77 ]
Hernandez 2009 IPD 17/196 20/195 0.84 [ 0.44, 1.60 ]
Hoskin 2009 IPD 74/151 75/149 1.04 [ 0.75, 1.44 ]
Huddart 2002 IPD 8/48 8/47 1.19 [ 0.44, 3.21 ]
Kotasek 2002 IPD 4/129 0/32 3.49 [ 0.30, 40.45 ]
Kotasek 2003 IPD 4/208 1/51 0.99 [ 0.11, 8.84 ]
Leyland-Jones 2005 IPD 121/469 91/470 1.41 [ 1.08, 1.85 ]
Littlewood 2001 IPD 155/251 82/124 0.80 [ 0.61, 1.05 ]
Machtay 2007 IPD 37/77 32/71 1.19 [ 0.74, 1.91 ]
Milroy 2003 IPD 136/214 126/210 1.13 [ 0.88, 1.45 ]
Moebus 2007 IPD 59/324 56/319 1.01 [ 0.70, 1.46 ]
O’Shaugnessy 2005 IPD 1/51 0/49 7.69 [ 0.15, 387.58 ]
OBE/EPO-INT-03 IPD 5/35 6/37 1.07 [ 0.32, 3.56 ]
Oberhoff 1998 IPD 9/116 10/111 0.62 [ 0.24, 1.59 ]
Osterborg 1996 IPD 26/99 14/49 0.94 [ 0.49, 1.81 ]
Osterborg 2002 IPD 110/173 109/176 1.04 [ 0.80, 1.36 ]
P-174 IPD 1/33 1/12 0.44 [ 0.03, 7.27 ]
Pirker 2008 IPD 243/299 254/301 0.94 [ 0.78, 1.13 ]
Pronzato 2010 IPD 23/110 20/113 1.05 [ 0.58, 1.91 ]
Quirt 1996 IPD 2/28 0/28 5.90 [ 0.36, 97.07 ]
Ray-Coquard 2009 IPD 75/110 84/108 0.79 [ 0.58, 1.08 ]
Rose 1994 IPD 16/142 6/79 1.66 [ 0.70, 3.92 ]
Savonije 2005 IPD 132/211 61/104 1.14 [ 0.85, 1.53 ]
Smith 2008 IPD 250/517 216/472 1.22 [ 1.02, 1.47 ]
Strauss 2008 IPD 8/34 5/40 2.00 [ 0.65, 6.13 ]
Ten Bokkel1998 IPD 6/87 2/33 1.27 [ 0.26, 6.34 ]
Thatcher 1999 IPD 7/86 3/44 1.13 [ 0.29, 4.36 ]
Thomas 2002 IPD 4/65 5/65 0.79 [ 0.21, 2.95 ]
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Thomas 2008 IPD 22/58 17/56 1.28 [ 0.68, 2.40 ]
Vansteenkiste 2002 IPD 101/159 118/161 0.79 [ 0.60, 1.04 ]
Wilkinson 2006 IPD 3/121 0/61 4.48 [ 0.40, 50.03 ]
Witzig 2005 IPD 121/174 119/170 1.13 [ 0.87, 1.46 ]
Wright 2007 IPD 32/33 34/37 1.55 [ 0.94, 2.54 ]
Subtotal (95% CI) 7195 5823 1.06 [ 1.00, 1.12 ]
Heterogeneity: Chi2 = 52.72, df = 49 (P = 0.33); I2 =7%
Test for overall effect: Z = 1.86 (P = 0.063)
6 clinical trial result information
ML17616 2006 1/30 0/30 7.39 [ 0.15, 372.38 ]
Subtotal (95% CI) 30 30 7.39 [ 0.15, 372.38 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
7 other
Winquist 2009 24/26 27/30 0.58 [ 0.33, 1.03 ]
Subtotal (95% CI) 26 30 0.58 [ 0.33, 1.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.85 (P = 0.065)
Total (95% CI) 1.05 [ 1.00, 1.11 ]
Heterogeneity: Chi2 = 95.40, df = 75 (P = 0.06); I2 =21%
Test for overall effect: Z = 1.97 (P = 0.048)
Test for subgroup differences: Chi2 = 5.41, df = 5 (P = 0.37), I2 =8%
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Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 5 Overall survival
Outcome: 13 Overall survival - time-to-event or binary mortality data












1 binary mortality data at end of study
Bamias 2003 7/72 4/72 1.80 [ 0.53, 6.12 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Del Mastro 1997 1/31 3/31 0.36 [ 0.05, 2.53 ]
Dunphy 1999 0/15 1/15 0.14 [ 0.00, 6.82 ]
Hedenus 2002 0/55 0/11 0.0 [ 0.0, 0.0 ]
Krzakowski 2008a 6/104 2/52 1.48 [ 0.33, 6.67 ]
Krzakowski 2008b 10/105 3/52 1.64 [ 0.49, 5.44 ]
Kurz 1997 0/23 0/12 0.0 [ 0.0, 0.0 ]
ML17616 2006 1/30 0/30 7.39 [ 0.15, 372.38 ]
ML17620 2006 4/61 0/60 7.70 [ 1.05, 56.33 ]
Mystakidou 2005 1/50 2/50 0.50 [ 0.05, 5.00 ]
Razzouk 2004 2/112 2/110 0.98 [ 0.14, 7.03 ]
Smith 2003 3/64 0/22 3.96 [ 0.29, 54.28 ]
Sweeney 1998 0/24 0/24 0.0 [ 0.0, 0.0 ]
Thompson 2000 3/45 0/21 4.52 [ 0.38, 53.37 ]
Throuvalas 2000 0/28 1/27 0.13 [ 0.00, 6.55 ]
Tjulandin 2010a 5/76 6/37 0.28 [ 0.07, 1.08 ]
Tjulandin 2010b 4/73 6/37 0.34 [ 0.09, 1.26 ]
Tjulandin 2011 6/95 5/91 1.16 [ 0.34, 3.90 ]
Subtotal (95% CI) 1113 804 1.02 [ 0.66, 1.60 ]
Heterogeneity: Chi2 = 18.82, df = 14 (P = 0.17); I2 =26%
Test for overall effect: Z = 0.10 (P = 0.92)
2 Data from IPD review
Aapro 2008 IPD 169/231 169/232 1.07 [ 0.87, 1.32 ]
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Abels 1993 IPD 13/65 12/59 0.96 [ 0.44, 2.10 ]
Boogaerts 2003 IPD 16/132 12/127 1.53 [ 0.72, 3.26 ]
Case 1993 IPD 10/81 9/76 1.11 [ 0.45, 2.73 ]
Cazzola 1995 IPD 5/114 3/29 0.69 [ 0.13, 3.57 ]
Chang 2005 IPD 27/176 28/178 0.94 [ 0.55, 1.60 ]
Charu 2007 IPD 8/228 2/59 0.89 [ 0.19, 4.18 ]
Dammacco 2001 IPD 1/69 7/76 0.23 [ 0.06, 0.90 ]
Debus 2006 IPD 146/195 159/190 0.81 [ 0.64, 1.02 ]
EPO-GER-20 IPD 7/48 8/45 0.71 [ 0.26, 1.95 ]
EPO-INT-1 IPD 11/165 3/81 1.88 [ 0.63, 5.64 ]
EPO-INT-3 IPD 9/135 3/65 1.55 [ 0.47, 5.10 ]
Gordon 2008 IPD 11/164 5/56 0.74 [ 0.26, 2.14 ]
Goss 2005 IPD 28/52 29/52 1.13 [ 0.67, 1.91 ]
Grote 2005 IPD 100/109 101/115 1.17 [ 0.89, 1.54 ]
Hedenus 2003 IPD 101/176 82/173 1.32 [ 0.98, 1.77 ]
Henke 2003 IPD 109/180 89/171 1.27 [ 0.96, 1.68 ]
Henry 1995 IPD 7/67 10/65 0.68 [ 0.26, 1.77 ]
Hernandez 2009 IPD 17/196 20/195 0.84 [ 0.44, 1.60 ]
Hoskin 2009 IPD 74/151 75/149 1.04 [ 0.75, 1.44 ]
Huddart 2002 IPD 8/48 8/47 1.19 [ 0.44, 3.21 ]
Kotasek 2002 IPD 4/129 0/32 3.49 [ 0.30, 40.45 ]
Kotasek 2003 IPD 4/208 1/51 0.99 [ 0.11, 8.84 ]
Leyland-Jones 2005 IPD 121/469 91/470 1.41 [ 1.08, 1.85 ]
Littlewood 2001 IPD 155/251 82/124 0.80 [ 0.61, 1.05 ]
Machtay 2007 IPD 37/77 32/71 1.19 [ 0.74, 1.91 ]
Milroy 2003 IPD 136/214 126/210 1.13 [ 0.88, 1.45 ]
Moebus 2007 IPD 59/324 56/319 1.01 [ 0.70, 1.46 ]
O’Shaugnessy 2005 IPD 1/51 0/49 7.69 [ 0.15, 387.58 ]
OBE/EPO-INT-03 IPD 5/35 6/37 1.07 [ 0.32, 3.56 ]
Oberhoff 1998 IPD 9/116 10/111 0.62 [ 0.24, 1.59 ]
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Osterborg 1996 IPD 26/99 14/49 0.94 [ 0.49, 1.81 ]
Osterborg 2002 IPD 110/173 109/176 1.04 [ 0.80, 1.36 ]
P-174 IPD 1/33 1/12 0.44 [ 0.03, 7.27 ]
Pirker 2008 IPD 243/299 254/301 0.94 [ 0.78, 1.13 ]
Pronzato 2010 IPD 23/110 20/113 1.05 [ 0.58, 1.91 ]
Quirt 1996 IPD 2/28 0/28 5.90 [ 0.36, 97.07 ]
Ray-Coquard 2009 IPD 75/110 84/108 0.79 [ 0.58, 1.08 ]
Rose 1994 IPD 16/142 6/79 1.66 [ 0.70, 3.92 ]
Savonije 2005 IPD 132/211 61/104 1.14 [ 0.85, 1.53 ]
Smith 2008 IPD 250/517 216/472 1.22 [ 1.02, 1.47 ]
Strauss 2008 IPD 8/34 5/40 2.00 [ 0.65, 6.13 ]
Ten Bokkel1998 IPD 6/87 2/33 1.27 [ 0.26, 6.34 ]
Thatcher 1999 IPD 7/86 3/44 1.13 [ 0.29, 4.36 ]
Thomas 2002 IPD 4/65 5/65 0.79 [ 0.21, 2.95 ]
Thomas 2008 IPD 22/58 17/56 1.28 [ 0.68, 2.40 ]
Vansteenkiste 2002 IPD 101/159 118/161 0.79 [ 0.60, 1.04 ]
Wilkinson 2006 IPD 3/121 0/61 4.48 [ 0.40, 50.03 ]
Witzig 2005 IPD 121/174 119/170 1.13 [ 0.87, 1.46 ]
Wright 2007 IPD 32/33 34/37 1.55 [ 0.94, 2.54 ]
Subtotal (95% CI) 7195 5823 1.06 [ 1.00, 1.12 ]
Heterogeneity: Chi2 = 52.72, df = 49 (P = 0.33); I2 =7%
Test for overall effect: Z = 1.86 (P = 0.063)
3 Cox regression analysis, Hazard ratio, log-rank test, p-value
Blohmer 2011 25/127 29/129 0.88 [ 0.51, 1.51 ]
Engert 2010 27/648 36/655 0.74 [ 0.45, 1.22 ]
Fujisaka 2011 37/89 34/92 1.15 [ 0.72, 1.85 ]
Overgaard 2009 144/255 119/259 1.26 [ 0.99, 1.61 ]
Tsuboi 2009 21/61 19/56 0.94 [ 0.57, 1.54 ]
Untch 2011˙2 59/345 48/369 1.33 [ 0.91, 1.95 ]
Winquist 2009 24/26 27/30 0.58 [ 0.33, 1.03 ]
Subtotal (95% CI) 1551 1590 1.07 [ 0.92, 1.25 ]
Heterogeneity: Chi2 = 10.25, df = 6 (P = 0.11); I2 =41%
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Test for overall effect: Z = 0.89 (P = 0.38)
4 Survival curve and p-value
Antonadou 2001 10/190 30/195 0.35 [ 0.19, 0.66 ]
Christodoulou 2009 71/167 87/170 1.25 [ 0.92, 1.71 ]
Gupta 2009 17/58 14/57 0.90 [ 0.51, 1.59 ]
Rosen 2003 19/47 23/43 1.19 [ 0.65, 2.18 ]
Subtotal (95% CI) 462 465 0.99 [ 0.78, 1.24 ]
Heterogeneity: Chi2 = 13.23, df = 3 (P = 0.004); I2 =77%
Test for overall effect: Z = 0.12 (P = 0.91)
Total (95% CI) 1.05 [ 1.00, 1.11 ]
Heterogeneity: Chi2 = 95.40, df = 75 (P = 0.06); I2 =21%
Test for overall effect: Z = 1.97 (P = 0.048)
Test for subgroup differences: Chi2 = 0.38, df = 3 (P = 0.94), I2 =0.0%
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Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 5 Overall survival
Outcome: 14 Overall survival - allocation concealment













Aapro 2008 IPD 169/231 169/232 1.07 [ 0.87, 1.32 ]
Blohmer 2011 25/127 29/129 0.88 [ 0.51, 1.51 ]
Boogaerts 2003 IPD 16/132 12/127 1.53 [ 0.72, 3.26 ]
Cazzola 1995 IPD 5/114 3/29 0.69 [ 0.13, 3.57 ]
Chang 2005 IPD 27/176 28/178 0.94 [ 0.55, 1.60 ]
Charu 2007 IPD 8/228 2/59 0.89 [ 0.19, 4.18 ]
Christodoulou 2009 71/167 87/170 1.25 [ 0.92, 1.71 ]
Del Mastro 1997 1/31 3/31 0.36 [ 0.05, 2.53 ]
EPO-INT-3 IPD 9/135 3/65 1.55 [ 0.47, 5.10 ]
Fujisaka 2011 37/89 34/92 1.15 [ 0.72, 1.85 ]
Gordon 2008 IPD 11/164 5/56 0.74 [ 0.26, 2.14 ]
Goss 2005 IPD 28/52 29/52 1.13 [ 0.67, 1.91 ]
Hedenus 2002 0/55 0/11 0.0 [ 0.0, 0.0 ]
Hedenus 2003 IPD 101/176 82/173 1.32 [ 0.98, 1.77 ]
Henke 2003 IPD 109/180 89/171 1.27 [ 0.96, 1.68 ]
Hernandez 2009 IPD 17/196 20/195 0.84 [ 0.44, 1.60 ]
Kotasek 2002 IPD 4/129 0/32 3.49 [ 0.30, 40.45 ]
Kotasek 2003 IPD 4/208 1/51 0.99 [ 0.11, 8.84 ]
Kurz 1997 0/23 0/12 0.0 [ 0.0, 0.0 ]
Leyland-Jones 2005 IPD 121/469 91/470 1.41 [ 1.08, 1.85 ]
Littlewood 2001 IPD 155/251 82/124 0.80 [ 0.61, 1.05 ]
Machtay 2007 IPD 37/77 32/71 1.19 [ 0.74, 1.91 ]
Milroy 2003 IPD 136/214 126/210 1.13 [ 0.88, 1.45 ]
Moebus 2007 IPD 59/324 56/319 1.01 [ 0.70, 1.46 ]
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O’Shaugnessy 2005 IPD 1/51 0/49 7.69 [ 0.15, 387.58 ]
OBE/EPO-INT-03 IPD 5/35 6/37 1.07 [ 0.32, 3.56 ]
Oberhoff 1998 IPD 9/116 10/111 0.62 [ 0.24, 1.59 ]
Osterborg 1996 IPD 26/99 14/49 0.94 [ 0.49, 1.81 ]
Osterborg 2002 IPD 110/173 109/176 1.04 [ 0.80, 1.36 ]
Overgaard 2009 144/255 119/259 1.26 [ 0.99, 1.61 ]
Pirker 2008 IPD 243/299 254/301 0.94 [ 0.78, 1.13 ]
Pronzato 2010 IPD 23/110 20/113 1.05 [ 0.58, 1.91 ]
Ray-Coquard 2009 IPD 75/110 84/108 0.79 [ 0.58, 1.08 ]
Razzouk 2004 2/112 2/110 0.98 [ 0.14, 7.03 ]
Savonije 2005 IPD 132/211 61/104 1.14 [ 0.85, 1.53 ]
Smith 2008 IPD 250/517 216/472 1.22 [ 1.02, 1.47 ]
Sweeney 1998 0/24 0/24 0.0 [ 0.0, 0.0 ]
Ten Bokkel1998 IPD 6/87 2/33 1.27 [ 0.26, 6.34 ]
Thomas 2002 IPD 4/65 5/65 0.79 [ 0.21, 2.95 ]
Thomas 2008 IPD 22/58 17/56 1.28 [ 0.68, 2.40 ]
Thompson 2000 3/45 0/21 4.52 [ 0.38, 53.37 ]
Throuvalas 2000 0/28 1/27 0.13 [ 0.00, 6.55 ]
Tsuboi 2009 21/61 19/56 0.94 [ 0.57, 1.54 ]
Vansteenkiste 2002 IPD 101/159 118/161 0.79 [ 0.60, 1.04 ]
Winquist 2009 24/26 27/30 0.58 [ 0.33, 1.03 ]
Witzig 2005 IPD 121/174 119/170 1.13 [ 0.87, 1.46 ]
Wright 2007 IPD 32/33 34/37 1.55 [ 0.94, 2.54 ]
Subtotal (95% CI) 6796 5628 1.08 [ 1.02, 1.14 ]
Heterogeneity: Chi2 = 45.36, df = 43 (P = 0.37); I2 =5%
Test for overall effect: Z = 2.47 (P = 0.014)
2 unclear
Abels 1993 IPD 13/65 12/59 0.96 [ 0.44, 2.10 ]
Antonadou 2001 10/190 30/195 0.35 [ 0.19, 0.66 ]
Bamias 2003 7/72 4/72 1.80 [ 0.53, 6.12 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Case 1993 IPD 10/81 9/76 1.11 [ 0.45, 2.73 ]
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Dammacco 2001 IPD 1/69 7/76 0.23 [ 0.06, 0.90 ]
Debus 2006 IPD 146/195 159/190 0.81 [ 0.64, 1.02 ]
Dunphy 1999 0/15 1/15 0.14 [ 0.00, 6.82 ]
Engert 2010 27/648 36/655 0.74 [ 0.45, 1.22 ]
EPO-GER-20 IPD 7/48 8/45 0.71 [ 0.26, 1.95 ]
EPO-INT-1 IPD 11/165 3/81 1.88 [ 0.63, 5.64 ]
Grote 2005 IPD 100/109 101/115 1.17 [ 0.89, 1.54 ]
Gupta 2009 17/58 14/57 0.90 [ 0.51, 1.59 ]
Henry 1995 IPD 7/67 10/65 0.68 [ 0.26, 1.77 ]
Hoskin 2009 IPD 74/151 75/149 1.04 [ 0.75, 1.44 ]
Huddart 2002 IPD 8/48 8/47 1.19 [ 0.44, 3.21 ]
Krzakowski 2008a 6/104 2/52 1.48 [ 0.33, 6.67 ]
Krzakowski 2008b 10/105 3/52 1.64 [ 0.49, 5.44 ]
ML17616 2006 1/30 0/30 7.39 [ 0.15, 372.38 ]
ML17620 2006 4/61 0/60 7.70 [ 1.05, 56.33 ]
Mystakidou 2005 1/50 2/50 0.50 [ 0.05, 5.00 ]
P-174 IPD 1/33 1/12 0.44 [ 0.03, 7.27 ]
Quirt 1996 IPD 2/28 0/28 5.90 [ 0.36, 97.07 ]
Rose 1994 IPD 16/142 6/79 1.66 [ 0.70, 3.92 ]
Rosen 2003 19/47 23/43 1.19 [ 0.65, 2.18 ]
Smith 2003 3/64 0/22 3.96 [ 0.29, 54.28 ]
Strauss 2008 IPD 8/34 5/40 2.00 [ 0.65, 6.13 ]
Thatcher 1999 IPD 7/86 3/44 1.13 [ 0.29, 4.36 ]
Tjulandin 2010a 5/76 6/37 0.28 [ 0.07, 1.08 ]
Tjulandin 2010b 4/73 6/37 0.34 [ 0.09, 1.26 ]
Tjulandin 2011 6/95 5/91 1.16 [ 0.34, 3.90 ]
Untch 2011˙2 59/345 48/369 1.33 [ 0.91, 1.95 ]
Wilkinson 2006 IPD 3/121 0/61 4.48 [ 0.40, 50.03 ]
Subtotal (95% CI) 3525 3054 0.97 [ 0.87, 1.09 ]
Heterogeneity: Chi2 = 47.60, df = 31 (P = 0.03); I2 =35%
Test for overall effect: Z = 0.51 (P = 0.61)
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Total (95% CI) 1.05 [ 1.00, 1.11 ]
Heterogeneity: Chi2 = 95.40, df = 75 (P = 0.06); I2 =21%
Test for overall effect: Z = 1.97 (P = 0.048)
Test for subgroup differences: Chi2 = 2.45, df = 1 (P = 0.12), I2 =59%
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Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 5 Overall survival
Outcome: 15 Overall survival - masking













Abels 1993 IPD 13/65 12/59 0.96 [ 0.44, 2.10 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Case 1993 IPD 10/81 9/76 1.11 [ 0.45, 2.73 ]
Dammacco 2001 IPD 1/69 7/76 0.23 [ 0.06, 0.90 ]
Engert 2010 27/648 36/655 0.74 [ 0.45, 1.22 ]
EPO-INT-1 IPD 11/165 3/81 1.88 [ 0.63, 5.64 ]
EPO-INT-3 IPD 9/135 3/65 1.55 [ 0.47, 5.10 ]
Fujisaka 2011 37/89 34/92 1.15 [ 0.72, 1.85 ]
Gordon 2008 IPD 11/164 5/56 0.74 [ 0.26, 2.14 ]
Goss 2005 IPD 28/52 29/52 1.13 [ 0.67, 1.91 ]
Grote 2005 IPD 100/109 101/115 1.17 [ 0.89, 1.54 ]
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Hedenus 2002 0/55 0/11 0.0 [ 0.0, 0.0 ]
Hedenus 2003 IPD 101/176 82/173 1.32 [ 0.98, 1.77 ]
Henke 2003 IPD 109/180 89/171 1.27 [ 0.96, 1.68 ]
Henry 1995 IPD 7/67 10/65 0.68 [ 0.26, 1.77 ]
Hernandez 2009 IPD 17/196 20/195 0.84 [ 0.44, 1.60 ]
Kotasek 2002 IPD 4/129 0/32 3.49 [ 0.30, 40.45 ]
Kotasek 2003 IPD 4/208 1/51 0.99 [ 0.11, 8.84 ]
Krzakowski 2008a 6/104 2/52 1.48 [ 0.33, 6.67 ]
Krzakowski 2008b 10/105 3/52 1.64 [ 0.49, 5.44 ]
Kurz 1997 0/23 0/12 0.0 [ 0.0, 0.0 ]
Leyland-Jones 2005 IPD 121/469 91/470 1.41 [ 1.08, 1.85 ]
Littlewood 2001 IPD 155/251 82/124 0.80 [ 0.61, 1.05 ]
Mystakidou 2005 1/50 2/50 0.50 [ 0.05, 5.00 ]
O’Shaugnessy 2005 IPD 1/51 0/49 7.69 [ 0.15, 387.58 ]
Osterborg 2002 IPD 110/173 109/176 1.04 [ 0.80, 1.36 ]
P-174 IPD 1/33 1/12 0.44 [ 0.03, 7.27 ]
Pirker 2008 IPD 243/299 254/301 0.94 [ 0.78, 1.13 ]
Quirt 1996 IPD 2/28 0/28 5.90 [ 0.36, 97.07 ]
Razzouk 2004 2/112 2/110 0.98 [ 0.14, 7.03 ]
Rose 1994 IPD 16/142 6/79 1.66 [ 0.70, 3.92 ]
Smith 2003 3/64 0/22 3.96 [ 0.29, 54.28 ]
Smith 2008 IPD 250/517 216/472 1.22 [ 1.02, 1.47 ]
Thompson 2000 3/45 0/21 4.52 [ 0.38, 53.37 ]
Tjulandin 2010a 5/76 6/37 0.28 [ 0.07, 1.08 ]
Tjulandin 2010b 4/73 6/37 0.34 [ 0.09, 1.26 ]
Tjulandin 2011 6/95 5/91 1.16 [ 0.34, 3.90 ]
Tsuboi 2009 21/61 19/56 0.94 [ 0.57, 1.54 ]
Vansteenkiste 2002 IPD 101/159 118/161 0.79 [ 0.60, 1.04 ]
Winquist 2009 24/26 27/30 0.58 [ 0.33, 1.03 ]
Witzig 2005 IPD 121/174 119/170 1.13 [ 0.87, 1.46 ]
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Wright 2007 IPD 32/33 34/37 1.55 [ 0.94, 2.54 ]
Subtotal (95% CI) 5801 4724 1.06 [ 0.99, 1.14 ]
Heterogeneity: Chi2 = 53.03, df = 38 (P = 0.05); I2 =28%
Test for overall effect: Z = 1.77 (P = 0.077)
2 unblinded
Aapro 2008 IPD 169/231 169/232 1.07 [ 0.87, 1.32 ]
Antonadou 2001 10/190 30/195 0.35 [ 0.19, 0.66 ]
Bamias 2003 7/72 4/72 1.80 [ 0.53, 6.12 ]
Blohmer 2011 25/127 29/129 0.88 [ 0.51, 1.51 ]
Boogaerts 2003 IPD 16/132 12/127 1.53 [ 0.72, 3.26 ]
Cazzola 1995 IPD 5/114 3/29 0.69 [ 0.13, 3.57 ]
Chang 2005 IPD 27/176 28/178 0.94 [ 0.55, 1.60 ]
Charu 2007 IPD 8/228 2/59 0.89 [ 0.19, 4.18 ]
Christodoulou 2009 71/167 87/170 1.25 [ 0.92, 1.71 ]
Debus 2006 IPD 146/195 159/190 0.81 [ 0.64, 1.02 ]
Del Mastro 1997 1/31 3/31 0.36 [ 0.05, 2.53 ]
Dunphy 1999 0/15 1/15 0.14 [ 0.00, 6.82 ]
EPO-GER-20 IPD 7/48 8/45 0.71 [ 0.26, 1.95 ]
Gupta 2009 17/58 14/57 0.90 [ 0.51, 1.59 ]
Hoskin 2009 IPD 74/151 75/149 1.04 [ 0.75, 1.44 ]
Huddart 2002 IPD 8/48 8/47 1.19 [ 0.44, 3.21 ]
Machtay 2007 IPD 37/77 32/71 1.19 [ 0.74, 1.91 ]
Milroy 2003 IPD 136/214 126/210 1.13 [ 0.88, 1.45 ]
ML17616 2006 1/30 0/30 7.39 [ 0.15, 372.38 ]
ML17620 2006 4/61 0/60 7.70 [ 1.05, 56.33 ]
Moebus 2007 IPD 59/324 56/319 1.01 [ 0.70, 1.46 ]
OBE/EPO-INT-03 IPD 5/35 6/37 1.07 [ 0.32, 3.56 ]
Oberhoff 1998 IPD 9/116 10/111 0.62 [ 0.24, 1.59 ]
Osterborg 1996 IPD 26/99 14/49 0.94 [ 0.49, 1.81 ]
Overgaard 2009 144/255 119/259 1.26 [ 0.99, 1.61 ]
Pronzato 2010 IPD 23/110 20/113 1.05 [ 0.58, 1.91 ]
Ray-Coquard 2009 IPD 75/110 84/108 0.79 [ 0.58, 1.08 ]
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Rosen 2003 19/47 23/43 1.19 [ 0.65, 2.18 ]
Savonije 2005 IPD 132/211 61/104 1.14 [ 0.85, 1.53 ]
Strauss 2008 IPD 8/34 5/40 2.00 [ 0.65, 6.13 ]
Sweeney 1998 0/24 0/24 0.0 [ 0.0, 0.0 ]
Ten Bokkel1998 IPD 6/87 2/33 1.27 [ 0.26, 6.34 ]
Thatcher 1999 IPD 7/86 3/44 1.13 [ 0.29, 4.36 ]
Thomas 2002 IPD 4/65 5/65 0.79 [ 0.21, 2.95 ]
Thomas 2008 IPD 22/58 17/56 1.28 [ 0.68, 2.40 ]
Throuvalas 2000 0/28 1/27 0.13 [ 0.00, 6.55 ]
Untch 2011˙2 59/345 48/369 1.33 [ 0.91, 1.95 ]
Wilkinson 2006 IPD 3/121 0/61 4.48 [ 0.40, 50.03 ]
Subtotal (95% CI) 4520 3958 1.04 [ 0.96, 1.12 ]
Heterogeneity: Chi2 = 42.17, df = 36 (P = 0.22); I2 =15%
Test for overall effect: Z = 0.99 (P = 0.32)
Total (95% CI) 1.05 [ 1.00, 1.11 ]
Heterogeneity: Chi2 = 95.40, df = 75 (P = 0.06); I2 =21%
Test for overall effect: Z = 1.97 (P = 0.048)
Test for subgroup differences: Chi2 = 0.20, df = 1 (P = 0.65), I2 =0.0%
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Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 5 Overall survival
Outcome: 16 Overall survival - intention-to-treat












1 ITT or less than 10% of participants per study arm excluded
Aapro 2008 IPD 169/231 169/232 1.07 [ 0.87, 1.32 ]
Abels 1993 IPD 13/65 12/59 0.96 [ 0.44, 2.10 ]
Bamias 2003 7/72 4/72 1.80 [ 0.53, 6.12 ]
Blohmer 2011 25/127 29/129 0.88 [ 0.51, 1.51 ]
Boogaerts 2003 IPD 16/132 12/127 1.53 [ 0.72, 3.26 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Case 1993 IPD 10/81 9/76 1.11 [ 0.45, 2.73 ]
Cazzola 1995 IPD 5/114 3/29 0.69 [ 0.13, 3.57 ]
Chang 2005 IPD 27/176 28/178 0.94 [ 0.55, 1.60 ]
Charu 2007 IPD 8/228 2/59 0.89 [ 0.19, 4.18 ]
Dammacco 2001 IPD 1/69 7/76 0.23 [ 0.06, 0.90 ]
Debus 2006 IPD 146/195 159/190 0.81 [ 0.64, 1.02 ]
Del Mastro 1997 1/31 3/31 0.36 [ 0.05, 2.53 ]
Dunphy 1999 0/15 1/15 0.14 [ 0.00, 6.82 ]
Engert 2010 27/648 36/655 0.74 [ 0.45, 1.22 ]
EPO-GER-20 IPD 7/48 8/45 0.71 [ 0.26, 1.95 ]
EPO-INT-1 IPD 11/165 3/81 1.88 [ 0.63, 5.64 ]
EPO-INT-3 IPD 9/135 3/65 1.55 [ 0.47, 5.10 ]
Fujisaka 2011 37/89 34/92 1.15 [ 0.72, 1.85 ]
Gordon 2008 IPD 11/164 5/56 0.74 [ 0.26, 2.14 ]
Goss 2005 IPD 28/52 29/52 1.13 [ 0.67, 1.91 ]
Grote 2005 IPD 100/109 101/115 1.17 [ 0.89, 1.54 ]
Gupta 2009 17/58 14/57 0.90 [ 0.51, 1.59 ]
Hedenus 2002 0/55 0/11 0.0 [ 0.0, 0.0 ]
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Hedenus 2003 IPD 101/176 82/173 1.32 [ 0.98, 1.77 ]
Henke 2003 IPD 109/180 89/171 1.27 [ 0.96, 1.68 ]
Henry 1995 IPD 7/67 10/65 0.68 [ 0.26, 1.77 ]
Hernandez 2009 IPD 17/196 20/195 0.84 [ 0.44, 1.60 ]
Hoskin 2009 IPD 74/151 75/149 1.04 [ 0.75, 1.44 ]
Huddart 2002 IPD 8/48 8/47 1.19 [ 0.44, 3.21 ]
Kotasek 2002 IPD 4/129 0/32 3.49 [ 0.30, 40.45 ]
Kotasek 2003 IPD 4/208 1/51 0.99 [ 0.11, 8.84 ]
Krzakowski 2008a 6/104 2/52 1.48 [ 0.33, 6.67 ]
Krzakowski 2008b 10/105 3/52 1.64 [ 0.49, 5.44 ]
Kurz 1997 0/23 0/12 0.0 [ 0.0, 0.0 ]
Leyland-Jones 2005 IPD 121/469 91/470 1.41 [ 1.08, 1.85 ]
Littlewood 2001 IPD 155/251 82/124 0.80 [ 0.61, 1.05 ]
Machtay 2007 IPD 37/77 32/71 1.19 [ 0.74, 1.91 ]
Milroy 2003 IPD 136/214 126/210 1.13 [ 0.88, 1.45 ]
Moebus 2007 IPD 59/324 56/319 1.01 [ 0.70, 1.46 ]
Mystakidou 2005 1/50 2/50 0.50 [ 0.05, 5.00 ]
O’Shaugnessy 2005 IPD 1/51 0/49 7.69 [ 0.15, 387.58 ]
OBE/EPO-INT-03 IPD 5/35 6/37 1.07 [ 0.32, 3.56 ]
Oberhoff 1998 IPD 9/116 10/111 0.62 [ 0.24, 1.59 ]
Osterborg 1996 IPD 26/99 14/49 0.94 [ 0.49, 1.81 ]
Osterborg 2002 IPD 110/173 109/176 1.04 [ 0.80, 1.36 ]
Overgaard 2009 144/255 119/259 1.26 [ 0.99, 1.61 ]
P-174 IPD 1/33 1/12 0.44 [ 0.03, 7.27 ]
Pirker 2008 IPD 243/299 254/301 0.94 [ 0.78, 1.13 ]
Pronzato 2010 IPD 23/110 20/113 1.05 [ 0.58, 1.91 ]
Quirt 1996 IPD 2/28 0/28 5.90 [ 0.36, 97.07 ]
Ray-Coquard 2009 IPD 75/110 84/108 0.79 [ 0.58, 1.08 ]
Razzouk 2004 2/112 2/110 0.98 [ 0.14, 7.03 ]
Rose 1994 IPD 16/142 6/79 1.66 [ 0.70, 3.92 ]
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Rosen 2003 19/47 23/43 1.19 [ 0.65, 2.18 ]
Savonije 2005 IPD 132/211 61/104 1.14 [ 0.85, 1.53 ]
Smith 2003 3/64 0/22 3.96 [ 0.29, 54.28 ]
Smith 2008 IPD 250/517 216/472 1.22 [ 1.02, 1.47 ]
Strauss 2008 IPD 8/34 5/40 2.00 [ 0.65, 6.13 ]
Ten Bokkel1998 IPD 6/87 2/33 1.27 [ 0.26, 6.34 ]
Thatcher 1999 IPD 7/86 3/44 1.13 [ 0.29, 4.36 ]
Thomas 2002 IPD 4/65 5/65 0.79 [ 0.21, 2.95 ]
Thomas 2008 IPD 22/58 17/56 1.28 [ 0.68, 2.40 ]
Thompson 2000 3/45 0/21 4.52 [ 0.38, 53.37 ]
Throuvalas 2000 0/28 1/27 0.13 [ 0.00, 6.55 ]
Tjulandin 2010a 5/76 6/37 0.28 [ 0.07, 1.08 ]
Tjulandin 2010b 4/73 6/37 0.34 [ 0.09, 1.26 ]
Tjulandin 2011 6/95 5/91 1.16 [ 0.34, 3.90 ]
Tsuboi 2009 21/61 19/56 0.94 [ 0.57, 1.54 ]
Untch 2011˙2 59/345 48/369 1.33 [ 0.91, 1.95 ]
Vansteenkiste 2002 IPD 101/159 118/161 0.79 [ 0.60, 1.04 ]
Wilkinson 2006 IPD 3/121 0/61 4.48 [ 0.40, 50.03 ]
Winquist 2009 24/26 27/30 0.58 [ 0.33, 1.03 ]
Witzig 2005 IPD 121/174 119/170 1.13 [ 0.87, 1.46 ]
Wright 2007 IPD 32/33 34/37 1.55 [ 0.94, 2.54 ]
Subtotal (95% CI) 9849 8203 1.05 [ 1.00, 1.11 ]
Heterogeneity: Chi2 = 77.52, df = 71 (P = 0.28); I2 =8%
Test for overall effect: Z = 1.99 (P = 0.047)
2 more than 10% of participants per study arm excluded
Christodoulou 2009 71/167 87/170 1.25 [ 0.92, 1.71 ]
Sweeney 1998 0/24 0/24 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 191 194 1.25 [ 0.92, 1.71 ]
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 1.40 (P = 0.16)
3 Unclear
Antonadou 2001 10/190 30/195 0.35 [ 0.19, 0.66 ]
ML17616 2006 1/30 0/30 7.39 [ 0.15, 372.38 ]
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ML17620 2006 4/61 0/60 7.70 [ 1.05, 56.33 ]
Subtotal (95% CI) 281 285 0.49 [ 0.27, 0.89 ]
Heterogeneity: Chi2 = 10.27, df = 2 (P = 0.01); I2 =81%
Test for overall effect: Z = 2.36 (P = 0.018)
Total (95% CI) 1.05 [ 1.00, 1.11 ]
Heterogeneity: Chi2 = 95.40, df = 75 (P = 0.06); I2 =21%
Test for overall effect: Z = 1.97 (P = 0.048)
Test for subgroup differences: Chi2 = 7.61, df = 2 (P = 0.02), I2 =74%
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Analysis 5.17. Comparison 5 Overall survival, Outcome 17 Overall survival - follow up.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 5 Overall survival
Outcome: 17 Overall survival - follow up












1 follow up longer than on-study mortality
Aapro 2008 IPD 169/231 169/232 1.07 [ 0.87, 1.32 ]
Antonadou 2001 10/190 30/195 0.35 [ 0.19, 0.66 ]
Blohmer 2011 25/127 29/129 0.88 [ 0.51, 1.51 ]
Boogaerts 2003 IPD 16/132 12/127 1.53 [ 0.72, 3.26 ]
Cazzola 1995 IPD 5/114 3/29 0.69 [ 0.13, 3.57 ]
Chang 2005 IPD 27/176 28/178 0.94 [ 0.55, 1.60 ]
Christodoulou 2009 71/167 87/170 1.25 [ 0.92, 1.71 ]
Debus 2006 IPD 146/195 159/190 0.81 [ 0.64, 1.02 ]
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Del Mastro 1997 1/31 3/31 0.36 [ 0.05, 2.53 ]
Engert 2010 27/648 36/655 0.74 [ 0.45, 1.22 ]
EPO-GER-20 IPD 7/48 8/45 0.71 [ 0.26, 1.95 ]
EPO-INT-1 IPD 11/165 3/81 1.88 [ 0.63, 5.64 ]
Fujisaka 2011 37/89 34/92 1.15 [ 0.72, 1.85 ]
Goss 2005 IPD 28/52 29/52 1.13 [ 0.67, 1.91 ]
Grote 2005 IPD 100/109 101/115 1.17 [ 0.89, 1.54 ]
Gupta 2009 17/58 14/57 0.90 [ 0.51, 1.59 ]
Hedenus 2003 IPD 101/176 82/173 1.32 [ 0.98, 1.77 ]
Henke 2003 IPD 109/180 89/171 1.27 [ 0.96, 1.68 ]
Hoskin 2009 IPD 74/151 75/149 1.04 [ 0.75, 1.44 ]
Huddart 2002 IPD 8/48 8/47 1.19 [ 0.44, 3.21 ]
Littlewood 2001 IPD 155/251 82/124 0.80 [ 0.61, 1.05 ]
Machtay 2007 IPD 37/77 32/71 1.19 [ 0.74, 1.91 ]
Milroy 2003 IPD 136/214 126/210 1.13 [ 0.88, 1.45 ]
Moebus 2007 IPD 59/324 56/319 1.01 [ 0.70, 1.46 ]
OBE/EPO-INT-03 IPD 5/35 6/37 1.07 [ 0.32, 3.56 ]
Osterborg 1996 IPD 26/99 14/49 0.94 [ 0.49, 1.81 ]
Osterborg 2002 IPD 110/173 109/176 1.04 [ 0.80, 1.36 ]
Overgaard 2009 144/255 119/259 1.26 [ 0.99, 1.61 ]
Pirker 2008 IPD 243/299 254/301 0.94 [ 0.78, 1.13 ]
Pronzato 2010 IPD 23/110 20/113 1.05 [ 0.58, 1.91 ]
Ray-Coquard 2009 IPD 75/110 84/108 0.79 [ 0.58, 1.08 ]
Rosen 2003 19/47 23/43 1.19 [ 0.65, 2.18 ]
Savonije 2005 IPD 132/211 61/104 1.14 [ 0.85, 1.53 ]
Smith 2008 IPD 250/517 216/472 1.22 [ 1.02, 1.47 ]
Strauss 2008 IPD 8/34 5/40 2.00 [ 0.65, 6.13 ]
Ten Bokkel1998 IPD 6/87 2/33 1.27 [ 0.26, 6.34 ]
Thomas 2008 IPD 22/58 17/56 1.28 [ 0.68, 2.40 ]
Tsuboi 2009 21/61 19/56 0.94 [ 0.57, 1.54 ]
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Untch 2011˙2 59/345 48/369 1.33 [ 0.91, 1.95 ]
Vansteenkiste 2002 IPD 101/159 118/161 0.79 [ 0.60, 1.04 ]
Wilkinson 2006 IPD 3/121 0/61 4.48 [ 0.40, 50.03 ]
Winquist 2009 24/26 27/30 0.58 [ 0.33, 1.03 ]
Witzig 2005 IPD 121/174 119/170 1.13 [ 0.87, 1.46 ]
Wright 2007 IPD 32/33 34/37 1.55 [ 0.94, 2.54 ]
Subtotal (95% CI) 6907 6317 1.05 [ 0.99, 1.10 ]
Heterogeneity: Chi2 = 59.95, df = 43 (P = 0.04); I2 =28%
Test for overall effect: Z = 1.63 (P = 0.10)
2 Short term follow up
Abels 1993 IPD 13/65 12/59 0.96 [ 0.44, 2.10 ]
Bamias 2003 7/72 4/72 1.80 [ 0.53, 6.12 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Case 1993 IPD 10/81 9/76 1.11 [ 0.45, 2.73 ]
Charu 2007 IPD 8/228 2/59 0.89 [ 0.19, 4.18 ]
Dammacco 2001 IPD 1/69 7/76 0.23 [ 0.06, 0.90 ]
Dunphy 1999 0/15 1/15 0.14 [ 0.00, 6.82 ]
EPO-INT-3 IPD 9/135 3/65 1.55 [ 0.47, 5.10 ]
Gordon 2008 IPD 11/164 5/56 0.74 [ 0.26, 2.14 ]
Hedenus 2002 0/55 0/11 0.0 [ 0.0, 0.0 ]
Henry 1995 IPD 7/67 10/65 0.68 [ 0.26, 1.77 ]
Hernandez 2009 IPD 17/196 20/195 0.84 [ 0.44, 1.60 ]
Kotasek 2002 IPD 4/129 0/32 3.49 [ 0.30, 40.45 ]
Kotasek 2003 IPD 4/208 1/51 0.99 [ 0.11, 8.84 ]
Krzakowski 2008a 6/104 2/52 1.48 [ 0.33, 6.67 ]
Krzakowski 2008b 10/105 3/52 1.64 [ 0.49, 5.44 ]
Kurz 1997 0/23 0/12 0.0 [ 0.0, 0.0 ]
Leyland-Jones 2005 IPD 121/469 91/470 1.41 [ 1.08, 1.85 ]
ML17616 2006 1/30 0/30 7.39 [ 0.15, 372.38 ]
ML17620 2006 4/61 0/60 7.70 [ 1.05, 56.33 ]
Mystakidou 2005 1/50 2/50 0.50 [ 0.05, 5.00 ]
O’Shaugnessy 2005 IPD 1/51 0/49 7.69 [ 0.15, 387.58 ]
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Oberhoff 1998 IPD 9/116 10/111 0.62 [ 0.24, 1.59 ]
P-174 IPD 1/33 1/12 0.44 [ 0.03, 7.27 ]
Quirt 1996 IPD 2/28 0/28 5.90 [ 0.36, 97.07 ]
Razzouk 2004 2/112 2/110 0.98 [ 0.14, 7.03 ]
Rose 1994 IPD 16/142 6/79 1.66 [ 0.70, 3.92 ]
Smith 2003 3/64 0/22 3.96 [ 0.29, 54.28 ]
Sweeney 1998 0/24 0/24 0.0 [ 0.0, 0.0 ]
Thatcher 1999 IPD 7/86 3/44 1.13 [ 0.29, 4.36 ]
Thomas 2002 IPD 4/65 5/65 0.79 [ 0.21, 2.95 ]
Thompson 2000 3/45 0/21 4.52 [ 0.38, 53.37 ]
Throuvalas 2000 0/28 1/27 0.13 [ 0.00, 6.55 ]
Tjulandin 2010a 5/76 6/37 0.28 [ 0.07, 1.08 ]
Tjulandin 2010b 4/73 6/37 0.34 [ 0.09, 1.26 ]
Tjulandin 2011 6/95 5/91 1.16 [ 0.34, 3.90 ]
Subtotal (95% CI) 3414 2365 1.14 [ 0.95, 1.36 ]
Heterogeneity: Chi2 = 34.67, df = 31 (P = 0.30); I2 =11%
Test for overall effect: Z = 1.42 (P = 0.16)
Total (95% CI) 1.05 [ 1.00, 1.11 ]
Heterogeneity: Chi2 = 95.40, df = 75 (P = 0.06); I2 =21%
Test for overall effect: Z = 1.97 (P = 0.048)
Test for subgroup differences: Chi2 = 0.78, df = 1 (P = 0.38), I2 =0.0%
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Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 5 Overall survival
Outcome: 18 Overall survival - follow up and design












1 Long term follow up and designed for long term follow up
Aapro 2008 IPD 169/231 169/232 1.07 [ 0.87, 1.32 ]
Blohmer 2011 25/127 29/129 0.88 [ 0.51, 1.51 ]
Chang 2005 IPD 27/176 28/178 0.94 [ 0.55, 1.60 ]
Debus 2006 IPD 146/195 159/190 0.81 [ 0.64, 1.02 ]
Engert 2010 27/648 36/655 0.74 [ 0.45, 1.22 ]
Goss 2005 IPD 28/52 29/52 1.13 [ 0.67, 1.91 ]
Grote 2005 IPD 100/109 101/115 1.17 [ 0.89, 1.54 ]
Hedenus 2003 IPD 101/176 82/173 1.32 [ 0.98, 1.77 ]
Henke 2003 IPD 109/180 89/171 1.27 [ 0.96, 1.68 ]
Hoskin 2009 IPD 74/151 75/149 1.04 [ 0.75, 1.44 ]
Littlewood 2001 IPD 155/251 82/124 0.80 [ 0.61, 1.05 ]
Machtay 2007 IPD 37/77 32/71 1.19 [ 0.74, 1.91 ]
Milroy 2003 IPD 136/214 126/210 1.13 [ 0.88, 1.45 ]
Moebus 2007 IPD 59/324 56/319 1.01 [ 0.70, 1.46 ]
OBE/EPO-INT-03 IPD 5/35 6/37 1.07 [ 0.32, 3.56 ]
Overgaard 2009 144/255 119/259 1.26 [ 0.99, 1.61 ]
Pirker 2008 IPD 243/299 254/301 0.94 [ 0.78, 1.13 ]
Pronzato 2010 IPD 23/110 20/113 1.05 [ 0.58, 1.91 ]
Rosen 2003 19/47 23/43 1.19 [ 0.65, 2.18 ]
Savonije 2005 IPD 132/211 61/104 1.14 [ 0.85, 1.53 ]
Smith 2008 IPD 250/517 216/472 1.22 [ 1.02, 1.47 ]
Strauss 2008 IPD 8/34 5/40 2.00 [ 0.65, 6.13 ]
Thomas 2008 IPD 22/58 17/56 1.28 [ 0.68, 2.40 ]
Untch 2011˙2 59/345 48/369 1.33 [ 0.91, 1.95 ]
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Vansteenkiste 2002 IPD 101/159 118/161 0.79 [ 0.60, 1.04 ]
Subtotal (95% CI) 4981 4723 1.06 [ 0.99, 1.12 ]
Heterogeneity: Chi2 = 30.66, df = 24 (P = 0.16); I2 =22%
Test for overall effect: Z = 1.78 (P = 0.075)
2 Long term follow up but not designed for long term follow up
Boogaerts 2003 IPD 16/132 12/127 1.53 [ 0.72, 3.26 ]
Cazzola 1995 IPD 5/114 3/29 0.69 [ 0.13, 3.57 ]
EPO-GER-20 IPD 7/48 8/45 0.71 [ 0.26, 1.95 ]
EPO-INT-1 IPD 11/165 3/81 1.88 [ 0.63, 5.64 ]
Huddart 2002 IPD 8/48 8/47 1.19 [ 0.44, 3.21 ]
Osterborg 1996 IPD 26/99 14/49 0.94 [ 0.49, 1.81 ]
Osterborg 2002 IPD 110/173 109/176 1.04 [ 0.80, 1.36 ]
Ray-Coquard 2009 IPD 75/110 84/108 0.79 [ 0.58, 1.08 ]
Ten Bokkel1998 IPD 6/87 2/33 1.27 [ 0.26, 6.34 ]
Wilkinson 2006 IPD 3/121 0/61 4.48 [ 0.40, 50.03 ]
Witzig 2005 IPD 121/174 119/170 1.13 [ 0.87, 1.46 ]
Subtotal (95% CI) 1271 926 1.02 [ 0.89, 1.18 ]
Heterogeneity: Chi2 = 7.91, df = 10 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.32 (P = 0.75)
3 Long term follow up and design unclear
Antonadou 2001 10/190 30/195 0.35 [ 0.19, 0.66 ]
Christodoulou 2009 71/167 87/170 1.25 [ 0.92, 1.71 ]
Del Mastro 1997 1/31 3/31 0.36 [ 0.05, 2.53 ]
Gupta 2009 17/58 14/57 0.90 [ 0.51, 1.59 ]
Tsuboi 2009 21/61 19/56 0.94 [ 0.57, 1.54 ]
Winquist 2009 24/26 27/30 0.58 [ 0.33, 1.03 ]
Wright 2007 IPD 32/33 34/37 1.55 [ 0.94, 2.54 ]
Subtotal (95% CI) 566 576 0.96 [ 0.79, 1.16 ]
Heterogeneity: Chi2 = 20.26, df = 6 (P = 0.002); I2 =70%
Test for overall effect: Z = 0.41 (P = 0.68)
4 Short term follow up but designed for long term follow up
Fujisaka 2011 37/89 34/92 1.15 [ 0.72, 1.85 ]
Leyland-Jones 2005 IPD 121/469 91/470 1.41 [ 1.08, 1.85 ]
Thomas 2002 IPD 4/65 5/65 0.79 [ 0.21, 2.95 ]
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Subtotal (95% CI) 623 627 1.32 [ 1.05, 1.66 ]
Heterogeneity: Chi2 = 1.14, df = 2 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 2.36 (P = 0.018)
5 Short term follow up and not designed for long term follow up
Abels 1993 IPD 13/65 12/59 0.96 [ 0.44, 2.10 ]
Bamias 2003 7/72 4/72 1.80 [ 0.53, 6.12 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Case 1993 IPD 10/81 9/76 1.11 [ 0.45, 2.73 ]
Charu 2007 IPD 8/228 2/59 0.89 [ 0.19, 4.18 ]
Dammacco 2001 IPD 1/69 7/76 0.23 [ 0.06, 0.90 ]
Dunphy 1999 0/15 1/15 0.14 [ 0.00, 6.82 ]
EPO-INT-3 IPD 9/135 3/65 1.55 [ 0.47, 5.10 ]
Gordon 2008 IPD 11/164 5/56 0.74 [ 0.26, 2.14 ]
Hedenus 2002 0/55 0/11 0.0 [ 0.0, 0.0 ]
Henry 1995 IPD 7/67 10/65 0.68 [ 0.26, 1.77 ]
Hernandez 2009 IPD 17/196 20/195 0.84 [ 0.44, 1.60 ]
Kotasek 2002 IPD 4/129 0/32 3.49 [ 0.30, 40.45 ]
Kotasek 2003 IPD 4/208 1/51 0.99 [ 0.11, 8.84 ]
Krzakowski 2008a 6/104 2/52 1.48 [ 0.33, 6.67 ]
Krzakowski 2008b 10/105 3/52 1.64 [ 0.49, 5.44 ]
Kurz 1997 0/23 0/12 0.0 [ 0.0, 0.0 ]
ML17616 2006 1/30 0/30 7.39 [ 0.15, 372.38 ]
ML17620 2006 4/61 0/60 7.70 [ 1.05, 56.33 ]
Mystakidou 2005 1/50 2/50 0.50 [ 0.05, 5.00 ]
O’Shaugnessy 2005 IPD 1/51 0/49 7.69 [ 0.15, 387.58 ]
Oberhoff 1998 IPD 9/116 10/111 0.62 [ 0.24, 1.59 ]
P-174 IPD 1/33 1/12 0.44 [ 0.03, 7.27 ]
Quirt 1996 IPD 2/28 0/28 5.90 [ 0.36, 97.07 ]
Razzouk 2004 2/112 2/110 0.98 [ 0.14, 7.03 ]
Rose 1994 IPD 16/142 6/79 1.66 [ 0.70, 3.92 ]
Smith 2003 3/64 0/22 3.96 [ 0.29, 54.28 ]
Sweeney 1998 0/24 0/24 0.0 [ 0.0, 0.0 ]
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Thatcher 1999 IPD 7/86 3/44 1.13 [ 0.29, 4.36 ]
Thompson 2000 3/45 0/21 4.52 [ 0.38, 53.37 ]
Throuvalas 2000 0/28 1/27 0.13 [ 0.00, 6.55 ]
Tjulandin 2010a 5/76 6/37 0.28 [ 0.07, 1.08 ]
Tjulandin 2010b 4/73 6/37 0.34 [ 0.09, 1.26 ]
Tjulandin 2011 6/95 5/91 1.16 [ 0.34, 3.90 ]
Subtotal (95% CI) 2880 1830 0.97 [ 0.76, 1.23 ]
Heterogeneity: Chi2 = 30.24, df = 29 (P = 0.40); I2 =4%
Test for overall effect: Z = 0.24 (P = 0.81)
6 short term follow up and design unclear
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 1.05 [ 1.00, 1.11 ]
Heterogeneity: Chi2 = 95.40, df = 75 (P = 0.06); I2 =21%
Test for overall effect: Z = 1.97 (P = 0.048)
Test for subgroup differences: Chi2 = 5.19, df = 4 (P = 0.27), I2 =23%
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Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 5 Overall survival
Outcome: 19 Overall survival- experimental arms merged












Aapro 2008 IPD 169/231 169/232 1.07 [ 0.87, 1.32 ]
Abels 1993 IPD 13/65 12/59 0.96 [ 0.44, 2.10 ]
Antonadou 2001 10/190 30/195 0.35 [ 0.19, 0.66 ]
Bamias 2003 7/72 4/72 1.80 [ 0.53, 6.12 ]
Blohmer 2011 25/127 29/129 0.88 [ 0.51, 1.51 ]
Boogaerts 2003 IPD 16/132 12/127 1.53 [ 0.72, 3.26 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Case 1993 IPD 10/81 9/76 1.11 [ 0.45, 2.73 ]
Cazzola 1995 IPD 5/114 3/29 0.69 [ 0.13, 3.57 ]
Chang 2005 IPD 27/176 28/178 0.94 [ 0.55, 1.60 ]
Charu 2007 IPD 8/228 2/59 0.89 [ 0.19, 4.18 ]
Christodoulou 2009 71/167 87/170 1.25 [ 0.92, 1.71 ]
Dammacco 2001 IPD 1/69 7/76 0.23 [ 0.06, 0.90 ]
Debus 2006 IPD 146/195 159/190 0.81 [ 0.64, 1.02 ]
Del Mastro 1997 1/31 3/31 0.36 [ 0.05, 2.53 ]
Dunphy 1999 0/15 1/15 0.14 [ 0.00, 6.82 ]
Engert 2010 27/648 36/655 0.74 [ 0.45, 1.22 ]
EPO-GER-20 IPD 7/48 8/45 0.71 [ 0.26, 1.95 ]
EPO-INT-1 IPD 11/165 3/81 1.88 [ 0.63, 5.64 ]
EPO-INT-3 IPD 9/135 3/65 1.55 [ 0.47, 5.10 ]
Fujisaka 2011 37/89 34/92 1.15 [ 0.72, 1.85 ]
Gordon 2008 IPD 11/164 5/56 0.74 [ 0.26, 2.14 ]
Goss 2005 IPD 28/52 29/52 1.13 [ 0.67, 1.91 ]
Grote 2005 IPD 100/109 101/115 1.17 [ 0.89, 1.54 ]
Gupta 2009 17/58 14/57 0.90 [ 0.51, 1.59 ]
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Hedenus 2002 0/55 0/11 0.0 [ 0.0, 0.0 ]
Hedenus 2003 IPD 101/176 82/173 1.32 [ 0.98, 1.77 ]
Henke 2003 IPD 109/180 89/171 1.27 [ 0.96, 1.68 ]
Henry 1995 IPD 7/67 10/65 0.68 [ 0.26, 1.77 ]
Hernandez 2009 IPD 17/196 20/195 0.84 [ 0.44, 1.60 ]
Hoskin 2009 IPD 74/151 75/149 1.04 [ 0.75, 1.44 ]
Huddart 2002 IPD 8/48 8/47 1.19 [ 0.44, 3.21 ]
Kotasek 2002 IPD 4/129 0/32 3.49 [ 0.30, 40.45 ]
Kotasek 2003 IPD 4/208 1/51 0.99 [ 0.11, 8.84 ]
Krzakowski 2008 16/209 5/104 1.57 [ 0.62, 4.03 ]
Kurz 1997 0/23 0/12 0.0 [ 0.0, 0.0 ]
Leyland-Jones 2005 IPD 121/469 91/470 1.41 [ 1.08, 1.85 ]
Littlewood 2001 IPD 155/251 82/124 0.80 [ 0.61, 1.05 ]
Machtay 2007 IPD 37/77 32/71 1.19 [ 0.74, 1.91 ]
Milroy 2003 IPD 136/214 126/210 1.13 [ 0.88, 1.45 ]
ML17616 2006 1/30 0/30 7.39 [ 0.15, 372.38 ]
ML17620 2006 4/61 0/60 7.70 [ 1.05, 56.33 ]
Moebus 2007 IPD 59/324 56/319 1.01 [ 0.70, 1.46 ]
Mystakidou 2005 1/50 2/50 0.50 [ 0.05, 5.00 ]
O’Shaugnessy 2005 IPD 1/51 0/49 7.69 [ 0.15, 387.58 ]
OBE/EPO-INT-03 IPD 5/35 6/37 1.07 [ 0.32, 3.56 ]
Oberhoff 1998 IPD 9/116 10/111 0.62 [ 0.24, 1.59 ]
Osterborg 1996 IPD 26/99 14/49 0.94 [ 0.49, 1.81 ]
Osterborg 2002 IPD 110/173 109/176 1.04 [ 0.80, 1.36 ]
Overgaard 2009 144/255 119/259 1.26 [ 0.99, 1.61 ]
P-174 IPD 1/33 1/12 0.44 [ 0.03, 7.27 ]
Pirker 2008 IPD 243/299 254/301 0.94 [ 0.78, 1.13 ]
Pronzato 2010 IPD 23/110 20/113 1.05 [ 0.58, 1.91 ]
Quirt 1996 IPD 2/28 0/28 5.90 [ 0.36, 97.07 ]
Ray-Coquard 2009 IPD 75/110 84/108 0.79 [ 0.58, 1.08 ]
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Razzouk 2004 2/112 2/110 0.98 [ 0.14, 7.03 ]
Rose 1994 IPD 16/142 6/79 1.66 [ 0.70, 3.92 ]
Rosen 2003 19/47 23/43 1.19 [ 0.65, 2.18 ]
Savonije 2005 IPD 132/211 61/104 1.14 [ 0.85, 1.53 ]
Smith 2003 3/64 0/22 3.96 [ 0.29, 54.28 ]
Smith 2008 IPD 250/517 216/472 1.22 [ 1.02, 1.47 ]
Strauss 2008 IPD 8/34 5/40 2.00 [ 0.65, 6.13 ]
Sweeney 1998 0/24 0/24 0.0 [ 0.0, 0.0 ]
Ten Bokkel1998 IPD 6/87 2/33 1.27 [ 0.26, 6.34 ]
Thatcher 1999 IPD 7/86 3/44 1.13 [ 0.29, 4.36 ]
Thomas 2002 IPD 4/65 5/65 0.79 [ 0.21, 2.95 ]
Thomas 2008 IPD 22/58 17/56 1.28 [ 0.68, 2.40 ]
Thompson 2000 3/45 0/21 4.52 [ 0.38, 53.37 ]
Throuvalas 2000 0/28 1/27 0.13 [ 0.00, 6.55 ]
Tjulandin 2010 9/149 12/74 0.31 [ 0.12, 0.79 ]
Tjulandin 2011 6/95 5/91 1.16 [ 0.34, 3.90 ]
Tsuboi 2009 21/61 19/56 0.94 [ 0.57, 1.54 ]
Untch 2011˙2 59/345 48/369 1.33 [ 0.91, 1.95 ]
Vansteenkiste 2002 IPD 101/159 118/161 0.79 [ 0.60, 1.04 ]
Wilkinson 2006 IPD 3/121 0/61 4.48 [ 0.40, 50.03 ]
Winquist 2009 24/26 27/30 0.58 [ 0.33, 1.03 ]
Witzig 2005 IPD 121/174 119/170 1.13 [ 0.87, 1.46 ]
Wright 2007 IPD 32/33 34/37 1.55 [ 0.94, 2.54 ]
Total (95% CI) 1.05 [ 1.00, 1.11 ]
Heterogeneity: Chi2 = 95.35, df = 73 (P = 0.04); I2 =23%
Test for overall effect: Z = 1.97 (P = 0.048)
Test for subgroup differences: Not applicable
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Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 5 Overall survival
Outcome: 20 Overall survival- experimental arms merged sens pos












Abels 1993 IPD 13/65 12/59 0.96 [ 0.44, 2.10 ]
Antonadou 2001 10/190 30/195 0.35 [ 0.19, 0.66 ]
Bamias 2003 7/72 4/72 1.80 [ 0.53, 6.12 ]
Blohmer 2011 25/127 29/129 0.88 [ 0.51, 1.51 ]
Boogaerts 2003 IPD 16/132 12/127 1.53 [ 0.72, 3.26 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Case 1993 IPD 10/81 9/76 1.11 [ 0.45, 2.73 ]
Cazzola 1995 IPD 5/114 3/29 0.69 [ 0.13, 3.57 ]
Chang 2005 IPD 27/176 28/178 0.94 [ 0.55, 1.60 ]
Charu 2007 IPD 8/228 2/59 0.89 [ 0.19, 4.18 ]
Christodoulou 2009 71/167 87/170 1.25 [ 0.92, 1.71 ]
Dammacco 2001 IPD 1/69 7/76 0.23 [ 0.06, 0.90 ]
Debus 2006 IPD 146/195 159/190 0.81 [ 0.64, 1.02 ]
Del Mastro 1997 1/31 3/31 0.36 [ 0.05, 2.53 ]
Dunphy 1999 0/15 1/15 0.14 [ 0.00, 6.82 ]
Engert 2010 27/648 36/655 0.74 [ 0.45, 1.22 ]
EPO-GER-20 IPD 7/48 8/45 0.71 [ 0.26, 1.95 ]
EPO-INT-1 IPD 11/165 3/81 1.88 [ 0.63, 5.64 ]
EPO-INT-3 IPD 9/135 3/65 1.55 [ 0.47, 5.10 ]
Fujisaka 2011 37/89 34/92 1.15 [ 0.72, 1.85 ]
Gordon 2008 IPD 11/164 5/56 0.74 [ 0.26, 2.14 ]
Goss 2005 IPD 28/52 29/52 1.13 [ 0.67, 1.91 ]
Grote 2005 IPD 100/109 101/115 1.17 [ 0.89, 1.54 ]
Gupta 2009 17/58 14/57 0.90 [ 0.51, 1.59 ]
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Hedenus 2002 0/55 0/11 0.0 [ 0.0, 0.0 ]
Hedenus 2003 IPD 101/176 82/173 1.32 [ 0.98, 1.77 ]
Henke 2003 IPD 109/180 89/171 1.27 [ 0.96, 1.68 ]
Henry 1995 IPD 7/67 10/65 0.68 [ 0.26, 1.77 ]
Hernandez 2009 IPD 17/196 20/195 0.84 [ 0.44, 1.60 ]
Hoskin 2009 IPD 74/151 75/149 1.04 [ 0.75, 1.44 ]
Huddart 2002 IPD 8/48 8/47 1.19 [ 0.44, 3.21 ]
Kotasek 2002 IPD 4/129 0/32 3.49 [ 0.30, 40.45 ]
Kotasek 2003 IPD 4/208 1/51 0.99 [ 0.11, 8.84 ]
Krzakowski 2008 16/209 5/104 1.57 [ 0.62, 4.03 ]
Kurz 1997 0/23 0/12 0.0 [ 0.0, 0.0 ]
Leyland-Jones 2005 IPD 121/469 91/470 1.41 [ 1.08, 1.85 ]
Littlewood 2001 IPD 155/251 82/124 0.80 [ 0.61, 1.05 ]
Machtay 2007 IPD 37/77 32/71 1.19 [ 0.74, 1.91 ]
Milroy 2003 IPD 136/214 126/210 1.13 [ 0.88, 1.45 ]
ML17616 2006 1/30 0/30 7.39 [ 0.15, 372.38 ]
ML17620 2006 4/61 0/60 7.70 [ 1.05, 56.33 ]
Moebus 2007 IPD 59/324 56/319 1.01 [ 0.70, 1.46 ]
Mystakidou 2005 1/50 2/50 0.50 [ 0.05, 5.00 ]
O’Shaugnessy 2005 IPD 1/51 0/49 7.69 [ 0.15, 387.58 ]
OBE/EPO-INT-03 IPD 5/35 6/37 1.07 [ 0.32, 3.56 ]
Oberhoff 1998 IPD 9/116 10/111 0.62 [ 0.24, 1.59 ]
Osterborg 1996 IPD 26/99 14/49 0.94 [ 0.49, 1.81 ]
Osterborg 2002 IPD 110/173 109/176 1.04 [ 0.80, 1.36 ]
Overgaard 2009 144/255 119/259 1.26 [ 0.99, 1.61 ]
P-174 IPD 1/33 1/12 0.44 [ 0.03, 7.27 ]
Pirker 2008 IPD 243/299 254/301 0.94 [ 0.78, 1.13 ]
Pronzato 2010 IPD 23/110 20/113 1.05 [ 0.58, 1.91 ]
Quirt 1996 IPD 2/28 0/28 5.90 [ 0.36, 97.07 ]
Ray-Coquard 2009 IPD 75/110 84/108 0.79 [ 0.58, 1.08 ]
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Razzouk 2004 2/112 2/110 0.98 [ 0.14, 7.03 ]
Rose 1994 IPD 16/142 6/79 1.66 [ 0.70, 3.92 ]
Rosen 2003 19/47 23/43 1.19 [ 0.65, 2.18 ]
Savonije 2005 IPD 132/211 61/104 1.14 [ 0.85, 1.53 ]
Smith 2003 3/64 0/22 3.96 [ 0.29, 54.28 ]
Strauss 2008 IPD 8/34 5/40 2.00 [ 0.65, 6.13 ]
Sweeney 1998 0/24 0/24 0.0 [ 0.0, 0.0 ]
Ten Bokkel1998 IPD 6/87 2/33 1.27 [ 0.26, 6.34 ]
Thatcher 1999 IPD 7/86 3/44 1.13 [ 0.29, 4.36 ]
Thomas 2002 IPD 4/65 5/65 0.79 [ 0.21, 2.95 ]
Thomas 2008 IPD 22/58 17/56 1.28 [ 0.68, 2.40 ]
Thompson 2000 3/45 0/21 4.52 [ 0.38, 53.37 ]
Throuvalas 2000 0/28 1/27 0.13 [ 0.00, 6.55 ]
Tjulandin 2010 9/149 12/74 0.31 [ 0.12, 0.79 ]
Tjulandin 2011 6/95 5/91 1.16 [ 0.34, 3.90 ]
Tsuboi 2009 21/61 19/56 0.94 [ 0.57, 1.54 ]
Untch 2011˙2 59/345 48/369 1.33 [ 0.91, 1.95 ]
Vansteenkiste 2002 IPD 101/159 118/161 0.79 [ 0.60, 1.04 ]
Wilkinson 2006 IPD 3/121 0/61 4.48 [ 0.40, 50.03 ]
Winquist 2009 24/26 27/30 0.58 [ 0.33, 1.03 ]
Witzig 2005 IPD 121/174 119/170 1.13 [ 0.87, 1.46 ]
Wright 2007 IPD 32/33 34/37 1.55 [ 0.94, 2.54 ]
Total (95% CI) 1.04 [ 0.98, 1.10 ]
Heterogeneity: Chi2 = 92.54, df = 71 (P = 0.04); I2 =23%
Test for overall effect: Z = 1.31 (P = 0.19)
Test for subgroup differences: Not applicable
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Outcome: 21 Overall survival- experimental arms merged sens neg












Aapro 2008 IPD 169/231 169/232 1.07 [ 0.87, 1.32 ]
Abels 1993 IPD 13/65 12/59 0.96 [ 0.44, 2.10 ]
Antonadou 2001 10/190 30/195 0.35 [ 0.19, 0.66 ]
Bamias 2003 7/72 4/72 1.80 [ 0.53, 6.12 ]
Blohmer 2011 25/127 29/129 0.88 [ 0.51, 1.51 ]
Boogaerts 2003 IPD 16/132 12/127 1.53 [ 0.72, 3.26 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Case 1993 IPD 10/81 9/76 1.11 [ 0.45, 2.73 ]
Cazzola 1995 IPD 5/114 3/29 0.69 [ 0.13, 3.57 ]
Chang 2005 IPD 27/176 28/178 0.94 [ 0.55, 1.60 ]
Charu 2007 IPD 8/228 2/59 0.89 [ 0.19, 4.18 ]
Christodoulou 2009 71/167 87/170 1.25 [ 0.92, 1.71 ]
Dammacco 2001 IPD 1/69 7/76 0.23 [ 0.06, 0.90 ]
Del Mastro 1997 1/31 3/31 0.36 [ 0.05, 2.53 ]
Dunphy 1999 0/15 1/15 0.14 [ 0.00, 6.82 ]
Engert 2010 27/648 36/655 0.74 [ 0.45, 1.22 ]
EPO-GER-20 IPD 7/48 8/45 0.71 [ 0.26, 1.95 ]
EPO-INT-1 IPD 11/165 3/81 1.88 [ 0.63, 5.64 ]
EPO-INT-3 IPD 9/135 3/65 1.55 [ 0.47, 5.10 ]
Fujisaka 2011 37/89 34/92 1.15 [ 0.72, 1.85 ]
Gordon 2008 IPD 11/164 5/56 0.74 [ 0.26, 2.14 ]
Goss 2005 IPD 28/52 29/52 1.13 [ 0.67, 1.91 ]
Grote 2005 IPD 100/109 101/115 1.17 [ 0.89, 1.54 ]
Gupta 2009 17/58 14/57 0.90 [ 0.51, 1.59 ]
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Hedenus 2002 0/55 0/11 0.0 [ 0.0, 0.0 ]
Hedenus 2003 IPD 101/176 82/173 1.32 [ 0.98, 1.77 ]
Henke 2003 IPD 109/180 89/171 1.27 [ 0.96, 1.68 ]
Henry 1995 IPD 7/67 10/65 0.68 [ 0.26, 1.77 ]
Hernandez 2009 IPD 17/196 20/195 0.84 [ 0.44, 1.60 ]
Hoskin 2009 IPD 74/151 75/149 1.04 [ 0.75, 1.44 ]
Huddart 2002 IPD 8/48 8/47 1.19 [ 0.44, 3.21 ]
Kotasek 2002 IPD 4/129 0/32 3.49 [ 0.30, 40.45 ]
Kotasek 2003 IPD 4/208 1/51 0.99 [ 0.11, 8.84 ]
Krzakowski 2008 16/209 5/104 1.57 [ 0.62, 4.03 ]
Kurz 1997 0/23 0/12 0.0 [ 0.0, 0.0 ]
Leyland-Jones 2005 IPD 121/469 91/470 1.41 [ 1.08, 1.85 ]
Littlewood 2001 IPD 155/251 82/124 0.80 [ 0.61, 1.05 ]
Machtay 2007 IPD 37/77 32/71 1.19 [ 0.74, 1.91 ]
Milroy 2003 IPD 136/214 126/210 1.13 [ 0.88, 1.45 ]
ML17616 2006 1/30 0/30 7.39 [ 0.15, 372.38 ]
ML17620 2006 4/61 0/60 7.70 [ 1.05, 56.33 ]
Moebus 2007 IPD 59/324 56/319 1.01 [ 0.70, 1.46 ]
Mystakidou 2005 1/50 2/50 0.50 [ 0.05, 5.00 ]
O’Shaugnessy 2005 IPD 1/51 0/49 7.69 [ 0.15, 387.58 ]
OBE/EPO-INT-03 IPD 5/35 6/37 1.07 [ 0.32, 3.56 ]
Oberhoff 1998 IPD 9/116 10/111 0.62 [ 0.24, 1.59 ]
Osterborg 1996 IPD 26/99 14/49 0.94 [ 0.49, 1.81 ]
Osterborg 2002 IPD 110/173 109/176 1.04 [ 0.80, 1.36 ]
Overgaard 2009 144/255 119/259 1.26 [ 0.99, 1.61 ]
P-174 IPD 1/33 1/12 0.44 [ 0.03, 7.27 ]
Pronzato 2010 IPD 23/110 20/113 1.05 [ 0.58, 1.91 ]
Quirt 1996 IPD 2/28 0/28 5.90 [ 0.36, 97.07 ]
Ray-Coquard 2009 IPD 75/110 84/108 0.79 [ 0.58, 1.08 ]
Razzouk 2004 2/112 2/110 0.98 [ 0.14, 7.03 ]
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Rose 1994 IPD 16/142 6/79 1.66 [ 0.70, 3.92 ]
Rosen 2003 19/47 23/43 1.19 [ 0.65, 2.18 ]
Savonije 2005 IPD 132/211 61/104 1.14 [ 0.85, 1.53 ]
Smith 2003 3/64 0/22 3.96 [ 0.29, 54.28 ]
Smith 2008 IPD 250/517 216/472 1.22 [ 1.02, 1.47 ]
Strauss 2008 IPD 8/34 5/40 2.00 [ 0.65, 6.13 ]
Sweeney 1998 0/24 0/24 0.0 [ 0.0, 0.0 ]
Ten Bokkel1998 IPD 6/87 2/33 1.27 [ 0.26, 6.34 ]
Thatcher 1999 IPD 7/86 3/44 1.13 [ 0.29, 4.36 ]
Thomas 2002 IPD 4/65 5/65 0.79 [ 0.21, 2.95 ]
Thomas 2008 IPD 22/58 17/56 1.28 [ 0.68, 2.40 ]
Thompson 2000 3/45 0/21 4.52 [ 0.38, 53.37 ]
Throuvalas 2000 0/28 1/27 0.13 [ 0.00, 6.55 ]
Tjulandin 2010 9/149 12/74 0.31 [ 0.12, 0.79 ]
Tjulandin 2011 6/95 5/91 1.16 [ 0.34, 3.90 ]
Tsuboi 2009 21/61 19/56 0.94 [ 0.57, 1.54 ]
Untch 2011˙2 59/345 48/369 1.33 [ 0.91, 1.95 ]
Vansteenkiste 2002 IPD 101/159 118/161 0.79 [ 0.60, 1.04 ]
Wilkinson 2006 IPD 3/121 0/61 4.48 [ 0.40, 50.03 ]
Winquist 2009 24/26 27/30 0.58 [ 0.33, 1.03 ]
Witzig 2005 IPD 121/174 119/170 1.13 [ 0.87, 1.46 ]
Wright 2007 IPD 32/33 34/37 1.55 [ 0.94, 2.54 ]
Total (95% CI) 1.08 [ 1.02, 1.14 ]
Heterogeneity: Chi2 = 87.87, df = 71 (P = 0.09); I2 =19%
Test for overall effect: Z = 2.77 (P = 0.0057)
Test for subgroup differences: Not applicable
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Comparison: 5 Overall survival
Outcome: 22 Overall survival - sensitivity analysis baseline Hb












1 Hb < 10 g/dL
Abels 1993 IPD 13/65 12/59 0.96 [ 0.44, 2.10 ]
Antonadou 2001 10/190 30/195 0.35 [ 0.19, 0.66 ]
Boogaerts 2003 IPD 16/132 12/127 1.53 [ 0.72, 3.26 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Case 1993 IPD 10/81 9/76 1.11 [ 0.45, 2.73 ]
Cazzola 1995 IPD 5/114 3/29 0.69 [ 0.13, 3.57 ]
Dammacco 2001 IPD 1/69 7/76 0.23 [ 0.06, 0.90 ]
Fujisaka 2011 37/89 34/92 1.15 [ 0.72, 1.85 ]
Hedenus 2002 0/55 0/11 0.0 [ 0.0, 0.0 ]
Hedenus 2003 IPD 101/176 82/173 1.32 [ 0.98, 1.76 ]
Henry 1995 IPD 7/67 10/65 0.68 [ 0.26, 1.77 ]
Kotasek 2003 IPD 4/208 1/51 0.99 [ 0.11, 8.84 ]
Krzakowski 2008a 6/104 2/52 1.48 [ 0.33, 6.67 ]
Krzakowski 2008b 10/105 3/52 1.64 [ 0.49, 5.44 ]
Kurz 1997 0/23 0/12 0.0 [ 0.0, 0.0 ]
Littlewood 2001 IPD 155/251 82/124 0.80 [ 0.61, 1.05 ]
ML17616 2006 1/30 0/30 7.39 [ 0.15, 372.38 ]
Oberhoff 1998 IPD 9/116 10/111 0.62 [ 0.24, 1.59 ]
Osterborg 1996 IPD 26/99 14/49 0.94 [ 0.49, 1.81 ]
Osterborg 2002 IPD 110/173 109/176 1.04 [ 0.80, 1.36 ]
Razzouk 2004 2/112 2/110 0.98 [ 0.14, 7.03 ]
Rose 1994 IPD 16/142 6/79 1.66 [ 0.70, 3.92 ]
Smith 2003 3/64 0/22 3.96 [ 0.29, 54.28 ]
Smith 2008 IPD 250/517 216/472 1.22 [ 1.02, 1.47 ]
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Thompson 2000 3/45 0/21 4.52 [ 0.38, 53.37 ]
Tjulandin 2010a 5/76 6/37 0.28 [ 0.07, 1.08 ]
Tjulandin 2010b 4/73 6/37 0.34 [ 0.09, 1.26 ]
Tjulandin 2011 6/95 5/91 1.16 [ 0.34, 3.90 ]
Witzig 2005 IPD 121/174 119/170 1.13 [ 0.87, 1.46 ]
Subtotal (95% CI) 3495 2649 1.06 [ 0.96, 1.17 ]
Heterogeneity: Chi2 = 40.70, df = 25 (P = 0.02); I2 =39%
Test for overall effect: Z = 1.13 (P = 0.26)
2 Hb 10 to 12 g/dL
Aapro 2008 IPD 169/231 169/232 1.07 [ 0.87, 1.32 ]
Bamias 2003 7/72 4/72 1.80 [ 0.53, 6.12 ]
Blohmer 2011 25/127 29/129 0.88 [ 0.51, 1.51 ]
Chang 2005 IPD 27/176 28/178 0.94 [ 0.55, 1.60 ]
Charu 2007 IPD 8/228 2/59 0.89 [ 0.19, 4.18 ]
Christodoulou 2009 71/167 87/170 1.25 [ 0.92, 1.71 ]
EPO-INT-1 IPD 11/165 3/81 1.88 [ 0.63, 5.64 ]
EPO-INT-3 IPD 9/135 3/65 1.55 [ 0.47, 5.10 ]
Gordon 2008 IPD 11/164 5/56 0.74 [ 0.26, 2.14 ]
Gupta 2009 17/58 14/57 0.90 [ 0.51, 1.59 ]
Henke 2003 IPD 109/180 89/171 1.27 [ 0.96, 1.68 ]
Hernandez 2009 IPD 17/196 20/195 0.84 [ 0.44, 1.60 ]
Huddart 2002 IPD 8/48 8/47 1.19 [ 0.44, 3.21 ]
Kotasek 2002 IPD 4/129 0/32 3.49 [ 0.30, 40.45 ]
Mystakidou 2005 1/50 2/50 0.50 [ 0.05, 5.00 ]
Pirker 2008 IPD 243/299 254/301 0.94 [ 0.78, 1.13 ]
Pronzato 2010 IPD 23/110 20/113 1.05 [ 0.58, 1.91 ]
Quirt 1996 IPD 2/28 0/28 5.90 [ 0.36, 97.07 ]
Ray-Coquard 2009 IPD 75/110 84/108 0.79 [ 0.58, 1.08 ]
Savonije 2005 IPD 132/211 61/104 1.14 [ 0.85, 1.53 ]
Strauss 2008 IPD 8/34 5/40 2.00 [ 0.65, 6.13 ]
Sweeney 1998 0/24 0/24 0.0 [ 0.0, 0.0 ]
Ten Bokkel1998 IPD 6/87 2/33 1.27 [ 0.26, 6.34 ]
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Thomas 2002 IPD 4/65 5/65 0.79 [ 0.21, 2.95 ]
Thomas 2008 IPD 22/58 17/56 1.28 [ 0.68, 2.40 ]
Throuvalas 2000 0/28 1/27 0.13 [ 0.00, 6.55 ]
Tsuboi 2009 21/61 19/56 0.94 [ 0.57, 1.54 ]
Vansteenkiste 2002 IPD 101/159 118/161 0.79 [ 0.60, 1.04 ]
Wilkinson 2006 IPD 3/121 0/61 4.48 [ 0.40, 50.03 ]
Winquist 2009 24/26 27/30 0.58 [ 0.33, 1.03 ]
Wright 2007 IPD 32/33 34/37 1.55 [ 0.94, 2.54 ]
Subtotal (95% CI) 3580 2838 1.01 [ 0.93, 1.10 ]
Heterogeneity: Chi2 = 29.34, df = 29 (P = 0.45); I2 =1%
Test for overall effect: Z = 0.33 (P = 0.74)
3 Hb > 12 g/dL
Del Mastro 1997 1/31 3/31 0.36 [ 0.05, 2.53 ]
Dunphy 1999 0/15 1/15 0.14 [ 0.00, 6.82 ]
Engert 2010 27/648 36/655 0.74 [ 0.45, 1.22 ]
Goss 2005 IPD 28/52 29/52 1.13 [ 0.67, 1.91 ]
Grote 2005 IPD 100/109 101/115 1.17 [ 0.89, 1.54 ]
Hoskin 2009 IPD 74/151 75/149 1.04 [ 0.75, 1.44 ]
Leyland-Jones 2005 IPD 121/469 91/470 1.41 [ 1.08, 1.85 ]
Machtay 2007 IPD 37/77 32/71 1.19 [ 0.74, 1.91 ]
Milroy 2003 IPD 136/214 126/210 1.13 [ 0.88, 1.45 ]
Moebus 2007 IPD 59/324 56/319 1.01 [ 0.70, 1.46 ]
O’Shaugnessy 2005 IPD 1/51 0/49 7.69 [ 0.15, 387.58 ]
Overgaard 2009 144/255 119/259 1.26 [ 0.99, 1.61 ]
Rosen 2003 19/47 23/43 1.19 [ 0.65, 2.18 ]
Thatcher 1999 IPD 7/86 3/44 1.13 [ 0.29, 4.36 ]
Untch 2011˙2 59/345 48/369 1.33 [ 0.91, 1.95 ]
Subtotal (95% CI) 2874 2851 1.17 [ 1.06, 1.29 ]
Heterogeneity: Chi2 = 10.57, df = 14 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 3.02 (P = 0.0025)
Total (95% CI) 1.07 [ 1.01, 1.13 ]
Heterogeneity: Chi2 = 85.18, df = 70 (P = 0.10); I2 =18%
Test for overall effect: Z = 2.44 (P = 0.015)
Test for subgroup differences: Chi2 = 4.57, df = 2 (P = 0.10), I2 =56%
0.05 0.2 1 5 20
Favours treatment Favours control
468Erythropoietin or darbepoetin for patients with cancer (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 5.23. Comparison 5 Overall survival, Outcome 23 Overall survival - sensitivity analysis iron
supplementation.
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Comparison: 5 Overall survival
Outcome: 23 Overall survival - sensitivity analysis iron supplementation












1 fixed iron supplementation
Christodoulou 2009 71/167 87/170 1.25 [ 0.92, 1.71 ]
Dunphy 1999 0/15 1/15 0.14 [ 0.00, 6.82 ]
Gupta 2009 17/58 14/57 0.90 [ 0.51, 1.59 ]
Hoskin 2009 IPD 74/151 75/149 1.04 [ 0.75, 1.44 ]
Huddart 2002 IPD 8/48 8/47 1.19 [ 0.44, 3.21 ]
Krzakowski 2008a 6/104 2/52 1.48 [ 0.33, 6.67 ]
Krzakowski 2008b 10/105 3/52 1.64 [ 0.49, 5.44 ]
Mystakidou 2005 1/50 2/50 0.50 [ 0.05, 5.00 ]
Untch 2011˙2 59/345 48/369 1.33 [ 0.91, 1.95 ]
Witzig 2005 IPD 121/174 119/170 1.13 [ 0.87, 1.46 ]
Subtotal (95% CI) 1217 1131 1.15 [ 0.99, 1.33 ]
Heterogeneity: Chi2 = 4.02, df = 9 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 1.87 (P = 0.061)
2 iron supplementation as necessary
Aapro 2008 IPD 169/231 169/232 1.07 [ 0.87, 1.32 ]
Abels 1993 IPD 13/65 12/59 0.96 [ 0.44, 2.10 ]
Boogaerts 2003 IPD 16/132 12/127 1.53 [ 0.72, 3.26 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Case 1993 IPD 10/81 9/76 1.11 [ 0.45, 2.73 ]
Cazzola 1995 IPD 5/114 3/29 0.69 [ 0.13, 3.57 ]
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Chang 2005 IPD 27/176 28/178 0.94 [ 0.55, 1.60 ]
Charu 2007 IPD 8/228 2/59 0.89 [ 0.19, 4.18 ]
Dammacco 2001 IPD 1/69 7/76 0.23 [ 0.06, 0.90 ]
Del Mastro 1997 1/31 3/31 0.36 [ 0.05, 2.53 ]
Engert 2010 27/648 36/655 0.74 [ 0.45, 1.22 ]
EPO-INT-1 IPD 11/165 3/81 1.88 [ 0.63, 5.64 ]
EPO-INT-3 IPD 9/135 3/65 1.55 [ 0.47, 5.10 ]
Fujisaka 2011 37/89 34/92 1.15 [ 0.72, 1.85 ]
Gordon 2008 IPD 11/164 5/56 0.74 [ 0.26, 2.14 ]
Goss 2005 IPD 28/52 29/52 1.13 [ 0.67, 1.91 ]
Grote 2005 IPD 100/109 101/115 1.17 [ 0.89, 1.54 ]
Hedenus 2003 IPD 101/176 82/173 1.32 [ 0.98, 1.77 ]
Henke 2003 IPD 109/180 89/171 1.27 [ 0.96, 1.68 ]
Henry 1995 IPD 7/67 10/65 0.68 [ 0.26, 1.77 ]
Hernandez 2009 IPD 17/196 20/195 0.84 [ 0.44, 1.60 ]
Kotasek 2002 IPD 4/129 0/32 3.49 [ 0.30, 40.45 ]
Kotasek 2003 IPD 4/208 1/51 0.99 [ 0.11, 8.84 ]
Kurz 1997 0/23 0/12 0.0 [ 0.0, 0.0 ]
Leyland-Jones 2005 IPD 121/469 91/470 1.41 [ 1.08, 1.85 ]
Littlewood 2001 IPD 155/251 82/124 0.80 [ 0.61, 1.05 ]
Milroy 2003 IPD 136/214 126/210 1.13 [ 0.88, 1.45 ]
ML17616 2006 1/30 0/30 7.39 [ 0.15, 372.38 ]
ML17620 2006 4/61 0/60 7.70 [ 1.05, 56.33 ]
O’Shaugnessy 2005 IPD 1/51 0/49 7.69 [ 0.15, 387.58 ]
Oberhoff 1998 IPD 9/116 10/111 0.62 [ 0.24, 1.59 ]
Osterborg 1996 IPD 26/99 14/49 0.94 [ 0.49, 1.81 ]
Osterborg 2002 IPD 110/173 109/176 1.04 [ 0.80, 1.36 ]
Overgaard 2009 144/255 119/259 1.26 [ 0.99, 1.61 ]
P-174 IPD 1/33 1/12 0.44 [ 0.03, 7.27 ]
Pirker 2008 IPD 243/299 254/301 0.94 [ 0.78, 1.13 ]
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Pronzato 2010 IPD 23/110 20/113 1.05 [ 0.58, 1.91 ]
Quirt 1996 IPD 2/28 0/28 5.90 [ 0.36, 97.07 ]
Ray-Coquard 2009 IPD 75/110 84/108 0.79 [ 0.58, 1.08 ]
Razzouk 2004 2/112 2/110 0.98 [ 0.14, 7.03 ]
Rose 1994 IPD 16/142 6/79 1.66 [ 0.70, 3.92 ]
Smith 2003 3/64 0/22 3.96 [ 0.29, 54.28 ]
Smith 2008 IPD 250/517 216/472 1.22 [ 1.02, 1.47 ]
Strauss 2008 IPD 8/34 5/40 2.00 [ 0.65, 6.13 ]
Ten Bokkel1998 IPD 6/87 2/33 1.27 [ 0.26, 6.34 ]
Thatcher 1999 IPD 7/86 3/44 1.13 [ 0.29, 4.36 ]
Thomas 2002 IPD 4/65 5/65 0.79 [ 0.21, 2.95 ]
Thomas 2008 IPD 22/58 17/56 1.28 [ 0.68, 2.40 ]
Throuvalas 2000 0/28 1/27 0.13 [ 0.00, 6.55 ]
Tjulandin 2010a 5/76 6/37 0.28 [ 0.07, 1.08 ]
Tjulandin 2010b 4/73 6/37 0.34 [ 0.09, 1.26 ]
Tjulandin 2011 6/95 5/91 1.16 [ 0.34, 3.90 ]
Tsuboi 2009 21/61 19/56 0.94 [ 0.57, 1.54 ]
Vansteenkiste 2002 IPD 101/159 118/161 0.79 [ 0.60, 1.04 ]
Wilkinson 2006 IPD 3/121 0/61 4.48 [ 0.40, 50.03 ]
Wright 2007 IPD 32/33 34/37 1.55 [ 0.94, 2.54 ]
Subtotal (95% CI) 7628 6260 1.07 [ 1.01, 1.14 ]
Heterogeneity: Chi2 = 64.77, df = 53 (P = 0.13); I2 =18%
Test for overall effect: Z = 2.21 (P = 0.027)
3 iron handled differently in the study arms
Blohmer 2011 25/127 29/129 0.88 [ 0.51, 1.51 ]
Debus 2006 IPD 146/195 159/190 0.81 [ 0.64, 1.02 ]
EPO-GER-20 IPD 7/48 8/45 0.71 [ 0.26, 1.95 ]
Machtay 2007 IPD 37/77 32/71 1.19 [ 0.74, 1.91 ]
Moebus 2007 IPD 59/324 56/319 1.01 [ 0.70, 1.46 ]
OBE/EPO-INT-03 IPD 5/35 6/37 1.07 [ 0.32, 3.56 ]
Rosen 2003 19/47 23/43 1.19 [ 0.65, 2.18 ]
Savonije 2005 IPD 132/211 61/104 1.14 [ 0.85, 1.53 ]
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
(Continued . . . )
471Erythropoietin or darbepoetin for patients with cancer (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)












Sweeney 1998 0/24 0/24 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 1088 962 0.96 [ 0.84, 1.11 ]
Heterogeneity: Chi2 = 5.27, df = 7 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.54 (P = 0.59)
4 explicitly stated NO IRON
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 1.07 [ 1.01, 1.12 ]
Heterogeneity: Chi2 = 77.15, df = 71 (P = 0.29); I2 =8%
Test for overall effect: Z = 2.37 (P = 0.018)
Test for subgroup differences: Chi2 = 3.10, df = 2 (P = 0.21), I2 =35%
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Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 5 Overall survival
Outcome: 24 Overall survival - sensitivity analysis intention-to-treat












1 ITT or less than 10% of participants per study arm excluded
Aapro 2008 IPD 169/231 169/232 1.07 [ 0.87, 1.32 ]
Abels 1993 IPD 13/65 12/59 0.96 [ 0.44, 2.10 ]
Bamias 2003 7/72 4/72 1.80 [ 0.53, 6.12 ]
Blohmer 2011 25/127 29/129 0.88 [ 0.51, 1.51 ]
Boogaerts 2003 IPD 16/132 12/127 1.53 [ 0.72, 3.26 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Case 1993 IPD 10/81 9/76 1.11 [ 0.45, 2.73 ]
Cazzola 1995 IPD 5/114 3/29 0.69 [ 0.13, 3.57 ]
Chang 2005 IPD 27/176 28/178 0.94 [ 0.55, 1.60 ]
Charu 2007 IPD 8/228 2/59 0.89 [ 0.19, 4.18 ]
Dammacco 2001 IPD 1/69 7/76 0.23 [ 0.06, 0.90 ]
Debus 2006 IPD 146/195 159/190 0.81 [ 0.64, 1.02 ]
Del Mastro 1997 1/31 3/31 0.36 [ 0.05, 2.53 ]
Dunphy 1999 0/15 1/15 0.14 [ 0.00, 6.82 ]
Engert 2010 27/648 36/655 0.74 [ 0.45, 1.22 ]
EPO-GER-20 IPD 7/48 8/45 0.71 [ 0.26, 1.95 ]
EPO-INT-1 IPD 11/165 3/81 1.88 [ 0.63, 5.64 ]
EPO-INT-3 IPD 9/135 3/65 1.55 [ 0.47, 5.10 ]
Fujisaka 2011 37/89 34/92 1.15 [ 0.72, 1.85 ]
Gordon 2008 IPD 11/164 5/56 0.74 [ 0.26, 2.14 ]
Goss 2005 IPD 28/52 29/52 1.13 [ 0.67, 1.91 ]
Grote 2005 IPD 100/109 101/115 1.17 [ 0.89, 1.54 ]
Gupta 2009 17/58 14/57 0.90 [ 0.51, 1.59 ]
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Hedenus 2002 0/55 0/11 0.0 [ 0.0, 0.0 ]
Hedenus 2003 IPD 101/176 82/173 1.32 [ 0.98, 1.77 ]
Henke 2003 IPD 109/180 89/171 1.27 [ 0.96, 1.68 ]
Henry 1995 IPD 7/67 10/65 0.68 [ 0.26, 1.77 ]
Hernandez 2009 IPD 17/196 20/195 0.84 [ 0.44, 1.60 ]
Hoskin 2009 IPD 74/151 75/149 1.04 [ 0.75, 1.44 ]
Huddart 2002 IPD 8/48 8/47 1.19 [ 0.44, 3.21 ]
Kotasek 2002 IPD 4/129 0/32 3.49 [ 0.30, 40.45 ]
Kotasek 2003 IPD 4/208 1/51 0.99 [ 0.11, 8.84 ]
Krzakowski 2008a 6/104 2/52 1.48 [ 0.33, 6.67 ]
Krzakowski 2008b 10/105 3/52 1.64 [ 0.49, 5.44 ]
Kurz 1997 0/23 0/12 0.0 [ 0.0, 0.0 ]
Leyland-Jones 2005 IPD 121/469 91/470 1.41 [ 1.08, 1.85 ]
Littlewood 2001 IPD 155/251 82/124 0.80 [ 0.61, 1.05 ]
Machtay 2007 IPD 37/77 32/71 1.19 [ 0.74, 1.91 ]
Milroy 2003 IPD 136/214 126/210 1.13 [ 0.88, 1.45 ]
Moebus 2007 IPD 59/324 56/319 1.01 [ 0.70, 1.46 ]
Mystakidou 2005 1/50 2/50 0.50 [ 0.05, 5.00 ]
O’Shaugnessy 2005 IPD 1/51 0/49 7.69 [ 0.15, 387.58 ]
OBE/EPO-INT-03 IPD 5/35 6/37 1.07 [ 0.32, 3.56 ]
Oberhoff 1998 IPD 9/116 10/111 0.62 [ 0.24, 1.59 ]
Osterborg 1996 IPD 26/99 14/49 0.94 [ 0.49, 1.81 ]
Osterborg 2002 IPD 110/173 109/176 1.04 [ 0.80, 1.36 ]
Overgaard 2009 144/255 119/259 1.26 [ 0.99, 1.61 ]
P-174 IPD 1/33 1/12 0.44 [ 0.03, 7.27 ]
Pirker 2008 IPD 243/299 254/301 0.94 [ 0.78, 1.13 ]
Pronzato 2010 IPD 23/110 20/113 1.05 [ 0.58, 1.91 ]
Quirt 1996 IPD 2/28 0/28 5.90 [ 0.36, 97.07 ]
Ray-Coquard 2009 IPD 75/110 84/108 0.79 [ 0.58, 1.08 ]
Razzouk 2004 2/112 2/110 0.98 [ 0.14, 7.03 ]
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Rose 1994 IPD 16/142 6/79 1.66 [ 0.70, 3.92 ]
Rosen 2003 19/47 23/43 1.19 [ 0.65, 2.18 ]
Savonije 2005 IPD 132/211 61/104 1.14 [ 0.85, 1.53 ]
Smith 2003 3/64 0/22 3.96 [ 0.29, 54.28 ]
Smith 2008 IPD 250/517 216/472 1.22 [ 1.02, 1.47 ]
Strauss 2008 IPD 8/34 5/40 2.00 [ 0.65, 6.13 ]
Ten Bokkel1998 IPD 6/87 2/33 1.27 [ 0.26, 6.34 ]
Thatcher 1999 IPD 7/86 3/44 1.13 [ 0.29, 4.36 ]
Thomas 2002 IPD 4/65 5/65 0.79 [ 0.21, 2.95 ]
Thomas 2008 IPD 22/58 17/56 1.28 [ 0.68, 2.40 ]
Thompson 2000 3/45 0/21 4.52 [ 0.38, 53.37 ]
Throuvalas 2000 0/28 1/27 0.13 [ 0.00, 6.55 ]
Tjulandin 2010a 5/76 6/37 0.28 [ 0.07, 1.08 ]
Tjulandin 2010b 4/73 6/37 0.34 [ 0.09, 1.26 ]
Tjulandin 2011 6/95 5/91 1.16 [ 0.34, 3.90 ]
Tsuboi 2009 21/61 19/56 0.94 [ 0.57, 1.54 ]
Untch 2011˙2 59/345 48/369 1.33 [ 0.91, 1.95 ]
Vansteenkiste 2002 IPD 101/159 118/161 0.79 [ 0.60, 1.04 ]
Wilkinson 2006 IPD 3/121 0/61 4.48 [ 0.40, 50.03 ]
Winquist 2009 24/26 27/30 0.58 [ 0.33, 1.03 ]
Witzig 2005 IPD 121/174 119/170 1.13 [ 0.87, 1.46 ]
Wright 2007 IPD 32/33 34/37 1.55 [ 0.94, 2.54 ]
Subtotal (95% CI) 9849 8203 1.05 [ 1.00, 1.11 ]
Heterogeneity: Chi2 = 77.52, df = 71 (P = 0.28); I2 =8%
Test for overall effect: Z = 1.99 (P = 0.047)
2 more than 10% of participants per study arm excluded
Christodoulou 2009 71/167 87/170 1.25 [ 0.92, 1.71 ]
Sweeney 1998 0/24 0/24 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 191 194 1.25 [ 0.92, 1.71 ]
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 1.40 (P = 0.16)
Total (95% CI) 1.06 [ 1.01, 1.12 ]
Heterogeneity: Chi2 = 78.64, df = 72 (P = 0.28); I2 =8%
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Test for overall effect: Z = 2.19 (P = 0.028)
Test for subgroup differences: Chi2 = 1.11, df = 1 (P = 0.29), I2 =10%
0.01 0.1 1 10 100
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Analysis 6.1. Comparison 6 On-study mortality, Outcome 1 On-study mortality - overall.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 6 On-study mortality
Outcome: 1 On-study mortality - overall












Aapro 2008 IPD 47/231 35/232 1.38 [ 0.89, 2.13 ]
Abels 1993 IPD 13/65 12/59 0.96 [ 0.44, 2.10 ]
Bamias 2003 7/72 4/72 1.80 [ 0.53, 6.12 ]
Boogaerts 2003 IPD 10/132 10/127 1.02 [ 0.42, 2.46 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Case 1993 IPD 10/81 9/76 1.11 [ 0.45, 2.73 ]
Cazzola 1995 IPD 3/114 2/29 0.38 [ 0.06, 2.30 ]
Chang 2005 IPD 7/176 5/178 1.36 [ 0.44, 4.22 ]
Charu 2007 IPD 8/228 2/59 0.89 [ 0.19, 4.18 ]
Dammacco 2001 IPD 1/69 7/76 0.23 [ 0.06, 0.90 ]
Debus 2006 IPD 26/195 18/190 1.38 [ 0.76, 2.50 ]
Del Mastro 1997 0/31 0/31 0.0 [ 0.0, 0.0 ]
Dunphy 1999 0/15 1/15 0.14 [ 0.00, 6.82 ]
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EPO-GER-20 IPD 6/48 8/45 0.61 [ 0.21, 1.77 ]
EPO-INT-1 IPD 6/165 2/81 1.51 [ 0.35, 6.54 ]
EPO-INT-3 IPD 9/135 3/65 1.55 [ 0.47, 5.10 ]
Fujisaka 2011 1/89 0/92 7.69 [ 0.15, 387.58 ]
Gordon 2008 IPD 11/164 5/56 0.74 [ 0.26, 2.14 ]
Goss 2005 IPD 4/52 1/52 3.40 [ 0.59, 19.63 ]
Grote 2005 IPD 16/109 21/115 0.79 [ 0.41, 1.52 ]
Hedenus 2002 0/55 0/11 0.0 [ 0.0, 0.0 ]
Hedenus 2003 IPD 10/176 4/173 2.40 [ 0.84, 6.87 ]
Henke 2003 IPD 9/180 7/171 1.22 [ 0.46, 3.25 ]
Henry 1995 IPD 7/67 10/65 0.68 [ 0.26, 1.77 ]
Hernandez 2009 IPD 17/196 20/195 0.84 [ 0.44, 1.60 ]
Hoskin 2009 IPD 5/151 2/149 2.36 [ 0.54, 10.33 ]
Huddart 2002 IPD 3/48 7/47 0.62 [ 0.16, 2.43 ]
Kotasek 2002 IPD 4/129 0/32 3.49 [ 0.30, 40.45 ]
Kotasek 2003 IPD 4/208 1/51 0.99 [ 0.11, 8.84 ]
Krzakowski 2008a 6/104 2/52 1.48 [ 0.33, 6.67 ]
Krzakowski 2008b 10/105 3/52 1.64 [ 0.49, 5.44 ]
Kurz 1997 0/23 0/12 0.0 [ 0.0, 0.0 ]
Leyland-Jones 2005 IPD 121/469 91/470 1.41 [ 1.08, 1.85 ]
Littlewood 2001 IPD 40/251 22/124 0.78 [ 0.46, 1.34 ]
Machtay 2007 IPD 5/77 3/71 1.57 [ 0.39, 6.31 ]
Milroy 2003 IPD 51/214 38/210 1.45 [ 0.95, 2.21 ]
ML17616 2006 1/30 0/30 7.39 [ 0.15, 372.38 ]
ML17620 2006 4/61 0/60 7.70 [ 1.05, 56.33 ]
Moebus 2007 IPD 0/324 0/319 0.0 [ 0.0, 0.0 ]
Mystakidou 2005 1/50 2/50 0.50 [ 0.05, 5.00 ]
O’Shaugnessy 2005 IPD 1/51 0/49 7.69 [ 0.15, 387.58 ]
OBE/EPO-INT-03 IPD 2/35 3/37 0.76 [ 0.13, 4.55 ]
Oberhoff 1998 IPD 9/116 10/111 0.62 [ 0.24, 1.59 ]
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Osterborg 1996 IPD 24/99 12/49 1.00 [ 0.50, 2.00 ]
Osterborg 2002 IPD 24/173 19/176 1.29 [ 0.71, 2.35 ]
P-174 IPD 1/33 1/12 0.44 [ 0.03, 7.27 ]
Pirker 2008 IPD 53/299 51/301 1.02 [ 0.70, 1.49 ]
Pronzato 2010 IPD 4/110 8/113 0.52 [ 0.17, 1.60 ]
Quirt 1996 IPD 2/28 0/28 5.78 [ 0.35, 95.11 ]
Ray-Coquard 2009 IPD 18/110 23/108 0.74 [ 0.40, 1.36 ]
Razzouk 2004 2/112 2/110 0.98 [ 0.14, 7.03 ]
Rose 1994 IPD 16/142 6/79 1.66 [ 0.70, 3.92 ]
Rosen 2003 1/47 0/43 6.82 [ 0.14, 343.75 ]
Savonije 2005 IPD 24/211 13/104 0.91 [ 0.45, 1.82 ]
Smith 2003 3/64 0/22 3.96 [ 0.29, 54.28 ]
Smith 2008 IPD 136/517 94/472 1.37 [ 1.05, 1.78 ]
Strauss 2008 IPD 0/34 0/40 0.0 [ 0.0, 0.0 ]
Sweeney 1998 0/24 0/24 0.0 [ 0.0, 0.0 ]
Ten Bokkel1998 IPD 5/87 2/33 0.99 [ 0.19, 5.11 ]
Thatcher 1999 IPD 7/86 3/44 1.13 [ 0.29, 4.36 ]
Thomas 2002 IPD 4/65 4/65 0.99 [ 0.25, 3.95 ]
Thomas 2008 IPD 1/58 1/56 0.94 [ 0.06, 15.06 ]
Thompson 2000 3/45 0/21 4.52 [ 0.38, 53.37 ]
Throuvalas 2000 0/28 1/27 0.13 [ 0.00, 6.55 ]
Tjulandin 2010a 5/76 6/37 0.28 [ 0.07, 1.08 ]
Tjulandin 2010b 4/73 6/37 0.34 [ 0.09, 1.26 ]
Tjulandin 2011 6/95 5/91 1.16 [ 0.34, 3.90 ]
Untch 2008 IPD 0/353 0/376 0.0 [ 0.0, 0.0 ]
Vansteenkiste 2002 IPD 23/159 21/161 1.06 [ 0.58, 1.92 ]
Wilkinson 2006 IPD 2/121 0/61 4.63 [ 0.25, 86.06 ]
Witzig 2005 IPD 31/174 25/170 1.22 [ 0.72, 2.06 ]
Wright 2007 IPD 25/33 23/37 1.68 [ 0.95, 2.99 ]
Total (95% CI) 1.17 [ 1.06, 1.29 ]
Heterogeneity: Chi2 = 59.49, df = 63 (P = 0.60); I2 =0.0%
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Test for overall effect: Z = 3.06 (P = 0.0022)
Test for subgroup differences: Not applicable
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Analysis 6.2. Comparison 6 On-study mortality, Outcome 2 On-study mortality - baseline Hb.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 6 On-study mortality
Outcome: 2 On-study mortality - baseline Hb












1 Hb < 10 g/dL
Abels 1993 IPD 13/65 12/59 0.96 [ 0.44, 2.10 ]
Boogaerts 2003 IPD 10/132 10/127 1.02 [ 0.42, 2.46 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Case 1993 IPD 10/81 9/76 1.11 [ 0.45, 2.73 ]
Cazzola 1995 IPD 3/114 2/29 0.38 [ 0.06, 2.30 ]
Dammacco 2001 IPD 1/69 7/76 0.23 [ 0.06, 0.90 ]
Fujisaka 2011 1/89 0/92 7.69 [ 0.15, 387.58 ]
Hedenus 2002 0/55 0/11 0.0 [ 0.0, 0.0 ]
Hedenus 2003 IPD 10/176 4/173 2.40 [ 0.84, 6.87 ]
Henry 1995 IPD 7/67 10/65 0.68 [ 0.26, 1.77 ]
Kotasek 2003 IPD 4/208 1/51 0.99 [ 0.11, 8.84 ]
Krzakowski 2008a 6/104 2/52 1.48 [ 0.33, 6.67 ]
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Krzakowski 2008b 10/105 3/52 1.64 [ 0.49, 5.44 ]
Kurz 1997 0/23 0/12 0.0 [ 0.0, 0.0 ]
Littlewood 2001 IPD 40/251 22/124 0.78 [ 0.46, 1.34 ]
ML17616 2006 1/30 0/30 7.39 [ 0.15, 372.38 ]
Oberhoff 1998 IPD 9/116 10/111 0.62 [ 0.24, 1.59 ]
Osterborg 1996 IPD 24/99 12/49 1.00 [ 0.50, 2.00 ]
Osterborg 2002 IPD 24/173 19/176 1.29 [ 0.71, 2.35 ]
Razzouk 2004 2/112 2/110 0.98 [ 0.14, 7.03 ]
Rose 1994 IPD 16/142 6/79 1.66 [ 0.70, 3.92 ]
Smith 2003 3/64 0/22 3.96 [ 0.29, 54.28 ]
Smith 2008 IPD 136/517 94/472 1.37 [ 1.05, 1.78 ]
Thompson 2000 3/45 0/21 4.52 [ 0.38, 53.37 ]
Tjulandin 2010a 5/76 6/37 0.28 [ 0.07, 1.08 ]
Tjulandin 2010b 4/73 6/37 0.34 [ 0.09, 1.26 ]
Tjulandin 2011 6/95 5/91 1.16 [ 0.34, 3.90 ]
Witzig 2005 IPD 31/174 25/170 1.22 [ 0.72, 2.06 ]
Subtotal (95% CI) 3305 2454 1.12 [ 0.96, 1.32 ]
Heterogeneity: Chi2 = 28.22, df = 24 (P = 0.25); I2 =15%
Test for overall effect: Z = 1.44 (P = 0.15)
2 Hb 10 to 12 g/dL
Aapro 2008 IPD 47/231 35/232 1.38 [ 0.89, 2.13 ]
Bamias 2003 7/72 4/72 1.80 [ 0.53, 6.12 ]
Chang 2005 IPD 7/176 5/178 1.36 [ 0.44, 4.22 ]
Charu 2007 IPD 8/228 2/59 0.89 [ 0.19, 4.18 ]
EPO-INT-1 IPD 6/165 2/81 1.51 [ 0.35, 6.54 ]
EPO-INT-3 IPD 9/135 3/65 1.55 [ 0.47, 5.10 ]
Gordon 2008 IPD 11/164 5/56 0.74 [ 0.26, 2.14 ]
Henke 2003 IPD 9/180 7/171 1.22 [ 0.46, 3.25 ]
Hernandez 2009 IPD 17/196 20/195 0.84 [ 0.44, 1.60 ]
Huddart 2002 IPD 3/48 7/47 0.62 [ 0.16, 2.43 ]
Kotasek 2002 IPD 4/129 0/32 3.49 [ 0.30, 40.45 ]
Mystakidou 2005 1/50 2/50 0.50 [ 0.05, 5.00 ]
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Pirker 2008 IPD 53/299 51/301 1.02 [ 0.70, 1.49 ]
Pronzato 2010 IPD 4/110 8/113 0.52 [ 0.17, 1.60 ]
Quirt 1996 IPD 2/28 0/28 5.78 [ 0.35, 95.11 ]
Ray-Coquard 2009 IPD 18/110 23/108 0.74 [ 0.40, 1.36 ]
Savonije 2005 IPD 24/211 13/104 0.91 [ 0.45, 1.82 ]
Strauss 2008 IPD 0/34 0/40 0.0 [ 0.0, 0.0 ]
Sweeney 1998 0/24 0/24 0.0 [ 0.0, 0.0 ]
Ten Bokkel1998 IPD 5/87 2/33 0.99 [ 0.19, 5.11 ]
Thomas 2002 IPD 4/65 4/65 0.99 [ 0.25, 3.95 ]
Thomas 2008 IPD 1/58 1/56 0.94 [ 0.06, 15.06 ]
Throuvalas 2000 0/28 1/27 0.13 [ 0.00, 6.55 ]
Vansteenkiste 2002 IPD 23/159 21/161 1.06 [ 0.58, 1.92 ]
Wilkinson 2006 IPD 2/121 0/61 4.63 [ 0.25, 86.06 ]
Wright 2007 IPD 25/33 23/37 1.68 [ 0.95, 2.99 ]
Subtotal (95% CI) 3141 2396 1.09 [ 0.91, 1.29 ]
Heterogeneity: Chi2 = 14.91, df = 23 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 0.93 (P = 0.35)
3 Hb > 12 g/dL
Del Mastro 1997 0/31 0/31 0.0 [ 0.0, 0.0 ]
Dunphy 1999 0/15 1/15 0.14 [ 0.00, 6.82 ]
Goss 2005 IPD 4/52 1/52 3.40 [ 0.59, 19.63 ]
Grote 2005 IPD 16/109 21/115 0.79 [ 0.41, 1.52 ]
Hoskin 2009 IPD 5/151 2/149 2.36 [ 0.54, 10.33 ]
Leyland-Jones 2005 IPD 121/469 91/470 1.41 [ 1.08, 1.85 ]
Machtay 2007 IPD 5/77 3/71 1.57 [ 0.39, 6.31 ]
Milroy 2003 IPD 51/214 38/210 1.45 [ 0.95, 2.21 ]
Moebus 2007 IPD 0/324 0/319 0.0 [ 0.0, 0.0 ]
O’Shaugnessy 2005 IPD 1/51 0/49 7.69 [ 0.15, 387.58 ]
Rosen 2003 1/47 0/43 6.82 [ 0.14, 343.75 ]
Thatcher 1999 IPD 7/86 3/44 1.13 [ 0.29, 4.36 ]
Untch 2008 IPD 0/353 0/376 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 1979 1944 1.37 [ 1.12, 1.68 ]
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Heterogeneity: Chi2 = 7.25, df = 9 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 3.02 (P = 0.0026)
4 unclear
Debus 2006 IPD 26/195 18/190 1.38 [ 0.76, 2.50 ]
EPO-GER-20 IPD 6/48 8/45 0.61 [ 0.21, 1.77 ]
ML17620 2006 4/61 0/60 7.70 [ 1.05, 56.33 ]
OBE/EPO-INT-03 IPD 2/35 3/37 0.76 [ 0.13, 4.55 ]
P-174 IPD 1/33 1/12 0.44 [ 0.03, 7.27 ]
Subtotal (95% CI) 372 344 1.20 [ 0.75, 1.93 ]
Heterogeneity: Chi2 = 5.86, df = 4 (P = 0.21); I2 =32%
Test for overall effect: Z = 0.75 (P = 0.45)
Total (95% CI) 1.17 [ 1.06, 1.29 ]
Heterogeneity: Chi2 = 59.49, df = 63 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 3.06 (P = 0.0022)
Test for subgroup differences: Chi2 = 3.24, df = 3 (P = 0.36), I2 =7%
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Analysis 6.3. Comparison 6 On-study mortality, Outcome 3 On-study mortality - different malignancies.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 6 On-study mortality
Outcome: 3 On-study mortality - different malignancies













Aapro 2008 IPD 47/231 35/232 1.38 [ 0.89, 2.13 ]
Bamias 2003 7/72 4/72 1.80 [ 0.53, 6.12 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Chang 2005 IPD 7/176 5/178 1.36 [ 0.44, 4.22 ]
Debus 2006 IPD 26/195 18/190 1.38 [ 0.76, 2.50 ]
Del Mastro 1997 0/31 0/31 0.0 [ 0.0, 0.0 ]
Dunphy 1999 0/15 1/15 0.14 [ 0.00, 6.82 ]
EPO-GER-20 IPD 6/48 8/45 0.61 [ 0.21, 1.77 ]
EPO-INT-1 IPD 6/165 2/81 1.51 [ 0.35, 6.54 ]
Fujisaka 2011 1/89 0/92 7.69 [ 0.15, 387.58 ]
Goss 2005 IPD 4/52 1/52 3.40 [ 0.59, 19.63 ]
Grote 2005 IPD 16/109 21/115 0.79 [ 0.41, 1.52 ]
Henke 2003 IPD 9/180 7/171 1.22 [ 0.46, 3.25 ]
Hoskin 2009 IPD 5/151 2/149 2.36 [ 0.54, 10.33 ]
Huddart 2002 IPD 3/48 7/47 0.62 [ 0.16, 2.43 ]
Kotasek 2002 IPD 4/129 0/32 3.49 [ 0.30, 40.45 ]
Kotasek 2003 IPD 4/208 1/51 0.99 [ 0.11, 8.84 ]
Kurz 1997 0/23 0/12 0.0 [ 0.0, 0.0 ]
Leyland-Jones 2005 IPD 121/469 91/470 1.41 [ 1.08, 1.85 ]
Machtay 2007 IPD 5/77 3/71 1.57 [ 0.39, 6.31 ]
Milroy 2003 IPD 51/214 38/210 1.45 [ 0.95, 2.21 ]
ML17620 2006 4/61 0/60 7.70 [ 1.05, 56.33 ]
Moebus 2007 IPD 0/324 0/319 0.0 [ 0.0, 0.0 ]
Mystakidou 2005 1/50 2/50 0.50 [ 0.05, 5.00 ]
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O’Shaugnessy 2005 IPD 1/51 0/49 7.69 [ 0.15, 387.58 ]
Oberhoff 1998 IPD 9/116 10/111 0.62 [ 0.24, 1.59 ]
Pirker 2008 IPD 53/299 51/301 1.02 [ 0.70, 1.49 ]
Pronzato 2010 IPD 4/110 8/113 0.52 [ 0.17, 1.60 ]
Rosen 2003 1/47 0/43 6.82 [ 0.14, 343.75 ]
Savonije 2005 IPD 24/211 13/104 0.91 [ 0.45, 1.82 ]
Strauss 2008 IPD 0/34 0/40 0.0 [ 0.0, 0.0 ]
Sweeney 1998 0/24 0/24 0.0 [ 0.0, 0.0 ]
Ten Bokkel1998 IPD 5/87 2/33 0.99 [ 0.19, 5.11 ]
Thatcher 1999 IPD 7/86 3/44 1.13 [ 0.29, 4.36 ]
Thomas 2002 IPD 4/65 4/65 0.99 [ 0.25, 3.95 ]
Thomas 2008 IPD 1/58 1/56 0.94 [ 0.06, 15.06 ]
Throuvalas 2000 0/28 1/27 0.13 [ 0.00, 6.55 ]
Tjulandin 2010a 5/76 6/37 0.28 [ 0.07, 1.08 ]
Tjulandin 2010b 4/73 6/37 0.34 [ 0.09, 1.26 ]
Untch 2008 IPD 0/353 0/376 0.0 [ 0.0, 0.0 ]
Vansteenkiste 2002 IPD 23/159 21/161 1.06 [ 0.58, 1.92 ]
Wilkinson 2006 IPD 2/121 0/61 4.63 [ 0.25, 86.06 ]
Witzig 2005 IPD 31/174 25/170 1.22 [ 0.72, 2.06 ]
Wright 2007 IPD 25/33 23/37 1.68 [ 0.95, 2.99 ]
Subtotal (95% CI) 5372 4684 1.21 [ 1.06, 1.37 ]
Heterogeneity: Chi2 = 35.02, df = 36 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 2.85 (P = 0.0044)
2 haematological malignancies
Cazzola 1995 IPD 3/114 2/29 0.38 [ 0.06, 2.30 ]
Dammacco 2001 IPD 1/69 7/76 0.23 [ 0.06, 0.90 ]
Hedenus 2002 0/55 0/11 0.0 [ 0.0, 0.0 ]
Hedenus 2003 IPD 10/176 4/173 2.40 [ 0.84, 6.87 ]
ML17616 2006 1/30 0/30 7.39 [ 0.15, 372.38 ]
OBE/EPO-INT-03 IPD 2/35 3/37 0.76 [ 0.13, 4.55 ]
Osterborg 1996 IPD 24/99 12/49 1.00 [ 0.50, 2.00 ]
Osterborg 2002 IPD 24/173 19/176 1.29 [ 0.71, 2.35 ]
0.01 0.1 1 10 100
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P-174 IPD 1/33 1/12 0.44 [ 0.03, 7.27 ]
Rose 1994 IPD 16/142 6/79 1.66 [ 0.70, 3.92 ]
Subtotal (95% CI) 926 672 1.13 [ 0.80, 1.59 ]
Heterogeneity: Chi2 = 11.19, df = 8 (P = 0.19); I2 =29%
Test for overall effect: Z = 0.70 (P = 0.49)
3 MDS
Thompson 2000 3/45 0/21 4.52 [ 0.38, 53.37 ]
Subtotal (95% CI) 45 21 4.52 [ 0.38, 53.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.20 (P = 0.23)
4 mixed
Abels 1993 IPD 13/65 12/59 0.96 [ 0.44, 2.10 ]
Boogaerts 2003 IPD 10/132 10/127 1.02 [ 0.42, 2.46 ]
Case 1993 IPD 10/81 9/76 1.11 [ 0.45, 2.73 ]
Charu 2007 IPD 8/228 2/59 0.89 [ 0.19, 4.18 ]
EPO-INT-3 IPD 9/135 3/65 1.55 [ 0.47, 5.10 ]
Gordon 2008 IPD 11/164 5/56 0.74 [ 0.26, 2.14 ]
Henry 1995 IPD 7/67 10/65 0.68 [ 0.26, 1.77 ]
Hernandez 2009 IPD 17/196 20/195 0.84 [ 0.44, 1.60 ]
Krzakowski 2008a 6/104 2/52 1.48 [ 0.33, 6.67 ]
Krzakowski 2008b 10/105 3/52 1.64 [ 0.49, 5.44 ]
Littlewood 2001 IPD 40/251 22/124 0.78 [ 0.46, 1.34 ]
Quirt 1996 IPD 2/28 0/28 5.78 [ 0.35, 95.11 ]
Ray-Coquard 2009 IPD 18/110 23/108 0.74 [ 0.40, 1.36 ]
Razzouk 2004 2/112 2/110 0.98 [ 0.14, 7.03 ]
Smith 2003 3/64 0/22 3.96 [ 0.29, 54.28 ]
Smith 2008 IPD 136/517 94/472 1.37 [ 1.05, 1.78 ]
Tjulandin 2011 6/95 5/91 1.16 [ 0.34, 3.90 ]
Subtotal (95% CI) 2454 1761 1.10 [ 0.92, 1.31 ]
Heterogeneity: Chi2 = 11.42, df = 16 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 1.09 (P = 0.28)
5 not reported
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
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Total (95% CI) 1.17 [ 1.06, 1.29 ]
Heterogeneity: Chi2 = 59.49, df = 63 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 3.06 (P = 0.0022)
Test for subgroup differences: Chi2 = 1.86, df = 3 (P = 0.60), I2 =0.0%
0.01 0.1 1 10 100
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Analysis 6.4. Comparison 6 On-study mortality, Outcome 4 On-study mortality - age.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 6 On-study mortality
Outcome: 4 On-study mortality - age













Razzouk 2004 2/112 2/110 0.98 [ 0.14, 7.03 ]
Subtotal (95% CI) 112 110 0.98 [ 0.14, 7.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.98)
2 adults
Aapro 2008 IPD 47/231 35/232 1.38 [ 0.89, 2.13 ]
Abels 1993 IPD 13/65 12/59 0.96 [ 0.44, 2.10 ]
Bamias 2003 7/72 4/72 1.80 [ 0.53, 6.12 ]
Boogaerts 2003 IPD 10/132 10/127 1.02 [ 0.42, 2.46 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Case 1993 IPD 10/81 9/76 1.11 [ 0.45, 2.73 ]
Cazzola 1995 IPD 3/114 2/29 0.38 [ 0.06, 2.30 ]
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Chang 2005 IPD 7/176 5/178 1.36 [ 0.44, 4.22 ]
Charu 2007 IPD 8/228 2/59 0.89 [ 0.19, 4.18 ]
Dammacco 2001 IPD 1/69 7/76 0.23 [ 0.06, 0.90 ]
Debus 2006 IPD 26/195 18/190 1.38 [ 0.76, 2.50 ]
Del Mastro 1997 0/31 0/31 0.0 [ 0.0, 0.0 ]
Dunphy 1999 0/15 1/15 0.14 [ 0.00, 6.82 ]
EPO-GER-20 IPD 6/48 8/45 0.61 [ 0.21, 1.77 ]
EPO-INT-1 IPD 6/165 2/81 1.51 [ 0.35, 6.54 ]
EPO-INT-3 IPD 9/135 3/65 1.55 [ 0.47, 5.10 ]
Fujisaka 2011 1/89 0/92 7.69 [ 0.15, 387.58 ]
Gordon 2008 IPD 11/164 5/56 0.74 [ 0.26, 2.14 ]
Goss 2005 IPD 4/52 1/52 3.40 [ 0.59, 19.63 ]
Grote 2005 IPD 16/109 21/115 0.79 [ 0.41, 1.52 ]
Hedenus 2002 0/55 0/11 0.0 [ 0.0, 0.0 ]
Hedenus 2003 IPD 10/176 4/173 2.40 [ 0.84, 6.87 ]
Henke 2003 IPD 9/180 7/171 1.22 [ 0.46, 3.25 ]
Henry 1995 IPD 7/67 10/65 0.68 [ 0.26, 1.77 ]
Hernandez 2009 IPD 17/196 20/195 0.84 [ 0.44, 1.60 ]
Hoskin 2009 IPD 5/151 2/149 2.36 [ 0.54, 10.33 ]
Huddart 2002 IPD 3/48 7/47 0.62 [ 0.16, 2.43 ]
Kotasek 2002 IPD 4/129 0/32 3.49 [ 0.30, 40.45 ]
Kotasek 2003 IPD 4/208 1/51 0.99 [ 0.11, 8.84 ]
Krzakowski 2008a 6/104 2/52 1.48 [ 0.33, 6.67 ]
Krzakowski 2008b 10/105 3/52 1.64 [ 0.49, 5.44 ]
Kurz 1997 0/23 0/12 0.0 [ 0.0, 0.0 ]
Leyland-Jones 2005 IPD 121/469 91/470 1.41 [ 1.08, 1.85 ]
Littlewood 2001 IPD 40/251 22/124 0.78 [ 0.46, 1.34 ]
Machtay 2007 IPD 5/77 3/71 1.57 [ 0.39, 6.31 ]
Milroy 2003 IPD 51/214 38/210 1.45 [ 0.95, 2.21 ]
ML17616 2006 1/30 0/30 7.39 [ 0.15, 372.38 ]
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ML17620 2006 4/61 0/60 7.70 [ 1.05, 56.33 ]
Moebus 2007 IPD 0/324 0/319 0.0 [ 0.0, 0.0 ]
Mystakidou 2005 1/50 2/50 0.50 [ 0.05, 5.00 ]
O’Shaugnessy 2005 IPD 1/51 0/49 7.69 [ 0.15, 387.58 ]
OBE/EPO-INT-03 IPD 2/35 3/37 0.76 [ 0.13, 4.55 ]
Oberhoff 1998 IPD 9/116 10/111 0.62 [ 0.24, 1.59 ]
Osterborg 1996 IPD 24/99 12/49 1.00 [ 0.50, 2.00 ]
Osterborg 2002 IPD 24/173 19/176 1.29 [ 0.71, 2.35 ]
P-174 IPD 1/33 1/12 0.44 [ 0.03, 7.27 ]
Pirker 2008 IPD 53/299 51/301 1.02 [ 0.70, 1.49 ]
Pronzato 2010 IPD 4/110 8/113 0.52 [ 0.17, 1.60 ]
Quirt 1996 IPD 2/28 0/28 5.78 [ 0.35, 95.11 ]
Ray-Coquard 2009 IPD 18/110 23/108 0.74 [ 0.40, 1.36 ]
Rose 1994 IPD 16/142 6/79 1.66 [ 0.70, 3.92 ]
Rosen 2003 1/47 0/43 6.82 [ 0.14, 343.75 ]
Savonije 2005 IPD 24/211 13/104 0.91 [ 0.45, 1.82 ]
Smith 2003 3/64 0/22 3.96 [ 0.29, 54.28 ]
Smith 2008 IPD 136/517 94/472 1.37 [ 1.05, 1.78 ]
Strauss 2008 IPD 0/34 0/40 0.0 [ 0.0, 0.0 ]
Sweeney 1998 0/24 0/24 0.0 [ 0.0, 0.0 ]
Ten Bokkel1998 IPD 5/87 2/33 0.99 [ 0.19, 5.11 ]
Thatcher 1999 IPD 7/86 3/44 1.13 [ 0.29, 4.36 ]
Thomas 2002 IPD 4/65 4/65 0.99 [ 0.25, 3.95 ]
Thomas 2008 IPD 1/58 1/56 0.94 [ 0.06, 15.06 ]
Thompson 2000 3/45 0/21 4.52 [ 0.38, 53.37 ]
Throuvalas 2000 0/28 1/27 0.13 [ 0.00, 6.55 ]
Tjulandin 2010a 5/76 6/37 0.28 [ 0.07, 1.08 ]
Tjulandin 2010b 4/73 6/37 0.34 [ 0.09, 1.26 ]
Tjulandin 2011 6/95 5/91 1.16 [ 0.34, 3.90 ]
Untch 2008 IPD 0/353 0/376 0.0 [ 0.0, 0.0 ]
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Vansteenkiste 2002 IPD 23/159 21/161 1.06 [ 0.58, 1.92 ]
Wilkinson 2006 IPD 2/121 0/61 4.63 [ 0.25, 86.06 ]
Witzig 2005 IPD 31/174 25/170 1.22 [ 0.72, 2.06 ]
Wright 2007 IPD 25/33 23/37 1.68 [ 0.95, 2.99 ]
Subtotal (95% CI) 8685 7028 1.17 [ 1.06, 1.29 ]
Heterogeneity: Chi2 = 59.46, df = 62 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 3.07 (P = 0.0022)
Total (95% CI) 1.17 [ 1.06, 1.29 ]
Heterogeneity: Chi2 = 59.49, df = 63 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 3.06 (P = 0.0022)
Test for subgroup differences: Chi2 = 0.03, df = 1 (P = 0.86), I2 =0.0%
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Analysis 6.5. Comparison 6 On-study mortality, Outcome 5 On-study mortality - age differentiated.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 6 On-study mortality
Outcome: 5 On-study mortality - age differentiated













Razzouk 2004 2/112 2/110 0.98 [ 0.14, 7.03 ]
Subtotal (95% CI) 112 110 0.98 [ 0.14, 7.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.98)
2 adults >= 18
Aapro 2008 IPD 47/231 35/232 1.38 [ 0.89, 2.13 ]
Abels 1993 IPD 13/65 12/59 0.96 [ 0.44, 2.10 ]
Bamias 2003 7/72 4/72 1.80 [ 0.53, 6.12 ]
Boogaerts 2003 IPD 10/132 10/127 1.02 [ 0.42, 2.46 ]
Case 1993 IPD 10/81 9/76 1.11 [ 0.45, 2.73 ]
Cazzola 1995 IPD 3/114 2/29 0.38 [ 0.06, 2.30 ]
Charu 2007 IPD 8/228 2/59 0.89 [ 0.19, 4.18 ]
Dammacco 2001 IPD 1/69 7/76 0.23 [ 0.06, 0.90 ]
Debus 2006 IPD 26/195 18/190 1.38 [ 0.76, 2.50 ]
Dunphy 1999 0/15 1/15 0.14 [ 0.00, 6.82 ]
EPO-GER-20 IPD 6/48 8/45 0.61 [ 0.21, 1.77 ]
EPO-INT-1 IPD 6/165 2/81 1.51 [ 0.35, 6.54 ]
EPO-INT-3 IPD 9/135 3/65 1.55 [ 0.47, 5.10 ]
Fujisaka 2011 1/89 0/92 7.69 [ 0.15, 387.58 ]
Gordon 2008 IPD 11/164 5/56 0.74 [ 0.26, 2.14 ]
Goss 2005 IPD 4/52 1/52 3.40 [ 0.59, 19.63 ]
Grote 2005 IPD 16/109 21/115 0.79 [ 0.41, 1.52 ]
Hedenus 2002 0/55 0/11 0.0 [ 0.0, 0.0 ]
Hedenus 2003 IPD 10/176 4/173 2.40 [ 0.84, 6.87 ]
Henke 2003 IPD 9/180 7/171 1.22 [ 0.46, 3.25 ]
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Henry 1995 IPD 7/67 10/65 0.68 [ 0.26, 1.77 ]
Hernandez 2009 IPD 17/196 20/195 0.84 [ 0.44, 1.60 ]
Hoskin 2009 IPD 5/151 2/149 2.36 [ 0.54, 10.33 ]
Huddart 2002 IPD 3/48 7/47 0.62 [ 0.16, 2.43 ]
Kotasek 2002 IPD 4/129 0/32 3.49 [ 0.30, 40.45 ]
Kotasek 2003 IPD 4/208 1/51 0.99 [ 0.11, 8.84 ]
Krzakowski 2008a 6/104 2/52 1.48 [ 0.33, 6.67 ]
Krzakowski 2008b 10/105 3/52 1.64 [ 0.49, 5.44 ]
Leyland-Jones 2005 IPD 121/469 91/470 1.41 [ 1.08, 1.85 ]
Littlewood 2001 IPD 40/251 22/124 0.78 [ 0.46, 1.34 ]
Machtay 2007 IPD 5/77 3/71 1.57 [ 0.39, 6.31 ]
Milroy 2003 IPD 51/214 38/210 1.45 [ 0.95, 2.21 ]
ML17616 2006 1/30 0/30 7.39 [ 0.15, 372.38 ]
ML17620 2006 4/61 0/60 7.70 [ 1.05, 56.33 ]
Mystakidou 2005 1/50 2/50 0.50 [ 0.05, 5.00 ]
O’Shaugnessy 2005 IPD 1/51 0/49 7.69 [ 0.15, 387.58 ]
OBE/EPO-INT-03 IPD 2/35 3/37 0.76 [ 0.13, 4.55 ]
Osterborg 1996 IPD 24/99 12/49 1.00 [ 0.50, 2.00 ]
Osterborg 2002 IPD 24/173 19/176 1.29 [ 0.71, 2.35 ]
P-174 IPD 1/33 1/12 0.44 [ 0.03, 7.27 ]
Pirker 2008 IPD 53/299 51/301 1.02 [ 0.70, 1.49 ]
Quirt 1996 IPD 2/28 0/28 5.78 [ 0.35, 95.11 ]
Ray-Coquard 2009 IPD 18/110 23/108 0.74 [ 0.40, 1.36 ]
Rose 1994 IPD 16/142 6/79 1.66 [ 0.70, 3.92 ]
Savonije 2005 IPD 24/211 13/104 0.91 [ 0.45, 1.82 ]
Smith 2003 3/64 0/22 3.96 [ 0.29, 54.28 ]
Smith 2008 IPD 136/517 94/472 1.37 [ 1.05, 1.78 ]
Sweeney 1998 0/24 0/24 0.0 [ 0.0, 0.0 ]
Ten Bokkel1998 IPD 5/87 2/33 0.99 [ 0.19, 5.11 ]
Thatcher 1999 IPD 7/86 3/44 1.13 [ 0.29, 4.36 ]
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Thomas 2002 IPD 4/65 4/65 0.99 [ 0.25, 3.95 ]
Thompson 2000 3/45 0/21 4.52 [ 0.38, 53.37 ]
Tjulandin 2010a 5/76 6/37 0.28 [ 0.07, 1.08 ]
Tjulandin 2010b 4/73 6/37 0.34 [ 0.09, 1.26 ]
Tjulandin 2011 6/95 5/91 1.16 [ 0.34, 3.90 ]
Vansteenkiste 2002 IPD 23/159 21/161 1.06 [ 0.58, 1.92 ]
Wilkinson 2006 IPD 2/121 0/61 4.63 [ 0.25, 86.06 ]
Witzig 2005 IPD 31/174 25/170 1.22 [ 0.72, 2.06 ]
Wright 2007 IPD 25/33 23/37 1.68 [ 0.95, 2.99 ]
Subtotal (95% CI) 7335 5672 1.18 [ 1.07, 1.31 ]
Heterogeneity: Chi2 = 53.58, df = 56 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 3.28 (P = 0.0011)
3 > 68% non elderly, 18-65
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Chang 2005 IPD 7/176 5/178 1.36 [ 0.44, 4.22 ]
Del Mastro 1997 0/31 0/31 0.0 [ 0.0, 0.0 ]
Kurz 1997 0/23 0/12 0.0 [ 0.0, 0.0 ]
Oberhoff 1998 IPD 9/116 10/111 0.62 [ 0.24, 1.59 ]
Pronzato 2010 IPD 4/110 8/113 0.52 [ 0.17, 1.60 ]
Rosen 2003 1/47 0/43 6.82 [ 0.14, 343.75 ]
Strauss 2008 IPD 0/34 0/40 0.0 [ 0.0, 0.0 ]
Thomas 2008 IPD 1/58 1/56 0.94 [ 0.06, 15.06 ]
Throuvalas 2000 0/28 1/27 0.13 [ 0.00, 6.55 ]
Subtotal (95% CI) 673 661 0.76 [ 0.42, 1.35 ]
Heterogeneity: Chi2 = 3.65, df = 5 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.95 (P = 0.34)
4 only non elderly adults
Moebus 2007 IPD 0/324 0/319 0.0 [ 0.0, 0.0 ]
Untch 2008 IPD 0/353 0/376 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 677 695 0.0 [ 0.0, 0.0 ]
Heterogeneity: Chi2 = 0.0, df = 0 (P<0.00001); I2 =0.0%
Test for overall effect: Z = 0.0 (P < 0.00001)
5 > 68% elderly > 65 years
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
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Test for overall effect: not applicable
6 only elderly
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 1.17 [ 1.06, 1.29 ]
Heterogeneity: Chi2 = 59.49, df = 63 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 3.06 (P = 0.0022)
Test for subgroup differences: Chi2 = 2.26, df = 2 (P = 0.32), I2 =11%
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Analysis 6.6. Comparison 6 On-study mortality, Outcome 6 On-study mortality - different therapies.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 6 On-study mortality
Outcome: 6 On-study mortality - different therapies













Aapro 2008 IPD 47/231 35/232 1.38 [ 0.89, 2.13 ]
Bamias 2003 7/72 4/72 1.80 [ 0.53, 6.12 ]
Boogaerts 2003 IPD 10/132 10/127 1.02 [ 0.42, 2.46 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Case 1993 IPD 10/81 9/76 1.11 [ 0.45, 2.73 ]
Cazzola 1995 IPD 3/114 2/29 0.38 [ 0.06, 2.30 ]
Chang 2005 IPD 7/176 5/178 1.36 [ 0.44, 4.22 ]
Dammacco 2001 IPD 1/69 7/76 0.23 [ 0.06, 0.90 ]
Del Mastro 1997 0/31 0/31 0.0 [ 0.0, 0.0 ]
Dunphy 1999 0/15 1/15 0.14 [ 0.00, 6.82 ]
EPO-GER-20 IPD 6/48 8/45 0.61 [ 0.21, 1.77 ]
EPO-INT-1 IPD 6/165 2/81 1.51 [ 0.35, 6.54 ]
EPO-INT-3 IPD 9/135 3/65 1.55 [ 0.47, 5.10 ]
Fujisaka 2011 1/89 0/92 7.69 [ 0.15, 387.58 ]
Grote 2005 IPD 16/109 21/115 0.79 [ 0.41, 1.52 ]
Hedenus 2002 0/55 0/11 0.0 [ 0.0, 0.0 ]
Hedenus 2003 IPD 10/176 4/173 2.40 [ 0.84, 6.87 ]
Henry 1995 IPD 7/67 10/65 0.68 [ 0.26, 1.77 ]
Hernandez 2009 IPD 17/196 20/195 0.84 [ 0.44, 1.60 ]
Huddart 2002 IPD 3/48 7/47 0.62 [ 0.16, 2.43 ]
Kotasek 2002 IPD 4/129 0/32 3.49 [ 0.30, 40.45 ]
Kotasek 2003 IPD 4/208 1/51 0.99 [ 0.11, 8.84 ]
Krzakowski 2008a 6/104 2/52 1.48 [ 0.33, 6.67 ]
Krzakowski 2008b 10/105 3/52 1.64 [ 0.49, 5.44 ]
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Kurz 1997 0/23 0/12 0.0 [ 0.0, 0.0 ]
Leyland-Jones 2005 IPD 121/469 91/470 1.41 [ 1.08, 1.85 ]
Littlewood 2001 IPD 40/251 22/124 0.78 [ 0.46, 1.34 ]
Milroy 2003 IPD 51/214 38/210 1.45 [ 0.95, 2.21 ]
ML17616 2006 1/30 0/30 7.39 [ 0.15, 372.38 ]
ML17620 2006 4/61 0/60 7.70 [ 1.05, 56.33 ]
Moebus 2007 IPD 0/324 0/319 0.0 [ 0.0, 0.0 ]
O’Shaugnessy 2005 IPD 1/51 0/49 7.69 [ 0.15, 387.58 ]
OBE/EPO-INT-03 IPD 2/35 3/37 0.76 [ 0.13, 4.55 ]
Oberhoff 1998 IPD 9/116 10/111 0.62 [ 0.24, 1.59 ]
Osterborg 1996 IPD 24/99 12/49 1.00 [ 0.50, 2.00 ]
Osterborg 2002 IPD 24/173 19/176 1.29 [ 0.71, 2.35 ]
Pirker 2008 IPD 53/299 51/301 1.02 [ 0.70, 1.49 ]
Pronzato 2010 IPD 4/110 8/113 0.52 [ 0.17, 1.60 ]
Quirt 1996 IPD 2/28 0/28 5.78 [ 0.35, 95.11 ]
Ray-Coquard 2009 IPD 18/110 23/108 0.74 [ 0.40, 1.36 ]
Razzouk 2004 2/112 2/110 0.98 [ 0.14, 7.03 ]
Savonije 2005 IPD 24/211 13/104 0.91 [ 0.45, 1.82 ]
Ten Bokkel1998 IPD 5/87 2/33 0.99 [ 0.19, 5.11 ]
Thatcher 1999 IPD 7/86 3/44 1.13 [ 0.29, 4.36 ]
Thomas 2002 IPD 4/65 4/65 0.99 [ 0.25, 3.95 ]
Tjulandin 2010a 5/76 6/37 0.28 [ 0.07, 1.08 ]
Tjulandin 2010b 4/73 6/37 0.34 [ 0.09, 1.26 ]
Tjulandin 2011 6/95 5/91 1.16 [ 0.34, 3.90 ]
Untch 2008 IPD 0/353 0/376 0.0 [ 0.0, 0.0 ]
Vansteenkiste 2002 IPD 23/159 21/161 1.06 [ 0.58, 1.92 ]
Wilkinson 2006 IPD 2/121 0/61 4.63 [ 0.25, 86.06 ]
Witzig 2005 IPD 31/174 25/170 1.22 [ 0.72, 2.06 ]
Subtotal (95% CI) 6610 5448 1.10 [ 0.98, 1.24 ]
Heterogeneity: Chi2 = 46.04, df = 45 (P = 0.43); I2 =2%
Test for overall effect: Z = 1.59 (P = 0.11)
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Debus 2006 IPD 26/195 18/190 1.38 [ 0.76, 2.50 ]
Goss 2005 IPD 4/52 1/52 3.40 [ 0.59, 19.63 ]
Henke 2003 IPD 9/180 7/171 1.22 [ 0.46, 3.25 ]
Hoskin 2009 IPD 5/151 2/149 2.36 [ 0.54, 10.33 ]
Machtay 2007 IPD 5/77 3/71 1.57 [ 0.39, 6.31 ]
Rosen 2003 1/47 0/43 6.82 [ 0.14, 343.75 ]
Strauss 2008 IPD 0/34 0/40 0.0 [ 0.0, 0.0 ]
Sweeney 1998 0/24 0/24 0.0 [ 0.0, 0.0 ]
Thomas 2008 IPD 1/58 1/56 0.94 [ 0.06, 15.06 ]
Throuvalas 2000 0/28 1/27 0.13 [ 0.00, 6.55 ]
Subtotal (95% CI) 846 823 1.48 [ 0.96, 2.27 ]
Heterogeneity: Chi2 = 3.62, df = 7 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 1.79 (P = 0.073)
3 no therapy
Abels 1993 IPD 13/65 12/59 0.96 [ 0.44, 2.10 ]
Charu 2007 IPD 8/228 2/59 0.89 [ 0.19, 4.18 ]
Gordon 2008 IPD 11/164 5/56 0.74 [ 0.26, 2.14 ]
Mystakidou 2005 1/50 2/50 0.50 [ 0.05, 5.00 ]
Smith 2003 3/64 0/22 3.96 [ 0.29, 54.28 ]
Smith 2008 IPD 136/517 94/472 1.37 [ 1.05, 1.78 ]
Thompson 2000 3/45 0/21 4.52 [ 0.38, 53.37 ]
Wright 2007 IPD 25/33 23/37 1.68 [ 0.95, 2.99 ]
Subtotal (95% CI) 1166 776 1.34 [ 1.07, 1.66 ]
Heterogeneity: Chi2 = 5.07, df = 7 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 2.60 (P = 0.0094)
4 unclear/other
P-174 IPD 1/33 1/12 0.44 [ 0.03, 7.27 ]
Rose 1994 IPD 16/142 6/79 1.66 [ 0.70, 3.92 ]
Subtotal (95% CI) 175 91 1.48 [ 0.65, 3.37 ]
Heterogeneity: Chi2 = 0.78, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 0.94 (P = 0.35)
Total (95% CI) 1.17 [ 1.06, 1.29 ]
Heterogeneity: Chi2 = 59.49, df = 63 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 3.06 (P = 0.0022)
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Test for subgroup differences: Chi2 = 3.97, df = 3 (P = 0.26), I2 =24%
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Analysis 6.7. Comparison 6 On-study mortality, Outcome 7 On-study mortality - different therapies
differentiated.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 6 On-study mortality
Outcome: 7 On-study mortality - different therapies differentiated












1 chemotherapy, > 70% with platinum
Bamias 2003 7/72 4/72 1.80 [ 0.53, 6.12 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Dunphy 1999 0/15 1/15 0.14 [ 0.00, 6.82 ]
EPO-INT-1 IPD 6/165 2/81 1.51 [ 0.35, 6.54 ]
Fujisaka 2011 1/89 0/92 7.69 [ 0.15, 387.58 ]
Grote 2005 IPD 16/109 21/115 0.79 [ 0.41, 1.52 ]
Henry 1995 IPD 7/67 10/65 0.68 [ 0.26, 1.77 ]
Huddart 2002 IPD 3/48 7/47 0.62 [ 0.16, 2.43 ]
Kurz 1997 0/23 0/12 0.0 [ 0.0, 0.0 ]
Milroy 2003 IPD 51/214 38/210 1.45 [ 0.95, 2.21 ]
ML17620 2006 4/61 0/60 7.70 [ 1.05, 56.33 ]
Pirker 2008 IPD 53/299 51/301 1.02 [ 0.70, 1.49 ]
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Savonije 2005 IPD 24/211 13/104 0.91 [ 0.45, 1.82 ]
Ten Bokkel1998 IPD 5/87 2/33 0.99 [ 0.19, 5.11 ]
Thatcher 1999 IPD 7/86 3/44 1.13 [ 0.29, 4.36 ]
Tjulandin 2010a 5/76 6/37 0.28 [ 0.07, 1.08 ]
Tjulandin 2010b 4/73 6/37 0.34 [ 0.09, 1.26 ]
Vansteenkiste 2002 IPD 23/159 21/161 1.06 [ 0.58, 1.92 ]
Wilkinson 2006 IPD 2/121 0/61 4.63 [ 0.25, 86.06 ]
Subtotal (95% CI) 2025 1597 1.04 [ 0.85, 1.27 ]
Heterogeneity: Chi2 = 18.93, df = 16 (P = 0.27); I2 =15%
Test for overall effect: Z = 0.40 (P = 0.69)
2 chemotherapy, <70% with platinum
EPO-INT-3 IPD 9/135 3/65 1.62 [ 0.44, 5.97 ]
Hernandez 2009 IPD 17/196 20/195 0.84 [ 0.44, 1.60 ]
Krzakowski 2008a 6/104 2/52 1.48 [ 0.33, 6.67 ]
Krzakowski 2008b 10/105 3/52 1.64 [ 0.49, 5.44 ]
Oberhoff 1998 IPD 9/116 10/111 0.62 [ 0.24, 1.59 ]
Witzig 2005 IPD 31/174 25/170 1.22 [ 0.72, 2.06 ]
Subtotal (95% CI) 830 645 1.06 [ 0.76, 1.49 ]
Heterogeneity: Chi2 = 3.12, df = 5 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 0.36 (P = 0.72)
3 chemotherapy without platinum, all patients
Aapro 2008 IPD 47/231 35/232 1.38 [ 0.89, 2.13 ]
Case 1993 IPD 10/81 9/76 1.11 [ 0.45, 2.73 ]
Cazzola 1995 IPD 3/114 2/29 0.38 [ 0.06, 2.30 ]
Chang 2005 IPD 7/176 5/178 1.36 [ 0.44, 4.22 ]
Del Mastro 1997 0/31 0/31 0.0 [ 0.0, 0.0 ]
Hedenus 2002 0/55 0/11 0.0 [ 0.0, 0.0 ]
Hedenus 2003 IPD 10/176 4/173 2.40 [ 0.84, 6.87 ]
Leyland-Jones 2005 IPD 121/469 91/470 1.41 [ 1.08, 1.85 ]
Littlewood 2001 IPD 40/251 22/124 0.78 [ 0.46, 1.34 ]
ML17616 2006 1/30 0/30 7.39 [ 0.15, 372.38 ]
Moebus 2007 IPD 0/324 0/319 0.0 [ 0.0, 0.0 ]
O’Shaugnessy 2005 IPD 1/51 0/49 7.69 [ 0.15, 387.58 ]
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OBE/EPO-INT-03 IPD 2/35 3/37 0.76 [ 0.13, 4.55 ]
Osterborg 1996 IPD 24/99 12/49 1.00 [ 0.50, 2.00 ]
Osterborg 2002 IPD 24/173 19/176 1.29 [ 0.71, 2.35 ]
Pronzato 2010 IPD 4/110 8/113 0.52 [ 0.17, 1.60 ]
Tjulandin 2011 6/95 5/91 1.16 [ 0.34, 3.90 ]
Untch 2008 IPD 0/353 0/376 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 2854 2564 1.24 [ 1.04, 1.47 ]
Heterogeneity: Chi2 = 11.83, df = 13 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 2.38 (P = 0.017)
4 chemotherapy, platinum and non-platinum containing, no numbers given
Boogaerts 2003 IPD 10/132 10/127 1.02 [ 0.42, 2.46 ]
Dammacco 2001 IPD 1/69 7/76 0.23 [ 0.06, 0.90 ]
Kotasek 2003 IPD 4/208 1/51 0.99 [ 0.11, 8.84 ]
Thomas 2002 IPD 4/65 4/65 0.99 [ 0.25, 3.95 ]
Subtotal (95% CI) 474 319 0.74 [ 0.40, 1.38 ]
Heterogeneity: Chi2 = 3.57, df = 3 (P = 0.31); I2 =16%
Test for overall effect: Z = 0.95 (P = 0.34)
5 chemotherapy, no details reported
EPO-GER-20 IPD 6/48 8/45 0.61 [ 0.21, 1.77 ]
Kotasek 2002 IPD 4/129 0/32 3.49 [ 0.30, 40.45 ]
Quirt 1996 IPD 2/28 0/28 5.78 [ 0.35, 95.11 ]
Ray-Coquard 2009 IPD 18/110 23/108 0.74 [ 0.40, 1.36 ]
Razzouk 2004 2/112 2/110 0.98 [ 0.14, 7.03 ]
Subtotal (95% CI) 427 323 0.82 [ 0.50, 1.34 ]
Heterogeneity: Chi2 = 3.65, df = 4 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.79 (P = 0.43)
6 radiochemotherapy
Debus 2006 IPD 26/195 18/190 1.38 [ 0.76, 2.50 ]
Goss 2005 IPD 4/52 1/52 3.40 [ 0.59, 19.63 ]
Rosen 2003 1/47 0/43 6.82 [ 0.14, 343.75 ]
Strauss 2008 IPD 0/34 0/40 0.0 [ 0.0, 0.0 ]
Thomas 2008 IPD 1/58 1/56 0.94 [ 0.06, 15.06 ]
Throuvalas 2000 0/28 1/27 0.13 [ 0.00, 6.55 ]
Subtotal (95% CI) 414 408 1.46 [ 0.85, 2.51 ]
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Heterogeneity: Chi2 = 3.08, df = 4 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 1.37 (P = 0.17)
7 radiotherapy
Henke 2003 IPD 9/180 7/171 1.22 [ 0.46, 3.25 ]
Hoskin 2009 IPD 5/151 2/149 2.36 [ 0.54, 10.33 ]
Machtay 2007 IPD 5/77 3/71 1.57 [ 0.39, 6.31 ]
Sweeney 1998 0/24 0/24 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 432 415 1.51 [ 0.75, 3.06 ]
Heterogeneity: Chi2 = 0.53, df = 2 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 1.15 (P = 0.25)
8 no therapy
Abels 1993 IPD 13/65 12/59 0.96 [ 0.44, 2.10 ]
Charu 2007 IPD 8/228 2/59 0.89 [ 0.19, 4.18 ]
Gordon 2008 IPD 11/164 5/56 0.74 [ 0.26, 2.14 ]
Mystakidou 2005 1/50 2/50 0.50 [ 0.05, 5.00 ]
Smith 2003 3/64 0/22 3.96 [ 0.29, 54.28 ]
Smith 2008 IPD 136/517 94/472 1.37 [ 1.05, 1.78 ]
Thompson 2000 3/45 0/21 4.52 [ 0.38, 53.37 ]
Wright 2007 IPD 25/33 23/37 1.68 [ 0.95, 2.99 ]
Subtotal (95% CI) 1166 776 1.34 [ 1.07, 1.66 ]
Heterogeneity: Chi2 = 5.07, df = 7 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 2.60 (P = 0.0094)
9 unclear/other
P-174 IPD 1/33 1/12 0.44 [ 0.03, 7.27 ]
Rose 1994 IPD 16/142 6/79 1.66 [ 0.70, 3.92 ]
Subtotal (95% CI) 175 91 1.48 [ 0.65, 3.37 ]
Heterogeneity: Chi2 = 0.78, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 0.94 (P = 0.35)
Total (95% CI) 1.17 [ 1.06, 1.29 ]
Heterogeneity: Chi2 = 59.51, df = 63 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 3.06 (P = 0.0022)
Test for subgroup differences: Chi2 = 8.94, df = 8 (P = 0.35), I2 =11%
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Analysis 6.8. Comparison 6 On-study mortality, Outcome 8 On-study mortality - duration of ESA
medication.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 6 On-study mortality
Outcome: 8 On-study mortality - duration of ESA medication












1 6 to 9 weeks
Abels 1993 IPD 13/65 12/59 0.96 [ 0.44, 2.10 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Cazzola 1995 IPD 3/114 2/29 0.38 [ 0.06, 2.30 ]
Dunphy 1999 0/15 1/15 0.14 [ 0.00, 6.82 ]
Henke 2003 IPD 9/180 7/171 1.22 [ 0.46, 3.25 ]
Machtay 2007 IPD 5/77 3/71 1.57 [ 0.39, 6.31 ]
Sweeney 1998 0/24 0/24 0.0 [ 0.0, 0.0 ]
Thomas 2008 IPD 1/58 1/56 0.94 [ 0.06, 15.06 ]
Throuvalas 2000 0/28 1/27 0.13 [ 0.00, 6.55 ]
Subtotal (95% CI) 611 502 0.95 [ 0.57, 1.59 ]
Heterogeneity: Chi2 = 3.68, df = 6 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.20 (P = 0.84)
2 12 to 16 weeks
Boogaerts 2003 IPD 10/132 10/127 1.02 [ 0.42, 2.46 ]
Case 1993 IPD 10/81 9/76 1.11 [ 0.45, 2.73 ]
Chang 2005 IPD 7/176 5/178 1.36 [ 0.44, 4.22 ]
Charu 2007 IPD 8/228 2/59 0.89 [ 0.19, 4.18 ]
Dammacco 2001 IPD 1/69 7/76 0.23 [ 0.06, 0.90 ]
Debus 2006 IPD 26/195 18/190 1.38 [ 0.76, 2.50 ]
Del Mastro 1997 0/31 0/31 0.0 [ 0.0, 0.0 ]
EPO-INT-3 IPD 9/135 3/65 1.55 [ 0.47, 5.10 ]
Fujisaka 2011 1/89 0/92 7.69 [ 0.15, 387.58 ]
Gordon 2008 IPD 11/164 5/56 0.74 [ 0.26, 2.14 ]
Grote 2005 IPD 16/109 21/115 0.79 [ 0.41, 1.52 ]
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Hedenus 2002 0/55 0/11 0.0 [ 0.0, 0.0 ]
Hedenus 2003 IPD 10/176 4/173 2.40 [ 0.84, 6.87 ]
Henry 1995 IPD 7/67 10/65 0.68 [ 0.26, 1.77 ]
Hernandez 2009 IPD 17/196 20/195 0.84 [ 0.44, 1.60 ]
Hoskin 2009 IPD 5/151 2/149 2.36 [ 0.54, 10.33 ]
Kotasek 2002 IPD 4/129 0/32 3.49 [ 0.30, 40.45 ]
Kotasek 2003 IPD 4/208 1/51 0.99 [ 0.11, 8.84 ]
Krzakowski 2008a 6/104 2/52 1.48 [ 0.33, 6.67 ]
Krzakowski 2008b 10/105 3/52 1.64 [ 0.49, 5.44 ]
Kurz 1997 0/23 0/12 0.0 [ 0.0, 0.0 ]
ML17616 2006 1/30 0/30 7.39 [ 0.15, 372.38 ]
ML17620 2006 4/61 0/60 7.70 [ 1.05, 56.33 ]
O’Shaugnessy 2005 IPD 1/51 0/49 7.69 [ 0.15, 387.58 ]
Oberhoff 1998 IPD 9/116 10/111 0.62 [ 0.24, 1.59 ]
Osterborg 2002 IPD 24/173 19/176 1.29 [ 0.71, 2.35 ]
P-174 IPD 1/33 1/12 0.44 [ 0.03, 7.27 ]
Quirt 1996 IPD 2/28 0/28 5.78 [ 0.35, 95.11 ]
Ray-Coquard 2009 IPD 18/110 23/108 0.74 [ 0.40, 1.36 ]
Razzouk 2004 2/112 2/110 0.98 [ 0.14, 7.03 ]
Rose 1994 IPD 16/142 6/79 1.66 [ 0.70, 3.92 ]
Rosen 2003 1/47 0/43 6.82 [ 0.14, 343.75 ]
Savonije 2005 IPD 24/211 13/104 0.91 [ 0.45, 1.82 ]
Smith 2003 3/64 0/22 3.96 [ 0.29, 54.28 ]
Smith 2008 IPD 136/517 94/472 1.37 [ 1.05, 1.78 ]
Strauss 2008 IPD 0/34 0/40 0.0 [ 0.0, 0.0 ]
Thomas 2002 IPD 4/65 4/65 0.99 [ 0.25, 3.95 ]
Thompson 2000 3/45 0/21 4.52 [ 0.38, 53.37 ]
Tjulandin 2010a 5/76 6/37 0.28 [ 0.07, 1.08 ]
Tjulandin 2010b 4/73 6/37 0.34 [ 0.09, 1.26 ]
Tjulandin 2011 6/95 5/91 1.16 [ 0.34, 3.90 ]
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Vansteenkiste 2002 IPD 23/159 21/161 1.06 [ 0.58, 1.92 ]
Witzig 2005 IPD 31/174 25/170 1.22 [ 0.72, 2.06 ]
Wright 2007 IPD 25/33 23/37 1.68 [ 0.95, 2.99 ]
Subtotal (95% CI) 5072 3920 1.16 [ 1.02, 1.33 ]
Heterogeneity: Chi2 = 40.96, df = 39 (P = 0.38); I2 =5%
Test for overall effect: Z = 2.19 (P = 0.029)
3 more than 17 weeks
Aapro 2008 IPD 47/231 35/232 1.38 [ 0.89, 2.13 ]
Bamias 2003 7/72 4/72 1.80 [ 0.53, 6.12 ]
Goss 2005 IPD 4/52 1/52 3.40 [ 0.59, 19.63 ]
Huddart 2002 IPD 3/48 7/47 0.62 [ 0.16, 2.43 ]
Leyland-Jones 2005 IPD 121/469 91/470 1.41 [ 1.08, 1.85 ]
Littlewood 2001 IPD 40/251 22/124 0.78 [ 0.46, 1.34 ]
Milroy 2003 IPD 51/214 38/210 1.45 [ 0.95, 2.21 ]
Moebus 2007 IPD 0/324 0/319 0.0 [ 0.0, 0.0 ]
Mystakidou 2005 1/50 2/50 0.50 [ 0.05, 5.00 ]
Osterborg 1996 IPD 24/99 12/49 1.00 [ 0.50, 2.00 ]
Pirker 2008 IPD 53/299 51/301 1.02 [ 0.70, 1.49 ]
Pronzato 2010 IPD 4/110 8/113 0.52 [ 0.17, 1.60 ]
Ten Bokkel1998 IPD 5/87 2/33 0.99 [ 0.19, 5.11 ]
Thatcher 1999 IPD 7/86 3/44 1.13 [ 0.29, 4.36 ]
Untch 2008 IPD 0/353 0/376 0.0 [ 0.0, 0.0 ]
Wilkinson 2006 IPD 2/121 0/61 4.63 [ 0.25, 86.06 ]
Subtotal (95% CI) 2866 2553 1.22 [ 1.04, 1.42 ]
Heterogeneity: Chi2 = 12.19, df = 13 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 2.45 (P = 0.014)
4 not reported
EPO-GER-20 IPD 6/48 8/45 0.61 [ 0.21, 1.77 ]
EPO-INT-1 IPD 6/165 2/81 1.51 [ 0.35, 6.54 ]
OBE/EPO-INT-03 IPD 2/35 3/37 0.76 [ 0.13, 4.55 ]
Subtotal (95% CI) 248 163 0.82 [ 0.38, 1.78 ]
Heterogeneity: Chi2 = 0.97, df = 2 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 0.50 (P = 0.62)
Total (95% CI) 1.17 [ 1.06, 1.29 ]
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Heterogeneity: Chi2 = 59.49, df = 63 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 3.06 (P = 0.0022)
Test for subgroup differences: Chi2 = 1.68, df = 3 (P = 0.64), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
Analysis 6.9. Comparison 6 On-study mortality, Outcome 9 On-study mortality - epoetin vs darbepoetin.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 6 On-study mortality
Outcome: 9 On-study mortality - epoetin vs darbepoetin













Aapro 2008 IPD 47/231 35/232 1.38 [ 0.89, 2.13 ]
Abels 1993 IPD 13/65 12/59 0.96 [ 0.44, 2.10 ]
Bamias 2003 7/72 4/72 1.80 [ 0.53, 6.12 ]
Boogaerts 2003 IPD 10/132 10/127 1.02 [ 0.42, 2.46 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Case 1993 IPD 10/81 9/76 1.11 [ 0.45, 2.73 ]
Cazzola 1995 IPD 3/114 2/29 0.38 [ 0.06, 2.30 ]
Chang 2005 IPD 7/176 5/178 1.36 [ 0.44, 4.22 ]
Dammacco 2001 IPD 1/69 7/76 0.23 [ 0.06, 0.90 ]
Debus 2006 IPD 26/195 18/190 1.38 [ 0.76, 2.50 ]
Del Mastro 1997 0/31 0/31 0.0 [ 0.0, 0.0 ]
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Dunphy 1999 0/15 1/15 0.14 [ 0.00, 6.82 ]
EPO-GER-20 IPD 6/48 8/45 0.61 [ 0.21, 1.77 ]
EPO-INT-1 IPD 6/165 2/81 1.51 [ 0.35, 6.54 ]
EPO-INT-3 IPD 9/135 3/65 1.55 [ 0.47, 5.10 ]
Fujisaka 2011 1/89 0/92 7.69 [ 0.15, 387.58 ]
Goss 2005 IPD 4/52 1/52 3.40 [ 0.59, 19.63 ]
Grote 2005 IPD 16/109 21/115 0.79 [ 0.41, 1.52 ]
Henke 2003 IPD 9/180 7/171 1.22 [ 0.46, 3.25 ]
Henry 1995 IPD 7/67 10/65 0.68 [ 0.26, 1.77 ]
Hoskin 2009 IPD 5/151 2/149 2.36 [ 0.54, 10.33 ]
Huddart 2002 IPD 3/48 7/47 0.62 [ 0.16, 2.43 ]
Krzakowski 2008a 6/104 2/52 1.48 [ 0.33, 6.67 ]
Krzakowski 2008b 10/105 3/52 1.64 [ 0.49, 5.44 ]
Kurz 1997 0/23 0/12 0.0 [ 0.0, 0.0 ]
Leyland-Jones 2005 IPD 121/469 91/470 1.41 [ 1.08, 1.85 ]
Littlewood 2001 IPD 40/251 22/124 0.78 [ 0.46, 1.34 ]
Machtay 2007 IPD 5/77 3/71 1.57 [ 0.39, 6.31 ]
Milroy 2003 IPD 51/214 38/210 1.45 [ 0.95, 2.21 ]
ML17616 2006 1/30 0/30 7.39 [ 0.15, 372.38 ]
ML17620 2006 4/61 0/60 7.70 [ 1.05, 56.33 ]
Moebus 2007 IPD 0/324 0/319 0.0 [ 0.0, 0.0 ]
Mystakidou 2005 1/50 2/50 0.50 [ 0.05, 5.00 ]
O’Shaugnessy 2005 IPD 1/51 0/49 7.69 [ 0.15, 387.58 ]
OBE/EPO-INT-03 IPD 2/35 3/37 0.76 [ 0.13, 4.55 ]
Oberhoff 1998 IPD 9/116 10/111 0.62 [ 0.24, 1.59 ]
Osterborg 1996 IPD 24/99 12/49 1.00 [ 0.50, 2.00 ]
Osterborg 2002 IPD 24/173 19/176 1.29 [ 0.71, 2.35 ]
P-174 IPD 1/33 1/12 0.44 [ 0.03, 7.27 ]
Pronzato 2010 IPD 4/110 8/113 0.52 [ 0.17, 1.60 ]
Quirt 1996 IPD 2/28 0/28 5.78 [ 0.35, 95.11 ]
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Ray-Coquard 2009 IPD 18/110 23/108 0.74 [ 0.40, 1.36 ]
Razzouk 2004 2/112 2/110 0.98 [ 0.14, 7.03 ]
Rose 1994 IPD 16/142 6/79 1.66 [ 0.70, 3.92 ]
Rosen 2003 1/47 0/43 6.82 [ 0.14, 343.75 ]
Savonije 2005 IPD 24/211 13/104 0.91 [ 0.45, 1.82 ]
Strauss 2008 IPD 0/34 0/40 0.0 [ 0.0, 0.0 ]
Sweeney 1998 0/24 0/24 0.0 [ 0.0, 0.0 ]
Ten Bokkel1998 IPD 5/87 2/33 0.99 [ 0.19, 5.11 ]
Thatcher 1999 IPD 7/86 3/44 1.13 [ 0.29, 4.36 ]
Thomas 2002 IPD 4/65 4/65 0.99 [ 0.25, 3.95 ]
Thomas 2008 IPD 1/58 1/56 0.94 [ 0.06, 15.06 ]
Thompson 2000 3/45 0/21 4.52 [ 0.38, 53.37 ]
Throuvalas 2000 0/28 1/27 0.13 [ 0.00, 6.55 ]
Tjulandin 2010a 5/76 6/37 0.28 [ 0.07, 1.08 ]
Tjulandin 2010b 4/73 6/37 0.34 [ 0.09, 1.26 ]
Tjulandin 2011 6/95 5/91 1.16 [ 0.34, 3.90 ]
Wilkinson 2006 IPD 2/121 0/61 4.63 [ 0.25, 86.06 ]
Witzig 2005 IPD 31/174 25/170 1.22 [ 0.72, 2.06 ]
Wright 2007 IPD 25/33 23/37 1.68 [ 0.95, 2.99 ]
Subtotal (95% CI) 6249 5229 1.16 [ 1.03, 1.30 ]
Heterogeneity: Chi2 = 52.19, df = 53 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 2.40 (P = 0.016)
2 Darbepoetin
Charu 2007 IPD 8/228 2/59 0.89 [ 0.19, 4.18 ]
Gordon 2008 IPD 11/164 5/56 0.74 [ 0.26, 2.14 ]
Hedenus 2002 0/55 0/11 0.0 [ 0.0, 0.0 ]
Hedenus 2003 IPD 10/176 4/173 2.40 [ 0.84, 6.87 ]
Hernandez 2009 IPD 17/196 20/195 0.84 [ 0.44, 1.60 ]
Kotasek 2002 IPD 4/129 0/32 3.49 [ 0.30, 40.45 ]
Kotasek 2003 IPD 4/208 1/51 0.99 [ 0.11, 8.84 ]
Pirker 2008 IPD 53/299 51/301 1.02 [ 0.70, 1.49 ]
Smith 2003 3/64 0/22 3.96 [ 0.29, 54.28 ]
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Smith 2008 IPD 136/517 94/472 1.37 [ 1.05, 1.78 ]
Untch 2008 IPD 0/353 0/376 0.0 [ 0.0, 0.0 ]
Vansteenkiste 2002 IPD 23/159 21/161 1.06 [ 0.58, 1.92 ]
Subtotal (95% CI) 2548 1909 1.20 [ 1.00, 1.44 ]
Heterogeneity: Chi2 = 7.19, df = 9 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 1.92 (P = 0.054)
Total (95% CI) 1.17 [ 1.06, 1.29 ]
Heterogeneity: Chi2 = 59.49, df = 63 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 3.06 (P = 0.0022)
Test for subgroup differences: Chi2 = 0.11, df = 1 (P = 0.74), I2 =0.0%
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Analysis 6.10. Comparison 6 On-study mortality, Outcome 10 On-study mortality - iron supplementation.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 6 On-study mortality
Outcome: 10 On-study mortality - iron supplementation












1 fixed iron supplementation
Dunphy 1999 0/15 1/15 0.14 [ 0.00, 6.82 ]
Hoskin 2009 IPD 5/151 2/149 2.36 [ 0.54, 10.33 ]
Huddart 2002 IPD 3/48 7/47 0.62 [ 0.16, 2.43 ]
Krzakowski 2008a 6/104 2/52 1.48 [ 0.33, 6.67 ]
Krzakowski 2008b 10/105 3/52 1.64 [ 0.49, 5.44 ]
Mystakidou 2005 1/50 2/50 0.50 [ 0.05, 5.00 ]
Untch 2008 IPD 0/353 0/376 0.0 [ 0.0, 0.0 ]
Witzig 2005 IPD 31/174 25/170 1.22 [ 0.72, 2.06 ]
Subtotal (95% CI) 1000 911 1.20 [ 0.80, 1.81 ]
Heterogeneity: Chi2 = 3.79, df = 6 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 0.89 (P = 0.37)
2 iron supplementation as necessary
Aapro 2008 IPD 47/231 35/232 1.38 [ 0.89, 2.13 ]
Abels 1993 IPD 13/65 12/59 0.96 [ 0.44, 2.10 ]
Boogaerts 2003 IPD 10/132 10/127 1.02 [ 0.42, 2.46 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Case 1993 IPD 10/81 9/76 1.11 [ 0.45, 2.73 ]
Cazzola 1995 IPD 3/114 2/29 0.38 [ 0.06, 2.30 ]
Chang 2005 IPD 7/176 5/178 1.36 [ 0.44, 4.22 ]
Charu 2007 IPD 8/228 2/59 0.89 [ 0.19, 4.18 ]
Dammacco 2001 IPD 1/69 7/76 0.23 [ 0.06, 0.90 ]
Del Mastro 1997 0/31 0/31 0.0 [ 0.0, 0.0 ]
EPO-INT-1 IPD 6/165 2/81 1.51 [ 0.35, 6.54 ]
EPO-INT-3 IPD 9/135 3/65 1.55 [ 0.47, 5.10 ]
Fujisaka 2011 1/89 0/92 7.69 [ 0.15, 387.58 ]
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Gordon 2008 IPD 11/164 5/56 0.74 [ 0.26, 2.14 ]
Goss 2005 IPD 4/52 1/52 3.40 [ 0.59, 19.63 ]
Grote 2005 IPD 16/109 21/115 0.79 [ 0.41, 1.52 ]
Hedenus 2003 IPD 10/176 4/173 2.40 [ 0.84, 6.87 ]
Henke 2003 IPD 9/180 7/171 1.22 [ 0.46, 3.25 ]
Henry 1995 IPD 7/67 10/65 0.68 [ 0.26, 1.77 ]
Hernandez 2009 IPD 17/196 20/195 0.84 [ 0.44, 1.60 ]
Kotasek 2002 IPD 4/129 0/32 3.49 [ 0.30, 40.45 ]
Kotasek 2003 IPD 4/208 1/51 0.99 [ 0.11, 8.84 ]
Kurz 1997 0/23 0/12 0.0 [ 0.0, 0.0 ]
Leyland-Jones 2005 IPD 121/469 91/470 1.41 [ 1.08, 1.85 ]
Littlewood 2001 IPD 40/251 22/124 0.78 [ 0.46, 1.34 ]
Milroy 2003 IPD 51/214 38/210 1.45 [ 0.95, 2.21 ]
ML17616 2006 1/30 0/30 7.39 [ 0.15, 372.38 ]
ML17620 2006 4/61 0/60 7.70 [ 1.05, 56.33 ]
O’Shaugnessy 2005 IPD 1/51 0/49 7.69 [ 0.15, 387.58 ]
Oberhoff 1998 IPD 9/116 10/111 0.62 [ 0.24, 1.59 ]
Osterborg 1996 IPD 24/99 12/49 1.00 [ 0.50, 2.00 ]
Osterborg 2002 IPD 24/173 19/176 1.29 [ 0.71, 2.35 ]
P-174 IPD 1/33 1/12 0.44 [ 0.03, 7.27 ]
Pirker 2008 IPD 53/299 51/301 1.02 [ 0.70, 1.49 ]
Pronzato 2010 IPD 4/110 8/113 0.52 [ 0.17, 1.60 ]
Quirt 1996 IPD 2/28 0/28 5.78 [ 0.35, 95.11 ]
Ray-Coquard 2009 IPD 18/110 23/108 0.74 [ 0.40, 1.36 ]
Razzouk 2004 2/112 2/110 0.98 [ 0.14, 7.03 ]
Rose 1994 IPD 16/142 6/79 1.66 [ 0.70, 3.92 ]
Smith 2003 3/64 0/22 3.96 [ 0.29, 54.28 ]
Smith 2008 IPD 136/517 94/472 1.37 [ 1.05, 1.78 ]
Strauss 2008 IPD 0/34 0/40 0.0 [ 0.0, 0.0 ]
Ten Bokkel1998 IPD 5/87 2/33 0.99 [ 0.19, 5.11 ]
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Thatcher 1999 IPD 7/86 3/44 1.13 [ 0.29, 4.36 ]
Thomas 2002 IPD 4/65 4/65 0.99 [ 0.25, 3.95 ]
Thomas 2008 IPD 1/58 1/56 0.94 [ 0.06, 15.06 ]
Throuvalas 2000 0/28 1/27 0.13 [ 0.00, 6.55 ]
Tjulandin 2010a 5/76 6/37 0.28 [ 0.07, 1.08 ]
Tjulandin 2010b 4/73 6/37 0.34 [ 0.09, 1.26 ]
Tjulandin 2011 6/95 5/91 1.16 [ 0.34, 3.90 ]
Vansteenkiste 2002 IPD 23/159 21/161 1.06 [ 0.58, 1.92 ]
Wilkinson 2006 IPD 2/121 0/61 4.63 [ 0.25, 86.06 ]
Wright 2007 IPD 25/33 23/37 1.68 [ 0.95, 2.99 ]
Subtotal (95% CI) 6664 5290 1.17 [ 1.05, 1.30 ]
Heterogeneity: Chi2 = 50.64, df = 48 (P = 0.37); I2 =5%
Test for overall effect: Z = 2.81 (P = 0.0050)
3 no explicit statement on iron supplementation or no iron given
Bamias 2003 7/72 4/72 1.80 [ 0.53, 6.12 ]
Hedenus 2002 0/55 0/11 0.0 [ 0.0, 0.0 ]
Thompson 2000 3/45 0/21 4.52 [ 0.38, 53.37 ]
Subtotal (95% CI) 172 104 2.16 [ 0.72, 6.46 ]
Heterogeneity: Chi2 = 0.43, df = 1 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 1.37 (P = 0.17)
4 explicitly stated no iron
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
5 iron handled differently in the study arms
Debus 2006 IPD 26/195 18/190 1.38 [ 0.76, 2.50 ]
EPO-GER-20 IPD 6/48 8/45 0.61 [ 0.21, 1.77 ]
Machtay 2007 IPD 5/77 3/71 1.57 [ 0.39, 6.31 ]
Moebus 2007 IPD 0/324 0/319 0.0 [ 0.0, 0.0 ]
OBE/EPO-INT-03 IPD 2/35 3/37 0.76 [ 0.13, 4.55 ]
Rosen 2003 1/47 0/43 6.82 [ 0.14, 343.75 ]
Savonije 2005 IPD 24/211 13/104 0.91 [ 0.45, 1.82 ]
Sweeney 1998 0/24 0/24 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 961 833 1.09 [ 0.74, 1.60 ]
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Heterogeneity: Chi2 = 3.27, df = 5 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 0.42 (P = 0.67)
Total (95% CI) 1.17 [ 1.06, 1.29 ]
Heterogeneity: Chi2 = 59.49, df = 63 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 3.06 (P = 0.0022)
Test for subgroup differences: Chi2 = 1.35, df = 3 (P = 0.72), I2 =0.0%
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Analysis 6.11. Comparison 6 On-study mortality, Outcome 11 On-study mortality - publication.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 6 On-study mortality
Outcome: 11 On-study mortality - publication












1 full text publication
Bamias 2003 7/72 4/72 1.80 [ 0.53, 6.12 ]
Dunphy 1999 0/15 1/15 0.14 [ 0.00, 6.82 ]
Fujisaka 2011 1/89 0/92 7.69 [ 0.15, 387.58 ]
Hedenus 2002 0/55 0/11 0.0 [ 0.0, 0.0 ]
Krzakowski 2008a 6/104 2/52 1.48 [ 0.33, 6.67 ]
Krzakowski 2008b 10/105 3/52 1.64 [ 0.49, 5.44 ]
Mystakidou 2005 1/50 2/50 0.50 [ 0.05, 5.00 ]
Razzouk 2004 2/112 2/110 0.98 [ 0.14, 7.03 ]
Rosen 2003 1/47 0/43 6.82 [ 0.14, 343.75 ]
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Smith 2003 3/64 0/22 3.96 [ 0.29, 54.28 ]
Sweeney 1998 0/24 0/24 0.0 [ 0.0, 0.0 ]
Tjulandin 2010a 5/76 6/37 0.28 [ 0.07, 1.08 ]
Tjulandin 2010b 4/73 6/37 0.34 [ 0.09, 1.26 ]
Tjulandin 2011 6/95 5/91 1.16 [ 0.34, 3.90 ]
Subtotal (95% CI) 981 708 0.97 [ 0.60, 1.57 ]
Heterogeneity: Chi2 = 12.20, df = 11 (P = 0.35); I2 =10%
Test for overall effect: Z = 0.11 (P = 0.91)
2 abstract publication
ML17616 2006 1/30 0/30 7.39 [ 0.15, 372.38 ]
ML17620 2006 4/61 0/60 7.70 [ 1.05, 56.33 ]
Subtotal (95% CI) 91 90 7.64 [ 1.29, 45.03 ]
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 2.25 (P = 0.025)
3 unpublished data
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Del Mastro 1997 0/31 0/31 0.0 [ 0.0, 0.0 ]
Kurz 1997 0/23 0/12 0.0 [ 0.0, 0.0 ]
Thompson 2000 3/45 0/21 4.52 [ 0.38, 53.37 ]
Throuvalas 2000 0/28 1/27 0.13 [ 0.00, 6.55 ]
Subtotal (95% CI) 177 141 1.65 [ 0.20, 13.32 ]
Heterogeneity: Chi2 = 2.25, df = 1 (P = 0.13); I2 =56%
Test for overall effect: Z = 0.47 (P = 0.64)
4 Data presented at FDA hearing
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
5 IPD Bohlius 2009
Aapro 2008 IPD 47/231 35/232 1.38 [ 0.89, 2.13 ]
Abels 1993 IPD 13/65 12/59 0.96 [ 0.44, 2.10 ]
Boogaerts 2003 IPD 10/132 10/127 1.02 [ 0.42, 2.46 ]
Case 1993 IPD 10/81 9/76 1.11 [ 0.45, 2.73 ]
Cazzola 1995 IPD 3/114 2/29 0.38 [ 0.06, 2.30 ]
Chang 2005 IPD 7/176 5/178 1.36 [ 0.44, 4.22 ]
Charu 2007 IPD 8/228 2/59 0.89 [ 0.19, 4.18 ]
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Dammacco 2001 IPD 1/69 7/76 0.23 [ 0.06, 0.90 ]
Debus 2006 IPD 26/195 18/190 1.38 [ 0.76, 2.50 ]
EPO-GER-20 IPD 6/48 8/45 0.61 [ 0.21, 1.77 ]
EPO-INT-1 IPD 6/165 2/81 1.51 [ 0.35, 6.54 ]
EPO-INT-3 IPD 9/135 3/65 1.55 [ 0.47, 5.10 ]
Gordon 2008 IPD 11/164 5/56 0.74 [ 0.26, 2.14 ]
Goss 2005 IPD 4/52 1/52 3.40 [ 0.59, 19.63 ]
Grote 2005 IPD 16/109 21/115 0.79 [ 0.41, 1.52 ]
Hedenus 2003 IPD 10/176 4/173 2.40 [ 0.84, 6.87 ]
Henke 2003 IPD 9/180 7/171 1.22 [ 0.46, 3.25 ]
Henry 1995 IPD 7/67 10/65 0.68 [ 0.26, 1.77 ]
Hernandez 2009 IPD 17/196 20/195 0.84 [ 0.44, 1.60 ]
Hoskin 2009 IPD 5/151 2/149 2.36 [ 0.54, 10.33 ]
Huddart 2002 IPD 3/48 7/47 0.62 [ 0.16, 2.43 ]
Kotasek 2002 IPD 4/129 0/32 3.49 [ 0.30, 40.45 ]
Kotasek 2003 IPD 4/208 1/51 0.99 [ 0.11, 8.84 ]
Leyland-Jones 2005 IPD 121/469 91/470 1.41 [ 1.08, 1.85 ]
Littlewood 2001 IPD 40/251 22/124 0.78 [ 0.46, 1.34 ]
Machtay 2007 IPD 5/77 3/71 1.57 [ 0.39, 6.31 ]
Milroy 2003 IPD 51/214 38/210 1.45 [ 0.95, 2.21 ]
Moebus 2007 IPD 0/324 0/319 0.0 [ 0.0, 0.0 ]
O’Shaugnessy 2005 IPD 1/51 0/49 7.69 [ 0.15, 387.58 ]
OBE/EPO-INT-03 IPD 2/35 3/37 0.76 [ 0.13, 4.55 ]
Oberhoff 1998 IPD 9/116 10/111 0.62 [ 0.24, 1.59 ]
Osterborg 1996 IPD 24/99 12/49 1.00 [ 0.50, 2.00 ]
Osterborg 2002 IPD 24/173 19/176 1.29 [ 0.71, 2.35 ]
P-174 IPD 1/33 1/12 0.44 [ 0.03, 7.27 ]
Pirker 2008 IPD 53/299 51/301 1.02 [ 0.70, 1.49 ]
Pronzato 2010 IPD 4/110 8/113 0.52 [ 0.17, 1.60 ]
Quirt 1996 IPD 2/28 0/28 5.78 [ 0.35, 95.11 ]
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Ray-Coquard 2009 IPD 18/110 23/108 0.74 [ 0.40, 1.36 ]
Rose 1994 IPD 16/142 6/79 1.66 [ 0.70, 3.92 ]
Savonije 2005 IPD 24/211 13/104 0.91 [ 0.45, 1.82 ]
Smith 2008 IPD 136/517 94/472 1.37 [ 1.05, 1.78 ]
Strauss 2008 IPD 0/34 0/40 0.0 [ 0.0, 0.0 ]
Ten Bokkel1998 IPD 5/87 2/33 0.99 [ 0.19, 5.11 ]
Thatcher 1999 IPD 7/86 3/44 1.13 [ 0.29, 4.36 ]
Thomas 2002 IPD 4/65 4/65 0.99 [ 0.25, 3.95 ]
Thomas 2008 IPD 1/58 1/56 0.94 [ 0.06, 15.06 ]
Untch 2008 IPD 0/353 0/376 0.0 [ 0.0, 0.0 ]
Vansteenkiste 2002 IPD 23/159 21/161 1.06 [ 0.58, 1.92 ]
Wilkinson 2006 IPD 2/121 0/61 4.63 [ 0.25, 86.06 ]
Witzig 2005 IPD 31/174 25/170 1.22 [ 0.72, 2.06 ]
Wright 2007 IPD 25/33 23/37 1.68 [ 0.95, 2.99 ]
Subtotal (95% CI) 7548 6199 1.17 [ 1.06, 1.29 ]
Heterogeneity: Chi2 = 40.07, df = 47 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 3.01 (P = 0.0026)
Total (95% CI) 1.17 [ 1.06, 1.29 ]
Heterogeneity: Chi2 = 59.49, df = 63 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 3.06 (P = 0.0022)
Test for subgroup differences: Chi2 = 4.96, df = 3 (P = 0.17), I2 =40%
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Analysis 6.12. Comparison 6 On-study mortality, Outcome 12 On-study mortality - time-to-event or binary
mortality data.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 6 On-study mortality
Outcome: 12 On-study mortality - time-to-event or binary mortality data












1 binary mortality data at end of study
Bamias 2003 7/72 4/72 1.80 [ 0.53, 6.12 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Del Mastro 1997 0/31 0/31 0.0 [ 0.0, 0.0 ]
Dunphy 1999 0/15 1/15 0.14 [ 0.00, 6.82 ]
Fujisaka 2011 1/89 0/92 7.69 [ 0.15, 387.58 ]
Hedenus 2002 0/55 0/11 0.0 [ 0.0, 0.0 ]
Krzakowski 2008a 6/104 2/52 1.48 [ 0.33, 6.67 ]
Krzakowski 2008b 10/105 3/52 1.64 [ 0.49, 5.44 ]
Kurz 1997 0/23 0/12 0.0 [ 0.0, 0.0 ]
ML17616 2006 1/30 0/30 7.39 [ 0.15, 372.38 ]
ML17620 2006 4/61 0/60 7.70 [ 1.05, 56.33 ]
Mystakidou 2005 1/50 2/50 0.50 [ 0.05, 5.00 ]
Razzouk 2004 2/112 2/110 0.98 [ 0.14, 7.03 ]
Rosen 2003 1/47 0/43 6.82 [ 0.14, 343.75 ]
Smith 2003 3/64 0/22 3.96 [ 0.29, 54.28 ]
Sweeney 1998 0/24 0/24 0.0 [ 0.0, 0.0 ]
Thompson 2000 3/45 0/21 4.52 [ 0.38, 53.37 ]
Throuvalas 2000 0/28 1/27 0.13 [ 0.00, 6.55 ]
Tjulandin 2010a 5/76 6/37 0.28 [ 0.07, 1.08 ]
Tjulandin 2010b 4/73 6/37 0.34 [ 0.09, 1.26 ]
Tjulandin 2011 6/95 5/91 1.16 [ 0.34, 3.90 ]
Subtotal (95% CI) 1249 939 1.14 [ 0.73, 1.79 ]
Heterogeneity: Chi2 = 19.40, df = 15 (P = 0.20); I2 =23%
Test for overall effect: Z = 0.57 (P = 0.57)
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2 Results from IPD review
Aapro 2008 IPD 47/231 35/232 1.38 [ 0.89, 2.13 ]
Abels 1993 IPD 13/65 12/59 0.96 [ 0.44, 2.10 ]
Boogaerts 2003 IPD 10/132 10/127 1.02 [ 0.42, 2.46 ]
Case 1993 IPD 10/81 9/76 1.11 [ 0.45, 2.73 ]
Cazzola 1995 IPD 3/114 2/29 0.38 [ 0.06, 2.30 ]
Chang 2005 IPD 7/176 5/178 1.36 [ 0.44, 4.22 ]
Charu 2007 IPD 8/228 2/59 0.89 [ 0.19, 4.18 ]
Dammacco 2001 IPD 1/69 7/76 0.23 [ 0.06, 0.90 ]
Debus 2006 IPD 26/195 18/190 1.38 [ 0.76, 2.50 ]
EPO-GER-20 IPD 6/48 8/45 0.61 [ 0.21, 1.77 ]
EPO-INT-1 IPD 6/165 2/81 1.51 [ 0.35, 6.54 ]
EPO-INT-3 IPD 9/135 3/65 1.55 [ 0.47, 5.10 ]
Gordon 2008 IPD 11/164 5/56 0.74 [ 0.26, 2.14 ]
Goss 2005 IPD 4/52 1/52 3.40 [ 0.59, 19.63 ]
Grote 2005 IPD 16/109 21/115 0.79 [ 0.41, 1.52 ]
Hedenus 2003 IPD 10/176 4/173 2.40 [ 0.84, 6.87 ]
Henke 2003 IPD 9/180 7/171 1.22 [ 0.46, 3.25 ]
Henry 1995 IPD 7/67 10/65 0.68 [ 0.26, 1.77 ]
Hernandez 2009 IPD 17/196 20/195 0.84 [ 0.44, 1.60 ]
Hoskin 2009 IPD 5/151 2/149 2.36 [ 0.54, 10.33 ]
Huddart 2002 IPD 3/48 7/47 0.62 [ 0.16, 2.43 ]
Kotasek 2002 IPD 4/129 0/32 3.49 [ 0.30, 40.45 ]
Kotasek 2003 IPD 4/208 1/51 0.99 [ 0.11, 8.84 ]
Leyland-Jones 2005 IPD 121/469 91/470 1.41 [ 1.08, 1.85 ]
Littlewood 2001 IPD 40/251 22/124 0.78 [ 0.46, 1.34 ]
Machtay 2007 IPD 5/77 3/71 1.57 [ 0.39, 6.31 ]
Milroy 2003 IPD 51/214 38/210 1.45 [ 0.95, 2.21 ]
Moebus 2007 IPD 0/324 0/319 0.0 [ 0.0, 0.0 ]
O’Shaugnessy 2005 IPD 1/51 0/49 7.69 [ 0.15, 387.58 ]
OBE/EPO-INT-03 IPD 2/35 3/37 0.76 [ 0.13, 4.55 ]
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Oberhoff 1998 IPD 9/116 10/111 0.62 [ 0.24, 1.59 ]
Osterborg 1996 IPD 24/99 12/49 1.00 [ 0.50, 2.00 ]
Osterborg 2002 IPD 24/173 19/176 1.29 [ 0.71, 2.35 ]
P-174 IPD 1/33 1/12 0.44 [ 0.03, 7.27 ]
Pirker 2008 IPD 53/299 51/301 1.02 [ 0.70, 1.49 ]
Pronzato 2010 IPD 4/110 8/113 0.52 [ 0.17, 1.60 ]
Quirt 1996 IPD 2/28 0/28 5.78 [ 0.35, 95.11 ]
Ray-Coquard 2009 IPD 18/110 23/108 0.74 [ 0.40, 1.36 ]
Rose 1994 IPD 16/142 6/79 1.66 [ 0.70, 3.92 ]
Savonije 2005 IPD 24/211 13/104 0.91 [ 0.45, 1.82 ]
Smith 2008 IPD 136/517 94/472 1.37 [ 1.05, 1.78 ]
Strauss 2008 IPD 0/34 0/40 0.0 [ 0.0, 0.0 ]
Ten Bokkel1998 IPD 5/87 2/33 0.99 [ 0.19, 5.11 ]
Thatcher 1999 IPD 7/86 3/44 1.13 [ 0.29, 4.36 ]
Thomas 2002 IPD 4/65 4/65 0.99 [ 0.25, 3.95 ]
Thomas 2008 IPD 1/58 1/56 0.94 [ 0.06, 15.06 ]
Untch 2008 IPD 0/353 0/376 0.0 [ 0.0, 0.0 ]
Vansteenkiste 2002 IPD 23/159 21/161 1.06 [ 0.58, 1.92 ]
Wilkinson 2006 IPD 2/121 0/61 4.63 [ 0.25, 86.06 ]
Witzig 2005 IPD 31/174 25/170 1.22 [ 0.72, 2.06 ]
Wright 2007 IPD 25/33 23/37 1.68 [ 0.95, 2.99 ]
Subtotal (95% CI) 7548 6199 1.17 [ 1.06, 1.29 ]
Heterogeneity: Chi2 = 40.07, df = 47 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 3.01 (P = 0.0026)
3 Cox regression analysis, Hazard ratio, log-rank test, p-value
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Survival curve and p-value
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 1.17 [ 1.06, 1.29 ]
Heterogeneity: Chi2 = 59.49, df = 63 (P = 0.60); I2 =0.0%
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Test for overall effect: Z = 3.06 (P = 0.0022)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.91), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
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Analysis 6.13. Comparison 6 On-study mortality, Outcome 13 On-study mortality - allocation concealment.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 6 On-study mortality
Outcome: 13 On-study mortality - allocation concealment













Aapro 2008 IPD 47/231 35/232 1.38 [ 0.89, 2.13 ]
Boogaerts 2003 IPD 10/132 10/127 1.02 [ 0.42, 2.46 ]
Cazzola 1995 IPD 3/114 2/29 0.38 [ 0.06, 2.30 ]
Chang 2005 IPD 7/176 5/178 1.36 [ 0.44, 4.22 ]
Charu 2007 IPD 8/228 2/59 0.89 [ 0.19, 4.18 ]
Del Mastro 1997 0/31 0/31 0.0 [ 0.0, 0.0 ]
EPO-INT-3 IPD 9/135 3/65 1.55 [ 0.47, 5.10 ]
Fujisaka 2011 1/89 0/92 7.69 [ 0.15, 387.58 ]
Gordon 2008 IPD 11/164 5/56 0.74 [ 0.26, 2.14 ]
Goss 2005 IPD 4/52 1/52 3.40 [ 0.59, 19.63 ]
Hedenus 2002 0/55 0/11 0.0 [ 0.0, 0.0 ]
Hedenus 2003 IPD 10/176 4/173 2.40 [ 0.84, 6.87 ]
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Henke 2003 IPD 9/180 7/171 1.22 [ 0.46, 3.25 ]
Hernandez 2009 IPD 17/196 20/195 0.84 [ 0.44, 1.60 ]
Kotasek 2002 IPD 4/129 0/32 3.49 [ 0.30, 40.45 ]
Kotasek 2003 IPD 4/208 1/51 0.99 [ 0.11, 8.84 ]
Kurz 1997 0/23 0/12 0.0 [ 0.0, 0.0 ]
Leyland-Jones 2005 IPD 121/469 91/470 1.41 [ 1.08, 1.85 ]
Littlewood 2001 IPD 40/251 22/124 0.78 [ 0.46, 1.34 ]
Machtay 2007 IPD 5/77 3/71 1.57 [ 0.39, 6.31 ]
Milroy 2003 IPD 51/214 38/210 1.45 [ 0.95, 2.21 ]
Moebus 2007 IPD 0/324 0/319 0.0 [ 0.0, 0.0 ]
O’Shaugnessy 2005 IPD 1/51 0/49 7.69 [ 0.15, 387.58 ]
OBE/EPO-INT-03 IPD 2/35 3/37 0.76 [ 0.13, 4.55 ]
Oberhoff 1998 IPD 9/116 10/111 0.62 [ 0.24, 1.59 ]
Osterborg 1996 IPD 24/99 12/49 1.00 [ 0.50, 2.00 ]
Osterborg 2002 IPD 24/173 19/176 1.29 [ 0.71, 2.35 ]
Pirker 2008 IPD 53/299 51/301 1.02 [ 0.70, 1.49 ]
Pronzato 2010 IPD 4/110 8/113 0.52 [ 0.17, 1.60 ]
Ray-Coquard 2009 IPD 18/110 23/108 0.74 [ 0.40, 1.36 ]
Razzouk 2004 2/112 2/110 0.98 [ 0.14, 7.03 ]
Savonije 2005 IPD 24/211 13/104 0.91 [ 0.45, 1.82 ]
Smith 2008 IPD 136/517 94/472 1.37 [ 1.05, 1.78 ]
Sweeney 1998 0/24 0/24 0.0 [ 0.0, 0.0 ]
Ten Bokkel1998 IPD 5/87 2/33 0.99 [ 0.19, 5.11 ]
Thomas 2002 IPD 4/65 4/65 0.99 [ 0.25, 3.95 ]
Thomas 2008 IPD 1/58 1/56 0.94 [ 0.06, 15.06 ]
Thompson 2000 3/45 0/21 4.52 [ 0.38, 53.37 ]
Throuvalas 2000 0/28 1/27 0.13 [ 0.00, 6.55 ]
Vansteenkiste 2002 IPD 23/159 21/161 1.06 [ 0.58, 1.92 ]
Witzig 2005 IPD 31/174 25/170 1.22 [ 0.72, 2.06 ]
Wright 2007 IPD 25/33 23/37 1.68 [ 0.95, 2.99 ]
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Subtotal (95% CI) 6160 4984 1.20 [ 1.08, 1.34 ]
Heterogeneity: Chi2 = 28.02, df = 36 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 3.27 (P = 0.0011)
2 unclear
Abels 1993 IPD 13/65 12/59 0.96 [ 0.44, 2.10 ]
Bamias 2003 7/72 4/72 1.80 [ 0.53, 6.12 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Case 1993 IPD 10/81 9/76 1.11 [ 0.45, 2.73 ]
Dammacco 2001 IPD 1/69 7/76 0.23 [ 0.06, 0.90 ]
Debus 2006 IPD 26/195 18/190 1.38 [ 0.76, 2.50 ]
Dunphy 1999 0/15 1/15 0.14 [ 0.00, 6.82 ]
EPO-GER-20 IPD 6/48 8/45 0.61 [ 0.21, 1.77 ]
EPO-INT-1 IPD 6/165 2/81 1.51 [ 0.35, 6.54 ]
Grote 2005 IPD 16/109 21/115 0.79 [ 0.41, 1.52 ]
Henry 1995 IPD 7/67 10/65 0.68 [ 0.26, 1.77 ]
Hoskin 2009 IPD 5/151 2/149 2.36 [ 0.54, 10.33 ]
Huddart 2002 IPD 3/48 7/47 0.62 [ 0.16, 2.43 ]
Krzakowski 2008a 6/104 2/52 1.48 [ 0.33, 6.67 ]
Krzakowski 2008b 10/105 3/52 1.64 [ 0.49, 5.44 ]
ML17616 2006 1/30 0/30 7.39 [ 0.15, 372.38 ]
ML17620 2006 4/61 0/60 7.70 [ 1.05, 56.33 ]
Mystakidou 2005 1/50 2/50 0.50 [ 0.05, 5.00 ]
P-174 IPD 1/33 1/12 0.44 [ 0.03, 7.27 ]
Quirt 1996 IPD 2/28 0/28 5.78 [ 0.35, 95.11 ]
Rose 1994 IPD 16/142 6/79 1.66 [ 0.70, 3.92 ]
Rosen 2003 1/47 0/43 6.82 [ 0.14, 343.75 ]
Smith 2003 3/64 0/22 3.96 [ 0.29, 54.28 ]
Strauss 2008 IPD 0/34 0/40 0.0 [ 0.0, 0.0 ]
Thatcher 1999 IPD 7/86 3/44 1.13 [ 0.29, 4.36 ]
Tjulandin 2010a 5/76 6/37 0.28 [ 0.07, 1.08 ]
Tjulandin 2010b 4/73 6/37 0.34 [ 0.09, 1.26 ]
Tjulandin 2011 6/95 5/91 1.16 [ 0.34, 3.90 ]
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Untch 2008 IPD 0/353 0/376 0.0 [ 0.0, 0.0 ]
Wilkinson 2006 IPD 2/121 0/61 4.63 [ 0.25, 86.06 ]
Subtotal (95% CI) 2637 2154 1.03 [ 0.82, 1.30 ]
Heterogeneity: Chi2 = 30.08, df = 26 (P = 0.26); I2 =14%
Test for overall effect: Z = 0.25 (P = 0.80)
Total (95% CI) 1.17 [ 1.06, 1.29 ]
Heterogeneity: Chi2 = 59.49, df = 63 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 3.06 (P = 0.0022)
Test for subgroup differences: Chi2 = 1.39, df = 1 (P = 0.24), I2 =28%
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Analysis 6.14. Comparison 6 On-study mortality, Outcome 14 On-study mortality - masking.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 6 On-study mortality
Outcome: 14 On-study mortality - masking













Abels 1993 IPD 13/65 12/59 0.96 [ 0.44, 2.10 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Case 1993 IPD 10/81 9/76 1.11 [ 0.45, 2.73 ]
Dammacco 2001 IPD 1/69 7/76 0.23 [ 0.06, 0.90 ]
EPO-INT-1 IPD 6/165 2/81 1.51 [ 0.35, 6.54 ]
EPO-INT-3 IPD 9/135 3/65 1.55 [ 0.47, 5.10 ]
Fujisaka 2011 1/89 0/92 7.69 [ 0.15, 387.58 ]
Gordon 2008 IPD 11/164 5/56 0.74 [ 0.26, 2.14 ]
Goss 2005 IPD 4/52 1/52 3.40 [ 0.59, 19.63 ]
Grote 2005 IPD 16/109 21/115 0.79 [ 0.41, 1.52 ]
Hedenus 2002 0/55 0/11 0.0 [ 0.0, 0.0 ]
Hedenus 2003 IPD 10/176 4/173 2.40 [ 0.84, 6.87 ]
Henke 2003 IPD 9/180 7/171 1.22 [ 0.46, 3.25 ]
Henry 1995 IPD 7/67 10/65 0.68 [ 0.26, 1.77 ]
Hernandez 2009 IPD 17/196 20/195 0.84 [ 0.44, 1.60 ]
Kotasek 2002 IPD 4/129 0/32 3.49 [ 0.30, 40.45 ]
Kotasek 2003 IPD 4/208 1/51 0.99 [ 0.11, 8.84 ]
Krzakowski 2008a 6/104 2/52 1.48 [ 0.33, 6.67 ]
Krzakowski 2008b 10/105 3/52 1.64 [ 0.49, 5.44 ]
Kurz 1997 0/23 0/12 0.0 [ 0.0, 0.0 ]
Leyland-Jones 2005 IPD 121/469 91/470 1.41 [ 1.08, 1.85 ]
Littlewood 2001 IPD 40/251 22/124 0.78 [ 0.46, 1.34 ]
Mystakidou 2005 1/50 2/50 0.50 [ 0.05, 5.00 ]
O’Shaugnessy 2005 IPD 1/51 0/49 7.69 [ 0.15, 387.58 ]
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Osterborg 2002 IPD 24/173 19/176 1.29 [ 0.71, 2.35 ]
P-174 IPD 1/33 1/12 0.44 [ 0.03, 7.27 ]
Pirker 2008 IPD 53/299 51/301 1.02 [ 0.70, 1.49 ]
Quirt 1996 IPD 2/28 0/28 5.78 [ 0.35, 95.11 ]
Razzouk 2004 2/112 2/110 0.98 [ 0.14, 7.03 ]
Rose 1994 IPD 16/142 6/79 1.66 [ 0.70, 3.92 ]
Smith 2003 3/64 0/22 3.96 [ 0.29, 54.28 ]
Smith 2008 IPD 136/517 94/472 1.37 [ 1.05, 1.78 ]
Thompson 2000 3/45 0/21 4.52 [ 0.38, 53.37 ]
Tjulandin 2010a 5/76 6/37 0.28 [ 0.07, 1.08 ]
Tjulandin 2010b 4/73 6/37 0.34 [ 0.09, 1.26 ]
Tjulandin 2011 6/95 5/91 1.16 [ 0.34, 3.90 ]
Vansteenkiste 2002 IPD 23/159 21/161 1.06 [ 0.58, 1.92 ]
Witzig 2005 IPD 31/174 25/170 1.22 [ 0.72, 2.06 ]
Wright 2007 IPD 25/33 23/37 1.68 [ 0.95, 2.99 ]
Subtotal (95% CI) 5066 3983 1.19 [ 1.06, 1.34 ]
Heterogeneity: Chi2 = 36.76, df = 35 (P = 0.39); I2 =5%
Test for overall effect: Z = 2.84 (P = 0.0045)
2 unblinded
Aapro 2008 IPD 47/231 35/232 1.38 [ 0.89, 2.13 ]
Bamias 2003 7/72 4/72 1.80 [ 0.53, 6.12 ]
Boogaerts 2003 IPD 10/132 10/127 1.02 [ 0.42, 2.46 ]
Cazzola 1995 IPD 3/114 2/29 0.38 [ 0.06, 2.30 ]
Chang 2005 IPD 7/176 5/178 1.36 [ 0.44, 4.22 ]
Charu 2007 IPD 8/228 2/59 0.89 [ 0.19, 4.18 ]
Debus 2006 IPD 26/195 18/190 1.38 [ 0.76, 2.50 ]
Del Mastro 1997 0/31 0/31 0.0 [ 0.0, 0.0 ]
Dunphy 1999 0/15 1/15 0.14 [ 0.00, 6.82 ]
EPO-GER-20 IPD 6/48 8/45 0.61 [ 0.21, 1.77 ]
Hoskin 2009 IPD 5/151 2/149 2.36 [ 0.54, 10.33 ]
Huddart 2002 IPD 3/48 7/47 0.62 [ 0.16, 2.43 ]
Machtay 2007 IPD 5/77 3/71 1.57 [ 0.39, 6.31 ]
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Milroy 2003 IPD 51/214 38/210 1.45 [ 0.95, 2.21 ]
ML17616 2006 1/30 0/30 7.39 [ 0.15, 372.38 ]
ML17620 2006 4/61 0/60 7.70 [ 1.05, 56.33 ]
Moebus 2007 IPD 0/324 0/319 0.0 [ 0.0, 0.0 ]
OBE/EPO-INT-03 IPD 2/35 3/37 0.76 [ 0.13, 4.55 ]
Oberhoff 1998 IPD 9/116 10/111 0.62 [ 0.24, 1.59 ]
Osterborg 1996 IPD 24/99 12/49 1.00 [ 0.50, 2.00 ]
Pronzato 2010 IPD 4/110 8/113 0.52 [ 0.17, 1.60 ]
Ray-Coquard 2009 IPD 18/110 23/108 0.74 [ 0.40, 1.36 ]
Rosen 2003 1/47 0/43 6.82 [ 0.14, 343.75 ]
Savonije 2005 IPD 24/211 13/104 0.91 [ 0.45, 1.82 ]
Strauss 2008 IPD 0/34 0/40 0.0 [ 0.0, 0.0 ]
Sweeney 1998 0/24 0/24 0.0 [ 0.0, 0.0 ]
Ten Bokkel1998 IPD 5/87 2/33 0.99 [ 0.19, 5.11 ]
Thatcher 1999 IPD 7/86 3/44 1.13 [ 0.29, 4.36 ]
Thomas 2002 IPD 4/65 4/65 0.99 [ 0.25, 3.95 ]
Thomas 2008 IPD 1/58 1/56 0.94 [ 0.06, 15.06 ]
Throuvalas 2000 0/28 1/27 0.13 [ 0.00, 6.55 ]
Untch 2008 IPD 0/353 0/376 0.0 [ 0.0, 0.0 ]
Wilkinson 2006 IPD 2/121 0/61 4.63 [ 0.25, 86.06 ]
Subtotal (95% CI) 3731 3155 1.12 [ 0.94, 1.34 ]
Heterogeneity: Chi2 = 22.46, df = 27 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 1.26 (P = 0.21)
Total (95% CI) 1.17 [ 1.06, 1.29 ]
Heterogeneity: Chi2 = 59.49, df = 63 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 3.06 (P = 0.0022)
Test for subgroup differences: Chi2 = 0.27, df = 1 (P = 0.60), I2 =0.0%
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Analysis 6.15. Comparison 6 On-study mortality, Outcome 15 On-study mortality - intention-to-treat.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 6 On-study mortality
Outcome: 15 On-study mortality - intention-to-treat












1 ITT or less than 10% of participants per study arm excluded
Aapro 2008 IPD 47/231 35/232 1.38 [ 0.89, 2.13 ]
Abels 1993 IPD 13/65 12/59 0.96 [ 0.44, 2.10 ]
Bamias 2003 7/72 4/72 1.80 [ 0.53, 6.12 ]
Boogaerts 2003 IPD 10/132 10/127 1.02 [ 0.42, 2.46 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Case 1993 IPD 10/81 9/76 1.11 [ 0.45, 2.73 ]
Cazzola 1995 IPD 3/114 2/29 0.38 [ 0.06, 2.30 ]
Chang 2005 IPD 7/176 5/178 1.36 [ 0.44, 4.22 ]
Charu 2007 IPD 8/228 2/59 0.89 [ 0.19, 4.18 ]
Dammacco 2001 IPD 1/69 7/76 0.23 [ 0.06, 0.90 ]
Debus 2006 IPD 26/195 18/190 1.38 [ 0.76, 2.50 ]
Del Mastro 1997 0/31 0/31 0.0 [ 0.0, 0.0 ]
Dunphy 1999 0/15 1/15 0.14 [ 0.00, 6.82 ]
EPO-GER-20 IPD 6/48 8/45 0.61 [ 0.21, 1.77 ]
EPO-INT-1 IPD 6/165 2/81 1.51 [ 0.35, 6.54 ]
EPO-INT-3 IPD 9/135 3/65 1.55 [ 0.47, 5.10 ]
Fujisaka 2011 1/89 0/92 7.69 [ 0.15, 387.58 ]
Gordon 2008 IPD 11/164 5/56 0.74 [ 0.26, 2.14 ]
Goss 2005 IPD 4/52 1/52 3.40 [ 0.59, 19.63 ]
Grote 2005 IPD 16/109 21/115 0.79 [ 0.41, 1.52 ]
Hedenus 2002 0/55 0/11 0.0 [ 0.0, 0.0 ]
Hedenus 2003 IPD 10/176 4/173 2.40 [ 0.84, 6.87 ]
Henke 2003 IPD 9/180 7/171 1.22 [ 0.46, 3.25 ]
Henry 1995 IPD 7/67 10/65 0.68 [ 0.26, 1.77 ]
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Hernandez 2009 IPD 17/196 20/195 0.84 [ 0.44, 1.60 ]
Hoskin 2009 IPD 5/151 2/149 2.36 [ 0.54, 10.33 ]
Huddart 2002 IPD 3/48 7/47 0.62 [ 0.16, 2.43 ]
Kotasek 2002 IPD 4/129 0/32 3.49 [ 0.30, 40.45 ]
Kotasek 2003 IPD 4/208 1/51 0.99 [ 0.11, 8.84 ]
Krzakowski 2008a 6/104 2/52 1.48 [ 0.33, 6.67 ]
Krzakowski 2008b 10/105 3/52 1.64 [ 0.49, 5.44 ]
Kurz 1997 0/23 0/12 0.0 [ 0.0, 0.0 ]
Leyland-Jones 2005 IPD 121/469 91/470 1.41 [ 1.08, 1.85 ]
Littlewood 2001 IPD 40/251 22/124 0.78 [ 0.46, 1.34 ]
Machtay 2007 IPD 5/77 3/71 1.57 [ 0.39, 6.31 ]
Milroy 2003 IPD 51/214 38/210 1.45 [ 0.95, 2.21 ]
Moebus 2007 IPD 0/324 0/319 0.0 [ 0.0, 0.0 ]
Mystakidou 2005 1/50 2/50 0.50 [ 0.05, 5.00 ]
O’Shaugnessy 2005 IPD 1/51 0/49 7.69 [ 0.15, 387.58 ]
OBE/EPO-INT-03 IPD 2/35 3/37 0.76 [ 0.13, 4.55 ]
Oberhoff 1998 IPD 9/116 10/111 0.62 [ 0.24, 1.59 ]
Osterborg 1996 IPD 24/99 12/49 1.00 [ 0.50, 2.00 ]
Osterborg 2002 IPD 24/173 19/176 1.29 [ 0.71, 2.35 ]
P-174 IPD 1/33 1/12 0.44 [ 0.03, 7.27 ]
Pirker 2008 IPD 53/299 51/301 1.02 [ 0.70, 1.49 ]
Pronzato 2010 IPD 4/110 8/113 0.52 [ 0.17, 1.60 ]
Quirt 1996 IPD 2/28 0/28 5.78 [ 0.35, 95.11 ]
Ray-Coquard 2009 IPD 18/110 23/108 0.74 [ 0.40, 1.36 ]
Razzouk 2004 2/112 2/110 0.98 [ 0.14, 7.03 ]
Rose 1994 IPD 16/142 6/79 1.66 [ 0.70, 3.92 ]
Rosen 2003 1/47 0/43 6.82 [ 0.14, 343.75 ]
Savonije 2005 IPD 24/211 13/104 0.91 [ 0.45, 1.82 ]
Smith 2003 3/64 0/22 3.96 [ 0.29, 54.28 ]
Smith 2008 IPD 136/517 94/472 1.37 [ 1.05, 1.78 ]
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Strauss 2008 IPD 0/34 0/40 0.0 [ 0.0, 0.0 ]
Ten Bokkel1998 IPD 5/87 2/33 0.99 [ 0.19, 5.11 ]
Thatcher 1999 IPD 7/86 3/44 1.13 [ 0.29, 4.36 ]
Thomas 2002 IPD 4/65 4/65 0.99 [ 0.25, 3.95 ]
Thomas 2008 IPD 1/58 1/56 0.94 [ 0.06, 15.06 ]
Thompson 2000 3/45 0/21 4.52 [ 0.38, 53.37 ]
Throuvalas 2000 0/28 1/27 0.13 [ 0.00, 6.55 ]
Tjulandin 2010a 5/76 6/37 0.28 [ 0.07, 1.08 ]
Tjulandin 2010b 4/73 6/37 0.34 [ 0.09, 1.26 ]
Tjulandin 2011 6/95 5/91 1.16 [ 0.34, 3.90 ]
Untch 2008 IPD 0/353 0/376 0.0 [ 0.0, 0.0 ]
Vansteenkiste 2002 IPD 23/159 21/161 1.06 [ 0.58, 1.92 ]
Wilkinson 2006 IPD 2/121 0/61 4.63 [ 0.25, 86.06 ]
Witzig 2005 IPD 31/174 25/170 1.22 [ 0.72, 2.06 ]
Wright 2007 IPD 25/33 23/37 1.68 [ 0.95, 2.99 ]
Subtotal (95% CI) 8682 7024 1.16 [ 1.05, 1.28 ]
Heterogeneity: Chi2 = 55.17, df = 61 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 2.94 (P = 0.0033)
2 more than 10% of participants per study arm excluded
Sweeney 1998 0/24 0/24 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 24 24 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
3 Unclear
ML17616 2006 1/30 0/30 7.39 [ 0.15, 372.38 ]
ML17620 2006 4/61 0/60 7.70 [ 1.05, 56.33 ]
Subtotal (95% CI) 91 90 7.64 [ 1.29, 45.03 ]
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 2.25 (P = 0.025)
Total (95% CI) 1.17 [ 1.06, 1.29 ]
Heterogeneity: Chi2 = 59.49, df = 63 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 3.06 (P = 0.0022)
Test for subgroup differences: Chi2 = 4.31, df = 1 (P = 0.04), I2 =77%
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Analysis 6.16. Comparison 6 On-study mortality, Outcome 16 On-study mortality - sensitivity analysis -
follow-up.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 6 On-study mortality
Outcome: 16 On-study mortality - sensitivity analysis - follow-up












1 Short term follow subgroup
Aapro 2008 IPD 47/231 35/232 1.38 [ 0.89, 2.13 ]
Abels 1993 IPD 13/65 12/59 0.96 [ 0.44, 2.10 ]
Bamias 2003 7/72 4/72 1.80 [ 0.53, 6.12 ]
Boogaerts 2003 IPD 10/132 10/127 1.02 [ 0.42, 2.46 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Case 1993 IPD 10/81 9/76 1.11 [ 0.45, 2.73 ]
Cazzola 1995 IPD 3/114 2/29 0.38 [ 0.06, 2.30 ]
Chang 2005 IPD 7/176 5/178 1.36 [ 0.44, 4.22 ]
Charu 2007 IPD 8/228 2/59 0.89 [ 0.19, 4.18 ]
Dammacco 2001 IPD 1/69 7/76 0.23 [ 0.06, 0.90 ]
Debus 2006 IPD 26/195 18/190 1.38 [ 0.76, 2.50 ]
Del Mastro 1997 0/31 0/31 0.0 [ 0.0, 0.0 ]
Dunphy 1999 0/15 1/15 0.14 [ 0.00, 6.82 ]
EPO-GER-20 IPD 6/48 8/45 0.61 [ 0.21, 1.77 ]
EPO-INT-1 IPD 6/165 2/81 1.51 [ 0.35, 6.54 ]
EPO-INT-3 IPD 9/135 3/65 1.55 [ 0.47, 5.10 ]
Fujisaka 2011 1/89 0/92 7.69 [ 0.15, 387.58 ]
Gordon 2008 IPD 11/164 5/56 0.74 [ 0.26, 2.14 ]
Goss 2005 IPD 4/52 1/52 3.40 [ 0.59, 19.63 ]
Grote 2005 IPD 16/109 21/115 0.79 [ 0.41, 1.52 ]
Hedenus 2002 0/55 0/11 0.0 [ 0.0, 0.0 ]
Hedenus 2003 IPD 10/176 4/173 2.40 [ 0.84, 6.87 ]
0.01 0.1 1 10 100
Favours treatment Favours control
(Continued . . . )
528Erythropoietin or darbepoetin for patients with cancer (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)












Henke 2003 IPD 9/180 7/171 1.22 [ 0.46, 3.25 ]
Henry 1995 IPD 7/67 10/65 0.68 [ 0.26, 1.77 ]
Hernandez 2009 IPD 17/196 20/195 0.84 [ 0.44, 1.60 ]
Hoskin 2009 IPD 5/151 2/149 2.36 [ 0.54, 10.33 ]
Huddart 2002 IPD 3/48 7/47 0.62 [ 0.16, 2.43 ]
Kotasek 2002 IPD 4/129 0/32 3.49 [ 0.30, 40.45 ]
Kotasek 2003 IPD 4/208 1/51 0.99 [ 0.11, 8.84 ]
Krzakowski 2008a 6/104 2/52 1.48 [ 0.33, 6.67 ]
Krzakowski 2008b 10/105 3/52 1.64 [ 0.49, 5.44 ]
Kurz 1997 0/23 0/12 0.0 [ 0.0, 0.0 ]
Leyland-Jones 2005 IPD 121/469 91/470 1.41 [ 1.08, 1.85 ]
Littlewood 2001 IPD 40/251 22/124 0.78 [ 0.46, 1.34 ]
Machtay 2007 IPD 5/77 3/71 1.57 [ 0.39, 6.31 ]
Milroy 2003 IPD 51/214 38/210 1.45 [ 0.95, 2.21 ]
ML17616 2006 1/30 0/30 7.39 [ 0.15, 372.38 ]
ML17620 2006 4/61 0/60 7.70 [ 1.05, 56.33 ]
Moebus 2007 IPD 0/324 0/319 0.0 [ 0.0, 0.0 ]
Mystakidou 2005 1/50 2/50 0.50 [ 0.05, 5.00 ]
O’Shaugnessy 2005 IPD 1/51 0/49 7.69 [ 0.15, 387.58 ]
OBE/EPO-INT-03 IPD 2/35 3/37 0.76 [ 0.13, 4.55 ]
Oberhoff 1998 IPD 9/116 10/111 0.62 [ 0.24, 1.59 ]
Osterborg 1996 IPD 24/99 12/49 1.00 [ 0.50, 2.00 ]
Osterborg 2002 IPD 24/173 19/176 1.29 [ 0.71, 2.35 ]
P-174 IPD 1/33 1/12 0.44 [ 0.03, 7.27 ]
Pirker 2008 IPD 53/299 51/301 1.02 [ 0.70, 1.49 ]
Pronzato 2010 IPD 4/110 8/113 0.52 [ 0.17, 1.60 ]
Quirt 1996 IPD 2/28 0/28 5.78 [ 0.35, 95.11 ]
Ray-Coquard 2009 IPD 18/110 23/108 0.74 [ 0.40, 1.36 ]
Razzouk 2004 2/112 2/110 0.98 [ 0.14, 7.03 ]
Rose 1994 IPD 16/142 6/79 1.66 [ 0.70, 3.92 ]
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Rosen 2003 1/47 0/43 6.82 [ 0.14, 343.75 ]
Savonije 2005 IPD 24/211 13/104 0.91 [ 0.45, 1.82 ]
Smith 2003 3/64 0/22 3.96 [ 0.29, 54.28 ]
Smith 2008 IPD 136/517 94/472 1.37 [ 1.05, 1.78 ]
Strauss 2008 IPD 0/34 0/40 0.0 [ 0.0, 0.0 ]
Sweeney 1998 0/24 0/24 0.0 [ 0.0, 0.0 ]
Ten Bokkel1998 IPD 5/87 2/33 0.99 [ 0.19, 5.11 ]
Thatcher 1999 IPD 7/86 3/44 1.13 [ 0.29, 4.36 ]
Thomas 2002 IPD 4/65 4/65 0.99 [ 0.25, 3.95 ]
Thomas 2008 IPD 1/58 1/56 0.94 [ 0.06, 15.06 ]
Thompson 2000 3/45 0/21 4.52 [ 0.38, 53.37 ]
Throuvalas 2000 0/28 1/27 0.13 [ 0.00, 6.55 ]
Tjulandin 2010a 5/76 6/37 0.28 [ 0.07, 1.08 ]
Tjulandin 2010b 4/73 6/37 0.34 [ 0.09, 1.26 ]
Tjulandin 2011 6/95 5/91 1.16 [ 0.34, 3.90 ]
Untch 2008 IPD 0/353 0/376 0.0 [ 0.0, 0.0 ]
Vansteenkiste 2002 IPD 23/159 21/161 1.06 [ 0.58, 1.92 ]
Wilkinson 2006 IPD 2/121 0/61 4.63 [ 0.25, 86.06 ]
Witzig 2005 IPD 31/174 25/170 1.22 [ 0.72, 2.06 ]
Wright 2007 IPD 25/33 23/37 1.68 [ 0.95, 2.99 ]
Subtotal (95% CI) 8797 7138 1.17 [ 1.06, 1.29 ]
Heterogeneity: Chi2 = 59.49, df = 63 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 3.06 (P = 0.0022)
2 Short term from Kaplan Meier curve
Antonadou 2001 0/190 0/195 0.0 [ 0.0, 0.0 ]
Blohmer 2011 2/127 1/129 1.99 [ 0.20, 19.45 ]
Christodoulou 2009 17/167 14/170 1.26 [ 0.60, 2.64 ]
Engert 2010 3/648 6/655 0.52 [ 0.14, 1.91 ]
Gupta 2009 1/58 2/57 0.50 [ 0.05, 4.90 ]
Overgaard 2009 3/255 2/259 1.52 [ 0.26, 8.84 ]
Winquist 2009 8/26 10/30 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 1471 1495 1.06 [ 0.60, 1.86 ]
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Heterogeneity: Chi2 = 2.24, df = 4 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.20 (P = 0.84)
3 Long term follow up
Tsuboi 2009 21/61 19/56 0.94 [ 0.57, 1.54 ]
Subtotal (95% CI) 61 56 0.94 [ 0.57, 1.54 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.25 (P = 0.81)
Total (95% CI) 1.16 [ 1.05, 1.27 ]
Heterogeneity: Chi2 = 62.54, df = 69 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 2.94 (P = 0.0033)
Test for subgroup differences: Chi2 = 0.81, df = 2 (P = 0.67), I2 =0.0%
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Analysis 6.17. Comparison 6 On-study mortality, Outcome 17 On-study mortality - sensitivity analysis
experimental arms merged.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 6 On-study mortality
Outcome: 17 On-study mortality - sensitivity analysis experimental arms merged












Aapro 2008 IPD 47/231 35/232 1.38 [ 0.89, 2.13 ]
Abels 1993 IPD 13/65 12/59 0.96 [ 0.44, 2.10 ]
Bamias 2003 7/72 4/72 1.80 [ 0.53, 6.12 ]
Boogaerts 2003 IPD 10/132 10/127 1.02 [ 0.42, 2.46 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Case 1993 IPD 10/81 9/76 1.11 [ 0.45, 2.73 ]
Cazzola 1995 IPD 3/114 2/29 0.38 [ 0.06, 2.30 ]
Chang 2005 IPD 7/176 5/178 1.36 [ 0.44, 4.22 ]
Charu 2007 IPD 8/228 2/59 0.89 [ 0.19, 4.18 ]
Dammacco 2001 IPD 1/69 7/76 0.23 [ 0.06, 0.90 ]
Debus 2006 IPD 26/195 18/190 1.38 [ 0.76, 2.50 ]
Del Mastro 1997 0/31 0/31 0.0 [ 0.0, 0.0 ]
Dunphy 1999 0/15 1/15 0.14 [ 0.00, 6.82 ]
EPO-GER-20 IPD 6/48 8/45 0.61 [ 0.21, 1.77 ]
EPO-INT-1 IPD 6/165 2/81 1.51 [ 0.35, 6.54 ]
EPO-INT-3 IPD 9/135 3/65 1.55 [ 0.47, 5.10 ]
Fujisaka 2011 1/89 0/92 7.69 [ 0.15, 387.58 ]
Gordon 2008 IPD 11/164 5/56 0.74 [ 0.26, 2.14 ]
Goss 2005 IPD 4/52 1/52 3.40 [ 0.59, 19.63 ]
Grote 2005 IPD 16/109 21/115 0.79 [ 0.41, 1.52 ]
Hedenus 2002 0/55 0/11 0.0 [ 0.0, 0.0 ]
Hedenus 2003 IPD 10/176 4/173 2.40 [ 0.84, 6.87 ]
Henke 2003 IPD 9/180 7/171 1.22 [ 0.46, 3.25 ]
Henry 1995 IPD 7/67 10/65 0.68 [ 0.26, 1.77 ]
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Hernandez 2009 IPD 17/196 20/195 0.84 [ 0.44, 1.60 ]
Hoskin 2009 IPD 5/151 2/149 2.36 [ 0.54, 10.33 ]
Huddart 2002 IPD 3/48 7/47 0.62 [ 0.16, 2.43 ]
Kotasek 2002 IPD 4/129 0/32 3.49 [ 0.30, 40.45 ]
Kotasek 2003 IPD 4/208 1/51 0.99 [ 0.11, 8.84 ]
Krzakowski 2008 16/209 5/104 3.20 [ 0.71, 14.41 ]
Kurz 1997 0/23 0/12 0.0 [ 0.0, 0.0 ]
Leyland-Jones 2005 IPD 121/469 91/470 1.41 [ 1.08, 1.85 ]
Littlewood 2001 IPD 40/251 22/124 0.78 [ 0.46, 1.34 ]
Machtay 2007 IPD 5/77 3/71 1.57 [ 0.39, 6.31 ]
Milroy 2003 IPD 51/214 38/210 1.45 [ 0.95, 2.21 ]
ML17616 2006 1/30 0/30 7.39 [ 0.15, 372.38 ]
ML17620 2006 4/61 0/60 7.70 [ 1.05, 56.33 ]
Moebus 2007 IPD 0/324 0/319 0.0 [ 0.0, 0.0 ]
Mystakidou 2005 1/50 2/50 0.50 [ 0.05, 5.00 ]
O’Shaugnessy 2005 IPD 1/51 0/49 7.69 [ 0.15, 387.58 ]
OBE/EPO-INT-03 IPD 2/35 3/37 0.76 [ 0.13, 4.55 ]
Oberhoff 1998 IPD 9/116 10/111 0.62 [ 0.24, 1.59 ]
Osterborg 1996 IPD 24/99 12/49 1.00 [ 0.50, 2.00 ]
Osterborg 2002 IPD 24/173 19/176 1.29 [ 0.71, 2.35 ]
P-174 IPD 1/33 1/12 0.44 [ 0.03, 7.27 ]
Pirker 2008 IPD 53/299 51/301 1.02 [ 0.70, 1.49 ]
Pronzato 2010 IPD 4/110 8/113 0.52 [ 0.17, 1.60 ]
Quirt 1996 IPD 2/28 0/28 5.78 [ 0.35, 95.11 ]
Ray-Coquard 2009 IPD 18/110 23/108 0.74 [ 0.40, 1.36 ]
Razzouk 2004 2/112 2/110 0.98 [ 0.14, 7.03 ]
Rose 1994 IPD 16/142 6/79 1.66 [ 0.70, 3.92 ]
Rosen 2003 1/47 0/43 6.82 [ 0.14, 343.75 ]
Savonije 2005 IPD 24/211 13/104 0.91 [ 0.45, 1.82 ]
Smith 2003 3/64 0/22 3.96 [ 0.29, 54.28 ]
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Smith 2008 IPD 136/517 94/472 1.37 [ 1.05, 1.78 ]
Strauss 2008 IPD 0/34 0/40 0.0 [ 0.0, 0.0 ]
Sweeney 1998 0/24 0/24 0.0 [ 0.0, 0.0 ]
Ten Bokkel1998 IPD 5/87 2/33 0.99 [ 0.19, 5.11 ]
Thatcher 1999 IPD 7/86 3/44 1.13 [ 0.29, 4.36 ]
Thomas 2002 IPD 4/65 4/65 0.99 [ 0.25, 3.95 ]
Thomas 2008 IPD 1/58 1/56 0.94 [ 0.06, 15.06 ]
Thompson 2000 3/45 0/21 4.52 [ 0.38, 53.37 ]
Throuvalas 2000 0/28 1/27 0.13 [ 0.00, 6.55 ]
Tjulandin 2010 9/149 12/74 0.31 [ 0.12, 0.79 ]
Tjulandin 2011 6/95 5/91 1.16 [ 0.34, 3.90 ]
Untch 2008 IPD 0/353 0/376 0.0 [ 0.0, 0.0 ]
Vansteenkiste 2002 IPD 23/159 21/161 1.06 [ 0.58, 1.92 ]
Wilkinson 2006 IPD 2/121 0/61 4.63 [ 0.25, 86.06 ]
Witzig 2005 IPD 31/174 25/170 1.22 [ 0.72, 2.06 ]
Wright 2007 IPD 25/33 23/37 1.68 [ 0.95, 2.99 ]
Total (95% CI) 1.17 [ 1.06, 1.29 ]
Heterogeneity: Chi2 = 60.78, df = 61 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 3.07 (P = 0.0021)
Test for subgroup differences: Not applicable
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Analysis 6.18. Comparison 6 On-study mortality, Outcome 18 On-study mortality - sensitivity analysis
intention-to-treat.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 6 On-study mortality
Outcome: 18 On-study mortality - sensitivity analysis intention-to-treat












1 ITT or less than 10% of participants per study arm excluded
Aapro 2008 IPD 47/231 35/232 1.38 [ 0.89, 2.13 ]
Abels 1993 IPD 13/65 12/59 0.96 [ 0.44, 2.10 ]
Bamias 2003 7/72 4/72 1.80 [ 0.53, 6.12 ]
Boogaerts 2003 IPD 10/132 10/127 1.02 [ 0.42, 2.46 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Case 1993 IPD 10/81 9/76 1.11 [ 0.45, 2.73 ]
Cazzola 1995 IPD 3/114 2/29 0.38 [ 0.06, 2.30 ]
Chang 2005 IPD 7/176 5/178 1.36 [ 0.44, 4.22 ]
Charu 2007 IPD 8/228 2/59 0.89 [ 0.19, 4.18 ]
Dammacco 2001 IPD 1/69 7/76 0.23 [ 0.06, 0.90 ]
Debus 2006 IPD 26/195 18/190 1.38 [ 0.76, 2.50 ]
Del Mastro 1997 0/31 0/31 0.0 [ 0.0, 0.0 ]
Dunphy 1999 0/15 1/15 0.14 [ 0.00, 6.82 ]
EPO-GER-20 IPD 6/48 8/45 0.61 [ 0.21, 1.77 ]
EPO-INT-1 IPD 6/165 2/81 1.51 [ 0.35, 6.54 ]
EPO-INT-3 IPD 9/135 3/65 1.55 [ 0.47, 5.10 ]
Fujisaka 2011 1/89 0/92 7.69 [ 0.15, 387.58 ]
Gordon 2008 IPD 11/164 5/56 0.74 [ 0.26, 2.14 ]
Goss 2005 IPD 4/52 1/52 3.40 [ 0.59, 19.63 ]
Grote 2005 IPD 16/109 21/115 0.79 [ 0.41, 1.52 ]
Hedenus 2002 0/55 0/11 0.0 [ 0.0, 0.0 ]
Hedenus 2003 IPD 10/176 4/173 2.40 [ 0.84, 6.87 ]
Henke 2003 IPD 9/180 7/171 1.22 [ 0.46, 3.25 ]
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Henry 1995 IPD 7/67 10/65 0.68 [ 0.26, 1.77 ]
Hernandez 2009 IPD 17/196 20/195 0.84 [ 0.44, 1.60 ]
Hoskin 2009 IPD 5/151 2/149 2.36 [ 0.54, 10.33 ]
Huddart 2002 IPD 3/48 7/47 0.62 [ 0.16, 2.43 ]
Kotasek 2002 IPD 4/129 0/32 3.49 [ 0.30, 40.45 ]
Kotasek 2003 IPD 4/208 1/51 0.99 [ 0.11, 8.84 ]
Krzakowski 2008a 6/104 2/52 1.48 [ 0.33, 6.67 ]
Krzakowski 2008b 10/105 3/52 1.64 [ 0.49, 5.44 ]
Kurz 1997 0/23 0/12 0.0 [ 0.0, 0.0 ]
Leyland-Jones 2005 IPD 121/469 91/470 1.41 [ 1.08, 1.85 ]
Littlewood 2001 IPD 40/251 22/124 0.78 [ 0.46, 1.34 ]
Machtay 2007 IPD 5/77 3/71 1.57 [ 0.39, 6.31 ]
Milroy 2003 IPD 51/214 38/210 1.45 [ 0.95, 2.21 ]
Moebus 2007 IPD 0/324 0/319 0.0 [ 0.0, 0.0 ]
Mystakidou 2005 1/50 2/50 0.50 [ 0.05, 5.00 ]
O’Shaugnessy 2005 IPD 1/51 0/49 7.69 [ 0.15, 387.58 ]
OBE/EPO-INT-03 IPD 2/35 3/37 0.76 [ 0.13, 4.55 ]
Oberhoff 1998 IPD 9/116 10/111 0.62 [ 0.24, 1.59 ]
Osterborg 1996 IPD 24/99 12/49 1.00 [ 0.50, 2.00 ]
Osterborg 2002 IPD 24/173 19/176 1.29 [ 0.71, 2.35 ]
P-174 IPD 1/33 1/12 0.44 [ 0.03, 7.27 ]
Pirker 2008 IPD 53/299 51/301 1.02 [ 0.70, 1.49 ]
Pronzato 2010 IPD 4/110 8/113 0.52 [ 0.17, 1.60 ]
Quirt 1996 IPD 2/28 0/28 5.78 [ 0.35, 95.11 ]
Ray-Coquard 2009 IPD 18/110 23/108 0.74 [ 0.40, 1.36 ]
Razzouk 2004 2/112 2/110 0.98 [ 0.14, 7.03 ]
Rose 1994 IPD 16/142 6/79 1.66 [ 0.70, 3.92 ]
Rosen 2003 1/47 0/43 6.82 [ 0.14, 343.75 ]
Savonije 2005 IPD 24/211 13/104 0.91 [ 0.45, 1.82 ]
Smith 2003 3/64 0/22 3.96 [ 0.29, 54.28 ]
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Smith 2008 IPD 136/517 94/472 1.37 [ 1.05, 1.78 ]
Strauss 2008 IPD 0/34 0/40 0.0 [ 0.0, 0.0 ]
Ten Bokkel1998 IPD 5/87 2/33 0.99 [ 0.19, 5.11 ]
Thatcher 1999 IPD 7/86 3/44 1.13 [ 0.29, 4.36 ]
Thomas 2002 IPD 4/65 4/65 0.99 [ 0.25, 3.95 ]
Thomas 2008 IPD 1/58 1/56 0.94 [ 0.06, 15.06 ]
Thompson 2000 3/45 0/21 4.52 [ 0.38, 53.37 ]
Throuvalas 2000 0/28 1/27 0.13 [ 0.00, 6.55 ]
Tjulandin 2010a 5/76 6/37 0.28 [ 0.07, 1.08 ]
Tjulandin 2010b 4/73 6/37 0.34 [ 0.09, 1.26 ]
Tjulandin 2011 6/95 5/91 1.16 [ 0.34, 3.90 ]
Untch 2008 IPD 0/353 0/376 0.0 [ 0.0, 0.0 ]
Vansteenkiste 2002 IPD 23/159 21/161 1.06 [ 0.58, 1.92 ]
Wilkinson 2006 IPD 2/121 0/61 4.63 [ 0.25, 86.06 ]
Witzig 2005 IPD 31/174 25/170 1.22 [ 0.72, 2.06 ]
Wright 2007 IPD 25/33 23/37 1.68 [ 0.95, 2.99 ]
Subtotal (95% CI) 8682 7024 1.16 [ 1.05, 1.28 ]
Heterogeneity: Chi2 = 55.17, df = 61 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 2.94 (P = 0.0033)
2 more than 10% of participants per study arm excluded
Sweeney 1998 0/24 0/24 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 24 24 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Total (95% CI) 1.16 [ 1.05, 1.28 ]
Heterogeneity: Chi2 = 55.17, df = 61 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 2.94 (P = 0.0033)
Test for subgroup differences: Not applicable
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Analysis 6.19. Comparison 6 On-study mortality, Outcome 19 On-study mortality - sensitivity analysis
excluding Leyland and Smith.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 6 On-study mortality
Outcome: 19 On-study mortality - sensitivity analysis excluding Leyland and Smith












Aapro 2008 IPD 47/231 35/232 1.38 [ 0.89, 2.13 ]
Abels 1993 IPD 13/65 12/59 0.96 [ 0.44, 2.10 ]
Bamias 2003 7/72 4/72 1.80 [ 0.53, 6.12 ]
Boogaerts 2003 IPD 10/132 10/127 1.02 [ 0.42, 2.46 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Case 1993 IPD 10/81 9/76 1.11 [ 0.45, 2.73 ]
Cazzola 1995 IPD 3/114 2/29 0.38 [ 0.06, 2.30 ]
Chang 2005 IPD 7/176 5/178 1.36 [ 0.44, 4.22 ]
Charu 2007 IPD 8/228 2/59 0.89 [ 0.19, 4.18 ]
Dammacco 2001 IPD 1/69 7/76 0.23 [ 0.06, 0.90 ]
Debus 2006 IPD 26/195 18/190 1.38 [ 0.76, 2.50 ]
Del Mastro 1997 0/31 0/31 0.0 [ 0.0, 0.0 ]
Dunphy 1999 0/15 1/15 0.14 [ 0.00, 6.82 ]
EPO-GER-20 IPD 6/48 8/45 0.61 [ 0.21, 1.77 ]
EPO-INT-1 IPD 6/165 2/81 1.51 [ 0.35, 6.54 ]
EPO-INT-3 IPD 9/135 3/65 1.55 [ 0.47, 5.10 ]
Fujisaka 2011 1/89 0/92 7.69 [ 0.15, 387.58 ]
Gordon 2008 IPD 11/164 5/56 0.74 [ 0.26, 2.14 ]
Goss 2005 IPD 4/52 1/52 3.40 [ 0.59, 19.63 ]
Grote 2005 IPD 16/109 21/115 0.79 [ 0.41, 1.52 ]
Hedenus 2002 0/55 0/11 0.0 [ 0.0, 0.0 ]
Hedenus 2003 IPD 10/176 4/173 2.40 [ 0.84, 6.87 ]
Henke 2003 IPD 9/180 7/171 1.22 [ 0.46, 3.25 ]
Henry 1995 IPD 7/67 10/65 0.68 [ 0.26, 1.77 ]
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Hernandez 2009 IPD 17/196 20/195 0.84 [ 0.44, 1.60 ]
Hoskin 2009 IPD 5/151 2/149 2.36 [ 0.54, 10.33 ]
Huddart 2002 IPD 3/48 7/47 0.62 [ 0.16, 2.43 ]
Kotasek 2002 IPD 4/129 0/32 3.49 [ 0.30, 40.45 ]
Kotasek 2003 IPD 4/208 1/51 0.99 [ 0.11, 8.84 ]
Krzakowski 2008a 6/104 2/52 1.48 [ 0.33, 6.67 ]
Krzakowski 2008b 10/105 3/52 1.64 [ 0.49, 5.44 ]
Kurz 1997 0/23 0/12 0.0 [ 0.0, 0.0 ]
Littlewood 2001 IPD 40/251 22/124 0.78 [ 0.46, 1.34 ]
Machtay 2007 IPD 5/77 3/71 1.57 [ 0.39, 6.31 ]
Milroy 2003 IPD 51/214 38/210 1.45 [ 0.95, 2.21 ]
ML17616 2006 1/30 0/30 7.39 [ 0.15, 372.38 ]
ML17620 2006 4/61 0/60 7.70 [ 1.05, 56.33 ]
Moebus 2007 IPD 0/324 0/319 0.0 [ 0.0, 0.0 ]
Mystakidou 2005 1/50 2/50 0.50 [ 0.05, 5.00 ]
O’Shaugnessy 2005 IPD 1/51 0/49 7.69 [ 0.15, 387.58 ]
OBE/EPO-INT-03 IPD 2/35 3/37 0.76 [ 0.13, 4.55 ]
Oberhoff 1998 IPD 9/116 10/111 0.62 [ 0.24, 1.59 ]
Osterborg 1996 IPD 24/99 12/49 1.00 [ 0.50, 2.00 ]
Osterborg 2002 IPD 24/173 19/176 1.29 [ 0.71, 2.35 ]
P-174 IPD 1/33 1/12 0.44 [ 0.03, 7.27 ]
Pirker 2008 IPD 53/299 51/301 1.02 [ 0.70, 1.49 ]
Pronzato 2010 IPD 4/110 8/113 0.52 [ 0.17, 1.60 ]
Quirt 1996 IPD 2/28 0/28 5.78 [ 0.35, 95.11 ]
Ray-Coquard 2009 IPD 18/110 23/108 0.74 [ 0.40, 1.36 ]
Razzouk 2004 2/112 2/110 0.98 [ 0.14, 7.03 ]
Rose 1994 IPD 16/142 6/79 1.66 [ 0.70, 3.92 ]
Rosen 2003 1/47 0/43 6.82 [ 0.14, 343.75 ]
Savonije 2005 IPD 24/211 13/104 0.91 [ 0.45, 1.82 ]
Smith 2003 3/64 0/22 3.96 [ 0.29, 54.28 ]
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Strauss 2008 IPD 0/34 0/40 0.0 [ 0.0, 0.0 ]
Sweeney 1998 0/24 0/24 0.0 [ 0.0, 0.0 ]
Ten Bokkel1998 IPD 5/87 2/33 0.99 [ 0.19, 5.11 ]
Thatcher 1999 IPD 7/86 3/44 1.13 [ 0.29, 4.36 ]
Thomas 2002 IPD 4/65 4/65 0.99 [ 0.25, 3.95 ]
Thomas 2008 IPD 1/58 1/56 0.94 [ 0.06, 15.06 ]
Thompson 2000 3/45 0/21 4.52 [ 0.38, 53.37 ]
Throuvalas 2000 0/28 1/27 0.13 [ 0.00, 6.55 ]
Tjulandin 2010a 5/76 6/37 0.28 [ 0.07, 1.08 ]
Tjulandin 2010b 4/73 6/37 0.34 [ 0.09, 1.26 ]
Tjulandin 2011 6/95 5/91 1.16 [ 0.34, 3.90 ]
Untch 2008 IPD 0/353 0/376 0.0 [ 0.0, 0.0 ]
Vansteenkiste 2002 IPD 23/159 21/161 1.06 [ 0.58, 1.92 ]
Wilkinson 2006 IPD 2/121 0/61 4.63 [ 0.25, 86.06 ]
Witzig 2005 IPD 31/174 25/170 1.22 [ 0.72, 2.06 ]
Wright 2007 IPD 25/33 23/37 1.68 [ 0.95, 2.99 ]
Total (95% CI) 1.09 [ 0.97, 1.23 ]
Heterogeneity: Chi2 = 54.92, df = 61 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 1.47 (P = 0.14)
Test for subgroup differences: Not applicable
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Analysis 7.1. Comparison 7 Complete tumour response, Outcome 1 Complete tumour response.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 7 Complete tumour response
Outcome: 1 Complete tumour response
Study or subgroup control treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cascinu 1994 2/50 1/50 0.1 % 2.00 [ 0.19, 21.36 ]
Cazzola 1995a 2/24 0/6 0.1 % 1.40 [ 0.08, 25.92 ]
Cazzola 1995b 1/26 1/7 0.2 % 0.27 [ 0.02, 3.78 ]
Cazzola 1995c 2/26 0/6 0.1 % 1.30 [ 0.07, 24.04 ]
Cazzola 1995d 2/23 0/6 0.1 % 1.46 [ 0.08, 26.97 ]
Dammacco 2001 15/64 10/63 1.0 % 1.48 [ 0.72, 3.04 ]
Engert 2010 606/648 614/655 59.4 % 1.00 [ 0.97, 1.03 ]
Grote 2005 20/109 21/115 2.0 % 1.00 [ 0.58, 1.75 ]
Hoskin 2009 GBR-7 FDA 04 109/115 105/110 10.4 % 0.99 [ 0.94, 1.05 ]
Leyland-Jones 05 J%J 04 49/469 41/470 4.0 % 1.20 [ 0.81, 1.78 ]
Littlewood 2001 46/251 10/124 1.3 % 2.27 [ 1.19, 4.35 ]
Machtay 2007 52/71 52/70 5.1 % 0.99 [ 0.81, 1.20 ]
Osterborg 2002 9/154 5/162 0.5 % 1.89 [ 0.65, 5.52 ]
Strauss 2008 18/34 23/40 2.1 % 0.92 [ 0.61, 1.39 ]
Ten Bokkel 1998a 23/40 10/15 1.4 % 0.86 [ 0.55, 1.35 ]
Ten Bokkel 1998b 18/34 9/15 1.2 % 0.88 [ 0.52, 1.49 ]
Throuvalas 2000 22/28 18/26 1.8 % 1.13 [ 0.82, 1.56 ]
Untch 2011˙1 46/356 54/377 5.1 % 0.90 [ 0.63, 1.30 ]
Wilkinson 2006 55/114 33/59 4.2 % 0.86 [ 0.64, 1.16 ]
Total (95% CI) 2636 2376 100.0 % 1.02 [ 0.98, 1.06 ]
Total events: 1097 (control), 1007 (treatment)
Heterogeneity: Chi2 = 16.10, df = 18 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.83 (P = 0.40)
Test for subgroup differences: Not applicable
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Analysis 7.2. Comparison 7 Complete tumour response, Outcome 2 Tumour-response specific quality
criteria.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 7 Complete tumour response
Outcome: 2 Tumour-response specific quality criteria
Study or subgroup control treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 high quality
Engert 2010 606/648 614/655 59.4 % 1.00 [ 0.97, 1.03 ]
Hoskin 2009 GBR-7 FDA 04 109/115 105/110 10.4 % 0.99 [ 0.94, 1.05 ]
Machtay 2007 52/71 52/70 5.1 % 0.99 [ 0.81, 1.20 ]
Strauss 2008 18/34 23/40 2.1 % 0.92 [ 0.61, 1.39 ]
Untch 2011˙1 46/356 54/377 5.1 % 0.90 [ 0.63, 1.30 ]
Subtotal (95% CI) 1224 1252 82.1 % 0.99 [ 0.95, 1.02 ]
Total events: 831 (control), 848 (treatment)
Heterogeneity: Chi2 = 0.79, df = 4 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 0.66 (P = 0.51)
2 low quality
Cascinu 1994 2/50 1/50 0.1 % 2.00 [ 0.19, 21.36 ]
Cazzola 1995a 2/24 0/6 0.1 % 1.40 [ 0.08, 25.92 ]
Cazzola 1995b 1/26 1/7 0.2 % 0.27 [ 0.02, 3.78 ]
Cazzola 1995c 2/26 0/6 0.1 % 1.30 [ 0.07, 24.04 ]
Cazzola 1995d 2/23 0/6 0.1 % 1.46 [ 0.08, 26.97 ]
Dammacco 2001 15/64 10/63 1.0 % 1.48 [ 0.72, 3.04 ]
Grote 2005 20/109 21/115 2.0 % 1.00 [ 0.58, 1.75 ]
Leyland-Jones 05 J%J 04 49/469 41/470 4.0 % 1.20 [ 0.81, 1.78 ]
Littlewood 2001 46/251 10/124 1.3 % 2.27 [ 1.19, 4.35 ]
Osterborg 2002 9/154 5/162 0.5 % 1.89 [ 0.65, 5.52 ]
Ten Bokkel 1998a 23/40 10/15 1.4 % 0.86 [ 0.55, 1.35 ]
Ten Bokkel 1998b 18/34 9/15 1.2 % 0.88 [ 0.52, 1.49 ]
Throuvalas 2000 22/28 18/26 1.8 % 1.13 [ 0.82, 1.56 ]
Wilkinson 2006 55/114 33/59 4.2 % 0.86 [ 0.64, 1.16 ]
Subtotal (95% CI) 1412 1124 17.9 % 1.15 [ 0.98, 1.36 ]
Total events: 266 (control), 159 (treatment)
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Study or subgroup control treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: Chi2 = 13.53, df = 13 (P = 0.41); I2 =4%
Test for overall effect: Z = 1.72 (P = 0.086)
Total (95% CI) 2636 2376 100.0 % 1.02 [ 0.98, 1.06 ]
Total events: 1097 (control), 1007 (treatment)
Heterogeneity: Chi2 = 16.10, df = 18 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.83 (P = 0.40)
Test for subgroup differences: Chi2 = 3.29, df = 1 (P = 0.07), I2 =70%
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Analysis 7.3. Comparison 7 Complete tumour response, Outcome 3 Complete tumour response -
experimental study arms merged.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 7 Complete tumour response
Outcome: 3 Complete tumour response - experimental study arms merged
Study or subgroup control treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cascinu 1994 2/50 1/50 0.1 % 2.00 [ 0.19, 21.36 ]
Cazzola 1995 7/99 1/25 0.2 % 1.77 [ 0.23, 13.72 ]
Dammacco 2001 15/64 10/63 1.0 % 1.48 [ 0.72, 3.04 ]
Engert 2010 606/648 614/655 59.6 % 1.00 [ 0.97, 1.03 ]
Grote 2005 20/109 21/115 2.0 % 1.00 [ 0.58, 1.75 ]
Hoskin 2009 GBR-7 FDA 04 109/115 105/110 10.5 % 0.99 [ 0.94, 1.05 ]
Leyland-Jones 05 J%J 04 49/469 41/470 4.0 % 1.20 [ 0.81, 1.78 ]
Littlewood 2001 46/251 10/124 1.3 % 2.27 [ 1.19, 4.35 ]
Machtay 2007 52/71 52/70 5.1 % 0.99 [ 0.81, 1.20 ]
Osterborg 2002 9/154 5/162 0.5 % 1.89 [ 0.65, 5.52 ]
Strauss 2008 18/34 23/40 2.1 % 0.92 [ 0.61, 1.39 ]
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Study or subgroup control treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ten Bokkel 1998 41/74 19/30 2.6 % 0.87 [ 0.62, 1.23 ]
Throuvalas 2000 22/28 18/26 1.8 % 1.13 [ 0.82, 1.56 ]
Untch 2011˙1 46/356 54/377 5.1 % 0.90 [ 0.63, 1.30 ]
Wilkinson 2006 55/114 33/59 4.2 % 0.86 [ 0.64, 1.16 ]
Total (95% CI) 2636 2376 100.0 % 1.02 [ 0.98, 1.06 ]
Total events: 1097 (control), 1007 (treatment)
Heterogeneity: Chi2 = 15.61, df = 14 (P = 0.34); I2 =10%
Test for overall effect: Z = 0.91 (P = 0.36)
Test for subgroup differences: Not applicable
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Analysis 8.1. Comparison 8 Change in FACT-Fatigue 13, Outcome 1 Change in FACT-Fatigue (13 items) -
overall.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 8 Change in FACT-Fatigue 13
Outcome: 1 Change in FACT-Fatigue (13 items) - overall





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Boogaerts 2003 104 5.47 (14.47) 109 0.41 (8.47) 4.0 % 5.06 [ 1.86, 8.26 ]
Chang 2005 168 1.55 (10.52) 170 -3.55 (11.14) 7.7 % 5.10 [ 2.79, 7.41 ]
Charu 2007 203 6 (12.34) 42 2.2 (7.8) 4.9 % 3.80 [ 0.89, 6.71 ]
Christodoulou 2009 76 3.87 (11.99) 76 0.71 (12.43) 2.7 % 3.16 [ -0.72, 7.04 ]
Gordon 2008 150 4.8 (11.263) 50 5 (11.473) 3.1 % -0.20 [ -3.86, 3.46 ]
Hedenus 2003 152 2.68 (8.88) 151 0.8 (9.71) 9.4 % 1.88 [ -0.22, 3.98 ]
Hoskin 2009 151 -2.6 (10.67) 149 -2.6 (12.45) 6.0 % 0.0 [ -2.63, 2.63 ]
Iconomou 2003 57 4.6 (12.5) 55 -1 (12.8) 1.9 % 5.60 [ 0.91, 10.29 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Kotasek 2003 189 3.4 (12.6) 50 2.3 (11.6) 3.0 % 1.10 [ -2.58, 4.78 ]
Littlewood 2001 200 3 (13.5) 90 -2.2 (12.5) 4.0 % 5.20 [ 2.01, 8.39 ]
Osterborg 2002 133 5.2 (12.2) 130 3 (12.1) 4.8 % 2.20 [ -0.74, 5.14 ]
Pirker 2008 245 1.5 (13.15) 239 0.7 (13.3) 7.4 % 0.80 [ -1.56, 3.16 ]
Savonije 2005 156 3.48 (12.67) 65 -1.67 (11.61) 3.5 % 5.15 [ 1.70, 8.60 ]
Smith 2008 343 -0.02 (11.83) 362 0.52 (10.41) 15.1 % -0.54 [ -2.19, 1.11 ]
Tjulandin 2011 88 2.9 (7.9) 84 0.6 (8.8) 6.6 % 2.30 [ -0.20, 4.80 ]
Tsuboi 2009 61 -0.5 (9.4) 54 -3.6 (9) 3.6 % 3.10 [ -0.27, 6.47 ]
Vansteenkiste 2002 156 0.8 (10) 158 -0.6 (10.7) 7.8 % 1.40 [ -0.89, 3.69 ]
Witzig 2005 151 1.56 (12.07) 148 0.31 (14.48) 4.5 % 1.25 [ -1.77, 4.27 ]
Total (95% CI) 2783 2182 100.0 % 2.08 [ 1.43, 2.72 ]
Heterogeneity: Chi2 = 36.48, df = 17 (P = 0.004); I2 =53%
Test for overall effect: Z = 6.34 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 8.2. Comparison 8 Change in FACT-Fatigue 13, Outcome 2 Change in FACT-Fatigue sensitivity
analysis- Tsuboi.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 8 Change in FACT-Fatigue 13
Outcome: 2 Change in FACT-Fatigue sensitivity analysis- Tsuboi





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Boogaerts 2003 104 5.47 (14.47) 109 0.41 (8.47) 4.0 % 5.06 [ 1.86, 8.26 ]
Chang 2005 168 1.55 (10.52) 170 -3.55 (11.14) 7.7 % 5.10 [ 2.79, 7.41 ]
Charu 2007 203 6 (12.34) 42 2.2 (7.8) 4.9 % 3.80 [ 0.89, 6.71 ]
Christodoulou 2009 76 3.87 (11.99) 76 0.71 (12.43) 2.7 % 3.16 [ -0.72, 7.04 ]
Gordon 2008 150 4.8 (11.263) 50 5 (11.473) 3.1 % -0.20 [ -3.86, 3.46 ]
Hedenus 2003 152 2.68 (8.88) 151 0.8 (9.71) 9.4 % 1.88 [ -0.22, 3.98 ]
Hoskin 2009 151 -2.6 (10.67) 149 -2.6 (12.45) 6.0 % 0.0 [ -2.63, 2.63 ]
Iconomou 2003 57 4.6 (12.5) 55 -1 (12.8) 1.9 % 5.60 [ 0.91, 10.29 ]
Kotasek 2003 189 3.4 (12.6) 50 2.3 (11.6) 3.0 % 1.10 [ -2.58, 4.78 ]
Littlewood 2001 200 3 (13.5) 90 -2.2 (12.5) 4.1 % 5.20 [ 2.01, 8.39 ]
Osterborg 2002 133 5.2 (12.2) 130 3 (12.1) 4.8 % 2.20 [ -0.74, 5.14 ]
Pirker 2008 245 1.5 (13.15) 239 0.7 (13.3) 7.4 % 0.80 [ -1.56, 3.16 ]
Savonije 2005 156 3.48 (12.67) 65 -1.67 (11.61) 3.5 % 5.15 [ 1.70, 8.60 ]
Smith 2008 343 -0.02 (11.83) 362 0.52 (10.41) 15.2 % -0.54 [ -2.19, 1.11 ]
Tjulandin 2011 88 2.9 (7.9) 84 0.6 (8.8) 6.6 % 2.30 [ -0.20, 4.80 ]
Tsuboi 2009 61 -0.5 (9.4) 56 -4.5 (10) 3.3 % 4.00 [ 0.48, 7.52 ]
Vansteenkiste 2002 156 0.8 (10) 158 -0.6 (10.7) 7.9 % 1.40 [ -0.89, 3.69 ]
Witzig 2005 151 1.56 (12.07) 148 0.31 (14.48) 4.5 % 1.25 [ -1.77, 4.27 ]
Total (95% CI) 2783 2184 100.0 % 2.10 [ 1.46, 2.75 ]
Heterogeneity: Chi2 = 37.26, df = 17 (P = 0.003); I2 =54%
Test for overall effect: Z = 6.41 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 8.3. Comparison 8 Change in FACT-Fatigue 13, Outcome 3 Change in FACT-F 13 - baseline Hb.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 8 Change in FACT-Fatigue 13
Outcome: 3 Change in FACT-F 13 - baseline Hb





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Hb <= 10 g/dL
Boogaerts 2003 104 5.47 (14.47) 109 0.41 (8.47) 4.0 % 5.06 [ 1.86, 8.26 ]
Hedenus 2003 152 2.68 (8.88) 151 0.8 (9.71) 9.4 % 1.88 [ -0.22, 3.98 ]
Kotasek 2003 189 3.4 (12.6) 50 2.3 (11.6) 3.0 % 1.10 [ -2.58, 4.78 ]
Littlewood 2001 200 3 (13.5) 90 -2.2 (12.5) 4.0 % 5.20 [ 2.01, 8.39 ]
Osterborg 2002 133 5.2 (12.2) 130 3 (12.1) 4.8 % 2.20 [ -0.74, 5.14 ]
Smith 2008 343 -0.02 (11.83) 362 0.52 (10.41) 15.1 % -0.54 [ -2.19, 1.11 ]
Tjulandin 2011 88 2.9 (7.9) 84 0.6 (8.8) 6.6 % 2.30 [ -0.20, 4.80 ]
Witzig 2005 151 1.56 (12.07) 148 0.31 (14.48) 4.5 % 1.25 [ -1.77, 4.27 ]
Subtotal (95% CI) 1360 1124 51.4 % 1.66 [ 0.76, 2.55 ]
Heterogeneity: Chi2 = 16.49, df = 7 (P = 0.02); I2 =58%
Test for overall effect: Z = 3.64 (P = 0.00028)
2 Hb 10 to 12 g/dL
Chang 2005 168 1.55 (10.52) 170 -3.55 (11.14) 7.7 % 5.10 [ 2.79, 7.41 ]
Charu 2007 203 6 (12.34) 42 2.2 (7.8) 4.9 % 3.80 [ 0.89, 6.71 ]
Christodoulou 2009 76 3.87 (11.99) 76 0.71 (12.43) 2.7 % 3.16 [ -0.72, 7.04 ]
Gordon 2008 150 4.8 (11.263) 50 5 (11.473) 3.1 % -0.20 [ -3.86, 3.46 ]
Iconomou 2003 57 4.6 (12.5) 55 -1 (12.8) 1.9 % 5.60 [ 0.91, 10.29 ]
Pirker 2008 245 1.5 (13.15) 239 0.7 (13.3) 7.4 % 0.80 [ -1.56, 3.16 ]
Savonije 2005 156 3.48 (12.67) 65 -1.67 (11.61) 3.5 % 5.15 [ 1.70, 8.60 ]
Tsuboi 2009 61 -0.5 (9.4) 54 -3.6 (9) 3.6 % 3.10 [ -0.27, 6.47 ]
Vansteenkiste 2002 156 0.8 (10) 158 -0.6 (10.7) 7.8 % 1.40 [ -0.89, 3.69 ]
Subtotal (95% CI) 1272 909 42.6 % 2.87 [ 1.89, 3.85 ]
Heterogeneity: Chi2 = 14.25, df = 8 (P = 0.08); I2 =44%
Test for overall effect: Z = 5.72 (P < 0.00001)
3 Hb > 12 g/dL
Hoskin 2009 151 -2.6 (10.67) 149 -2.6 (12.45) 6.0 % 0.0 [ -2.63, 2.63 ]
Subtotal (95% CI) 151 149 6.0 % 0.0 [ -2.63, 2.63 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
4 Hb category unclear
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 2783 2182 100.0 % 2.08 [ 1.43, 2.72 ]
Heterogeneity: Chi2 = 36.48, df = 17 (P = 0.004); I2 =53%
Test for overall effect: Z = 6.34 (P < 0.00001)
Test for subgroup differences: Chi2 = 5.75, df = 2 (P = 0.06), I2 =65%
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Analysis 8.4. Comparison 8 Change in FACT-Fatigue 13, Outcome 4 Change in FACT-F 13 - different
malignancies.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 8 Change in FACT-Fatigue 13
Outcome: 4 Change in FACT-F 13 - different malignancies





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 solid tumours
Hoskin 2009 151 -2.6 (10.67) 149 -2.6 (12.45) 6.0 % 0.0 [ -2.63, 2.63 ]
Pirker 2008 245 1.5 (13.15) 239 0.7 (13.3) 7.4 % 0.80 [ -1.56, 3.16 ]
Kotasek 2003 189 3.4 (12.6) 50 2.3 (11.6) 3.0 % 1.10 [ -2.58, 4.78 ]
Witzig 2005 151 1.56 (12.07) 148 0.31 (14.48) 4.5 % 1.25 [ -1.77, 4.27 ]
Vansteenkiste 2002 156 0.8 (10) 158 -0.6 (10.7) 7.8 % 1.40 [ -0.89, 3.69 ]
Christodoulou 2009 76 3.87 (11.99) 76 0.71 (12.43) 2.7 % 3.16 [ -0.72, 7.04 ]
Chang 2005 168 1.55 (10.52) 170 -3.55 (11.14) 7.7 % 5.10 [ 2.79, 7.41 ]
Savonije 2005 156 3.48 (12.67) 65 -1.67 (11.61) 3.5 % 5.15 [ 1.70, 8.60 ]
Iconomou 2003 57 4.6 (12.5) 55 -1 (12.8) 1.9 % 5.60 [ 0.91, 10.29 ]
Subtotal (95% CI) 1349 1110 44.5 % 2.29 [ 1.33, 3.25 ]
Heterogeneity: Chi2 = 16.32, df = 8 (P = 0.04); I2 =51%
Test for overall effect: Z = 4.68 (P < 0.00001)
2 haematological malignancies
Hedenus 2003 152 2.68 (8.88) 151 0.8 (9.71) 9.4 % 1.88 [ -0.22, 3.98 ]
Osterborg 2002 133 5.2 (12.2) 130 3 (12.1) 4.8 % 2.20 [ -0.74, 5.14 ]
Subtotal (95% CI) 285 281 14.1 % 1.99 [ 0.28, 3.69 ]
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 2.28 (P = 0.022)
3 mixed
Smith 2008 343 -0.02 (11.83) 362 0.52 (10.41) 15.1 % -0.54 [ -2.19, 1.11 ]
Gordon 2008 150 4.8 (11.263) 50 5 (11.473) 3.1 % -0.20 [ -3.86, 3.46 ]
Tjulandin 2011 88 2.9 (7.9) 84 0.6 (8.8) 6.6 % 2.30 [ -0.20, 4.80 ]
Tsuboi 2009 61 -0.5 (9.4) 54 -3.6 (9) 3.6 % 3.10 [ -0.27, 6.47 ]
Charu 2007 203 6 (12.34) 42 2.2 (7.8) 4.9 % 3.80 [ 0.89, 6.71 ]
Boogaerts 2003 104 5.47 (14.47) 109 0.41 (8.47) 4.0 % 5.06 [ 1.86, 8.26 ]
Littlewood 2001 200 3 (13.5) 90 -2.2 (12.5) 4.0 % 5.20 [ 2.01, 8.39 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Subtotal (95% CI) 1149 791 41.3 % 1.87 [ 0.87, 2.87 ]
Heterogeneity: Chi2 = 19.76, df = 6 (P = 0.003); I2 =70%
Test for overall effect: Z = 3.68 (P = 0.00023)
4 unclear
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 2783 2182 100.0 % 2.08 [ 1.43, 2.72 ]
Heterogeneity: Chi2 = 36.48, df = 17 (P = 0.004); I2 =53%
Test for overall effect: Z = 6.34 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.37, df = 2 (P = 0.83), I2 =0.0%
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Analysis 8.5. Comparison 8 Change in FACT-Fatigue 13, Outcome 5 Change in FACT-F 13 - age.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 8 Change in FACT-Fatigue 13
Outcome: 5 Change in FACT-F 13 - age





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 only children < 18 years
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
2 adults >= 18 years
Boogaerts 2003 104 5.47 (14.47) 109 0.41 (8.47) 4.0 % 5.06 [ 1.86, 8.26 ]
Charu 2007 203 6 (12.34) 42 2.2 (7.8) 4.9 % 3.80 [ 0.89, 6.71 ]
Christodoulou 2009 76 3.87 (11.99) 76 0.71 (12.43) 2.7 % 3.16 [ -0.72, 7.04 ]
Gordon 2008 150 4.8 (11.263) 50 5 (11.473) 3.1 % -0.20 [ -3.86, 3.46 ]
Hedenus 2003 152 2.68 (8.88) 151 0.8 (9.71) 9.4 % 1.88 [ -0.22, 3.98 ]
Hoskin 2009 151 -2.6 (10.67) 149 -2.6 (12.45) 6.0 % 0.0 [ -2.63, 2.63 ]
Iconomou 2003 57 4.6 (12.5) 55 -1 (12.8) 1.9 % 5.60 [ 0.91, 10.29 ]
Kotasek 2003 189 3.4 (12.6) 50 2.3 (11.6) 3.0 % 1.10 [ -2.58, 4.78 ]
Littlewood 2001 200 3 (13.5) 90 -2.2 (12.5) 4.0 % 5.20 [ 2.01, 8.39 ]
Osterborg 2002 133 5.2 (12.2) 130 3 (12.1) 4.8 % 2.20 [ -0.74, 5.14 ]
Pirker 2008 245 1.5 (13.15) 239 0.7 (13.3) 7.4 % 0.80 [ -1.56, 3.16 ]
Savonije 2005 156 3.48 (12.67) 65 -1.67 (11.61) 3.5 % 5.15 [ 1.70, 8.60 ]
Smith 2008 343 -0.02 (11.83) 362 0.52 (10.41) 15.1 % -0.54 [ -2.19, 1.11 ]
Tjulandin 2011 88 2.9 (7.9) 84 0.6 (8.8) 6.6 % 2.30 [ -0.20, 4.80 ]
Tsuboi 2009 61 -0.5 (9.4) 54 -3.6 (9) 3.6 % 3.10 [ -0.27, 6.47 ]
Vansteenkiste 2002 156 0.8 (10) 158 -0.6 (10.7) 7.8 % 1.40 [ -0.89, 3.69 ]
Witzig 2005 151 1.56 (12.07) 148 0.31 (14.48) 4.5 % 1.25 [ -1.77, 4.27 ]
Subtotal (95% CI) 2615 2012 92.3 % 1.82 [ 1.16, 2.49 ]
Heterogeneity: Chi2 = 29.35, df = 16 (P = 0.02); I2 =45%
Test for overall effect: Z = 5.35 (P < 0.00001)
3 >70% non elderly 18-65 years
Chang 2005 168 1.55 (10.52) 170 -3.55 (11.14) 7.7 % 5.10 [ 2.79, 7.41 ]
Subtotal (95% CI) 168 170 7.7 % 5.10 [ 2.79, 7.41 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Heterogeneity: not applicable
Test for overall effect: Z = 4.33 (P = 0.000015)
4 only non-elderly adults
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
5 >70% elderly >65 years
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
6 only elderly > 65 years
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 2783 2182 100.0 % 2.08 [ 1.43, 2.72 ]
Heterogeneity: Chi2 = 36.48, df = 17 (P = 0.004); I2 =53%
Test for overall effect: Z = 6.34 (P < 0.00001)
Test for subgroup differences: Chi2 = 7.14, df = 1 (P = 0.01), I2 =86%
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Analysis 8.6. Comparison 8 Change in FACT-Fatigue 13, Outcome 6 Change in FACT-F 13 - different
therapies.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 8 Change in FACT-Fatigue 13
Outcome: 6 Change in FACT-F 13 - different therapies





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 chemotherapy
Boogaerts 2003 104 5.47 (14.47) 109 0.41 (8.47) 4.0 % 5.06 [ 1.86, 8.26 ]
Chang 2005 168 1.55 (10.52) 170 -3.55 (11.14) 7.7 % 5.10 [ 2.79, 7.41 ]
Christodoulou 2009 76 3.87 (11.99) 76 0.71 (12.43) 2.7 % 3.16 [ -0.72, 7.04 ]
Hedenus 2003 152 2.68 (8.88) 151 0.8 (9.71) 9.4 % 1.88 [ -0.22, 3.98 ]
Iconomou 2003 57 4.6 (12.5) 55 -1 (12.8) 1.9 % 5.60 [ 0.91, 10.29 ]
Kotasek 2003 189 3.4 (12.6) 50 2.3 (11.6) 3.0 % 1.10 [ -2.58, 4.78 ]
Littlewood 2001 200 3 (13.5) 90 -2.2 (12.5) 4.0 % 5.20 [ 2.01, 8.39 ]
Osterborg 2002 133 5.2 (12.2) 130 3 (12.1) 4.8 % 2.20 [ -0.74, 5.14 ]
Pirker 2008 245 1.5 (13.15) 239 0.7 (13.3) 7.4 % 0.80 [ -1.56, 3.16 ]
Savonije 2005 156 3.48 (12.67) 65 -1.67 (11.61) 3.5 % 5.15 [ 1.70, 8.60 ]
Tjulandin 2011 88 2.9 (7.9) 84 0.6 (8.8) 6.6 % 2.30 [ -0.20, 4.80 ]
Tsuboi 2009 61 -0.5 (9.4) 54 -3.6 (9) 3.6 % 3.10 [ -0.27, 6.47 ]
Vansteenkiste 2002 156 0.8 (10) 158 -0.6 (10.7) 7.8 % 1.40 [ -0.89, 3.69 ]
Witzig 2005 151 1.56 (12.07) 148 0.31 (14.48) 4.5 % 1.25 [ -1.77, 4.27 ]
Subtotal (95% CI) 1936 1579 70.9 % 2.79 [ 2.03, 3.55 ]
Heterogeneity: Chi2 = 18.19, df = 13 (P = 0.15); I2 =29%
Test for overall effect: Z = 7.18 (P < 0.00001)
2 radiotherapy
Hoskin 2009 151 -2.6 (10.67) 149 -2.6 (12.45) 6.0 % 0.0 [ -2.63, 2.63 ]
Subtotal (95% CI) 151 149 6.0 % 0.0 [ -2.63, 2.63 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 no therapy
Charu 2007 203 6 (12.34) 42 2.2 (7.8) 4.9 % 3.80 [ 0.89, 6.71 ]
Gordon 2008 150 4.8 (11.263) 50 5 (11.473) 3.1 % -0.20 [ -3.86, 3.46 ]
Smith 2008 343 -0.02 (11.83) 362 0.52 (10.41) 15.1 % -0.54 [ -2.19, 1.11 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Subtotal (95% CI) 696 454 23.1 % 0.42 [ -0.91, 1.76 ]
Heterogeneity: Chi2 = 6.61, df = 2 (P = 0.04); I2 =70%
Test for overall effect: Z = 0.62 (P = 0.54)
4 unclear
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 2783 2182 100.0 % 2.08 [ 1.43, 2.72 ]
Heterogeneity: Chi2 = 36.48, df = 17 (P = 0.004); I2 =53%
Test for overall effect: Z = 6.34 (P < 0.00001)
Test for subgroup differences: Chi2 = 11.68, df = 2 (P = 0.00), I2 =83%
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Analysis 8.7. Comparison 8 Change in FACT-Fatigue 13, Outcome 7 Change in FACT-F 13 - different
therapies differentiated.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 8 Change in FACT-Fatigue 13
Outcome: 7 Change in FACT-F 13 - different therapies differentiated





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 chemotherapy, >70% with platinum
Christodoulou 2009 25 4.56 (11.95) 25 2.7 (11.65) 1.0 % 1.86 [ -4.68, 8.40 ]
Pirker 2008 245 1.5 (13.15) 239 0.7 (13.3) 7.4 % 0.80 [ -1.56, 3.16 ]
Savonije 2005 156 3.48 (12.67) 65 -1.67 (11.61) 3.5 % 5.15 [ 1.70, 8.60 ]
Vansteenkiste 2002 156 0.8 (10) 158 -0.6 (10.7) 7.8 % 1.40 [ -0.89, 3.69 ]
Subtotal (95% CI) 582 487 19.7 % 1.85 [ 0.41, 3.30 ]
Heterogeneity: Chi2 = 4.42, df = 3 (P = 0.22); I2 =32%
Test for overall effect: Z = 2.51 (P = 0.012)
2 chemotherapy, <70% platinum containing
Iconomou 2003 57 4.6 (12.5) 55 -1 (12.8) 1.9 % 5.60 [ 0.91, 10.29 ]
Witzig 2005 151 1.56 (12.07) 148 0.31 (14.48) 4.5 % 1.25 [ -1.77, 4.27 ]
Subtotal (95% CI) 208 203 6.4 % 2.53 [ -0.01, 5.07 ]
Heterogeneity: Chi2 = 2.34, df = 1 (P = 0.13); I2 =57%
Test for overall effect: Z = 1.95 (P = 0.051)
3 chemotherapy without platinum (all patients)
Chang 2005 168 1.55 (10.52) 170 -3.55 (11.14) 7.7 % 5.10 [ 2.79, 7.41 ]
Christodoulou 2009 51 3.54 (12.04) 51 -0.26 (13.16) 1.7 % 3.80 [ -1.10, 8.70 ]
Hedenus 2003 152 2.68 (8.88) 151 0.8 (9.71) 9.4 % 1.88 [ -0.22, 3.98 ]
Littlewood 2001 200 3 (13.5) 90 -2.2 (12.5) 4.0 % 5.20 [ 2.01, 8.39 ]
Osterborg 2002 133 5.2 (12.2) 130 3 (12.1) 4.8 % 2.20 [ -0.74, 5.14 ]
Tjulandin 2011 88 2.9 (7.9) 84 0.6 (8.8) 6.6 % 2.30 [ -0.20, 4.80 ]
Subtotal (95% CI) 792 676 34.2 % 3.22 [ 2.12, 4.32 ]
Heterogeneity: Chi2 = 6.63, df = 5 (P = 0.25); I2 =25%
Test for overall effect: Z = 5.75 (P < 0.00001)
4 chemotherapy, platinum and non-platinum containing, no numbers given
Boogaerts 2003 104 5.47 (14.47) 109 0.41 (8.47) 4.0 % 5.06 [ 1.86, 8.26 ]
Kotasek 2003 189 3.4 (12.6) 50 2.3 (11.6) 3.0 % 1.10 [ -2.58, 4.78 ]
Tsuboi 2009 61 -0.5 (9.4) 54 -3.6 (9) 3.6 % 3.10 [ -0.27, 6.47 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Subtotal (95% CI) 354 213 10.7 % 3.27 [ 1.30, 5.23 ]
Heterogeneity: Chi2 = 2.54, df = 2 (P = 0.28); I2 =21%
Test for overall effect: Z = 3.26 (P = 0.0011)
5 radiochemotherapy NEW
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
6 radiotherapy
Hoskin 2009 151 -2.6 (10.67) 149 -2.6 (12.45) 6.0 % 0.0 [ -2.63, 2.63 ]
Subtotal (95% CI) 151 149 6.0 % 0.0 [ -2.63, 2.63 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
7 no therapy
Charu 2007 203 6 (12.34) 42 2.2 (7.8) 4.9 % 3.80 [ 0.89, 6.71 ]
Gordon 2008 150 4.8 (11.263) 50 5 (11.473) 3.1 % -0.20 [ -3.86, 3.46 ]
Smith 2008 343 -0.02 (11.83) 362 0.52 (10.41) 15.1 % -0.54 [ -2.19, 1.11 ]
Subtotal (95% CI) 696 454 23.1 % 0.42 [ -0.91, 1.76 ]
Heterogeneity: Chi2 = 6.61, df = 2 (P = 0.04); I2 =70%
Test for overall effect: Z = 0.62 (P = 0.54)
8 unclear
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
9 chemotherapy no details given
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 2783 2182 100.0 % 2.07 [ 1.43, 2.72 ]
Heterogeneity: Chi2 = 36.66, df = 18 (P = 0.01); I2 =51%
Test for overall effect: Z = 6.34 (P < 0.00001)
Test for subgroup differences: Chi2 = 14.12, df = 5 (P = 0.01), I2 =65%
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Analysis 8.8. Comparison 8 Change in FACT-Fatigue 13, Outcome 8 Change in FACT-F 13 - epoetin versus
darbepoetin.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 8 Change in FACT-Fatigue 13
Outcome: 8 Change in FACT-F 13 - epoetin versus darbepoetin





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Epoetin
Boogaerts 2003 104 5.47 (14.47) 109 0.41 (8.47) 4.0 % 5.06 [ 1.86, 8.26 ]
Chang 2005 168 1.55 (10.52) 170 -3.55 (11.14) 7.7 % 5.10 [ 2.79, 7.41 ]
Christodoulou 2009 76 3.87 (11.99) 76 0.71 (12.43) 2.7 % 3.16 [ -0.72, 7.04 ]
Hoskin 2009 151 -2.6 (10.67) 149 -2.6 (12.45) 6.0 % 0.0 [ -2.63, 2.63 ]
Iconomou 2003 57 4.6 (12.5) 55 -1 (12.8) 1.9 % 5.60 [ 0.91, 10.29 ]
Littlewood 2001 200 3 (13.5) 90 -2.2 (12.5) 4.0 % 5.20 [ 2.01, 8.39 ]
Osterborg 2002 133 5.2 (12.2) 130 3 (12.1) 4.8 % 2.20 [ -0.74, 5.14 ]
Savonije 2005 156 3.48 (12.67) 65 -1.67 (11.61) 3.5 % 5.15 [ 1.70, 8.60 ]
Tjulandin 2011 88 2.9 (7.9) 84 0.6 (8.8) 6.6 % 2.30 [ -0.20, 4.80 ]
Tsuboi 2009 61 -0.5 (9.4) 54 -3.6 (9) 3.6 % 3.10 [ -0.27, 6.47 ]
Witzig 2005 151 1.56 (12.07) 148 0.31 (14.48) 4.5 % 1.25 [ -1.77, 4.27 ]
Subtotal (95% CI) 1345 1130 49.3 % 3.25 [ 2.33, 4.16 ]
Heterogeneity: Chi2 = 15.88, df = 10 (P = 0.10); I2 =37%
Test for overall effect: Z = 6.97 (P < 0.00001)
2 Darbepoetin
Charu 2007 203 6 (12.34) 42 2.2 (7.8) 4.9 % 3.80 [ 0.89, 6.71 ]
Gordon 2008 150 4.8 (11.263) 50 5 (11.473) 3.1 % -0.20 [ -3.86, 3.46 ]
Hedenus 2003 152 2.68 (8.88) 151 0.8 (9.71) 9.4 % 1.88 [ -0.22, 3.98 ]
Kotasek 2003 189 3.4 (12.6) 50 2.3 (11.6) 3.0 % 1.10 [ -2.58, 4.78 ]
Pirker 2008 245 1.5 (13.15) 239 0.7 (13.3) 7.4 % 0.80 [ -1.56, 3.16 ]
Smith 2008 343 -0.02 (11.83) 362 0.52 (10.41) 15.1 % -0.54 [ -2.19, 1.11 ]
Vansteenkiste 2002 156 0.8 (10) 158 -0.6 (10.7) 7.8 % 1.40 [ -0.89, 3.69 ]
Subtotal (95% CI) 1438 1052 50.7 % 0.94 [ 0.04, 1.84 ]
Heterogeneity: Chi2 = 8.14, df = 6 (P = 0.23); I2 =26%
Test for overall effect: Z = 2.04 (P = 0.041)
Total (95% CI) 2783 2182 100.0 % 2.08 [ 1.43, 2.72 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Heterogeneity: Chi2 = 36.48, df = 17 (P = 0.004); I2 =53%
Test for overall effect: Z = 6.34 (P < 0.00001)
Test for subgroup differences: Chi2 = 12.47, df = 1 (P = 0.00), I2 =92%
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Analysis 8.9. Comparison 8 Change in FACT-Fatigue 13, Outcome 9 Change in FACT-F 13 - duration of
ESA medication.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 8 Change in FACT-Fatigue 13
Outcome: 9 Change in FACT-F 13 - duration of ESA medication





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 6 to 9 weeks
Tsuboi 2009 61 -0.5 (9.4) 54 -3.6 (9) 3.6 % 3.10 [ -0.27, 6.47 ]
Subtotal (95% CI) 61 54 3.6 % 3.10 [ -0.27, 6.47 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.81 (P = 0.071)
2 12 to 16 weeks
Boogaerts 2003 104 5.47 (14.47) 109 0.41 (8.47) 4.0 % 5.06 [ 1.86, 8.26 ]
Chang 2005 168 1.55 (10.52) 170 -3.55 (11.14) 7.7 % 5.10 [ 2.79, 7.41 ]
Charu 2007 203 6 (12.34) 42 2.2 (7.8) 4.9 % 3.80 [ 0.89, 6.71 ]
Christodoulou 2009 76 3.87 (11.99) 76 0.71 (12.43) 2.7 % 3.16 [ -0.72, 7.04 ]
Gordon 2008 150 4.8 (11.263) 50 5 (11.473) 3.1 % -0.20 [ -3.86, 3.46 ]
Hedenus 2003 152 2.68 (8.88) 151 0.8 (9.71) 9.4 % 1.88 [ -0.22, 3.98 ]
Hoskin 2009 151 -2.6 (10.67) 149 -2.6 (12.45) 6.0 % 0.0 [ -2.63, 2.63 ]
Iconomou 2003 57 4.6 (12.5) 55 -1 (12.8) 1.9 % 5.60 [ 0.91, 10.29 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Kotasek 2003 189 3.4 (12.6) 50 2.3 (11.6) 3.0 % 1.10 [ -2.58, 4.78 ]
Osterborg 2002 133 5.2 (12.2) 130 3 (12.1) 4.8 % 2.20 [ -0.74, 5.14 ]
Savonije 2005 156 3.48 (12.67) 65 -1.67 (11.61) 3.5 % 5.15 [ 1.70, 8.60 ]
Smith 2008 343 -0.02 (11.83) 362 0.52 (10.41) 15.1 % -0.54 [ -2.19, 1.11 ]
Tjulandin 2011 88 2.9 (7.9) 84 0.6 (8.8) 6.6 % 2.30 [ -0.20, 4.80 ]
Vansteenkiste 2002 156 0.8 (10) 158 -0.6 (10.7) 7.8 % 1.40 [ -0.89, 3.69 ]
Witzig 2005 151 1.56 (12.07) 148 0.31 (14.48) 4.5 % 1.25 [ -1.77, 4.27 ]
Subtotal (95% CI) 2277 1799 84.9 % 1.99 [ 1.30, 2.69 ]
Heterogeneity: Chi2 = 31.26, df = 14 (P = 0.01); I2 =55%
Test for overall effect: Z = 5.62 (P < 0.00001)
3 more than 17 weeks
Littlewood 2001 200 3 (13.5) 90 -2.2 (12.5) 4.0 % 5.20 [ 2.01, 8.39 ]
Pirker 2008 245 1.5 (13.15) 239 0.7 (13.3) 7.4 % 0.80 [ -1.56, 3.16 ]
Subtotal (95% CI) 445 329 11.5 % 2.35 [ 0.46, 4.25 ]
Heterogeneity: Chi2 = 4.73, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 2.43 (P = 0.015)
4 unclear
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 2783 2182 100.0 % 2.08 [ 1.43, 2.72 ]
Heterogeneity: Chi2 = 36.48, df = 17 (P = 0.004); I2 =53%
Test for overall effect: Z = 6.34 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.49, df = 2 (P = 0.78), I2 =0.0%
-50 -25 0 25 50
Favours control Favours experimental
559Erythropoietin or darbepoetin for patients with cancer (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 8.10. Comparison 8 Change in FACT-Fatigue 13, Outcome 10 Change in FACT-F 13 - iron
supplementation.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 8 Change in FACT-Fatigue 13
Outcome: 10 Change in FACT-F 13 - iron supplementation





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 fixed iron supplementation
Christodoulou 2009 76 3.87 (11.99) 76 0.71 (12.43) 2.7 % 3.16 [ -0.72, 7.04 ]
Hoskin 2009 151 -2.6 (10.67) 149 -2.6 (12.45) 6.0 % 0.0 [ -2.63, 2.63 ]
Iconomou 2003 57 4.6 (12.5) 55 -1 (12.8) 1.9 % 5.60 [ 0.91, 10.29 ]
Witzig 2005 151 1.56 (12.07) 148 0.31 (14.48) 4.5 % 1.25 [ -1.77, 4.27 ]
Subtotal (95% CI) 435 428 15.1 % 1.64 [ -0.01, 3.29 ]
Heterogeneity: Chi2 = 4.89, df = 3 (P = 0.18); I2 =39%
Test for overall effect: Z = 1.95 (P = 0.052)
2 iron supplementation as necessary
Boogaerts 2003 104 5.47 (14.47) 109 0.41 (8.47) 4.0 % 5.06 [ 1.86, 8.26 ]
Chang 2005 168 1.55 (10.52) 170 -3.55 (11.14) 7.7 % 5.10 [ 2.79, 7.41 ]
Charu 2007 203 6 (12.34) 42 2.2 (7.8) 4.9 % 3.80 [ 0.89, 6.71 ]
Gordon 2008 150 4.8 (11.263) 50 5 (11.473) 3.1 % -0.20 [ -3.86, 3.46 ]
Hedenus 2003 152 2.68 (8.88) 151 0.8 (9.71) 9.4 % 1.88 [ -0.22, 3.98 ]
Kotasek 2003 189 3.4 (12.6) 50 2.3 (11.6) 3.0 % 1.10 [ -2.58, 4.78 ]
Littlewood 2001 200 3 (13.5) 90 -2.2 (12.5) 4.0 % 5.20 [ 2.01, 8.39 ]
Osterborg 2002 133 5.2 (12.2) 130 3 (12.1) 4.8 % 2.20 [ -0.74, 5.14 ]
Pirker 2008 245 1.5 (13.15) 239 0.7 (13.3) 7.4 % 0.80 [ -1.56, 3.16 ]
Smith 2008 343 -0.02 (11.83) 362 0.52 (10.41) 15.1 % -0.54 [ -2.19, 1.11 ]
Tjulandin 2011 88 2.9 (7.9) 84 0.6 (8.8) 6.6 % 2.30 [ -0.20, 4.80 ]
Tsuboi 2009 61 -0.5 (9.4) 54 -3.6 (9) 3.6 % 3.10 [ -0.27, 6.47 ]
Vansteenkiste 2002 156 0.8 (10) 158 -0.6 (10.7) 7.8 % 1.40 [ -0.89, 3.69 ]
Subtotal (95% CI) 2192 1689 81.5 % 2.03 [ 1.32, 2.74 ]
Heterogeneity: Chi2 = 28.26, df = 12 (P = 0.01); I2 =58%
Test for overall effect: Z = 5.59 (P < 0.00001)
3 no explicit statement on iron supplementation or no iron given
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Heterogeneity: not applicable
Test for overall effect: not applicable
4 explicitly stated NO IRON
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
5 unclear
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
6 iron given differently in both study arms new
Savonije 2005 156 3.48 (12.67) 65 -1.67 (11.61) 3.5 % 5.15 [ 1.70, 8.60 ]
Subtotal (95% CI) 156 65 3.5 % 5.15 [ 1.70, 8.60 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.92 (P = 0.0035)
Total (95% CI) 2783 2182 100.0 % 2.08 [ 1.43, 2.72 ]
Heterogeneity: Chi2 = 36.48, df = 17 (P = 0.004); I2 =53%
Test for overall effect: Z = 6.34 (P < 0.00001)
Test for subgroup differences: Chi2 = 3.33, df = 2 (P = 0.19), I2 =40%
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Analysis 8.11. Comparison 8 Change in FACT-Fatigue 13, Outcome 11 Change in FACT-F 13 - allocation
concealment.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 8 Change in FACT-Fatigue 13
Outcome: 11 Change in FACT-F 13 - allocation concealment





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 adequate
Boogaerts 2003 104 5.47 (14.47) 109 0.41 (8.47) 4.0 % 5.06 [ 1.86, 8.26 ]
Chang 2005 168 1.55 (10.52) 170 -3.55 (11.14) 7.7 % 5.10 [ 2.79, 7.41 ]
Charu 2007 203 6 (12.34) 42 2.2 (7.8) 4.9 % 3.80 [ 0.89, 6.71 ]
Christodoulou 2009 76 3.87 (11.99) 76 0.71 (12.43) 2.7 % 3.16 [ -0.72, 7.04 ]
Gordon 2008 150 4.8 (11.263) 50 5 (11.473) 3.1 % -0.20 [ -3.86, 3.46 ]
Hedenus 2003 152 2.68 (8.88) 151 0.8 (9.71) 9.4 % 1.88 [ -0.22, 3.98 ]
Iconomou 2003 57 4.6 (12.5) 55 -1 (12.8) 1.9 % 5.60 [ 0.91, 10.29 ]
Kotasek 2003 189 3.4 (12.6) 50 2.3 (11.6) 3.0 % 1.10 [ -2.58, 4.78 ]
Littlewood 2001 200 3 (13.5) 90 -2.2 (12.5) 4.0 % 5.20 [ 2.01, 8.39 ]
Osterborg 2002 133 5.2 (12.2) 130 3 (12.1) 4.8 % 2.20 [ -0.74, 5.14 ]
Pirker 2008 245 1.5 (13.15) 239 0.7 (13.3) 7.4 % 0.80 [ -1.56, 3.16 ]
Savonije 2005 156 3.48 (12.67) 65 -1.67 (11.61) 3.5 % 5.15 [ 1.70, 8.60 ]
Smith 2008 343 -0.02 (11.83) 362 0.52 (10.41) 15.1 % -0.54 [ -2.19, 1.11 ]
Tsuboi 2009 61 -0.5 (9.4) 54 -3.6 (9) 3.6 % 3.10 [ -0.27, 6.47 ]
Vansteenkiste 2002 156 0.8 (10) 158 -0.6 (10.7) 7.8 % 1.40 [ -0.89, 3.69 ]
Witzig 2005 151 1.56 (12.07) 148 0.31 (14.48) 4.5 % 1.25 [ -1.77, 4.27 ]
Subtotal (95% CI) 2544 1949 87.5 % 2.20 [ 1.51, 2.89 ]
Heterogeneity: Chi2 = 33.92, df = 15 (P = 0.003); I2 =56%
Test for overall effect: Z = 6.29 (P < 0.00001)
2 unclear
Hoskin 2009 151 -2.6 (10.67) 149 -2.6 (12.45) 6.0 % 0.0 [ -2.63, 2.63 ]
Tjulandin 2011 88 2.9 (7.9) 84 0.6 (8.8) 6.6 % 2.30 [ -0.20, 4.80 ]
Subtotal (95% CI) 239 233 12.5 % 1.20 [ -0.61, 3.02 ]
Heterogeneity: Chi2 = 1.54, df = 1 (P = 0.21); I2 =35%
Test for overall effect: Z = 1.30 (P = 0.19)
3 unclear wether adequate or unclear :)
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 2783 2182 100.0 % 2.08 [ 1.43, 2.72 ]
Heterogeneity: Chi2 = 36.48, df = 17 (P = 0.004); I2 =53%
Test for overall effect: Z = 6.34 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.02, df = 1 (P = 0.31), I2 =2%
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Analysis 8.12. Comparison 8 Change in FACT-Fatigue 13, Outcome 12 Change in FACT-F 13 - masking.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 8 Change in FACT-Fatigue 13
Outcome: 12 Change in FACT-F 13 - masking





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 double-blind
Gordon 2008 150 4.8 (11.263) 50 5 (11.473) 3.1 % -0.20 [ -3.86, 3.46 ]
Hedenus 2003 152 2.68 (8.88) 151 0.8 (9.71) 9.4 % 1.88 [ -0.22, 3.98 ]
Kotasek 2003 189 3.4 (12.6) 50 2.3 (11.6) 3.0 % 1.10 [ -2.58, 4.78 ]
Littlewood 2001 200 3 (13.5) 90 -2.2 (12.5) 4.0 % 5.20 [ 2.01, 8.39 ]
Osterborg 2002 133 5.2 (12.2) 130 3 (12.1) 4.8 % 2.20 [ -0.74, 5.14 ]
Pirker 2008 245 1.5 (13.15) 239 0.7 (13.3) 7.4 % 0.80 [ -1.56, 3.16 ]
Smith 2008 343 -0.02 (11.83) 362 0.52 (10.41) 15.1 % -0.54 [ -2.19, 1.11 ]
Tjulandin 2011 88 2.9 (7.9) 84 0.6 (8.8) 6.6 % 2.30 [ -0.20, 4.80 ]
Tsuboi 2009 61 -0.5 (9.4) 54 -3.6 (9) 3.6 % 3.10 [ -0.27, 6.47 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Vansteenkiste 2002 156 0.8 (10) 158 -0.6 (10.7) 7.8 % 1.40 [ -0.89, 3.69 ]
Witzig 2005 151 1.56 (12.07) 148 0.31 (14.48) 4.5 % 1.25 [ -1.77, 4.27 ]
Subtotal (95% CI) 1868 1516 69.4 % 1.33 [ 0.56, 2.10 ]
Heterogeneity: Chi2 = 13.73, df = 10 (P = 0.19); I2 =27%
Test for overall effect: Z = 3.40 (P = 0.00068)
2 unblinded
Boogaerts 2003 104 5.47 (14.47) 109 0.41 (8.47) 4.0 % 5.06 [ 1.86, 8.26 ]
Chang 2005 168 1.55 (10.52) 170 -3.55 (11.14) 7.7 % 5.10 [ 2.79, 7.41 ]
Charu 2007 203 6 (12.34) 42 2.2 (7.8) 4.9 % 3.80 [ 0.89, 6.71 ]
Christodoulou 2009 76 3.87 (11.99) 76 0.71 (12.43) 2.7 % 3.16 [ -0.72, 7.04 ]
Hoskin 2009 151 -2.6 (10.67) 149 -2.6 (12.45) 6.0 % 0.0 [ -2.63, 2.63 ]
Iconomou 2003 57 4.6 (12.5) 55 -1 (12.8) 1.9 % 5.60 [ 0.91, 10.29 ]
Savonije 2005 156 3.48 (12.67) 65 -1.67 (11.61) 3.5 % 5.15 [ 1.70, 8.60 ]
Subtotal (95% CI) 915 666 30.6 % 3.76 [ 2.60, 4.92 ]
Heterogeneity: Chi2 = 11.11, df = 6 (P = 0.08); I2 =46%
Test for overall effect: Z = 6.35 (P < 0.00001)
Total (95% CI) 2783 2182 100.0 % 2.08 [ 1.43, 2.72 ]
Heterogeneity: Chi2 = 36.48, df = 17 (P = 0.004); I2 =53%
Test for overall effect: Z = 6.34 (P < 0.00001)
Test for subgroup differences: Chi2 = 11.64, df = 1 (P = 0.00), I2 =91%
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Analysis 8.13. Comparison 8 Change in FACT-Fatigue 13, Outcome 13 Change in FACT-F 13 - intention-to
treat.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 8 Change in FACT-Fatigue 13
Outcome: 13 Change in FACT-F 13 - intention-to treat





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ITT or less than 10% of participants per study arm excluded
Chang 2005 168 1.55 (10.52) 170 -3.55 (11.14) 7.7 % 5.10 [ 2.79, 7.41 ]
Kotasek 2003 189 3.4 (12.6) 50 2.3 (11.6) 3.0 % 1.10 [ -2.58, 4.78 ]
Tjulandin 2011 88 2.9 (7.9) 84 0.6 (8.8) 6.6 % 2.30 [ -0.20, 4.80 ]
Tsuboi 2009 61 -0.5 (9.4) 54 -3.6 (9) 3.6 % 3.10 [ -0.27, 6.47 ]
Subtotal (95% CI) 506 358 20.9 % 3.30 [ 1.89, 4.70 ]
Heterogeneity: Chi2 = 4.33, df = 3 (P = 0.23); I2 =31%
Test for overall effect: Z = 4.61 (P < 0.00001)
2 more than 10% of participants per study arm excluded
Boogaerts 2003 104 5.47 (14.47) 109 0.41 (8.47) 4.0 % 5.06 [ 1.86, 8.26 ]
Charu 2007 203 6 (12.34) 42 2.2 (7.8) 4.9 % 3.80 [ 0.89, 6.71 ]
Christodoulou 2009 76 3.87 (11.99) 76 0.71 (12.43) 2.7 % 3.16 [ -0.72, 7.04 ]
Gordon 2008 150 4.8 (11.263) 50 5 (11.473) 3.1 % -0.20 [ -3.86, 3.46 ]
Hedenus 2003 152 2.68 (8.88) 151 0.8 (9.71) 9.4 % 1.88 [ -0.22, 3.98 ]
Littlewood 2001 200 3 (13.5) 90 -2.2 (12.5) 4.0 % 5.20 [ 2.01, 8.39 ]
Osterborg 2002 133 5.2 (12.2) 130 3 (12.1) 4.8 % 2.20 [ -0.74, 5.14 ]
Pirker 2008 245 1.5 (13.15) 239 0.7 (13.3) 7.4 % 0.80 [ -1.56, 3.16 ]
Savonije 2005 156 3.48 (12.67) 65 -1.67 (11.61) 3.5 % 5.15 [ 1.70, 8.60 ]
Smith 2008 343 -0.02 (11.83) 362 0.52 (10.41) 15.1 % -0.54 [ -2.19, 1.11 ]
Vansteenkiste 2002 156 0.8 (10) 158 -0.6 (10.7) 7.8 % 1.40 [ -0.89, 3.69 ]
Witzig 2005 151 1.56 (12.07) 148 0.31 (14.48) 4.5 % 1.25 [ -1.77, 4.27 ]
Subtotal (95% CI) 2069 1620 71.2 % 1.80 [ 1.04, 2.56 ]
Heterogeneity: Chi2 = 24.16, df = 11 (P = 0.01); I2 =54%
Test for overall effect: Z = 4.64 (P < 0.00001)
3 unclear
Hoskin 2009 151 -2.6 (10.67) 149 -2.6 (12.45) 6.0 % 0.0 [ -2.63, 2.63 ]
Iconomou 2003 57 4.6 (12.5) 55 -1 (12.8) 1.9 % 5.60 [ 0.91, 10.29 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Subtotal (95% CI) 208 204 7.8 % 1.34 [ -0.95, 3.63 ]
Heterogeneity: Chi2 = 4.17, df = 1 (P = 0.04); I2 =76%
Test for overall effect: Z = 1.14 (P = 0.25)
Total (95% CI) 2783 2182 100.0 % 2.08 [ 1.43, 2.72 ]
Heterogeneity: Chi2 = 36.48, df = 17 (P = 0.004); I2 =53%
Test for overall effect: Z = 6.34 (P < 0.00001)
Test for subgroup differences: Chi2 = 3.82, df = 2 (P = 0.15), I2 =48%
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Analysis 8.14. Comparison 8 Change in FACT-Fatigue 13, Outcome 14 Change in FACT-F 13 - publication.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 8 Change in FACT-Fatigue 13
Outcome: 14 Change in FACT-F 13 - publication





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 full text publication
Boogaerts 2003 104 5.47 (14.47) 109 0.41 (8.47) 4.0 % 5.06 [ 1.86, 8.26 ]
Chang 2005 168 1.55 (10.52) 170 -3.55 (11.14) 7.7 % 5.10 [ 2.79, 7.41 ]
Charu 2007 203 6 (12.34) 42 2.2 (7.8) 4.9 % 3.80 [ 0.89, 6.71 ]
Christodoulou 2009 76 3.87 (11.99) 76 0.71 (12.43) 2.7 % 3.16 [ -0.72, 7.04 ]
Gordon 2008 150 4.8 (11.263) 50 5 (11.473) 3.1 % -0.20 [ -3.86, 3.46 ]
Hedenus 2003 152 2.68 (8.88) 151 0.8 (9.71) 9.4 % 1.88 [ -0.22, 3.98 ]
Hoskin 2009 151 -2.6 (10.67) 149 -2.6 (12.45) 6.0 % 0.0 [ -2.63, 2.63 ]
Iconomou 2003 57 4.6 (12.5) 55 -1 (12.8) 1.9 % 5.60 [ 0.91, 10.29 ]
Littlewood 2001 200 3 (13.5) 90 -2.2 (12.5) 4.0 % 5.20 [ 2.01, 8.39 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Osterborg 2002 133 5.2 (12.2) 130 3 (12.1) 4.8 % 2.20 [ -0.74, 5.14 ]
Pirker 2008 245 1.5 (13.15) 239 0.7 (13.3) 7.4 % 0.80 [ -1.56, 3.16 ]
Savonije 2005 156 3.48 (12.67) 65 -1.67 (11.61) 3.5 % 5.15 [ 1.70, 8.60 ]
Smith 2008 343 -0.02 (11.83) 362 0.52 (10.41) 15.1 % -0.54 [ -2.19, 1.11 ]
Tjulandin 2011 88 2.9 (7.9) 84 0.6 (8.8) 6.6 % 2.30 [ -0.20, 4.80 ]
Tsuboi 2009 61 -0.5 (9.4) 54 -3.6 (9) 3.6 % 3.10 [ -0.27, 6.47 ]
Witzig 2005 151 1.56 (12.07) 148 0.31 (14.48) 4.5 % 1.25 [ -1.77, 4.27 ]
Subtotal (95% CI) 2438 1974 89.1 % 2.17 [ 1.49, 2.85 ]
Heterogeneity: Chi2 = 35.81, df = 15 (P = 0.002); I2 =58%
Test for overall effect: Z = 6.26 (P < 0.00001)
2 abstract publication
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
3 unpublished data
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
4 FDA hearing
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
5 clinical trial result information
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
6 other source
Kotasek 2003 189 3.4 (12.6) 50 2.3 (11.6) 3.0 % 1.10 [ -2.58, 4.78 ]
Vansteenkiste 2002 156 0.8 (10) 158 -0.6 (10.7) 7.8 % 1.40 [ -0.89, 3.69 ]
Subtotal (95% CI) 345 208 10.9 % 1.32 [ -0.63, 3.26 ]
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 1.33 (P = 0.18)
Total (95% CI) 2783 2182 100.0 % 2.08 [ 1.43, 2.72 ]
Heterogeneity: Chi2 = 36.48, df = 17 (P = 0.004); I2 =53%
Test for overall effect: Z = 6.34 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.66, df = 1 (P = 0.42), I2 =0.0%
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Analysis 8.15. Comparison 8 Change in FACT-Fatigue 13, Outcome 15 Change in FACT-F 13 - type of data.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 8 Change in FACT-Fatigue 13
Outcome: 15 Change in FACT-F 13 - type of data





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Not imputed data
Chang 2005 168 1.55 (10.52) 170 -3.55 (11.14) 7.7 % 5.10 [ 2.79, 7.41 ]
Osterborg 2002 133 5.2 (12.2) 130 3 (12.1) 4.8 % 2.20 [ -0.74, 5.14 ]
Pirker 2008 245 1.5 (13.15) 239 0.7 (13.3) 7.4 % 0.80 [ -1.56, 3.16 ]
Savonije 2005 156 3.48 (12.67) 65 -1.67 (11.61) 3.5 % 5.15 [ 1.70, 8.60 ]
Smith 2008 343 -0.02 (11.83) 362 0.52 (10.41) 15.1 % -0.54 [ -2.19, 1.11 ]
Tjulandin 2011 88 2.9 (7.9) 84 0.6 (8.8) 6.6 % 2.30 [ -0.20, 4.80 ]
Tsuboi 2009 61 -0.5 (9.4) 54 -3.6 (9) 3.6 % 3.10 [ -0.27, 6.47 ]
Subtotal (95% CI) 1194 1104 48.7 % 1.88 [ 0.96, 2.80 ]
Heterogeneity: Chi2 = 20.66, df = 6 (P = 0.002); I2 =71%
Test for overall effect: Z = 4.02 (P = 0.000059)
2 Imputed data
Boogaerts 2003 104 5.47 (14.47) 109 0.41 (8.47) 4.0 % 5.06 [ 1.86, 8.26 ]
Charu 2007 203 6 (12.34) 42 2.2 (7.8) 4.9 % 3.80 [ 0.89, 6.71 ]
Christodoulou 2009 76 3.87 (11.99) 76 0.71 (12.43) 2.7 % 3.16 [ -0.72, 7.04 ]
Gordon 2008 150 4.8 (11.263) 50 5 (11.473) 3.1 % -0.20 [ -3.86, 3.46 ]
Hedenus 2003 152 2.68 (8.88) 151 0.8 (9.71) 9.4 % 1.88 [ -0.22, 3.98 ]
Hoskin 2009 151 -2.6 (10.67) 149 -2.6 (12.45) 6.0 % 0.0 [ -2.63, 2.63 ]
Iconomou 2003 57 4.6 (12.5) 55 -1 (12.8) 1.9 % 5.60 [ 0.91, 10.29 ]
Kotasek 2003 189 3.4 (12.6) 50 2.3 (11.6) 3.0 % 1.10 [ -2.58, 4.78 ]
Littlewood 2001 200 3 (13.5) 90 -2.2 (12.5) 4.0 % 5.20 [ 2.01, 8.39 ]
Vansteenkiste 2002 156 0.8 (10) 158 -0.6 (10.7) 7.8 % 1.40 [ -0.89, 3.69 ]
Witzig 2005 151 1.56 (12.07) 148 0.31 (14.48) 4.5 % 1.25 [ -1.77, 4.27 ]
Subtotal (95% CI) 1589 1078 51.3 % 2.26 [ 1.36, 3.15 ]
Heterogeneity: Chi2 = 15.50, df = 10 (P = 0.11); I2 =35%
Test for overall effect: Z = 4.94 (P < 0.00001)
Total (95% CI) 2783 2182 100.0 % 2.08 [ 1.43, 2.72 ]
Heterogeneity: Chi2 = 36.48, df = 17 (P = 0.004); I2 =53%
Test for overall effect: Z = 6.34 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.33, df = 1 (P = 0.57), I2 =0.0%
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Analysis 9.1. Comparison 9 Change in FACT-An 20, Outcome 1 Change in FACT-An (20 items) - overall.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 9 Change in FACT-An 20
Outcome: 1 Change in FACT-An (20 items) - overall





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Chang 2005 168 2.16 (12.84) 170 -4.43 (13.42) 32.2 % 6.59 [ 3.79, 9.39 ]
Christodoulou 2009 63 4.64 (15.49) 63 1.11 (15.61) 8.6 % 3.53 [ -1.90, 8.96 ]
Littlewood 2001 200 4 (10.5) 90 -2.6 (10.9) 35.1 % 6.60 [ 3.92, 9.28 ]
O’Shaughnessy 2005 40 -3 (11.9) 42 -9.4 (13.8) 8.1 % 6.40 [ 0.83, 11.97 ]
Savonije 2005 151 3.93 (15.63) 64 -1.91 (14.66) 13.2 % 5.84 [ 1.47, 10.21 ]
Wright 2007 14 6.5 (14) 20 2.6 (14.3) 2.7 % 3.90 [ -5.75, 13.55 ]
Total (95% CI) 636 449 100.0 % 6.14 [ 4.55, 7.73 ]
Heterogeneity: Chi2 = 1.33, df = 5 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 7.58 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 9.2. Comparison 9 Change in FACT-An 20, Outcome 2 Change in FACT-An 20 - baseline Hb.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 9 Change in FACT-An 20
Outcome: 2 Change in FACT-An 20 - baseline Hb





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Hb <= 10 g/dL
Littlewood 2001 200 4 (10.5) 90 -2.6 (10.9) 35.1 % 6.60 [ 3.92, 9.28 ]
Subtotal (95% CI) 200 90 35.1 % 6.60 [ 3.92, 9.28 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.82 (P < 0.00001)
2 Hb 10 to 12 g/dL
Chang 2005 168 2.16 (12.84) 170 -4.43 (13.42) 32.2 % 6.59 [ 3.79, 9.39 ]
Christodoulou 2009 63 4.64 (15.49) 63 1.11 (15.61) 8.6 % 3.53 [ -1.90, 8.96 ]
Savonije 2005 151 3.93 (15.63) 64 -1.91 (14.66) 13.2 % 5.84 [ 1.47, 10.21 ]
Wright 2007 14 6.5 (14) 20 2.6 (14.3) 2.7 % 3.90 [ -5.75, 13.55 ]
Subtotal (95% CI) 396 317 56.7 % 5.82 [ 3.71, 7.93 ]
Heterogeneity: Chi2 = 1.13, df = 3 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 5.41 (P < 0.00001)
3 Hb > 12 g/dL
O’Shaughnessy 2005 40 -3 (11.9) 42 -9.4 (13.8) 8.1 % 6.40 [ 0.83, 11.97 ]
Subtotal (95% CI) 40 42 8.1 % 6.40 [ 0.83, 11.97 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.25 (P = 0.024)
4 Hb category unclear
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 636 449 100.0 % 6.14 [ 4.55, 7.73 ]
Heterogeneity: Chi2 = 1.33, df = 5 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 7.58 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.21, df = 2 (P = 0.90), I2 =0.0%
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Analysis 9.3. Comparison 9 Change in FACT-An 20, Outcome 3 Change in FACT-An 20 - different
malignancies.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 9 Change in FACT-An 20
Outcome: 3 Change in FACT-An 20 - different malignancies





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 solid tumours
Chang 2005 168 2.16 (12.84) 170 -4.43 (13.42) 32.2 % 6.59 [ 3.79, 9.39 ]
Christodoulou 2009 63 4.64 (15.49) 63 1.11 (15.61) 8.6 % 3.53 [ -1.90, 8.96 ]
O’Shaughnessy 2005 40 -3 (11.9) 42 -9.4 (13.8) 8.1 % 6.40 [ 0.83, 11.97 ]
Savonije 2005 151 3.93 (15.63) 64 -1.91 (14.66) 13.2 % 5.84 [ 1.47, 10.21 ]
Wright 2007 14 6.5 (14) 20 2.6 (14.3) 2.7 % 3.90 [ -5.75, 13.55 ]
Subtotal (95% CI) 436 359 64.9 % 5.90 [ 3.92, 7.87 ]
Heterogeneity: Chi2 = 1.16, df = 4 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 5.86 (P < 0.00001)
2 haematological malignancies
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
3 mixed
Littlewood 2001 200 4 (10.5) 90 -2.6 (10.9) 35.1 % 6.60 [ 3.92, 9.28 ]
Subtotal (95% CI) 200 90 35.1 % 6.60 [ 3.92, 9.28 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.82 (P < 0.00001)
4 unclear
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 636 449 100.0 % 6.14 [ 4.55, 7.73 ]
Heterogeneity: Chi2 = 1.33, df = 5 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 7.58 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.17, df = 1 (P = 0.68), I2 =0.0%
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Analysis 9.4. Comparison 9 Change in FACT-An 20, Outcome 4 Change in FACT-An 20 - age.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 9 Change in FACT-An 20
Outcome: 4 Change in FACT-An 20 - age





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 only children < 18 years
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
2 adults >= 18 years
Christodoulou 2009 63 4.64 (15.49) 63 1.11 (15.61) 8.6 % 3.53 [ -1.90, 8.96 ]
Littlewood 2001 200 4 (10.5) 90 -2.6 (10.9) 35.1 % 6.60 [ 3.92, 9.28 ]
O’Shaughnessy 2005 40 -3 (11.9) 42 -9.4 (13.8) 8.1 % 6.40 [ 0.83, 11.97 ]
Savonije 2005 151 3.93 (15.63) 64 -1.91 (14.66) 13.2 % 5.84 [ 1.47, 10.21 ]
Wright 2007 14 6.5 (14) 20 2.6 (14.3) 2.7 % 3.90 [ -5.75, 13.55 ]
Subtotal (95% CI) 468 279 67.8 % 5.93 [ 4.00, 7.86 ]
Heterogeneity: Chi2 = 1.19, df = 4 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 6.02 (P < 0.00001)
3 >70% non elderly 18-65 years
Chang 2005 168 2.16 (12.84) 170 -4.43 (13.42) 32.2 % 6.59 [ 3.79, 9.39 ]
Subtotal (95% CI) 168 170 32.2 % 6.59 [ 3.79, 9.39 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.61 (P < 0.00001)
4 only non-elderly adults
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
5 >70% elderly >65 years
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
6 only elderly > 65 years
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 636 449 100.0 % 6.14 [ 4.55, 7.73 ]
Heterogeneity: Chi2 = 1.33, df = 5 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 7.58 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.14, df = 1 (P = 0.70), I2 =0.0%
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Analysis 9.5. Comparison 9 Change in FACT-An 20, Outcome 5 Change in FACT-An 20 - different therapies.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 9 Change in FACT-An 20
Outcome: 5 Change in FACT-An 20 - different therapies





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 chemotherapy
Chang 2005 168 2.16 (12.84) 170 -4.43 (13.42) 32.2 % 6.59 [ 3.79, 9.39 ]
Christodoulou 2009 63 4.64 (15.49) 63 1.11 (15.61) 8.6 % 3.53 [ -1.90, 8.96 ]
Littlewood 2001 200 4 (10.5) 90 -2.6 (10.9) 35.1 % 6.60 [ 3.92, 9.28 ]
O’Shaughnessy 2005 40 -3 (11.9) 42 -9.4 (13.8) 8.1 % 6.40 [ 0.83, 11.97 ]
Savonije 2005 151 3.93 (15.63) 64 -1.91 (14.66) 13.2 % 5.84 [ 1.47, 10.21 ]
Subtotal (95% CI) 622 429 97.3 % 6.21 [ 4.60, 7.82 ]
Heterogeneity: Chi2 = 1.12, df = 4 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 7.55 (P < 0.00001)
2 radiotherapy
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
3 no therapy
Wright 2007 14 6.5 (14) 20 2.6 (14.3) 2.7 % 3.90 [ -5.75, 13.55 ]
Subtotal (95% CI) 14 20 2.7 % 3.90 [ -5.75, 13.55 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.79 (P = 0.43)
4 unclear
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 636 449 100.0 % 6.14 [ 4.55, 7.73 ]
Heterogeneity: Chi2 = 1.33, df = 5 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 7.58 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.21, df = 1 (P = 0.64), I2 =0.0%
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Analysis 9.6. Comparison 9 Change in FACT-An 20, Outcome 6 Change in FACT-An 20 - different therapies
differentiated.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 9 Change in FACT-An 20
Outcome: 6 Change in FACT-An 20 - different therapies differentiated





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 chemotherapy, >70% with platinum
Christodoulou 2009 21 4.78 (15.9) 20 3.15 (14.62) 2.9 % 1.63 [ -7.71, 10.97 ]
Savonije 2005 151 3.93 (15.63) 64 -1.91 (14.66) 13.2 % 5.84 [ 1.47, 10.21 ]
Subtotal (95% CI) 172 84 16.1 % 5.08 [ 1.12, 9.04 ]
Heterogeneity: Chi2 = 0.64, df = 1 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 2.52 (P = 0.012)
2 chemotherapy, <70% platinum containing
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
3 chemotherapy without platinum (all patients)
Chang 2005 168 2.16 (12.84) 170 -4.43 (13.42) 32.3 % 6.59 [ 3.79, 9.39 ]
Christodoulou 2009 43 4.57 (15.07) 42 0.13 (16.54) 5.6 % 4.44 [ -2.29, 11.17 ]
Littlewood 2001 200 4 (10.5) 90 -2.6 (10.9) 35.2 % 6.60 [ 3.92, 9.28 ]
O’Shaughnessy 2005 40 -3 (11.9) 42 -9.4 (13.8) 8.2 % 6.40 [ 0.83, 11.97 ]
Subtotal (95% CI) 451 344 81.2 % 6.43 [ 4.66, 8.19 ]
Heterogeneity: Chi2 = 0.36, df = 3 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 7.14 (P < 0.00001)
4 chemotherapy, platinum and non-platinum containing, no numbers given
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
5 radiochemotherapy NEW
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
6 radiotherapy
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
7 no therapy
Wright 2007 14 6.5 (14) 20 2.6 (14.3) 2.7 % 3.90 [ -5.75, 13.55 ]
Subtotal (95% CI) 14 20 2.7 % 3.90 [ -5.75, 13.55 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.79 (P = 0.43)
8 unclear
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
9 chemotherapy no details given
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 637 448 100.0 % 6.14 [ 4.55, 7.73 ]
Heterogeneity: Chi2 = 1.59, df = 6 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 7.57 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.58, df = 2 (P = 0.75), I2 =0.0%
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Analysis 9.7. Comparison 9 Change in FACT-An 20, Outcome 7 Change in FACT-An 20 - epoetin versus
darbepoetin.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 9 Change in FACT-An 20
Outcome: 7 Change in FACT-An 20 - epoetin versus darbepoetin





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Epoetin
Chang 2005 168 2.16 (12.84) 170 -4.43 (13.42) 32.2 % 6.59 [ 3.79, 9.39 ]
Christodoulou 2009 63 4.64 (15.49) 63 1.11 (15.61) 8.6 % 3.53 [ -1.90, 8.96 ]
Littlewood 2001 200 4 (10.5) 90 -2.6 (10.9) 35.1 % 6.60 [ 3.92, 9.28 ]
O’Shaughnessy 2005 40 -3 (11.9) 42 -9.4 (13.8) 8.1 % 6.40 [ 0.83, 11.97 ]
Savonije 2005 151 3.93 (15.63) 64 -1.91 (14.66) 13.2 % 5.84 [ 1.47, 10.21 ]
Wright 2007 14 6.5 (14) 20 2.6 (14.3) 2.7 % 3.90 [ -5.75, 13.55 ]
Subtotal (95% CI) 636 449 100.0 % 6.14 [ 4.55, 7.73 ]
Heterogeneity: Chi2 = 1.33, df = 5 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 7.58 (P < 0.00001)
2 Darbepoetin
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 636 449 100.0 % 6.14 [ 4.55, 7.73 ]
Heterogeneity: Chi2 = 1.33, df = 5 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 7.58 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 9.8. Comparison 9 Change in FACT-An 20, Outcome 8 Change in FACT-An 20 - duration of ESA
medication.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 9 Change in FACT-An 20
Outcome: 8 Change in FACT-An 20 - duration of ESA medication





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 6 to 9 weeks
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
2 12 to 16 weeks
Chang 2005 168 2.16 (12.84) 170 -4.43 (13.42) 32.2 % 6.59 [ 3.79, 9.39 ]
Christodoulou 2009 63 4.64 (15.49) 63 1.11 (15.61) 8.6 % 3.53 [ -1.90, 8.96 ]
O’Shaughnessy 2005 40 -3 (11.9) 42 -9.4 (13.8) 8.1 % 6.40 [ 0.83, 11.97 ]
Savonije 2005 151 3.93 (15.63) 64 -1.91 (14.66) 13.2 % 5.84 [ 1.47, 10.21 ]
Wright 2007 14 6.5 (14) 20 2.6 (14.3) 2.7 % 3.90 [ -5.75, 13.55 ]
Subtotal (95% CI) 436 359 64.9 % 5.90 [ 3.92, 7.87 ]
Heterogeneity: Chi2 = 1.16, df = 4 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 5.86 (P < 0.00001)
3 more than 17 weeks
Littlewood 2001 200 4 (10.5) 90 -2.6 (10.9) 35.1 % 6.60 [ 3.92, 9.28 ]
Subtotal (95% CI) 200 90 35.1 % 6.60 [ 3.92, 9.28 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.82 (P < 0.00001)
4 unclear
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 636 449 100.0 % 6.14 [ 4.55, 7.73 ]
Heterogeneity: Chi2 = 1.33, df = 5 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 7.58 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.17, df = 1 (P = 0.68), I2 =0.0%
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Analysis 9.9. Comparison 9 Change in FACT-An 20, Outcome 9 Change in FACT-An 20 - iron
supplementation.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 9 Change in FACT-An 20
Outcome: 9 Change in FACT-An 20 - iron supplementation





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 fixed iron supplementation
Christodoulou 2009 63 4.64 (15.49) 63 1.11 (15.61) 8.6 % 3.53 [ -1.90, 8.96 ]
Subtotal (95% CI) 63 63 8.6 % 3.53 [ -1.90, 8.96 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.27 (P = 0.20)
2 iron supplementation as necessary
Chang 2005 168 2.16 (12.84) 170 -4.43 (13.42) 32.2 % 6.59 [ 3.79, 9.39 ]
Littlewood 2001 200 4 (10.5) 90 -2.6 (10.9) 35.1 % 6.60 [ 3.92, 9.28 ]
O’Shaughnessy 2005 40 -3 (11.9) 42 -9.4 (13.8) 8.1 % 6.40 [ 0.83, 11.97 ]
Wright 2007 14 6.5 (14) 20 2.6 (14.3) 2.7 % 3.90 [ -5.75, 13.55 ]
Subtotal (95% CI) 422 322 78.2 % 6.48 [ 4.68, 8.28 ]
Heterogeneity: Chi2 = 0.29, df = 3 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 7.07 (P < 0.00001)
3 no explicit statement on iron supplementation or no iron given
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
4 explicitly stated NO IRON
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
5 unclear
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
6 iron given differently in both study arms new
Savonije 2005 151 3.93 (15.63) 64 -1.91 (14.66) 13.2 % 5.84 [ 1.47, 10.21 ]
Subtotal (95% CI) 151 64 13.2 % 5.84 [ 1.47, 10.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.62 (P = 0.0088)
Total (95% CI) 636 449 100.0 % 6.14 [ 4.55, 7.73 ]
Heterogeneity: Chi2 = 1.33, df = 5 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 7.58 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.04, df = 2 (P = 0.59), I2 =0.0%
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Analysis 9.10. Comparison 9 Change in FACT-An 20, Outcome 10 Change in FACT-An 20 - allocation
concealment.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 9 Change in FACT-An 20
Outcome: 10 Change in FACT-An 20 - allocation concealment





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 adequate
Chang 2005 168 2.16 (12.84) 170 -4.43 (13.42) 32.2 % 6.59 [ 3.79, 9.39 ]
Christodoulou 2009 63 4.64 (15.49) 63 1.11 (15.61) 8.6 % 3.53 [ -1.90, 8.96 ]
Littlewood 2001 200 4 (10.5) 90 -2.6 (10.9) 35.1 % 6.60 [ 3.92, 9.28 ]
O’Shaughnessy 2005 40 -3 (11.9) 42 -9.4 (13.8) 8.1 % 6.40 [ 0.83, 11.97 ]
Savonije 2005 151 3.93 (15.63) 64 -1.91 (14.66) 13.2 % 5.84 [ 1.47, 10.21 ]
Wright 2007 14 6.5 (14) 20 2.6 (14.3) 2.7 % 3.90 [ -5.75, 13.55 ]
Subtotal (95% CI) 636 449 100.0 % 6.14 [ 4.55, 7.73 ]
Heterogeneity: Chi2 = 1.33, df = 5 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 7.58 (P < 0.00001)
2 unclear
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
3 unclear wether adequate or unclear :)
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 636 449 100.0 % 6.14 [ 4.55, 7.73 ]
Heterogeneity: Chi2 = 1.33, df = 5 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 7.58 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 9.11. Comparison 9 Change in FACT-An 20, Outcome 11 Change in FACT-An 20 - masking.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 9 Change in FACT-An 20
Outcome: 11 Change in FACT-An 20 - masking





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 double-blind
Littlewood 2001 200 4 (10.5) 90 -2.6 (10.9) 35.1 % 6.60 [ 3.92, 9.28 ]
O’Shaughnessy 2005 40 -3 (11.9) 42 -9.4 (13.8) 8.1 % 6.40 [ 0.83, 11.97 ]
Wright 2007 14 6.5 (14) 20 2.6 (14.3) 2.7 % 3.90 [ -5.75, 13.55 ]
Subtotal (95% CI) 254 152 46.0 % 6.41 [ 4.06, 8.75 ]
Heterogeneity: Chi2 = 0.28, df = 2 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 5.36 (P < 0.00001)
2 unblinded
Chang 2005 168 2.16 (12.84) 170 -4.43 (13.42) 32.2 % 6.59 [ 3.79, 9.39 ]
Christodoulou 2009 63 4.64 (15.49) 63 1.11 (15.61) 8.6 % 3.53 [ -1.90, 8.96 ]
Savonije 2005 151 3.93 (15.63) 64 -1.91 (14.66) 13.2 % 5.84 [ 1.47, 10.21 ]
Subtotal (95% CI) 382 297 54.0 % 5.92 [ 3.76, 8.08 ]
Heterogeneity: Chi2 = 0.97, df = 2 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 5.37 (P < 0.00001)
Total (95% CI) 636 449 100.0 % 6.14 [ 4.55, 7.73 ]
Heterogeneity: Chi2 = 1.33, df = 5 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 7.58 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.09, df = 1 (P = 0.77), I2 =0.0%
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Analysis 9.12. Comparison 9 Change in FACT-An 20, Outcome 12 Change in FACT-An 20 - intention-to
treat.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 9 Change in FACT-An 20
Outcome: 12 Change in FACT-An 20 - intention-to treat





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ITT or less than 10% of participants per study arm excluded
Chang 2005 168 2.16 (12.84) 170 -4.43 (13.42) 32.2 % 6.59 [ 3.79, 9.39 ]
Subtotal (95% CI) 168 170 32.2 % 6.59 [ 3.79, 9.39 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.61 (P < 0.00001)
2 more than 10% of participants per study arm excluded
Christodoulou 2009 63 4.64 (15.49) 63 1.11 (15.61) 8.6 % 3.53 [ -1.90, 8.96 ]
Littlewood 2001 200 4 (10.5) 90 -2.6 (10.9) 35.1 % 6.60 [ 3.92, 9.28 ]
O’Shaughnessy 2005 40 -3 (11.9) 42 -9.4 (13.8) 8.1 % 6.40 [ 0.83, 11.97 ]
Savonije 2005 151 3.93 (15.63) 64 -1.91 (14.66) 13.2 % 5.84 [ 1.47, 10.21 ]
Wright 2007 14 6.5 (14) 20 2.6 (14.3) 2.7 % 3.90 [ -5.75, 13.55 ]
Subtotal (95% CI) 468 279 67.8 % 5.93 [ 4.00, 7.86 ]
Heterogeneity: Chi2 = 1.19, df = 4 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 6.02 (P < 0.00001)
3 unclear
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 636 449 100.0 % 6.14 [ 4.55, 7.73 ]
Heterogeneity: Chi2 = 1.33, df = 5 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 7.58 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.14, df = 1 (P = 0.70), I2 =0.0%
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Analysis 9.13. Comparison 9 Change in FACT-An 20, Outcome 13 Change in FACT-An 20 - publication.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 9 Change in FACT-An 20
Outcome: 13 Change in FACT-An 20 - publication





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 full text publication
Chang 2005 168 2.16 (12.84) 170 -4.43 (13.42) 32.2 % 6.59 [ 3.79, 9.39 ]
Christodoulou 2009 63 4.64 (15.49) 63 1.11 (15.61) 8.6 % 3.53 [ -1.90, 8.96 ]
Littlewood 2001 200 4 (10.5) 90 -2.6 (10.9) 35.1 % 6.60 [ 3.92, 9.28 ]
O’Shaughnessy 2005 40 -3 (11.9) 42 -9.4 (13.8) 8.1 % 6.40 [ 0.83, 11.97 ]
Savonije 2005 151 3.93 (15.63) 64 -1.91 (14.66) 13.2 % 5.84 [ 1.47, 10.21 ]
Wright 2007 14 6.5 (14) 20 2.6 (14.3) 2.7 % 3.90 [ -5.75, 13.55 ]
Subtotal (95% CI) 636 449 100.0 % 6.14 [ 4.55, 7.73 ]
Heterogeneity: Chi2 = 1.33, df = 5 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 7.58 (P < 0.00001)
2 abstract publication
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
3 unpublished data
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
4 FDA hearing
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
5 clinical trial result information
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 636 449 100.0 % 6.14 [ 4.55, 7.73 ]
Heterogeneity: Chi2 = 1.33, df = 5 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 7.58 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 9.14. Comparison 9 Change in FACT-An 20, Outcome 14 Change in FACT-An 20 - data type.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 9 Change in FACT-An 20
Outcome: 14 Change in FACT-An 20 - data type





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Not imputed data
Chang 2005 168 2.16 (12.84) 170 -4.43 (13.42) 32.2 % 6.59 [ 3.79, 9.39 ]
O’Shaughnessy 2005 40 -3 (11.9) 42 -9.4 (13.8) 8.1 % 6.40 [ 0.83, 11.97 ]
Savonije 2005 151 3.93 (15.63) 64 -1.91 (14.66) 13.2 % 5.84 [ 1.47, 10.21 ]
Subtotal (95% CI) 359 276 53.6 % 6.38 [ 4.20, 8.55 ]
Heterogeneity: Chi2 = 0.08, df = 2 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 5.76 (P < 0.00001)
2 Imputed data
Christodoulou 2009 63 4.64 (15.49) 63 1.11 (15.61) 8.6 % 3.53 [ -1.90, 8.96 ]
Littlewood 2001 200 4 (10.5) 90 -2.6 (10.9) 35.1 % 6.60 [ 3.92, 9.28 ]
Wright 2007 14 6.5 (14) 20 2.6 (14.3) 2.7 % 3.90 [ -5.75, 13.55 ]
Subtotal (95% CI) 277 173 46.4 % 5.88 [ 3.54, 8.21 ]
Heterogeneity: Chi2 = 1.16, df = 2 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 4.94 (P < 0.00001)
Total (95% CI) 636 449 100.0 % 6.14 [ 4.55, 7.73 ]
Heterogeneity: Chi2 = 1.33, df = 5 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 7.58 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.09, df = 1 (P = 0.76), I2 =0.0%
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Analysis 10.1. Comparison 10 Change in FACT-An Total 47, Outcome 1 Change in FACT-An Total (47
items) - overall.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 10 Change in FACT-An Total 47
Outcome: 1 Change in FACT-An Total (47 items) - overall





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Christodoulou 2009 64 9.93 (31.22) 63 2.18 (29.45) 4.9 % 7.75 [ -2.80, 18.30 ]
Hoskin 2009 151 -3.3 (26.41) 149 -5.2 (27.43) 14.6 % 1.90 [ -4.19, 7.99 ]
Huddart 2002 45 7.65 (32.87) 45 2.94 (19.72) 4.3 % 4.71 [ -6.49, 15.91 ]
Krzakowski 2008a 104 2.7 (25.4) 52 3.12 (23.83) 8.3 % -0.42 [ -8.53, 7.69 ]
Krzakowski 2008b 105 3.6 (23.4) 52 3.12 (23.83) 8.8 % 0.48 [ -7.39, 8.35 ]
Mystakidou 2005 50 43.3 (18.4) 50 13.4 (14.2) 13.1 % 29.90 [ 23.46, 36.34 ]
Osterborg 2002 105 14.8 (28) 101 8.7 (28.9) 9.0 % 6.10 [ -1.67, 13.87 ]
Savonije 2005 155 3.98 (26.75) 65 -3.69 (24.38) 10.3 % 7.67 [ 0.40, 14.94 ]
Tjulandin 2011 88 6.3 (21.7) 84 0.6 (22) 12.7 % 5.70 [ -0.83, 12.23 ]
Witzig 2005 148 0.56 (28.67) 139 0 (24.87) 14.1 % 0.56 [ -5.64, 6.76 ]
Total (95% CI) 1015 800 100.0 % 6.92 [ 4.59, 9.25 ]
Heterogeneity: Chi2 = 61.64, df = 9 (P<0.00001); I2 =85%
Test for overall effect: Z = 5.82 (P < 0.00001)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favors control Favors Epoetin
584Erythropoietin or darbepoetin for patients with cancer (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 10.2. Comparison 10 Change in FACT-An Total 47, Outcome 2 Change in FACT-An Total 47-
sensitivity analysis.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 10 Change in FACT-An Total 47
Outcome: 2 Change in FACT-An Total 47- sensitivity analysis





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Christodoulou 2009 64 9.93 (31.22) 63 2.18 (29.45) 5.6 % 7.75 [ -2.80, 18.30 ]
Hoskin 2009 151 -3.3 (26.41) 149 -5.2 (27.43) 16.8 % 1.90 [ -4.19, 7.99 ]
Huddart 2002 45 7.65 (32.87) 45 2.94 (19.72) 5.0 % 4.71 [ -6.49, 15.91 ]
Krzakowski 2008a 104 2.7 (25.4) 52 3.12 (23.83) 9.5 % -0.42 [ -8.53, 7.69 ]
Krzakowski 2008b 105 3.6 (23.4) 52 3.12 (23.83) 10.1 % 0.48 [ -7.39, 8.35 ]
Osterborg 2002 105 14.8 (28) 101 8.7 (28.9) 10.3 % 6.10 [ -1.67, 13.87 ]
Savonije 2005 155 3.98 (26.75) 65 -3.69 (24.38) 11.8 % 7.67 [ 0.40, 14.94 ]
Tjulandin 2011 88 6.3 (21.7) 84 0.6 (22) 14.6 % 5.70 [ -0.83, 12.23 ]
Witzig 2005 148 0.56 (28.67) 139 0 (24.87) 16.3 % 0.56 [ -5.64, 6.76 ]
Total (95% CI) 965 750 100.0 % 3.46 [ 0.96, 5.96 ]
Heterogeneity: Chi2 = 5.39, df = 8 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 2.71 (P = 0.0067)
Test for subgroup differences: Not applicable
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Analysis 10.3. Comparison 10 Change in FACT-An Total 47, Outcome 3 Change in FACT-An Total 47 -
baseline Hb.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 10 Change in FACT-An Total 47
Outcome: 3 Change in FACT-An Total 47 - baseline Hb





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Hb <= 10 g/dL
Krzakowski 2008a 104 2.7 (25.4) 52 3.12 (23.83) 8.3 % -0.42 [ -8.53, 7.69 ]
Krzakowski 2008b 105 3.6 (23.4) 52 3.12 (23.83) 8.8 % 0.48 [ -7.39, 8.35 ]
Osterborg 2002 105 14.8 (28) 101 8.7 (28.9) 9.0 % 6.10 [ -1.67, 13.87 ]
Tjulandin 2011 88 6.3 (21.7) 84 0.6 (22) 12.7 % 5.70 [ -0.83, 12.23 ]
Witzig 2005 148 0.56 (28.67) 139 0 (24.87) 14.1 % 0.56 [ -5.64, 6.76 ]
Subtotal (95% CI) 550 428 52.8 % 2.57 [ -0.63, 5.78 ]
Heterogeneity: Chi2 = 2.87, df = 4 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 1.57 (P = 0.12)
2 Hb 10 to 12 g/dL
Christodoulou 2009 64 9.93 (31.22) 63 2.18 (29.45) 4.9 % 7.75 [ -2.80, 18.30 ]
Huddart 2002 45 7.65 (32.87) 45 2.94 (19.72) 4.3 % 4.71 [ -6.49, 15.91 ]
Mystakidou 2005 50 43.3 (18.4) 50 13.4 (14.2) 13.1 % 29.90 [ 23.46, 36.34 ]
Savonije 2005 155 3.98 (26.75) 65 -3.69 (24.38) 10.3 % 7.67 [ 0.40, 14.94 ]
Subtotal (95% CI) 314 223 32.6 % 16.22 [ 12.14, 20.30 ]
Heterogeneity: Chi2 = 29.17, df = 3 (P<0.00001); I2 =90%
Test for overall effect: Z = 7.79 (P < 0.00001)
3 Hb > 12 g/dL
Hoskin 2009 151 -3.3 (26.41) 149 -5.2 (27.43) 14.6 % 1.90 [ -4.19, 7.99 ]
Subtotal (95% CI) 151 149 14.6 % 1.90 [ -4.19, 7.99 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
4 Hb category unclear
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 1015 800 100.0 % 6.92 [ 4.59, 9.25 ]
Heterogeneity: Chi2 = 61.64, df = 9 (P<0.00001); I2 =85%
Test for overall effect: Z = 5.82 (P < 0.00001)
Test for subgroup differences: Chi2 = 29.60, df = 2 (P = 0.00), I2 =93%
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Analysis 10.4. Comparison 10 Change in FACT-An Total 47, Outcome 4 Change in FACT-An Total 47 -
different malignancies.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 10 Change in FACT-An Total 47
Outcome: 4 Change in FACT-An Total 47 - different malignancies





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 solid tumours
Christodoulou 2009 64 9.93 (31.22) 63 2.18 (29.45) 4.9 % 7.75 [ -2.80, 18.30 ]
Hoskin 2009 151 -3.3 (26.41) 149 -5.2 (27.43) 14.6 % 1.90 [ -4.19, 7.99 ]
Huddart 2002 45 7.65 (32.87) 45 2.94 (19.72) 4.3 % 4.71 [ -6.49, 15.91 ]
Krzakowski 2008a 104 2.7 (25.4) 52 3.12 (23.83) 8.3 % -0.42 [ -8.53, 7.69 ]
Krzakowski 2008b 105 3.6 (23.4) 52 3.12 (23.83) 8.8 % 0.48 [ -7.39, 8.35 ]
Mystakidou 2005 50 43.3 (18.4) 50 13.4 (14.2) 13.1 % 29.90 [ 23.46, 36.34 ]
Savonije 2005 155 3.98 (26.75) 65 -3.69 (24.38) 10.3 % 7.67 [ 0.40, 14.94 ]
Witzig 2005 148 0.56 (28.67) 139 0 (24.87) 14.1 % 0.56 [ -5.64, 6.76 ]
Subtotal (95% CI) 822 615 78.3 % 7.21 [ 4.58, 9.84 ]
Heterogeneity: Chi2 = 61.41, df = 7 (P<0.00001); I2 =89%
Test for overall effect: Z = 5.37 (P < 0.00001)
2 haematological malignancies
Osterborg 2002 105 14.8 (28) 101 8.7 (28.9) 9.0 % 6.10 [ -1.67, 13.87 ]
Subtotal (95% CI) 105 101 9.0 % 6.10 [ -1.67, 13.87 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.54 (P = 0.12)
3 mixed
Tjulandin 2011 88 6.3 (21.7) 84 0.6 (22) 12.7 % 5.70 [ -0.83, 12.23 ]
Subtotal (95% CI) 88 84 12.7 % 5.70 [ -0.83, 12.23 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.71 (P = 0.087)
4 unclear
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 1015 800 100.0 % 6.92 [ 4.59, 9.25 ]
Heterogeneity: Chi2 = 61.64, df = 9 (P<0.00001); I2 =85%
Test for overall effect: Z = 5.82 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.22, df = 2 (P = 0.89), I2 =0.0%
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Analysis 10.5. Comparison 10 Change in FACT-An Total 47, Outcome 5 Change in FACT-An Total 47 - age.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 10 Change in FACT-An Total 47
Outcome: 5 Change in FACT-An Total 47 - age





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 only children < 18 years
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
2 adults >= 18 years
Christodoulou 2009 64 9.93 (31.22) 63 2.18 (29.45) 4.9 % 7.75 [ -2.80, 18.30 ]
Hoskin 2009 151 -3.3 (26.41) 149 -5.2 (27.43) 14.6 % 1.90 [ -4.19, 7.99 ]
Huddart 2002 45 7.65 (32.87) 45 2.94 (19.72) 4.3 % 4.71 [ -6.49, 15.91 ]
Krzakowski 2008a 104 2.7 (25.4) 52 3.12 (23.83) 8.3 % -0.42 [ -8.53, 7.69 ]
Krzakowski 2008b 105 3.6 (23.4) 52 3.12 (23.83) 8.8 % 0.48 [ -7.39, 8.35 ]
Mystakidou 2005 50 43.3 (18.4) 50 13.4 (14.2) 13.1 % 29.90 [ 23.46, 36.34 ]
Osterborg 2002 105 14.8 (28) 101 8.7 (28.9) 9.0 % 6.10 [ -1.67, 13.87 ]
Savonije 2005 155 3.98 (26.75) 65 -3.69 (24.38) 10.3 % 7.67 [ 0.40, 14.94 ]
Tjulandin 2011 88 6.3 (21.7) 84 0.6 (22) 12.7 % 5.70 [ -0.83, 12.23 ]
Witzig 2005 148 0.56 (28.67) 139 0 (24.87) 14.1 % 0.56 [ -5.64, 6.76 ]
Subtotal (95% CI) 1015 800 100.0 % 6.92 [ 4.59, 9.25 ]
Heterogeneity: Chi2 = 61.64, df = 9 (P<0.00001); I2 =85%
Test for overall effect: Z = 5.82 (P < 0.00001)
3 >70% non elderly 18-65 years
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
4 only non-elderly adults
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
5 >70% elderly >65 years
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
6 only elderly > 65 years
-100 -50 0 50 100
Favours control Favours ESA
(Continued . . . )
588Erythropoietin or darbepoetin for patients with cancer (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 1015 800 100.0 % 6.92 [ 4.59, 9.25 ]
Heterogeneity: Chi2 = 61.64, df = 9 (P<0.00001); I2 =85%
Test for overall effect: Z = 5.82 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 10.6. Comparison 10 Change in FACT-An Total 47, Outcome 6 Change in FACT-An Total 47 -
different therapies.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 10 Change in FACT-An Total 47
Outcome: 6 Change in FACT-An Total 47 - different therapies





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 chemotherapy
Christodoulou 2009 64 9.93 (31.22) 63 2.18 (29.45) 4.9 % 7.75 [ -2.80, 18.30 ]
Huddart 2002 45 7.65 (32.87) 45 2.94 (19.72) 4.3 % 4.71 [ -6.49, 15.91 ]
Krzakowski 2008a 104 2.7 (25.4) 52 3.12 (23.83) 8.3 % -0.42 [ -8.53, 7.69 ]
Krzakowski 2008b 105 3.6 (23.4) 52 3.12 (23.83) 8.8 % 0.48 [ -7.39, 8.35 ]
Osterborg 2002 105 14.8 (28) 101 8.7 (28.9) 9.0 % 6.10 [ -1.67, 13.87 ]
Savonije 2005 155 3.98 (26.75) 65 -3.69 (24.38) 10.3 % 7.67 [ 0.40, 14.94 ]
Tjulandin 2011 88 6.3 (21.7) 84 0.6 (22) 12.7 % 5.70 [ -0.83, 12.23 ]
Witzig 2005 148 0.56 (28.67) 139 0 (24.87) 14.1 % 0.56 [ -5.64, 6.76 ]
Subtotal (95% CI) 814 601 72.3 % 3.77 [ 1.03, 6.51 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Heterogeneity: Chi2 = 5.08, df = 7 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 2.70 (P = 0.0070)
2 radiotherapy
Hoskin 2009 151 -3.3 (26.41) 149 -5.2 (27.43) 14.6 % 1.90 [ -4.19, 7.99 ]
Subtotal (95% CI) 151 149 14.6 % 1.90 [ -4.19, 7.99 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
3 no therapy
Mystakidou 2005 50 43.3 (18.4) 50 13.4 (14.2) 13.1 % 29.90 [ 23.46, 36.34 ]
Subtotal (95% CI) 50 50 13.1 % 29.90 [ 23.46, 36.34 ]
Heterogeneity: not applicable
Test for overall effect: Z = 9.10 (P < 0.00001)
4 unclear
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 1015 800 100.0 % 6.92 [ 4.59, 9.25 ]
Heterogeneity: Chi2 = 61.64, df = 9 (P<0.00001); I2 =85%
Test for overall effect: Z = 5.82 (P < 0.00001)
Test for subgroup differences: Chi2 = 56.55, df = 2 (P = 0.00), I2 =96%
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Analysis 10.7. Comparison 10 Change in FACT-An Total 47, Outcome 7 Change in FACT-An Total 47 -
different therapies differentiated.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 10 Change in FACT-An Total 47
Outcome: 7 Change in FACT-An Total 47 - different therapies differentiated





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 chemotherapy, >70% with platinum
Christodoulou 2009 21 10.32 (32.28) 21 2.33 (28.61) 1.6 % 7.99 [ -10.46, 26.44 ]
Huddart 2002 45 7.65 (32.87) 45 2.94 (19.72) 4.3 % 4.71 [ -6.49, 15.91 ]
Savonije 2005 155 3.98 (26.75) 65 -3.69 (24.38) 10.3 % 7.67 [ 0.40, 14.94 ]
Subtotal (95% CI) 221 131 16.2 % 6.91 [ 1.12, 12.70 ]
Heterogeneity: Chi2 = 0.20, df = 2 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 2.34 (P = 0.019)
2 chemotherapy, <70% platinum containing
Krzakowski 2008a 104 2.7 (25.4) 52 3.12 (23.83) 8.3 % -0.42 [ -8.53, 7.69 ]
Krzakowski 2008b 105 3.6 (23.4) 52 3.12 (23.83) 8.8 % 0.48 [ -7.39, 8.35 ]
Witzig 2005 148 0.56 (28.67) 139 0 (24.87) 14.1 % 0.56 [ -5.64, 6.76 ]
Subtotal (95% CI) 357 243 31.1 % 0.28 [ -3.90, 4.45 ]
Heterogeneity: Chi2 = 0.04, df = 2 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.13 (P = 0.90)
3 chemotherapy without platinum (all patients)
Christodoulou 2009 43 9.74 (30.14) 42 2.11 (30.3) 3.3 % 7.63 [ -5.22, 20.48 ]
Osterborg 2002 105 14.8 (28) 101 8.7 (28.9) 9.0 % 6.10 [ -1.67, 13.87 ]
Tjulandin 2011 88 6.3 (21.7) 84 0.6 (22) 12.7 % 5.70 [ -0.83, 12.23 ]
Subtotal (95% CI) 236 227 25.0 % 6.10 [ 1.44, 10.76 ]
Heterogeneity: Chi2 = 0.07, df = 2 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 2.56 (P = 0.010)
4 chemotherapy, platinum and non-platinum containing, no numbers given
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
5 radiochemotherapy NEW
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
6 radiotherapy
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Hoskin 2009 151 -3.3 (26.41) 149 -5.2 (27.43) 14.6 % 1.90 [ -4.19, 7.99 ]
Subtotal (95% CI) 151 149 14.6 % 1.90 [ -4.19, 7.99 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
7 no therapy
Mystakidou 2005 50 43.3 (18.4) 50 13.4 (14.2) 13.1 % 29.90 [ 23.46, 36.34 ]
Subtotal (95% CI) 50 50 13.1 % 29.90 [ 23.46, 36.34 ]
Heterogeneity: not applicable
Test for overall effect: Z = 9.10 (P < 0.00001)
8 unclear
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
9 chemotherapy no details given
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 1015 800 100.0 % 6.92 [ 4.59, 9.25 ]
Heterogeneity: Chi2 = 61.64, df = 10 (P<0.00001); I2 =84%
Test for overall effect: Z = 5.82 (P < 0.00001)
Test for subgroup differences: Chi2 = 61.33, df = 4 (P = 0.00), I2 =93%
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Analysis 10.8. Comparison 10 Change in FACT-An Total 47, Outcome 8 Change in FACT-An Total 47 -
epoetin versus darbepoetin.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 10 Change in FACT-An Total 47
Outcome: 8 Change in FACT-An Total 47 - epoetin versus darbepoetin





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Epoetin
Christodoulou 2009 64 9.93 (31.22) 63 2.18 (29.45) 4.9 % 7.75 [ -2.80, 18.30 ]
Hoskin 2009 151 -3.3 (26.41) 149 -5.2 (27.43) 14.6 % 1.90 [ -4.19, 7.99 ]
Huddart 2002 45 7.65 (32.87) 45 2.94 (19.72) 4.3 % 4.71 [ -6.49, 15.91 ]
Krzakowski 2008a 104 2.7 (25.4) 52 3.12 (23.83) 8.3 % -0.42 [ -8.53, 7.69 ]
Krzakowski 2008b 105 3.6 (23.4) 52 3.12 (23.83) 8.8 % 0.48 [ -7.39, 8.35 ]
Mystakidou 2005 50 43.3 (18.4) 50 13.4 (14.2) 13.1 % 29.90 [ 23.46, 36.34 ]
Osterborg 2002 105 14.8 (28) 101 8.7 (28.9) 9.0 % 6.10 [ -1.67, 13.87 ]
Savonije 2005 155 3.98 (26.75) 65 -3.69 (24.38) 10.3 % 7.67 [ 0.40, 14.94 ]
Tjulandin 2011 88 6.3 (21.7) 84 0.6 (22) 12.7 % 5.70 [ -0.83, 12.23 ]
Witzig 2005 148 0.56 (28.67) 139 0 (24.87) 14.1 % 0.56 [ -5.64, 6.76 ]
Subtotal (95% CI) 1015 800 100.0 % 6.92 [ 4.59, 9.25 ]
Heterogeneity: Chi2 = 61.64, df = 9 (P<0.00001); I2 =85%
Test for overall effect: Z = 5.82 (P < 0.00001)
2 Darbepoetin
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 1015 800 100.0 % 6.92 [ 4.59, 9.25 ]
Heterogeneity: Chi2 = 61.64, df = 9 (P<0.00001); I2 =85%
Test for overall effect: Z = 5.82 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 10.9. Comparison 10 Change in FACT-An Total 47, Outcome 9 Change in FACT-An Total 47 -
duration of ESA medication.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 10 Change in FACT-An Total 47
Outcome: 9 Change in FACT-An Total 47 - duration of ESA medication





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 6 to 9 weeks
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
2 12 to 16 weeks
Christodoulou 2009 64 9.93 (31.22) 63 2.18 (29.45) 4.9 % 7.75 [ -2.80, 18.30 ]
Hoskin 2009 151 -3.3 (26.41) 149 -5.2 (27.43) 14.6 % 1.90 [ -4.19, 7.99 ]
Krzakowski 2008a 104 2.7 (25.4) 52 3.12 (23.83) 8.3 % -0.42 [ -8.53, 7.69 ]
Krzakowski 2008b 105 3.6 (23.4) 52 3.12 (23.83) 8.8 % 0.48 [ -7.39, 8.35 ]
Osterborg 2002 105 14.8 (28) 101 8.7 (28.9) 9.0 % 6.10 [ -1.67, 13.87 ]
Savonije 2005 155 3.98 (26.75) 65 -3.69 (24.38) 10.3 % 7.67 [ 0.40, 14.94 ]
Tjulandin 2011 88 6.3 (21.7) 84 0.6 (22) 12.7 % 5.70 [ -0.83, 12.23 ]
Witzig 2005 148 0.56 (28.67) 139 0 (24.87) 14.1 % 0.56 [ -5.64, 6.76 ]
Subtotal (95% CI) 920 705 82.6 % 3.39 [ 0.83, 5.96 ]
Heterogeneity: Chi2 = 5.34, df = 7 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 2.59 (P = 0.0095)
3 more than 17 weeks
Huddart 2002 45 7.65 (32.87) 45 2.94 (19.72) 4.3 % 4.71 [ -6.49, 15.91 ]
Mystakidou 2005 50 43.3 (18.4) 50 13.4 (14.2) 13.1 % 29.90 [ 23.46, 36.34 ]
Subtotal (95% CI) 95 95 17.4 % 23.64 [ 18.05, 29.22 ]
Heterogeneity: Chi2 = 14.60, df = 1 (P = 0.00013); I2 =93%
Test for overall effect: Z = 8.30 (P < 0.00001)
4 unclear
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 1015 800 100.0 % 6.92 [ 4.59, 9.25 ]
Heterogeneity: Chi2 = 61.64, df = 9 (P<0.00001); I2 =85%
Test for overall effect: Z = 5.82 (P < 0.00001)
Test for subgroup differences: Chi2 = 41.70, df = 1 (P = 0.00), I2 =98%
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Analysis 10.10. Comparison 10 Change in FACT-An Total 47, Outcome 10 Change in FACT-An Total 47 -
iron supplementation.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 10 Change in FACT-An Total 47
Outcome: 10 Change in FACT-An Total 47 - iron supplementation





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 fixed iron supplementation
Christodoulou 2009 64 9.93 (31.22) 63 2.18 (29.45) 4.9 % 7.75 [ -2.80, 18.30 ]
Hoskin 2009 151 -3.3 (26.41) 149 -5.2 (27.43) 14.6 % 1.90 [ -4.19, 7.99 ]
Huddart 2002 45 7.65 (32.87) 45 2.94 (19.72) 4.3 % 4.71 [ -6.49, 15.91 ]
Krzakowski 2008a 104 2.7 (25.4) 52 3.12 (23.83) 8.3 % -0.42 [ -8.53, 7.69 ]
Krzakowski 2008b 105 3.6 (23.4) 52 3.12 (23.83) 8.8 % 0.48 [ -7.39, 8.35 ]
Mystakidou 2005 50 43.3 (18.4) 50 13.4 (14.2) 13.1 % 29.90 [ 23.46, 36.34 ]
Witzig 2005 148 0.56 (28.67) 139 0 (24.87) 14.1 % 0.56 [ -5.64, 6.76 ]
Subtotal (95% CI) 667 550 68.0 % 7.14 [ 4.31, 9.96 ]
Heterogeneity: Chi2 = 61.39, df = 6 (P<0.00001); I2 =90%
Test for overall effect: Z = 4.95 (P < 0.00001)
2 iron supplementation as necessary
Osterborg 2002 105 14.8 (28) 101 8.7 (28.9) 9.0 % 6.10 [ -1.67, 13.87 ]
Tjulandin 2011 88 6.3 (21.7) 84 0.6 (22) 12.7 % 5.70 [ -0.83, 12.23 ]
Subtotal (95% CI) 193 185 21.7 % 5.87 [ 0.86, 10.87 ]
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 2.30 (P = 0.022)
3 no explicit statement on iron supplementation or no iron given
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
4 explicitly stated NO IRON
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
5 unclear
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
6 iron given differently in both study arms new
Savonije 2005 155 3.98 (26.75) 65 -3.69 (24.38) 10.3 % 7.67 [ 0.40, 14.94 ]
Subtotal (95% CI) 155 65 10.3 % 7.67 [ 0.40, 14.94 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.07 (P = 0.039)
Total (95% CI) 1015 800 100.0 % 6.92 [ 4.59, 9.25 ]
Heterogeneity: Chi2 = 61.64, df = 9 (P<0.00001); I2 =85%
Test for overall effect: Z = 5.82 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.23, df = 2 (P = 0.89), I2 =0.0%
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Analysis 10.11. Comparison 10 Change in FACT-An Total 47, Outcome 11 Change in FACT-An Total 47 -
allocation concealment.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 10 Change in FACT-An Total 47
Outcome: 11 Change in FACT-An Total 47 - allocation concealment





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 adequate
Christodoulou 2009 64 9.93 (31.22) 63 2.18 (29.45) 4.9 % 7.75 [ -2.80, 18.30 ]
Osterborg 2002 105 14.8 (28) 101 8.7 (28.9) 9.0 % 6.10 [ -1.67, 13.87 ]
Savonije 2005 155 3.98 (26.75) 65 -3.69 (24.38) 10.3 % 7.67 [ 0.40, 14.94 ]
Witzig 2005 148 0.56 (28.67) 139 0 (24.87) 14.1 % 0.56 [ -5.64, 6.76 ]
Subtotal (95% CI) 472 368 38.2 % 4.69 [ 0.92, 8.45 ]
Heterogeneity: Chi2 = 2.80, df = 3 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 2.44 (P = 0.015)
2 unclear
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Hoskin 2009 151 -3.3 (26.41) 149 -5.2 (27.43) 14.6 % 1.90 [ -4.19, 7.99 ]
Huddart 2002 45 7.65 (32.87) 45 2.94 (19.72) 4.3 % 4.71 [ -6.49, 15.91 ]
Krzakowski 2008a 104 2.7 (25.4) 52 3.12 (23.83) 8.3 % -0.42 [ -8.53, 7.69 ]
Krzakowski 2008b 105 3.6 (23.4) 52 3.12 (23.83) 8.8 % 0.48 [ -7.39, 8.35 ]
Mystakidou 2005 50 43.3 (18.4) 50 13.4 (14.2) 13.1 % 29.90 [ 23.46, 36.34 ]
Tjulandin 2011 88 6.3 (21.7) 84 0.6 (22) 12.7 % 5.70 [ -0.83, 12.23 ]
Subtotal (95% CI) 543 432 61.8 % 8.30 [ 5.33, 11.26 ]
Heterogeneity: Chi2 = 56.65, df = 5 (P<0.00001); I2 =91%
Test for overall effect: Z = 5.49 (P < 0.00001)
Total (95% CI) 1015 800 100.0 % 6.92 [ 4.59, 9.25 ]
Heterogeneity: Chi2 = 61.64, df = 9 (P<0.00001); I2 =85%
Test for overall effect: Z = 5.82 (P < 0.00001)
Test for subgroup differences: Chi2 = 2.18, df = 1 (P = 0.14), I2 =54%
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Analysis 10.12. Comparison 10 Change in FACT-An Total 47, Outcome 12 Change in FACT-An Total 47 -
masking.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 10 Change in FACT-An Total 47
Outcome: 12 Change in FACT-An Total 47 - masking





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 double-blind
Krzakowski 2008a 104 2.7 (25.4) 52 3.12 (23.83) 8.3 % -0.42 [ -8.53, 7.69 ]
Krzakowski 2008b 105 3.6 (23.4) 52 3.12 (23.83) 8.8 % 0.48 [ -7.39, 8.35 ]
Mystakidou 2005 50 43.3 (18.4) 50 13.4 (14.2) 13.1 % 29.90 [ 23.46, 36.34 ]
Osterborg 2002 105 14.8 (28) 101 8.7 (28.9) 9.0 % 6.10 [ -1.67, 13.87 ]
Tjulandin 2011 88 6.3 (21.7) 84 0.6 (22) 12.7 % 5.70 [ -0.83, 12.23 ]
Witzig 2005 148 0.56 (28.67) 139 0 (24.87) 14.1 % 0.56 [ -5.64, 6.76 ]
Subtotal (95% CI) 600 478 65.9 % 8.00 [ 5.13, 10.87 ]
Heterogeneity: Chi2 = 58.28, df = 5 (P<0.00001); I2 =91%
Test for overall effect: Z = 5.46 (P < 0.00001)
2 unblinded
Christodoulou 2009 64 9.93 (31.22) 63 2.18 (29.45) 4.9 % 7.75 [ -2.80, 18.30 ]
Hoskin 2009 151 -3.3 (26.41) 149 -5.2 (27.43) 14.6 % 1.90 [ -4.19, 7.99 ]
Huddart 2002 45 7.65 (32.87) 45 2.94 (19.72) 4.3 % 4.71 [ -6.49, 15.91 ]
Savonije 2005 155 3.98 (26.75) 65 -3.69 (24.38) 10.3 % 7.67 [ 0.40, 14.94 ]
Subtotal (95% CI) 415 322 34.1 % 4.83 [ 0.84, 8.82 ]
Heterogeneity: Chi2 = 1.77, df = 3 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 2.37 (P = 0.018)
Total (95% CI) 1015 800 100.0 % 6.92 [ 4.59, 9.25 ]
Heterogeneity: Chi2 = 61.64, df = 9 (P<0.00001); I2 =85%
Test for overall effect: Z = 5.82 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.59, df = 1 (P = 0.21), I2 =37%
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Analysis 10.13. Comparison 10 Change in FACT-An Total 47, Outcome 13 Change in FACT-An Total 47 -
intention-to treat.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 10 Change in FACT-An Total 47
Outcome: 13 Change in FACT-An Total 47 - intention-to treat





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ITT or less than 10% of participants per study arm excluded
Krzakowski 2008a 104 2.7 (25.4) 52 3.12 (23.83) 8.3 % -0.42 [ -8.53, 7.69 ]
Krzakowski 2008b 105 3.6 (23.4) 52 3.12 (23.83) 8.8 % 0.48 [ -7.39, 8.35 ]
Mystakidou 2005 50 43.3 (18.4) 50 13.4 (14.2) 13.1 % 29.90 [ 23.46, 36.34 ]
Tjulandin 2011 88 6.3 (21.7) 84 0.6 (22) 12.7 % 5.70 [ -0.83, 12.23 ]
Subtotal (95% CI) 347 238 42.8 % 10.85 [ 7.29, 14.41 ]
Heterogeneity: Chi2 = 50.06, df = 3 (P<0.00001); I2 =94%
Test for overall effect: Z = 5.97 (P < 0.00001)
2 more than 10% of participants per study arm excluded
Christodoulou 2009 64 9.93 (31.22) 63 2.18 (29.45) 4.9 % 7.75 [ -2.80, 18.30 ]
Osterborg 2002 105 14.8 (28) 101 8.7 (28.9) 9.0 % 6.10 [ -1.67, 13.87 ]
Savonije 2005 155 3.98 (26.75) 65 -3.69 (24.38) 10.3 % 7.67 [ 0.40, 14.94 ]
Witzig 2005 148 0.56 (28.67) 139 0 (24.87) 14.1 % 0.56 [ -5.64, 6.76 ]
Subtotal (95% CI) 472 368 38.2 % 4.69 [ 0.92, 8.45 ]
Heterogeneity: Chi2 = 2.80, df = 3 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 2.44 (P = 0.015)
3 unclear
Hoskin 2009 151 -3.3 (26.41) 149 -5.2 (27.43) 14.6 % 1.90 [ -4.19, 7.99 ]
Huddart 2002 45 7.65 (32.87) 45 2.94 (19.72) 4.3 % 4.71 [ -6.49, 15.91 ]
Subtotal (95% CI) 196 194 18.9 % 2.54 [ -2.81, 7.90 ]
Heterogeneity: Chi2 = 0.19, df = 1 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 0.93 (P = 0.35)
Total (95% CI) 1015 800 100.0 % 6.92 [ 4.59, 9.25 ]
Heterogeneity: Chi2 = 61.64, df = 9 (P<0.00001); I2 =85%
Test for overall effect: Z = 5.82 (P < 0.00001)
Test for subgroup differences: Chi2 = 8.59, df = 2 (P = 0.01), I2 =77%
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Analysis 10.14. Comparison 10 Change in FACT-An Total 47, Outcome 14 Change in FACT-An Total 47 -
publication.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 10 Change in FACT-An Total 47
Outcome: 14 Change in FACT-An Total 47 - publication





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 full text publication
Christodoulou 2009 64 9.93 (31.22) 63 2.18 (29.45) 4.9 % 7.75 [ -2.80, 18.30 ]
Hoskin 2009 151 -3.3 (26.41) 149 -5.2 (27.43) 14.6 % 1.90 [ -4.19, 7.99 ]
Krzakowski 2008a 104 2.7 (25.4) 52 3.12 (23.83) 8.3 % -0.42 [ -8.53, 7.69 ]
Krzakowski 2008b 105 3.6 (23.4) 52 3.12 (23.83) 8.8 % 0.48 [ -7.39, 8.35 ]
Mystakidou 2005 50 43.3 (18.4) 50 13.4 (14.2) 13.1 % 29.90 [ 23.46, 36.34 ]
Osterborg 2002 105 14.8 (28) 101 8.7 (28.9) 9.0 % 6.10 [ -1.67, 13.87 ]
Savonije 2005 155 3.98 (26.75) 65 -3.69 (24.38) 10.3 % 7.67 [ 0.40, 14.94 ]
Tjulandin 2011 88 6.3 (21.7) 84 0.6 (22) 12.7 % 5.70 [ -0.83, 12.23 ]
Witzig 2005 148 0.56 (28.67) 139 0 (24.87) 14.1 % 0.56 [ -5.64, 6.76 ]
Subtotal (95% CI) 970 755 95.7 % 7.02 [ 4.63, 9.40 ]
Heterogeneity: Chi2 = 61.48, df = 8 (P<0.00001); I2 =87%
Test for overall effect: Z = 5.77 (P < 0.00001)
2 abstract publication
Huddart 2002 45 7.65 (32.87) 45 2.94 (19.72) 4.3 % 4.71 [ -6.49, 15.91 ]
Subtotal (95% CI) 45 45 4.3 % 4.71 [ -6.49, 15.91 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.82 (P = 0.41)
3 unpublished data
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
4 FDA hearing
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
5 clinical trial result information
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Total (95% CI) 1015 800 100.0 % 6.92 [ 4.59, 9.25 ]
Heterogeneity: Chi2 = 61.64, df = 9 (P<0.00001); I2 =85%
Test for overall effect: Z = 5.82 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.16, df = 1 (P = 0.69), I2 =0.0%
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Analysis 10.15. Comparison 10 Change in FACT-An Total 47, Outcome 15 Change in Fact-An Total 47 -
data type.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 10 Change in FACT-An Total 47
Outcome: 15 Change in Fact-An Total 47 - data type





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Not imputed data
Huddart 2002 45 7.65 (32.87) 45 2.94 (19.72) 4.3 % 4.71 [ -6.49, 15.91 ]
Krzakowski 2008a 104 2.7 (25.4) 52 3.12 (23.83) 8.3 % -0.42 [ -8.53, 7.69 ]
Krzakowski 2008b 105 3.6 (23.4) 52 3.12 (23.83) 8.8 % 0.48 [ -7.39, 8.35 ]
Mystakidou 2005 50 43.3 (18.4) 50 13.4 (14.2) 13.1 % 29.90 [ 23.46, 36.34 ]
Osterborg 2002 105 14.8 (28) 101 8.7 (28.9) 9.0 % 6.10 [ -1.67, 13.87 ]
Savonije 2005 155 3.98 (26.75) 65 -3.69 (24.38) 10.3 % 7.67 [ 0.40, 14.94 ]
Tjulandin 2011 88 6.3 (21.7) 84 0.6 (22) 12.7 % 5.70 [ -0.83, 12.23 ]
Subtotal (95% CI) 652 449 66.4 % 9.31 [ 6.45, 12.17 ]
Heterogeneity: Chi2 = 52.27, df = 6 (P<0.00001); I2 =89%
Test for overall effect: Z = 6.38 (P < 0.00001)
2 Imputed data
Christodoulou 2009 64 9.93 (31.22) 63 2.18 (29.45) 4.9 % 7.75 [ -2.80, 18.30 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Hoskin 2009 151 -3.3 (26.41) 149 -5.2 (27.43) 14.6 % 1.90 [ -4.19, 7.99 ]
Witzig 2005 148 0.56 (28.67) 139 0 (24.87) 14.1 % 0.56 [ -5.64, 6.76 ]
Subtotal (95% CI) 363 351 33.6 % 2.19 [ -1.83, 6.20 ]
Heterogeneity: Chi2 = 1.34, df = 2 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 1.07 (P = 0.29)
Total (95% CI) 1015 800 100.0 % 6.92 [ 4.59, 9.25 ]
Heterogeneity: Chi2 = 61.64, df = 9 (P<0.00001); I2 =85%
Test for overall effect: Z = 5.82 (P < 0.00001)
Test for subgroup differences: Chi2 = 8.02, df = 1 (P = 0.00), I2 =88%
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Analysis 10.16. Comparison 10 Change in FACT-An Total 47, Outcome 16 FACT-An Total 47 - merged
experimental study arms.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 10 Change in FACT-An Total 47
Outcome: 16 FACT-An Total 47 - merged experimental study arms





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Christodoulou 2009 64 9.93 (31.22) 63 2.18 (29.45) 4.9 % 7.75 [ -2.80, 18.30 ]
Hoskin 2009 151 -3.3 (26.41) 149 -5.2 (27.43) 14.6 % 1.90 [ -4.19, 7.99 ]
Huddart 2002 45 7.65 (32.87) 45 2.94 (19.72) 4.3 % 4.71 [ -6.49, 15.91 ]
Krzakowski 2008 209 3.15 (24.42) 104 3.12 (23.83) 17.0 % 0.03 [ -5.62, 5.68 ]
Mystakidou 2005 50 43.3 (18.4) 50 13.4 (14.2) 13.1 % 29.90 [ 23.46, 36.34 ]
Osterborg 2002 105 14.8 (28) 101 8.7 (28.9) 9.0 % 6.10 [ -1.67, 13.87 ]
Savonije 2005 155 3.98 (26.75) 65 -3.69 (24.38) 10.3 % 7.67 [ 0.40, 14.94 ]
-100 -50 0 50 100
control treatment
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Tjulandin 2011 88 6.3 (21.7) 84 0.6 (22) 12.7 % 5.70 [ -0.83, 12.23 ]
Witzig 2005 148 0.56 (28.67) 139 0 (24.87) 14.1 % 0.56 [ -5.64, 6.76 ]
Total (95% CI) 1015 800 100.0 % 6.92 [ 4.59, 9.25 ]
Heterogeneity: Chi2 = 61.63, df = 8 (P<0.00001); I2 =87%
Test for overall effect: Z = 5.82 (P < 0.00001)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
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Analysis 11.1. Comparison 11 Thrombotic events, Outcome 1 Thrombotic events - overall.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 11 Thrombotic events
Outcome: 1 Thrombotic events - overall
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Aapro 2008 29/231 13/231 2.23 [ 1.19, 4.18 ]
Abels 1993 J%J 2004 1/65 0/59 2.73 [ 0.11, 65.68 ]
Bamias 2003 0/72 1/72 0.33 [ 0.01, 8.05 ]
Blohmer 2011 2/127 3/129 0.68 [ 0.12, 3.98 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Case 1993 J%J 2004 2/81 3/76 0.63 [ 0.11, 3.64 ]
Chang 2005 19/176 14/178 1.37 [ 0.71, 2.65 ]
Charu 2007 Amgen 2007 8/226 1/59 2.09 [ 0.27, 16.37 ]
Dammacco 2001 J%J 2004 5/69 1/76 5.51 [ 0.66, 45.98 ]
Debus 2006 J%J 2007 38/192 23/191 1.64 [ 1.02, 2.65 ]
Engert 2009 45/645 44/644 1.02 [ 0.68, 1.52 ]
0.02 0.1 1 10 50
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Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
EPO-INT-1 J%J 2004 3/164 1/80 1.46 [ 0.15, 13.85 ]
EPO-INT-3 J%J 2004 8/135 1/65 3.85 [ 0.49, 30.15 ]
Fujisaka 2011 1/89 0/92 3.10 [ 0.13, 75.10 ]
Gordon 2008 16/164 4/54 1.32 [ 0.46, 3.77 ]
Goss 2005 J%J 2004 16/52 2/52 8.00 [ 1.94, 33.06 ]
Grote 2005 J%J 2004 12/109 11/115 1.15 [ 0.53, 2.50 ]
Gupta 2009 0/57 0/59 0.0 [ 0.0, 0.0 ]
Hedenus 2003 FDA 2007 6/175 1/169 5.79 [ 0.71, 47.62 ]
Henke 2003 Roche 2004 10/180 6/171 1.58 [ 0.59, 4.26 ]
Henry 1995 J%J 2004 6/67 8/65 0.73 [ 0.27, 1.98 ]
Hernandez 2009 16/194 11/192 1.44 [ 0.69, 3.02 ]
Hoskin 2009 J%J 2004 4/133 2/149 2.24 [ 0.42, 12.04 ]
Italian 1998 1/44 0/43 2.93 [ 0.12, 70.08 ]
Leyland-Jones 05 J%J 04 36/448 25/456 1.47 [ 0.89, 2.40 ]
Littlewood 2001 J%J 2004 14/251 5/124 1.38 [ 0.51, 3.75 ]
Machtay 2007 2/72 0/68 4.73 [ 0.23, 96.70 ]
Milroy 2011 18/214 13/210 1.36 [ 0.68, 2.70 ]
Moebus 2007 J%J 2007 9/305 5/288 1.70 [ 0.58, 5.01 ]
Osterborg 1996a 2/47 0/25 2.71 [ 0.14, 54.32 ]
Osterborg 1996b 1/48 0/24 1.53 [ 0.06, 36.23 ]
Osterborg 2002 1/170 0/173 3.05 [ 0.13, 74.41 ]
Overgaard 2009 7/255 3/259 2.37 [ 0.62, 9.06 ]
P-174 J%J 2004 0/33 0/12 0.0 [ 0.0, 0.0 ]
Pirker 2008 65/301 43/296 1.49 [ 1.05, 2.11 ]
Pronzato 2010 4/109 1/111 4.07 [ 0.46, 35.87 ]
Ray-Coquard 2009 5/110 4/107 1.22 [ 0.34, 4.41 ]
Razzouk 2006 6/112 2/110 2.95 [ 0.61, 14.28 ]
Rose 1994 J%J 2004 9/142 2/79 2.50 [ 0.55, 11.30 ]
Rosenzweig 2004 4/14 0/13 8.40 [ 0.50, 142.27 ]
Savonije 2005 7/211 1/104 3.45 [ 0.43, 27.68 ]
Smith 2003 Amgen 2007 2/64 2/22 0.34 [ 0.05, 2.30 ]
0.02 0.1 1 10 50
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Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Smith 2008 50/515 36/470 1.27 [ 0.84, 1.91 ]
Strauss 2008 1/33 0/38 3.44 [ 0.14, 81.71 ]
Ten Bokkel 1998a 2/45 0/17 1.96 [ 0.10, 38.79 ]
Ten Bokkel 1998b 4/42 0/16 3.56 [ 0.20, 62.58 ]
Thatcher 1999a 0/42 0/22 0.0 [ 0.0, 0.0 ]
Thatcher 1999b 2/44 0/22 2.56 [ 0.13, 51.05 ]
Thomas 2008 J%J 2004 10/58 5/55 1.90 [ 0.69, 5.20 ]
Thompson 2000 1/45 0/21 1.43 [ 0.06, 33.82 ]
Throuvalas 2000 1/28 0/26 2.79 [ 0.12, 65.66 ]
Tjulandin 2011 0/95 1/91 0.32 [ 0.01, 7.74 ]
Tsuboi 2009 1/62 0/58 2.81 [ 0.12, 67.62 ]
Untch 2011˙1 20/318 17/396 1.47 [ 0.78, 2.75 ]
Vansteenkiste 2002 7/155 5/159 1.44 [ 0.47, 4.43 ]
Welch 1995 1/15 0/15 3.00 [ 0.13, 68.26 ]
Wilkinson 2006 10/121 1/60 4.96 [ 0.65, 37.84 ]
Winquist 2009 0/26 2/30 0.23 [ 0.01, 4.58 ]
Witzig 2005 J%J 2004 9/168 6/165 1.47 [ 0.54, 4.05 ]
Wright 2007 2/33 3/37 0.75 [ 0.13, 4.20 ]
Total (95% CI) 8248 7250 1.52 [ 1.34, 1.74 ]
Total events: 561 (Treatment), 332 (Control)
Heterogeneity: Chi2 = 34.99, df = 55 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 6.36 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 11.2. Comparison 11 Thrombotic events, Outcome 2 Thrombotic events - baseline Hb.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 11 Thrombotic events
Outcome: 2 Thrombotic events - baseline Hb
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hb < 10 g/dL
Abels 1993 J%J 2004 1/65 0/59 2.73 [ 0.11, 65.68 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Case 1993 J%J 2004 2/81 3/76 0.63 [ 0.11, 3.64 ]
Dammacco 2001 J%J 2004 5/69 1/76 5.51 [ 0.66, 45.98 ]
Fujisaka 2011 1/89 0/92 3.10 [ 0.13, 75.10 ]
Hedenus 2003 FDA 2007 6/175 1/169 5.79 [ 0.71, 47.62 ]
Henry 1995 J%J 2004 6/67 8/65 0.73 [ 0.27, 1.98 ]
Italian 1998 1/44 0/43 2.93 [ 0.12, 70.08 ]
Littlewood 2001 J%J 2004 14/251 5/124 1.38 [ 0.51, 3.75 ]
Osterborg 1996a 2/47 0/25 2.71 [ 0.14, 54.32 ]
Osterborg 1996b 1/48 0/24 1.53 [ 0.06, 36.23 ]
Osterborg 2002 1/170 0/173 3.05 [ 0.13, 74.41 ]
Razzouk 2006 6/112 2/110 2.95 [ 0.61, 14.28 ]
Rose 1994 J%J 2004 9/142 2/79 2.50 [ 0.55, 11.30 ]
Smith 2003 Amgen 2007 2/64 2/22 0.34 [ 0.05, 2.30 ]
Smith 2008 50/515 36/470 1.27 [ 0.84, 1.91 ]
Thompson 2000 1/45 0/21 1.43 [ 0.06, 33.82 ]
Tjulandin 2011 0/95 1/91 0.32 [ 0.01, 7.74 ]
Witzig 2005 J%J 2004 9/168 6/165 1.47 [ 0.54, 4.05 ]
Subtotal (95% CI) 2297 1934 1.41 [ 1.06, 1.88 ]
Total events: 117 (Treatment), 67 (Control)
Heterogeneity: Chi2 = 11.45, df = 17 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 2.39 (P = 0.017)
2 Hb 10 to 12 g/dL
Aapro 2008 29/231 13/231 2.23 [ 1.19, 4.18 ]
Bamias 2003 0/72 1/72 0.33 [ 0.01, 8.05 ]
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Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Blohmer 2011 2/127 3/129 0.68 [ 0.12, 3.98 ]
Chang 2005 19/176 14/178 1.37 [ 0.71, 2.65 ]
Charu 2007 Amgen 2007 8/226 1/59 2.09 [ 0.27, 16.37 ]
EPO-INT-1 J%J 2004 3/164 1/80 1.46 [ 0.15, 13.85 ]
EPO-INT-3 J%J 2004 8/135 1/65 3.85 [ 0.49, 30.15 ]
Gordon 2008 16/164 4/54 1.32 [ 0.46, 3.77 ]
Gupta 2009 0/57 0/59 0.0 [ 0.0, 0.0 ]
Henke 2003 Roche 2004 10/180 6/171 1.58 [ 0.59, 4.26 ]
Hernandez 2009 16/194 11/192 1.44 [ 0.69, 3.02 ]
Pirker 2008 65/301 43/296 1.49 [ 1.05, 2.11 ]
Pronzato 2010 4/109 1/111 4.07 [ 0.46, 35.87 ]
Ray-Coquard 2009 5/110 4/107 1.22 [ 0.34, 4.41 ]
Rosenzweig 2004 4/14 0/13 8.40 [ 0.50, 142.27 ]
Savonije 2005 7/211 1/104 3.45 [ 0.43, 27.68 ]
Strauss 2008 1/33 0/38 3.44 [ 0.14, 81.71 ]
Ten Bokkel 1998a 2/45 0/17 1.96 [ 0.10, 38.79 ]
Ten Bokkel 1998b 4/42 0/16 3.56 [ 0.20, 62.58 ]
Thomas 2008 J%J 2004 10/58 5/55 1.90 [ 0.69, 5.20 ]
Throuvalas 2000 1/28 0/26 2.79 [ 0.12, 65.66 ]
Tsuboi 2009 1/62 0/58 2.81 [ 0.12, 67.62 ]
Vansteenkiste 2002 7/155 5/159 1.44 [ 0.47, 4.43 ]
Wilkinson 2006 10/121 1/60 4.96 [ 0.65, 37.84 ]
Winquist 2009 0/26 2/30 0.23 [ 0.01, 4.58 ]
Wright 2007 2/33 3/37 0.75 [ 0.13, 4.20 ]
Subtotal (95% CI) 3074 2417 1.64 [ 1.33, 2.03 ]
Total events: 234 (Treatment), 120 (Control)
Heterogeneity: Chi2 = 11.55, df = 24 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 4.62 (P < 0.00001)
3 Hb > 12 g/dL
Engert 2009 45/645 44/644 1.02 [ 0.68, 1.52 ]
Goss 2005 J%J 2004 16/52 2/52 8.00 [ 1.94, 33.06 ]
Grote 2005 J%J 2004 12/109 11/115 1.15 [ 0.53, 2.50 ]
Hoskin 2009 J%J 2004 4/133 2/149 2.24 [ 0.42, 12.04 ]
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Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Leyland-Jones 05 J%J 04 36/448 25/456 1.47 [ 0.89, 2.40 ]
Machtay 2007 2/72 0/68 4.73 [ 0.23, 96.70 ]
Milroy 2011 18/214 13/210 1.36 [ 0.68, 2.70 ]
Moebus 2007 J%J 2007 9/305 5/288 1.70 [ 0.58, 5.01 ]
Overgaard 2009 7/255 3/259 2.37 [ 0.62, 9.06 ]
Thatcher 1999a 0/42 0/22 0.0 [ 0.0, 0.0 ]
Thatcher 1999b 2/44 0/22 2.56 [ 0.13, 51.05 ]
Untch 2011˙1 20/318 17/396 1.47 [ 0.78, 2.75 ]
Welch 1995 1/15 0/15 3.00 [ 0.13, 68.26 ]
Subtotal (95% CI) 2652 2696 1.44 [ 1.15, 1.80 ]
Total events: 172 (Treatment), 122 (Control)
Heterogeneity: Chi2 = 10.64, df = 11 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 3.21 (P = 0.0013)
4 Hb unclear
Debus 2006 J%J 2007 38/192 23/191 1.64 [ 1.02, 2.65 ]
P-174 J%J 2004 0/33 0/12 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 225 203 1.64 [ 1.02, 2.65 ]
Total events: 38 (Treatment), 23 (Control)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 2.04 (P = 0.041)
Total (95% CI) 8248 7250 1.52 [ 1.34, 1.74 ]
Total events: 561 (Treatment), 332 (Control)
Heterogeneity: Chi2 = 34.99, df = 55 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 6.36 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.09, df = 3 (P = 0.78), I2 =0.0%
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Analysis 11.3. Comparison 11 Thrombotic events, Outcome 3 Thrombotic events - different malignancies.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 11 Thrombotic events
Outcome: 3 Thrombotic events - different malignancies
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 solid tumours
Aapro 2008 29/231 13/231 2.23 [ 1.19, 4.18 ]
Bamias 2003 0/72 1/72 0.33 [ 0.01, 8.05 ]
Blohmer 2011 2/127 3/129 0.68 [ 0.12, 3.98 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Chang 2005 19/176 14/178 1.37 [ 0.71, 2.65 ]
Debus 2006 J%J 2007 38/192 23/191 1.64 [ 1.02, 2.65 ]
EPO-INT-1 J%J 2004 3/164 1/80 1.46 [ 0.15, 13.85 ]
Fujisaka 2011 1/89 0/92 3.10 [ 0.13, 75.10 ]
Goss 2005 J%J 2004 16/52 2/52 8.00 [ 1.94, 33.06 ]
Grote 2005 J%J 2004 12/109 11/115 1.15 [ 0.53, 2.50 ]
Gupta 2009 0/57 0/59 0.0 [ 0.0, 0.0 ]
Henke 2003 Roche 2004 10/180 6/171 1.58 [ 0.59, 4.26 ]
Hoskin 2009 J%J 2004 4/133 2/149 2.24 [ 0.42, 12.04 ]
Leyland-Jones 05 J%J 04 36/448 25/456 1.47 [ 0.89, 2.40 ]
Machtay 2007 2/72 0/68 4.73 [ 0.23, 96.70 ]
Milroy 2011 18/214 13/210 1.36 [ 0.68, 2.70 ]
Moebus 2007 J%J 2007 9/305 5/288 1.70 [ 0.58, 5.01 ]
Overgaard 2009 7/255 3/259 2.37 [ 0.62, 9.06 ]
Pirker 2008 65/301 43/296 1.49 [ 1.05, 2.11 ]
Pronzato 2010 4/109 1/111 4.07 [ 0.46, 35.87 ]
Rosenzweig 2004 4/14 0/13 8.40 [ 0.50, 142.27 ]
Savonije 2005 7/211 1/104 3.45 [ 0.43, 27.68 ]
Strauss 2008 1/33 0/38 3.44 [ 0.14, 81.71 ]
Ten Bokkel 1998a 2/45 0/17 1.96 [ 0.10, 38.79 ]
Ten Bokkel 1998b 4/42 0/16 3.56 [ 0.20, 62.58 ]
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Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Thatcher 1999a 0/42 0/22 0.0 [ 0.0, 0.0 ]
Thatcher 1999b 2/44 0/22 2.56 [ 0.13, 51.05 ]
Thomas 2008 J%J 2004 10/58 5/55 1.90 [ 0.69, 5.20 ]
Throuvalas 2000 1/28 0/26 2.79 [ 0.12, 65.66 ]
Untch 2011˙1 20/318 17/396 1.47 [ 0.78, 2.75 ]
Vansteenkiste 2002 7/155 5/159 1.44 [ 0.47, 4.43 ]
Welch 1995 1/15 0/15 3.00 [ 0.13, 68.26 ]
Wilkinson 2006 10/121 1/60 4.96 [ 0.65, 37.84 ]
Winquist 2009 0/26 2/30 0.23 [ 0.01, 4.58 ]
Witzig 2005 J%J 2004 9/168 6/165 1.47 [ 0.54, 4.05 ]
Wright 2007 2/33 3/37 0.75 [ 0.13, 4.20 ]
Subtotal (95% CI) 4689 4432 1.67 [ 1.41, 1.96 ]
Total events: 355 (Treatment), 206 (Control)
Heterogeneity: Chi2 = 17.86, df = 32 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 6.12 (P < 0.00001)
2 haematological malignancies
Dammacco 2001 J%J 2004 5/69 1/76 5.51 [ 0.66, 45.98 ]
Engert 2009 45/645 44/644 1.02 [ 0.68, 1.52 ]
Hedenus 2003 FDA 2007 6/175 1/169 5.79 [ 0.71, 47.62 ]
Osterborg 1996a 2/47 0/25 2.71 [ 0.14, 54.32 ]
Osterborg 1996b 1/48 0/24 1.53 [ 0.06, 36.23 ]
Osterborg 2002 1/170 0/173 3.05 [ 0.13, 74.41 ]
P-174 J%J 2004 0/33 0/12 0.0 [ 0.0, 0.0 ]
Rose 1994 J%J 2004 9/142 2/79 2.50 [ 0.55, 11.30 ]
Subtotal (95% CI) 1329 1202 1.33 [ 0.93, 1.90 ]
Total events: 69 (Treatment), 48 (Control)
Heterogeneity: Chi2 = 6.41, df = 6 (P = 0.38); I2 =6%
Test for overall effect: Z = 1.55 (P = 0.12)
3 mixed
Abels 1993 J%J 2004 1/65 0/59 2.73 [ 0.11, 65.68 ]
Case 1993 J%J 2004 2/81 3/76 0.63 [ 0.11, 3.64 ]
Charu 2007 Amgen 2007 8/226 1/59 2.09 [ 0.27, 16.37 ]
EPO-INT-3 J%J 2004 8/135 1/65 3.85 [ 0.49, 30.15 ]
Gordon 2008 16/164 4/54 1.32 [ 0.46, 3.77 ]
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Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Henry 1995 J%J 2004 6/67 8/65 0.73 [ 0.27, 1.98 ]
Hernandez 2009 16/194 11/192 1.44 [ 0.69, 3.02 ]
Littlewood 2001 J%J 2004 14/251 5/124 1.38 [ 0.51, 3.75 ]
Ray-Coquard 2009 5/110 4/107 1.22 [ 0.34, 4.41 ]
Razzouk 2006 6/112 2/110 2.95 [ 0.61, 14.28 ]
Smith 2003 Amgen 2007 2/64 2/22 0.34 [ 0.05, 2.30 ]
Smith 2008 50/515 36/470 1.27 [ 0.84, 1.91 ]
Tjulandin 2011 0/95 1/91 0.32 [ 0.01, 7.74 ]
Tsuboi 2009 1/62 0/58 2.81 [ 0.12, 67.62 ]
Subtotal (95% CI) 2141 1552 1.29 [ 0.98, 1.69 ]
Total events: 135 (Treatment), 78 (Control)
Heterogeneity: Chi2 = 7.41, df = 13 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 1.83 (P = 0.067)
4 MDS
Italian 1998 1/44 0/43 2.93 [ 0.12, 70.08 ]
Thompson 2000 1/45 0/21 1.43 [ 0.06, 33.82 ]
Subtotal (95% CI) 89 64 2.08 [ 0.23, 18.84 ]
Total events: 2 (Treatment), 0 (Control)
Heterogeneity: Chi2 = 0.10, df = 1 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.65 (P = 0.52)
5 not reported
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 0 (Treatment), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 8248 7250 1.52 [ 1.34, 1.74 ]
Total events: 561 (Treatment), 332 (Control)
Heterogeneity: Chi2 = 34.99, df = 55 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 6.36 (P < 0.00001)
Test for subgroup differences: Chi2 = 3.23, df = 3 (P = 0.36), I2 =7%
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Analysis 11.4. Comparison 11 Thrombotic events, Outcome 4 Thrombotic events - age.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 11 Thrombotic events
Outcome: 4 Thrombotic events - age
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 children
Razzouk 2006 6/112 2/110 2.95 [ 0.61, 14.28 ]
Subtotal (95% CI) 112 110 2.95 [ 0.61, 14.28 ]
Total events: 6 (Treatment), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.34 (P = 0.18)
2 adults
Aapro 2008 29/231 13/231 2.23 [ 1.19, 4.18 ]
Abels 1993 J%J 2004 1/65 0/59 2.73 [ 0.11, 65.68 ]
Bamias 2003 0/72 1/72 0.33 [ 0.01, 8.05 ]
Blohmer 2011 2/127 3/129 0.68 [ 0.12, 3.98 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Case 1993 J%J 2004 2/81 3/76 0.63 [ 0.11, 3.64 ]
Chang 2005 19/176 14/178 1.37 [ 0.71, 2.65 ]
Charu 2007 Amgen 2007 8/226 1/59 2.09 [ 0.27, 16.37 ]
Dammacco 2001 J%J 2004 5/69 1/76 5.51 [ 0.66, 45.98 ]
Debus 2006 J%J 2007 38/192 23/191 1.64 [ 1.02, 2.65 ]
Engert 2009 45/645 44/644 1.02 [ 0.68, 1.52 ]
EPO-INT-1 J%J 2004 3/164 1/80 1.46 [ 0.15, 13.85 ]
EPO-INT-3 J%J 2004 8/135 1/65 3.85 [ 0.49, 30.15 ]
Fujisaka 2011 1/89 0/92 3.10 [ 0.13, 75.10 ]
Gordon 2008 16/164 4/54 1.32 [ 0.46, 3.77 ]
Goss 2005 J%J 2004 16/52 2/52 8.00 [ 1.94, 33.06 ]
Grote 2005 J%J 2004 12/109 11/115 1.15 [ 0.53, 2.50 ]
Gupta 2009 0/57 0/59 0.0 [ 0.0, 0.0 ]
Hedenus 2003 FDA 2007 6/175 1/169 5.79 [ 0.71, 47.62 ]
Henke 2003 Roche 2004 10/180 6/171 1.58 [ 0.59, 4.26 ]
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Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Henry 1995 J%J 2004 6/67 8/65 0.73 [ 0.27, 1.98 ]
Hernandez 2009 16/194 11/192 1.44 [ 0.69, 3.02 ]
Hoskin 2009 J%J 2004 4/133 2/149 2.24 [ 0.42, 12.04 ]
Italian 1998 1/44 0/43 2.93 [ 0.12, 70.08 ]
Leyland-Jones 05 J%J 04 36/448 25/456 1.47 [ 0.89, 2.40 ]
Littlewood 2001 J%J 2004 14/251 5/124 1.38 [ 0.51, 3.75 ]
Machtay 2007 2/72 0/68 4.73 [ 0.23, 96.70 ]
Milroy 2011 18/214 13/210 1.36 [ 0.68, 2.70 ]
Moebus 2007 J%J 2007 9/305 5/288 1.70 [ 0.58, 5.01 ]
Osterborg 1996a 2/47 0/25 2.71 [ 0.14, 54.32 ]
Osterborg 1996b 1/48 0/24 1.53 [ 0.06, 36.23 ]
Osterborg 2002 1/170 0/173 3.05 [ 0.13, 74.41 ]
Overgaard 2009 7/255 3/259 2.37 [ 0.62, 9.06 ]
P-174 J%J 2004 0/33 0/12 0.0 [ 0.0, 0.0 ]
Pirker 2008 65/301 43/296 1.49 [ 1.05, 2.11 ]
Pronzato 2010 4/109 1/111 4.07 [ 0.46, 35.87 ]
Ray-Coquard 2009 5/110 4/107 1.22 [ 0.34, 4.41 ]
Rose 1994 J%J 2004 9/142 2/79 2.50 [ 0.55, 11.30 ]
Rosenzweig 2004 4/14 0/13 8.40 [ 0.50, 142.27 ]
Savonije 2005 7/211 1/104 3.45 [ 0.43, 27.68 ]
Smith 2003 Amgen 2007 2/64 2/22 0.34 [ 0.05, 2.30 ]
Smith 2008 50/515 36/470 1.27 [ 0.84, 1.91 ]
Strauss 2008 1/33 0/38 3.44 [ 0.14, 81.71 ]
Ten Bokkel 1998a 2/45 0/17 1.96 [ 0.10, 38.79 ]
Ten Bokkel 1998b 4/42 0/16 3.56 [ 0.20, 62.58 ]
Thatcher 1999a 0/42 0/22 0.0 [ 0.0, 0.0 ]
Thatcher 1999b 2/44 0/22 2.56 [ 0.13, 51.05 ]
Thomas 2008 J%J 2004 10/58 5/55 1.90 [ 0.69, 5.20 ]
Thompson 2000 1/45 0/21 1.43 [ 0.06, 33.82 ]
Throuvalas 2000 1/28 0/26 2.79 [ 0.12, 65.66 ]
Tjulandin 2011 0/95 1/91 0.32 [ 0.01, 7.74 ]
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Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tsuboi 2009 1/62 0/58 2.81 [ 0.12, 67.62 ]
Untch 2011˙1 20/318 17/396 1.47 [ 0.78, 2.75 ]
Vansteenkiste 2002 7/155 5/159 1.44 [ 0.47, 4.43 ]
Welch 1995 1/15 0/15 3.00 [ 0.13, 68.26 ]
Wilkinson 2006 10/121 1/60 4.96 [ 0.65, 37.84 ]
Winquist 2009 0/26 2/30 0.23 [ 0.01, 4.58 ]
Witzig 2005 J%J 2004 9/168 6/165 1.47 [ 0.54, 4.05 ]
Wright 2007 2/33 3/37 0.75 [ 0.13, 4.20 ]
Subtotal (95% CI) 8136 7140 1.52 [ 1.33, 1.73 ]
Total events: 555 (Treatment), 330 (Control)
Heterogeneity: Chi2 = 34.23, df = 54 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 6.25 (P < 0.00001)
Total (95% CI) 8248 7250 1.52 [ 1.34, 1.74 ]
Total events: 561 (Treatment), 332 (Control)
Heterogeneity: Chi2 = 34.99, df = 55 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 6.36 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.68, df = 1 (P = 0.41), I2 =0.0%
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Analysis 11.5. Comparison 11 Thrombotic events, Outcome 5 Thrombotic events - age differentiated.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 11 Thrombotic events
Outcome: 5 Thrombotic events - age differentiated
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 children
Razzouk 2006 6/112 2/110 2.95 [ 0.61, 14.28 ]
Subtotal (95% CI) 112 110 2.95 [ 0.61, 14.28 ]
Total events: 6 (Treatment), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.34 (P = 0.18)
2 adults >= 18
Aapro 2008 29/231 13/231 2.23 [ 1.19, 4.18 ]
Abels 1993 J%J 2004 1/65 0/59 2.73 [ 0.11, 65.68 ]
Bamias 2003 0/72 1/72 0.33 [ 0.01, 8.05 ]
Case 1993 J%J 2004 2/81 3/76 0.63 [ 0.11, 3.64 ]
Charu 2007 Amgen 2007 8/226 1/59 2.09 [ 0.27, 16.37 ]
Dammacco 2001 J%J 2004 5/69 1/76 5.51 [ 0.66, 45.98 ]
Debus 2006 J%J 2007 38/192 23/191 1.64 [ 1.02, 2.65 ]
EPO-INT-1 J%J 2004 3/164 1/80 1.46 [ 0.15, 13.85 ]
EPO-INT-3 J%J 2004 8/135 1/65 3.85 [ 0.49, 30.15 ]
Fujisaka 2011 1/89 0/92 3.10 [ 0.13, 75.10 ]
Gordon 2008 16/164 4/54 1.32 [ 0.46, 3.77 ]
Goss 2005 J%J 2004 16/52 2/52 8.00 [ 1.94, 33.06 ]
Grote 2005 J%J 2004 12/109 11/115 1.15 [ 0.53, 2.50 ]
Hedenus 2003 FDA 2007 6/175 1/169 5.79 [ 0.71, 47.62 ]
Henke 2003 Roche 2004 10/180 6/171 1.58 [ 0.59, 4.26 ]
Henry 1995 J%J 2004 6/67 8/65 0.73 [ 0.27, 1.98 ]
Hernandez 2009 16/194 11/192 1.44 [ 0.69, 3.02 ]
Hoskin 2009 J%J 2004 4/133 2/149 2.24 [ 0.42, 12.04 ]
Italian 1998 1/44 0/43 2.93 [ 0.12, 70.08 ]
Leyland-Jones 05 J%J 04 36/448 25/456 1.47 [ 0.89, 2.40 ]
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Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Littlewood 2001 J%J 2004 14/251 5/124 1.38 [ 0.51, 3.75 ]
Machtay 2007 2/72 0/68 4.73 [ 0.23, 96.70 ]
Milroy 2011 18/214 13/210 1.36 [ 0.68, 2.70 ]
Osterborg 1996a 2/47 0/25 2.71 [ 0.14, 54.32 ]
Osterborg 1996b 1/48 0/24 1.53 [ 0.06, 36.23 ]
Osterborg 2002 1/170 0/173 3.05 [ 0.13, 74.41 ]
Overgaard 2009 7/255 3/259 2.37 [ 0.62, 9.06 ]
P-174 J%J 2004 0/33 0/12 0.0 [ 0.0, 0.0 ]
Pirker 2008 65/301 43/296 1.49 [ 1.05, 2.11 ]
Ray-Coquard 2009 5/110 4/107 1.22 [ 0.34, 4.41 ]
Rose 1994 J%J 2004 9/142 2/79 2.50 [ 0.55, 11.30 ]
Rosenzweig 2004 4/14 0/13 8.40 [ 0.50, 142.27 ]
Savonije 2005 7/211 1/104 3.45 [ 0.43, 27.68 ]
Smith 2003 Amgen 2007 2/64 2/22 0.34 [ 0.05, 2.30 ]
Smith 2008 50/515 36/470 1.27 [ 0.84, 1.91 ]
Ten Bokkel 1998a 2/45 0/17 1.96 [ 0.10, 38.79 ]
Ten Bokkel 1998b 4/42 0/16 3.56 [ 0.20, 62.58 ]
Thatcher 1999a 0/42 0/22 0.0 [ 0.0, 0.0 ]
Thatcher 1999b 2/44 0/22 2.56 [ 0.13, 51.05 ]
Thompson 2000 1/45 0/21 1.43 [ 0.06, 33.82 ]
Tjulandin 2011 0/95 1/91 0.32 [ 0.01, 7.74 ]
Tsuboi 2009 1/62 0/58 2.81 [ 0.12, 67.62 ]
Vansteenkiste 2002 7/155 5/159 1.44 [ 0.47, 4.43 ]
Wilkinson 2006 10/121 1/60 4.96 [ 0.65, 37.84 ]
Witzig 2005 J%J 2004 9/168 6/165 1.47 [ 0.54, 4.05 ]
Wright 2007 2/33 3/37 0.75 [ 0.13, 4.20 ]
Subtotal (95% CI) 6189 5121 1.60 [ 1.38, 1.86 ]
Total events: 443 (Treatment), 239 (Control)
Heterogeneity: Chi2 = 26.75, df = 43 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 6.16 (P < 0.00001)
3 > 68% non elderly, 18-65
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Chang 2005 19/176 14/178 1.37 [ 0.71, 2.65 ]
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Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gupta 2009 0/57 0/59 0.0 [ 0.0, 0.0 ]
Pronzato 2010 4/109 1/111 4.07 [ 0.46, 35.87 ]
Strauss 2008 1/33 0/38 3.44 [ 0.14, 81.71 ]
Thomas 2008 J%J 2004 10/58 5/55 1.90 [ 0.69, 5.20 ]
Throuvalas 2000 1/28 0/26 2.79 [ 0.12, 65.66 ]
Subtotal (95% CI) 511 517 1.71 [ 1.02, 2.86 ]
Total events: 35 (Treatment), 20 (Control)
Heterogeneity: Chi2 = 1.36, df = 4 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 2.04 (P = 0.041)
4 only non elderly
Blohmer 2011 2/127 3/129 0.68 [ 0.12, 3.98 ]
Engert 2009 45/645 44/644 1.02 [ 0.68, 1.52 ]
Moebus 2007 J%J 2007 9/305 5/288 1.70 [ 0.58, 5.01 ]
Untch 2011˙1 20/318 17/396 1.47 [ 0.78, 2.75 ]
Welch 1995 1/15 0/15 3.00 [ 0.13, 68.26 ]
Subtotal (95% CI) 1410 1472 1.17 [ 0.86, 1.60 ]
Total events: 77 (Treatment), 69 (Control)
Heterogeneity: Chi2 = 2.11, df = 4 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.99 (P = 0.32)
5 > 68% elderly > 65 years
Winquist 2009 0/26 2/30 0.23 [ 0.01, 4.58 ]
Subtotal (95% CI) 26 30 0.23 [ 0.01, 4.58 ]
Total events: 0 (Treatment), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.96 (P = 0.34)
6 only elderly
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 0 (Treatment), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 8248 7250 1.52 [ 1.34, 1.74 ]
Total events: 561 (Treatment), 332 (Control)
Heterogeneity: Chi2 = 34.99, df = 55 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 6.36 (P < 0.00001)
Test for subgroup differences: Chi2 = 5.53, df = 4 (P = 0.24), I2 =28%
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Analysis 11.6. Comparison 11 Thrombotic events, Outcome 6 Thrombotic events - different therapies.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 11 Thrombotic events
Outcome: 6 Thrombotic events - different therapies
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 chemotherapy
Aapro 2008 29/231 13/231 2.23 [ 1.19, 4.18 ]
Bamias 2003 0/72 1/72 0.33 [ 0.01, 8.05 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Case 1993 J%J 2004 2/81 3/76 0.63 [ 0.11, 3.64 ]
Chang 2005 19/176 14/178 1.37 [ 0.71, 2.65 ]
Dammacco 2001 J%J 2004 5/69 1/76 5.51 [ 0.66, 45.98 ]
Engert 2009 45/645 44/644 1.02 [ 0.68, 1.52 ]
EPO-INT-1 J%J 2004 3/164 1/80 1.46 [ 0.15, 13.85 ]
EPO-INT-3 J%J 2004 8/135 1/65 3.85 [ 0.49, 30.15 ]
Fujisaka 2011 1/89 0/92 3.10 [ 0.13, 75.10 ]
Grote 2005 J%J 2004 12/109 11/115 1.15 [ 0.53, 2.50 ]
Hedenus 2003 FDA 2007 6/175 1/169 5.79 [ 0.71, 47.62 ]
Henry 1995 J%J 2004 6/67 8/65 0.73 [ 0.27, 1.98 ]
Hernandez 2009 16/194 11/192 1.44 [ 0.69, 3.02 ]
Leyland-Jones 05 J%J 04 36/448 25/456 1.47 [ 0.89, 2.40 ]
Littlewood 2001 J%J 2004 14/251 5/124 1.38 [ 0.51, 3.75 ]
Milroy 2011 18/214 13/210 1.36 [ 0.68, 2.70 ]
Moebus 2007 J%J 2007 9/305 5/288 1.70 [ 0.58, 5.01 ]
Osterborg 1996a 2/47 0/25 2.71 [ 0.14, 54.32 ]
Osterborg 1996b 1/48 0/24 1.53 [ 0.06, 36.23 ]
Osterborg 2002 1/170 0/173 3.05 [ 0.13, 74.41 ]
Pirker 2008 65/301 43/296 1.49 [ 1.05, 2.11 ]
Pronzato 2010 4/109 1/111 4.07 [ 0.46, 35.87 ]
Ray-Coquard 2009 5/110 4/107 1.22 [ 0.34, 4.41 ]
Razzouk 2006 6/112 2/110 2.95 [ 0.61, 14.28 ]
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Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Savonije 2005 7/211 1/104 3.45 [ 0.43, 27.68 ]
Ten Bokkel 1998a 2/45 0/17 1.96 [ 0.10, 38.79 ]
Ten Bokkel 1998b 4/42 0/16 3.56 [ 0.20, 62.58 ]
Thatcher 1999a 0/42 0/22 0.0 [ 0.0, 0.0 ]
Thatcher 1999b 2/44 0/22 2.56 [ 0.13, 51.05 ]
Tjulandin 2011 0/95 1/91 0.32 [ 0.01, 7.74 ]
Tsuboi 2009 1/62 0/58 2.81 [ 0.12, 67.62 ]
Untch 2011˙1 20/318 17/396 1.47 [ 0.78, 2.75 ]
Vansteenkiste 2002 7/155 5/159 1.44 [ 0.47, 4.43 ]
Welch 1995 1/15 0/15 3.00 [ 0.13, 68.26 ]
Wilkinson 2006 10/121 1/60 4.96 [ 0.65, 37.84 ]
Witzig 2005 J%J 2004 9/168 6/165 1.47 [ 0.54, 4.05 ]
Subtotal (95% CI) 5690 5154 1.48 [ 1.27, 1.73 ]
Total events: 376 (Treatment), 238 (Control)
Heterogeneity: Chi2 = 19.10, df = 34 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 4.92 (P < 0.00001)
2 radiotherapy/radiochemotherapy
Blohmer 2011 2/127 3/129 0.68 [ 0.12, 3.98 ]
Debus 2006 J%J 2007 38/192 23/191 1.64 [ 1.02, 2.65 ]
Goss 2005 J%J 2004 16/52 2/52 8.00 [ 1.94, 33.06 ]
Gupta 2009 0/57 0/59 0.0 [ 0.0, 0.0 ]
Henke 2003 Roche 2004 10/180 6/171 1.58 [ 0.59, 4.26 ]
Hoskin 2009 J%J 2004 4/133 2/149 2.24 [ 0.42, 12.04 ]
Machtay 2007 2/72 0/68 4.73 [ 0.23, 96.70 ]
Overgaard 2009 7/255 3/259 2.37 [ 0.62, 9.06 ]
Strauss 2008 1/33 0/38 3.44 [ 0.14, 81.71 ]
Thomas 2008 J%J 2004 10/58 5/55 1.90 [ 0.69, 5.20 ]
Throuvalas 2000 1/28 0/26 2.79 [ 0.12, 65.66 ]
Subtotal (95% CI) 1187 1197 2.02 [ 1.44, 2.83 ]
Total events: 91 (Treatment), 44 (Control)
Heterogeneity: Chi2 = 6.56, df = 9 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 4.08 (P = 0.000045)
3 no therapy
Abels 1993 J%J 2004 1/65 0/59 2.73 [ 0.11, 65.68 ]
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Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Charu 2007 Amgen 2007 8/226 1/59 2.09 [ 0.27, 16.37 ]
Gordon 2008 16/164 4/54 1.32 [ 0.46, 3.77 ]
Italian 1998 1/44 0/43 2.93 [ 0.12, 70.08 ]
Smith 2003 Amgen 2007 2/64 2/22 0.34 [ 0.05, 2.30 ]
Smith 2008 50/515 36/470 1.27 [ 0.84, 1.91 ]
Thompson 2000 1/45 0/21 1.43 [ 0.06, 33.82 ]
Wright 2007 2/33 3/37 0.75 [ 0.13, 4.20 ]
Subtotal (95% CI) 1156 765 1.25 [ 0.88, 1.78 ]
Total events: 81 (Treatment), 46 (Control)
Heterogeneity: Chi2 = 2.88, df = 7 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 1.25 (P = 0.21)
4 unclear/other
P-174 J%J 2004 0/33 0/12 0.0 [ 0.0, 0.0 ]
Rose 1994 J%J 2004 9/142 2/79 2.50 [ 0.55, 11.30 ]
Rosenzweig 2004 4/14 0/13 8.40 [ 0.50, 142.27 ]
Winquist 2009 0/26 2/30 0.23 [ 0.01, 4.58 ]
Subtotal (95% CI) 215 134 2.09 [ 0.74, 5.93 ]
Total events: 13 (Treatment), 4 (Control)
Heterogeneity: Chi2 = 3.08, df = 2 (P = 0.21); I2 =35%
Test for overall effect: Z = 1.38 (P = 0.17)
Total (95% CI) 8248 7250 1.52 [ 1.34, 1.74 ]
Total events: 561 (Treatment), 332 (Control)
Heterogeneity: Chi2 = 34.99, df = 55 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 6.36 (P < 0.00001)
Test for subgroup differences: Chi2 = 4.37, df = 3 (P = 0.22), I2 =31%
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Analysis 11.7. Comparison 11 Thrombotic events, Outcome 7 Thrombotic events - different therapies
differentiated.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 11 Thrombotic events
Outcome: 7 Thrombotic events - different therapies differentiated
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 chemotherapy, > 70% with platinum
Bamias 2003 0/72 1/72 0.33 [ 0.01, 8.05 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
EPO-INT-1 J%J 2004 3/164 1/80 1.46 [ 0.15, 13.85 ]
Fujisaka 2011 1/89 0/92 3.10 [ 0.13, 75.10 ]
Grote 2005 J%J 2004 12/109 11/115 1.15 [ 0.53, 2.50 ]
Henry 1995 J%J 2004 6/67 8/65 0.73 [ 0.27, 1.98 ]
Milroy 2011 18/214 13/210 1.36 [ 0.68, 2.70 ]
Pirker 2008 65/301 43/296 1.49 [ 1.05, 2.11 ]
Savonije 2005 7/211 1/104 3.45 [ 0.43, 27.68 ]
Ten Bokkel 1998a 2/45 0/17 1.96 [ 0.10, 38.79 ]
Ten Bokkel 1998b 4/42 0/16 3.56 [ 0.20, 62.58 ]
Thatcher 1999a 0/42 0/22 0.0 [ 0.0, 0.0 ]
Thatcher 1999b 2/44 0/22 2.56 [ 0.13, 51.05 ]
Vansteenkiste 2002 7/155 5/159 1.44 [ 0.47, 4.43 ]
Welch 1995 1/15 0/15 3.00 [ 0.13, 68.26 ]
Wilkinson 2006 10/121 1/60 4.96 [ 0.65, 37.84 ]
Subtotal (95% CI) 1741 1395 1.46 [ 1.13, 1.89 ]
Total events: 138 (Treatment), 84 (Control)
Heterogeneity: Chi2 = 6.11, df = 13 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 2.91 (P = 0.0036)
2 chemotherapy, < 70% with platinum
EPO-INT-3 J%J 2004 8/135 1/65 3.85 [ 0.49, 30.15 ]
Hernandez 2009 16/194 11/192 1.44 [ 0.69, 3.02 ]
Witzig 2005 J%J 2004 9/168 6/165 1.47 [ 0.54, 4.05 ]
Subtotal (95% CI) 497 422 1.63 [ 0.92, 2.88 ]
Total events: 33 (Treatment), 18 (Control)
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Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: Chi2 = 0.82, df = 2 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 1.67 (P = 0.095)
3 chemotherapy, without platinum, all patients
Aapro 2008 29/231 13/231 2.23 [ 1.19, 4.18 ]
Case 1993 J%J 2004 2/81 3/76 0.63 [ 0.11, 3.64 ]
Chang 2005 19/176 14/178 1.37 [ 0.71, 2.65 ]
Engert 2009 45/645 44/644 1.02 [ 0.68, 1.52 ]
Hedenus 2003 FDA 2007 6/175 1/169 5.79 [ 0.71, 47.62 ]
Leyland-Jones 05 J%J 04 36/448 25/456 1.47 [ 0.89, 2.40 ]
Littlewood 2001 J%J 2004 14/251 5/124 1.38 [ 0.51, 3.75 ]
Moebus 2007 J%J 2007 9/305 5/288 1.70 [ 0.58, 5.01 ]
Osterborg 1996a 2/47 0/25 2.71 [ 0.14, 54.32 ]
Osterborg 1996b 1/48 0/24 1.53 [ 0.06, 36.23 ]
Osterborg 2002 1/170 0/173 3.05 [ 0.13, 74.41 ]
Pronzato 2010 4/109 1/111 4.07 [ 0.46, 35.87 ]
Tjulandin 2011 0/95 1/91 0.32 [ 0.01, 7.74 ]
Untch 2011˙1 20/318 17/396 1.47 [ 0.78, 2.75 ]
Subtotal (95% CI) 3099 2986 1.42 [ 1.14, 1.76 ]
Total events: 188 (Treatment), 129 (Control)
Heterogeneity: Chi2 = 9.42, df = 13 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 3.17 (P = 0.0015)
4 chemotherapy, platinum and non platinum containing, no numbers given
Dammacco 2001 J%J 2004 5/69 1/76 5.51 [ 0.66, 45.98 ]
Tsuboi 2009 1/62 0/58 2.81 [ 0.12, 67.62 ]
Subtotal (95% CI) 131 134 4.56 [ 0.79, 26.20 ]
Total events: 6 (Treatment), 1 (Control)
Heterogeneity: Chi2 = 0.12, df = 1 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 1.70 (P = 0.089)
5 chemotherapy no details given
Ray-Coquard 2009 5/110 4/107 1.22 [ 0.34, 4.41 ]
Razzouk 2006 6/112 2/110 2.95 [ 0.61, 14.28 ]
Subtotal (95% CI) 222 217 1.79 [ 0.67, 4.76 ]
Total events: 11 (Treatment), 6 (Control)
Heterogeneity: Chi2 = 0.73, df = 1 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 1.17 (P = 0.24)
6 radiochemotherapy
Blohmer 2011 2/127 3/129 0.68 [ 0.12, 3.98 ]
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Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Debus 2006 J%J 2007 38/192 23/191 1.64 [ 1.02, 2.65 ]
Goss 2005 J%J 2004 16/52 2/52 8.00 [ 1.94, 33.06 ]
Gupta 2009 0/57 0/59 0.0 [ 0.0, 0.0 ]
Strauss 2008 1/33 0/38 3.44 [ 0.14, 81.71 ]
Thomas 2008 J%J 2004 10/58 5/55 1.90 [ 0.69, 5.20 ]
Throuvalas 2000 1/28 0/26 2.79 [ 0.12, 65.66 ]
Subtotal (95% CI) 547 550 2.01 [ 1.37, 2.96 ]
Total events: 68 (Treatment), 33 (Control)
Heterogeneity: Chi2 = 5.94, df = 5 (P = 0.31); I2 =16%
Test for overall effect: Z = 3.56 (P = 0.00038)
7 radiotherapy
Henke 2003 Roche 2004 10/180 6/171 1.58 [ 0.59, 4.26 ]
Hoskin 2009 J%J 2004 4/133 2/149 2.24 [ 0.42, 12.04 ]
Machtay 2007 2/72 0/68 4.73 [ 0.23, 96.70 ]
Overgaard 2009 7/255 3/259 2.37 [ 0.62, 9.06 ]
Subtotal (95% CI) 640 647 2.03 [ 1.02, 4.07 ]
Total events: 23 (Treatment), 11 (Control)
Heterogeneity: Chi2 = 0.61, df = 3 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 2.00 (P = 0.045)
8 no therapy
Abels 1993 J%J 2004 1/65 0/59 2.73 [ 0.11, 65.68 ]
Charu 2007 Amgen 2007 8/226 1/59 2.09 [ 0.27, 16.37 ]
Gordon 2008 16/164 4/54 1.32 [ 0.46, 3.77 ]
Italian 1998 1/44 0/43 2.93 [ 0.12, 70.08 ]
Smith 2003 Amgen 2007 2/64 2/22 0.34 [ 0.05, 2.30 ]
Smith 2008 50/515 36/470 1.27 [ 0.84, 1.91 ]
Thompson 2000 1/45 0/21 1.43 [ 0.06, 33.82 ]
Wright 2007 2/33 3/37 0.75 [ 0.13, 4.20 ]
Subtotal (95% CI) 1156 765 1.25 [ 0.88, 1.78 ]
Total events: 81 (Treatment), 46 (Control)
Heterogeneity: Chi2 = 2.88, df = 7 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 1.25 (P = 0.21)
9 unclear/other
P-174 J%J 2004 0/33 0/12 0.0 [ 0.0, 0.0 ]
Rose 1994 J%J 2004 9/142 2/79 2.50 [ 0.55, 11.30 ]
Rosenzweig 2004 4/14 0/13 8.40 [ 0.50, 142.27 ]
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Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Winquist 2009 0/26 2/30 0.23 [ 0.01, 4.58 ]
Subtotal (95% CI) 215 134 2.09 [ 0.74, 5.93 ]
Total events: 13 (Treatment), 4 (Control)
Heterogeneity: Chi2 = 3.08, df = 2 (P = 0.21); I2 =35%
Test for overall effect: Z = 1.38 (P = 0.17)
Total (95% CI) 8248 7250 1.52 [ 1.34, 1.74 ]
Total events: 561 (Treatment), 332 (Control)
Heterogeneity: Chi2 = 34.99, df = 55 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 6.36 (P < 0.00001)
Test for subgroup differences: Chi2 = 6.40, df = 8 (P = 0.60), I2 =0.0%
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Analysis 11.8. Comparison 11 Thrombotic events, Outcome 8 Thrombotic events - epoetin versus
darbepoetin.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 11 Thrombotic events
Outcome: 8 Thrombotic events - epoetin versus darbepoetin
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Epoetin
Aapro 2008 29/231 13/231 2.23 [ 1.19, 4.18 ]
Abels 1993 J%J 2004 1/65 0/59 2.73 [ 0.11, 65.68 ]
Bamias 2003 0/72 1/72 0.33 [ 0.01, 8.05 ]
Blohmer 2011 2/127 3/129 0.68 [ 0.12, 3.98 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Case 1993 J%J 2004 2/81 3/76 0.63 [ 0.11, 3.64 ]
Chang 2005 19/176 14/178 1.37 [ 0.71, 2.65 ]
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Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dammacco 2001 J%J 2004 5/69 1/76 5.51 [ 0.66, 45.98 ]
Debus 2006 J%J 2007 38/192 23/191 1.64 [ 1.02, 2.65 ]
Engert 2009 45/645 44/644 1.02 [ 0.68, 1.52 ]
EPO-INT-1 J%J 2004 3/164 1/80 1.46 [ 0.15, 13.85 ]
EPO-INT-3 J%J 2004 8/135 1/65 3.85 [ 0.49, 30.15 ]
Fujisaka 2011 1/89 0/92 3.10 [ 0.13, 75.10 ]
Goss 2005 J%J 2004 16/52 2/52 8.00 [ 1.94, 33.06 ]
Grote 2005 J%J 2004 12/109 11/115 1.15 [ 0.53, 2.50 ]
Gupta 2009 0/57 0/59 0.0 [ 0.0, 0.0 ]
Henke 2003 Roche 2004 10/180 6/171 1.58 [ 0.59, 4.26 ]
Henry 1995 J%J 2004 6/67 8/65 0.73 [ 0.27, 1.98 ]
Hoskin 2009 J%J 2004 4/133 2/149 2.24 [ 0.42, 12.04 ]
Italian 1998 1/44 0/43 2.93 [ 0.12, 70.08 ]
Leyland-Jones 05 J%J 04 36/448 25/456 1.47 [ 0.89, 2.40 ]
Littlewood 2001 J%J 2004 14/251 5/124 1.38 [ 0.51, 3.75 ]
Machtay 2007 2/72 0/68 4.73 [ 0.23, 96.70 ]
Milroy 2011 18/214 13/210 1.36 [ 0.68, 2.70 ]
Moebus 2007 J%J 2007 9/305 5/288 1.70 [ 0.58, 5.01 ]
Osterborg 1996a 2/47 0/25 2.71 [ 0.14, 54.32 ]
Osterborg 1996b 1/48 0/24 1.53 [ 0.06, 36.23 ]
Osterborg 2002 1/170 0/173 3.05 [ 0.13, 74.41 ]
P-174 J%J 2004 0/33 0/12 0.0 [ 0.0, 0.0 ]
Pronzato 2010 4/109 1/111 4.07 [ 0.46, 35.87 ]
Ray-Coquard 2009 5/110 4/107 1.22 [ 0.34, 4.41 ]
Razzouk 2006 6/112 2/110 2.95 [ 0.61, 14.28 ]
Rose 1994 J%J 2004 9/142 2/79 2.50 [ 0.55, 11.30 ]
Rosenzweig 2004 4/14 0/13 8.40 [ 0.50, 142.27 ]
Savonije 2005 7/211 1/104 3.45 [ 0.43, 27.68 ]
Strauss 2008 1/33 0/38 3.44 [ 0.14, 81.71 ]
Ten Bokkel 1998a 2/45 0/17 1.96 [ 0.10, 38.79 ]
Ten Bokkel 1998b 4/42 0/16 3.56 [ 0.20, 62.58 ]
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Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Thatcher 1999a 0/42 0/22 0.0 [ 0.0, 0.0 ]
Thatcher 1999b 2/44 0/22 2.56 [ 0.13, 51.05 ]
Thomas 2008 J%J 2004 10/58 5/55 1.90 [ 0.69, 5.20 ]
Thompson 2000 1/45 0/21 1.43 [ 0.06, 33.82 ]
Throuvalas 2000 1/28 0/26 2.79 [ 0.12, 65.66 ]
Tjulandin 2011 0/95 1/91 0.32 [ 0.01, 7.74 ]
Tsuboi 2009 1/62 0/58 2.81 [ 0.12, 67.62 ]
Welch 1995 1/15 0/15 3.00 [ 0.13, 68.26 ]
Wilkinson 2006 10/121 1/60 4.96 [ 0.65, 37.84 ]
Winquist 2009 0/26 2/30 0.23 [ 0.01, 4.58 ]
Witzig 2005 J%J 2004 9/168 6/165 1.47 [ 0.54, 4.05 ]
Wright 2007 2/33 3/37 0.75 [ 0.13, 4.20 ]
Subtotal (95% CI) 5881 5174 1.57 [ 1.33, 1.85 ]
Total events: 364 (Treatment), 209 (Control)
Heterogeneity: Chi2 = 29.91, df = 45 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 5.43 (P < 0.00001)
2 Darbepoetin
Charu 2007 Amgen 2007 8/226 1/59 2.09 [ 0.27, 16.37 ]
Gordon 2008 16/164 4/54 1.32 [ 0.46, 3.77 ]
Hedenus 2003 FDA 2007 6/175 1/169 5.79 [ 0.71, 47.62 ]
Hernandez 2009 16/194 11/192 1.44 [ 0.69, 3.02 ]
Overgaard 2009 7/255 3/259 2.37 [ 0.62, 9.06 ]
Pirker 2008 65/301 43/296 1.49 [ 1.05, 2.11 ]
Smith 2003 Amgen 2007 2/64 2/22 0.34 [ 0.05, 2.30 ]
Smith 2008 50/515 36/470 1.27 [ 0.84, 1.91 ]
Untch 2011˙1 20/318 17/396 1.47 [ 0.78, 2.75 ]
Vansteenkiste 2002 7/155 5/159 1.44 [ 0.47, 4.43 ]
Subtotal (95% CI) 2367 2076 1.44 [ 1.16, 1.79 ]
Total events: 197 (Treatment), 123 (Control)
Heterogeneity: Chi2 = 4.95, df = 9 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 3.33 (P = 0.00087)
Total (95% CI) 8248 7250 1.52 [ 1.34, 1.74 ]
Total events: 561 (Treatment), 332 (Control)
Heterogeneity: Chi2 = 34.99, df = 55 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 6.36 (P < 0.00001)
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Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Test for subgroup differences: Chi2 = 0.40, df = 1 (P = 0.53), I2 =0.0%
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Control Treatment
Analysis 11.9. Comparison 11 Thrombotic events, Outcome 9 Thrombotic events - duration of ESA
treatment.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 11 Thrombotic events
Outcome: 9 Thrombotic events - duration of ESA treatment
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 6 to 9 weeks
Abels 1993 J%J 2004 1/65 0/59 2.73 [ 0.11, 65.68 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Gupta 2009 0/57 0/59 0.0 [ 0.0, 0.0 ]
Henke 2003 Roche 2004 10/180 6/171 1.58 [ 0.59, 4.26 ]
Italian 1998 1/44 0/43 2.93 [ 0.12, 70.08 ]
Machtay 2007 2/72 0/68 4.73 [ 0.23, 96.70 ]
Overgaard 2009 7/255 3/259 2.37 [ 0.62, 9.06 ]
Thomas 2008 J%J 2004 10/58 5/55 1.90 [ 0.69, 5.20 ]
Throuvalas 2000 1/28 0/26 2.79 [ 0.12, 65.66 ]
Tsuboi 2009 1/62 0/58 2.81 [ 0.12, 67.62 ]
Subtotal (95% CI) 871 848 2.06 [ 1.17, 3.64 ]
Total events: 33 (Treatment), 14 (Control)
Heterogeneity: Chi2 = 0.78, df = 7 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 2.50 (P = 0.012)
2 12 to 16 weeks
Case 1993 J%J 2004 2/81 3/76 0.63 [ 0.11, 3.64 ]
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Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chang 2005 19/176 14/178 1.37 [ 0.71, 2.65 ]
Charu 2007 Amgen 2007 8/226 1/59 2.09 [ 0.27, 16.37 ]
Dammacco 2001 J%J 2004 5/69 1/76 5.51 [ 0.66, 45.98 ]
Debus 2006 J%J 2007 38/192 23/191 1.64 [ 1.02, 2.65 ]
EPO-INT-3 J%J 2004 8/135 1/65 3.85 [ 0.49, 30.15 ]
Fujisaka 2011 1/89 0/92 3.10 [ 0.13, 75.10 ]
Gordon 2008 16/164 4/54 1.32 [ 0.46, 3.77 ]
Grote 2005 J%J 2004 12/109 11/115 1.15 [ 0.53, 2.50 ]
Hedenus 2003 FDA 2007 6/175 1/169 5.79 [ 0.71, 47.62 ]
Henry 1995 J%J 2004 6/67 8/65 0.73 [ 0.27, 1.98 ]
Hernandez 2009 16/194 11/192 1.44 [ 0.69, 3.02 ]
Hoskin 2009 J%J 2004 4/133 2/149 2.24 [ 0.42, 12.04 ]
Littlewood 2001 J%J 2004 14/251 5/124 1.38 [ 0.51, 3.75 ]
Osterborg 2002 1/170 0/173 3.05 [ 0.13, 74.41 ]
P-174 J%J 2004 0/33 0/12 0.0 [ 0.0, 0.0 ]
Ray-Coquard 2009 5/110 4/107 1.22 [ 0.34, 4.41 ]
Razzouk 2006 6/112 2/110 2.95 [ 0.61, 14.28 ]
Rose 1994 J%J 2004 9/142 2/79 2.50 [ 0.55, 11.30 ]
Rosenzweig 2004 4/14 0/13 8.40 [ 0.50, 142.27 ]
Savonije 2005 7/211 1/104 3.45 [ 0.43, 27.68 ]
Smith 2003 Amgen 2007 2/64 2/22 0.34 [ 0.05, 2.30 ]
Smith 2008 50/515 36/470 1.27 [ 0.84, 1.91 ]
Strauss 2008 1/33 0/38 3.44 [ 0.14, 81.71 ]
Thompson 2000 1/45 0/21 1.43 [ 0.06, 33.82 ]
Tjulandin 2011 0/95 1/91 0.32 [ 0.01, 7.74 ]
Vansteenkiste 2002 7/155 5/159 1.44 [ 0.47, 4.43 ]
Winquist 2009 0/26 2/30 0.23 [ 0.01, 4.58 ]
Witzig 2005 J%J 2004 9/168 6/165 1.47 [ 0.54, 4.05 ]
Wright 2007 2/33 3/37 0.75 [ 0.13, 4.20 ]
Subtotal (95% CI) 3987 3236 1.46 [ 1.20, 1.77 ]
Total events: 259 (Treatment), 149 (Control)
Heterogeneity: Chi2 = 17.55, df = 28 (P = 0.94); I2 =0.0%
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Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Test for overall effect: Z = 3.80 (P = 0.00014)
3 more than 17 weeks
Aapro 2008 29/231 13/231 2.23 [ 1.19, 4.18 ]
Bamias 2003 0/72 1/72 0.33 [ 0.01, 8.05 ]
Blohmer 2011 2/127 3/129 0.68 [ 0.12, 3.98 ]
Engert 2009 45/645 44/644 1.02 [ 0.68, 1.52 ]
Goss 2005 J%J 2004 16/52 2/52 8.00 [ 1.94, 33.06 ]
Leyland-Jones 05 J%J 04 36/448 25/456 1.47 [ 0.89, 2.40 ]
Milroy 2011 18/214 13/210 1.36 [ 0.68, 2.70 ]
Moebus 2007 J%J 2007 9/305 5/288 1.70 [ 0.58, 5.01 ]
Osterborg 1996a 2/47 0/25 2.71 [ 0.14, 54.32 ]
Osterborg 1996b 1/48 0/24 1.53 [ 0.06, 36.23 ]
Pirker 2008 65/301 43/296 1.49 [ 1.05, 2.11 ]
Pronzato 2010 4/109 1/111 4.07 [ 0.46, 35.87 ]
Ten Bokkel 1998a 2/45 0/17 1.96 [ 0.10, 38.79 ]
Ten Bokkel 1998b 4/42 0/16 3.56 [ 0.20, 62.58 ]
Thatcher 1999a 0/42 0/22 0.0 [ 0.0, 0.0 ]
Thatcher 1999b 2/44 0/22 2.56 [ 0.13, 51.05 ]
Untch 2011˙1 20/318 17/396 1.47 [ 0.78, 2.75 ]
Welch 1995 1/15 0/15 3.00 [ 0.13, 68.26 ]
Wilkinson 2006 10/121 1/60 4.96 [ 0.65, 37.84 ]
Subtotal (95% CI) 3226 3086 1.53 [ 1.27, 1.84 ]
Total events: 266 (Treatment), 168 (Control)
Heterogeneity: Chi2 = 15.30, df = 17 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 4.54 (P < 0.00001)
4 not reported
EPO-INT-1 J%J 2004 3/164 1/80 1.46 [ 0.15, 13.85 ]
Subtotal (95% CI) 164 80 1.46 [ 0.15, 13.85 ]
Total events: 3 (Treatment), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.33 (P = 0.74)
Total (95% CI) 8248 7250 1.52 [ 1.34, 1.74 ]
Total events: 561 (Treatment), 332 (Control)
Heterogeneity: Chi2 = 34.99, df = 55 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 6.36 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.30, df = 3 (P = 0.73), I2 =0.0%
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Analysis 11.10. Comparison 11 Thrombotic events, Outcome 10 Thrombotic events - iron supplementation.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 11 Thrombotic events
Outcome: 10 Thrombotic events - iron supplementation
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 fixed iron supplementation
Gupta 2009 0/57 0/59 0.0 [ 0.0, 0.0 ]
Hoskin 2009 J%J 2004 4/133 2/149 2.24 [ 0.42, 12.04 ]
Untch 2011˙1 20/318 17/396 1.47 [ 0.78, 2.75 ]
Witzig 2005 J%J 2004 9/168 6/165 1.47 [ 0.54, 4.05 ]
Subtotal (95% CI) 676 769 1.53 [ 0.92, 2.54 ]
Total events: 33 (Treatment), 25 (Control)
Heterogeneity: Chi2 = 0.22, df = 2 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 1.64 (P = 0.10)
2 iron supplementation as necessary
Aapro 2008 29/231 13/231 2.23 [ 1.19, 4.18 ]
Abels 1993 J%J 2004 1/65 0/59 2.73 [ 0.11, 65.68 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Case 1993 J%J 2004 2/81 3/76 0.63 [ 0.11, 3.64 ]
Chang 2005 19/176 14/178 1.37 [ 0.71, 2.65 ]
Charu 2007 Amgen 2007 8/226 1/59 2.09 [ 0.27, 16.37 ]
Dammacco 2001 J%J 2004 5/69 1/76 5.51 [ 0.66, 45.98 ]
Engert 2009 45/645 44/644 1.02 [ 0.68, 1.52 ]
EPO-INT-1 J%J 2004 3/164 1/80 1.46 [ 0.15, 13.85 ]
EPO-INT-3 J%J 2004 8/135 1/65 3.85 [ 0.49, 30.15 ]
Fujisaka 2011 1/89 0/92 3.10 [ 0.13, 75.10 ]
Gordon 2008 16/164 4/54 1.32 [ 0.46, 3.77 ]
Goss 2005 J%J 2004 16/52 2/52 8.00 [ 1.94, 33.06 ]
Grote 2005 J%J 2004 12/109 11/115 1.15 [ 0.53, 2.50 ]
Hedenus 2003 FDA 2007 6/175 1/169 5.79 [ 0.71, 47.62 ]
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Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Henke 2003 Roche 2004 10/180 6/171 1.58 [ 0.59, 4.26 ]
Henry 1995 J%J 2004 6/67 8/65 0.73 [ 0.27, 1.98 ]
Hernandez 2009 16/194 11/192 1.44 [ 0.69, 3.02 ]
Italian 1998 1/44 0/43 2.93 [ 0.12, 70.08 ]
Leyland-Jones 05 J%J 04 36/448 25/456 1.47 [ 0.89, 2.40 ]
Littlewood 2001 J%J 2004 14/251 5/124 1.38 [ 0.51, 3.75 ]
Milroy 2011 18/214 13/210 1.36 [ 0.68, 2.70 ]
Osterborg 1996a 2/47 0/25 2.71 [ 0.14, 54.32 ]
Osterborg 1996b 1/48 0/24 1.53 [ 0.06, 36.23 ]
Osterborg 2002 1/170 0/173 3.05 [ 0.13, 74.41 ]
Overgaard 2009 7/255 3/259 2.37 [ 0.62, 9.06 ]
P-174 J%J 2004 0/33 0/12 0.0 [ 0.0, 0.0 ]
Pirker 2008 65/301 43/296 1.49 [ 1.05, 2.11 ]
Pronzato 2010 4/109 1/111 4.07 [ 0.46, 35.87 ]
Ray-Coquard 2009 5/110 4/107 1.22 [ 0.34, 4.41 ]
Razzouk 2006 6/112 2/110 2.95 [ 0.61, 14.28 ]
Rose 1994 J%J 2004 9/142 2/79 2.50 [ 0.55, 11.30 ]
Smith 2003 Amgen 2007 2/64 2/22 0.34 [ 0.05, 2.30 ]
Smith 2008 50/515 36/470 1.27 [ 0.84, 1.91 ]
Strauss 2008 1/33 0/38 3.44 [ 0.14, 81.71 ]
Ten Bokkel 1998a 2/45 0/17 1.96 [ 0.10, 38.79 ]
Ten Bokkel 1998b 4/42 0/16 3.56 [ 0.20, 62.58 ]
Thatcher 1999a 0/42 0/22 0.0 [ 0.0, 0.0 ]
Thatcher 1999b 2/44 0/22 2.56 [ 0.13, 51.05 ]
Thomas 2008 J%J 2004 10/58 5/55 1.90 [ 0.69, 5.20 ]
Throuvalas 2000 1/28 0/26 2.79 [ 0.12, 65.66 ]
Tjulandin 2011 0/95 1/91 0.32 [ 0.01, 7.74 ]
Tsuboi 2009 1/62 0/58 2.81 [ 0.12, 67.62 ]
Vansteenkiste 2002 7/155 5/159 1.44 [ 0.47, 4.43 ]
Welch 1995 1/15 0/15 3.00 [ 0.13, 68.26 ]
Wilkinson 2006 10/121 1/60 4.96 [ 0.65, 37.84 ]
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Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Wright 2007 2/33 3/37 0.75 [ 0.13, 4.20 ]
Subtotal (95% CI) 6508 5565 1.51 [ 1.31, 1.74 ]
Total events: 465 (Treatment), 272 (Control)
Heterogeneity: Chi2 = 28.73, df = 43 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 5.63 (P < 0.00001)
3 no explicit statement on iron supplementation or no iron given
Bamias 2003 0/72 1/72 0.33 [ 0.01, 8.05 ]
Rosenzweig 2004 4/14 0/13 8.40 [ 0.50, 142.27 ]
Thompson 2000 1/45 0/21 1.43 [ 0.06, 33.82 ]
Winquist 2009 0/26 2/30 0.23 [ 0.01, 4.58 ]
Subtotal (95% CI) 157 136 1.26 [ 0.39, 4.06 ]
Total events: 5 (Treatment), 3 (Control)
Heterogeneity: Chi2 = 3.65, df = 3 (P = 0.30); I2 =18%
Test for overall effect: Z = 0.39 (P = 0.69)
4 iron handled differently in the study arms
Blohmer 2011 2/127 3/129 0.68 [ 0.12, 3.98 ]
Debus 2006 J%J 2007 38/192 23/191 1.64 [ 1.02, 2.65 ]
Machtay 2007 2/72 0/68 4.73 [ 0.23, 96.70 ]
Moebus 2007 J%J 2007 9/305 5/288 1.70 [ 0.58, 5.01 ]
Savonije 2005 7/211 1/104 3.45 [ 0.43, 27.68 ]
Subtotal (95% CI) 907 780 1.69 [ 1.12, 2.54 ]
Total events: 58 (Treatment), 32 (Control)
Heterogeneity: Chi2 = 1.93, df = 4 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 2.50 (P = 0.012)
5 explicitly stated NO IRON
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 0 (Treatment), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 8248 7250 1.52 [ 1.34, 1.74 ]
Total events: 561 (Treatment), 332 (Control)
Heterogeneity: Chi2 = 34.99, df = 55 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 6.36 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.35, df = 3 (P = 0.95), I2 =0.0%
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Analysis 11.11. Comparison 11 Thrombotic events, Outcome 11 Thrombotic events - concealment of
allocation.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 11 Thrombotic events
Outcome: 11 Thrombotic events - concealment of allocation
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 adequate
Aapro 2008 29/231 13/231 2.23 [ 1.19, 4.18 ]
Blohmer 2011 2/127 3/129 0.68 [ 0.12, 3.98 ]
Chang 2005 19/176 14/178 1.37 [ 0.71, 2.65 ]
Charu 2007 Amgen 2007 8/226 1/59 2.09 [ 0.27, 16.37 ]
EPO-INT-3 J%J 2004 8/135 1/65 3.85 [ 0.49, 30.15 ]
Fujisaka 2011 1/89 0/92 3.10 [ 0.13, 75.10 ]
Gordon 2008 16/164 4/54 1.32 [ 0.46, 3.77 ]
Goss 2005 J%J 2004 16/52 2/52 8.00 [ 1.94, 33.06 ]
Hedenus 2003 FDA 2007 6/175 1/169 5.79 [ 0.71, 47.62 ]
Henke 2003 Roche 2004 10/180 6/171 1.58 [ 0.59, 4.26 ]
Hernandez 2009 16/194 11/192 1.44 [ 0.69, 3.02 ]
Italian 1998 1/44 0/43 2.93 [ 0.12, 70.08 ]
Leyland-Jones 05 J%J 04 36/448 25/456 1.47 [ 0.89, 2.40 ]
Littlewood 2001 J%J 2004 14/251 5/124 1.38 [ 0.51, 3.75 ]
Machtay 2007 2/72 0/68 4.73 [ 0.23, 96.70 ]
Milroy 2011 18/214 13/210 1.36 [ 0.68, 2.70 ]
Moebus 2007 J%J 2007 9/305 5/288 1.70 [ 0.58, 5.01 ]
Osterborg 1996a 2/47 0/25 2.71 [ 0.14, 54.32 ]
Osterborg 1996b 1/48 0/24 1.53 [ 0.06, 36.23 ]
Osterborg 2002 1/170 0/173 3.05 [ 0.13, 74.41 ]
Overgaard 2009 7/255 3/259 2.37 [ 0.62, 9.06 ]
Pirker 2008 65/301 43/296 1.49 [ 1.05, 2.11 ]
Pronzato 2010 4/109 1/111 4.07 [ 0.46, 35.87 ]
Ray-Coquard 2009 5/110 4/107 1.22 [ 0.34, 4.41 ]
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Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Razzouk 2006 6/112 2/110 2.95 [ 0.61, 14.28 ]
Rosenzweig 2004 4/14 0/13 8.40 [ 0.50, 142.27 ]
Savonije 2005 7/211 1/104 3.45 [ 0.43, 27.68 ]
Smith 2008 50/515 36/470 1.27 [ 0.84, 1.91 ]
Ten Bokkel 1998a 2/45 0/17 1.96 [ 0.10, 38.79 ]
Ten Bokkel 1998b 4/42 0/16 3.56 [ 0.20, 62.58 ]
Thomas 2008 J%J 2004 10/58 5/55 1.90 [ 0.69, 5.20 ]
Thompson 2000 1/45 0/21 1.43 [ 0.06, 33.82 ]
Throuvalas 2000 1/28 0/26 2.79 [ 0.12, 65.66 ]
Tsuboi 2009 1/62 0/58 2.81 [ 0.12, 67.62 ]
Vansteenkiste 2002 7/155 5/159 1.44 [ 0.47, 4.43 ]
Winquist 2009 0/26 2/30 0.23 [ 0.01, 4.58 ]
Witzig 2005 J%J 2004 9/168 6/165 1.47 [ 0.54, 4.05 ]
Wright 2007 2/33 3/37 0.75 [ 0.13, 4.20 ]
Subtotal (95% CI) 5637 4857 1.64 [ 1.40, 1.92 ]
Total events: 400 (Treatment), 215 (Control)
Heterogeneity: Chi2 = 19.36, df = 37 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 6.08 (P < 0.00001)
2 unclear
Abels 1993 J%J 2004 1/65 0/59 2.73 [ 0.11, 65.68 ]
Bamias 2003 0/72 1/72 0.33 [ 0.01, 8.05 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Case 1993 J%J 2004 2/81 3/76 0.63 [ 0.11, 3.64 ]
Dammacco 2001 J%J 2004 5/69 1/76 5.51 [ 0.66, 45.98 ]
Debus 2006 J%J 2007 38/192 23/191 1.64 [ 1.02, 2.65 ]
Engert 2009 45/645 44/644 1.02 [ 0.68, 1.52 ]
EPO-INT-1 J%J 2004 3/164 1/80 1.46 [ 0.15, 13.85 ]
Grote 2005 J%J 2004 12/109 11/115 1.15 [ 0.53, 2.50 ]
Gupta 2009 0/57 0/59 0.0 [ 0.0, 0.0 ]
Henry 1995 J%J 2004 6/67 8/65 0.73 [ 0.27, 1.98 ]
Hoskin 2009 J%J 2004 4/133 2/149 2.24 [ 0.42, 12.04 ]
P-174 J%J 2004 0/33 0/12 0.0 [ 0.0, 0.0 ]
Rose 1994 J%J 2004 9/142 2/79 2.50 [ 0.55, 11.30 ]
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Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Smith 2003 Amgen 2007 2/64 2/22 0.34 [ 0.05, 2.30 ]
Strauss 2008 1/33 0/38 3.44 [ 0.14, 81.71 ]
Thatcher 1999a 0/42 0/22 0.0 [ 0.0, 0.0 ]
Thatcher 1999b 2/44 0/22 2.56 [ 0.13, 51.05 ]
Tjulandin 2011 0/95 1/91 0.32 [ 0.01, 7.74 ]
Untch 2011˙1 20/318 17/396 1.47 [ 0.78, 2.75 ]
Welch 1995 1/15 0/15 3.00 [ 0.13, 68.26 ]
Wilkinson 2006 10/121 1/60 4.96 [ 0.65, 37.84 ]
Subtotal (95% CI) 2611 2393 1.31 [ 1.04, 1.65 ]
Total events: 161 (Treatment), 117 (Control)
Heterogeneity: Chi2 = 13.49, df = 17 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 2.33 (P = 0.020)
Total (95% CI) 8248 7250 1.52 [ 1.34, 1.74 ]
Total events: 561 (Treatment), 332 (Control)
Heterogeneity: Chi2 = 34.99, df = 55 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 6.36 (P < 0.00001)
Test for subgroup differences: Chi2 = 2.43, df = 1 (P = 0.12), I2 =59%
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Analysis 11.12. Comparison 11 Thrombotic events, Outcome 12 Thrombotic events - masking.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 11 Thrombotic events
Outcome: 12 Thrombotic events - masking
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 double-blind
Abels 1993 J%J 2004 1/65 0/59 2.73 [ 0.11, 65.68 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Case 1993 J%J 2004 2/81 3/76 0.63 [ 0.11, 3.64 ]
Dammacco 2001 J%J 2004 5/69 1/76 5.51 [ 0.66, 45.98 ]
Engert 2009 45/645 44/644 1.02 [ 0.68, 1.52 ]
EPO-INT-1 J%J 2004 3/164 1/80 1.46 [ 0.15, 13.85 ]
EPO-INT-3 J%J 2004 8/135 1/65 3.85 [ 0.49, 30.15 ]
Fujisaka 2011 1/89 0/92 3.10 [ 0.13, 75.10 ]
Gordon 2008 16/164 4/54 1.32 [ 0.46, 3.77 ]
Goss 2005 J%J 2004 16/52 2/52 8.00 [ 1.94, 33.06 ]
Grote 2005 J%J 2004 12/109 11/115 1.15 [ 0.53, 2.50 ]
Hedenus 2003 FDA 2007 6/175 1/169 5.79 [ 0.71, 47.62 ]
Henke 2003 Roche 2004 10/180 6/171 1.58 [ 0.59, 4.26 ]
Henry 1995 J%J 2004 6/67 8/65 0.73 [ 0.27, 1.98 ]
Hernandez 2009 16/194 11/192 1.44 [ 0.69, 3.02 ]
Italian 1998 1/44 0/43 2.93 [ 0.12, 70.08 ]
Leyland-Jones 05 J%J 04 36/448 25/456 1.47 [ 0.89, 2.40 ]
Littlewood 2001 J%J 2004 14/251 5/124 1.38 [ 0.51, 3.75 ]
Osterborg 2002 1/170 0/173 3.05 [ 0.13, 74.41 ]
P-174 J%J 2004 0/33 0/12 0.0 [ 0.0, 0.0 ]
Pirker 2008 65/301 43/296 1.49 [ 1.05, 2.11 ]
Razzouk 2006 6/112 2/110 2.95 [ 0.61, 14.28 ]
Rose 1994 J%J 2004 9/142 2/79 2.50 [ 0.55, 11.30 ]
Smith 2003 Amgen 2007 2/64 2/22 0.34 [ 0.05, 2.30 ]
Smith 2008 50/515 36/470 1.27 [ 0.84, 1.91 ]
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Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Thompson 2000 1/45 0/21 1.43 [ 0.06, 33.82 ]
Tjulandin 2011 0/95 1/91 0.32 [ 0.01, 7.74 ]
Tsuboi 2009 1/62 0/58 2.81 [ 0.12, 67.62 ]
Vansteenkiste 2002 7/155 5/159 1.44 [ 0.47, 4.43 ]
Winquist 2009 0/26 2/30 0.23 [ 0.01, 4.58 ]
Witzig 2005 J%J 2004 9/168 6/165 1.47 [ 0.54, 4.05 ]
Wright 2007 2/33 3/37 0.75 [ 0.13, 4.20 ]
Subtotal (95% CI) 4903 4306 1.40 [ 1.19, 1.64 ]
Total events: 351 (Treatment), 225 (Control)
Heterogeneity: Chi2 = 22.90, df = 29 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 4.13 (P = 0.000037)
2 unblinded
Aapro 2008 29/231 13/231 2.23 [ 1.19, 4.18 ]
Bamias 2003 0/72 1/72 0.33 [ 0.01, 8.05 ]
Blohmer 2011 2/127 3/129 0.68 [ 0.12, 3.98 ]
Chang 2005 19/176 14/178 1.37 [ 0.71, 2.65 ]
Charu 2007 Amgen 2007 8/226 1/59 2.09 [ 0.27, 16.37 ]
Debus 2006 J%J 2007 38/192 23/191 1.64 [ 1.02, 2.65 ]
Gupta 2009 0/57 0/59 0.0 [ 0.0, 0.0 ]
Hoskin 2009 J%J 2004 4/133 2/149 2.24 [ 0.42, 12.04 ]
Machtay 2007 2/72 0/68 4.73 [ 0.23, 96.70 ]
Milroy 2011 18/214 13/210 1.36 [ 0.68, 2.70 ]
Moebus 2007 J%J 2007 9/305 5/288 1.70 [ 0.58, 5.01 ]
Osterborg 1996a 2/47 0/25 2.71 [ 0.14, 54.32 ]
Osterborg 1996b 1/48 0/24 1.53 [ 0.06, 36.23 ]
Overgaard 2009 7/255 3/259 2.37 [ 0.62, 9.06 ]
Pronzato 2010 4/109 1/111 4.07 [ 0.46, 35.87 ]
Ray-Coquard 2009 5/110 4/107 1.22 [ 0.34, 4.41 ]
Rosenzweig 2004 4/14 0/13 8.40 [ 0.50, 142.27 ]
Savonije 2005 7/211 1/104 3.45 [ 0.43, 27.68 ]
Strauss 2008 1/33 0/38 3.44 [ 0.14, 81.71 ]
Ten Bokkel 1998a 2/45 0/17 1.96 [ 0.10, 38.79 ]
Ten Bokkel 1998b 4/42 0/16 3.56 [ 0.20, 62.58 ]
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Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Thatcher 1999a 0/42 0/22 0.0 [ 0.0, 0.0 ]
Thatcher 1999b 2/44 0/22 2.56 [ 0.13, 51.05 ]
Thomas 2008 J%J 2004 10/58 5/55 1.90 [ 0.69, 5.20 ]
Throuvalas 2000 1/28 0/26 2.79 [ 0.12, 65.66 ]
Untch 2011˙1 20/318 17/396 1.47 [ 0.78, 2.75 ]
Welch 1995 1/15 0/15 3.00 [ 0.13, 68.26 ]
Wilkinson 2006 10/121 1/60 4.96 [ 0.65, 37.84 ]
Subtotal (95% CI) 3345 2944 1.78 [ 1.43, 2.23 ]
Total events: 210 (Treatment), 107 (Control)
Heterogeneity: Chi2 = 9.20, df = 25 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 5.07 (P < 0.00001)
Total (95% CI) 8248 7250 1.52 [ 1.34, 1.74 ]
Total events: 561 (Treatment), 332 (Control)
Heterogeneity: Chi2 = 34.99, df = 55 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 6.36 (P < 0.00001)
Test for subgroup differences: Chi2 = 2.95, df = 1 (P = 0.09), I2 =66%
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Analysis 11.13. Comparison 11 Thrombotic events, Outcome 13 Thrombotic events - intention-to-treat.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 11 Thrombotic events
Outcome: 13 Thrombotic events - intention-to-treat
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ITT or less than 10% of participants per study arm excluded
Aapro 2008 29/231 13/231 2.23 [ 1.19, 4.18 ]
Abels 1993 J%J 2004 1/65 0/59 2.73 [ 0.11, 65.68 ]
Bamias 2003 0/72 1/72 0.33 [ 0.01, 8.05 ]
Blohmer 2011 2/127 3/129 0.68 [ 0.12, 3.98 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Case 1993 J%J 2004 2/81 3/76 0.63 [ 0.11, 3.64 ]
Chang 2005 19/176 14/178 1.37 [ 0.71, 2.65 ]
Charu 2007 Amgen 2007 8/226 1/59 2.09 [ 0.27, 16.37 ]
Dammacco 2001 J%J 2004 5/69 1/76 5.51 [ 0.66, 45.98 ]
Engert 2009 45/645 44/644 1.02 [ 0.68, 1.52 ]
EPO-INT-1 J%J 2004 3/164 1/80 1.46 [ 0.15, 13.85 ]
EPO-INT-3 J%J 2004 8/135 1/65 3.85 [ 0.49, 30.15 ]
Fujisaka 2011 1/89 0/92 3.10 [ 0.13, 75.10 ]
Gordon 2008 16/164 4/54 1.32 [ 0.46, 3.77 ]
Goss 2005 J%J 2004 16/52 2/52 8.00 [ 1.94, 33.06 ]
Grote 2005 J%J 2004 12/109 11/115 1.15 [ 0.53, 2.50 ]
Gupta 2009 0/57 0/59 0.0 [ 0.0, 0.0 ]
Henke 2003 Roche 2004 10/180 6/171 1.58 [ 0.59, 4.26 ]
Henry 1995 J%J 2004 6/67 8/65 0.73 [ 0.27, 1.98 ]
Hernandez 2009 16/194 11/192 1.44 [ 0.69, 3.02 ]
Italian 1998 1/44 0/43 2.93 [ 0.12, 70.08 ]
Leyland-Jones 05 J%J 04 36/448 25/456 1.47 [ 0.89, 2.40 ]
Littlewood 2001 J%J 2004 14/251 5/124 1.38 [ 0.51, 3.75 ]
Machtay 2007 2/72 0/68 4.73 [ 0.23, 96.70 ]
Milroy 2011 18/214 13/210 1.36 [ 0.68, 2.70 ]
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Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Osterborg 1996a 2/47 0/25 2.71 [ 0.14, 54.32 ]
Osterborg 1996b 1/48 0/24 1.53 [ 0.06, 36.23 ]
Osterborg 2002 1/170 0/173 3.05 [ 0.13, 74.41 ]
Overgaard 2009 7/255 3/259 2.37 [ 0.62, 9.06 ]
P-174 J%J 2004 0/33 0/12 0.0 [ 0.0, 0.0 ]
Pirker 2008 65/301 43/296 1.49 [ 1.05, 2.11 ]
Pronzato 2010 4/109 1/111 4.07 [ 0.46, 35.87 ]
Ray-Coquard 2009 5/110 4/107 1.22 [ 0.34, 4.41 ]
Razzouk 2006 6/112 2/110 2.95 [ 0.61, 14.28 ]
Rose 1994 J%J 2004 9/142 2/79 2.50 [ 0.55, 11.30 ]
Rosenzweig 2004 4/14 0/13 8.40 [ 0.50, 142.27 ]
Savonije 2005 7/211 1/104 3.45 [ 0.43, 27.68 ]
Smith 2003 Amgen 2007 2/64 2/22 0.34 [ 0.05, 2.30 ]
Smith 2008 50/515 36/470 1.27 [ 0.84, 1.91 ]
Strauss 2008 1/33 0/38 3.44 [ 0.14, 81.71 ]
Ten Bokkel 1998a 2/45 0/17 1.96 [ 0.10, 38.79 ]
Ten Bokkel 1998b 4/42 0/16 3.56 [ 0.20, 62.58 ]
Thatcher 1999a 0/42 0/22 0.0 [ 0.0, 0.0 ]
Thatcher 1999b 2/44 0/22 2.56 [ 0.13, 51.05 ]
Thomas 2008 J%J 2004 10/58 5/55 1.90 [ 0.69, 5.20 ]
Thompson 2000 1/45 0/21 1.43 [ 0.06, 33.82 ]
Throuvalas 2000 1/28 0/26 2.79 [ 0.12, 65.66 ]
Tjulandin 2011 0/95 1/91 0.32 [ 0.01, 7.74 ]
Tsuboi 2009 1/62 0/58 2.81 [ 0.12, 67.62 ]
Vansteenkiste 2002 7/155 5/159 1.44 [ 0.47, 4.43 ]
Welch 1995 1/15 0/15 3.00 [ 0.13, 68.26 ]
Wilkinson 2006 10/121 1/60 4.96 [ 0.65, 37.84 ]
Winquist 2009 0/26 2/30 0.23 [ 0.01, 4.58 ]
Witzig 2005 J%J 2004 9/168 6/165 1.47 [ 0.54, 4.05 ]
Wright 2007 2/33 3/37 0.75 [ 0.13, 4.20 ]
Subtotal (95% CI) 7125 6057 1.50 [ 1.30, 1.72 ]
Total events: 484 (Treatment), 284 (Control)
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Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: Chi2 = 32.77, df = 50 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 5.63 (P < 0.00001)
2 more than 10% of participants per study arm excluded
Hoskin 2009 J%J 2004 4/133 2/149 2.24 [ 0.42, 12.04 ]
Moebus 2007 J%J 2007 9/305 5/288 1.70 [ 0.58, 5.01 ]
Untch 2011˙1 20/318 17/396 1.47 [ 0.78, 2.75 ]
Subtotal (95% CI) 756 833 1.59 [ 0.95, 2.66 ]
Total events: 33 (Treatment), 24 (Control)
Heterogeneity: Chi2 = 0.24, df = 2 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 1.75 (P = 0.081)
3 unclear
Debus 2006 J%J 2007 38/192 23/191 1.64 [ 1.02, 2.65 ]
Hedenus 2003 FDA 2007 6/175 1/169 5.79 [ 0.71, 47.62 ]
Subtotal (95% CI) 367 360 1.82 [ 1.15, 2.89 ]
Total events: 44 (Treatment), 24 (Control)
Heterogeneity: Chi2 = 1.34, df = 1 (P = 0.25); I2 =25%
Test for overall effect: Z = 2.53 (P = 0.011)
Total (95% CI) 8248 7250 1.52 [ 1.34, 1.74 ]
Total events: 561 (Treatment), 332 (Control)
Heterogeneity: Chi2 = 34.99, df = 55 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 6.36 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.65, df = 2 (P = 0.72), I2 =0.0%
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Analysis 11.14. Comparison 11 Thrombotic events, Outcome 14 Thrombotic events - publication.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 11 Thrombotic events
Outcome: 14 Thrombotic events - publication
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 full text publication
Aapro 2008 29/231 13/231 2.23 [ 1.19, 4.18 ]
Bamias 2003 0/72 1/72 0.33 [ 0.01, 8.05 ]
Blohmer 2011 2/127 3/129 0.68 [ 0.12, 3.98 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Chang 2005 19/176 14/178 1.37 [ 0.71, 2.65 ]
Fujisaka 2011 1/89 0/92 3.10 [ 0.13, 75.10 ]
Gordon 2008 16/164 4/54 1.32 [ 0.46, 3.77 ]
Gupta 2009 0/57 0/59 0.0 [ 0.0, 0.0 ]
Hernandez 2009 16/194 11/192 1.44 [ 0.69, 3.02 ]
Italian 1998 1/44 0/43 2.93 [ 0.12, 70.08 ]
Machtay 2007 2/72 0/68 4.73 [ 0.23, 96.70 ]
Milroy 2011 18/214 13/210 1.36 [ 0.68, 2.70 ]
Osterborg 1996a 2/47 0/25 2.71 [ 0.14, 54.32 ]
Osterborg 1996b 1/48 0/24 1.53 [ 0.06, 36.23 ]
Osterborg 2002 1/170 0/173 3.05 [ 0.13, 74.41 ]
Overgaard 2009 7/255 3/259 2.37 [ 0.62, 9.06 ]
Pirker 2008 65/301 43/296 1.49 [ 1.05, 2.11 ]
Pronzato 2010 4/109 1/111 4.07 [ 0.46, 35.87 ]
Ray-Coquard 2009 5/110 4/107 1.22 [ 0.34, 4.41 ]
Razzouk 2006 6/112 2/110 2.95 [ 0.61, 14.28 ]
Rosenzweig 2004 4/14 0/13 8.40 [ 0.50, 142.27 ]
Savonije 2005 7/211 1/104 3.45 [ 0.43, 27.68 ]
Smith 2008 50/515 36/470 1.27 [ 0.84, 1.91 ]
Strauss 2008 1/33 0/38 3.44 [ 0.14, 81.71 ]
Ten Bokkel 1998a 2/45 0/17 1.96 [ 0.10, 38.79 ]
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Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ten Bokkel 1998b 4/42 0/16 3.56 [ 0.20, 62.58 ]
Thatcher 1999a 0/42 0/22 0.0 [ 0.0, 0.0 ]
Thatcher 1999b 2/44 0/22 2.56 [ 0.13, 51.05 ]
Tjulandin 2011 0/95 1/91 0.32 [ 0.01, 7.74 ]
Tsuboi 2009 1/62 0/58 2.81 [ 0.12, 67.62 ]
Untch 2011˙1 20/318 17/396 1.47 [ 0.78, 2.75 ]
Vansteenkiste 2002 7/155 5/159 1.44 [ 0.47, 4.43 ]
Welch 1995 1/15 0/15 3.00 [ 0.13, 68.26 ]
Wilkinson 2006 10/121 1/60 4.96 [ 0.65, 37.84 ]
Wright 2007 2/33 3/37 0.75 [ 0.13, 4.20 ]
Subtotal (95% CI) 4387 4001 1.57 [ 1.32, 1.87 ]
Total events: 306 (Treatment), 176 (Control)
Heterogeneity: Chi2 = 13.43, df = 31 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 5.02 (P < 0.00001)
2 abstract publication
Engert 2009 45/645 44/644 1.02 [ 0.68, 1.52 ]
Throuvalas 2000 1/28 0/26 2.79 [ 0.12, 65.66 ]
Subtotal (95% CI) 673 670 1.04 [ 0.70, 1.55 ]
Total events: 46 (Treatment), 44 (Control)
Heterogeneity: Chi2 = 0.38, df = 1 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.20 (P = 0.84)
3 unpublished data
Thompson 2000 1/45 0/21 1.43 [ 0.06, 33.82 ]
Subtotal (95% CI) 45 21 1.43 [ 0.06, 33.82 ]
Total events: 1 (Treatment), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.22 (P = 0.82)
4 data presented at ODAC hearing
Abels 1993 J%J 2004 1/65 0/59 2.73 [ 0.11, 65.68 ]
Case 1993 J%J 2004 2/81 3/76 0.63 [ 0.11, 3.64 ]
Charu 2007 Amgen 2007 8/226 1/59 2.09 [ 0.27, 16.37 ]
Dammacco 2001 J%J 2004 5/69 1/76 5.51 [ 0.66, 45.98 ]
Debus 2006 J%J 2007 38/192 23/191 1.64 [ 1.02, 2.65 ]
EPO-INT-1 J%J 2004 3/164 1/80 1.46 [ 0.15, 13.85 ]
EPO-INT-3 J%J 2004 8/135 1/65 3.85 [ 0.49, 30.15 ]
Goss 2005 J%J 2004 16/52 2/52 8.00 [ 1.94, 33.06 ]
0.01 0.1 1 10 100
Control Treatment
(Continued . . . )
643Erythropoietin or darbepoetin for patients with cancer (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Grote 2005 J%J 2004 12/109 11/115 1.15 [ 0.53, 2.50 ]
Hedenus 2003 FDA 2007 6/175 1/169 5.79 [ 0.71, 47.62 ]
Henke 2003 Roche 2004 10/180 6/171 1.58 [ 0.59, 4.26 ]
Henry 1995 J%J 2004 6/67 8/65 0.73 [ 0.27, 1.98 ]
Hoskin 2009 J%J 2004 4/133 2/149 2.24 [ 0.42, 12.04 ]
Leyland-Jones 05 J%J 04 36/448 25/456 1.47 [ 0.89, 2.40 ]
Littlewood 2001 J%J 2004 14/251 5/124 1.38 [ 0.51, 3.75 ]
Moebus 2007 J%J 2007 9/305 5/288 1.70 [ 0.58, 5.01 ]
P-174 J%J 2004 0/33 0/12 0.0 [ 0.0, 0.0 ]
Rose 1994 J%J 2004 9/142 2/79 2.50 [ 0.55, 11.30 ]
Smith 2003 Amgen 2007 2/64 2/22 0.34 [ 0.05, 2.30 ]
Thomas 2008 J%J 2004 10/58 5/55 1.90 [ 0.69, 5.20 ]
Witzig 2005 J%J 2004 9/168 6/165 1.47 [ 0.54, 4.05 ]
Subtotal (95% CI) 3117 2528 1.66 [ 1.33, 2.08 ]
Total events: 208 (Treatment), 110 (Control)
Heterogeneity: Chi2 = 16.31, df = 19 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 4.46 (P < 0.00001)
5 other
Winquist 2009 0/26 2/30 0.23 [ 0.01, 4.58 ]
Subtotal (95% CI) 26 30 0.23 [ 0.01, 4.58 ]
Total events: 0 (Treatment), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.96 (P = 0.34)
Total (95% CI) 8248 7250 1.52 [ 1.34, 1.74 ]
Total events: 561 (Treatment), 332 (Control)
Heterogeneity: Chi2 = 34.99, df = 55 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 6.36 (P < 0.00001)
Test for subgroup differences: Chi2 = 5.76, df = 4 (P = 0.22), I2 =31%
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Analysis 11.15. Comparison 11 Thrombotic events, Outcome 15 Thrombotic events - experimental arms
merged.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 11 Thrombotic events
Outcome: 15 Thrombotic events - experimental arms merged
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Aapro 2008 29/231 13/231 2.23 [ 1.19, 4.18 ]
Abels 1993 J%J 2004 1/65 0/59 2.73 [ 0.11, 65.68 ]
Bamias 2003 0/72 1/72 0.33 [ 0.01, 8.05 ]
Blohmer 2011 2/127 3/129 0.68 [ 0.12, 3.98 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Case 1993 J%J 2004 2/81 3/76 0.63 [ 0.11, 3.64 ]
Chang 2005 19/176 14/178 1.37 [ 0.71, 2.65 ]
Charu 2007 Amgen 2007 8/226 1/59 2.09 [ 0.27, 16.37 ]
Dammacco 2001 J%J 2004 5/69 1/76 5.51 [ 0.66, 45.98 ]
Debus 2006 J%J 2007 38/192 23/191 1.64 [ 1.02, 2.65 ]
Engert 2009 45/645 44/644 1.02 [ 0.68, 1.52 ]
EPO-INT-1 J%J 2004 3/164 1/80 1.46 [ 0.15, 13.85 ]
EPO-INT-3 J%J 2004 8/135 1/65 3.85 [ 0.49, 30.15 ]
Fujisaka 2011 1/89 0/92 3.10 [ 0.13, 75.10 ]
Gordon 2008 16/164 4/54 1.32 [ 0.46, 3.77 ]
Goss 2005 J%J 2004 16/52 2/52 8.00 [ 1.94, 33.06 ]
Grote 2005 J%J 2004 12/109 11/115 1.15 [ 0.53, 2.50 ]
Gupta 2009 0/57 0/59 0.0 [ 0.0, 0.0 ]
Hedenus 2003 FDA 2007 6/175 1/169 5.79 [ 0.71, 47.62 ]
Henke 2003 Roche 2004 10/180 6/171 1.58 [ 0.59, 4.26 ]
Henry 1995 J%J 2004 6/67 8/65 0.73 [ 0.27, 1.98 ]
Hernandez 2009 16/194 11/192 1.44 [ 0.69, 3.02 ]
Hoskin 2009 J%J 2004 4/133 2/149 2.24 [ 0.42, 12.04 ]
Italian 1998 1/44 0/43 2.93 [ 0.12, 70.08 ]
Leyland-Jones 05 J%J 04 36/448 25/456 1.47 [ 0.89, 2.40 ]
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(. . . Continued)
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Littlewood 2001 J%J 2004 14/251 5/124 1.38 [ 0.51, 3.75 ]
Machtay 2007 2/72 0/68 4.73 [ 0.23, 96.70 ]
Milroy 2011 18/214 13/210 1.36 [ 0.68, 2.70 ]
Moebus 2007 J%J 2007 9/305 5/288 1.70 [ 0.58, 5.01 ]
Osterborg 1996 3/95 0/49 3.65 [ 0.19, 69.20 ]
Osterborg 2002 1/170 0/173 3.05 [ 0.13, 74.41 ]
Overgaard 2009 7/255 3/259 2.37 [ 0.62, 9.06 ]
P-174 J%J 2004 0/33 0/12 0.0 [ 0.0, 0.0 ]
Pirker 2008 65/301 43/296 1.49 [ 1.05, 2.11 ]
Pronzato 2010 4/109 1/111 4.07 [ 0.46, 35.87 ]
Ray-Coquard 2009 5/110 4/107 1.22 [ 0.34, 4.41 ]
Razzouk 2006 6/112 2/110 2.95 [ 0.61, 14.28 ]
Rose 1994 J%J 2004 9/142 2/79 2.50 [ 0.55, 11.30 ]
Rosenzweig 2004 4/14 0/13 8.40 [ 0.50, 142.27 ]
Savonije 2005 7/211 1/104 3.45 [ 0.43, 27.68 ]
Smith 2003 Amgen 2007 2/64 2/22 0.34 [ 0.05, 2.30 ]
Smith 2008 50/515 36/470 1.27 [ 0.84, 1.91 ]
Strauss 2008 1/33 0/38 3.44 [ 0.14, 81.71 ]
Ten Bokkel 1998 6/87 0/33 5.02 [ 0.29, 86.75 ]
Thatcher 1999 2/86 0/44 2.59 [ 0.13, 52.73 ]
Thomas 2008 J%J 2004 10/58 5/55 1.90 [ 0.69, 5.20 ]
Thompson 2000 1/45 0/21 1.43 [ 0.06, 33.82 ]
Throuvalas 2000 1/28 0/26 2.79 [ 0.12, 65.66 ]
Tjulandin 2011 0/95 1/91 0.32 [ 0.01, 7.74 ]
Tsuboi 2009 1/62 0/58 2.81 [ 0.12, 67.62 ]
Untch 2011˙1 20/318 17/396 1.47 [ 0.78, 2.75 ]
Vansteenkiste 2002 7/155 5/159 1.44 [ 0.47, 4.43 ]
Welch 1995 1/15 0/15 3.00 [ 0.13, 68.26 ]
Wilkinson 2006 10/121 1/60 4.96 [ 0.65, 37.84 ]
Winquist 2009 0/26 2/30 0.23 [ 0.01, 4.58 ]
Witzig 2005 J%J 2004 9/168 6/165 1.47 [ 0.54, 4.05 ]
0.02 0.1 1 10 50
Favours control Favours treatment
(Continued . . . )
646Erythropoietin or darbepoetin for patients with cancer (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
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Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Wright 2007 2/33 3/37 0.75 [ 0.13, 4.20 ]
Total (95% CI) 8248 7250 1.53 [ 1.34, 1.74 ]
Total events: 561 (Treatment), 332 (Control)
Heterogeneity: Chi2 = 35.54, df = 53 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 6.38 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 12.1. Comparison 12 Hypertension, Outcome 1 Hypertension - overall.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 12 Hypertension
Outcome: 1 Hypertension - overall
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bamias 2003 2/72 0/72 5.00 [ 0.24, 102.35 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Case 1993 4/81 2/76 1.88 [ 0.35, 9.95 ]
Dammacco 2001 3/69 1/76 3.30 [ 0.35, 31.03 ]
Fujisaka 2011 5/89 3/92 1.72 [ 0.42, 7.00 ]
Gordon 2008 1/164 0/54 1.00 [ 0.04, 24.19 ]
Henry 1995 2/67 4/65 0.49 [ 0.09, 2.56 ]
Hernandez 2009 6/194 4/192 1.48 [ 0.43, 5.18 ]
Hoskin 2009 5/133 5/149 1.12 [ 0.33, 3.78 ]
Iconomou 2003 0/61 0/61 0.0 [ 0.0, 0.0 ]
Krzakowski 2008a 2/100 1/50 1.00 [ 0.09, 10.77 ]
Krzakowski 2008b 1/103 0/49 1.44 [ 0.06, 34.78 ]
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Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kunikane 2001a 3/22 2/9 0.61 [ 0.12, 3.08 ]
Kunikane 2001b 2/21 2/8 0.38 [ 0.06, 2.27 ]
Littlewood 2001 9/251 1/124 4.45 [ 0.57, 34.70 ]
Milroy 2011 6/214 3/210 1.96 [ 0.50, 7.74 ]
Osterborg 1996a 4/47 1/25 2.13 [ 0.25, 18.03 ]
Osterborg 1996b 5/48 0/24 5.61 [ 0.32, 97.48 ]
Osterborg 2002 15/170 9/173 1.70 [ 0.76, 3.77 ]
Pirker 2008 18/301 15/296 1.18 [ 0.61, 2.30 ]
Razzouk 2006 2/112 1/110 1.96 [ 0.18, 21.35 ]
Rose 1994 80/142 47/79 0.95 [ 0.75, 1.19 ]
Rosenzweig 2004 1/14 0/13 2.80 [ 0.12, 63.20 ]
Savonije 2005 7/211 3/104 1.15 [ 0.30, 4.36 ]
Silvestris 1995 4/30 0/24 7.26 [ 0.41, 128.50 ]
Smith 2008 8/515 12/470 0.61 [ 0.25, 1.48 ]
Ten Bokkel 1998a 4/43 1/14 1.30 [ 0.16, 10.71 ]
Ten Bokkel 1998b 7/37 0/14 5.92 [ 0.36, 97.33 ]
Thatcher 1999a 2/42 0/22 2.67 [ 0.13, 53.39 ]
Thatcher 1999b 1/44 0/22 1.53 [ 0.06, 36.18 ]
Tjulandin 2010a 2/76 1/37 0.97 [ 0.09, 10.40 ]
Tjulandin 2010b 2/73 1/37 1.01 [ 0.09, 10.82 ]
Tjulandin 2011 8/95 1/91 7.66 [ 0.98, 60.06 ]
Tsuboi 2009 4/62 2/58 1.87 [ 0.36, 9.83 ]
Vansteenkiste 2002 9/155 6/159 1.54 [ 0.56, 4.22 ]
Welch 1995 2/15 0/15 5.00 [ 0.26, 96.13 ]
Wilkinson 2006 3/121 0/60 3.50 [ 0.18, 66.68 ]
Total (95% CI) 4044 3184 1.30 [ 1.08, 1.56 ]
Total events: 239 (Treatment), 128 (Control)
Heterogeneity: Chi2 = 26.87, df = 34 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 2.73 (P = 0.0064)
Test for subgroup differences: Not applicable
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Analysis 12.2. Comparison 12 Hypertension, Outcome 2 Hypertension - merged experimental study arms.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 12 Hypertension
Outcome: 2 Hypertension - merged experimental study arms
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bamias 2003 2/72 0/72 5.00 [ 0.24, 102.35 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Case 1993 4/81 2/76 1.88 [ 0.35, 9.95 ]
Dammacco 2001 3/69 1/76 3.30 [ 0.35, 31.03 ]
Fujisaka 2011 5/89 3/92 1.72 [ 0.42, 7.00 ]
Gordon 2008 1/164 0/54 1.00 [ 0.04, 24.19 ]
Henry 1995 2/67 4/65 0.49 [ 0.09, 2.56 ]
Hernandez 2009 6/194 4/192 1.48 [ 0.43, 5.18 ]
Hoskin 2009 5/133 5/149 1.12 [ 0.33, 3.78 ]
Iconomou 2003 0/61 0/61 0.0 [ 0.0, 0.0 ]
Krzakowski 2008 3/203 1/99 1.46 [ 0.15, 13.89 ]
Kunikane 2001 5/43 4/17 0.49 [ 0.15, 1.62 ]
Littlewood 2001 9/251 1/124 4.45 [ 0.57, 34.70 ]
Milroy 2011 6/214 3/210 1.96 [ 0.50, 7.74 ]
Osterborg 1996 9/95 1/49 4.64 [ 0.61, 35.59 ]
Osterborg 2002 15/170 9/173 1.70 [ 0.76, 3.77 ]
Pirker 2008 18/301 15/296 1.18 [ 0.61, 2.30 ]
Razzouk 2006 2/112 1/110 1.96 [ 0.18, 21.35 ]
Rose 1994 80/142 47/79 0.95 [ 0.75, 1.19 ]
Rosenzweig 2004 1/14 0/13 2.80 [ 0.12, 63.20 ]
Savonije 2005 7/211 3/104 1.15 [ 0.30, 4.36 ]
Silvestris 1995 4/30 0/24 7.26 [ 0.41, 128.50 ]
Smith 2008 8/515 12/470 0.61 [ 0.25, 1.48 ]
Ten Bokkel 1998 11/80 1/28 3.85 [ 0.52, 28.49 ]
Thatcher 1999 3/86 0/44 3.62 [ 0.19, 68.57 ]
Tjulandin 2010 4/149 2/74 0.99 [ 0.19, 5.30 ]
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(. . . Continued)
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tjulandin 2011 8/95 1/91 7.66 [ 0.98, 60.06 ]
Tsuboi 2009 4/62 2/58 1.87 [ 0.36, 9.83 ]
Vansteenkiste 2002 9/155 6/159 1.54 [ 0.56, 4.22 ]
Welch 1995 2/15 0/15 5.00 [ 0.26, 96.13 ]
Wilkinson 2006 3/121 0/60 3.50 [ 0.18, 66.68 ]
Total (95% CI) 4044 3184 1.31 [ 1.09, 1.58 ]
Total events: 239 (Treatment), 128 (Control)
Heterogeneity: Chi2 = 27.60, df = 28 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 2.81 (P = 0.0049)
Test for subgroup differences: Not applicable
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Analysis 12.3. Comparison 12 Hypertension, Outcome 3 Hypertension - sensitivity analysis Dammacco.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 12 Hypertension
Outcome: 3 Hypertension - sensitivity analysis Dammacco
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bamias 2003 2/72 0/72 5.00 [ 0.24, 102.35 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Case 1993 4/81 2/76 1.88 [ 0.35, 9.95 ]
Dammacco 2001 43/69 36/76 1.32 [ 0.97, 1.78 ]
Fujisaka 2011 5/89 3/92 1.72 [ 0.42, 7.00 ]
Gordon 2008 1/164 0/54 1.00 [ 0.04, 24.19 ]
Henry 1995 2/67 4/65 0.49 [ 0.09, 2.56 ]
Hernandez 2009 6/194 4/192 1.48 [ 0.43, 5.18 ]
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Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hoskin 2009 5/133 5/149 1.12 [ 0.33, 3.78 ]
Iconomou 2003 0/61 0/61 0.0 [ 0.0, 0.0 ]
Krzakowski 2008a 2/100 1/50 1.00 [ 0.09, 10.77 ]
Krzakowski 2008b 1/103 0/49 1.44 [ 0.06, 34.78 ]
Kunikane 2001a 3/22 2/9 0.61 [ 0.12, 3.08 ]
Kunikane 2001b 2/21 2/8 0.38 [ 0.06, 2.27 ]
Littlewood 2001 9/251 1/124 4.45 [ 0.57, 34.70 ]
Milroy 2011 6/214 3/210 1.96 [ 0.50, 7.74 ]
Osterborg 1996a 4/47 1/25 2.13 [ 0.25, 18.03 ]
Osterborg 1996b 5/48 0/24 5.61 [ 0.32, 97.48 ]
Osterborg 2002 15/170 9/173 1.70 [ 0.76, 3.77 ]
Pirker 2008 18/301 15/296 1.18 [ 0.61, 2.30 ]
Razzouk 2006 2/112 1/110 1.96 [ 0.18, 21.35 ]
Rose 1994 80/142 47/79 0.95 [ 0.75, 1.19 ]
Rosenzweig 2004 1/14 0/13 2.80 [ 0.12, 63.20 ]
Savonije 2005 7/211 3/104 1.15 [ 0.30, 4.36 ]
Silvestris 1995 4/30 0/24 7.26 [ 0.41, 128.50 ]
Smith 2008 8/515 12/470 0.61 [ 0.25, 1.48 ]
Ten Bokkel 1998a 4/43 1/14 1.30 [ 0.16, 10.71 ]
Ten Bokkel 1998b 7/37 0/14 5.92 [ 0.36, 97.33 ]
Thatcher 1999a 2/42 0/22 2.67 [ 0.13, 53.39 ]
Thatcher 1999b 1/44 0/22 1.53 [ 0.06, 36.18 ]
Tjulandin 2010a 2/76 1/37 0.97 [ 0.09, 10.40 ]
Tjulandin 2010b 2/73 1/37 1.01 [ 0.09, 10.82 ]
Tjulandin 2011 8/95 1/91 7.66 [ 0.98, 60.06 ]
Tsuboi 2009 4/62 2/58 1.87 [ 0.36, 9.83 ]
Vansteenkiste 2002 9/155 6/159 1.54 [ 0.56, 4.22 ]
Welch 1995 2/15 0/15 5.00 [ 0.26, 96.13 ]
Wilkinson 2006 3/121 0/60 3.50 [ 0.18, 66.68 ]
Total (95% CI) 4044 3184 1.29 [ 1.10, 1.52 ]
Total events: 279 (Treatment), 163 (Control)
Heterogeneity: Chi2 = 26.02, df = 34 (P = 0.83); I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Control Treatment
(Continued . . . )
651Erythropoietin or darbepoetin for patients with cancer (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Test for overall effect: Z = 3.07 (P = 0.0021)
Test for subgroup differences: Not applicable
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Analysis 12.4. Comparison 12 Hypertension, Outcome 4 Hypertension - sensitivity analysis random effects.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 12 Hypertension
Outcome: 4 Hypertension - sensitivity analysis random effects








Bamias 2003 2/72 0/72 5.00 [ 0.24, 102.35 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Case 1993 4/81 2/76 1.88 [ 0.35, 9.95 ]
Dammacco 2001 3/69 1/76 3.30 [ 0.35, 31.03 ]
Fujisaka 2011 5/89 3/92 1.72 [ 0.42, 7.00 ]
Gordon 2008 1/164 0/54 1.00 [ 0.04, 24.19 ]
Henry 1995 2/67 4/65 0.49 [ 0.09, 2.56 ]
Hernandez 2009 6/194 4/192 1.48 [ 0.43, 5.18 ]
Hoskin 2009 5/133 5/149 1.12 [ 0.33, 3.78 ]
Iconomou 2003 0/61 0/61 0.0 [ 0.0, 0.0 ]
Krzakowski 2008a 2/100 1/50 1.00 [ 0.09, 10.77 ]
Krzakowski 2008b 1/103 0/49 1.44 [ 0.06, 34.78 ]
Kunikane 2001a 3/22 2/9 0.61 [ 0.12, 3.08 ]
Kunikane 2001b 2/21 2/8 0.38 [ 0.06, 2.27 ]
0.1 0.2 0.5 1 2 5 10
Control Treatment
(Continued . . . )
652Erythropoietin or darbepoetin for patients with cancer (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)








Littlewood 2001 9/251 1/124 4.45 [ 0.57, 34.70 ]
Milroy 2011 6/214 3/210 1.96 [ 0.50, 7.74 ]
Osterborg 1996a 4/47 1/25 2.13 [ 0.25, 18.03 ]
Osterborg 1996b 5/48 0/24 5.61 [ 0.32, 97.48 ]
Osterborg 2002 15/170 9/173 1.70 [ 0.76, 3.77 ]
Pirker 2008 18/301 15/296 1.18 [ 0.61, 2.30 ]
Razzouk 2006 2/112 1/110 1.96 [ 0.18, 21.35 ]
Rose 1994 80/142 47/79 0.95 [ 0.75, 1.19 ]
Rosenzweig 2004 1/14 0/13 2.80 [ 0.12, 63.20 ]
Savonije 2005 7/211 3/104 1.15 [ 0.30, 4.36 ]
Silvestris 1995 4/30 0/24 7.26 [ 0.41, 128.50 ]
Smith 2008 8/515 12/470 0.61 [ 0.25, 1.48 ]
Ten Bokkel 1998a 4/43 1/14 1.30 [ 0.16, 10.71 ]
Ten Bokkel 1998b 7/37 0/14 5.92 [ 0.36, 97.33 ]
Thatcher 1999a 2/42 0/22 2.67 [ 0.13, 53.39 ]
Thatcher 1999b 1/44 0/22 1.53 [ 0.06, 36.18 ]
Tjulandin 2010a 2/76 1/37 0.97 [ 0.09, 10.40 ]
Tjulandin 2010b 2/73 1/37 1.01 [ 0.09, 10.82 ]
Tjulandin 2011 8/95 1/91 7.66 [ 0.98, 60.06 ]
Tsuboi 2009 4/62 2/58 1.87 [ 0.36, 9.83 ]
Vansteenkiste 2002 9/155 6/159 1.54 [ 0.56, 4.22 ]
Welch 1995 2/15 0/15 5.00 [ 0.26, 96.13 ]
Wilkinson 2006 3/121 0/60 3.50 [ 0.18, 66.68 ]
Total (95% CI) 4044 3184 1.12 [ 0.94, 1.33 ]
Total events: 239 (Treatment), 128 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 26.87, df = 34 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 1.25 (P = 0.21)
Test for subgroup differences: Not applicable
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Analysis 12.5. Comparison 12 Hypertension, Outcome 5 Hypertension - sensitivity analysis without Rose.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 12 Hypertension
Outcome: 5 Hypertension - sensitivity analysis without Rose
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bamias 2003 2/72 0/72 5.00 [ 0.24, 102.35 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Case 1993 4/81 2/76 1.88 [ 0.35, 9.95 ]
Dammacco 2001 3/69 1/76 3.30 [ 0.35, 31.03 ]
Fujisaka 2011 5/89 3/92 1.72 [ 0.42, 7.00 ]
Gordon 2008 1/164 0/54 1.00 [ 0.04, 24.19 ]
Henry 1995 2/67 4/65 0.49 [ 0.09, 2.56 ]
Hernandez 2009 6/194 4/192 1.48 [ 0.43, 5.18 ]
Hoskin 2009 5/133 5/149 1.12 [ 0.33, 3.78 ]
Iconomou 2003 0/61 0/61 0.0 [ 0.0, 0.0 ]
Krzakowski 2008a 2/100 1/50 1.00 [ 0.09, 10.77 ]
Krzakowski 2008b 1/103 0/49 1.44 [ 0.06, 34.78 ]
Kunikane 2001a 3/22 2/9 0.61 [ 0.12, 3.08 ]
Kunikane 2001b 2/21 2/8 0.38 [ 0.06, 2.27 ]
Littlewood 2001 9/251 1/124 4.45 [ 0.57, 34.70 ]
Milroy 2011 6/214 3/210 1.96 [ 0.50, 7.74 ]
Osterborg 1996a 4/47 1/25 2.13 [ 0.25, 18.03 ]
Osterborg 1996b 5/48 0/24 5.61 [ 0.32, 97.48 ]
Osterborg 2002 15/170 9/173 1.70 [ 0.76, 3.77 ]
Pirker 2008 18/301 15/296 1.18 [ 0.61, 2.30 ]
Razzouk 2006 2/112 1/110 1.96 [ 0.18, 21.35 ]
Rosenzweig 2004 1/14 0/13 2.80 [ 0.12, 63.20 ]
Savonije 2005 7/211 3/104 1.15 [ 0.30, 4.36 ]
Silvestris 1995 4/30 0/24 7.26 [ 0.41, 128.50 ]
Smith 2008 8/515 12/470 0.61 [ 0.25, 1.48 ]
Ten Bokkel 1998a 4/43 1/14 1.30 [ 0.16, 10.71 ]
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Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ten Bokkel 1998b 7/37 0/14 5.92 [ 0.36, 97.33 ]
Thatcher 1999a 2/42 0/22 2.67 [ 0.13, 53.39 ]
Thatcher 1999b 1/44 0/22 1.53 [ 0.06, 36.18 ]
Tjulandin 2010a 2/76 1/37 0.97 [ 0.09, 10.40 ]
Tjulandin 2010b 2/73 1/37 1.01 [ 0.09, 10.82 ]
Tjulandin 2011 8/95 1/91 7.66 [ 0.98, 60.06 ]
Tsuboi 2009 4/62 2/58 1.87 [ 0.36, 9.83 ]
Vansteenkiste 2002 9/155 6/159 1.54 [ 0.56, 4.22 ]
Welch 1995 2/15 0/15 5.00 [ 0.26, 96.13 ]
Wilkinson 2006 3/121 0/60 3.50 [ 0.18, 66.68 ]
Total (95% CI) 3902 3105 1.52 [ 1.18, 1.97 ]
Total events: 159 (Treatment), 81 (Control)
Heterogeneity: Chi2 = 19.94, df = 33 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 3.20 (P = 0.0014)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Control Treatment
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Analysis 13.1. Comparison 13 Thrombocytopenia or haemorrhage, Outcome 1 Thrombocytopenia - overall.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 13 Thrombocytopenia or haemorrhage
Outcome: 1 Thrombocytopenia - overall
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bamias 2003 2/72 0/72 5.00 [ 0.24, 102.35 ]
Boogaerts 2003 8/133 13/129 0.60 [ 0.26, 1.39 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Dammacco 2001 5/69 5/76 1.10 [ 0.33, 3.64 ]
Del Mastro 1997 4/31 4/31 1.00 [ 0.27, 3.65 ]
Fujisaka 2011 61/89 55/92 1.15 [ 0.92, 1.43 ]
Gebbia 2003 3/22 3/23 1.05 [ 0.24, 4.64 ]
Goss 2005 1/52 0/52 3.00 [ 0.13, 71.99 ]
Gupta 2009 0/58 0/57 0.0 [ 0.0, 0.0 ]
Kunikane 2001a 12/22 2/9 2.45 [ 0.68, 8.83 ]
Kunikane 2001b 7/21 1/8 2.67 [ 0.39, 18.38 ]
Littlewood 2001 18/251 9/124 0.99 [ 0.46, 2.14 ]
Milroy 2011 15/214 9/210 1.64 [ 0.73, 3.66 ]
Osterborg 1996a 3/47 1/25 1.60 [ 0.17, 14.55 ]
Osterborg 1996b 0/48 0/24 0.0 [ 0.0, 0.0 ]
Pirker 2008 60/301 38/296 1.55 [ 1.07, 2.26 ]
Savonije 2005 22/211 6/104 1.81 [ 0.76, 4.32 ]
Strauss 2008 1/33 4/38 0.29 [ 0.03, 2.45 ]
Thatcher 1999a 11/42 5/22 1.15 [ 0.46, 2.90 ]
Thatcher 1999b 9/44 4/22 1.13 [ 0.39, 3.25 ]
Thompson 2000 5/45 0/21 5.26 [ 0.30, 90.96 ]
Tsuboi 2009 31/62 28/58 1.04 [ 0.72, 1.49 ]
Untch 2011˙1 8/318 10/396 1.00 [ 0.40, 2.49 ]
Witzig 2005 7/168 10/165 0.69 [ 0.27, 1.76 ]
Total (95% CI) 2403 2104 1.21 [ 1.04, 1.42 ]
Total events: 293 (Treatment), 207 (Control)
0.1 0.2 0.5 1 2 5 10
Control Treatment
(Continued . . . )
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(. . . Continued)
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: Chi2 = 14.50, df = 20 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 2.49 (P = 0.013)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Control Treatment
Analysis 13.2. Comparison 13 Thrombocytopenia or haemorrhage, Outcome 2 Thrombocytopenia -
merged experimental arms.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 13 Thrombocytopenia or haemorrhage
Outcome: 2 Thrombocytopenia - merged experimental arms
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bamias 2003 2/72 0/72 5.00 [ 0.24, 102.35 ]
Boogaerts 2003 8/133 13/129 0.60 [ 0.26, 1.39 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Dammacco 2001 5/69 5/76 1.10 [ 0.33, 3.64 ]
Del Mastro 1997 4/31 4/31 1.00 [ 0.27, 3.65 ]
Fujisaka 2011 61/89 55/92 1.15 [ 0.92, 1.43 ]
Gebbia 2003 3/22 3/23 1.05 [ 0.24, 4.64 ]
Goss 2005 1/52 0/52 3.00 [ 0.13, 71.99 ]
Gupta 2009 0/58 0/57 0.0 [ 0.0, 0.0 ]
Kunikane 2001 19/43 3/17 2.50 [ 0.85, 7.38 ]
Littlewood 2001 18/251 9/124 0.99 [ 0.46, 2.14 ]
Milroy 2011 15/214 9/210 1.64 [ 0.73, 3.66 ]
Osterborg 1996 3/95 1/49 1.55 [ 0.17, 14.49 ]
0.1 0.2 0.5 1 2 5 10
control treatment
(Continued . . . )
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(. . . Continued)
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Pirker 2008 60/301 38/296 1.55 [ 1.07, 2.26 ]
Savonije 2005 22/211 6/104 1.81 [ 0.76, 4.32 ]
Strauss 2008 1/33 4/38 0.29 [ 0.03, 2.45 ]
Thatcher 1999 20/86 9/44 1.14 [ 0.57, 2.28 ]
Thompson 2000 5/45 0/21 5.26 [ 0.30, 90.96 ]
Tsuboi 2009 31/62 28/58 1.04 [ 0.72, 1.49 ]
Untch 2011˙1 8/318 10/396 1.00 [ 0.40, 2.49 ]
Witzig 2005 7/168 10/165 0.69 [ 0.27, 1.76 ]
Total (95% CI) 2403 2104 1.21 [ 1.04, 1.41 ]
Total events: 293 (Treatment), 207 (Control)
Heterogeneity: Chi2 = 14.40, df = 18 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 2.48 (P = 0.013)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
control treatment
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Analysis 13.3. Comparison 13 Thrombocytopenia or haemorrhage, Outcome 3 Thrombocytopenia -
sensitivity analysis random effects.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 13 Thrombocytopenia or haemorrhage
Outcome: 3 Thrombocytopenia - sensitivity analysis random effects








Bamias 2003 2/72 0/72 5.00 [ 0.24, 102.35 ]
Boogaerts 2003 8/133 13/129 0.60 [ 0.26, 1.39 ]
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Dammacco 2001 5/69 5/76 1.10 [ 0.33, 3.64 ]
Del Mastro 1997 4/31 4/31 1.00 [ 0.27, 3.65 ]
Fujisaka 2011 61/89 55/92 1.15 [ 0.92, 1.43 ]
Gebbia 2003 3/22 3/23 1.05 [ 0.24, 4.64 ]
Goss 2005 1/52 0/52 3.00 [ 0.13, 71.99 ]
Gupta 2009 0/58 0/57 0.0 [ 0.0, 0.0 ]
Kunikane 2001a 12/22 2/9 2.45 [ 0.68, 8.83 ]
Kunikane 2001b 7/21 1/8 2.67 [ 0.39, 18.38 ]
Littlewood 2001 18/251 9/124 0.99 [ 0.46, 2.14 ]
Milroy 2011 15/214 9/210 1.64 [ 0.73, 3.66 ]
Osterborg 1996a 3/47 1/25 1.60 [ 0.17, 14.55 ]
Osterborg 1996b 0/48 0/24 0.0 [ 0.0, 0.0 ]
Pirker 2008 60/301 38/296 1.55 [ 1.07, 2.26 ]
Savonije 2005 22/211 6/104 1.81 [ 0.76, 4.32 ]
Strauss 2008 1/33 4/38 0.29 [ 0.03, 2.45 ]
Thatcher 1999a 11/42 5/22 1.15 [ 0.46, 2.90 ]
Thatcher 1999b 9/44 4/22 1.13 [ 0.39, 3.25 ]
Thompson 2000 5/45 0/21 5.26 [ 0.30, 90.96 ]
Tsuboi 2009 31/62 28/58 1.04 [ 0.72, 1.49 ]
Untch 2011˙1 8/318 10/396 1.00 [ 0.40, 2.49 ]
Witzig 2005 7/168 10/165 0.69 [ 0.27, 1.76 ]
0.1 0.2 0.5 1 2 5 10
Control Treatment
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Total (95% CI) 2403 2104 1.18 [ 1.02, 1.36 ]
Total events: 293 (Treatment), 207 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 14.50, df = 20 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 2.27 (P = 0.023)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Control Treatment
Analysis 14.1. Comparison 14 Rash, Outcome 1 Rash - overall.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 14 Rash
Outcome: 1 Rash - overall
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Del Mastro 1997 2/31 0/31 5.00 [ 0.25, 100.08 ]
Gordon 2008 1/164 0/54 1.00 [ 0.04, 24.19 ]
Gupta 2009 0/58 0/57 0.0 [ 0.0, 0.0 ]
Henry 1995 7/67 2/65 3.40 [ 0.73, 15.74 ]
Italian 1998 0/44 1/43 0.33 [ 0.01, 7.79 ]
Kurz 1997 0/12 0/12 0.0 [ 0.0, 0.0 ]
Milroy 2011 3/214 0/210 6.87 [ 0.36, 132.19 ]
Osterborg 1996a 1/47 0/25 1.63 [ 0.07, 38.49 ]
Osterborg 1996b 1/48 0/24 1.53 [ 0.06, 36.23 ]
Osterborg 2002 2/170 0/173 5.09 [ 0.25, 105.20 ]
Strauss 2008 1/33 0/38 3.44 [ 0.14, 81.71 ]
Thatcher 1999a 5/42 2/22 1.31 [ 0.28, 6.21 ]
0.1 0.2 0.5 1 2 5 10
Control Treatment
(Continued . . . )
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(. . . Continued)
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Thatcher 1999b 1/44 2/22 0.25 [ 0.02, 2.61 ]
Thompson 2000 3/45 4/21 0.35 [ 0.09, 1.43 ]
Tjulandin 2011 13/95 7/91 1.78 [ 0.74, 4.26 ]
Tsuboi 2009 0/62 2/58 0.19 [ 0.01, 3.82 ]
Welch 1995 1/15 0/15 3.00 [ 0.13, 68.26 ]
Witzig 2005 12/168 7/165 1.68 [ 0.68, 4.17 ]
Total (95% CI) 1359 1126 1.49 [ 0.99, 2.24 ]
Total events: 53 (Treatment), 27 (Control)
Heterogeneity: Chi2 = 13.18, df = 15 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 1.90 (P = 0.058)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Control Treatment
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Analysis 14.2. Comparison 14 Rash, Outcome 2 Rash - merged experimental arms.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 14 Rash
Outcome: 2 Rash - merged experimental arms
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Del Mastro 1997 2/31 0/31 5.00 [ 0.25, 100.08 ]
Gordon 2008 1/164 0/54 1.00 [ 0.04, 24.19 ]
Gupta 2009 0/58 0/57 0.0 [ 0.0, 0.0 ]
Henry 1995 7/67 2/65 3.40 [ 0.73, 15.74 ]
Italian 1998 0/44 1/43 0.33 [ 0.01, 7.79 ]
Kurz 1997 0/12 0/12 0.0 [ 0.0, 0.0 ]
Milroy 2011 3/214 0/210 6.87 [ 0.36, 132.19 ]
Osterborg 1996 2/95 0/49 2.60 [ 0.13, 53.21 ]
Osterborg 2002 2/170 0/173 5.09 [ 0.25, 105.20 ]
Strauss 2008 1/33 0/38 3.44 [ 0.14, 81.71 ]
Thatcher 1999 6/86 4/44 0.77 [ 0.23, 2.58 ]
Thompson 2000 3/45 4/21 0.35 [ 0.09, 1.43 ]
Tjulandin 2011 13/95 7/91 1.78 [ 0.74, 4.26 ]
Tsuboi 2009 0/62 2/58 0.19 [ 0.01, 3.82 ]
Welch 1995 1/15 0/15 3.00 [ 0.13, 68.26 ]
Witzig 2005 12/168 7/165 1.68 [ 0.68, 4.17 ]
Total (95% CI) 1359 1126 1.50 [ 1.00, 2.27 ]
Total events: 53 (Treatment), 27 (Control)
Heterogeneity: Chi2 = 12.22, df = 13 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 1.94 (P = 0.053)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
control treatment
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Analysis 15.1. Comparison 15 Seizure, Outcome 1 Seizure - overall.
Review: Erythropoietin or darbepoetin for patients with cancer
Comparison: 15 Seizure
Outcome: 1 Seizure - overall
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cascinu 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Case 1993 2/81 2/76 0.94 [ 0.14, 6.50 ]
Gordon 2008 0/164 1/54 0.11 [ 0.00, 2.69 ]
Henry 1995 3/67 2/65 1.46 [ 0.25, 8.43 ]
Hernandez 2009 3/194 1/192 2.97 [ 0.31, 28.29 ]
Pirker 2008 4/301 9/296 0.44 [ 0.14, 1.40 ]
Savonije 2005 4/211 0/104 4.46 [ 0.24, 82.02 ]
Smith 2008 3/515 6/470 0.46 [ 0.11, 1.81 ]
Total (95% CI) 1583 1307 0.77 [ 0.42, 1.41 ]
Total events: 19 (Treatment), 21 (Control)
Heterogeneity: Chi2 = 6.19, df = 6 (P = 0.40); I2 =3%
Test for overall effect: Z = 0.85 (P = 0.39)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Control Treatment
A D D I T I O N A L T A B L E S
Table 1. Haematologic response: results of meta-regression analysis
Variable log (effect size) standard error P value
Intercept 0.81 0.1189 <0.0001
Hb baseline 10-12 g/dL 0.62 0.1430 <0.0001
Hb baseline > 12 g/dL 0.85 0.4694 0.0688
Children -0.68 0.1653 <0.0001
Iron given differently in both
study arms
-0.64 0.2348 0.0068
663Erythropoietin or darbepoetin for patients with cancer (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 1. Haematologic response: results of meta-regression analysis (Continued)




Table 2. Hb change: results of meta-regression analysis
Variable mean difference standard error P value
Intercept 1.15 0.1792 <0.0001
Children -1.41 0.6911 0.0414
Short acting ESA 0.56 0.2041 0.0060
ESA: erythropoiesis stimulating agent
Table 3. Participants receiving RBC transfusions: results of meta-regression analysis
Variable log(effect size) Standard error P value
Intercept -0.22 0.0506 <0.0001
Hb 10 - 12 g/dL -0.15 0.0650 0.0254
Hb > 12 g/dL 0.07 0.0601 0.2774
MDS 0.01 0.1004 0.8967
Solid and haematological tu-
mours
-0.03 0.0648 0.6726
Solid tumours -0.39 0.0637 <0.0001
MDS: myelodysplastic syndrome
RBC: red blood cell
Table 4. FACT-F 13: results of meta-regression analysis
Variable mean difference standard error P value
Intercept 1.09 0.6158 0.0779
Short acting ESA 2.20 0.8346 0.0083
664Erythropoietin or darbepoetin for patients with cancer (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
ESA: erythropoiesis stimulating agent
Table 5. FACT-An 47: results of meta-regression analysis
Variable mean difference Standard error P value
Intercept 6.10 2.3783 0.0103








No anticancer therapy 23.80 4.0571 <0.0001
Radiotherapy -4.20 3.9147 0.2836
A P P E N D I C E S
Appendix 1. EMBASE search strategy
Please note that the same search strategy was used for the other searches conducted on the dates mentioned in the main text.
No. Query
#70 #68 AND [1-8-2009]/sd NOT [11-1-2011]/sd
#68 #38 AND #67
#67 #63 NOT #66
#66 #64 NOT #65
#65 ’human’/exp OR human
#64 ’animal’/exp OR animal
#63 #58 NOT #62
#62 #59 OR #60 OR #61
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(Continued)
#61 ’abstract report’ OR letter
#60 ’case report’
#59 ’case study’
#58 #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46 OR #47 OR #48 OR #49 OR #50 OR #51 OR #52 OR
#53 OR #54 OR #55 OR #56 OR #57
#57 ’prospective study’
#56 placebo*
#55 ’triple’ NEAR/5 ’blind’
#54 ’treble’ NEAR/5 ’blind’
#53 double AND blind*
#52 single AND blind*





#46 randomi?ed AND controlled AND trial?
#45 ’placebo’/exp OR placebo
#44 ’crossover procedure’/exp OR ’crossover procedure’
#43 ’double blind procedure’/exp OR ’double blind procedure’
#42 ’single blind procedure’/exp OR ’single blind procedure’
#41 ’randomization’/exp OR ’randomization’
#40 ’randomized controlled trial’/exp OR ’randomized controlled trial’
#39 ’clinical trial’/exp OR ’clinical trial’
#38 #36 AND #37
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(Continued)
#37 #21 AND #27








#28 ’neoplasm’/exp OR neoplasm





#22 ’anemia’/exp OR anemia
#21 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #
16 OR #17 OR #18 OR #19 OR #20
#20 ’erythropoietin receptor’/exp OR ’erythropoietin receptor’
#19 micer*
#18 mircer*
#17 methoxy AND polyethylene AND ’glycol epoetin’ AND beta
#16 continuous AND erythropo?es* AND (’receptor’/exp OR receptor) AND activator
#15 cera*
#14 darbepo?eti*
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#1 ’erythropoietin’ OR ’recombinant erythropoietin’/exp
Appendix 2. MEDLINE search strategy
Please note that the same search strategy was used for the other searches conducted on the dates mentioned in the main text.
MEDLINE /Ovid (February 2011 to November 2011)
# Searches
1 exp ERYTHROPOIETIN/
2 exp ERYTHROPOIETIN, RECOMBINANT/
3 erythropoietin.mp.
4 erythropoiesis.mp.
5 exp EPOETIN ALFA/
6 epoetin.mp.
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20 exp ANEMIA/dt, th [Drug Therapy, Therapy]
21 anaemia.mp.
22 anemia.mp.
23 (anemi$ adj3 cancer).mp.
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35 19 and 25
36 34 and 35
37 randomized controlled trial.pt.









47 45 and 46
48 36 and 47
49 limit 48 to ed=20080101-20081231
50 randomized controlled trial.pt.
51 controlled clinical trial.pt.
52 randomized controlled trials as topic/
53 random allocation/
54 double blind method/
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(Continued)
55 single blind method/
56 or/50-55
57 (ANIMALS not HUMANS).sh.
58 56 not 57
59 clinical trial.pt.
60 exp clinical trial as topic/
61 (clin$ adj25 trial$).ti,ab.






68 67 not 57
69 68 not 58
70 comparative study/
71 exp evaluation studies/
72 follow up studies/
73 prospective studies/
74 (control$ or prospectiv$ or volunteer$).ti,ab.
75 or/70-74
76 75 not 57
77 76 not (58 or 69)
78 58 or 69 or 77
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(Continued)
79 36 and 78
80 48 or 79
81 limit 80 to ed=20090801-20110201
82 limit 80 to ed=20110201-20111201
Appendix 3. CENTRAL search strategy
Please note that the same search strategy was used for the other searches conducted on the dates mentioned in the main text.
Cochrane Central Register of Controlled Trials (Cochrane Library 2011, Issue 3)
ID Search
#1 (erythropoietin)
#2 MeSH descriptor Erythropoietin explode all trees
#3 epoetin
#4 epo
#5 (epoetin next alfa)
#6 (epoetin next beta)





#12 (recombinant near erythropoietin)
#13 “continuous erythropoietin receptor activation”
#14 “continuous erythropoietin receptor activator”
#15 CERA
#16 C.E.R.A.
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#19 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15
OR #16 OR #17 OR #18)
#20 anemia
#21 anaemia
#22 MeSH descriptor Anemia explode all trees
#23 (anemi* near cancer)
#24 (anaemi* near cancer)
#25 (#20 OR #21 OR #22 OR #23 OR #24)
#26 (#19 AND #25)
#27 (#26), from 2007 to 2008
#28 (#26), from 2008 to 2009
#29 (#26), from 2009
#30 (#28 OR #29)
#31 (#26), from 2009 to 2011
#32 (#26), in 2011
WH A T ’ S N E W
Last assessed as up-to-date: 2 May 2012.
Date Event Description
11 May 2012 New citation required and conclusions have changed Authors changed (new authors: Tonia T, Mettler A,
Robert N)
Substantive update, in the previous review the out-
come haematological response was restricted to studies
with baseline Hb levels < 12 g/dL; in the current up-
date this restriction was removed. On-study mortality
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(Continued)
was added as a new outcome to the current update
of the review. Studies using iron supplements in one
study arm only were included, in the previous version
these studies were excluded. Studies using any dose of
ESAs were included, in the previous review studies us-
ing very low dosages had been excluded. Any type of
ESA was included in the review
30 November 2011 New search has been performed New search
H I S T O R Y
Protocol first published: Issue 4, 2002
Review first published: Issue 3, 2004
Date Event Description
15 August 2008 Amended Converted to new review format.
24 May 2006 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
Thomy Tonia: Quality of Life analysis, searching for trials, eligibility and quality assessment, fact checking, data extraction and analysis,
drafting of QoL and discussion, revision of review
Annette Mettler: Searching for trials, eligibility and quality assessment, data extraction and analysis
Nadège Robert: Searching for trials, eligibility and quality assessment, data extraction and analysis
Guido Schwarzer: Statistical and methodological advice, data analysis, content input
Olaf Weingart: eligibility and quality assessment, fact checking, creating summary of findings table
Jerome Seidenfeld: Clinical and scientific advice, content input, revision of draft review
Chris Hyde: Protocol development, searching for trials, eligibility and quality assessment, data extraction and analysis
Andreas Engert: Clinical and scientific advice, content input
Julia Bohlius: Protocol development, searching for trials, eligibility and quality assessment, data extraction and analysis, drafting and
revision of review
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D E C L A R A T I O N S O F I N T E R E S T
Thomy Tonia, Annette Mettler, Nadège Robert, Olaf Weingart, Guido Schwarzer, Jerome Seidenfeld, Chris Hyde, Andreas Engert,
Julia Bohlius: none known.
S O U R C E S O F S U P P O R T
Internal sources
• Department of Internal Medicine I, University of Cologne, Germany.
• Cochrane Haematological Malignancies Group (CHMG), Germany.
• Institute of Social and Preventive Medicine, University of Bern, Switzerland.
External sources
• Department of Health, UK.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In previous versions of this review, we required dosages of at least 300 U/kg body weight per week (epoetin-a and beta) given for at
least four weeks. For the current update this criterion was removed and we included studies or study arms with low dosages as well. In
previous versions of this review, iron supplementation had to be identical in the study arms of a given trial. For the current update, we
changed this criterion and included trials using iron supplementation in the experimental but not in the control arm as well.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Anemia [∗drug therapy; etiology]; Erythrocyte Transfusion [utilization]; Erythropoietin [∗analogs & derivatives; ∗therapeutic use];
Neoplasms [blood; ∗complications]; Randomized Controlled Trials as Topic; Recombinant Proteins
MeSH check words
Humans
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